data_2mql_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mql _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.4 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.2 p . . . . . 0 CA--C 1.531 0.237 0 N-CA-C 111.487 0.18 . . . . 0.0 111.487 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.4 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 77.7 Cg_endo -70.19 3.02 3.23 Favored 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 124.199 3.266 . . . . 0.0 112.452 178.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.3 t -115.64 141.31 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.087 0.555 . . . . 0.0 109.798 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.0 m -130.71 151.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-O 121.231 0.538 . . . . 0.0 110.898 177.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 22.9 t-80 -100.49 139.23 36.47 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.076 0.95 . . . . 0.0 110.03 179.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 29.7 mm -108.54 145.15 15.86 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 123.646 0.778 . . . . 0.0 110.089 -178.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -143.59 161.2 39.12 Favored 'General case' 0 C--N 1.337 0.044 0 C-N-CA 123.352 0.661 . . . . 0.0 110.376 -177.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.35 25.09 59.8 Favored Glycine 0 CA--C 1.528 0.845 0 CA-C-O 119.442 -0.644 . . . . 0.0 113.658 173.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 68.9 mt -61.21 157.56 15.94 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.398 1.099 . . . . 0.0 109.864 177.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.3 pt -73.08 -41.64 59.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -173.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -173.39 -35.08 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.277 0.631 . . . . 0.0 110.553 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.98 50.59 0.1 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -175.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.9 t -52.32 144.58 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.159 0 C-N-CA 123.5 0.72 . . . . 0.0 109.743 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.82 161.24 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.036 0 CA-C-O 121.084 0.469 . . . . 0.0 111.564 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -60.95 -25.05 66.52 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 123.288 0.635 . . . . 0.0 111.201 -177.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.23 -3.62 52.9 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -178.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -99.43 -31.22 11.76 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.369 0.531 . . . . 0.0 110.757 178.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.4 mp -75.18 -34.05 61.51 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.162 -0.336 . . . . 0.0 110.361 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -77.63 -30.63 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 118.099 0.409 . . . . 0.0 110.348 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -82.14 -17.02 47.84 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.369 -0.207 . . . . 0.0 111.433 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.1 -11.51 16.56 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.5 mt -115.97 -9.97 11.68 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.695 0.68 . . . . 0.0 112.404 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -68.45 -7.05 28.41 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 118.567 0.621 . . . . 0.0 111.637 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -76.01 -14.44 60.22 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 122.692 0.397 . . . . 0.0 110.859 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -98.68 -16.8 18.88 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 122.685 0.394 . . . . 0.0 111.639 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.05 177.05 35.72 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -71.5 141.21 37.91 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 123.775 2.984 . . . . 0.0 110.524 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.2 mt -110.65 147.05 15.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 C-N-CA 122.824 0.45 . . . . 0.0 110.356 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.0 t -107.31 -42.55 4.8 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.279 0.632 . . . . 0.0 111.348 -177.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 54.5 t80 -158.79 159.67 35.41 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 120.778 0.323 . . . . 0.0 111.076 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 76.7 t -143.35 146.85 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 124.008 0.923 . . . . 0.0 109.071 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -147.71 151.26 13.76 Favored 'Isoleucine or valine' 0 C--O 1.231 0.096 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 175.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 45.4 t -128.05 151.01 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.065 0 C-N-CA 122.503 0.321 . . . . 0.0 110.6 -175.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.7 mtm -133.7 81.19 54.04 Favored Pre-proline 0 N--CA 1.455 -0.192 0 C-N-CA 124.113 0.965 . . . . 0.0 108.732 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.43 -12.29 33.2 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.577 2.852 . . . . 0.0 111.729 -175.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -82.02 -5.14 58.12 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.676 0.39 . . . . 0.0 110.685 177.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 35.8 mmtp -130.4 3.83 4.69 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.245 1.018 . . . . 0.0 111.132 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 53.62 33.22 16.0 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.336 1.054 . . . . 0.0 112.087 -176.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -136.51 168.45 19.45 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.309 0.644 . . . . 0.0 110.413 -176.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.49 172.22 18.61 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.591 0.356 . . . . 0.0 110.457 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 36.8 mt -131.4 146.65 52.36 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.566 0.746 . . . . 0.0 110.219 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 84.7 t -137.83 131.75 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -115.37 121.21 42.1 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.055 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.56 153.61 21.69 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.984 0.421 . . . . 0.0 110.325 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -74.83 -13.38 60.56 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.936 0.398 . . . . 0.0 110.496 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -147.46 151.65 36.77 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.58 0.752 . . . . 0.0 109.412 177.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.01 -20.43 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 111.663 0.245 . . . . 0.0 111.663 -175.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.1 tp -74.13 -27.01 60.65 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.946 -0.471 . . . . 0.0 110.743 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.32 -30.44 69.31 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.58 -29.57 27.7 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 117.132 0.466 . . . . 0.0 110.189 178.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 32.0 t -71.97 -12.95 61.48 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.208 0.603 . . . . 0.0 111.366 179.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -102.0 -17.71 15.97 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 122.623 0.369 . . . . 0.0 111.764 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.49 -30.43 25.19 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.135 0.425 . . . . 0.0 111.587 -176.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 25.9 t -88.06 -17.19 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -72.17 -3.75 25.22 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.448 0.299 . . . . 0.0 111.063 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -116.18 -33.43 5.01 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 122.925 0.49 . . . . 0.0 111.113 177.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.02 -7.77 58.4 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -177.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.03 -1.0 56.31 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 122.077 -0.389 . . . . 0.0 111.806 177.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -140.18 -5.94 1.25 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 122.821 0.448 . . . . 0.0 111.725 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.78 173.24 16.71 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -90.73 156.76 17.84 Favored 'General case' 0 CA--C 1.529 0.136 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 175.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.05 136.4 59.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -90.33 150.98 21.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 O-C-N 122.068 -0.395 . . . . 0.0 110.698 -178.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.1 mt -137.43 -38.79 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.932 -177.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -132.9 28.76 4.17 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.288 0.635 . . . . 0.0 111.126 -176.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.01 4.83 86.64 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -176.178 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -130.82 151.9 79.64 Favored Pre-proline 0 N--CA 1.453 -0.287 0 C-N-CA 124.303 1.041 . . . . 0.0 109.066 178.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -70.5 145.26 52.38 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 123.49 2.793 . . . . 0.0 111.905 -176.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.63 -175.79 5.34 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.852 1.261 . . . . 0.0 108.898 178.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -138.68 160.07 40.56 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-O 120.948 0.404 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.67 143.1 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.854 0.862 . . . . 0.0 109.647 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 N--CA 1.455 -0.195 0 C-N-CA 122.973 0.509 . . . . 0.0 110.089 179.022 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.0 m . . . . . 0 CA--C 1.532 0.27 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -70.87 2.61 3.98 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 124.184 3.256 . . . . 0.0 112.325 178.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.6 t -115.26 141.53 31.77 Favored 'Isoleucine or valine' 0 C--N 1.339 0.112 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.59 152.34 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.381 0.61 . . . . 0.0 111.025 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -100.65 141.07 34.02 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.307 1.043 . . . . 0.0 109.882 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.1 mm -110.37 144.92 17.51 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 C-N-CA 123.048 0.539 . . . . 0.0 109.801 -178.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -140.56 159.28 42.54 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 123.464 0.705 . . . . 0.0 110.21 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.66 24.64 60.05 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 119.322 -0.71 . . . . 0.0 113.615 173.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 51.3 mt -59.47 155.82 14.32 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.172 0.986 . . . . 0.0 109.533 177.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -70.58 -38.01 71.85 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.102 0 O-C-N 122.35 -0.219 . . . . 0.0 111.305 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -172.08 -37.19 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.908 0.883 . . . . 0.0 109.506 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.0 56.19 0.04 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 m -53.2 151.4 1.19 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 117.243 0.522 . . . . 0.0 110.422 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.2 m -86.68 166.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.122 0 CA-C-O 121.166 0.508 . . . . 0.0 110.855 -177.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.6 -26.72 68.16 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 122.871 0.468 . . . . 0.0 110.786 -178.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.62 -7.98 56.33 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -94.45 -34.65 12.65 Favored 'General case' 0 N--CA 1.457 -0.11 0 CA-C-N 118.248 0.476 . . . . 0.0 109.772 176.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.4 mt -72.73 -40.23 66.28 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 122.389 0.276 . . . . 0.0 110.93 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.1 p -77.3 -29.87 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 O-C-N 122.083 -0.385 . . . . 0.0 110.739 -176.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -85.88 -14.64 44.26 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 122.128 -0.357 . . . . 0.0 111.146 -178.022 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -101.52 -14.11 17.62 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 178.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.6 mt -115.12 -8.47 12.4 Favored 'General case' 0 CA--C 1.529 0.14 0 CA-C-N 118.566 0.621 . . . . 0.0 112.568 -178.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.3 pt20 -70.54 -6.09 33.78 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.849 0.749 . . . . 0.0 111.67 176.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -76.82 -16.39 59.45 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.53 0.332 . . . . 0.0 110.449 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -95.94 -18.79 20.02 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.529 0.332 . . . . 0.0 111.525 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.43 177.57 37.88 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.6 140.28 35.74 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 124.047 3.165 . . . . 0.0 110.576 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 70.1 mt -110.81 147.1 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.869 0.468 . . . . 0.0 110.258 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -108.48 -39.42 5.42 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.333 0.653 . . . . 0.0 111.494 -177.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -158.83 157.68 32.02 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 117.719 0.236 . . . . 0.0 111.167 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 63.7 t -145.08 146.57 19.74 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 C-N-CA 123.775 0.83 . . . . 0.0 110.091 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.0 p -150.68 151.8 12.14 Favored 'Isoleucine or valine' 0 C--O 1.231 0.102 0 C-N-CA 123.566 0.746 . . . . 0.0 109.24 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.8 p -134.13 150.29 31.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-O 120.736 0.303 . . . . 0.0 110.804 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.2 mpp? -130.55 83.73 61.29 Favored Pre-proline 0 CA--C 1.53 0.202 0 C-N-CA 123.567 0.747 . . . . 0.0 109.51 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -58.79 -18.88 43.77 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 123.938 3.092 . . . . 0.0 113.066 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -78.85 -6.27 55.63 Favored 'General case' 0 C--N 1.341 0.222 0 C-N-CA 122.944 0.498 . . . . 0.0 111.473 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -131.28 3.27 4.29 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.755 0.822 . . . . 0.0 111.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.0 tpp85 54.68 33.65 19.86 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.404 1.082 . . . . 0.0 111.977 -176.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -136.35 165.49 25.67 Favored 'General case' 0 C--O 1.23 0.078 0 C-N-CA 123.005 0.522 . . . . 0.0 110.78 -176.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.97 171.2 17.66 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 122.59 0.356 . . . . 0.0 110.582 178.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.3 mt -131.05 145.16 51.93 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.022 0.929 . . . . 0.0 109.688 178.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -137.9 131.92 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -113.36 121.29 43.92 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 177.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -87.74 154.86 20.24 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-O 120.816 0.341 . . . . 0.0 110.216 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -75.38 -13.24 60.39 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.189 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -147.87 150.25 33.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.72 0.808 . . . . 0.0 109.274 177.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -67.34 -21.98 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.7 tp -74.93 -28.78 60.74 Favored 'General case' 0 N--CA 1.455 -0.204 0 O-C-N 121.875 -0.516 . . . . 0.0 110.534 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.29 -30.46 69.36 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.42 -30.06 33.67 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.699 -0.295 . . . . 0.0 110.618 178.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.5 t -74.22 -32.97 63.21 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.669 0.271 . . . . 0.0 110.685 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -74.81 -17.52 60.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.211 -0.306 . . . . 0.0 110.906 -179.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.37 -30.17 23.86 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -176.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.0 t -89.17 -22.63 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 O-C-N 122.095 -0.378 . . . . 0.0 110.732 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -70.19 -1.67 10.91 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 122.132 -0.355 . . . . 0.0 111.535 179.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.2 t80 -112.75 -37.82 4.76 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 122.836 0.454 . . . . 0.0 110.969 176.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.81 -6.8 57.96 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -79.69 -4.99 54.23 Favored 'General case' 0 N--CA 1.453 -0.284 0 O-C-N 122.027 -0.42 . . . . 0.0 111.7 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -141.39 -4.84 1.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 122.654 0.382 . . . . 0.0 111.894 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 27.2 m-80 -145.53 174.53 11.08 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.505 0.722 . . . . 0.0 109.821 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . 0.423 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -94.73 151.72 19.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 173.972 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -121.96 134.98 63.57 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -88.54 152.19 22.02 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.136 -0.353 . . . . 0.0 110.576 -178.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.7 mt -136.56 -41.57 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.22 -177.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.75 30.09 3.77 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.098 0.559 . . . . 0.0 110.858 -178.157 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.9 4.99 78.15 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -131.7 152.72 80.87 Favored Pre-proline 0 N--CA 1.455 -0.214 0 C-N-CA 124.024 0.93 . . . . 0.0 109.399 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -70.77 144.82 49.69 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 123.408 2.739 . . . . 0.0 111.866 -175.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.99 -175.95 5.35 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.891 1.276 . . . . 0.0 108.929 178.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -140.53 160.46 39.95 Favored 'General case' 0 C--O 1.231 0.092 0 CA-C-O 120.995 0.426 . . . . 0.0 111.503 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -146.96 141.52 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 C-N-CA 123.772 0.829 . . . . 0.0 109.916 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.6 t30 . . . . . 0 N--CA 1.456 -0.151 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.578 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 71.3 p . . . . . 0 CA--C 1.533 0.317 0 N-CA-C 111.45 0.167 . . . . 0.0 111.45 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -71.7 5.82 2.29 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 124.471 3.447 . . . . 0.0 112.179 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.8 t -120.57 141.67 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.124 0 C-N-CA 123.066 0.546 . . . . 0.0 109.57 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 31.6 m -130.28 149.86 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.115 0 CA-C-O 121.199 0.523 . . . . 0.0 111.063 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -98.14 142.08 30.27 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.338 1.055 . . . . 0.0 110.127 177.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.6 mm -111.56 145.5 17.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 C-N-CA 123.06 0.544 . . . . 0.0 109.723 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -142.11 161.21 38.57 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.254 0.622 . . . . 0.0 110.377 -179.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 81.67 24.23 56.44 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.592 -0.56 . . . . 0.0 113.641 173.151 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.5 mt -63.01 159.23 17.53 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.1 0.95 . . . . 0.0 110.072 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.3 pt -74.2 -42.45 51.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.93 -35.46 0.01 OUTLIER 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.074 0.55 . . . . 0.0 110.676 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -177.04 50.31 0.1 Allowed Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.1 t -50.61 146.19 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 123.565 0.746 . . . . 0.0 109.735 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.8 m -96.53 161.92 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.072 0 CA-C-O 121.182 0.515 . . . . 0.0 111.4 -176.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -60.1 -24.72 64.86 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.01 0.524 . . . . 0.0 111.376 -176.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.22 -6.17 56.0 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -99.43 -31.58 11.58 Favored 'General case' 0 CA--C 1.529 0.137 0 CA-C-N 118.155 0.434 . . . . 0.0 110.204 177.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -69.83 -39.11 76.67 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.1 p -78.44 -30.79 15.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 121.157 -0.217 . . . . 0.0 110.52 -176.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -82.2 -14.37 55.68 Favored 'General case' 0 N--CA 1.456 -0.14 0 O-C-N 122.072 -0.393 . . . . 0.0 111.715 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.67 -11.8 15.36 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 94.3 mt -115.95 -8.36 11.89 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.847 0.749 . . . . 0.0 112.481 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -70.42 -6.55 36.54 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.564 0.62 . . . . 0.0 111.9 176.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -76.42 -15.58 59.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 122.488 0.315 . . . . 0.0 110.518 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -96.33 -17.15 20.88 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 122.446 0.298 . . . . 0.0 111.355 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.72 176.35 35.56 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -71.46 140.4 36.44 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 124.186 3.257 . . . . 0.0 110.586 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.7 mt -111.63 145.69 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.091 0 C-N-CA 122.563 0.345 . . . . 0.0 110.232 -177.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.8 t -105.36 -41.96 5.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 123.287 0.635 . . . . 0.0 111.278 -177.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -158.92 159.55 35.06 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.742 0.306 . . . . 0.0 111.098 178.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 87.7 t -143.6 147.46 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.827 0.851 . . . . 0.0 109.692 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.1 p -148.5 149.74 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.094 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 175.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.87 149.35 33.53 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -130.54 82.02 66.2 Favored Pre-proline 0 N--CA 1.456 -0.137 0 C-N-CA 123.667 0.787 . . . . 0.0 109.32 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -58.82 -19.09 45.09 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.849 3.032 . . . . 0.0 112.838 -178.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -75.15 -13.47 60.47 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.905 0.482 . . . . 0.0 111.071 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -125.82 4.65 7.37 Favored 'General case' 0 CA--C 1.527 0.089 0 C-N-CA 123.541 0.737 . . . . 0.0 111.284 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.1 tpp85 55.18 32.08 17.72 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.128 0.971 . . . . 0.0 111.993 -177.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -135.87 166.32 23.57 Favored 'General case' 0 N--CA 1.457 -0.106 0 C-N-CA 123.059 0.544 . . . . 0.0 110.803 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.72 172.38 15.68 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 122.863 0.465 . . . . 0.0 110.725 179.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 30.6 mt -132.97 145.81 51.21 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.645 0.778 . . . . 0.0 109.772 177.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 86.2 t -137.26 132.42 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -114.53 117.72 31.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -85.2 153.5 22.59 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 120.99 0.424 . . . . 0.0 110.251 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -74.62 -13.15 60.61 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.388 -177.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -148.32 151.28 35.1 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.76 0.824 . . . . 0.0 108.965 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.9 p -66.42 -21.95 29.36 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.8 tp -73.31 -24.63 60.42 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 121.948 -0.47 . . . . 0.0 110.492 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.24 -31.16 64.04 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.22 -31.23 23.28 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-N 117.126 0.463 . . . . 0.0 110.133 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 t -71.54 -18.48 62.26 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.904 0.482 . . . . 0.0 110.913 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -96.68 -17.83 20.08 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 122.74 0.416 . . . . 0.0 111.127 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.82 -31.42 28.12 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.13 -0.356 . . . . 0.0 111.663 -177.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 32.1 t -85.74 -14.36 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 177.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -72.97 -2.79 22.41 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.137 0.575 . . . . 0.0 111.118 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -121.03 -34.85 3.44 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 122.701 0.401 . . . . 0.0 110.996 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.73 -9.59 58.06 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -176.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.72 -0.21 55.89 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 122.663 0.385 . . . . 0.0 111.654 176.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -136.51 -10.13 1.89 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.907 0.483 . . . . 0.0 111.726 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 50.0 t30 -154.12 170.62 20.74 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -86.88 155.63 20.17 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 175.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.73 136.15 61.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -178.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -89.04 151.21 22.39 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.121 -0.362 . . . . 0.0 110.758 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.8 mt -136.5 -38.46 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.839 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.37 29.43 3.0 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.28 0.632 . . . . 0.0 111.027 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.18 3.79 81.97 Favored Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.716 -0.554 . . . . 0.0 111.716 -176.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -130.56 151.8 79.29 Favored Pre-proline 0 N--CA 1.454 -0.24 0 C-N-CA 124.436 1.094 . . . . 0.0 109.03 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo -70.77 146.22 53.37 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 123.666 2.91 . . . . 0.0 112.143 -177.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.86 -175.55 5.37 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.193 1.397 . . . . 0.0 109.205 179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -140.59 159.44 42.19 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.004 0.43 . . . . 0.0 111.759 -178.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.72 143.13 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 C-N-CA 123.903 0.881 . . . . 0.0 109.902 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.5 t30 . . . . . 0 N--CA 1.455 -0.218 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -179.868 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.0 m . . . . . 0 CA--C 1.53 0.189 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.51 0.06 5.99 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 124.229 3.286 . . . . 0.0 111.904 177.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 54.1 t -114.29 141.41 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 176.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.9 m -129.56 151.81 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.139 0 CA-C-O 121.332 0.587 . . . . 0.0 110.906 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.9 t-80 -98.72 136.21 39.1 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.201 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.3 mm -106.62 144.59 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.099 0.56 . . . . 0.0 109.752 -178.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -141.77 161.82 37.0 Favored 'General case' 0 C--N 1.338 0.074 0 C-N-CA 123.345 0.658 . . . . 0.0 110.584 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 77.3 24.93 64.69 Favored Glycine 0 CA--C 1.527 0.843 0 CA-C-O 119.642 -0.532 . . . . 0.0 113.086 174.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.6 mt -61.44 159.52 12.62 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 117.956 0.878 . . . . 0.0 110.638 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.1 pt -73.34 -41.52 57.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -173.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -173.94 -35.58 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 123.634 0.774 . . . . 0.0 109.97 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.45 49.65 0.06 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -176.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 14.5 p -52.83 148.49 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 122.897 0.479 . . . . 0.0 110.083 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -88.2 163.06 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 CA-C-O 121.324 0.583 . . . . 0.0 111.996 -171.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -62.24 -27.48 69.03 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.799 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.71 -3.07 49.41 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 123.087 0.555 . . . . 0.0 112.318 -178.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -104.29 -29.84 10.52 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.427 0.558 . . . . 0.0 109.711 177.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 49.8 mt -72.67 -38.97 67.46 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 122.546 0.339 . . . . 0.0 110.924 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.67 -30.23 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.442 -178.32 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -82.38 -16.01 50.68 Favored 'General case' 0 N--CA 1.453 -0.279 0 O-C-N 122.168 -0.332 . . . . 0.0 111.506 -178.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.44 -12.91 16.27 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 112.918 0.711 . . . . 0.0 112.918 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.9 mt -114.05 -7.62 13.08 Favored 'General case' 0 C--N 1.339 0.11 0 CA-C-N 118.516 0.598 . . . . 0.0 112.506 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.15 -6.07 31.56 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 118.731 0.696 . . . . 0.0 111.784 176.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -77.09 -13.62 59.93 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.801 0.44 . . . . 0.0 110.769 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -98.64 -18.16 18.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 122.531 0.332 . . . . 0.0 111.477 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.94 177.08 36.43 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -70.94 140.28 37.92 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 124.176 3.251 . . . . 0.0 110.3 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.405 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.1 mt -112.21 145.9 17.71 Favored 'Isoleucine or valine' 0 C--O 1.231 0.092 0 C-N-CA 122.746 0.419 . . . . 0.0 110.237 -177.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 t -105.88 -41.96 5.27 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.243 0.617 . . . . 0.0 111.395 -177.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -159.85 160.27 33.52 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-O 120.695 0.283 . . . . 0.0 111.035 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.8 t -145.24 147.01 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 123.906 0.882 . . . . 0.0 109.526 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.89 155.39 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.141 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 176.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 29.1 t -125.87 153.38 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.08 0 C-N-CA 122.503 0.321 . . . . 0.0 110.995 -177.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.5 mtm -135.56 77.13 53.35 Favored Pre-proline 0 CA--C 1.532 0.265 0 C-N-CA 124.237 1.015 . . . . 0.0 109.385 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -60.59 -16.68 44.33 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.972 3.115 . . . . 0.0 113.245 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -77.13 -6.56 53.34 Favored 'General case' 0 C--N 1.339 0.132 0 C-N-CA 123.009 0.524 . . . . 0.0 111.618 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -133.22 3.68 3.68 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.216 0.606 . . . . 0.0 111.386 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 13.4 tpp85 55.3 38.26 30.1 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.7 0.8 . . . . 0.0 111.152 -173.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 83.1 mt-30 -134.0 166.24 23.16 Favored 'General case' 0 N--CA 1.458 -0.05 0 C-N-CA 123.684 0.794 . . . . 0.0 110.608 -176.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.04 171.31 18.06 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 122.985 0.514 . . . . 0.0 109.871 176.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -132.18 146.01 51.74 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 123.407 0.683 . . . . 0.0 110.072 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 93.3 t -137.37 128.71 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 118.1 33.78 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.405 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.6 m-85 -85.85 154.87 21.24 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.348 -179.148 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -75.23 -12.24 60.24 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 120.704 0.287 . . . . 0.0 110.399 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -148.62 152.16 36.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 123.784 0.834 . . . . 0.0 109.14 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.49 -21.41 26.19 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 122.076 -0.39 . . . . 0.0 111.614 -175.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.6 tp -75.56 -28.87 59.17 Favored 'General case' 0 N--CA 1.452 -0.353 0 O-C-N 122.008 -0.433 . . . . 0.0 110.529 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.16 -30.92 71.71 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.37 -31.41 37.84 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.894 0.347 . . . . 0.0 110.301 178.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 44.2 t -70.81 -29.53 65.72 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 122.205 0.202 . . . . 0.0 110.983 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -78.07 -19.6 53.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 119.462 -0.304 . . . . 0.0 111.476 -179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.88 -32.06 23.4 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.108 0.413 . . . . 0.0 111.606 -176.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.5 t -86.76 -19.51 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -68.65 -14.1 62.79 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.102 -0.374 . . . . 0.0 110.99 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -104.4 -37.85 7.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.487 0.315 . . . . 0.0 111.256 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.65 -4.33 58.96 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -77.9 -9.15 58.93 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.228 0.467 . . . . 0.0 111.486 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -141.07 -1.86 1.34 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.681 0.392 . . . . 0.0 111.652 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.5 m-80 -144.41 175.7 9.92 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.131 0.572 . . . . 0.0 109.921 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . 0.411 ' CD ' ' H ' ' A' ' 156' ' ' GLN . 0.0 OUTLIER -98.48 155.86 17.05 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.714 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.95 135.59 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -89.38 155.94 19.01 Favored 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 122.045 -0.409 . . . . 0.0 111.085 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.9 mt -138.0 -42.51 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.786 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.84 32.2 2.99 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.236 0.614 . . . . 0.0 111.122 -177.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.07 4.84 81.32 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 -176.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -128.99 150.67 75.95 Favored Pre-proline 0 N--CA 1.455 -0.202 0 C-N-CA 123.83 0.852 . . . . 0.0 109.215 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -71.55 147.58 52.02 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.464 2.776 . . . . 0.0 111.702 -177.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -153.45 -174.6 5.01 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.072 1.349 . . . . 0.0 108.731 178.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -139.04 160.24 40.24 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-O 120.986 0.422 . . . . 0.0 111.345 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.7 p -147.23 140.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.575 0.75 . . . . 0.0 109.264 179.087 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 N--CA 1.454 -0.232 0 C-N-CA 122.91 0.484 . . . . 0.0 110.398 179.599 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 63.8 m . . . . . 0 CA--C 1.53 0.18 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -71.88 -3.76 13.81 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.831 3.021 . . . . 0.0 111.568 177.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 67.5 t -111.11 139.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.62 148.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 CA-C-O 121.319 0.58 . . . . 0.0 110.732 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -95.46 137.25 34.78 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.189 0.995 . . . . 0.0 110.35 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 26.0 mm -105.85 143.92 16.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 123.194 0.597 . . . . 0.0 109.787 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -142.56 160.53 40.11 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 123.132 0.573 . . . . 0.0 110.822 -178.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.81 26.09 56.86 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 119.457 -0.635 . . . . 0.0 113.523 173.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.9 mt -62.53 156.06 24.04 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.144 0.972 . . . . 0.0 109.814 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -70.57 -41.63 77.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -173.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -173.12 -34.78 0.01 OUTLIER 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.31 0.644 . . . . 0.0 110.676 -179.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.93 48.93 0.12 Allowed Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -176.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.7 t -51.56 143.21 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 C-N-CA 123.41 0.684 . . . . 0.0 109.697 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.8 m -95.72 164.98 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.119 0 CA-C-O 121.308 0.575 . . . . 0.0 111.637 -175.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -61.08 -26.02 67.36 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.538 0.735 . . . . 0.0 111.247 -178.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.45 -5.56 56.75 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 -177.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -98.11 -30.46 12.65 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.28 0.491 . . . . 0.0 109.922 177.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.2 mt -73.33 -38.8 65.65 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 122.556 0.342 . . . . 0.0 110.95 -178.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.6 p -77.27 -29.96 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.241 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.6 mm-40 -82.76 -15.14 52.92 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 119.445 -0.312 . . . . 0.0 111.643 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -108.31 -10.61 15.33 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -116.96 -9.61 11.1 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 118.501 0.591 . . . . 0.0 112.396 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -69.83 -7.34 39.13 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.7 0.682 . . . . 0.0 111.633 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -74.12 -18.47 60.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.508 0.323 . . . . 0.0 110.593 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -92.64 -19.07 22.25 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 122.369 0.268 . . . . 0.0 111.535 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.39 176.77 35.71 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 139.64 41.24 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.978 3.118 . . . . 0.0 110.93 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.9 mt -111.59 145.67 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.876 0.471 . . . . 0.0 110.226 -177.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.5 t -104.09 -41.28 5.88 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.193 0.597 . . . . 0.0 111.355 -177.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -161.42 161.18 30.16 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.563 0.22 . . . . 0.0 111.532 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 69.2 t -143.97 147.16 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 123.903 0.881 . . . . 0.0 109.625 179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -147.29 153.33 12.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 176.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 37.7 t -128.46 152.99 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.052 0 C-N-CA 122.42 0.288 . . . . 0.0 111.019 -174.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.6 mtm -134.28 79.17 56.1 Favored Pre-proline 0 CA--C 1.532 0.274 0 C-N-CA 124.21 1.004 . . . . 0.0 109.314 178.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.85 -21.54 57.81 Favored 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 123.598 2.866 . . . . 0.0 113.134 -177.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -83.48 1.89 39.5 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 122.939 0.495 . . . . 0.0 112.015 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -128.79 0.67 5.41 Favored 'General case' 0 C--N 1.338 0.086 0 C-N-CA 123.802 0.841 . . . . 0.0 111.158 176.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.5 tpp85 53.35 33.04 14.84 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.014 0.926 . . . . 0.0 111.116 -172.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -136.81 167.86 20.65 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.305 0.642 . . . . 0.0 110.825 -175.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.36 173.57 15.45 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.89 0.476 . . . . 0.0 110.175 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 40.4 mt -132.81 145.11 50.7 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 123.187 0.595 . . . . 0.0 109.837 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.2 t -135.44 131.33 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -114.83 117.74 31.58 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 60.8 m-85 -84.16 156.75 21.94 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.303 179.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -70.4 -18.41 63.03 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.284 -178.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -154.19 159.21 41.27 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 123.784 0.834 . . . . 0.0 109.579 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 27.2 m -65.42 -15.23 18.16 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.099 0 O-C-N 122.053 -0.405 . . . . 0.0 111.843 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 10.3 tt -67.61 -33.2 74.51 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.327 0.512 . . . . 0.0 110.384 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -76.14 -31.85 54.06 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.48 -32.46 32.49 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.372 0.586 . . . . 0.0 110.535 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.9 t -75.73 -8.08 55.95 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 123.101 0.56 . . . . 0.0 111.302 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -106.74 -16.31 14.52 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 122.409 0.283 . . . . 0.0 111.039 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -86.79 -34.93 19.41 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.063 -0.398 . . . . 0.0 111.33 -178.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.5 t -83.32 -15.78 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -71.37 -5.33 31.75 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 122.797 0.439 . . . . 0.0 111.265 179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -116.52 -37.68 3.67 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 122.899 0.48 . . . . 0.0 110.911 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.68 -5.73 59.01 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -176.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.4 -4.36 58.4 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 122.069 -0.394 . . . . 0.0 111.441 177.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -142.07 -6.5 0.96 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 122.773 0.429 . . . . 0.0 111.686 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -144.76 175.13 10.4 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 123.387 0.675 . . . . 0.0 109.5 -179.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . 0.441 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -95.98 152.43 18.52 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 172.733 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.84 135.32 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.12 149.67 23.07 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 121.954 -0.466 . . . . 0.0 110.758 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 56.4 mt -137.38 -39.67 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.939 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.42 29.48 3.94 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.151 0.58 . . . . 0.0 111.033 -176.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.09 4.54 84.15 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -132.09 152.84 80.91 Favored Pre-proline 0 C--O 1.233 0.224 0 C-N-CA 124.102 0.961 . . . . 0.0 109.269 177.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -71.47 144.47 45.3 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 123.583 2.855 . . . . 0.0 111.764 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.74 -175.85 5.19 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.983 1.313 . . . . 0.0 108.765 177.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -138.5 160.26 40.0 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-O 120.927 0.394 . . . . 0.0 111.628 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.1 p -147.84 143.48 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.13 0 C-N-CA 123.785 0.834 . . . . 0.0 109.693 178.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 . . . . . 0 N--CA 1.457 -0.119 0 C-N-CA 123.259 0.624 . . . . 0.0 110.066 179.092 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 60.8 p . . . . . 0 CA--C 1.532 0.278 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -72.76 4.25 3.74 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 124.159 3.239 . . . . 0.0 112.358 178.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.5 140.43 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 123.279 0.631 . . . . 0.0 109.454 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.0 m -128.16 145.37 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 CA-C-O 121.199 0.523 . . . . 0.0 110.831 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -96.9 134.4 40.28 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.241 1.016 . . . . 0.0 109.932 177.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -107.4 145.78 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.432 0.693 . . . . 0.0 109.408 -178.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.0 mtt180 -141.33 160.98 38.99 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.64 0.776 . . . . 0.0 109.892 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.84 28.49 50.54 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-O 119.545 -0.586 . . . . 0.0 113.438 175.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.9 mt -57.73 154.88 10.97 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 118.241 1.02 . . . . 0.0 109.877 177.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -68.19 -39.39 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.077 0 O-C-N 122.084 -0.385 . . . . 0.0 111.071 -176.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -171.62 -35.92 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.307 1.043 . . . . 0.0 109.742 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.48 55.92 0.04 OUTLIER Glycine 0 C--N 1.339 0.718 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -177.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.7 m -52.75 151.17 1.1 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-N 117.076 0.438 . . . . 0.0 110.511 178.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.7 m -87.46 166.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.953 0.406 . . . . 0.0 111.262 -177.004 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -61.99 -23.71 66.58 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.163 0.585 . . . . 0.0 111.242 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.31 -6.03 57.28 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -92.9 -35.14 13.5 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.565 0.62 . . . . 0.0 110.213 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 91.4 mt -73.25 -36.28 66.36 Favored 'General case' 0 N--CA 1.454 -0.274 0 O-C-N 122.385 -0.197 . . . . 0.0 111.266 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -76.97 -31.04 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.317 -177.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -82.14 -17.68 45.54 Favored 'General case' 0 N--CA 1.455 -0.219 0 O-C-N 122.185 -0.322 . . . . 0.0 111.167 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -9.13 18.31 Favored 'General case' 0 N--CA 1.455 -0.21 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.0 mt -120.82 -8.97 9.37 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -69.3 -7.19 34.79 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.866 0.757 . . . . 0.0 111.687 177.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -76.91 -14.99 59.81 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 122.025 -0.422 . . . . 0.0 110.731 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -96.08 -16.82 21.34 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.578 0.351 . . . . 0.0 111.592 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.4 176.55 34.6 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -70.59 140.75 40.24 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 123.889 3.06 . . . . 0.0 110.877 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 78.3 mt -110.81 146.63 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.083 0 C-N-CA 122.816 0.446 . . . . 0.0 110.487 -178.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -106.43 -42.5 5.0 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.009 0.524 . . . . 0.0 111.478 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -159.11 159.28 34.32 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 120.837 0.351 . . . . 0.0 111.231 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.6 t -143.78 146.57 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.086 0 C-N-CA 124.001 0.92 . . . . 0.0 109.841 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.97 153.45 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 42.8 t -131.69 149.63 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.069 0 CA-C-O 120.717 0.294 . . . . 0.0 110.595 -176.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 81.55 67.52 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -60.29 -17.67 48.11 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.811 3.008 . . . . 0.0 112.877 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -82.9 -4.28 57.97 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.802 0.441 . . . . 0.0 111.484 179.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -129.23 4.04 5.22 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.861 0.864 . . . . 0.0 111.194 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 3.3 tpt180 54.58 30.44 13.16 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 123.847 0.859 . . . . 0.0 112.058 -177.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -138.89 166.59 24.05 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 123.119 0.568 . . . . 0.0 110.813 -174.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.98 172.17 16.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.213 0.605 . . . . 0.0 110.487 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.5 mt -134.14 146.48 50.26 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.443 0.697 . . . . 0.0 109.794 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.91 132.7 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -115.81 122.29 44.97 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -87.89 156.03 19.57 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -178.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.3 -14.24 60.87 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.563 -178.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -149.49 153.47 37.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.68 0.792 . . . . 0.0 108.935 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.4 p -67.64 -20.92 26.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 O-C-N 122.175 -0.328 . . . . 0.0 111.717 -176.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.2 tp -74.52 -27.08 60.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 117.867 0.303 . . . . 0.0 110.997 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.91 -32.47 60.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.29 -29.39 34.31 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 117.018 0.409 . . . . 0.0 110.518 177.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -73.63 -19.28 60.9 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 122.681 0.392 . . . . 0.0 110.92 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -93.63 -17.27 23.46 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 122.191 -0.318 . . . . 0.0 111.03 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.33 -31.98 26.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 O-C-N 121.912 -0.492 . . . . 0.0 111.386 -178.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 37.0 t -85.75 -15.29 10.46 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 178.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -71.52 -7.67 49.06 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.784 0.434 . . . . 0.0 110.875 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 71.7 t80 -113.73 -36.93 4.71 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.621 0.369 . . . . 0.0 110.982 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.87 -7.17 59.68 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.44 -2.72 56.51 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 122.283 -0.261 . . . . 0.0 111.592 177.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -141.19 -7.88 1.02 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 122.73 0.412 . . . . 0.0 112.053 179.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -145.41 170.4 16.42 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.332 0.653 . . . . 0.0 109.982 -179.057 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -86.17 155.98 20.52 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -125.53 135.58 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -88.05 156.35 19.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 122.014 -0.429 . . . . 0.0 110.585 -178.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 62.9 mt -137.53 -43.79 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.536 -178.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.01 31.47 3.57 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.326 0.651 . . . . 0.0 111.185 -177.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.22 6.37 78.54 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.19 151.81 79.52 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.119 0.968 . . . . 0.0 109.142 177.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -71.86 143.61 41.6 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 123.558 2.839 . . . . 0.0 111.764 -176.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.76 -173.87 4.61 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 125.238 1.415 . . . . 0.0 108.395 177.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.01 160.12 40.53 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 121.042 0.448 . . . . 0.0 111.666 -178.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.6 p -149.74 144.98 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 C-N-CA 123.398 0.679 . . . . 0.0 110.064 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 . . . . . 0 N--CA 1.456 -0.148 0 C-N-CA 123.264 0.626 . . . . 0.0 110.148 179.5 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 65.5 m . . . . . 0 N--CA 1.455 -0.215 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -70.41 0.44 6.14 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 124.158 3.239 . . . . 0.0 111.773 176.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.1 t -112.4 139.9 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 123.6 0.76 . . . . 0.0 109.239 177.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.6 m -128.91 152.82 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 CA-C-O 121.08 0.467 . . . . 0.0 110.728 178.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -102.45 137.86 40.14 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.709 0.804 . . . . 0.0 110.112 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 18.8 mm -106.49 144.59 15.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 C-N-CA 123.527 0.731 . . . . 0.0 109.799 -178.228 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -143.14 160.95 39.46 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.07 0.548 . . . . 0.0 110.698 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.96 23.87 60.87 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-O 119.77 -0.461 . . . . 0.0 113.151 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 56.1 mt -60.34 157.55 13.48 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 117.952 0.876 . . . . 0.0 109.979 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 16.5 pt -72.34 -37.32 57.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 O-C-N 122.244 -0.285 . . . . 0.0 111.35 -176.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -172.92 -36.93 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 123.887 0.875 . . . . 0.0 109.7 -179.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 171.21 61.84 0.04 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -176.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.2 m -52.31 154.66 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 122.688 0.395 . . . . 0.0 110.608 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.467 HG13 ' H ' ' A' ' 111' ' ' ALA . 8.7 t -76.99 155.64 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 CA-C-O 120.936 0.398 . . . . 0.0 110.473 -175.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -59.4 -26.88 65.52 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.723 0.409 . . . . 0.0 110.239 174.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . 0.467 ' H ' HG13 ' A' ' 109' ' ' VAL . . . -81.79 -6.83 59.41 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.513 0.725 . . . . 0.0 111.886 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -90.08 -34.11 16.04 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 118.341 0.519 . . . . 0.0 109.999 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.0 mt -73.52 -34.97 65.49 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 122.573 0.349 . . . . 0.0 111.373 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.89 -30.59 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.135 0 CA-C-N 118.041 0.382 . . . . 0.0 110.428 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -82.84 -15.81 50.13 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 119.526 -0.273 . . . . 0.0 111.155 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -11.15 16.96 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -119.26 -9.18 9.99 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 118.6 0.636 . . . . 0.0 112.535 -178.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -69.82 -6.9 35.49 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.156 0.889 . . . . 0.0 111.874 177.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -76.5 -12.64 60.07 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 122.117 -0.365 . . . . 0.0 110.695 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -100.1 -19.97 16.23 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 122.678 0.391 . . . . 0.0 111.337 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 166.05 175.97 36.93 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.396 -0.681 . . . . 0.0 111.396 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -71.33 141.42 38.96 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 123.918 3.079 . . . . 0.0 110.505 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 76.2 mt -112.61 146.26 17.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 122.875 0.47 . . . . 0.0 110.226 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.0 t -103.58 -44.81 5.01 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.009 0.523 . . . . 0.0 111.216 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.2 t80 -158.84 162.08 36.95 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-O 120.852 0.358 . . . . 0.0 111.465 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 95.2 t -142.55 144.81 24.15 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 124.167 0.987 . . . . 0.0 109.673 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.42 153.02 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.097 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 175.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 41.3 t -130.6 148.21 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.1 0 CA-C-O 120.604 0.24 . . . . 0.0 110.986 -175.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 84.0 60.52 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.808 0.843 . . . . 0.0 109.087 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.22 -12.32 33.64 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 123.489 2.793 . . . . 0.0 111.725 -176.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.9 tptt -76.94 -12.15 59.91 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 122.869 0.468 . . . . 0.0 110.9 177.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -129.29 6.92 5.36 Favored 'General case' 0 C--N 1.34 0.163 0 C-N-CA 123.636 0.775 . . . . 0.0 111.904 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 53.9 33.93 18.33 Favored 'General case' 0 N--CA 1.463 0.183 0 C-N-CA 124.449 1.1 . . . . 0.0 112.197 -177.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -136.66 166.26 23.98 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.175 0.59 . . . . 0.0 110.637 -177.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.91 172.36 16.34 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.673 0.389 . . . . 0.0 110.49 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 37.2 mt -131.32 149.05 52.71 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 123.406 0.682 . . . . 0.0 110.166 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -140.11 133.32 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.199 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -114.21 120.71 41.39 Favored 'General case' 0 N--CA 1.452 -0.325 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 177.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -85.83 152.22 23.18 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.041 0.448 . . . . 0.0 110.018 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -71.34 -15.15 62.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.349 -178.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.12 152.45 39.3 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.744 0.818 . . . . 0.0 109.469 177.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.0 p -68.89 -21.45 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 O-C-N 122.18 -0.325 . . . . 0.0 111.751 -175.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.6 tp -75.25 -28.89 60.02 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.83 -0.544 . . . . 0.0 110.334 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.68 -29.62 71.17 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.69 -30.28 36.46 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 117.029 0.414 . . . . 0.0 110.5 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.14 -28.17 62.09 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 122.501 0.32 . . . . 0.0 110.67 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -79.21 -19.43 50.79 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 119.541 -0.266 . . . . 0.0 111.532 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -32.67 27.03 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 118.157 0.435 . . . . 0.0 111.467 -177.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 30.0 t -85.73 -17.51 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -69.44 -11.63 60.98 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.539 0.336 . . . . 0.0 111.08 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -112.0 -36.85 5.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.635 0.374 . . . . 0.0 111.0 178.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.03 -11.67 59.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -176.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.48 -0.26 56.55 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -135.44 -10.85 2.16 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 117.921 0.328 . . . . 0.0 111.503 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.6 t30 -153.97 164.09 39.01 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.601 0.76 . . . . 0.0 109.065 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.6 pm0 -81.32 154.7 26.38 Favored 'General case' 0 CA--C 1.529 0.139 0 O-C-N 121.8 -0.563 . . . . 0.0 109.783 174.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.06 135.57 61.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -87.75 153.83 21.04 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.077 -0.389 . . . . 0.0 110.708 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.4 mt -136.99 -43.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.662 0.385 . . . . 0.0 110.802 -177.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.14 30.64 3.92 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.103 0.561 . . . . 0.0 111.333 -176.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 88.27 4.25 77.75 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -131.44 152.49 80.59 Favored Pre-proline 0 C--O 1.233 0.219 0 C-N-CA 124.013 0.925 . . . . 0.0 109.318 177.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.72 146.18 48.0 Favored 'Trans proline' 0 N--CA 1.453 -0.884 0 C-N-CA 123.438 2.759 . . . . 0.0 111.573 -176.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.43 -175.75 5.41 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.952 1.301 . . . . 0.0 109.021 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -139.42 160.76 39.08 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 121.174 0.511 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 2.9 p -147.76 141.18 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 123.962 0.905 . . . . 0.0 109.532 177.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.4 t30 . . . . . 0 CA--C 1.531 0.217 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.31 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 66.2 m . . . . . 0 CA--C 1.532 0.263 0 N-CA-C 111.509 0.189 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -69.53 1.36 4.35 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 124.138 3.225 . . . . 0.0 112.374 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.8 t -116.53 141.28 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.6 m -129.81 151.85 36.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-O 120.92 0.391 . . . . 0.0 110.958 178.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.4 t-80 -100.93 135.05 42.99 Favored 'General case' 0 N--CA 1.457 -0.086 0 C-N-CA 124.068 0.947 . . . . 0.0 109.974 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -109.93 145.18 16.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 -177.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -141.67 163.7 32.21 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 123.602 0.761 . . . . 0.0 110.481 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 25.56 56.15 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-O 119.452 -0.638 . . . . 0.0 113.611 172.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.8 mt -61.68 158.15 16.11 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.185 0.992 . . . . 0.0 110.186 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 12.4 pt -73.1 -39.94 57.74 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -173.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -172.78 -37.44 0.01 OUTLIER 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.243 0.617 . . . . 0.0 110.246 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.22 52.25 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -176.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 65.1 t -51.11 146.04 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.158 0.583 . . . . 0.0 110.082 178.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.4 m -95.74 163.69 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 CA-C-O 121.18 0.514 . . . . 0.0 111.47 -175.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -60.47 -28.02 68.01 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 123.27 0.628 . . . . 0.0 111.215 -178.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.79 -6.44 55.96 Favored 'General case' 0 CA--C 1.53 0.187 0 N-CA-C 112.294 0.479 . . . . 0.0 112.294 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -101.47 -31.03 11.09 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 176.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 76.5 mt -71.36 -41.21 70.01 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.515 0.326 . . . . 0.0 110.654 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.5 p -77.56 -29.63 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 121.278 -0.169 . . . . 0.0 110.915 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.2 mt-10 -85.87 -13.35 48.2 Favored 'General case' 0 N--CA 1.454 -0.225 0 O-C-N 122.006 -0.434 . . . . 0.0 111.365 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.21 -15.15 16.09 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.94 -7.21 13.17 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.522 0.601 . . . . 0.0 112.457 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -72.46 -5.55 37.51 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.662 0.665 . . . . 0.0 111.537 176.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -74.96 -16.13 60.65 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.493 0.317 . . . . 0.0 110.544 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.83 -17.21 21.32 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 122.537 0.335 . . . . 0.0 111.824 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.88 178.0 37.11 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.16 140.31 37.22 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 123.86 3.04 . . . . 0.0 110.821 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.5 mt -112.42 144.4 20.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 C-N-CA 122.993 0.517 . . . . 0.0 110.519 -178.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -102.77 -42.25 5.93 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.362 0.665 . . . . 0.0 111.05 -178.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -158.57 160.09 36.22 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.712 0.291 . . . . 0.0 111.275 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 84.9 t -143.97 147.6 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.053 0 C-N-CA 123.761 0.824 . . . . 0.0 109.841 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.3 p -148.0 154.57 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 176.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 9.5 p -136.93 151.45 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.07 0 CA-C-O 120.824 0.345 . . . . 0.0 110.948 -178.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -130.26 84.44 59.87 Favored Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.855 0.862 . . . . 0.0 109.004 179.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -59.54 -18.54 47.57 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.897 3.064 . . . . 0.0 112.779 -179.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -82.02 -5.8 58.65 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.08 0.552 . . . . 0.0 111.316 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -129.05 2.58 5.26 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.722 0.809 . . . . 0.0 111.461 178.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.4 tpp85 53.37 32.5 13.9 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.496 1.118 . . . . 0.0 112.0 -177.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -136.43 166.4 23.58 Favored 'General case' 0 CA--C 1.527 0.094 0 C-N-CA 123.144 0.578 . . . . 0.0 110.941 -176.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 171.4 17.3 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.88 0.472 . . . . 0.0 110.819 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.32 146.71 50.23 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 123.769 0.828 . . . . 0.0 109.797 178.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.8 t -136.64 131.96 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.231 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -112.23 116.11 29.9 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -84.54 152.6 23.8 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.835 0.35 . . . . 0.0 110.481 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -73.08 -14.5 61.41 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.409 -178.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -147.2 151.34 36.57 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.696 0.798 . . . . 0.0 109.103 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.2 p -67.39 -19.85 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 O-C-N 122.29 -0.256 . . . . 0.0 111.484 -175.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.9 tp -75.08 -27.24 59.85 Favored 'General case' 0 N--CA 1.454 -0.236 0 O-C-N 121.986 -0.446 . . . . 0.0 110.498 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.91 -31.2 69.85 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.36 -29.99 33.89 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 116.956 0.378 . . . . 0.0 110.395 177.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.46 -26.48 63.66 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 122.716 0.406 . . . . 0.0 110.825 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -84.05 -20.3 32.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.192 -0.318 . . . . 0.0 111.646 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.47 -29.1 26.31 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 118.125 0.42 . . . . 0.0 112.075 -175.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -89.63 -15.49 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -75.0 0.12 16.95 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.768 0.427 . . . . 0.0 111.038 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -120.17 -38.73 2.88 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.842 0.457 . . . . 0.0 110.852 177.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.29 -4.66 58.99 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.68 -4.13 58.34 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 122.103 -0.373 . . . . 0.0 111.506 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -141.66 -4.17 1.11 Allowed 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 122.609 0.364 . . . . 0.0 111.59 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -146.29 170.57 16.49 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.534 0.734 . . . . 0.0 109.972 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -90.84 153.16 20.42 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 172.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.48 135.18 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -88.55 150.61 23.0 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 122.01 -0.431 . . . . 0.0 110.749 -178.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.1 mt -136.97 -39.1 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.789 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.18 29.28 3.71 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 123.085 0.554 . . . . 0.0 110.937 -177.051 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.48 5.02 85.29 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -176.434 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -130.41 152.28 80.01 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 124.266 1.026 . . . . 0.0 109.144 177.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.52 144.21 44.45 Favored 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.076 2.518 . . . . 0.0 111.825 -176.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.96 -176.11 5.31 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 124.826 1.25 . . . . 0.0 109.024 177.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -139.46 161.13 38.24 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.949 0.404 . . . . 0.0 111.67 -178.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.6 p -150.04 143.27 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.411 0.684 . . . . 0.0 109.724 178.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 . . . . . 0 N--CA 1.456 -0.161 0 C-N-CA 123.055 0.542 . . . . 0.0 109.989 179.983 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.412 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.4 p . . . . . 0 N--CA 1.456 -0.164 0 N-CA-C 111.729 0.27 . . . . 0.0 111.729 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.412 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 96.4 Cg_endo -71.26 3.05 3.77 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.903 3.069 . . . . 0.0 112.504 177.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.7 t -115.02 141.39 31.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.116 0 C-N-CA 122.989 0.515 . . . . 0.0 109.877 178.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 20.9 m -126.69 152.57 34.59 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -107.7 141.01 39.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 124.079 0.952 . . . . 0.0 109.61 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 23.6 mm -111.23 143.82 20.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 122.883 0.473 . . . . 0.0 110.116 -175.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 -142.38 159.26 42.59 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 123.092 0.557 . . . . 0.0 110.176 -177.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.03 24.87 58.91 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.358 -0.69 . . . . 0.0 113.198 174.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.6 mt -60.52 157.87 13.36 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 118.234 1.017 . . . . 0.0 110.163 177.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.2 pt -70.88 -43.35 76.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -173.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -172.4 -34.5 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.375 0.67 . . . . 0.0 110.749 -179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.9 49.07 0.11 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.704 -0.559 . . . . 0.0 111.704 -175.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.1 t -51.09 146.54 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 123.387 0.675 . . . . 0.0 110.026 178.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.2 m -101.33 166.41 2.42 Favored 'Isoleucine or valine' 0 C--N 1.337 0.045 0 CA-C-O 121.211 0.529 . . . . 0.0 111.584 -175.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.39 -27.48 67.47 Favored 'General case' 0 N--CA 1.456 -0.131 0 C-N-CA 123.196 0.598 . . . . 0.0 111.152 -177.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.46 -5.03 51.35 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -104.59 -30.86 9.72 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 175.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.6 mt -70.12 -38.41 75.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 122.506 0.322 . . . . 0.0 110.595 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -80.13 -29.63 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 CA-C-N 117.537 0.153 . . . . 0.0 110.731 -178.329 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.0 mm-40 -81.4 -13.91 57.75 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.28 -0.263 . . . . 0.0 111.321 -178.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -99.89 -25.97 14.16 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.2 mp -100.73 -9.76 21.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.921 0.711 . . . . 0.0 112.921 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -67.15 -8.63 32.55 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 118.604 0.638 . . . . 0.0 111.647 177.16 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.96 -14.62 59.1 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.663 0.385 . . . . 0.0 110.827 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -101.08 -18.31 16.29 Favored 'General case' 0 C--O 1.231 0.117 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -178.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.91 177.51 37.52 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -72.73 140.21 31.98 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 C-N-CA 124.268 3.312 . . . . 0.0 110.717 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 73.6 mt -110.07 146.69 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 C-N-CA 122.778 0.431 . . . . 0.0 110.3 -177.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -107.46 -40.16 5.43 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.158 0.583 . . . . 0.0 111.367 -177.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -159.52 158.44 31.83 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-O 120.739 0.304 . . . . 0.0 110.94 179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 93.1 t -144.15 145.42 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.038 0 C-N-CA 123.924 0.89 . . . . 0.0 109.858 -178.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.3 p -148.31 152.74 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 12.4 p -130.22 156.58 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 CA-C-O 120.805 0.336 . . . . 0.0 111.156 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 48.6 mtt -130.45 78.14 74.73 Favored Pre-proline 0 C--O 1.232 0.168 0 C-N-CA 124.046 0.938 . . . . 0.0 109.54 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.62 -17.74 43.73 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 123.584 2.856 . . . . 0.0 113.048 -177.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.5 mtpt -89.52 -2.15 58.26 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.926 0.49 . . . . 0.0 111.807 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -130.84 0.39 4.3 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.652 0.781 . . . . 0.0 111.548 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 55.14 33.98 21.63 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.019 0.928 . . . . 0.0 111.861 -176.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -134.7 168.21 19.43 Favored 'General case' 0 C--O 1.232 0.14 0 C-N-CA 123.479 0.712 . . . . 0.0 110.602 -177.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.74 172.24 18.27 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.39 176.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.34 144.31 48.19 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.716 0.806 . . . . 0.0 109.468 177.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 77.9 t -137.0 131.29 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -113.44 120.26 40.44 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -83.93 153.87 23.69 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.872 0.368 . . . . 0.0 110.361 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -74.54 -12.58 60.51 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-O 120.907 0.384 . . . . 0.0 110.25 -178.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -149.54 152.48 35.62 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.843 0.857 . . . . 0.0 109.022 176.136 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.2 p -68.13 -20.43 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 O-C-N 122.031 -0.418 . . . . 0.0 111.657 -175.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.3 tp -71.96 -26.27 62.2 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.924 -0.485 . . . . 0.0 110.561 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.95 -31.47 64.45 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 178.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -84.42 -27.95 27.23 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 117.293 0.546 . . . . 0.0 110.555 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.1 t -77.89 -7.17 56.35 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 122.802 0.441 . . . . 0.0 110.602 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -107.14 -21.71 12.88 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.976 0.511 . . . . 0.0 110.754 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.42 -28.01 31.61 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 -178.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -91.01 -18.98 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -71.34 -14.24 62.13 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.36 0.264 . . . . 0.0 110.763 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -99.92 -36.79 9.28 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.568 0.347 . . . . 0.0 111.001 178.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -85.44 -6.43 59.21 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.832 0.678 . . . . 0.0 112.832 -176.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -78.64 -5.0 51.8 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 122.139 -0.351 . . . . 0.0 111.839 176.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -143.52 -3.59 0.91 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.58 0.352 . . . . 0.0 111.901 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 -145.42 175.09 10.58 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.455 0.702 . . . . 0.0 109.948 -178.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . 0.429 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.1 pm0 -96.94 152.68 18.47 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 173.162 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.17 134.44 63.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -89.55 148.91 23.11 Favored 'General case' 0 C--N 1.332 -0.17 0 O-C-N 122.193 -0.317 . . . . 0.0 110.71 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -136.01 -38.75 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.219 -176.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.37 29.45 3.63 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.112 0.565 . . . . 0.0 110.89 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.67 3.36 83.79 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -176.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -130.08 152.84 80.73 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 123.902 0.881 . . . . 0.0 108.968 177.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -72.11 145.97 45.45 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.306 2.671 . . . . 0.0 111.681 -176.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.48 -176.84 5.64 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.014 1.325 . . . . 0.0 108.475 177.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -137.84 160.02 40.43 Favored 'General case' 0 C--O 1.232 0.14 0 CA-C-O 120.885 0.374 . . . . 0.0 111.466 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.66 139.61 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 123.514 0.726 . . . . 0.0 110.174 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 . . . . . 0 CA--C 1.53 0.198 0 C-N-CA 123.445 0.698 . . . . 0.0 109.592 178.45 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.1 m . . . . . 0 CA--C 1.53 0.196 0 N-CA-C 112.368 0.507 . . . . 0.0 112.368 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.05 -0.98 9.84 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 124.024 3.149 . . . . 0.0 111.769 174.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.5 t -112.0 142.49 24.21 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 123.431 0.692 . . . . 0.0 109.461 178.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 21.3 m -128.29 152.41 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 C-N-CA 122.835 0.454 . . . . 0.0 110.171 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 -106.15 136.41 45.89 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.971 0.909 . . . . 0.0 109.359 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.7 mm -106.07 142.4 19.14 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 C-N-CA 122.859 0.464 . . . . 0.0 109.859 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -141.67 160.44 40.17 Favored 'General case' 0 C--O 1.231 0.1 0 C-N-CA 123.231 0.612 . . . . 0.0 110.334 -178.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.16 23.11 61.82 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.13 174.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 63.8 mt -60.02 158.45 10.97 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 118.151 0.975 . . . . 0.0 109.708 177.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 13.7 pt -73.37 -43.6 56.02 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.035 0 O-C-N 122.275 -0.266 . . . . 0.0 111.686 -174.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.72 -34.83 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.14 0.576 . . . . 0.0 110.371 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -173.82 48.46 0.15 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -176.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.2 t -49.48 141.34 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 C-N-CA 122.835 0.454 . . . . 0.0 109.809 177.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.4 m -92.21 163.44 2.25 Favored 'Isoleucine or valine' 0 C--O 1.23 0.04 0 CA-C-O 121.157 0.504 . . . . 0.0 111.624 -174.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -61.83 -26.31 68.04 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.224 -177.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.23 -6.39 57.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.661 0.384 . . . . 0.0 112.0 -178.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.8 -29.71 13.59 Favored 'General case' 0 CA--C 1.527 0.063 0 O-C-N 121.743 -0.598 . . . . 0.0 109.822 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.0 mt -74.01 -37.51 64.36 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.284 0.234 . . . . 0.0 110.92 -178.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.7 p -77.99 -29.96 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.323 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -85.55 -13.07 50.03 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 122.023 -0.423 . . . . 0.0 111.709 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -109.2 -9.18 15.03 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.8 mt -118.51 -7.4 10.63 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.815 0.734 . . . . 0.0 112.265 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.0 pt20 -74.0 -5.35 40.86 Favored 'General case' 0 C--N 1.34 0.157 0 CA-C-N 118.794 0.725 . . . . 0.0 110.342 175.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -77.6 -4.48 46.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.587 0.755 . . . . 0.0 111.095 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -111.53 -15.91 13.4 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.318 0.647 . . . . 0.0 111.272 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.84 176.73 36.02 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -72.14 140.19 33.83 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.0 3.133 . . . . 0.0 110.571 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.422 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.2 mt -109.86 148.92 13.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 122.844 0.457 . . . . 0.0 110.457 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.3 t -111.05 -41.26 4.25 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.251 0.62 . . . . 0.0 111.784 -177.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -158.1 158.09 34.05 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 117.839 0.291 . . . . 0.0 111.462 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 67.1 t -144.05 146.91 20.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.085 0.954 . . . . 0.0 109.699 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -148.95 151.42 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.9 t -128.07 149.5 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.073 0 CA-C-O 120.612 0.244 . . . . 0.0 111.32 -175.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.5 mpp? -130.44 83.07 63.54 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.982 0.913 . . . . 0.0 108.564 177.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -69.41 -11.7 31.89 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 123.482 2.788 . . . . 0.0 111.577 -175.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -81.58 -10.5 59.43 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 122.95 0.5 . . . . 0.0 110.81 177.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -126.35 6.47 7.01 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.576 0.75 . . . . 0.0 111.646 -178.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 55.19 31.0 15.56 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 123.982 0.913 . . . . 0.0 112.432 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -136.79 167.34 21.63 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.149 0.58 . . . . 0.0 111.103 -175.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.05 172.84 16.25 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.978 0.511 . . . . 0.0 110.319 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.0 mt -133.03 146.55 51.83 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 123.308 0.643 . . . . 0.0 110.054 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.82 133.15 41.23 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -117.08 121.88 42.56 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.422 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.7 m-85 -87.08 156.28 19.8 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 121.067 0.461 . . . . 0.0 110.555 -178.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -76.3 -13.57 60.15 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.14 -179.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -146.74 150.91 36.29 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.575 0.75 . . . . 0.0 109.319 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.7 p -69.33 -21.8 25.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.6 tp -75.91 -29.77 58.53 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.85 -0.531 . . . . 0.0 110.203 -179.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.83 -28.22 73.25 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 -25.77 33.48 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 117.05 0.425 . . . . 0.0 110.962 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.55 -34.09 41.31 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -68.69 -21.28 64.43 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 119.712 -0.185 . . . . 0.0 110.87 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.39 -27.62 27.51 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -178.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.3 t -92.58 -23.03 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.06 0 O-C-N 122.154 -0.342 . . . . 0.0 110.888 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -71.62 -7.77 49.91 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.105 -0.372 . . . . 0.0 111.472 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -106.29 -34.43 7.47 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.677 0.391 . . . . 0.0 110.477 176.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -10.39 59.07 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.91 -0.56 56.74 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -136.87 -11.4 1.76 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 122.677 0.391 . . . . 0.0 111.71 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -153.25 170.34 20.83 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -87.6 155.13 20.1 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 175.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.3 135.56 60.18 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -177.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -90.36 150.54 21.84 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 121.952 -0.467 . . . . 0.0 110.772 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.2 mt -137.43 -39.02 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.457 -0.076 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.869 -176.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.57 28.84 3.61 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 123.139 0.576 . . . . 0.0 110.908 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.9 5.64 83.43 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -176.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -131.21 153.14 81.61 Favored Pre-proline 0 N--CA 1.453 -0.275 0 C-N-CA 124.175 0.99 . . . . 0.0 109.152 177.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -72.26 145.9 44.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 123.251 2.634 . . . . 0.0 111.701 -176.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.11 -177.25 6.05 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 124.778 1.231 . . . . 0.0 108.839 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -139.64 160.39 39.97 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 120.976 0.417 . . . . 0.0 111.357 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -148.59 139.51 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 C-N-CA 123.339 0.655 . . . . 0.0 110.213 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.455 -0.21 0 C-N-CA 123.227 0.611 . . . . 0.0 109.858 178.836 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.2 m . . . . . 0 CA--C 1.531 0.244 0 N-CA-C 112.577 0.584 . . . . 0.0 112.577 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -65.4 -7.43 15.92 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.983 3.122 . . . . 0.0 113.382 177.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -109.85 141.43 25.17 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 123.032 0.533 . . . . 0.0 109.993 -178.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 28.0 m -125.61 156.29 35.12 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.242 0.617 . . . . 0.0 110.091 176.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -116.41 131.61 56.9 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.875 0.87 . . . . 0.0 109.421 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 mp -106.17 144.82 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -174.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -141.93 163.08 33.85 Favored 'General case' 0 N--CA 1.46 0.063 0 C-N-CA 123.557 0.743 . . . . 0.0 110.392 -177.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.32 23.27 61.19 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.213 -0.771 . . . . 0.0 113.017 174.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 70.9 mt -59.86 156.27 14.66 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.436 1.118 . . . . 0.0 110.141 178.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.6 pt -70.83 -41.23 77.32 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -172.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -173.92 -34.39 0.01 OUTLIER 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.413 0.685 . . . . 0.0 110.648 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.91 48.09 0.12 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.8 t -51.39 143.14 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 177.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -97.78 165.51 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.064 0 CA-C-O 121.35 0.595 . . . . 0.0 111.886 -174.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.16 -26.24 66.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.537 0.735 . . . . 0.0 111.334 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.88 -6.88 58.25 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -97.7 -28.98 13.65 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 118.181 0.446 . . . . 0.0 110.16 177.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 89.4 mt -74.35 -36.09 63.61 Favored 'General case' 0 N--CA 1.455 -0.191 0 O-C-N 122.255 -0.278 . . . . 0.0 110.979 -178.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.9 p -79.1 -30.28 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.189 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -82.59 -15.39 52.39 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 119.423 -0.322 . . . . 0.0 111.474 -178.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.87 -12.53 15.17 Favored 'General case' 0 C--N 1.339 0.132 0 N-CA-C 113.11 0.781 . . . . 0.0 113.11 -179.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.4 mt -116.46 -9.32 11.47 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -69.19 -6.88 31.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 118.809 0.731 . . . . 0.0 111.424 176.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -76.68 -15.13 59.88 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.089 -0.382 . . . . 0.0 110.649 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -97.24 -17.77 19.63 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 122.558 0.343 . . . . 0.0 111.454 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.68 177.05 36.21 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -70.54 139.91 38.59 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.077 3.185 . . . . 0.0 110.768 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 77.7 mt -110.33 146.31 15.71 Favored 'Isoleucine or valine' 0 C--O 1.232 0.133 0 C-N-CA 122.765 0.426 . . . . 0.0 110.205 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -107.73 -40.2 5.36 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.383 0.673 . . . . 0.0 111.348 -177.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -157.73 158.83 36.08 Favored 'General case' 0 C--N 1.338 0.096 0 CA-C-O 120.559 0.219 . . . . 0.0 111.342 -179.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 59.0 t -144.05 145.27 22.0 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 C-N-CA 124.175 0.99 . . . . 0.0 109.549 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.8 p -149.34 152.46 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 34.2 t -130.41 150.8 35.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 CA-C-O 120.675 0.274 . . . . 0.0 111.251 -175.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.4 81.36 68.3 Favored Pre-proline 0 CA--C 1.531 0.238 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 177.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -59.97 -17.88 46.98 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.945 3.097 . . . . 0.0 112.862 -177.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 mtmt -83.48 -5.82 59.27 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.876 0.47 . . . . 0.0 111.326 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -126.55 2.71 6.88 Favored 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.733 0.813 . . . . 0.0 111.112 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.3 tpp85 54.14 32.73 16.41 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 124.035 0.934 . . . . 0.0 111.865 -176.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -137.18 165.3 26.43 Favored 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 123.119 0.567 . . . . 0.0 110.956 -176.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 169.92 20.55 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 122.953 0.501 . . . . 0.0 110.569 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.8 mt -131.65 145.6 51.75 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.509 0.724 . . . . 0.0 109.824 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.74 134.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -116.16 121.8 43.17 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -86.39 155.85 20.42 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.027 0.442 . . . . 0.0 110.576 -179.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -74.86 -13.14 60.52 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.558 -178.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -147.73 152.87 38.5 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.883 0.873 . . . . 0.0 109.038 177.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.97 -21.61 25.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -175.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.8 tp -74.79 -29.85 61.24 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 122.108 -0.37 . . . . 0.0 110.692 -179.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.25 -28.58 71.25 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 179.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.17 -30.37 27.86 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 117.079 0.439 . . . . 0.0 110.898 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.8 t -75.21 -28.73 60.08 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.1 t30 -78.33 -21.21 49.91 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.321 0.248 . . . . 0.0 110.722 179.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.22 -31.25 30.38 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.301 -0.249 . . . . 0.0 111.505 -178.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 60.1 t -88.36 -21.97 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 O-C-N 122.252 -0.28 . . . . 0.0 110.556 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -66.9 -17.05 64.71 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 122.194 -0.316 . . . . 0.0 110.96 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -100.05 -36.54 9.32 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.189 0.196 . . . . 0.0 110.645 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.59 -11.04 59.95 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -176.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -89.29 1.42 55.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.578 0.351 . . . . 0.0 111.847 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -134.44 -15.64 2.15 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.76 0.424 . . . . 0.0 111.588 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -153.26 168.2 26.81 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.494 0.718 . . . . 0.0 109.186 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -82.78 155.54 24.17 Favored 'General case' 0 N--CA 1.457 -0.092 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 175.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -121.61 135.48 61.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -177.46 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -89.67 151.83 21.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.102 -0.374 . . . . 0.0 110.789 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -138.14 -39.06 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.894 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.69 29.41 3.53 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 122.876 0.47 . . . . 0.0 111.041 -176.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.87 4.86 84.42 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -176.254 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -131.59 152.08 79.8 Favored Pre-proline 0 N--CA 1.454 -0.231 0 C-N-CA 124.115 0.966 . . . . 0.0 108.95 177.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -71.54 146.55 49.84 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 123.58 2.854 . . . . 0.0 111.88 -176.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.8 -175.72 5.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.651 1.18 . . . . 0.0 108.811 178.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -138.82 159.44 42.12 Favored 'General case' 0 N--CA 1.457 -0.099 0 CA-C-O 120.644 0.259 . . . . 0.0 111.005 -179.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.9 p -149.26 139.11 16.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 C-N-CA 123.341 0.657 . . . . 0.0 110.247 178.736 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.1 t30 . . . . . 0 N--CA 1.456 -0.157 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.7 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.416 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.3 p . . . . . 0 CA--C 1.531 0.249 0 N-CA-C 111.586 0.217 . . . . 0.0 111.586 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.416 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 90.1 Cg_endo -70.49 5.7 1.87 Allowed 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 123.865 3.043 . . . . 0.0 112.119 177.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.3 t -117.85 139.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 C-N-CA 123.153 0.581 . . . . 0.0 109.864 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.2 m -131.37 146.83 33.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-O 120.911 0.386 . . . . 0.0 110.807 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.1 t-80 -96.58 137.41 35.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.845 0.858 . . . . 0.0 110.165 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.0 mp -111.77 145.82 17.45 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 123.552 0.741 . . . . 0.0 109.392 -177.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -142.56 164.94 28.75 Favored 'General case' 0 C--O 1.228 -0.04 0 C-N-CA 123.655 0.782 . . . . 0.0 110.724 -177.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.44 25.26 57.29 Favored Glycine 0 CA--C 1.525 0.711 0 CA-C-O 119.575 -0.569 . . . . 0.0 113.343 173.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.7 mt -60.33 156.5 15.61 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.987 0.894 . . . . 0.0 109.983 178.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.7 pt -71.84 -39.93 68.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 O-C-N 122.268 -0.27 . . . . 0.0 111.088 -175.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -172.92 -36.0 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.08 0 C-N-CA 123.612 0.765 . . . . 0.0 109.985 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 173.92 56.5 0.05 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -177.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.4 m -53.21 156.62 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 123.003 0.521 . . . . 0.0 110.782 178.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.446 HG13 ' H ' ' A' ' 111' ' ' ALA . 6.5 t -78.03 155.51 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 CA-C-O 121.032 0.444 . . . . 0.0 110.39 -176.341 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -60.76 -25.81 66.77 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.638 0.375 . . . . 0.0 110.265 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . 0.446 ' H ' HG13 ' A' ' 109' ' ' VAL . . . -81.32 -8.27 59.71 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.079 0.551 . . . . 0.0 111.62 -179.15 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -85.7 -32.79 21.74 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.828 -0.545 . . . . 0.0 110.238 -179.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.1 mp -77.49 -30.94 53.28 Favored 'General case' 0 N--CA 1.456 -0.142 0 O-C-N 122.323 -0.236 . . . . 0.0 111.18 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.8 p -78.25 -31.76 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-N 118.18 0.445 . . . . 0.0 110.04 -178.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -82.23 -17.57 45.61 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 122.217 -0.302 . . . . 0.0 111.082 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.47 -10.34 18.62 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -117.6 -8.55 10.92 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.606 0.639 . . . . 0.0 112.21 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -67.54 -6.88 21.95 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 118.663 0.665 . . . . 0.0 111.874 175.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -76.59 -13.05 60.1 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.956 -0.465 . . . . 0.0 110.634 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -100.82 -16.9 17.13 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 122.567 0.347 . . . . 0.0 111.606 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.15 177.64 36.27 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -72.25 140.44 33.94 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.81 3.007 . . . . 0.0 110.52 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.2 mt -111.13 147.31 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.085 0 C-N-CA 122.75 0.42 . . . . 0.0 110.246 -177.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.8 t -107.63 -41.56 5.0 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.076 0.551 . . . . 0.0 111.656 -177.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 46.1 t80 -159.65 160.51 34.33 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 117.623 0.192 . . . . 0.0 111.258 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 88.9 t -143.65 146.51 21.04 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 C-N-CA 124.122 0.969 . . . . 0.0 109.829 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.8 p -144.19 151.4 16.12 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 174.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 60.4 t -133.36 149.73 31.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -176.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 72.1 mtm -134.41 86.66 34.69 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 123.612 0.765 . . . . 0.0 109.284 -179.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.35 -11.55 30.26 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 123.061 2.507 . . . . 0.0 111.649 -177.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -81.11 -10.34 59.67 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.062 0.545 . . . . 0.0 110.7 176.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -128.88 3.18 5.36 Favored 'General case' 0 C--N 1.34 0.155 0 C-N-CA 123.73 0.812 . . . . 0.0 111.353 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.7 tpp85 53.05 34.05 16.29 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.335 1.054 . . . . 0.0 111.964 -176.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -137.84 168.55 19.47 Favored 'General case' 0 C--N 1.334 -0.08 0 C-N-CA 123.402 0.681 . . . . 0.0 110.282 -177.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.98 170.86 19.37 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 123.139 0.576 . . . . 0.0 110.262 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 14.1 tp -137.54 142.87 41.38 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 92.0 t -137.8 141.55 38.56 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -176.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -120.79 124.76 45.86 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.43 0.692 . . . . 0.0 109.219 177.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -89.16 153.23 21.12 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 120.919 0.39 . . . . 0.0 110.303 178.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -73.32 -14.39 61.29 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.409 -177.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -146.75 151.25 36.86 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 176.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -67.49 -20.65 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.302 0.241 . . . . 0.0 111.558 -175.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.4 tp -75.92 -25.79 56.32 Favored 'General case' 0 N--CA 1.456 -0.165 0 O-C-N 122.09 -0.381 . . . . 0.0 110.485 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.14 -30.31 65.41 Favored Glycine 0 C--N 1.339 0.722 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.69 -31.55 28.53 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.025 0.412 . . . . 0.0 110.34 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 47.5 t -73.75 -19.67 60.72 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 122.705 0.402 . . . . 0.0 110.974 179.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 122.694 0.398 . . . . 0.0 111.315 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.36 -31.52 22.92 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 122.169 -0.332 . . . . 0.0 111.386 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.4 t -85.06 -13.53 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -72.52 -1.95 17.87 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.295 0.638 . . . . 0.0 111.212 178.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 53.1 t80 -124.02 -36.75 2.66 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.827 0.451 . . . . 0.0 110.914 178.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.59 -8.7 59.35 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -176.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.41 -0.89 57.45 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.721 0.408 . . . . 0.0 111.986 178.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -138.73 -12.56 1.3 Allowed 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -151.88 163.21 39.71 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 9.3 pm0 -76.59 159.71 30.06 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 122.06 -0.4 . . . . 0.0 110.027 177.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -126.74 136.17 61.59 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -89.2 152.73 21.43 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.092 -0.38 . . . . 0.0 110.654 -178.161 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 47.2 mt -137.67 -39.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.177 -177.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.22 28.94 3.72 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 122.819 0.448 . . . . 0.0 110.986 -177.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.1 5.61 80.11 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 -176.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -131.35 152.98 81.49 Favored Pre-proline 0 N--CA 1.453 -0.319 0 C-N-CA 124.228 1.011 . . . . 0.0 109.01 177.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -71.44 145.34 47.52 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.357 2.705 . . . . 0.0 111.751 -176.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.38 -174.93 4.98 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.945 1.298 . . . . 0.0 108.668 177.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.35 160.42 39.87 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 120.989 0.423 . . . . 0.0 111.28 -178.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.13 144.66 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 C-N-CA 123.66 0.784 . . . . 0.0 109.415 178.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 . . . . . 0 N--CA 1.455 -0.186 0 C-N-CA 123.163 0.585 . . . . 0.0 110.047 -179.342 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.407 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.3 p . . . . . 0 CA--C 1.533 0.292 0 N-CA-C 111.627 0.232 . . . . 0.0 111.627 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 81.8 Cg_endo -70.18 4.53 2.31 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 124.295 3.33 . . . . 0.0 112.373 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.8 t -117.95 142.63 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 178.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -131.55 151.59 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 CA-C-O 121.114 0.483 . . . . 0.0 110.635 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.3 t-80 -101.89 136.12 42.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.253 1.021 . . . . 0.0 109.993 178.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.13 145.02 17.17 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 C-N-CA 123.465 0.706 . . . . 0.0 109.116 -176.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -142.26 165.14 28.24 Favored 'General case' 0 CA--C 1.526 0.054 0 C-N-CA 123.543 0.737 . . . . 0.0 110.339 -176.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.61 24.08 63.45 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 119.37 -0.683 . . . . 0.0 113.499 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 73.0 mt -61.38 157.96 15.61 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.282 1.041 . . . . 0.0 109.977 177.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.21 -40.14 74.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 O-C-N 122.411 -0.181 . . . . 0.0 111.416 -175.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -171.52 -42.17 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.479 0.712 . . . . 0.0 109.961 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -172.72 54.33 0.16 Allowed Glycine 0 C--N 1.337 0.625 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -175.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.5 t -50.21 144.59 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.299 0.639 . . . . 0.0 109.567 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -91.94 164.03 2.16 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-O 121.092 0.472 . . . . 0.0 111.613 -175.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -61.76 -27.69 68.91 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.885 0.474 . . . . 0.0 110.858 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.1 -4.58 51.0 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -178.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -103.83 -30.37 10.41 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-N 118.379 0.536 . . . . 0.0 109.8 175.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 75.9 mt -71.48 -41.53 69.23 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.555 0.342 . . . . 0.0 110.368 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.84 -30.04 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 121.154 -0.218 . . . . 0.0 111.041 -177.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -84.67 -14.88 47.22 Favored 'General case' 0 N--CA 1.456 -0.16 0 O-C-N 122.116 -0.365 . . . . 0.0 111.777 -177.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.16 -15.66 16.61 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 178.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -110.92 -8.26 14.51 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -71.77 -6.17 39.45 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.736 0.698 . . . . 0.0 111.401 175.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -77.04 -13.82 59.91 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 122.591 0.356 . . . . 0.0 110.323 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -99.05 -17.57 18.18 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.518 0.327 . . . . 0.0 111.742 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.21 176.69 36.28 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.79 139.48 33.64 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 124.106 3.204 . . . . 0.0 110.464 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 75.1 mt -110.87 145.95 16.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 C-N-CA 122.735 0.414 . . . . 0.0 110.352 -177.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -105.62 -40.44 5.76 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.226 0.61 . . . . 0.0 111.287 -178.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -159.07 159.2 34.34 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-O 120.788 0.328 . . . . 0.0 110.895 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -144.05 145.71 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.755 0.822 . . . . 0.0 109.619 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.23 152.14 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.11 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.061 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 10.3 p -134.5 153.69 35.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 122.815 0.446 . . . . 0.0 111.105 -176.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 18.8 ptp -136.03 82.83 35.54 Favored Pre-proline 0 CA--C 1.532 0.267 0 C-N-CA 124.001 0.92 . . . . 0.0 109.606 179.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -58.45 -21.2 52.67 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 124.255 3.304 . . . . 0.0 113.131 -178.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.3 mtpt -78.78 -1.15 33.35 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.718 0.407 . . . . 0.0 111.293 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 22.6 tptm -131.66 -0.75 3.88 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.359 1.064 . . . . 0.0 110.481 179.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 57.75 28.95 16.64 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.947 0.899 . . . . 0.0 112.51 -177.004 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -134.32 169.98 16.4 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.808 0.443 . . . . 0.0 111.226 -175.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.63 171.25 18.46 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.211 0.604 . . . . 0.0 110.758 178.224 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.4 mt -132.96 146.04 51.43 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.917 0.887 . . . . 0.0 109.673 178.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.8 t -138.85 133.42 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -114.64 120.75 41.19 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 177.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -86.7 153.58 21.63 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 120.958 0.409 . . . . 0.0 110.598 -179.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -74.7 -13.34 60.6 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.517 -177.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -147.08 152.41 38.47 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 123.82 0.848 . . . . 0.0 108.995 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -67.71 -21.85 27.74 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -175.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.3 tp -72.75 -27.1 61.82 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.137 -0.352 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.59 -30.35 66.6 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.18 -34.36 25.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 117.105 0.452 . . . . 0.0 110.292 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -72.41 -20.94 61.34 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 122.487 0.315 . . . . 0.0 110.876 178.441 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -94.29 4.59 53.67 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 122.939 0.496 . . . . 0.0 111.475 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -108.46 -26.57 10.39 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 117.967 0.349 . . . . 0.0 111.87 179.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 45.3 t -89.43 -18.89 7.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 CA-C-N 117.8 0.273 . . . . 0.0 110.506 178.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -73.32 1.44 9.53 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.979 -0.451 . . . . 0.0 111.787 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 55.3 t80 -119.08 -34.67 3.82 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 123.045 0.538 . . . . 0.0 110.825 178.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.84 -3.18 58.96 Favored 'General case' 0 CA--C 1.533 0.314 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.94 -2.16 57.75 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.597 0.359 . . . . 0.0 111.417 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.14 -5.52 1.65 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.045 0.538 . . . . 0.0 111.528 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.56 173.93 15.64 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.841 0.856 . . . . 0.0 108.864 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.5 pt20 -93.07 155.58 17.41 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.53 135.18 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -178.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.48 151.7 21.85 Favored 'General case' 0 N--CA 1.455 -0.183 0 O-C-N 122.195 -0.316 . . . . 0.0 110.552 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.0 mt -137.71 -39.01 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.144 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.13 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.17 30.59 2.99 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.042 0.537 . . . . 0.0 110.823 -176.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.66 4.86 84.95 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -176.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -131.17 151.98 79.82 Favored Pre-proline 0 N--CA 1.455 -0.211 0 C-N-CA 123.994 0.918 . . . . 0.0 109.106 177.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -71.29 145.57 48.8 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 C-N-CA 123.694 2.929 . . . . 0.0 111.749 -177.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.67 -176.38 5.59 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.565 1.146 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -139.05 159.38 42.28 Favored 'General case' 0 CA--C 1.527 0.082 0 CA-C-O 120.969 0.414 . . . . 0.0 111.271 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.7 p -148.45 142.34 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.481 0.713 . . . . 0.0 109.483 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 . . . . . 0 N--CA 1.455 -0.178 0 C-N-CA 123.2 0.6 . . . . 0.0 110.186 -179.352 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.401 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 57.8 p . . . . . 0 CA--C 1.533 0.327 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.401 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 91.2 Cg_endo -72.7 2.46 5.25 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 124.306 3.337 . . . . 0.0 112.649 179.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.2 t -121.88 140.92 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.137 0 CA-C-N 118.42 0.555 . . . . 0.0 109.655 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.21 154.37 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 CA-C-O 121.385 0.612 . . . . 0.0 110.728 178.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -105.73 141.81 36.53 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.208 1.003 . . . . 0.0 109.514 -179.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 20.7 mm -110.26 144.05 19.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 C-N-CA 123.04 0.536 . . . . 0.0 110.142 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 42.4 mtm105 -141.24 159.4 42.29 Favored 'General case' 0 CA--C 1.527 0.063 0 C-N-CA 123.492 0.717 . . . . 0.0 110.315 -178.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.41 25.03 59.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-O 119.552 -0.582 . . . . 0.0 113.366 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 53.9 mt -59.55 156.24 13.77 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 118.098 0.949 . . . . 0.0 109.482 176.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.8 pt -70.31 -37.96 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.135 0 N-CA-C 111.383 0.142 . . . . 0.0 111.383 -174.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.74 -35.53 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 123.954 0.901 . . . . 0.0 109.648 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 170.48 55.97 0.04 OUTLIER Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -176.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.8 m -53.21 151.72 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 117.236 0.518 . . . . 0.0 110.501 178.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -87.18 166.45 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.082 0 CA-C-O 121.314 0.578 . . . . 0.0 110.809 -177.232 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -60.3 -25.21 65.59 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.002 0.521 . . . . 0.0 110.698 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.89 -6.35 53.99 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 122.811 0.444 . . . . 0.0 112.038 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 79.4 m-20 -97.34 -33.11 11.55 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 118.371 0.532 . . . . 0.0 109.733 176.201 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.47 -40.76 66.71 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.308 0.243 . . . . 0.0 110.83 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.08 -30.06 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 O-C-N 122.158 -0.339 . . . . 0.0 110.855 -176.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.7 mm-40 -81.67 -18.22 45.28 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 117.822 0.283 . . . . 0.0 111.616 -178.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.35 -14.37 16.95 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -113.9 -7.43 13.17 Favored 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -178.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.0 pt20 -71.49 -5.84 36.01 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.666 0.666 . . . . 0.0 111.735 175.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -76.58 -14.3 60.01 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 122.962 0.505 . . . . 0.0 110.677 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -98.71 -17.01 18.77 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.56 0.344 . . . . 0.0 111.562 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.91 176.67 35.2 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -71.12 140.31 37.36 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 123.935 3.09 . . . . 0.0 110.631 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 72.4 mt -110.16 146.4 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.103 0 C-N-CA 122.863 0.465 . . . . 0.0 110.4 -178.006 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.8 t -108.26 -39.93 5.32 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 123.279 0.631 . . . . 0.0 111.62 -177.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -157.78 158.13 34.66 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 120.57 0.224 . . . . 0.0 111.04 178.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.5 t -145.01 146.36 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.079 0 C-N-CA 123.642 0.777 . . . . 0.0 109.507 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.28 153.24 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 175.352 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 11.1 p -133.7 151.74 33.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.118 0 CA-C-O 120.806 0.336 . . . . 0.0 111.191 -176.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 19.3 ptp -136.24 84.89 28.54 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.739 0.816 . . . . 0.0 109.159 179.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.5 -12.31 33.1 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.386 2.724 . . . . 0.0 111.666 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -77.93 -5.04 49.82 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 122.683 0.393 . . . . 0.0 111.018 176.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -132.79 5.17 3.92 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 123.645 0.778 . . . . 0.0 111.213 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 54.27 35.72 23.44 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.292 1.037 . . . . 0.0 112.343 -177.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -137.54 169.83 17.12 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.132 0.573 . . . . 0.0 111.039 -176.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.44 172.82 17.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.112 0.565 . . . . 0.0 110.494 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.4 mt -132.92 146.22 51.6 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.9 0.88 . . . . 0.0 109.374 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 89.8 t -138.36 133.03 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -116.26 121.68 42.74 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.578 0.751 . . . . 0.0 109.192 178.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 44.3 m-85 -88.5 155.52 19.61 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.052 0.453 . . . . 0.0 110.547 -178.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -75.77 -13.49 60.3 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.475 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -145.76 152.82 40.17 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.691 0.796 . . . . 0.0 109.097 177.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.8 p -69.55 -21.84 24.9 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 58.7 tp -77.44 -29.51 52.89 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.003 -0.436 . . . . 0.0 110.418 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.27 -31.09 73.94 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.15 -32.03 33.86 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 116.984 0.392 . . . . 0.0 110.534 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.6 t -70.6 -29.72 66.2 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 122.076 0.15 . . . . 0.0 110.628 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -75.84 -21.0 57.7 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.194 -0.316 . . . . 0.0 111.247 179.18 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -81.31 -28.19 34.7 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.971 0.35 . . . . 0.0 111.617 -177.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 33.3 t -92.16 -19.66 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 O-C-N 122.382 -0.199 . . . . 0.0 110.688 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -71.34 -11.69 61.04 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 122.117 -0.364 . . . . 0.0 110.888 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -104.88 -34.05 8.18 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 122.942 0.497 . . . . 0.0 110.764 178.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.71 -7.24 59.52 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -177.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -84.84 -2.51 57.84 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -141.47 -3.87 1.15 Allowed 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 122.829 0.452 . . . . 0.0 111.946 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 54.1 t30 -154.68 165.23 37.21 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 123.303 0.641 . . . . 0.0 109.456 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -85.14 158.3 20.43 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.04 135.72 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.058 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.2 m-85 -89.78 152.97 21.03 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.04 -0.413 . . . . 0.0 110.862 -178.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.2 mt -137.29 -41.0 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.227 -0.101 0 C-N-CA 122.669 0.388 . . . . 0.0 110.755 -177.137 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.92 29.91 3.73 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.817 0.447 . . . . 0.0 110.944 -177.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.05 4.24 81.96 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -176.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -130.31 151.81 79.14 Favored Pre-proline 0 N--CA 1.455 -0.223 0 C-N-CA 124.14 0.976 . . . . 0.0 109.053 177.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.69 146.04 53.4 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 123.526 2.817 . . . . 0.0 112.038 -176.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.35 -176.21 5.49 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.267 1.427 . . . . 0.0 108.902 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -138.99 161.51 37.17 Favored 'General case' 0 N--CA 1.457 -0.086 0 CA-C-O 120.943 0.402 . . . . 0.0 111.521 -179.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.0 p -150.09 141.55 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.842 0.857 . . . . 0.0 109.751 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 . . . . . 0 N--CA 1.458 -0.074 0 C-N-CA 123.333 0.653 . . . . 0.0 109.747 178.373 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.1 m . . . . . 0 CA--C 1.529 0.16 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -72.35 -1.52 10.3 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 123.92 3.08 . . . . 0.0 112.073 175.606 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.4 t -113.42 139.38 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 123.215 0.606 . . . . 0.0 109.707 178.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.2 m -125.17 159.49 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 C-N-CA 122.928 0.491 . . . . 0.0 110.316 178.417 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -114.55 135.65 53.89 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 123.834 0.854 . . . . 0.0 109.687 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.8 mm -106.74 143.88 16.76 Favored 'Isoleucine or valine' 0 C--O 1.23 0.068 0 C-N-CA 122.888 0.475 . . . . 0.0 110.365 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 72.1 mtm-85 -143.64 163.5 33.05 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 123.368 0.667 . . . . 0.0 110.523 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.84 22.27 66.69 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 119.572 -0.571 . . . . 0.0 113.148 174.046 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.48 156.08 16.95 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 118.173 0.986 . . . . 0.0 110.041 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.1 pt -70.97 -41.46 76.99 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.112 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -173.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.2 -35.9 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.228 0.611 . . . . 0.0 110.437 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.86 50.5 0.12 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.648 -0.581 . . . . 0.0 111.648 -177.329 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 88.1 t -50.16 143.09 2.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.419 0.688 . . . . 0.0 109.8 177.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 33.8 m -94.48 164.7 2.05 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 121.229 0.538 . . . . 0.0 111.73 -174.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -61.22 -25.87 67.35 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.431 0.692 . . . . 0.0 111.224 -178.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.42 -6.3 57.85 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -177.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -97.75 -29.06 13.59 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 118.222 0.465 . . . . 0.0 110.282 177.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 98.0 mt -74.02 -35.9 64.41 Favored 'General case' 0 N--CA 1.452 -0.325 0 O-C-N 122.401 -0.187 . . . . 0.0 110.93 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.05 -31.47 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.363 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -81.55 -16.56 51.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 119.565 -0.255 . . . . 0.0 111.596 -178.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.95 -13.36 15.51 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.4 mt -116.1 -6.13 11.92 Favored 'General case' 0 N--CA 1.461 0.094 0 CA-C-N 118.483 0.583 . . . . 0.0 112.479 -178.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -72.44 -6.41 43.4 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.678 0.672 . . . . 0.0 110.26 175.004 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -77.33 -3.89 42.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 123.923 0.889 . . . . 0.0 111.059 179.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -112.85 -16.49 12.71 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.006 0.522 . . . . 0.0 111.282 179.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.48 175.78 35.62 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -71.35 140.77 37.54 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 123.812 3.008 . . . . 0.0 110.564 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.3 mt -110.13 147.05 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.822 0.449 . . . . 0.0 110.572 -178.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -109.53 -41.15 4.66 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 123.206 0.603 . . . . 0.0 111.564 -176.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -158.06 158.03 34.0 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 117.666 0.212 . . . . 0.0 111.261 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.7 t -143.89 147.42 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 C-N-CA 123.932 0.893 . . . . 0.0 109.591 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -149.53 151.52 12.8 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.032 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 175.407 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.95 152.59 36.24 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 C-N-CA 122.437 0.295 . . . . 0.0 110.899 -175.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 21.2 ptp -138.58 78.76 31.07 Favored Pre-proline 0 CA--C 1.534 0.33 0 C-N-CA 123.675 0.79 . . . . 0.0 109.741 177.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.57 -18.43 47.15 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.89 3.06 . . . . 0.0 113.306 -177.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -71.66 -12.28 61.26 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 122.8 0.44 . . . . 0.0 110.873 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.69 4.55 6.73 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.703 0.801 . . . . 0.0 111.286 179.273 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 55.31 34.98 23.97 Favored 'General case' 0 CA--C 1.533 0.288 0 C-N-CA 124.095 0.958 . . . . 0.0 112.191 -176.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -134.03 169.02 17.75 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 123.054 0.541 . . . . 0.0 110.843 -177.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.81 171.8 19.01 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.167 176.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 43.2 mt -131.86 146.44 52.12 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.522 0.729 . . . . 0.0 109.825 178.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.6 t -138.28 131.75 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -114.92 122.84 47.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 177.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -87.26 155.35 20.11 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.41 -179.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -76.37 -11.65 59.93 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.246 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.73 152.92 38.58 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.928 0.891 . . . . 0.0 109.282 177.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -69.9 -21.33 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 O-C-N 122.224 -0.298 . . . . 0.0 111.702 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.2 tp -75.85 -28.97 58.42 Favored 'General case' 0 N--CA 1.454 -0.231 0 O-C-N 121.865 -0.522 . . . . 0.0 110.626 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.03 -29.51 73.52 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.12 -28.12 29.66 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.99 0.395 . . . . 0.0 110.74 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.6 t -74.06 -30.89 62.61 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.244 -0.285 . . . . 0.0 110.467 179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -76.24 -21.67 56.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.268 -0.27 . . . . 0.0 111.249 179.329 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -33.31 26.79 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 117.778 0.263 . . . . 0.0 111.396 -177.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.15 -22.67 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 O-C-N 122.308 -0.245 . . . . 0.0 110.535 179.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -68.79 -16.56 63.83 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.943 -0.473 . . . . 0.0 111.01 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -99.03 -34.79 10.27 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 122.695 0.398 . . . . 0.0 110.691 178.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.21 -10.76 59.02 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -177.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.54 -1.01 52.78 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 178.019 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -139.61 -7.48 1.29 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -155.02 165.39 36.88 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.257 0.623 . . . . 0.0 109.363 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.68 157.57 23.29 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 173.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.43 135.99 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 64.1 m-85 -90.29 151.11 21.64 Favored 'General case' 0 N--CA 1.457 -0.082 0 O-C-N 122.109 -0.369 . . . . 0.0 110.92 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.5 mt -137.14 -38.89 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.12 -176.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.65 29.07 3.25 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.149 0.58 . . . . 0.0 111.012 -176.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.82 4.66 82.18 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.53 151.98 79.64 Favored Pre-proline 0 C--O 1.234 0.253 0 C-N-CA 124.322 1.049 . . . . 0.0 109.322 177.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_endo -70.9 146.57 53.46 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 123.522 2.814 . . . . 0.0 111.702 -177.179 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.71 -177.72 6.28 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 125.205 1.402 . . . . 0.0 109.104 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -137.54 159.7 41.23 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.061 0.458 . . . . 0.0 111.792 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.5 p -151.23 139.98 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 123.347 0.659 . . . . 0.0 110.149 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.0 t30 . . . . . 0 CA--C 1.528 0.132 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.743 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.426 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.7 p . . . . . 0 CA--C 1.532 0.288 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.426 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 98.9 Cg_endo -71.17 1.22 5.59 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 124.008 3.139 . . . . 0.0 112.758 178.229 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.57 139.05 37.62 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.094 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 178.277 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.3 154.22 37.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 122.928 0.491 . . . . 0.0 110.339 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 31.5 t-80 -110.65 138.18 47.37 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.993 0.917 . . . . 0.0 109.507 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.1 mm -107.49 144.77 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 C-N-CA 122.893 0.477 . . . . 0.0 110.33 -176.228 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -143.01 161.48 38.0 Favored 'General case' 0 C--N 1.338 0.088 0 C-N-CA 123.195 0.598 . . . . 0.0 110.553 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.36 23.51 62.85 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 119.498 -0.612 . . . . 0.0 113.488 173.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 76.4 mt -60.87 158.01 13.98 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 118.332 1.066 . . . . 0.0 110.523 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -72.31 -40.93 65.65 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -173.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -172.12 -38.22 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 C-N-CA 123.107 0.563 . . . . 0.0 110.079 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.33 51.91 0.11 Allowed Glycine 0 C--N 1.338 0.646 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -176.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 57.9 t -49.65 144.03 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 123.546 0.738 . . . . 0.0 110.153 178.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -90.0 161.95 2.57 Favored 'Isoleucine or valine' 0 C--N 1.338 0.072 0 CA-C-O 121.292 0.567 . . . . 0.0 111.655 -174.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -62.0 -24.05 66.8 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.259 0.624 . . . . 0.0 111.766 -176.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.48 -5.5 58.74 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -95.63 -31.55 13.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.312 0.505 . . . . 0.0 110.498 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.56 -34.07 60.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 O-C-N 121.921 -0.487 . . . . 0.0 110.752 -177.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.3 p -78.06 -30.64 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 120.709 -0.396 . . . . 0.0 109.979 -178.68 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -85.72 -12.03 52.17 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.274 -0.266 . . . . 0.0 111.558 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.84 -11.79 15.31 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 178.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -114.8 -9.37 12.52 Favored 'General case' 0 C--N 1.34 0.19 0 CA-C-N 118.457 0.571 . . . . 0.0 112.255 -179.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.64 -3.87 16.92 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 118.615 0.643 . . . . 0.0 111.71 176.696 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -78.49 -16.1 57.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.865 0.466 . . . . 0.0 110.511 178.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -96.67 -18.94 19.35 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.343 -0.223 . . . . 0.0 111.397 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.34 178.14 38.25 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.75 140.78 36.22 Favored 'Trans proline' 0 N--CA 1.451 -0.985 0 C-N-CA 124.061 3.174 . . . . 0.0 110.46 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.5 mt -110.05 148.44 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 C-N-CA 122.604 0.362 . . . . 0.0 110.449 -177.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -110.63 -39.78 4.78 Favored 'General case' 0 N--CA 1.457 -0.101 0 C-N-CA 123.247 0.619 . . . . 0.0 111.851 -177.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -158.68 158.06 33.02 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 117.76 0.255 . . . . 0.0 111.601 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 79.3 t -143.72 146.29 21.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 124.036 0.934 . . . . 0.0 109.586 179.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.9 p -147.53 153.49 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 174.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.8 t -128.75 150.8 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 CA-C-O 120.833 0.349 . . . . 0.0 110.659 -176.299 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -134.54 79.77 52.93 Favored Pre-proline 0 CA--C 1.531 0.237 0 C-N-CA 124.492 1.117 . . . . 0.0 109.195 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -68.96 -14.06 37.86 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.389 2.726 . . . . 0.0 111.778 -175.407 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -81.71 -1.88 48.56 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 122.824 0.45 . . . . 0.0 111.585 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -133.39 4.46 3.69 Favored 'General case' 0 C--N 1.339 0.14 0 C-N-CA 123.797 0.839 . . . . 0.0 111.113 175.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.4 tpp85 55.59 35.76 25.84 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.069 0.948 . . . . 0.0 111.667 -175.193 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -134.11 170.49 15.58 Favored 'General case' 0 N--CA 1.457 -0.076 0 C-N-CA 123.415 0.686 . . . . 0.0 110.929 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.88 170.94 20.5 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 176.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.7 tp -135.17 142.54 46.12 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.5 t -138.21 141.54 37.78 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.1 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -123.9 125.03 43.91 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.086 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -87.75 154.9 20.2 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.875 0.369 . . . . 0.0 110.341 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -74.97 -12.36 60.32 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.246 -178.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -147.8 152.49 37.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.988 0.915 . . . . 0.0 109.265 176.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.8 p -68.63 -21.85 26.37 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.0 tp -73.95 -26.08 60.3 Favored 'General case' 0 N--CA 1.453 -0.303 0 O-C-N 121.999 -0.438 . . . . 0.0 110.544 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.24 -29.13 68.92 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.042 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.66 -30.23 23.38 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 117.237 0.519 . . . . 0.0 110.513 178.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 36.8 t -75.55 -17.77 59.97 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 122.49 0.316 . . . . 0.0 110.484 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -93.35 -20.84 19.97 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.705 0.402 . . . . 0.0 110.723 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.35 -31.01 25.02 Favored 'General case' 0 N--CA 1.455 -0.177 0 O-C-N 122.112 -0.367 . . . . 0.0 111.501 -178.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.62 -19.4 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 O-C-N 122.04 -0.413 . . . . 0.0 110.698 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -70.5 -17.54 62.96 Favored 'General case' 0 CA--C 1.529 0.142 0 O-C-N 122.221 -0.3 . . . . 0.0 111.195 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.9 t80 -97.42 -36.79 10.24 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 122.686 0.394 . . . . 0.0 111.172 178.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.25 -6.61 59.42 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.22 -4.81 56.67 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.078 -0.389 . . . . 0.0 111.543 176.238 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -141.64 -4.99 1.07 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 23.9 m-80 -145.01 175.26 10.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.358 0.663 . . . . 0.0 109.615 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.1 pt20 -99.35 150.52 22.05 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 172.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -118.91 134.51 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -88.04 151.46 22.74 Favored 'General case' 0 N--CA 1.453 -0.278 0 O-C-N 122.183 -0.323 . . . . 0.0 110.853 -179.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 41.2 mt -138.22 -37.3 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.19 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.91 29.54 3.14 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.24 0.616 . . . . 0.0 111.087 -176.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.73 4.69 84.93 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -176.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.36 152.78 81.13 Favored Pre-proline 0 N--CA 1.454 -0.234 0 C-N-CA 124.24 1.016 . . . . 0.0 108.982 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -71.53 146.83 50.52 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 123.377 2.718 . . . . 0.0 111.792 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.67 -176.54 5.77 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 124.784 1.234 . . . . 0.0 109.011 178.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -137.83 159.79 41.05 Favored 'General case' 0 CA--C 1.527 0.081 0 CA-C-O 120.776 0.322 . . . . 0.0 111.428 -178.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.84 138.14 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.324 0.649 . . . . 0.0 110.23 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.456 -0.126 0 C-N-CA 123.502 0.721 . . . . 0.0 109.303 179.594 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.454 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 77.8 p . . . . . 0 CA--C 1.529 0.147 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.454 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 84.6 Cg_endo -70.5 2.15 4.23 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 123.89 3.06 . . . . 0.0 112.854 177.046 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.7 t -112.92 139.15 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 CA-C-N 118.327 0.512 . . . . 0.0 109.926 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.0 m -125.51 157.74 34.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 C-N-CA 122.908 0.483 . . . . 0.0 110.359 178.421 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.6 t-80 -115.39 137.63 51.84 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.179 0.991 . . . . 0.0 109.392 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.6 mm -107.67 145.69 14.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 C-N-CA 122.616 0.366 . . . . 0.0 110.044 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -142.64 157.74 44.38 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.418 0.687 . . . . 0.0 109.947 -178.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 24.98 57.51 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.314 174.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.3 mt -59.08 156.72 11.43 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 118.026 0.913 . . . . 0.0 109.812 177.562 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.1 pt -72.45 -39.07 61.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 O-C-N 122.181 -0.324 . . . . 0.0 111.773 -174.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -173.41 -36.2 0.01 OUTLIER 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 123.653 0.781 . . . . 0.0 110.033 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.31 54.75 0.05 OUTLIER Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -177.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.3 m -52.9 151.57 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 117.156 0.478 . . . . 0.0 110.271 177.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.1 m -88.34 165.74 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.039 0 CA-C-O 121.161 0.505 . . . . 0.0 111.36 -175.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.61 -23.92 66.35 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.132 0.573 . . . . 0.0 111.21 -178.173 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.2 -6.85 57.53 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 122.743 0.417 . . . . 0.0 111.867 -179.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -91.49 -34.96 14.59 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.236 0.471 . . . . 0.0 110.617 179.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.6 mp -75.87 -33.81 59.98 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 122.214 -0.304 . . . . 0.0 110.948 -176.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -76.57 -29.49 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.068 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 37.7 mm-40 -84.36 -14.26 50.02 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 122.206 0.202 . . . . 0.0 110.982 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.69 -21.79 16.24 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.8 mp -109.83 -10.68 14.75 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -177.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.36 -4.43 14.54 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.978 0.808 . . . . 0.0 111.956 177.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -83.6 -12.27 56.28 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.881 0.473 . . . . 0.0 110.413 178.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -103.97 -16.41 15.33 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 122.753 0.421 . . . . 0.0 111.425 -179.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.42 178.54 37.2 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -72.37 140.33 33.34 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 124.085 3.19 . . . . 0.0 110.671 179.268 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 79.4 mt -109.72 148.62 13.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.889 0.476 . . . . 0.0 110.684 -178.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 12.9 t -114.32 -36.39 4.67 Favored 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.384 0.673 . . . . 0.0 112.09 -177.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -155.96 156.06 33.86 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.626 0.25 . . . . 0.0 111.589 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.0 t -146.49 144.37 20.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.038 0.935 . . . . 0.0 109.183 179.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.7 p -151.33 152.82 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 175.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.8 150.59 34.07 Favored 'Isoleucine or valine' 0 C--N 1.335 -0.055 0 C-N-CA 122.587 0.355 . . . . 0.0 110.393 -175.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 70.0 mtm -132.74 84.74 49.18 Favored Pre-proline 0 N--CA 1.454 -0.237 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.57 -12.5 33.4 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.325 2.683 . . . . 0.0 111.964 -176.17 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -84.78 -1.75 56.77 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 122.842 0.457 . . . . 0.0 111.107 176.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -132.45 1.24 3.74 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 123.871 0.868 . . . . 0.0 111.157 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.2 tpp85 52.38 34.61 15.39 Favored 'General case' 0 C--N 1.341 0.197 0 C-N-CA 124.257 1.023 . . . . 0.0 111.846 -175.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.26 167.86 20.95 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.554 0.741 . . . . 0.0 110.354 -177.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.62 173.58 16.5 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.508 0.323 . . . . 0.0 110.792 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 45.0 mt -134.16 147.09 50.73 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.623 0.769 . . . . 0.0 110.14 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.6 t -140.06 135.28 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -116.75 122.63 45.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -84.77 156.02 21.58 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 120.974 0.416 . . . . 0.0 110.193 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -75.94 -12.29 60.12 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.325 -179.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -148.21 153.13 38.34 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 124.099 0.96 . . . . 0.0 109.362 177.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -70.5 -21.8 23.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.7 tp -74.34 -27.43 60.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 O-C-N 121.939 -0.476 . . . . 0.0 110.742 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.88 -30.63 67.86 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.88 -29.36 29.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 117.11 0.455 . . . . 0.0 111.028 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -77.58 -25.97 50.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.537 -0.171 . . . . 0.0 110.537 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -85.21 -17.22 37.75 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.135 0.174 . . . . 0.0 111.084 178.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.01 -28.56 25.66 Favored 'General case' 0 N--CA 1.456 -0.148 0 O-C-N 122.246 -0.284 . . . . 0.0 111.48 179.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.9 t -88.23 -21.91 6.88 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 O-C-N 122.196 -0.315 . . . . 0.0 110.618 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.16 -15.9 62.51 Favored 'General case' 0 CA--C 1.534 0.331 0 O-C-N 122.365 -0.209 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 58.0 t80 -93.76 -33.09 13.74 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.422 0.289 . . . . 0.0 110.927 178.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.99 -3.1 57.55 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 112.697 0.628 . . . . 0.0 112.697 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.81 -5.08 59.12 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 122.001 -0.437 . . . . 0.0 112.11 178.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -143.59 2.47 1.24 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 122.71 0.404 . . . . 0.0 111.52 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -155.27 173.72 16.23 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.032 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -98.48 156.34 16.82 Favored 'General case' 0 CA--C 1.527 0.094 0 CA-C-N 118.222 0.464 . . . . 0.0 110.276 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -119.56 136.49 56.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -177.607 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -92.89 147.65 22.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.98 -0.45 . . . . 0.0 110.384 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.8 mt -134.19 -40.15 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.131 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.83 29.78 3.78 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 123.012 0.525 . . . . 0.0 111.164 -177.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.11 5.14 83.51 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.394 -0.683 . . . . 0.0 111.394 -177.158 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -131.36 152.87 81.29 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 124.526 1.13 . . . . 0.0 108.84 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -71.1 146.23 51.44 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.531 2.821 . . . . 0.0 111.784 -177.212 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.5 -176.11 5.46 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.158 1.383 . . . . 0.0 108.772 177.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -138.98 159.43 42.16 Favored 'General case' 0 N--CA 1.456 -0.128 0 O-C-N 122.134 -0.353 . . . . 0.0 111.265 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.6 p -147.08 139.68 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 C-N-CA 123.237 0.615 . . . . 0.0 110.606 179.24 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 . . . . . 0 N--CA 1.456 -0.144 0 C-N-CA 123.355 0.662 . . . . 0.0 109.582 176.24 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.407 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 48.2 p . . . . . 0 CA--C 1.532 0.262 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 88.9 Cg_endo -70.11 4.79 2.14 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.583 3.522 . . . . 0.0 113.362 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.84 140.82 45.43 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.076 0 CA-C-N 118.579 0.627 . . . . 0.0 109.855 178.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.95 157.88 43.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 121.07 0.462 . . . . 0.0 110.643 179.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -107.84 142.63 37.61 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.908 0.883 . . . . 0.0 109.723 -179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.0 mm -111.42 144.88 18.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 123.006 0.523 . . . . 0.0 110.016 -176.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -141.36 160.12 40.78 Favored 'General case' 0 C--N 1.334 -0.068 0 C-N-CA 123.514 0.726 . . . . 0.0 110.068 -178.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.67 25.67 58.01 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.432 173.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 47.7 mt -59.07 154.87 14.8 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.388 1.094 . . . . 0.0 109.189 176.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.0 pt -69.95 -40.37 78.61 Favored 'Isoleucine or valine' 0 C--N 1.338 0.076 0 O-C-N 122.184 -0.322 . . . . 0.0 111.652 -172.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -172.91 -35.16 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.484 0.713 . . . . 0.0 109.979 -179.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.84 51.96 0.05 OUTLIER Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 -177.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.1 m -53.72 151.64 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 117.138 0.469 . . . . 0.0 110.087 177.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.3 m -88.46 163.88 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-O 120.881 0.372 . . . . 0.0 110.832 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.68 -22.33 63.8 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 122.819 0.448 . . . . 0.0 111.065 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.82 -8.04 58.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 122.868 0.467 . . . . 0.0 111.991 -179.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -91.12 -32.74 15.73 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 118.476 0.58 . . . . 0.0 110.48 178.007 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -71.41 -39.05 71.37 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.119 0.167 . . . . 0.0 110.601 -177.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.71 -31.28 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 C-N-CA 121.191 -0.203 . . . . 0.0 110.783 -175.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.7 mm-40 -81.26 -17.23 50.15 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 122.131 -0.356 . . . . 0.0 111.554 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.9 -12.47 16.21 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.3 mt -114.53 -9.11 12.71 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.491 0.587 . . . . 0.0 112.444 -179.059 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -70.06 -5.98 30.48 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.508 0.595 . . . . 0.0 111.778 176.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -76.28 -12.78 60.14 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 122.13 -0.356 . . . . 0.0 110.498 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -100.39 -16.9 17.46 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 122.455 0.302 . . . . 0.0 111.523 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.12 177.32 35.99 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.59 140.97 37.12 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.875 3.05 . . . . 0.0 110.451 -179.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.8 mt -111.07 146.73 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 122.675 0.39 . . . . 0.0 110.098 -178.125 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.2 t -108.26 -40.33 5.2 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.336 0.655 . . . . 0.0 111.436 -177.098 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -159.12 158.49 32.98 Favored 'General case' 0 N--CA 1.457 -0.078 0 CA-C-O 120.577 0.227 . . . . 0.0 111.355 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 65.1 t -145.23 147.92 18.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.801 0.84 . . . . 0.0 109.602 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.4 p -148.2 150.75 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 174.139 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 43.9 t -132.28 150.38 33.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.053 0 C-N-CA 122.628 0.371 . . . . 0.0 110.043 -174.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.7 mtm -135.62 80.59 43.98 Favored Pre-proline 0 N--CA 1.456 -0.171 0 C-N-CA 123.858 0.863 . . . . 0.0 109.486 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -58.88 -20.37 52.03 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.948 3.098 . . . . 0.0 113.041 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -76.09 -12.43 60.12 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.168 0.587 . . . . 0.0 111.139 179.334 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -124.06 3.57 8.65 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.644 0.778 . . . . 0.0 111.294 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.1 tpp85 52.83 32.84 13.03 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.473 1.109 . . . . 0.0 111.826 -176.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -136.93 166.74 22.94 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 123.435 0.694 . . . . 0.0 110.71 -177.044 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.03 172.18 17.25 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 122.748 0.419 . . . . 0.0 110.412 178.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 35.6 mt -132.09 146.52 52.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.728 0.811 . . . . 0.0 109.816 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 90.4 t -138.17 131.84 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.71 117.98 31.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.679 0.791 . . . . 0.0 109.169 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -86.26 155.36 20.71 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.012 0.434 . . . . 0.0 110.267 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -77.94 -11.04 59.86 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.497 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -146.47 152.02 38.34 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.522 0.729 . . . . 0.0 109.183 178.022 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -69.08 -21.48 25.42 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.76 -28.67 44.86 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 122.039 -0.413 . . . . 0.0 110.594 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.38 -28.73 73.11 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.82 -31.82 25.64 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.887 0.344 . . . . 0.0 110.66 178.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -69.95 -33.12 71.71 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 122.359 0.264 . . . . 0.0 110.578 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -73.72 -20.38 60.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 122.277 0.231 . . . . 0.0 111.447 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.44 -29.41 30.71 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 117.797 0.271 . . . . 0.0 111.585 -177.185 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.36 -21.96 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.096 0 O-C-N 122.312 -0.242 . . . . 0.0 110.648 178.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -68.41 -17.06 64.13 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 122.275 -0.266 . . . . 0.0 110.51 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 50.0 t80 -97.9 -36.0 10.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 122.426 0.29 . . . . 0.0 110.611 177.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.84 -15.06 59.82 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 122.648 0.379 . . . . 0.0 111.855 -177.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.24 52.4 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.982 0.513 . . . . 0.0 111.922 177.175 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -135.29 -18.33 1.75 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.129 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -151.33 166.21 31.67 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -81.12 154.25 26.86 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 175.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.588 HD11 ' H ' ' A' ' 158' ' ' TYR . 0.5 OUTLIER -110.04 164.52 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.173 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.588 ' H ' HD11 ' A' ' 157' ' ' ILE . 75.9 m-85 -119.52 154.64 33.53 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.094 -0.379 . . . . 0.0 110.3 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.6 mt -137.0 -42.28 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 O-C-N 123.165 0.291 . . . . 0.0 110.802 -177.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.08 29.83 3.69 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.268 0.627 . . . . 0.0 111.11 -177.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.48 6.75 80.3 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -176.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -129.7 153.67 80.83 Favored Pre-proline 0 C--O 1.233 0.203 0 C-N-CA 124.013 0.925 . . . . 0.0 109.245 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.97 144.18 52.09 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.184 2.589 . . . . 0.0 112.285 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.44 -177.59 6.31 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.473 1.509 . . . . 0.0 108.668 178.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -137.99 160.61 38.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.114 0.483 . . . . 0.0 111.471 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.4 p -150.25 140.86 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 123.888 0.875 . . . . 0.0 109.323 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 . . . . . 0 N--CA 1.455 -0.218 0 C-N-CA 123.149 0.58 . . . . 0.0 109.893 178.893 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.408 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 71.0 p . . . . . 0 CA--C 1.532 0.254 0 N-CA-C 111.484 0.179 . . . . 0.0 111.484 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 80.6 Cg_endo -69.78 4.27 2.3 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 124.098 3.198 . . . . 0.0 112.342 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.5 t -115.06 140.43 36.34 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 C-N-CA 123.076 0.55 . . . . 0.0 109.802 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.12 150.74 34.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.1 0 CA-C-O 121.035 0.445 . . . . 0.0 110.699 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.3 t-80 -99.39 136.21 39.67 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.249 1.019 . . . . 0.0 110.178 178.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.42 146.4 15.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.463 0.705 . . . . 0.0 109.168 -177.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -142.3 162.56 35.17 Favored 'General case' 0 N--CA 1.461 0.084 0 C-N-CA 123.573 0.749 . . . . 0.0 110.385 -176.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.27 26.99 53.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.66 -0.522 . . . . 0.0 113.239 172.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.4 mt -59.41 155.74 14.27 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 118.176 0.988 . . . . 0.0 109.798 177.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.2 pt -71.12 -39.5 74.08 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.111 0 O-C-N 122.189 -0.319 . . . . 0.0 111.308 -174.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -173.21 -37.05 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.882 0.873 . . . . 0.0 110.107 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.63 52.22 0.06 OUTLIER Glycine 0 C--N 1.337 0.612 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -176.44 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.1 m -54.04 154.4 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 CA-C-N 117.037 0.418 . . . . 0.0 110.203 177.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.9 m -90.84 166.11 1.85 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.063 0 CA-C-O 121.213 0.53 . . . . 0.0 111.091 -176.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -60.58 -24.2 65.25 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.24 0.616 . . . . 0.0 111.217 -178.663 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.5 -4.71 54.92 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 122.694 0.398 . . . . 0.0 112.015 -178.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -91.74 -35.76 13.96 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.256 0.48 . . . . 0.0 110.471 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.67 -31.9 52.86 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 122.225 -0.297 . . . . 0.0 111.105 -176.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.39 -31.5 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 O-C-N 122.057 -0.402 . . . . 0.0 110.184 -178.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.8 mm-40 -82.33 -18.55 41.77 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.244 -0.285 . . . . 0.0 111.054 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.01 -12.19 18.34 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.2 mt -117.6 -8.48 10.93 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.627 0.649 . . . . 0.0 112.525 -177.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.3 pt20 -68.8 -6.92 29.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 118.575 0.625 . . . . 0.0 111.563 176.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -76.47 -14.65 60.03 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.791 0.436 . . . . 0.0 110.607 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -99.41 -13.56 19.51 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 122.49 0.316 . . . . 0.0 111.613 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.62 176.32 32.59 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -71.27 140.35 36.97 Favored 'Trans proline' 0 N--CA 1.452 -0.93 0 C-N-CA 124.023 3.149 . . . . 0.0 110.51 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.6 mt -111.28 146.3 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.939 0.496 . . . . 0.0 110.519 -178.029 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -106.36 -41.26 5.36 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 123.433 0.693 . . . . 0.0 111.438 -177.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.0 t80 -159.29 158.89 33.32 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 122.225 0.21 . . . . 0.0 111.51 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -143.56 147.22 20.34 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 C-N-CA 123.827 0.851 . . . . 0.0 109.815 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.43 152.68 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.064 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 175.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 56.4 t -133.71 150.06 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 C-N-CA 122.852 0.461 . . . . 0.0 110.352 -176.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -133.79 86.47 38.58 Favored Pre-proline 0 N--CA 1.454 -0.262 0 C-N-CA 123.83 0.852 . . . . 0.0 109.318 -179.181 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -68.61 -14.64 39.98 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.463 2.776 . . . . 0.0 111.645 -176.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.0 tttp -79.24 -10.29 59.78 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.114 0.566 . . . . 0.0 110.91 177.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -126.76 1.22 6.73 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 123.683 0.793 . . . . 0.0 111.369 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.8 tpp85 53.05 32.33 12.75 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 124.358 1.063 . . . . 0.0 111.948 -176.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -135.77 166.56 22.99 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 123.551 0.74 . . . . 0.0 110.147 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.66 172.22 18.24 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-O 120.773 0.321 . . . . 0.0 110.921 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.5 mt -134.09 147.75 50.92 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.41 0.684 . . . . 0.0 109.929 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 81.6 t -138.24 133.61 43.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.8 tt0 -115.44 119.59 36.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 178.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 50.2 m-85 -86.13 155.0 20.96 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.987 0.422 . . . . 0.0 110.361 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -75.23 -14.41 60.52 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.379 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.29 153.03 39.25 Favored 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 123.697 0.799 . . . . 0.0 109.456 177.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -68.06 -22.0 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 52.5 tp -73.96 -25.45 59.95 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.184 -0.322 . . . . 0.0 110.494 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.25 -30.17 65.37 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 179.327 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.44 -31.17 22.99 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 122.864 0.466 . . . . 0.0 110.612 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.91 -19.98 60.53 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.601 0.36 . . . . 0.0 111.166 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -94.46 -15.48 24.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.45 0.3 . . . . 0.0 111.314 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.63 -32.6 25.61 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.31 -0.244 . . . . 0.0 111.491 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -84.86 -16.35 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -72.54 -4.39 30.34 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.656 0.382 . . . . 0.0 111.003 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -115.29 -35.78 4.55 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.806 0.442 . . . . 0.0 110.935 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -81.39 -7.77 59.63 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -177.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.7 -1.82 58.03 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.947 -0.471 . . . . 0.0 112.027 178.36 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.87 -6.7 1.45 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.678 0.391 . . . . 0.0 112.043 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -153.85 164.42 38.4 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.226 0.61 . . . . 0.0 109.563 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.26 158.18 23.6 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 174.161 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.96 135.45 64.01 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 -178.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -86.88 151.41 23.35 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.196 -0.315 . . . . 0.0 110.661 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.1 mt -137.09 -40.04 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 122.429 0.291 . . . . 0.0 111.095 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.34 29.12 4.0 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 122.842 0.457 . . . . 0.0 111.058 -178.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.96 78.1 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -177.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -131.58 152.4 80.36 Favored Pre-proline 0 N--CA 1.453 -0.32 0 C-N-CA 124.205 1.002 . . . . 0.0 108.774 177.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.68 145.26 57.06 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 123.147 2.565 . . . . 0.0 111.627 -177.101 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.09 -175.03 5.08 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 124.846 1.258 . . . . 0.0 108.905 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -138.35 162.01 35.48 Favored 'General case' 0 N--CA 1.456 -0.137 0 CA-C-O 120.915 0.388 . . . . 0.0 111.797 -178.067 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.14 144.05 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 C-N-CA 123.692 0.797 . . . . 0.0 109.378 178.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.454 -0.226 0 C-N-CA 122.966 0.506 . . . . 0.0 109.875 179.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 51.8 m . . . . . 0 CA--C 1.531 0.243 0 N-CA-C 112.225 0.454 . . . . 0.0 112.225 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -70.98 -1.33 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 124.114 3.209 . . . . 0.0 111.927 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.7 t -116.14 140.44 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 176.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.53 152.08 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.062 0.458 . . . . 0.0 110.761 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -102.48 136.38 42.41 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 123.982 0.913 . . . . 0.0 110.162 179.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.5 mp -111.95 145.87 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -177.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -141.39 162.95 34.24 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.692 0.797 . . . . 0.0 110.574 -177.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.83 27.22 54.31 Favored Glycine 0 CA--C 1.527 0.818 0 CA-C-O 119.469 -0.628 . . . . 0.0 113.185 174.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 54.0 mt -61.42 158.88 13.72 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 117.893 0.847 . . . . 0.0 110.415 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.87 -47.98 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -172.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -175.69 -35.86 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.208 0.603 . . . . 0.0 110.601 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -171.95 34.18 0.14 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.684 -0.509 . . . . 0.0 111.955 -175.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 8.8 p -52.32 148.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-N 117.425 0.612 . . . . 0.0 109.732 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.4 m -103.31 168.87 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.082 0 CA-C-O 121.364 0.602 . . . . 0.0 112.141 -172.202 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -57.99 -28.13 64.11 Favored 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 123.985 0.914 . . . . 0.0 111.602 -177.133 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.58 -2.31 38.27 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -176.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -104.17 -32.59 9.07 Favored 'General case' 0 N--CA 1.457 -0.121 0 CA-C-N 118.235 0.47 . . . . 0.0 110.415 177.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.75 -34.33 60.27 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.898 -0.501 . . . . 0.0 110.524 -179.325 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.0 p -76.5 -31.26 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.358 -179.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -83.0 -15.98 49.04 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 119.666 -0.207 . . . . 0.0 111.267 -178.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.72 -10.89 17.15 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -116.02 -9.15 11.78 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 118.632 0.651 . . . . 0.0 112.18 -179.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -68.9 -7.15 32.13 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 118.719 0.691 . . . . 0.0 111.523 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.67 -14.45 60.35 Favored 'General case' 0 CA--C 1.532 0.269 0 O-C-N 122.141 -0.35 . . . . 0.0 110.819 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.5 m-85 -97.13 -16.02 20.66 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 122.54 0.336 . . . . 0.0 111.591 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.78 178.56 35.8 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.85 139.5 33.48 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 124.046 3.164 . . . . 0.0 110.557 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 73.9 mt -110.94 145.76 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.688 0.395 . . . . 0.0 110.501 -177.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.1 t -106.73 -38.42 6.12 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 123.331 0.652 . . . . 0.0 111.463 -177.296 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -160.17 157.05 27.67 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.668 0.27 . . . . 0.0 111.23 179.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 94.4 t -144.14 146.23 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 C-N-CA 123.858 0.863 . . . . 0.0 109.666 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.83 153.79 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 C-N-CA 123.314 0.645 . . . . 0.0 109.513 176.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 46.0 t -127.34 150.66 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -177.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 68.2 mtm -132.27 77.85 69.77 Favored Pre-proline 0 CA--C 1.531 0.222 0 C-N-CA 124.3 1.04 . . . . 0.0 109.104 -177.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.8 -8.81 24.44 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 123.418 2.746 . . . . 0.0 111.72 -175.33 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -72.3 -17.11 61.89 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 122.656 0.382 . . . . 0.0 110.77 178.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 62.9 pttt -138.92 15.08 2.67 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 123.146 0.578 . . . . 0.0 111.91 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 57.53 39.68 27.63 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 124.079 0.952 . . . . 0.0 113.247 178.255 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.58 170.07 15.25 Favored 'General case' 0 CA--C 1.527 0.06 0 C-N-CA 123.043 0.537 . . . . 0.0 110.621 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.43 170.33 22.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 122.863 0.465 . . . . 0.0 110.564 177.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 34.1 mt -134.81 147.11 49.87 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.663 0.785 . . . . 0.0 110.179 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 85.0 t -139.08 132.07 38.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -114.15 119.79 38.31 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -86.97 154.79 20.51 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.426 -179.471 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -74.39 -14.63 60.89 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.507 -177.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -148.08 152.97 38.27 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.703 0.801 . . . . 0.0 109.108 176.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.1 p -66.72 -22.0 29.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -176.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.61 -26.11 60.64 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 122.031 -0.418 . . . . 0.0 110.629 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.03 -31.39 64.34 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.57 -32.12 25.98 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.047 0.423 . . . . 0.0 110.335 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.8 t -70.86 -15.64 62.65 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.198 0.599 . . . . 0.0 110.938 178.518 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 60.2 t30 -99.89 -14.03 18.92 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.029 0.532 . . . . 0.0 111.412 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -87.23 -31.65 20.18 Favored 'General case' 0 N--CA 1.456 -0.175 0 O-C-N 122.128 -0.358 . . . . 0.0 111.717 -177.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.6 t -86.82 -16.12 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.078 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -70.43 -4.69 23.78 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 122.913 0.485 . . . . 0.0 111.161 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -117.32 -32.21 5.03 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.969 0.508 . . . . 0.0 111.459 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.84 -0.93 55.52 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 113.083 0.771 . . . . 0.0 113.083 -176.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.67 -6.64 59.21 Favored 'General case' 0 CA--C 1.534 0.341 0 O-C-N 121.98 -0.45 . . . . 0.0 112.032 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -145.26 3.75 1.04 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.704 0.402 . . . . 0.0 111.88 179.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 49.0 t30 -151.52 171.3 17.79 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -178.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -95.61 155.88 16.56 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 118.38 0.536 . . . . 0.0 110.17 177.568 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -123.35 136.31 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -179.15 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -90.58 154.32 19.68 Favored 'General case' 0 N--CA 1.454 -0.235 0 O-C-N 122.047 -0.408 . . . . 0.0 110.851 -178.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.3 mt -137.33 -42.24 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.916 -177.337 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.49 30.88 3.47 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.936 0.494 . . . . 0.0 111.002 -177.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.7 5.94 80.82 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -130.59 151.21 78.3 Favored Pre-proline 0 N--CA 1.455 -0.207 0 C-N-CA 124.046 0.938 . . . . 0.0 109.01 177.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -72.17 145.97 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 123.375 2.717 . . . . 0.0 111.936 -176.219 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.0 -177.91 6.29 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.757 1.223 . . . . 0.0 108.845 177.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -137.34 158.78 43.66 Favored 'General case' 0 N--CA 1.457 -0.106 0 O-C-N 122.296 -0.253 . . . . 0.0 111.096 -178.552 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.01 142.09 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.23 0.612 . . . . 0.0 109.918 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 . . . . . 0 N--CA 1.456 -0.15 0 C-N-CA 123.187 0.595 . . . . 0.0 110.332 178.15 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.299 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -149.17 166.68 28.1 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 123.087 0.555 . . . . 0.0 110.627 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -148.86 166.93 27.07 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.844 0.458 . . . . 0.0 110.012 -179.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -73.0 -11.48 60.58 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 123.279 0.632 . . . . 0.0 112.163 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -147.14 159.43 43.62 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 123.497 0.719 . . . . 0.0 109.687 178.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 38.5 m-20 -73.87 139.81 77.15 Favored Pre-proline 0 N--CA 1.454 -0.232 0 O-C-N 122.127 -0.358 . . . . 0.0 110.892 -177.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_endo -75.33 -27.59 9.37 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 123.58 2.853 . . . . 0.0 112.83 -177.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.9 p-80 -158.65 2.26 0.1 Allowed 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -178.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -84.82 163.96 18.75 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 118.577 0.626 . . . . 0.0 110.762 -178.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.6 p -135.07 156.0 78.64 Favored Pre-proline 0 C--O 1.231 0.13 0 C-N-CA 123.404 0.682 . . . . 0.0 110.599 -178.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -75.77 -5.04 16.01 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 123.881 3.054 . . . . 0.0 112.543 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.26 35.08 9.77 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.146 0.578 . . . . 0.0 111.656 -177.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.4 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.2 p -66.22 160.51 64.22 Favored Pre-proline 0 CA--C 1.531 0.237 0 C-N-CA 124.08 0.952 . . . . 0.0 111.487 -177.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.4 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 77.7 Cg_endo -70.19 3.02 3.23 Favored 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 124.199 3.266 . . . . 0.0 112.452 178.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.3 t -115.64 141.31 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.087 0.555 . . . . 0.0 109.798 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.0 m -130.71 151.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-O 121.231 0.538 . . . . 0.0 110.898 177.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 22.9 t-80 -100.49 139.23 36.47 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.076 0.95 . . . . 0.0 110.03 179.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 29.7 mm -108.54 145.15 15.86 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 123.646 0.778 . . . . 0.0 110.089 -178.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -143.59 161.2 39.12 Favored 'General case' 0 C--N 1.337 0.044 0 C-N-CA 123.352 0.661 . . . . 0.0 110.376 -177.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.35 25.09 59.8 Favored Glycine 0 CA--C 1.528 0.845 0 CA-C-O 119.442 -0.644 . . . . 0.0 113.658 173.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 68.9 mt -61.21 157.56 15.94 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.398 1.099 . . . . 0.0 109.864 177.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.3 pt -73.08 -41.64 59.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -173.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -173.39 -35.08 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.277 0.631 . . . . 0.0 110.553 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.98 50.59 0.1 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -175.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.9 t -52.32 144.58 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.159 0 C-N-CA 123.5 0.72 . . . . 0.0 109.743 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.82 161.24 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.036 0 CA-C-O 121.084 0.469 . . . . 0.0 111.564 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -60.95 -25.05 66.52 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 123.288 0.635 . . . . 0.0 111.201 -177.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.23 -3.62 52.9 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -178.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -99.43 -31.22 11.76 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.369 0.531 . . . . 0.0 110.757 178.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.4 mp -75.18 -34.05 61.51 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.162 -0.336 . . . . 0.0 110.361 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -77.63 -30.63 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 118.099 0.409 . . . . 0.0 110.348 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -82.14 -17.02 47.84 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.369 -0.207 . . . . 0.0 111.433 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.1 -11.51 16.56 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.5 mt -115.97 -9.97 11.68 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.695 0.68 . . . . 0.0 112.404 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -68.45 -7.05 28.41 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 118.567 0.621 . . . . 0.0 111.637 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -76.01 -14.44 60.22 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 122.692 0.397 . . . . 0.0 110.859 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -98.68 -16.8 18.88 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 122.685 0.394 . . . . 0.0 111.639 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.05 177.05 35.72 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -71.5 141.21 37.91 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 123.775 2.984 . . . . 0.0 110.524 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.2 mt -110.65 147.05 15.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 C-N-CA 122.824 0.45 . . . . 0.0 110.356 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.0 t -107.31 -42.55 4.8 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.279 0.632 . . . . 0.0 111.348 -177.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 54.5 t80 -158.79 159.67 35.41 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 120.778 0.323 . . . . 0.0 111.076 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 76.7 t -143.35 146.85 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 124.008 0.923 . . . . 0.0 109.071 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -147.71 151.26 13.76 Favored 'Isoleucine or valine' 0 C--O 1.231 0.096 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 175.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 45.4 t -128.05 151.01 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.065 0 C-N-CA 122.503 0.321 . . . . 0.0 110.6 -175.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.7 mtm -133.7 81.19 54.04 Favored Pre-proline 0 N--CA 1.455 -0.192 0 C-N-CA 124.113 0.965 . . . . 0.0 108.732 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.43 -12.29 33.2 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.577 2.852 . . . . 0.0 111.729 -175.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -82.02 -5.14 58.12 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.676 0.39 . . . . 0.0 110.685 177.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 35.8 mmtp -130.4 3.83 4.69 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.245 1.018 . . . . 0.0 111.132 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 53.62 33.22 16.0 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.336 1.054 . . . . 0.0 112.087 -176.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -136.51 168.45 19.45 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.309 0.644 . . . . 0.0 110.413 -176.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.49 172.22 18.61 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.591 0.356 . . . . 0.0 110.457 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 36.8 mt -131.4 146.65 52.36 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.566 0.746 . . . . 0.0 110.219 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 84.7 t -137.83 131.75 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -115.37 121.21 42.1 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.055 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.56 153.61 21.69 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.984 0.421 . . . . 0.0 110.325 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -74.83 -13.38 60.56 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.936 0.398 . . . . 0.0 110.496 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -147.46 151.65 36.77 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.58 0.752 . . . . 0.0 109.412 177.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.01 -20.43 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 111.663 0.245 . . . . 0.0 111.663 -175.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.1 tp -74.13 -27.01 60.65 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.946 -0.471 . . . . 0.0 110.743 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.32 -30.44 69.31 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.58 -29.57 27.7 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 117.132 0.466 . . . . 0.0 110.189 178.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 32.0 t -71.97 -12.95 61.48 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.208 0.603 . . . . 0.0 111.366 179.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -102.0 -17.71 15.97 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 122.623 0.369 . . . . 0.0 111.764 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.49 -30.43 25.19 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.135 0.425 . . . . 0.0 111.587 -176.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 25.9 t -88.06 -17.19 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -72.17 -3.75 25.22 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.448 0.299 . . . . 0.0 111.063 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -116.18 -33.43 5.01 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 122.925 0.49 . . . . 0.0 111.113 177.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.02 -7.77 58.4 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -177.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.03 -1.0 56.31 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 122.077 -0.389 . . . . 0.0 111.806 177.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -140.18 -5.94 1.25 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 122.821 0.448 . . . . 0.0 111.725 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.78 173.24 16.71 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -90.73 156.76 17.84 Favored 'General case' 0 CA--C 1.529 0.136 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 175.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.05 136.4 59.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -90.33 150.98 21.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 O-C-N 122.068 -0.395 . . . . 0.0 110.698 -178.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.1 mt -137.43 -38.79 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.932 -177.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -132.9 28.76 4.17 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.288 0.635 . . . . 0.0 111.126 -176.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.01 4.83 86.64 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -176.178 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -130.82 151.9 79.64 Favored Pre-proline 0 N--CA 1.453 -0.287 0 C-N-CA 124.303 1.041 . . . . 0.0 109.066 178.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -70.5 145.26 52.38 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 123.49 2.793 . . . . 0.0 111.905 -176.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.63 -175.79 5.34 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.852 1.261 . . . . 0.0 108.898 178.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -138.68 160.07 40.56 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-O 120.948 0.404 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.67 143.1 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.854 0.862 . . . . 0.0 109.647 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -156.93 162.69 39.63 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 122.973 0.509 . . . . 0.0 110.089 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 34.3 m-85 -65.1 166.38 9.63 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-O 120.817 0.342 . . . . 0.0 110.278 177.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 88.4 p -147.16 176.39 9.99 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 122.956 0.502 . . . . 0.0 109.833 178.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 62.4 p -72.4 -4.18 28.53 Favored 'General case' 0 CA--C 1.529 0.146 0 C-N-CA 122.301 0.24 . . . . 0.0 111.015 178.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 59.7 m -79.07 150.18 31.92 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 122.913 0.485 . . . . 0.0 110.477 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -139.04 -3.76 1.57 Allowed 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 122.706 0.402 . . . . 0.0 111.326 176.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -159.27 135.27 8.83 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 124.005 0.922 . . . . 0.0 108.593 -178.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 78.8 mt -89.23 142.35 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 174.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 46.1 m -78.47 139.56 38.69 Favored 'General case' 0 N--CA 1.457 -0.113 0 N-CA-C 111.627 0.232 . . . . 0.0 111.627 -175.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 54.7 mtp180 40.54 58.87 7.88 Favored Pre-proline 0 CA--C 1.532 0.251 0 C-N-CA 124.851 1.26 . . . . 0.0 112.712 176.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -73.06 137.83 27.12 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 122.821 2.347 . . . . 0.0 110.19 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 79.4 3.57 88.72 Favored Glycine 0 CA--C 1.529 0.928 0 CA-C-O 119.215 -0.769 . . . . 0.0 113.491 177.015 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -147.05 172.95 12.94 Favored 'General case' 0 CA--C 1.528 0.116 0 CA-C-N 118.681 1.24 . . . . 0.0 111.404 178.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 29.0 t -144.03 162.6 35.81 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.27 0.628 . . . . 0.0 109.803 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -79.51 -8.22 59.0 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 111.685 0.254 . . . . 0.0 111.685 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -151.48 144.83 24.78 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 122.899 0.48 . . . . 0.0 110.027 177.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 25.0 t -156.41 -22.64 0.1 Allowed 'General case' 0 C--O 1.233 0.23 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 21.8 tpp85 -154.39 153.32 31.39 Favored 'General case' 0 N--CA 1.456 -0.132 0 C-N-CA 122.657 0.383 . . . . 0.0 110.628 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 48.8 m -132.97 135.64 45.61 Favored 'General case' 0 N--CA 1.456 -0.129 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 176.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 17.0 m -146.32 167.08 7.66 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 C-N-CA 123.911 0.885 . . . . 0.0 109.721 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 48.2 t30 53.73 28.59 8.33 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 123.84 0.856 . . . . 0.0 112.134 -178.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 33.0 t . . . . . 0 C--O 1.251 1.158 0 CA-C-O 117.609 -1.186 . . . . 0.0 110.004 -178.756 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.059 0 N-CA-C 110.558 -1.017 . . . . 0.0 110.558 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.4 167.93 28.76 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 122.975 0.51 . . . . 0.0 110.818 -177.26 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -150.71 162.95 39.72 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 122.983 0.513 . . . . 0.0 110.088 177.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -68.31 -11.38 59.38 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.621 0.768 . . . . 0.0 112.535 -177.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -95.81 7.13 47.17 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 117.934 0.334 . . . . 0.0 111.607 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 55.3 m-20 47.27 61.85 12.91 Favored Pre-proline 0 CA--C 1.533 0.308 0 C-N-CA 123.665 0.786 . . . . 0.0 111.995 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -64.68 -21.21 65.38 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 123.448 2.766 . . . . 0.0 112.657 -176.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 4.3 p-80 -155.52 27.17 0.39 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.072 0.549 . . . . 0.0 110.784 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 28.2 mtpp -129.06 23.06 5.67 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.896 0.878 . . . . 0.0 111.139 -178.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 70.5 p -70.38 154.73 94.28 Favored Pre-proline 0 C--O 1.234 0.242 0 C-N-CA 123.188 0.595 . . . . 0.0 112.149 -175.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.92 -1.74 11.92 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 124.365 3.377 . . . . 0.0 112.327 177.39 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 53.38 33.59 16.15 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.703 0.801 . . . . 0.0 112.468 -178.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.0 m -63.36 158.66 55.85 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 123.797 0.839 . . . . 0.0 112.018 -178.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -70.87 2.61 3.98 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 124.184 3.256 . . . . 0.0 112.325 178.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.6 t -115.26 141.53 31.77 Favored 'Isoleucine or valine' 0 C--N 1.339 0.112 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.59 152.34 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.381 0.61 . . . . 0.0 111.025 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -100.65 141.07 34.02 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.307 1.043 . . . . 0.0 109.882 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.1 mm -110.37 144.92 17.51 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 C-N-CA 123.048 0.539 . . . . 0.0 109.801 -178.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -140.56 159.28 42.54 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 123.464 0.705 . . . . 0.0 110.21 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.66 24.64 60.05 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 119.322 -0.71 . . . . 0.0 113.615 173.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 51.3 mt -59.47 155.82 14.32 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.172 0.986 . . . . 0.0 109.533 177.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -70.58 -38.01 71.85 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.102 0 O-C-N 122.35 -0.219 . . . . 0.0 111.305 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -172.08 -37.19 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.908 0.883 . . . . 0.0 109.506 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.0 56.19 0.04 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 m -53.2 151.4 1.19 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 117.243 0.522 . . . . 0.0 110.422 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.2 m -86.68 166.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.122 0 CA-C-O 121.166 0.508 . . . . 0.0 110.855 -177.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.6 -26.72 68.16 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 122.871 0.468 . . . . 0.0 110.786 -178.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.62 -7.98 56.33 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -94.45 -34.65 12.65 Favored 'General case' 0 N--CA 1.457 -0.11 0 CA-C-N 118.248 0.476 . . . . 0.0 109.772 176.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.4 mt -72.73 -40.23 66.28 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 122.389 0.276 . . . . 0.0 110.93 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.1 p -77.3 -29.87 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 O-C-N 122.083 -0.385 . . . . 0.0 110.739 -176.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -85.88 -14.64 44.26 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 122.128 -0.357 . . . . 0.0 111.146 -178.022 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -101.52 -14.11 17.62 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 178.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.6 mt -115.12 -8.47 12.4 Favored 'General case' 0 CA--C 1.529 0.14 0 CA-C-N 118.566 0.621 . . . . 0.0 112.568 -178.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.3 pt20 -70.54 -6.09 33.78 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.849 0.749 . . . . 0.0 111.67 176.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -76.82 -16.39 59.45 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.53 0.332 . . . . 0.0 110.449 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -95.94 -18.79 20.02 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.529 0.332 . . . . 0.0 111.525 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.43 177.57 37.88 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.6 140.28 35.74 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 124.047 3.165 . . . . 0.0 110.576 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 70.1 mt -110.81 147.1 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.869 0.468 . . . . 0.0 110.258 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -108.48 -39.42 5.42 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.333 0.653 . . . . 0.0 111.494 -177.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -158.83 157.68 32.02 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 117.719 0.236 . . . . 0.0 111.167 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 63.7 t -145.08 146.57 19.74 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 C-N-CA 123.775 0.83 . . . . 0.0 110.091 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.0 p -150.68 151.8 12.14 Favored 'Isoleucine or valine' 0 C--O 1.231 0.102 0 C-N-CA 123.566 0.746 . . . . 0.0 109.24 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.8 p -134.13 150.29 31.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-O 120.736 0.303 . . . . 0.0 110.804 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.2 mpp? -130.55 83.73 61.29 Favored Pre-proline 0 CA--C 1.53 0.202 0 C-N-CA 123.567 0.747 . . . . 0.0 109.51 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -58.79 -18.88 43.77 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 123.938 3.092 . . . . 0.0 113.066 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -78.85 -6.27 55.63 Favored 'General case' 0 C--N 1.341 0.222 0 C-N-CA 122.944 0.498 . . . . 0.0 111.473 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -131.28 3.27 4.29 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.755 0.822 . . . . 0.0 111.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.0 tpp85 54.68 33.65 19.86 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.404 1.082 . . . . 0.0 111.977 -176.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -136.35 165.49 25.67 Favored 'General case' 0 C--O 1.23 0.078 0 C-N-CA 123.005 0.522 . . . . 0.0 110.78 -176.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.97 171.2 17.66 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 122.59 0.356 . . . . 0.0 110.582 178.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.3 mt -131.05 145.16 51.93 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.022 0.929 . . . . 0.0 109.688 178.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -137.9 131.92 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -113.36 121.29 43.92 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 177.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -87.74 154.86 20.24 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-O 120.816 0.341 . . . . 0.0 110.216 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -75.38 -13.24 60.39 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.189 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -147.87 150.25 33.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.72 0.808 . . . . 0.0 109.274 177.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -67.34 -21.98 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.7 tp -74.93 -28.78 60.74 Favored 'General case' 0 N--CA 1.455 -0.204 0 O-C-N 121.875 -0.516 . . . . 0.0 110.534 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.29 -30.46 69.36 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.42 -30.06 33.67 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.699 -0.295 . . . . 0.0 110.618 178.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.5 t -74.22 -32.97 63.21 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.669 0.271 . . . . 0.0 110.685 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -74.81 -17.52 60.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.211 -0.306 . . . . 0.0 110.906 -179.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.37 -30.17 23.86 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -176.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.0 t -89.17 -22.63 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 O-C-N 122.095 -0.378 . . . . 0.0 110.732 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -70.19 -1.67 10.91 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 122.132 -0.355 . . . . 0.0 111.535 179.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.2 t80 -112.75 -37.82 4.76 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 122.836 0.454 . . . . 0.0 110.969 176.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.81 -6.8 57.96 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -79.69 -4.99 54.23 Favored 'General case' 0 N--CA 1.453 -0.284 0 O-C-N 122.027 -0.42 . . . . 0.0 111.7 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -141.39 -4.84 1.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 122.654 0.382 . . . . 0.0 111.894 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 27.2 m-80 -145.53 174.53 11.08 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.505 0.722 . . . . 0.0 109.821 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . 0.423 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -94.73 151.72 19.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 173.972 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -121.96 134.98 63.57 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -88.54 152.19 22.02 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.136 -0.353 . . . . 0.0 110.576 -178.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.7 mt -136.56 -41.57 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.22 -177.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.75 30.09 3.77 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.098 0.559 . . . . 0.0 110.858 -178.157 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.9 4.99 78.15 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -131.7 152.72 80.87 Favored Pre-proline 0 N--CA 1.455 -0.214 0 C-N-CA 124.024 0.93 . . . . 0.0 109.399 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -70.77 144.82 49.69 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 123.408 2.739 . . . . 0.0 111.866 -175.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.99 -175.95 5.35 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.891 1.276 . . . . 0.0 108.929 178.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -140.53 160.46 39.95 Favored 'General case' 0 C--O 1.231 0.092 0 CA-C-O 120.995 0.426 . . . . 0.0 111.503 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -146.96 141.52 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 C-N-CA 123.772 0.829 . . . . 0.0 109.916 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -155.43 160.2 40.45 Favored 'General case' 0 N--CA 1.456 -0.151 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 29.3 m-85 -62.22 170.41 2.29 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 121.114 0.483 . . . . 0.0 111.073 178.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 35.1 t -146.46 172.67 13.18 Favored 'General case' 0 N--CA 1.455 -0.208 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 179.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 52.0 p -72.19 -7.84 51.45 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 122.475 0.31 . . . . 0.0 110.252 176.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 71.2 m -74.55 146.5 42.56 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.638 0.775 . . . . 0.0 110.395 176.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -137.86 -5.19 1.72 Allowed 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 122.958 0.503 . . . . 0.0 111.21 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -160.17 131.25 5.74 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.962 0.905 . . . . 0.0 109.108 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 8.8 tp -76.18 148.66 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 43.8 t -90.24 131.6 35.97 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 122.375 -0.203 . . . . 0.0 111.453 -177.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 45.18 55.52 14.32 Favored Pre-proline 0 CA--C 1.534 0.359 0 C-N-CA 124.501 1.12 . . . . 0.0 113.336 173.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -71.99 -10.25 25.83 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 123.208 2.605 . . . . 0.0 112.465 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 176.56 -2.22 0.03 OUTLIER Glycine 0 CA--C 1.529 0.944 0 CA-C-O 119.732 -0.482 . . . . 0.0 112.725 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -146.29 156.51 43.41 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-N 117.928 0.864 . . . . 0.0 110.014 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 79.6 p -151.44 163.92 37.91 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 122.525 0.33 . . . . 0.0 110.835 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -151.26 156.87 41.75 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.462 0.705 . . . . 0.0 110.028 179.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -147.86 169.98 18.63 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-O 120.994 0.426 . . . . 0.0 110.768 -179.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 77.5 p -130.72 175.51 8.96 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.432 0.693 . . . . 0.0 110.587 179.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 8.7 tpp85 -147.2 163.41 36.43 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-O 120.688 0.28 . . . . 0.0 111.095 -178.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 35.6 m -84.92 9.44 14.39 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.913 0.485 . . . . 0.0 112.174 -179.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 33.7 m -138.51 164.14 27.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.143 0 C-N-CA 123.644 0.778 . . . . 0.0 109.783 -178.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.6 t30 -76.49 132.03 39.36 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.25 1.11 0 CA-C-O 116.809 -1.567 . . . . 0.0 111.129 179.324 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.186 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -148.49 166.01 29.48 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.077 0.551 . . . . 0.0 110.693 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 56.8 t30 -148.91 169.71 19.94 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.031 0.533 . . . . 0.0 110.114 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -77.32 -9.72 59.0 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 123.704 0.802 . . . . 0.0 111.819 178.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -150.96 158.5 44.22 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.548 0.739 . . . . 0.0 109.371 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -70.73 140.52 86.67 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 122.218 -0.301 . . . . 0.0 110.825 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -74.87 -31.34 6.52 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 123.27 2.647 . . . . 0.0 112.124 -177.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -160.71 0.18 0.06 Allowed 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -178.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -80.79 156.81 26.0 Favored 'General case' 0 C--N 1.338 0.075 0 CA-C-N 118.341 0.519 . . . . 0.0 110.578 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 43.7 p -86.47 154.0 56.32 Favored Pre-proline 0 CA--C 1.53 0.196 0 C-N-CA 122.834 0.454 . . . . 0.0 111.058 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -76.67 -4.02 14.48 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 123.742 2.961 . . . . 0.0 112.379 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.17 35.55 13.58 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 123.36 0.664 . . . . 0.0 111.724 -178.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 71.3 p -67.92 160.53 73.46 Favored Pre-proline 0 CA--C 1.533 0.317 0 C-N-CA 123.772 0.829 . . . . 0.0 111.45 -177.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -71.7 5.82 2.29 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 124.471 3.447 . . . . 0.0 112.179 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.8 t -120.57 141.67 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.124 0 C-N-CA 123.066 0.546 . . . . 0.0 109.57 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 31.6 m -130.28 149.86 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.115 0 CA-C-O 121.199 0.523 . . . . 0.0 111.063 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -98.14 142.08 30.27 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.338 1.055 . . . . 0.0 110.127 177.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.6 mm -111.56 145.5 17.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 C-N-CA 123.06 0.544 . . . . 0.0 109.723 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -142.11 161.21 38.57 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.254 0.622 . . . . 0.0 110.377 -179.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 81.67 24.23 56.44 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.592 -0.56 . . . . 0.0 113.641 173.151 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.5 mt -63.01 159.23 17.53 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.1 0.95 . . . . 0.0 110.072 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.3 pt -74.2 -42.45 51.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.93 -35.46 0.01 OUTLIER 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.074 0.55 . . . . 0.0 110.676 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -177.04 50.31 0.1 Allowed Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.1 t -50.61 146.19 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 123.565 0.746 . . . . 0.0 109.735 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.8 m -96.53 161.92 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.072 0 CA-C-O 121.182 0.515 . . . . 0.0 111.4 -176.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -60.1 -24.72 64.86 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.01 0.524 . . . . 0.0 111.376 -176.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.22 -6.17 56.0 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -99.43 -31.58 11.58 Favored 'General case' 0 CA--C 1.529 0.137 0 CA-C-N 118.155 0.434 . . . . 0.0 110.204 177.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -69.83 -39.11 76.67 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.1 p -78.44 -30.79 15.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 121.157 -0.217 . . . . 0.0 110.52 -176.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -82.2 -14.37 55.68 Favored 'General case' 0 N--CA 1.456 -0.14 0 O-C-N 122.072 -0.393 . . . . 0.0 111.715 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.67 -11.8 15.36 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 94.3 mt -115.95 -8.36 11.89 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.847 0.749 . . . . 0.0 112.481 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -70.42 -6.55 36.54 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.564 0.62 . . . . 0.0 111.9 176.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -76.42 -15.58 59.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 122.488 0.315 . . . . 0.0 110.518 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -96.33 -17.15 20.88 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 122.446 0.298 . . . . 0.0 111.355 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.72 176.35 35.56 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -71.46 140.4 36.44 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 124.186 3.257 . . . . 0.0 110.586 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.7 mt -111.63 145.69 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.091 0 C-N-CA 122.563 0.345 . . . . 0.0 110.232 -177.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.8 t -105.36 -41.96 5.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 123.287 0.635 . . . . 0.0 111.278 -177.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -158.92 159.55 35.06 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.742 0.306 . . . . 0.0 111.098 178.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 87.7 t -143.6 147.46 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.827 0.851 . . . . 0.0 109.692 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.1 p -148.5 149.74 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.094 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 175.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.87 149.35 33.53 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -130.54 82.02 66.2 Favored Pre-proline 0 N--CA 1.456 -0.137 0 C-N-CA 123.667 0.787 . . . . 0.0 109.32 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -58.82 -19.09 45.09 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.849 3.032 . . . . 0.0 112.838 -178.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -75.15 -13.47 60.47 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.905 0.482 . . . . 0.0 111.071 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -125.82 4.65 7.37 Favored 'General case' 0 CA--C 1.527 0.089 0 C-N-CA 123.541 0.737 . . . . 0.0 111.284 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.1 tpp85 55.18 32.08 17.72 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.128 0.971 . . . . 0.0 111.993 -177.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -135.87 166.32 23.57 Favored 'General case' 0 N--CA 1.457 -0.106 0 C-N-CA 123.059 0.544 . . . . 0.0 110.803 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.72 172.38 15.68 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 122.863 0.465 . . . . 0.0 110.725 179.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 30.6 mt -132.97 145.81 51.21 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.645 0.778 . . . . 0.0 109.772 177.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 86.2 t -137.26 132.42 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -114.53 117.72 31.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -85.2 153.5 22.59 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 120.99 0.424 . . . . 0.0 110.251 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -74.62 -13.15 60.61 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.388 -177.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -148.32 151.28 35.1 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.76 0.824 . . . . 0.0 108.965 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.9 p -66.42 -21.95 29.36 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.8 tp -73.31 -24.63 60.42 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 121.948 -0.47 . . . . 0.0 110.492 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.24 -31.16 64.04 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.22 -31.23 23.28 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-N 117.126 0.463 . . . . 0.0 110.133 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 t -71.54 -18.48 62.26 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.904 0.482 . . . . 0.0 110.913 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -96.68 -17.83 20.08 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 122.74 0.416 . . . . 0.0 111.127 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.82 -31.42 28.12 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.13 -0.356 . . . . 0.0 111.663 -177.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 32.1 t -85.74 -14.36 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 177.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -72.97 -2.79 22.41 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.137 0.575 . . . . 0.0 111.118 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -121.03 -34.85 3.44 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 122.701 0.401 . . . . 0.0 110.996 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.73 -9.59 58.06 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -176.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.72 -0.21 55.89 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 122.663 0.385 . . . . 0.0 111.654 176.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -136.51 -10.13 1.89 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.907 0.483 . . . . 0.0 111.726 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 50.0 t30 -154.12 170.62 20.74 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -86.88 155.63 20.17 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 175.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.73 136.15 61.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -178.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -89.04 151.21 22.39 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.121 -0.362 . . . . 0.0 110.758 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.8 mt -136.5 -38.46 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.839 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.37 29.43 3.0 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.28 0.632 . . . . 0.0 111.027 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.18 3.79 81.97 Favored Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.716 -0.554 . . . . 0.0 111.716 -176.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -130.56 151.8 79.29 Favored Pre-proline 0 N--CA 1.454 -0.24 0 C-N-CA 124.436 1.094 . . . . 0.0 109.03 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo -70.77 146.22 53.37 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 123.666 2.91 . . . . 0.0 112.143 -177.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.86 -175.55 5.37 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.193 1.397 . . . . 0.0 109.205 179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -140.59 159.44 42.19 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.004 0.43 . . . . 0.0 111.759 -178.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.72 143.13 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 C-N-CA 123.903 0.881 . . . . 0.0 109.902 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -156.91 162.96 39.64 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -60.86 168.45 2.34 Favored 'General case' 0 N--CA 1.455 -0.206 0 O-C-N 122.078 -0.389 . . . . 0.0 111.284 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 41.3 t -140.66 164.35 30.43 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 123.117 0.567 . . . . 0.0 110.377 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 23.9 m -68.65 -12.76 61.77 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 174.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 35.5 t -73.04 152.74 41.16 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.664 0.786 . . . . 0.0 110.986 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.3 pt20 -138.74 -1.0 1.87 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.159 0.584 . . . . 0.0 110.743 175.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -160.86 129.81 4.71 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 123.854 0.861 . . . . 0.0 108.948 -177.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 77.2 mt -83.25 148.2 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 175.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.2 m -79.3 139.5 37.82 Favored 'General case' 0 N--CA 1.457 -0.101 0 CA-C-O 120.676 0.275 . . . . 0.0 111.741 -177.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 44.97 52.63 10.61 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 124.651 1.18 . . . . 0.0 113.132 176.231 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -76.06 166.38 28.02 Favored 'Trans proline' 0 N--CA 1.451 -1.008 0 C-N-CA 123.35 2.7 . . . . 0.0 111.072 -177.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 62.81 -130.87 43.01 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -147.76 165.08 31.6 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 123.397 0.679 . . . . 0.0 110.516 -178.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 30.9 t -150.23 158.14 43.84 Favored 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 122.796 0.438 . . . . 0.0 110.638 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -150.2 154.83 38.66 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.219 0.608 . . . . 0.0 110.043 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -148.93 155.97 41.62 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 122.775 0.43 . . . . 0.0 110.933 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 51.1 m -134.7 148.15 50.25 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 123.913 0.885 . . . . 0.0 109.267 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 17.1 ttm180 -151.97 163.61 38.9 Favored 'General case' 0 CA--C 1.528 0.134 0 O-C-N 122.414 -0.179 . . . . 0.0 110.926 -174.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.4 m -99.59 6.22 45.79 Favored 'General case' 0 CA--C 1.528 0.108 0 N-CA-C 112.738 0.644 . . . . 0.0 112.738 -176.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.8 m -80.18 164.94 2.96 Favored 'Isoleucine or valine' 0 C--O 1.23 0.034 0 CA-C-N 117.982 0.356 . . . . 0.0 110.946 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -90.72 5.46 48.1 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 122.917 0.487 . . . . 0.0 111.718 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 28.0 m . . . . . 0 C--O 1.251 1.179 0 CA-C-O 117.27 -1.348 . . . . 0.0 111.196 -179.821 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.134 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -147.4 164.46 33.23 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 122.892 0.477 . . . . 0.0 110.726 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -149.83 170.96 17.55 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.156 0.582 . . . . 0.0 109.746 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -69.28 147.33 51.34 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 176.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 40.9 m-20 54.98 -179.66 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.156 0.982 . . . . 0.0 112.124 -176.059 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -86.99 136.53 33.93 Favored Pre-proline 0 CA--C 1.531 0.243 0 O-C-N 121.904 -0.498 . . . . 0.0 110.44 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -83.79 157.34 13.83 Favored 'Trans proline' 0 N--CA 1.451 -0.985 0 C-N-CA 123.956 3.104 . . . . 0.0 110.401 176.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.4 p-80 48.83 15.48 0.09 Allowed 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 116.369 1.988 . . . . 0.0 116.369 173.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -101.5 158.72 15.87 Favored 'General case' 0 N--CA 1.461 0.093 0 CA-C-N 118.925 0.784 . . . . 0.0 110.093 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 49.1 p -139.93 156.98 70.36 Favored Pre-proline 0 C--O 1.232 0.178 0 C-N-CA 123.419 0.688 . . . . 0.0 110.048 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -74.64 -3.51 13.98 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 123.584 2.856 . . . . 0.0 112.35 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.34 35.74 14.6 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.474 0.71 . . . . 0.0 112.057 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.0 m -61.43 158.79 36.2 Favored Pre-proline 0 CA--C 1.53 0.189 0 C-N-CA 124.091 0.956 . . . . 0.0 112.207 -177.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.51 0.06 5.99 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 124.229 3.286 . . . . 0.0 111.904 177.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 54.1 t -114.29 141.41 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 176.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.9 m -129.56 151.81 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.139 0 CA-C-O 121.332 0.587 . . . . 0.0 110.906 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.9 t-80 -98.72 136.21 39.1 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.201 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.3 mm -106.62 144.59 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.099 0.56 . . . . 0.0 109.752 -178.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -141.77 161.82 37.0 Favored 'General case' 0 C--N 1.338 0.074 0 C-N-CA 123.345 0.658 . . . . 0.0 110.584 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 77.3 24.93 64.69 Favored Glycine 0 CA--C 1.527 0.843 0 CA-C-O 119.642 -0.532 . . . . 0.0 113.086 174.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.6 mt -61.44 159.52 12.62 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 117.956 0.878 . . . . 0.0 110.638 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.1 pt -73.34 -41.52 57.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -173.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -173.94 -35.58 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 123.634 0.774 . . . . 0.0 109.97 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.45 49.65 0.06 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -176.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 14.5 p -52.83 148.49 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 122.897 0.479 . . . . 0.0 110.083 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -88.2 163.06 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 CA-C-O 121.324 0.583 . . . . 0.0 111.996 -171.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -62.24 -27.48 69.03 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.799 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.71 -3.07 49.41 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 123.087 0.555 . . . . 0.0 112.318 -178.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -104.29 -29.84 10.52 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.427 0.558 . . . . 0.0 109.711 177.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 49.8 mt -72.67 -38.97 67.46 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 122.546 0.339 . . . . 0.0 110.924 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.67 -30.23 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.442 -178.32 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -82.38 -16.01 50.68 Favored 'General case' 0 N--CA 1.453 -0.279 0 O-C-N 122.168 -0.332 . . . . 0.0 111.506 -178.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.44 -12.91 16.27 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 112.918 0.711 . . . . 0.0 112.918 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.9 mt -114.05 -7.62 13.08 Favored 'General case' 0 C--N 1.339 0.11 0 CA-C-N 118.516 0.598 . . . . 0.0 112.506 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.15 -6.07 31.56 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 118.731 0.696 . . . . 0.0 111.784 176.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -77.09 -13.62 59.93 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.801 0.44 . . . . 0.0 110.769 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -98.64 -18.16 18.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 122.531 0.332 . . . . 0.0 111.477 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.94 177.08 36.43 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -70.94 140.28 37.92 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 124.176 3.251 . . . . 0.0 110.3 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.405 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.1 mt -112.21 145.9 17.71 Favored 'Isoleucine or valine' 0 C--O 1.231 0.092 0 C-N-CA 122.746 0.419 . . . . 0.0 110.237 -177.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 t -105.88 -41.96 5.27 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.243 0.617 . . . . 0.0 111.395 -177.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -159.85 160.27 33.52 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-O 120.695 0.283 . . . . 0.0 111.035 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.8 t -145.24 147.01 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 123.906 0.882 . . . . 0.0 109.526 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.89 155.39 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.141 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 176.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 29.1 t -125.87 153.38 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.08 0 C-N-CA 122.503 0.321 . . . . 0.0 110.995 -177.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.5 mtm -135.56 77.13 53.35 Favored Pre-proline 0 CA--C 1.532 0.265 0 C-N-CA 124.237 1.015 . . . . 0.0 109.385 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -60.59 -16.68 44.33 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.972 3.115 . . . . 0.0 113.245 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -77.13 -6.56 53.34 Favored 'General case' 0 C--N 1.339 0.132 0 C-N-CA 123.009 0.524 . . . . 0.0 111.618 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -133.22 3.68 3.68 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.216 0.606 . . . . 0.0 111.386 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 13.4 tpp85 55.3 38.26 30.1 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.7 0.8 . . . . 0.0 111.152 -173.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 83.1 mt-30 -134.0 166.24 23.16 Favored 'General case' 0 N--CA 1.458 -0.05 0 C-N-CA 123.684 0.794 . . . . 0.0 110.608 -176.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.04 171.31 18.06 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 122.985 0.514 . . . . 0.0 109.871 176.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -132.18 146.01 51.74 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 123.407 0.683 . . . . 0.0 110.072 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 93.3 t -137.37 128.71 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 118.1 33.78 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.405 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.6 m-85 -85.85 154.87 21.24 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.348 -179.148 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -75.23 -12.24 60.24 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 120.704 0.287 . . . . 0.0 110.399 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -148.62 152.16 36.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 123.784 0.834 . . . . 0.0 109.14 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.49 -21.41 26.19 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 122.076 -0.39 . . . . 0.0 111.614 -175.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.6 tp -75.56 -28.87 59.17 Favored 'General case' 0 N--CA 1.452 -0.353 0 O-C-N 122.008 -0.433 . . . . 0.0 110.529 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.16 -30.92 71.71 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.37 -31.41 37.84 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.894 0.347 . . . . 0.0 110.301 178.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 44.2 t -70.81 -29.53 65.72 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 122.205 0.202 . . . . 0.0 110.983 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -78.07 -19.6 53.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 119.462 -0.304 . . . . 0.0 111.476 -179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.88 -32.06 23.4 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.108 0.413 . . . . 0.0 111.606 -176.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.5 t -86.76 -19.51 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -68.65 -14.1 62.79 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.102 -0.374 . . . . 0.0 110.99 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -104.4 -37.85 7.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.487 0.315 . . . . 0.0 111.256 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.65 -4.33 58.96 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -77.9 -9.15 58.93 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.228 0.467 . . . . 0.0 111.486 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -141.07 -1.86 1.34 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.681 0.392 . . . . 0.0 111.652 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.5 m-80 -144.41 175.7 9.92 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.131 0.572 . . . . 0.0 109.921 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . 0.411 ' CD ' ' H ' ' A' ' 156' ' ' GLN . 0.0 OUTLIER -98.48 155.86 17.05 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.714 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.95 135.59 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -89.38 155.94 19.01 Favored 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 122.045 -0.409 . . . . 0.0 111.085 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.9 mt -138.0 -42.51 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.786 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.84 32.2 2.99 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.236 0.614 . . . . 0.0 111.122 -177.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.07 4.84 81.32 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 -176.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -128.99 150.67 75.95 Favored Pre-proline 0 N--CA 1.455 -0.202 0 C-N-CA 123.83 0.852 . . . . 0.0 109.215 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -71.55 147.58 52.02 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.464 2.776 . . . . 0.0 111.702 -177.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -153.45 -174.6 5.01 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.072 1.349 . . . . 0.0 108.731 178.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -139.04 160.24 40.24 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-O 120.986 0.422 . . . . 0.0 111.345 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.7 p -147.23 140.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.575 0.75 . . . . 0.0 109.264 179.087 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -157.26 161.12 39.19 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 122.91 0.484 . . . . 0.0 110.398 179.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -66.19 163.78 17.04 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 175.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 94.3 p -149.86 -175.8 5.18 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 176.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 58.7 p -72.97 1.95 7.87 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 122.614 0.366 . . . . 0.0 111.33 177.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 91.4 p -73.35 155.28 39.56 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 122.868 0.467 . . . . 0.0 110.771 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -145.55 -9.78 0.55 Allowed 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 175.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -161.46 136.7 7.54 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.748 0.819 . . . . 0.0 108.844 -178.16 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 73.5 mt -86.72 143.41 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.122 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 174.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.9 m -72.94 134.68 44.85 Favored 'General case' 0 C--N 1.334 -0.085 0 C-N-CA 122.183 0.193 . . . . 0.0 110.993 -177.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 71.5 ttt180 40.16 66.0 3.53 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 124.767 1.227 . . . . 0.0 112.199 179.148 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -77.03 62.49 7.46 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 124.34 3.36 . . . . 0.0 111.13 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 82.33 0.77 90.11 Favored Glycine 0 CA--C 1.527 0.823 0 C-N-CA 123.304 0.478 . . . . 0.0 112.144 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -83.28 159.17 21.98 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 117.435 0.618 . . . . 0.0 110.364 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 66.3 m -146.42 160.65 41.79 Favored 'General case' 0 C--O 1.23 0.077 0 C-N-CA 123.273 0.629 . . . . 0.0 110.012 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -147.24 154.39 40.95 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 123.03 0.532 . . . . 0.0 110.262 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 26.8 t0 -142.8 9.33 1.74 Allowed 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.363 0.665 . . . . 0.0 110.952 179.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 33.6 t -61.8 144.27 55.04 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.579 -0.701 . . . . 0.0 109.86 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 18.3 ptp180 -152.1 170.7 19.31 Favored 'General case' 0 CA--C 1.528 0.116 0 C-N-CA 122.947 0.499 . . . . 0.0 111.033 -175.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.8 m -82.24 8.33 11.4 Favored 'General case' 0 C--O 1.232 0.155 0 C-N-CA 124.113 0.965 . . . . 0.0 113.166 -175.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 31.3 m -136.35 165.61 28.58 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 C-N-CA 122.948 0.499 . . . . 0.0 110.888 -177.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 30.9 m120 -80.82 -15.3 56.75 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 122.25 0.22 . . . . 0.0 111.032 178.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 33.0 t . . . . . 0 C--O 1.252 1.201 0 CA-C-O 117.694 -1.146 . . . . 0.0 109.855 178.099 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.054 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -136.91 154.91 50.34 Favored 'General case' 0 CA--C 1.527 0.077 0 C-N-CA 123.467 0.707 . . . . 0.0 109.39 179.325 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 -146.83 -5.58 0.53 Allowed 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -176.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 85.0 m-85 -142.12 180.0 6.57 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 123.283 0.633 . . . . 0.0 109.717 -177.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -89.23 133.63 34.36 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 177.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 44.42 47.99 4.09 Favored Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 113.963 1.098 . . . . 0.0 113.963 -178.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.36 -23.22 24.17 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 122.184 1.923 . . . . 0.0 111.563 -179.075 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -157.12 9.15 0.19 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.481 0.713 . . . . 0.0 111.542 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -76.33 163.99 26.47 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 122.961 0.504 . . . . 0.0 110.517 -178.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 33.2 p -136.5 152.47 74.83 Favored Pre-proline 0 CA--C 1.528 0.121 0 C-N-CA 122.96 0.504 . . . . 0.0 110.359 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -76.57 -5.3 15.95 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 123.893 3.062 . . . . 0.0 112.749 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.09 33.12 8.65 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 123.487 0.715 . . . . 0.0 111.918 -177.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 63.8 m -63.41 157.55 63.72 Favored Pre-proline 0 CA--C 1.53 0.18 0 C-N-CA 123.805 0.842 . . . . 0.0 111.757 -177.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -71.88 -3.76 13.81 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.831 3.021 . . . . 0.0 111.568 177.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 67.5 t -111.11 139.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.62 148.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 CA-C-O 121.319 0.58 . . . . 0.0 110.732 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -95.46 137.25 34.78 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.189 0.995 . . . . 0.0 110.35 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 26.0 mm -105.85 143.92 16.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 123.194 0.597 . . . . 0.0 109.787 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -142.56 160.53 40.11 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 123.132 0.573 . . . . 0.0 110.822 -178.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.81 26.09 56.86 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 119.457 -0.635 . . . . 0.0 113.523 173.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.9 mt -62.53 156.06 24.04 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.144 0.972 . . . . 0.0 109.814 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -70.57 -41.63 77.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -173.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -173.12 -34.78 0.01 OUTLIER 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.31 0.644 . . . . 0.0 110.676 -179.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.93 48.93 0.12 Allowed Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -176.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.7 t -51.56 143.21 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 C-N-CA 123.41 0.684 . . . . 0.0 109.697 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.8 m -95.72 164.98 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.119 0 CA-C-O 121.308 0.575 . . . . 0.0 111.637 -175.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -61.08 -26.02 67.36 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.538 0.735 . . . . 0.0 111.247 -178.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.45 -5.56 56.75 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 -177.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -98.11 -30.46 12.65 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.28 0.491 . . . . 0.0 109.922 177.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.2 mt -73.33 -38.8 65.65 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 122.556 0.342 . . . . 0.0 110.95 -178.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.6 p -77.27 -29.96 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.241 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.6 mm-40 -82.76 -15.14 52.92 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 119.445 -0.312 . . . . 0.0 111.643 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -108.31 -10.61 15.33 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -116.96 -9.61 11.1 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 118.501 0.591 . . . . 0.0 112.396 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -69.83 -7.34 39.13 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.7 0.682 . . . . 0.0 111.633 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -74.12 -18.47 60.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.508 0.323 . . . . 0.0 110.593 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -92.64 -19.07 22.25 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 122.369 0.268 . . . . 0.0 111.535 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.39 176.77 35.71 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 139.64 41.24 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.978 3.118 . . . . 0.0 110.93 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.9 mt -111.59 145.67 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.876 0.471 . . . . 0.0 110.226 -177.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.5 t -104.09 -41.28 5.88 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.193 0.597 . . . . 0.0 111.355 -177.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . 0.411 ' CG ' ' HA ' ' A' ' 177' ' ' PRO . 55.5 t80 -161.42 161.18 30.16 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.563 0.22 . . . . 0.0 111.532 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 69.2 t -143.97 147.16 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 123.903 0.881 . . . . 0.0 109.625 179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -147.29 153.33 12.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 176.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 37.7 t -128.46 152.99 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.052 0 C-N-CA 122.42 0.288 . . . . 0.0 111.019 -174.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.6 mtm -134.28 79.17 56.1 Favored Pre-proline 0 CA--C 1.532 0.274 0 C-N-CA 124.21 1.004 . . . . 0.0 109.314 178.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.85 -21.54 57.81 Favored 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 123.598 2.866 . . . . 0.0 113.134 -177.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -83.48 1.89 39.5 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 122.939 0.495 . . . . 0.0 112.015 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -128.79 0.67 5.41 Favored 'General case' 0 C--N 1.338 0.086 0 C-N-CA 123.802 0.841 . . . . 0.0 111.158 176.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.5 tpp85 53.35 33.04 14.84 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.014 0.926 . . . . 0.0 111.116 -172.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -136.81 167.86 20.65 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.305 0.642 . . . . 0.0 110.825 -175.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.36 173.57 15.45 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.89 0.476 . . . . 0.0 110.175 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 40.4 mt -132.81 145.11 50.7 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 123.187 0.595 . . . . 0.0 109.837 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.2 t -135.44 131.33 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -114.83 117.74 31.58 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 60.8 m-85 -84.16 156.75 21.94 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.303 179.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -70.4 -18.41 63.03 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.284 -178.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -154.19 159.21 41.27 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 123.784 0.834 . . . . 0.0 109.579 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 27.2 m -65.42 -15.23 18.16 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.099 0 O-C-N 122.053 -0.405 . . . . 0.0 111.843 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 10.3 tt -67.61 -33.2 74.51 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.327 0.512 . . . . 0.0 110.384 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -76.14 -31.85 54.06 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.48 -32.46 32.49 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.372 0.586 . . . . 0.0 110.535 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.9 t -75.73 -8.08 55.95 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 123.101 0.56 . . . . 0.0 111.302 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -106.74 -16.31 14.52 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 122.409 0.283 . . . . 0.0 111.039 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -86.79 -34.93 19.41 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.063 -0.398 . . . . 0.0 111.33 -178.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.5 t -83.32 -15.78 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -71.37 -5.33 31.75 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 122.797 0.439 . . . . 0.0 111.265 179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -116.52 -37.68 3.67 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 122.899 0.48 . . . . 0.0 110.911 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.68 -5.73 59.01 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -176.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.4 -4.36 58.4 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 122.069 -0.394 . . . . 0.0 111.441 177.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -142.07 -6.5 0.96 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 122.773 0.429 . . . . 0.0 111.686 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -144.76 175.13 10.4 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 123.387 0.675 . . . . 0.0 109.5 -179.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . 0.441 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -95.98 152.43 18.52 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 172.733 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.84 135.32 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.12 149.67 23.07 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 121.954 -0.466 . . . . 0.0 110.758 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 56.4 mt -137.38 -39.67 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.939 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.42 29.48 3.94 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.151 0.58 . . . . 0.0 111.033 -176.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.09 4.54 84.15 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -132.09 152.84 80.91 Favored Pre-proline 0 C--O 1.233 0.224 0 C-N-CA 124.102 0.961 . . . . 0.0 109.269 177.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -71.47 144.47 45.3 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 123.583 2.855 . . . . 0.0 111.764 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.74 -175.85 5.19 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.983 1.313 . . . . 0.0 108.765 177.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -138.5 160.26 40.0 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-O 120.927 0.394 . . . . 0.0 111.628 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.1 p -147.84 143.48 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.13 0 C-N-CA 123.785 0.834 . . . . 0.0 109.693 178.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -156.04 161.45 40.43 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.259 0.624 . . . . 0.0 110.066 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -64.64 162.91 14.76 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.725 0.298 . . . . 0.0 110.648 177.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 44.3 t -147.98 159.87 43.43 Favored 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 59.1 p -74.69 8.32 2.47 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 122.69 0.396 . . . . 0.0 110.253 176.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.453 ' C ' ' H ' ' A' ' 173' ' ' LYS . 83.5 p -59.46 -43.85 93.12 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 124.369 1.068 . . . . 0.0 110.901 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 48.86 -10.72 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 128.906 2.882 . . . . 0.0 116.898 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.453 ' H ' ' C ' ' A' ' 171' ' ' SER . 16.5 tppt? -165.15 138.3 4.58 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 123.556 0.743 . . . . 0.0 109.526 -177.252 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 81.5 mt -84.34 156.99 3.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 174.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 80.8 p -81.18 -8.28 59.73 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 114.339 1.237 . . . . 0.0 114.339 -172.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . 0.446 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 37.7 ptt180 -154.89 36.49 0.07 OUTLIER Pre-proline 0 CA--C 1.535 0.383 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -177.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . 0.446 ' CD ' ' N ' ' A' ' 176' ' ' ARG . 87.6 Cg_endo -72.66 111.67 3.3 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.62 2.213 . . . . 0.0 111.123 -176.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 70.45 -9.81 3.13 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 123.958 0.79 . . . . 0.0 114.021 176.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -157.81 158.88 36.03 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.094 0.947 . . . . 0.0 110.051 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.2 m -133.31 153.33 51.66 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 123.073 0.549 . . . . 0.0 110.422 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -150.36 155.17 39.11 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 122.691 0.396 . . . . 0.0 110.752 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -140.62 154.12 46.32 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.688 0.795 . . . . 0.0 109.816 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 49.5 m -67.5 137.34 55.72 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 120.665 0.269 . . . . 0.0 110.321 -178.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 31.4 ptt-85 -160.38 167.19 27.9 Favored 'General case' 0 N--CA 1.458 -0.072 0 C-N-CA 123.594 0.758 . . . . 0.0 110.115 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.4 m -78.63 130.26 35.68 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 122.401 0.281 . . . . 0.0 110.25 178.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 11.2 m -149.38 163.09 4.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 C-N-CA 124.272 1.029 . . . . 0.0 109.159 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.6 t30 -79.06 134.14 36.77 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 178.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 60.5 m . . . . . 0 C--O 1.251 1.156 0 CA-C-O 117.527 -1.225 . . . . 0.0 110.075 179.878 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 111.141 -0.783 . . . . 0.0 111.141 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -149.41 162.16 40.65 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.896 0.478 . . . . 0.0 110.988 179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 45.9 t30 -151.98 163.53 39.09 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.638 0.775 . . . . 0.0 108.943 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 53.82 -163.92 0.1 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.689 0.796 . . . . 0.0 111.695 -177.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -115.23 2.13 13.98 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.007 0.523 . . . . 0.0 111.458 178.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.422 ' N ' ' CD ' ' A' ' 90' ' ' PRO . 14.9 p-10 -144.09 43.34 0.42 Allowed Pre-proline 0 CA--C 1.537 0.478 0 N-CA-C 113.17 0.804 . . . . 0.0 113.17 -177.691 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.422 ' CD ' ' N ' ' A' ' 89' ' ' ASP . 73.6 Cg_endo -69.71 -14.83 36.82 Favored 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 122.735 2.29 . . . . 0.0 112.324 -177.759 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -147.52 11.0 0.98 Allowed 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -177.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -83.6 158.57 21.87 Favored 'General case' 0 C--O 1.231 0.108 0 O-C-N 122.154 -0.341 . . . . 0.0 110.673 -179.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 22.2 p -80.31 153.42 74.11 Favored Pre-proline 0 C--N 1.333 -0.118 0 C-N-CA 122.806 0.442 . . . . 0.0 111.121 -178.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -76.03 -8.05 18.62 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.574 2.849 . . . . 0.0 112.299 -178.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.32 34.89 9.6 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.48 0.712 . . . . 0.0 111.42 -177.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 60.8 p -72.2 159.38 85.58 Favored Pre-proline 0 CA--C 1.532 0.278 0 C-N-CA 123.956 0.902 . . . . 0.0 112.486 -175.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -72.76 4.25 3.74 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 124.159 3.239 . . . . 0.0 112.358 178.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.5 140.43 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 123.279 0.631 . . . . 0.0 109.454 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.0 m -128.16 145.37 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 CA-C-O 121.199 0.523 . . . . 0.0 110.831 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -96.9 134.4 40.28 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.241 1.016 . . . . 0.0 109.932 177.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -107.4 145.78 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.432 0.693 . . . . 0.0 109.408 -178.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.0 mtt180 -141.33 160.98 38.99 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.64 0.776 . . . . 0.0 109.892 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.84 28.49 50.54 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-O 119.545 -0.586 . . . . 0.0 113.438 175.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.9 mt -57.73 154.88 10.97 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 118.241 1.02 . . . . 0.0 109.877 177.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -68.19 -39.39 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.077 0 O-C-N 122.084 -0.385 . . . . 0.0 111.071 -176.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -171.62 -35.92 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.307 1.043 . . . . 0.0 109.742 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.48 55.92 0.04 OUTLIER Glycine 0 C--N 1.339 0.718 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -177.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.7 m -52.75 151.17 1.1 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-N 117.076 0.438 . . . . 0.0 110.511 178.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.7 m -87.46 166.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.953 0.406 . . . . 0.0 111.262 -177.004 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -61.99 -23.71 66.58 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.163 0.585 . . . . 0.0 111.242 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.31 -6.03 57.28 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -92.9 -35.14 13.5 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.565 0.62 . . . . 0.0 110.213 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 91.4 mt -73.25 -36.28 66.36 Favored 'General case' 0 N--CA 1.454 -0.274 0 O-C-N 122.385 -0.197 . . . . 0.0 111.266 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -76.97 -31.04 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.317 -177.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -82.14 -17.68 45.54 Favored 'General case' 0 N--CA 1.455 -0.219 0 O-C-N 122.185 -0.322 . . . . 0.0 111.167 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -9.13 18.31 Favored 'General case' 0 N--CA 1.455 -0.21 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.0 mt -120.82 -8.97 9.37 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -69.3 -7.19 34.79 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.866 0.757 . . . . 0.0 111.687 177.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -76.91 -14.99 59.81 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 122.025 -0.422 . . . . 0.0 110.731 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -96.08 -16.82 21.34 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.578 0.351 . . . . 0.0 111.592 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.4 176.55 34.6 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -70.59 140.75 40.24 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 123.889 3.06 . . . . 0.0 110.877 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 78.3 mt -110.81 146.63 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.083 0 C-N-CA 122.816 0.446 . . . . 0.0 110.487 -178.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -106.43 -42.5 5.0 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.009 0.524 . . . . 0.0 111.478 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -159.11 159.28 34.32 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 120.837 0.351 . . . . 0.0 111.231 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.6 t -143.78 146.57 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.086 0 C-N-CA 124.001 0.92 . . . . 0.0 109.841 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.97 153.45 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 42.8 t -131.69 149.63 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.069 0 CA-C-O 120.717 0.294 . . . . 0.0 110.595 -176.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 81.55 67.52 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -60.29 -17.67 48.11 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.811 3.008 . . . . 0.0 112.877 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -82.9 -4.28 57.97 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.802 0.441 . . . . 0.0 111.484 179.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -129.23 4.04 5.22 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.861 0.864 . . . . 0.0 111.194 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 3.3 tpt180 54.58 30.44 13.16 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 123.847 0.859 . . . . 0.0 112.058 -177.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -138.89 166.59 24.05 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 123.119 0.568 . . . . 0.0 110.813 -174.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.98 172.17 16.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.213 0.605 . . . . 0.0 110.487 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.5 mt -134.14 146.48 50.26 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.443 0.697 . . . . 0.0 109.794 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.91 132.7 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -115.81 122.29 44.97 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -87.89 156.03 19.57 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -178.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.3 -14.24 60.87 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.563 -178.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -149.49 153.47 37.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.68 0.792 . . . . 0.0 108.935 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.4 p -67.64 -20.92 26.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 O-C-N 122.175 -0.328 . . . . 0.0 111.717 -176.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.2 tp -74.52 -27.08 60.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 117.867 0.303 . . . . 0.0 110.997 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.91 -32.47 60.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.29 -29.39 34.31 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 117.018 0.409 . . . . 0.0 110.518 177.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -73.63 -19.28 60.9 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 122.681 0.392 . . . . 0.0 110.92 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -93.63 -17.27 23.46 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 122.191 -0.318 . . . . 0.0 111.03 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.33 -31.98 26.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 O-C-N 121.912 -0.492 . . . . 0.0 111.386 -178.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 37.0 t -85.75 -15.29 10.46 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 178.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -71.52 -7.67 49.06 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.784 0.434 . . . . 0.0 110.875 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 71.7 t80 -113.73 -36.93 4.71 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.621 0.369 . . . . 0.0 110.982 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.87 -7.17 59.68 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.44 -2.72 56.51 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 122.283 -0.261 . . . . 0.0 111.592 177.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -141.19 -7.88 1.02 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 122.73 0.412 . . . . 0.0 112.053 179.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -145.41 170.4 16.42 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.332 0.653 . . . . 0.0 109.982 -179.057 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -86.17 155.98 20.52 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -125.53 135.58 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -88.05 156.35 19.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 122.014 -0.429 . . . . 0.0 110.585 -178.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 62.9 mt -137.53 -43.79 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.536 -178.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.01 31.47 3.57 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.326 0.651 . . . . 0.0 111.185 -177.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.22 6.37 78.54 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.19 151.81 79.52 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.119 0.968 . . . . 0.0 109.142 177.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -71.86 143.61 41.6 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 123.558 2.839 . . . . 0.0 111.764 -176.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.76 -173.87 4.61 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 125.238 1.415 . . . . 0.0 108.395 177.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.01 160.12 40.53 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 121.042 0.448 . . . . 0.0 111.666 -178.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.6 p -149.74 144.98 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 C-N-CA 123.398 0.679 . . . . 0.0 110.064 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -156.43 163.99 38.79 Favored 'General case' 0 N--CA 1.456 -0.148 0 C-N-CA 123.264 0.626 . . . . 0.0 110.148 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -61.95 164.26 6.75 Favored 'General case' 0 C--O 1.231 0.086 0 CA-C-O 120.556 0.217 . . . . 0.0 110.618 177.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 47.2 t -148.38 152.57 37.24 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 120.731 0.301 . . . . 0.0 110.461 177.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 60.1 p -75.75 -1.63 25.87 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 122.558 0.343 . . . . 0.0 111.097 178.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.436 ' C ' ' H ' ' A' ' 173' ' ' LYS . 68.4 m -59.69 -36.18 75.97 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 122.975 0.51 . . . . 0.0 110.827 179.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 47.72 -1.51 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 128.001 2.52 . . . . 0.0 116.157 177.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.436 ' H ' ' C ' ' A' ' 171' ' ' SER . 15.9 tppt? -163.64 142.66 8.04 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 124.312 1.045 . . . . 0.0 109.003 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 69.2 mt -98.22 148.05 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.264 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 173.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 34.2 t -80.82 142.32 33.81 Favored 'General case' 0 N--CA 1.455 -0.177 0 O-C-N 122.272 -0.268 . . . . 0.0 111.35 -177.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 85.0 mtm180 46.43 51.22 9.56 Favored Pre-proline 0 CA--C 1.534 0.343 0 C-N-CA 124.665 1.186 . . . . 0.0 113.208 177.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -79.07 -5.15 14.35 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 123.42 2.746 . . . . 0.0 112.151 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -168.54 7.03 0.05 OUTLIER Glycine 0 CA--C 1.529 0.913 0 CA-C-O 119.661 -0.521 . . . . 0.0 112.986 -178.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -143.88 151.03 39.32 Favored 'General case' 0 N--CA 1.456 -0.129 0 CA-C-N 117.779 0.789 . . . . 0.0 110.029 -178.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 17.8 t -151.78 167.71 27.38 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.096 0.559 . . . . 0.0 110.202 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -141.75 155.73 45.62 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.298 0.639 . . . . 0.0 110.768 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -138.87 164.53 29.41 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 123.588 0.755 . . . . 0.0 110.512 -178.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 75.8 p -69.19 156.09 39.3 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.795 0.331 . . . . 0.0 111.086 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.7 mpt_? -84.13 163.71 19.63 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 122.872 0.469 . . . . 0.0 110.8 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 17.5 t -139.0 24.96 2.54 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.453 0.701 . . . . 0.0 110.548 -177.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.37 165.93 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.135 0 C-N-CA 124.019 0.928 . . . . 0.0 110.086 -177.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -71.12 131.51 43.69 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 32.3 t . . . . . 0 C--O 1.251 1.147 0 CA-C-O 117.251 -1.357 . . . . 0.0 110.178 179.874 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.194 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -149.82 167.22 27.18 Favored 'General case' 0 C--N 1.334 -0.09 0 C-N-CA 122.993 0.517 . . . . 0.0 110.921 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -90.48 36.47 0.89 Allowed 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.178 0.591 . . . . 0.0 110.432 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 56.21 28.4 13.12 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.536 0.734 . . . . 0.0 111.944 -176.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -144.51 163.47 33.76 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.972 0.909 . . . . 0.0 109.815 -178.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -121.83 64.78 18.06 Favored Pre-proline 0 CA--C 1.535 0.366 0 C-N-CA 123.857 0.863 . . . . 0.0 110.891 -178.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -72.6 -16.62 26.93 Favored 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.674 2.916 . . . . 0.0 112.776 -174.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -149.57 8.88 0.7 Allowed 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 -177.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -89.23 165.1 14.65 Favored 'General case' 0 C--O 1.231 0.095 0 O-C-N 121.944 -0.473 . . . . 0.0 110.556 178.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 58.5 p -136.46 155.06 77.25 Favored Pre-proline 0 C--O 1.231 0.098 0 C-N-CA 123.202 0.601 . . . . 0.0 110.344 -179.151 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -74.88 -4.25 15.13 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 124.058 3.172 . . . . 0.0 112.481 178.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.29 35.44 13.71 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.274 0.63 . . . . 0.0 112.208 -178.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 65.5 m -60.88 158.65 31.91 Favored Pre-proline 0 N--CA 1.455 -0.215 0 C-N-CA 123.9 0.88 . . . . 0.0 111.883 -178.27 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -70.41 0.44 6.14 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 124.158 3.239 . . . . 0.0 111.773 176.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.1 t -112.4 139.9 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 123.6 0.76 . . . . 0.0 109.239 177.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.6 m -128.91 152.82 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 CA-C-O 121.08 0.467 . . . . 0.0 110.728 178.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -102.45 137.86 40.14 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.709 0.804 . . . . 0.0 110.112 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 18.8 mm -106.49 144.59 15.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 C-N-CA 123.527 0.731 . . . . 0.0 109.799 -178.228 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -143.14 160.95 39.46 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.07 0.548 . . . . 0.0 110.698 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.96 23.87 60.87 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-O 119.77 -0.461 . . . . 0.0 113.151 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 56.1 mt -60.34 157.55 13.48 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 117.952 0.876 . . . . 0.0 109.979 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 16.5 pt -72.34 -37.32 57.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 O-C-N 122.244 -0.285 . . . . 0.0 111.35 -176.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -172.92 -36.93 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 123.887 0.875 . . . . 0.0 109.7 -179.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 171.21 61.84 0.04 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -176.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.2 m -52.31 154.66 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 122.688 0.395 . . . . 0.0 110.608 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.467 HG13 ' H ' ' A' ' 111' ' ' ALA . 8.7 t -76.99 155.64 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 CA-C-O 120.936 0.398 . . . . 0.0 110.473 -175.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -59.4 -26.88 65.52 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.723 0.409 . . . . 0.0 110.239 174.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . 0.467 ' H ' HG13 ' A' ' 109' ' ' VAL . . . -81.79 -6.83 59.41 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.513 0.725 . . . . 0.0 111.886 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -90.08 -34.11 16.04 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 118.341 0.519 . . . . 0.0 109.999 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.0 mt -73.52 -34.97 65.49 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 122.573 0.349 . . . . 0.0 111.373 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.89 -30.59 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.135 0 CA-C-N 118.041 0.382 . . . . 0.0 110.428 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -82.84 -15.81 50.13 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 119.526 -0.273 . . . . 0.0 111.155 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -11.15 16.96 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -119.26 -9.18 9.99 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 118.6 0.636 . . . . 0.0 112.535 -178.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -69.82 -6.9 35.49 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.156 0.889 . . . . 0.0 111.874 177.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -76.5 -12.64 60.07 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 122.117 -0.365 . . . . 0.0 110.695 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -100.1 -19.97 16.23 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 122.678 0.391 . . . . 0.0 111.337 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 166.05 175.97 36.93 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.396 -0.681 . . . . 0.0 111.396 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -71.33 141.42 38.96 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 123.918 3.079 . . . . 0.0 110.505 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 76.2 mt -112.61 146.26 17.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 122.875 0.47 . . . . 0.0 110.226 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.0 t -103.58 -44.81 5.01 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.009 0.523 . . . . 0.0 111.216 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . 0.475 ' CE2' ' HA ' ' A' ' 177' ' ' PRO . 58.2 t80 -158.84 162.08 36.95 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-O 120.852 0.358 . . . . 0.0 111.465 178.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 95.2 t -142.55 144.81 24.15 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 124.167 0.987 . . . . 0.0 109.673 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.42 153.02 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.097 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 175.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 41.3 t -130.6 148.21 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.1 0 CA-C-O 120.604 0.24 . . . . 0.0 110.986 -175.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 84.0 60.52 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.808 0.843 . . . . 0.0 109.087 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.22 -12.32 33.64 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 123.489 2.793 . . . . 0.0 111.725 -176.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.9 tptt -76.94 -12.15 59.91 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 122.869 0.468 . . . . 0.0 110.9 177.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -129.29 6.92 5.36 Favored 'General case' 0 C--N 1.34 0.163 0 C-N-CA 123.636 0.775 . . . . 0.0 111.904 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 53.9 33.93 18.33 Favored 'General case' 0 N--CA 1.463 0.183 0 C-N-CA 124.449 1.1 . . . . 0.0 112.197 -177.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -136.66 166.26 23.98 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.175 0.59 . . . . 0.0 110.637 -177.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.91 172.36 16.34 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.673 0.389 . . . . 0.0 110.49 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 37.2 mt -131.32 149.05 52.71 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 123.406 0.682 . . . . 0.0 110.166 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -140.11 133.32 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.199 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -114.21 120.71 41.39 Favored 'General case' 0 N--CA 1.452 -0.325 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 177.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -85.83 152.22 23.18 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.041 0.448 . . . . 0.0 110.018 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -71.34 -15.15 62.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.349 -178.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.12 152.45 39.3 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.744 0.818 . . . . 0.0 109.469 177.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.0 p -68.89 -21.45 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 O-C-N 122.18 -0.325 . . . . 0.0 111.751 -175.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.6 tp -75.25 -28.89 60.02 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.83 -0.544 . . . . 0.0 110.334 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.68 -29.62 71.17 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.69 -30.28 36.46 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 117.029 0.414 . . . . 0.0 110.5 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.14 -28.17 62.09 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 122.501 0.32 . . . . 0.0 110.67 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -79.21 -19.43 50.79 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 119.541 -0.266 . . . . 0.0 111.532 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -32.67 27.03 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 118.157 0.435 . . . . 0.0 111.467 -177.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 30.0 t -85.73 -17.51 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -69.44 -11.63 60.98 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.539 0.336 . . . . 0.0 111.08 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -112.0 -36.85 5.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.635 0.374 . . . . 0.0 111.0 178.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.03 -11.67 59.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -176.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.48 -0.26 56.55 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -135.44 -10.85 2.16 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 117.921 0.328 . . . . 0.0 111.503 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.6 t30 -153.97 164.09 39.01 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.601 0.76 . . . . 0.0 109.065 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.6 pm0 -81.32 154.7 26.38 Favored 'General case' 0 CA--C 1.529 0.139 0 O-C-N 121.8 -0.563 . . . . 0.0 109.783 174.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.06 135.57 61.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -87.75 153.83 21.04 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.077 -0.389 . . . . 0.0 110.708 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.4 mt -136.99 -43.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.662 0.385 . . . . 0.0 110.802 -177.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.14 30.64 3.92 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.103 0.561 . . . . 0.0 111.333 -176.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 88.27 4.25 77.75 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -131.44 152.49 80.59 Favored Pre-proline 0 C--O 1.233 0.219 0 C-N-CA 124.013 0.925 . . . . 0.0 109.318 177.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.72 146.18 48.0 Favored 'Trans proline' 0 N--CA 1.453 -0.884 0 C-N-CA 123.438 2.759 . . . . 0.0 111.573 -176.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.43 -175.75 5.41 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.952 1.301 . . . . 0.0 109.021 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -139.42 160.76 39.08 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 121.174 0.511 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 2.9 p -147.76 141.18 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 123.962 0.905 . . . . 0.0 109.532 177.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -156.81 161.93 39.73 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -64.27 168.06 6.02 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-O 121.025 0.44 . . . . 0.0 110.541 177.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 93.5 p -146.35 178.9 7.9 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 123.152 0.581 . . . . 0.0 109.856 176.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 54.5 p -75.52 2.15 12.38 Favored 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 122.274 0.23 . . . . 0.0 111.212 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 70.9 m -81.51 152.23 27.41 Favored 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 123.012 0.525 . . . . 0.0 110.988 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 18.6 pt20 -133.2 0.27 3.39 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 123.32 0.648 . . . . 0.0 110.643 176.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 3.3 tppp? -152.88 136.29 15.86 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.48 1.112 . . . . 0.0 108.689 -178.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 19.4 tt -82.38 153.87 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 123.012 0.525 . . . . 0.0 110.18 178.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.7 m -74.75 130.99 40.46 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -174.029 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 40.37 65.3 4.09 Favored Pre-proline 0 CA--C 1.532 0.259 0 C-N-CA 125.313 1.445 . . . . 0.0 112.799 172.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . 0.475 ' HA ' ' CE2' ' A' ' 125' ' ' TYR . 86.1 Cg_endo -73.85 -7.1 19.6 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 123.23 2.62 . . . . 0.0 112.335 179.282 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 64.4 -130.19 37.55 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 176.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -126.98 178.71 5.81 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.838 0.855 . . . . 0.0 110.466 -177.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.4 m -71.49 2.36 5.14 Favored 'General case' 0 CA--C 1.529 0.136 0 C-N-CA 123.155 0.582 . . . . 0.0 112.458 -178.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -145.57 147.72 32.39 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.311 0.645 . . . . 0.0 110.21 177.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -151.73 143.66 23.8 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.345 0.658 . . . . 0.0 109.845 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 38.4 t -78.86 122.67 26.39 Favored 'General case' 0 C--O 1.232 0.155 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 94.9 mtt180 -146.87 167.75 23.16 Favored 'General case' 0 CA--C 1.523 -0.081 0 C-N-CA 123.453 0.701 . . . . 0.0 110.509 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 66.2 m -68.26 -0.33 4.62 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.292 1.037 . . . . 0.0 111.994 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 4.0 t -124.52 11.75 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 C-N-CA 123.734 0.813 . . . . 0.0 109.753 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -134.54 22.92 3.68 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 123.125 0.57 . . . . 0.0 110.45 -178.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 C--O 1.249 1.069 0 CA-C-O 116.914 -1.517 . . . . 0.0 111.577 -179.444 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.113 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -73.46 -20.44 60.7 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 116.925 0.363 . . . . 0.0 110.52 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -150.14 139.12 21.01 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 174.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.409 ' CG ' ' N ' ' A' ' 88' ' ' ASP . 25.1 t80 51.09 -160.9 0.08 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 123.357 0.411 . . . . 0.0 111.216 -179.536 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . 0.409 ' N ' ' CG ' ' A' ' 87' ' ' TYR . 38.0 t70 -69.47 -26.44 64.57 Favored 'General case' 0 N--CA 1.454 -0.226 0 O-C-N 121.745 -0.597 . . . . 0.0 109.59 175.101 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -155.89 143.99 14.34 Favored Pre-proline 0 CA--C 1.532 0.268 0 C-N-CA 124.142 0.977 . . . . 0.0 109.08 174.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -78.79 -30.6 2.85 Favored 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.945 2.43 . . . . 0.0 113.36 -176.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 4.7 p-80 -161.01 10.62 0.09 Allowed 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 113.197 0.814 . . . . 0.0 113.197 -175.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -77.45 171.29 15.12 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.273 0.488 . . . . 0.0 111.343 -176.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.4 p -138.0 154.88 74.66 Favored Pre-proline 0 C--O 1.232 0.139 0 C-N-CA 123.4 0.68 . . . . 0.0 109.879 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -76.09 -5.82 16.68 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 123.658 2.906 . . . . 0.0 112.119 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.41 34.89 9.85 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.332 0.653 . . . . 0.0 111.986 -178.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 66.2 m -61.9 158.24 44.75 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 124.088 0.955 . . . . 0.0 111.509 -177.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -69.53 1.36 4.35 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 124.138 3.225 . . . . 0.0 112.374 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.8 t -116.53 141.28 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.6 m -129.81 151.85 36.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-O 120.92 0.391 . . . . 0.0 110.958 178.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.4 t-80 -100.93 135.05 42.99 Favored 'General case' 0 N--CA 1.457 -0.086 0 C-N-CA 124.068 0.947 . . . . 0.0 109.974 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -109.93 145.18 16.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 -177.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -141.67 163.7 32.21 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 123.602 0.761 . . . . 0.0 110.481 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 25.56 56.15 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-O 119.452 -0.638 . . . . 0.0 113.611 172.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.8 mt -61.68 158.15 16.11 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.185 0.992 . . . . 0.0 110.186 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 12.4 pt -73.1 -39.94 57.74 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -173.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -172.78 -37.44 0.01 OUTLIER 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.243 0.617 . . . . 0.0 110.246 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.22 52.25 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -176.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 65.1 t -51.11 146.04 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.158 0.583 . . . . 0.0 110.082 178.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.4 m -95.74 163.69 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 CA-C-O 121.18 0.514 . . . . 0.0 111.47 -175.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -60.47 -28.02 68.01 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 123.27 0.628 . . . . 0.0 111.215 -178.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.79 -6.44 55.96 Favored 'General case' 0 CA--C 1.53 0.187 0 N-CA-C 112.294 0.479 . . . . 0.0 112.294 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -101.47 -31.03 11.09 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 176.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 76.5 mt -71.36 -41.21 70.01 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.515 0.326 . . . . 0.0 110.654 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.5 p -77.56 -29.63 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 121.278 -0.169 . . . . 0.0 110.915 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.2 mt-10 -85.87 -13.35 48.2 Favored 'General case' 0 N--CA 1.454 -0.225 0 O-C-N 122.006 -0.434 . . . . 0.0 111.365 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.21 -15.15 16.09 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.94 -7.21 13.17 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.522 0.601 . . . . 0.0 112.457 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -72.46 -5.55 37.51 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.662 0.665 . . . . 0.0 111.537 176.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -74.96 -16.13 60.65 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.493 0.317 . . . . 0.0 110.544 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.83 -17.21 21.32 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 122.537 0.335 . . . . 0.0 111.824 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.88 178.0 37.11 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.16 140.31 37.22 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 123.86 3.04 . . . . 0.0 110.821 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.5 mt -112.42 144.4 20.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 C-N-CA 122.993 0.517 . . . . 0.0 110.519 -178.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -102.77 -42.25 5.93 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.362 0.665 . . . . 0.0 111.05 -178.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -158.57 160.09 36.22 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.712 0.291 . . . . 0.0 111.275 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 84.9 t -143.97 147.6 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.053 0 C-N-CA 123.761 0.824 . . . . 0.0 109.841 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.3 p -148.0 154.57 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 176.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 9.5 p -136.93 151.45 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.07 0 CA-C-O 120.824 0.345 . . . . 0.0 110.948 -178.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -130.26 84.44 59.87 Favored Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.855 0.862 . . . . 0.0 109.004 179.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -59.54 -18.54 47.57 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.897 3.064 . . . . 0.0 112.779 -179.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -82.02 -5.8 58.65 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.08 0.552 . . . . 0.0 111.316 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -129.05 2.58 5.26 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.722 0.809 . . . . 0.0 111.461 178.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.4 tpp85 53.37 32.5 13.9 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.496 1.118 . . . . 0.0 112.0 -177.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -136.43 166.4 23.58 Favored 'General case' 0 CA--C 1.527 0.094 0 C-N-CA 123.144 0.578 . . . . 0.0 110.941 -176.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 171.4 17.3 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.88 0.472 . . . . 0.0 110.819 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.32 146.71 50.23 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 123.769 0.828 . . . . 0.0 109.797 178.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.8 t -136.64 131.96 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.231 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -112.23 116.11 29.9 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -84.54 152.6 23.8 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.835 0.35 . . . . 0.0 110.481 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -73.08 -14.5 61.41 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.409 -178.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -147.2 151.34 36.57 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.696 0.798 . . . . 0.0 109.103 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.2 p -67.39 -19.85 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 O-C-N 122.29 -0.256 . . . . 0.0 111.484 -175.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.9 tp -75.08 -27.24 59.85 Favored 'General case' 0 N--CA 1.454 -0.236 0 O-C-N 121.986 -0.446 . . . . 0.0 110.498 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.91 -31.2 69.85 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.36 -29.99 33.89 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 116.956 0.378 . . . . 0.0 110.395 177.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.46 -26.48 63.66 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 122.716 0.406 . . . . 0.0 110.825 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -84.05 -20.3 32.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.192 -0.318 . . . . 0.0 111.646 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.47 -29.1 26.31 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 118.125 0.42 . . . . 0.0 112.075 -175.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -89.63 -15.49 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -75.0 0.12 16.95 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.768 0.427 . . . . 0.0 111.038 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -120.17 -38.73 2.88 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.842 0.457 . . . . 0.0 110.852 177.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.29 -4.66 58.99 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.68 -4.13 58.34 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 122.103 -0.373 . . . . 0.0 111.506 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -141.66 -4.17 1.11 Allowed 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 122.609 0.364 . . . . 0.0 111.59 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -146.29 170.57 16.49 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.534 0.734 . . . . 0.0 109.972 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -90.84 153.16 20.42 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 172.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.48 135.18 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -88.55 150.61 23.0 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 122.01 -0.431 . . . . 0.0 110.749 -178.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.1 mt -136.97 -39.1 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.789 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.18 29.28 3.71 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 123.085 0.554 . . . . 0.0 110.937 -177.051 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.48 5.02 85.29 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -176.434 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -130.41 152.28 80.01 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 124.266 1.026 . . . . 0.0 109.144 177.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.52 144.21 44.45 Favored 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.076 2.518 . . . . 0.0 111.825 -176.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.96 -176.11 5.31 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 124.826 1.25 . . . . 0.0 109.024 177.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -139.46 161.13 38.24 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.949 0.404 . . . . 0.0 111.67 -178.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.6 p -150.04 143.27 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.411 0.684 . . . . 0.0 109.724 178.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -154.29 163.13 40.62 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.055 0.542 . . . . 0.0 109.989 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -63.31 164.31 9.15 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 120.904 0.383 . . . . 0.0 110.601 177.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 87.8 p -145.78 174.52 11.15 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 123.201 0.6 . . . . 0.0 109.766 176.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 57.8 p -77.35 -0.71 26.64 Favored 'General case' 0 C--O 1.232 0.152 0 C-N-CA 122.562 0.345 . . . . 0.0 111.132 178.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 49.4 m -77.31 150.1 35.26 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.285 0.634 . . . . 0.0 110.215 179.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -138.19 -3.85 1.74 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 122.795 0.438 . . . . 0.0 111.202 177.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -158.24 135.51 10.1 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.932 0.893 . . . . 0.0 108.857 -178.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 73.1 mt -93.15 147.85 5.15 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 175.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 39.6 m -75.45 141.31 43.16 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-O 120.429 0.157 . . . . 0.0 111.401 -176.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 70.0 ttt180 45.17 56.04 14.65 Favored Pre-proline 0 CA--C 1.535 0.394 0 C-N-CA 124.745 1.218 . . . . 0.0 112.539 177.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -80.45 5.04 6.36 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 123.605 2.87 . . . . 0.0 112.007 -177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 80.55 6.16 89.48 Favored Glycine 0 CA--C 1.531 1.045 0 O-C-N 122.085 -0.384 . . . . 0.0 112.32 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -74.93 161.58 29.39 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 117.428 0.614 . . . . 0.0 110.683 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 88.7 p -140.21 163.67 32.13 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 123.093 0.557 . . . . 0.0 110.998 -178.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -109.58 7.62 24.68 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.214 0.606 . . . . 0.0 111.887 -178.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -145.35 157.99 43.92 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 122.845 0.458 . . . . 0.0 110.443 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 51.0 m -134.22 166.93 21.64 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 123.301 0.64 . . . . 0.0 110.591 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 11.4 tpp85 -148.98 163.32 37.84 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-O 120.523 0.201 . . . . 0.0 110.634 -178.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 25.4 m -82.13 7.54 13.25 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.161 0.584 . . . . 0.0 112.285 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 34.1 m -135.42 161.02 39.9 Favored 'Isoleucine or valine' 0 C--N 1.34 0.164 0 C-N-CA 123.082 0.553 . . . . 0.0 110.395 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 45.8 t30 -144.03 15.0 1.7 Allowed 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 122.836 0.454 . . . . 0.0 110.529 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 49.4 m . . . . . 0 C--O 1.252 1.198 0 CA-C-O 117.628 -1.177 . . . . 0.0 110.441 -178.534 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.178 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -86.49 -6.29 58.94 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 117.124 0.462 . . . . 0.0 111.647 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -70.06 -11.2 60.71 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.111 0.564 . . . . 0.0 111.414 -177.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -92.92 3.41 55.76 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.152 0.581 . . . . 0.0 111.256 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -105.06 11.34 33.43 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.671 0.789 . . . . 0.0 110.638 178.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 49.05 49.92 8.33 Favored Pre-proline 0 CA--C 1.533 0.316 0 C-N-CA 124.764 1.225 . . . . 0.0 113.128 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -73.43 -20.03 21.32 Favored 'Trans proline' 0 N--CA 1.452 -0.934 0 C-N-CA 123.527 2.818 . . . . 0.0 112.079 -176.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -147.9 10.96 0.93 Allowed 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.167 0.587 . . . . 0.0 111.262 -178.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.7 mtpt -91.26 167.14 12.53 Favored 'General case' 0 N--CA 1.456 -0.127 0 C-N-CA 123.161 0.584 . . . . 0.0 110.574 -179.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 53.1 p -133.29 153.12 80.47 Favored Pre-proline 0 C--N 1.334 -0.098 0 C-N-CA 123.345 0.658 . . . . 0.0 110.437 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -75.94 -7.76 18.52 Favored 'Trans proline' 0 N--CA 1.453 -0.91 0 C-N-CA 123.838 3.026 . . . . 0.0 111.855 178.329 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.08 34.75 8.76 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.343 0.657 . . . . 0.0 111.31 -177.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.412 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.4 p -78.23 161.39 70.57 Favored Pre-proline 0 N--CA 1.456 -0.164 0 C-N-CA 123.938 0.895 . . . . 0.0 111.729 -174.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.412 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 96.4 Cg_endo -71.26 3.05 3.77 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.903 3.069 . . . . 0.0 112.504 177.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.7 t -115.02 141.39 31.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.116 0 C-N-CA 122.989 0.515 . . . . 0.0 109.877 178.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 20.9 m -126.69 152.57 34.59 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -107.7 141.01 39.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 124.079 0.952 . . . . 0.0 109.61 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 23.6 mm -111.23 143.82 20.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 122.883 0.473 . . . . 0.0 110.116 -175.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 -142.38 159.26 42.59 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 123.092 0.557 . . . . 0.0 110.176 -177.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.03 24.87 58.91 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.358 -0.69 . . . . 0.0 113.198 174.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.6 mt -60.52 157.87 13.36 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 118.234 1.017 . . . . 0.0 110.163 177.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.2 pt -70.88 -43.35 76.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -173.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -172.4 -34.5 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.375 0.67 . . . . 0.0 110.749 -179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.9 49.07 0.11 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.704 -0.559 . . . . 0.0 111.704 -175.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.1 t -51.09 146.54 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 123.387 0.675 . . . . 0.0 110.026 178.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.2 m -101.33 166.41 2.42 Favored 'Isoleucine or valine' 0 C--N 1.337 0.045 0 CA-C-O 121.211 0.529 . . . . 0.0 111.584 -175.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.39 -27.48 67.47 Favored 'General case' 0 N--CA 1.456 -0.131 0 C-N-CA 123.196 0.598 . . . . 0.0 111.152 -177.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.46 -5.03 51.35 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -104.59 -30.86 9.72 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 175.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.6 mt -70.12 -38.41 75.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 122.506 0.322 . . . . 0.0 110.595 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -80.13 -29.63 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 CA-C-N 117.537 0.153 . . . . 0.0 110.731 -178.329 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.0 mm-40 -81.4 -13.91 57.75 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.28 -0.263 . . . . 0.0 111.321 -178.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -99.89 -25.97 14.16 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.2 mp -100.73 -9.76 21.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.921 0.711 . . . . 0.0 112.921 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -67.15 -8.63 32.55 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 118.604 0.638 . . . . 0.0 111.647 177.16 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.96 -14.62 59.1 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.663 0.385 . . . . 0.0 110.827 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -101.08 -18.31 16.29 Favored 'General case' 0 C--O 1.231 0.117 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -178.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.91 177.51 37.52 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -72.73 140.21 31.98 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 C-N-CA 124.268 3.312 . . . . 0.0 110.717 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 73.6 mt -110.07 146.69 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 C-N-CA 122.778 0.431 . . . . 0.0 110.3 -177.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -107.46 -40.16 5.43 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.158 0.583 . . . . 0.0 111.367 -177.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -159.52 158.44 31.83 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-O 120.739 0.304 . . . . 0.0 110.94 179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 93.1 t -144.15 145.42 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.038 0 C-N-CA 123.924 0.89 . . . . 0.0 109.858 -178.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.3 p -148.31 152.74 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 12.4 p -130.22 156.58 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 CA-C-O 120.805 0.336 . . . . 0.0 111.156 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 48.6 mtt -130.45 78.14 74.73 Favored Pre-proline 0 C--O 1.232 0.168 0 C-N-CA 124.046 0.938 . . . . 0.0 109.54 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.62 -17.74 43.73 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 123.584 2.856 . . . . 0.0 113.048 -177.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.5 mtpt -89.52 -2.15 58.26 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.926 0.49 . . . . 0.0 111.807 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -130.84 0.39 4.3 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.652 0.781 . . . . 0.0 111.548 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 55.14 33.98 21.63 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.019 0.928 . . . . 0.0 111.861 -176.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -134.7 168.21 19.43 Favored 'General case' 0 C--O 1.232 0.14 0 C-N-CA 123.479 0.712 . . . . 0.0 110.602 -177.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.74 172.24 18.27 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.39 176.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.34 144.31 48.19 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.716 0.806 . . . . 0.0 109.468 177.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 77.9 t -137.0 131.29 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -113.44 120.26 40.44 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -83.93 153.87 23.69 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.872 0.368 . . . . 0.0 110.361 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -74.54 -12.58 60.51 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-O 120.907 0.384 . . . . 0.0 110.25 -178.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -149.54 152.48 35.62 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.843 0.857 . . . . 0.0 109.022 176.136 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.2 p -68.13 -20.43 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 O-C-N 122.031 -0.418 . . . . 0.0 111.657 -175.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.3 tp -71.96 -26.27 62.2 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.924 -0.485 . . . . 0.0 110.561 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.95 -31.47 64.45 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 178.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -84.42 -27.95 27.23 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 117.293 0.546 . . . . 0.0 110.555 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.1 t -77.89 -7.17 56.35 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 122.802 0.441 . . . . 0.0 110.602 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -107.14 -21.71 12.88 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.976 0.511 . . . . 0.0 110.754 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.42 -28.01 31.61 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 -178.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -91.01 -18.98 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -71.34 -14.24 62.13 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.36 0.264 . . . . 0.0 110.763 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -99.92 -36.79 9.28 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.568 0.347 . . . . 0.0 111.001 178.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -85.44 -6.43 59.21 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.832 0.678 . . . . 0.0 112.832 -176.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -78.64 -5.0 51.8 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 122.139 -0.351 . . . . 0.0 111.839 176.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -143.52 -3.59 0.91 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.58 0.352 . . . . 0.0 111.901 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 -145.42 175.09 10.58 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.455 0.702 . . . . 0.0 109.948 -178.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . 0.429 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.1 pm0 -96.94 152.68 18.47 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 173.162 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.17 134.44 63.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -89.55 148.91 23.11 Favored 'General case' 0 C--N 1.332 -0.17 0 O-C-N 122.193 -0.317 . . . . 0.0 110.71 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -136.01 -38.75 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.219 -176.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.37 29.45 3.63 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.112 0.565 . . . . 0.0 110.89 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.67 3.36 83.79 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -176.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -130.08 152.84 80.73 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 123.902 0.881 . . . . 0.0 108.968 177.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -72.11 145.97 45.45 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.306 2.671 . . . . 0.0 111.681 -176.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.48 -176.84 5.64 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.014 1.325 . . . . 0.0 108.475 177.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -137.84 160.02 40.43 Favored 'General case' 0 C--O 1.232 0.14 0 CA-C-O 120.885 0.374 . . . . 0.0 111.466 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.66 139.61 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 123.514 0.726 . . . . 0.0 110.174 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -159.98 150.7 18.98 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.445 0.698 . . . . 0.0 109.592 178.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -98.54 124.51 43.33 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 121.321 0.581 . . . . 0.0 111.801 178.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 27.5 t -166.46 150.04 7.25 Favored 'General case' 0 C--O 1.231 0.131 0 C-N-CA 122.926 0.49 . . . . 0.0 110.049 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 80.6 p 44.06 26.04 0.13 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.19 1.396 . . . . 0.0 114.291 177.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 67.1 p -149.48 149.63 31.08 Favored 'General case' 0 N--CA 1.456 -0.128 0 CA-C-O 120.914 0.388 . . . . 0.0 110.818 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.1 pt20 -150.36 -6.83 0.3 Allowed 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 116.187 -0.46 . . . . 0.0 112.215 176.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -158.96 137.36 10.77 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.752 0.821 . . . . 0.0 109.164 -178.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 66.2 mt -91.09 145.18 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 174.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.3 m -77.71 139.81 39.45 Favored 'General case' 0 C--N 1.335 -0.061 0 N-CA-C 111.56 0.208 . . . . 0.0 111.56 -177.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 28.5 mmt85 42.68 56.86 11.2 Favored Pre-proline 0 CA--C 1.534 0.346 0 C-N-CA 124.312 1.045 . . . . 0.0 112.625 177.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -77.75 56.88 5.81 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 124.316 3.344 . . . . 0.0 111.32 -177.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 81.49 9.73 85.4 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.511 -0.636 . . . . 0.0 111.511 -177.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -139.89 165.16 28.06 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.782 0.833 . . . . 0.0 109.505 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 80.1 p -119.85 164.8 15.48 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 123.058 0.543 . . . . 0.0 111.459 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -74.04 154.02 39.41 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 122.71 0.404 . . . . 0.0 111.121 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -86.83 -2.19 58.38 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.009 0.524 . . . . 0.0 111.25 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 63.6 m -90.22 8.73 31.64 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 123.37 0.668 . . . . 0.0 111.73 -179.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.6 tpt180 -140.74 148.19 40.31 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.215 0.606 . . . . 0.0 110.303 -178.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 57.9 m -139.07 138.32 37.01 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 177.024 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 10.4 m -148.8 163.33 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 C-N-CA 123.697 0.799 . . . . 0.0 108.999 -177.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -76.36 138.2 40.29 Favored 'General case' 0 N--CA 1.454 -0.271 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.7 m . . . . . 0 C--O 1.25 1.109 0 C-N-CA 124.422 1.089 . . . . 0.0 111.966 -179.882 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.096 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -145.91 149.88 35.06 Favored 'General case' 0 N--CA 1.456 -0.131 0 C-N-CA 123.239 0.615 . . . . 0.0 109.753 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -67.94 -15.27 63.54 Favored 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 111.748 0.277 . . . . 0.0 111.748 -174.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 -86.97 4.19 42.75 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.804 0.441 . . . . 0.0 111.471 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -108.35 10.22 27.63 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.495 0.718 . . . . 0.0 110.414 177.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 23.9 m-20 48.33 49.1 6.84 Favored Pre-proline 0 CA--C 1.533 0.29 0 C-N-CA 124.644 1.178 . . . . 0.0 112.775 -178.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -76.62 -12.99 18.31 Favored 'Trans proline' 0 N--CA 1.457 -0.663 0 C-N-CA 123.926 3.084 . . . . 0.0 113.538 -172.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -146.74 18.81 1.3 Allowed 'General case' 0 C--O 1.231 0.1 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -174.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -93.17 6.0 49.54 Favored 'General case' 0 CA--C 1.529 0.167 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -176.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 30.1 p -74.75 152.03 86.96 Favored Pre-proline 0 CA--C 1.529 0.139 0 O-C-N 122.121 -0.362 . . . . 0.0 110.693 178.751 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -78.78 -6.19 15.08 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 124.086 3.19 . . . . 0.0 112.314 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.41 34.47 12.04 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.564 0.746 . . . . 0.0 112.112 -177.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.1 m -70.97 159.0 86.92 Favored Pre-proline 0 CA--C 1.53 0.196 0 C-N-CA 123.446 0.698 . . . . 0.0 112.368 -176.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.05 -0.98 9.84 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 124.024 3.149 . . . . 0.0 111.769 174.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.5 t -112.0 142.49 24.21 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 123.431 0.692 . . . . 0.0 109.461 178.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 21.3 m -128.29 152.41 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 C-N-CA 122.835 0.454 . . . . 0.0 110.171 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 -106.15 136.41 45.89 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.971 0.909 . . . . 0.0 109.359 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.7 mm -106.07 142.4 19.14 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 C-N-CA 122.859 0.464 . . . . 0.0 109.859 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -141.67 160.44 40.17 Favored 'General case' 0 C--O 1.231 0.1 0 C-N-CA 123.231 0.612 . . . . 0.0 110.334 -178.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.16 23.11 61.82 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.13 174.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 63.8 mt -60.02 158.45 10.97 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 118.151 0.975 . . . . 0.0 109.708 177.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 13.7 pt -73.37 -43.6 56.02 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.035 0 O-C-N 122.275 -0.266 . . . . 0.0 111.686 -174.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.72 -34.83 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.14 0.576 . . . . 0.0 110.371 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -173.82 48.46 0.15 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -176.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.2 t -49.48 141.34 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 C-N-CA 122.835 0.454 . . . . 0.0 109.809 177.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.4 m -92.21 163.44 2.25 Favored 'Isoleucine or valine' 0 C--O 1.23 0.04 0 CA-C-O 121.157 0.504 . . . . 0.0 111.624 -174.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -61.83 -26.31 68.04 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.224 -177.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.23 -6.39 57.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.661 0.384 . . . . 0.0 112.0 -178.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.8 -29.71 13.59 Favored 'General case' 0 CA--C 1.527 0.063 0 O-C-N 121.743 -0.598 . . . . 0.0 109.822 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.0 mt -74.01 -37.51 64.36 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.284 0.234 . . . . 0.0 110.92 -178.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.7 p -77.99 -29.96 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.323 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -85.55 -13.07 50.03 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 122.023 -0.423 . . . . 0.0 111.709 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -109.2 -9.18 15.03 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.8 mt -118.51 -7.4 10.63 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.815 0.734 . . . . 0.0 112.265 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.0 pt20 -74.0 -5.35 40.86 Favored 'General case' 0 C--N 1.34 0.157 0 CA-C-N 118.794 0.725 . . . . 0.0 110.342 175.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -77.6 -4.48 46.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.587 0.755 . . . . 0.0 111.095 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -111.53 -15.91 13.4 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.318 0.647 . . . . 0.0 111.272 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.84 176.73 36.02 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -72.14 140.19 33.83 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.0 3.133 . . . . 0.0 110.571 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.422 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.2 mt -109.86 148.92 13.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 122.844 0.457 . . . . 0.0 110.457 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.3 t -111.05 -41.26 4.25 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.251 0.62 . . . . 0.0 111.784 -177.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -158.1 158.09 34.05 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 117.839 0.291 . . . . 0.0 111.462 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 67.1 t -144.05 146.91 20.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.085 0.954 . . . . 0.0 109.699 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -148.95 151.42 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.9 t -128.07 149.5 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.073 0 CA-C-O 120.612 0.244 . . . . 0.0 111.32 -175.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.5 mpp? -130.44 83.07 63.54 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.982 0.913 . . . . 0.0 108.564 177.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -69.41 -11.7 31.89 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 123.482 2.788 . . . . 0.0 111.577 -175.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -81.58 -10.5 59.43 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 122.95 0.5 . . . . 0.0 110.81 177.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -126.35 6.47 7.01 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.576 0.75 . . . . 0.0 111.646 -178.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 55.19 31.0 15.56 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 123.982 0.913 . . . . 0.0 112.432 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -136.79 167.34 21.63 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.149 0.58 . . . . 0.0 111.103 -175.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.05 172.84 16.25 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.978 0.511 . . . . 0.0 110.319 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.0 mt -133.03 146.55 51.83 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 123.308 0.643 . . . . 0.0 110.054 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.82 133.15 41.23 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -117.08 121.88 42.56 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.422 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.7 m-85 -87.08 156.28 19.8 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 121.067 0.461 . . . . 0.0 110.555 -178.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -76.3 -13.57 60.15 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.14 -179.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -146.74 150.91 36.29 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.575 0.75 . . . . 0.0 109.319 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.7 p -69.33 -21.8 25.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.6 tp -75.91 -29.77 58.53 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.85 -0.531 . . . . 0.0 110.203 -179.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.83 -28.22 73.25 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 -25.77 33.48 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 117.05 0.425 . . . . 0.0 110.962 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.55 -34.09 41.31 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -68.69 -21.28 64.43 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 119.712 -0.185 . . . . 0.0 110.87 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.39 -27.62 27.51 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -178.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.3 t -92.58 -23.03 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.06 0 O-C-N 122.154 -0.342 . . . . 0.0 110.888 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -71.62 -7.77 49.91 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.105 -0.372 . . . . 0.0 111.472 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -106.29 -34.43 7.47 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.677 0.391 . . . . 0.0 110.477 176.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -10.39 59.07 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.91 -0.56 56.74 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -136.87 -11.4 1.76 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 122.677 0.391 . . . . 0.0 111.71 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -153.25 170.34 20.83 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -87.6 155.13 20.1 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 175.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.3 135.56 60.18 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -177.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -90.36 150.54 21.84 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 121.952 -0.467 . . . . 0.0 110.772 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.2 mt -137.43 -39.02 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.457 -0.076 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.869 -176.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.57 28.84 3.61 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 123.139 0.576 . . . . 0.0 110.908 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.9 5.64 83.43 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -176.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -131.21 153.14 81.61 Favored Pre-proline 0 N--CA 1.453 -0.275 0 C-N-CA 124.175 0.99 . . . . 0.0 109.152 177.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -72.26 145.9 44.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 123.251 2.634 . . . . 0.0 111.701 -176.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.11 -177.25 6.05 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 124.778 1.231 . . . . 0.0 108.839 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -139.64 160.39 39.97 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 120.976 0.417 . . . . 0.0 111.357 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -148.59 139.51 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 C-N-CA 123.339 0.655 . . . . 0.0 110.213 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -159.05 150.97 20.86 Favored 'General case' 0 N--CA 1.455 -0.21 0 C-N-CA 123.227 0.611 . . . . 0.0 109.858 178.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -98.04 124.57 42.59 Favored 'General case' 0 N--CA 1.457 -0.117 0 CA-C-O 121.193 0.52 . . . . 0.0 111.918 177.181 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 28.4 t -165.75 148.53 7.57 Favored 'General case' 0 N--CA 1.456 -0.156 0 C-N-CA 122.841 0.457 . . . . 0.0 110.374 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 81.8 p 45.27 25.0 0.17 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 125.407 1.483 . . . . 0.0 114.324 176.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 71.2 p -148.95 149.91 32.01 Favored 'General case' 0 N--CA 1.457 -0.124 0 O-C-N 121.909 -0.495 . . . . 0.0 111.185 -179.088 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -149.72 -6.49 0.34 Allowed 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 176.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -159.87 137.38 9.75 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 123.543 0.737 . . . . 0.0 109.045 -177.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 66.9 mt -89.07 145.06 7.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.197 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 174.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.5 m -80.9 141.15 34.85 Favored 'General case' 0 C--O 1.231 0.106 0 N-CA-C 111.749 0.278 . . . . 0.0 111.749 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 82.5 mtp180 44.71 52.74 10.45 Favored Pre-proline 0 CA--C 1.533 0.291 0 C-N-CA 124.577 1.151 . . . . 0.0 113.181 177.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -75.81 176.58 9.83 Favored 'Trans proline' 0 N--CA 1.451 -1.004 0 C-N-CA 123.133 2.556 . . . . 0.0 110.918 -179.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 84.17 134.86 2.81 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 24.6 m-20 -72.84 164.34 26.75 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 123.319 0.648 . . . . 0.0 111.122 178.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 88.4 p -77.71 167.75 21.06 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 122.944 0.497 . . . . 0.0 110.954 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -125.7 1.8 7.49 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.106 0.562 . . . . 0.0 111.711 -178.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -150.59 155.52 39.58 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.102 0.561 . . . . 0.0 110.112 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 78.6 p -144.4 152.88 41.31 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.619 0.768 . . . . 0.0 109.255 177.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.0 ttm180 -152.43 164.86 36.69 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 120.719 0.295 . . . . 0.0 111.257 -175.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 41.4 m -92.08 10.48 29.01 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.183 0.593 . . . . 0.0 111.9 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 28.0 m -139.25 166.63 21.43 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 C-N-CA 123.41 0.684 . . . . 0.0 109.901 -178.018 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -74.09 133.37 42.85 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 63.6 m . . . . . 0 C--O 1.252 1.191 0 CA-C-O 117.642 -1.17 . . . . 0.0 110.531 -178.62 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.158 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -150.02 165.36 32.95 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.193 0.597 . . . . 0.0 110.812 -177.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.5 t30 -149.06 169.37 20.82 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 123.285 0.634 . . . . 0.0 109.894 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -75.11 -12.3 60.28 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 123.673 0.789 . . . . 0.0 111.711 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -150.15 155.26 39.48 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 123.416 0.686 . . . . 0.0 109.653 178.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -75.38 136.36 71.94 Favored Pre-proline 0 CA--C 1.533 0.313 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 -176.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -69.64 -24.05 30.64 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 123.604 2.869 . . . . 0.0 114.708 -174.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 2.8 p-80 -157.16 -3.69 0.1 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 115.672 1.73 . . . . 0.0 115.672 -174.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -81.61 157.23 24.78 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 119.585 1.084 . . . . 0.0 110.996 178.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.2 p -84.22 153.76 62.92 Favored Pre-proline 0 C--O 1.231 0.13 0 C-N-CA 123.13 0.572 . . . . 0.0 111.011 -178.363 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -79.55 -8.76 14.86 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 124.142 3.228 . . . . 0.0 111.556 177.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.79 35.03 14.34 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 123.711 0.804 . . . . 0.0 112.293 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.2 m -76.01 163.47 66.52 Favored Pre-proline 0 CA--C 1.531 0.244 0 C-N-CA 123.289 0.636 . . . . 0.0 112.577 -175.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -65.4 -7.43 15.92 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.983 3.122 . . . . 0.0 113.382 177.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -109.85 141.43 25.17 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 123.032 0.533 . . . . 0.0 109.993 -178.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 28.0 m -125.61 156.29 35.12 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.242 0.617 . . . . 0.0 110.091 176.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -116.41 131.61 56.9 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.875 0.87 . . . . 0.0 109.421 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.8 mp -106.17 144.82 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -174.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -141.93 163.08 33.85 Favored 'General case' 0 N--CA 1.46 0.063 0 C-N-CA 123.557 0.743 . . . . 0.0 110.392 -177.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.32 23.27 61.19 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.213 -0.771 . . . . 0.0 113.017 174.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 70.9 mt -59.86 156.27 14.66 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.436 1.118 . . . . 0.0 110.141 178.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.6 pt -70.83 -41.23 77.32 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -172.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -173.92 -34.39 0.01 OUTLIER 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.413 0.685 . . . . 0.0 110.648 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.91 48.09 0.12 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.8 t -51.39 143.14 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 177.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -97.78 165.51 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.064 0 CA-C-O 121.35 0.595 . . . . 0.0 111.886 -174.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.16 -26.24 66.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.537 0.735 . . . . 0.0 111.334 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.88 -6.88 58.25 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -97.7 -28.98 13.65 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 118.181 0.446 . . . . 0.0 110.16 177.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 89.4 mt -74.35 -36.09 63.61 Favored 'General case' 0 N--CA 1.455 -0.191 0 O-C-N 122.255 -0.278 . . . . 0.0 110.979 -178.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.9 p -79.1 -30.28 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.189 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -82.59 -15.39 52.39 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 119.423 -0.322 . . . . 0.0 111.474 -178.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.87 -12.53 15.17 Favored 'General case' 0 C--N 1.339 0.132 0 N-CA-C 113.11 0.781 . . . . 0.0 113.11 -179.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.4 mt -116.46 -9.32 11.47 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -69.19 -6.88 31.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 118.809 0.731 . . . . 0.0 111.424 176.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -76.68 -15.13 59.88 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.089 -0.382 . . . . 0.0 110.649 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -97.24 -17.77 19.63 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 122.558 0.343 . . . . 0.0 111.454 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.68 177.05 36.21 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -70.54 139.91 38.59 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.077 3.185 . . . . 0.0 110.768 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 77.7 mt -110.33 146.31 15.71 Favored 'Isoleucine or valine' 0 C--O 1.232 0.133 0 C-N-CA 122.765 0.426 . . . . 0.0 110.205 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -107.73 -40.2 5.36 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.383 0.673 . . . . 0.0 111.348 -177.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -157.73 158.83 36.08 Favored 'General case' 0 C--N 1.338 0.096 0 CA-C-O 120.559 0.219 . . . . 0.0 111.342 -179.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 59.0 t -144.05 145.27 22.0 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 C-N-CA 124.175 0.99 . . . . 0.0 109.549 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.8 p -149.34 152.46 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 34.2 t -130.41 150.8 35.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 CA-C-O 120.675 0.274 . . . . 0.0 111.251 -175.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.4 81.36 68.3 Favored Pre-proline 0 CA--C 1.531 0.238 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 177.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -59.97 -17.88 46.98 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.945 3.097 . . . . 0.0 112.862 -177.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 mtmt -83.48 -5.82 59.27 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.876 0.47 . . . . 0.0 111.326 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -126.55 2.71 6.88 Favored 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.733 0.813 . . . . 0.0 111.112 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.3 tpp85 54.14 32.73 16.41 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 124.035 0.934 . . . . 0.0 111.865 -176.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -137.18 165.3 26.43 Favored 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 123.119 0.567 . . . . 0.0 110.956 -176.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 169.92 20.55 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 122.953 0.501 . . . . 0.0 110.569 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.8 mt -131.65 145.6 51.75 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.509 0.724 . . . . 0.0 109.824 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.74 134.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -116.16 121.8 43.17 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -86.39 155.85 20.42 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.027 0.442 . . . . 0.0 110.576 -179.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -74.86 -13.14 60.52 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.558 -178.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -147.73 152.87 38.5 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.883 0.873 . . . . 0.0 109.038 177.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.97 -21.61 25.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -175.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.8 tp -74.79 -29.85 61.24 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 122.108 -0.37 . . . . 0.0 110.692 -179.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.25 -28.58 71.25 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 179.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.17 -30.37 27.86 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 117.079 0.439 . . . . 0.0 110.898 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.8 t -75.21 -28.73 60.08 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.1 t30 -78.33 -21.21 49.91 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.321 0.248 . . . . 0.0 110.722 179.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.22 -31.25 30.38 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.301 -0.249 . . . . 0.0 111.505 -178.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 60.1 t -88.36 -21.97 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 O-C-N 122.252 -0.28 . . . . 0.0 110.556 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -66.9 -17.05 64.71 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 122.194 -0.316 . . . . 0.0 110.96 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -100.05 -36.54 9.32 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.189 0.196 . . . . 0.0 110.645 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.59 -11.04 59.95 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -176.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -89.29 1.42 55.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.578 0.351 . . . . 0.0 111.847 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -134.44 -15.64 2.15 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.76 0.424 . . . . 0.0 111.588 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -153.26 168.2 26.81 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.494 0.718 . . . . 0.0 109.186 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -82.78 155.54 24.17 Favored 'General case' 0 N--CA 1.457 -0.092 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 175.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -121.61 135.48 61.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -177.46 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -89.67 151.83 21.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.102 -0.374 . . . . 0.0 110.789 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -138.14 -39.06 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.894 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.69 29.41 3.53 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 122.876 0.47 . . . . 0.0 111.041 -176.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.87 4.86 84.42 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -176.254 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -131.59 152.08 79.8 Favored Pre-proline 0 N--CA 1.454 -0.231 0 C-N-CA 124.115 0.966 . . . . 0.0 108.95 177.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -71.54 146.55 49.84 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 123.58 2.854 . . . . 0.0 111.88 -176.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.8 -175.72 5.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.651 1.18 . . . . 0.0 108.811 178.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -138.82 159.44 42.12 Favored 'General case' 0 N--CA 1.457 -0.099 0 CA-C-O 120.644 0.259 . . . . 0.0 111.005 -179.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.9 p -149.26 139.11 16.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 C-N-CA 123.341 0.657 . . . . 0.0 110.247 178.736 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -159.9 152.94 21.77 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -103.5 132.37 49.82 Favored 'General case' 0 CA--C 1.527 0.089 0 CA-C-O 121.385 0.612 . . . . 0.0 112.607 178.468 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 38.1 t -166.09 145.63 6.12 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.639 178.045 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 3.1 m 49.44 28.25 2.34 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.81 1.244 . . . . 0.0 113.457 173.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 34.6 t -151.36 152.11 32.67 Favored 'General case' 0 N--CA 1.458 -0.068 0 O-C-N 121.632 -0.668 . . . . 0.0 111.037 179.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -149.11 -3.73 0.43 Allowed 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 123.395 0.678 . . . . 0.0 111.752 176.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -160.57 133.76 6.64 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -176.435 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 70.8 mt -82.68 150.36 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.112 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 176.567 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 44.6 m -74.45 132.14 41.66 Favored 'General case' 0 N--CA 1.457 -0.096 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 -176.091 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . 0.424 ' N ' ' HD3' ' A' ' 177' ' ' PRO . 98.8 mtt180 39.44 56.75 6.31 Favored Pre-proline 0 CA--C 1.534 0.364 0 C-N-CA 125.495 1.518 . . . . 0.0 114.101 175.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . 0.424 ' HD3' ' N ' ' A' ' 176' ' ' ARG . 23.3 Cg_exo -68.18 -13.77 38.83 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.518 2.145 . . . . 0.0 112.237 -179.344 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -81.0 3.06 78.4 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-O 119.611 -0.549 . . . . 0.0 112.727 -178.288 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -66.88 146.92 53.89 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 118.059 0.93 . . . . 0.0 110.817 -179.428 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.4 m -141.35 14.89 2.2 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 123.652 0.781 . . . . 0.0 111.34 -177.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -73.47 150.25 41.77 Favored 'General case' 0 N--CA 1.455 -0.206 0 O-C-N 122.097 -0.377 . . . . 0.0 111.009 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -142.53 165.72 26.63 Favored 'General case' 0 N--CA 1.457 -0.121 0 C-N-CA 123.594 0.758 . . . . 0.0 110.324 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 65.6 p -79.8 -3.17 46.53 Favored 'General case' 0 C--O 1.232 0.169 0 C-N-CA 123.129 0.572 . . . . 0.0 112.151 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 24.0 tpt180 -148.2 148.26 30.34 Favored 'General case' 0 CA--C 1.523 -0.071 0 C-N-CA 123.077 0.551 . . . . 0.0 109.835 -178.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 51.1 m -82.58 132.55 35.19 Favored 'General case' 0 N--CA 1.456 -0.171 0 N-CA-C 110.0 -0.371 . . . . 0.0 110.0 177.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 17.7 m -146.36 161.29 10.35 Favored 'Isoleucine or valine' 0 C--O 1.231 0.124 0 C-N-CA 123.496 0.719 . . . . 0.0 110.238 -178.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -142.86 15.04 1.93 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 122.788 0.435 . . . . 0.0 110.791 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.5 m . . . . . 0 C--O 1.251 1.133 0 CA-C-O 117.278 -1.344 . . . . 0.0 109.887 -178.184 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.261 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -138.95 154.95 48.37 Favored 'General case' 0 C--O 1.23 0.078 0 C-N-CA 123.213 0.605 . . . . 0.0 110.538 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 56.53 176.85 0.04 OUTLIER 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.614 1.165 . . . . 0.0 113.186 -179.479 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -91.81 0.2 57.5 Favored 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 123.252 0.621 . . . . 0.0 111.087 178.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -150.12 162.19 40.9 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.149 0.98 . . . . 0.0 108.619 178.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 50.7 m-20 -62.41 120.7 61.36 Favored Pre-proline 0 CA--C 1.533 0.295 0 O-C-N 122.181 -0.325 . . . . 0.0 110.651 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -75.81 -28.26 8.04 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.364 2.709 . . . . 0.0 112.239 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 4.0 p-80 -157.41 0.72 0.11 Allowed 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -178.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -87.06 167.42 14.21 Favored 'General case' 0 C--O 1.23 0.064 0 CA-C-N 118.286 0.494 . . . . 0.0 110.558 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 54.9 p -124.51 154.63 69.65 Favored Pre-proline 0 C--O 1.231 0.096 0 C-N-CA 123.283 0.633 . . . . 0.0 110.63 -178.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -74.28 -4.0 14.72 Favored 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 123.734 2.956 . . . . 0.0 112.434 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.16 36.02 11.48 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.218 0.607 . . . . 0.0 111.446 -177.075 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.416 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.3 p -67.92 161.13 69.87 Favored Pre-proline 0 CA--C 1.531 0.249 0 C-N-CA 123.799 0.84 . . . . 0.0 111.586 -177.177 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.416 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 90.1 Cg_endo -70.49 5.7 1.87 Allowed 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 123.865 3.043 . . . . 0.0 112.119 177.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.3 t -117.85 139.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 C-N-CA 123.153 0.581 . . . . 0.0 109.864 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.2 m -131.37 146.83 33.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-O 120.911 0.386 . . . . 0.0 110.807 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.1 t-80 -96.58 137.41 35.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.845 0.858 . . . . 0.0 110.165 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.0 mp -111.77 145.82 17.45 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 123.552 0.741 . . . . 0.0 109.392 -177.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -142.56 164.94 28.75 Favored 'General case' 0 C--O 1.228 -0.04 0 C-N-CA 123.655 0.782 . . . . 0.0 110.724 -177.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.44 25.26 57.29 Favored Glycine 0 CA--C 1.525 0.711 0 CA-C-O 119.575 -0.569 . . . . 0.0 113.343 173.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.7 mt -60.33 156.5 15.61 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.987 0.894 . . . . 0.0 109.983 178.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.7 pt -71.84 -39.93 68.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 O-C-N 122.268 -0.27 . . . . 0.0 111.088 -175.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -172.92 -36.0 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.08 0 C-N-CA 123.612 0.765 . . . . 0.0 109.985 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 173.92 56.5 0.05 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -177.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.4 m -53.21 156.62 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 123.003 0.521 . . . . 0.0 110.782 178.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.446 HG13 ' H ' ' A' ' 111' ' ' ALA . 6.5 t -78.03 155.51 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 CA-C-O 121.032 0.444 . . . . 0.0 110.39 -176.341 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -60.76 -25.81 66.77 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.638 0.375 . . . . 0.0 110.265 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . 0.446 ' H ' HG13 ' A' ' 109' ' ' VAL . . . -81.32 -8.27 59.71 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.079 0.551 . . . . 0.0 111.62 -179.15 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -85.7 -32.79 21.74 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.828 -0.545 . . . . 0.0 110.238 -179.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.1 mp -77.49 -30.94 53.28 Favored 'General case' 0 N--CA 1.456 -0.142 0 O-C-N 122.323 -0.236 . . . . 0.0 111.18 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.8 p -78.25 -31.76 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-N 118.18 0.445 . . . . 0.0 110.04 -178.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -82.23 -17.57 45.61 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 122.217 -0.302 . . . . 0.0 111.082 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.47 -10.34 18.62 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -117.6 -8.55 10.92 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.606 0.639 . . . . 0.0 112.21 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -67.54 -6.88 21.95 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 118.663 0.665 . . . . 0.0 111.874 175.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -76.59 -13.05 60.1 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.956 -0.465 . . . . 0.0 110.634 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -100.82 -16.9 17.13 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 122.567 0.347 . . . . 0.0 111.606 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.15 177.64 36.27 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -72.25 140.44 33.94 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.81 3.007 . . . . 0.0 110.52 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.2 mt -111.13 147.31 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.085 0 C-N-CA 122.75 0.42 . . . . 0.0 110.246 -177.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.8 t -107.63 -41.56 5.0 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.076 0.551 . . . . 0.0 111.656 -177.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 46.1 t80 -159.65 160.51 34.33 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 117.623 0.192 . . . . 0.0 111.258 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 88.9 t -143.65 146.51 21.04 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 C-N-CA 124.122 0.969 . . . . 0.0 109.829 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.8 p -144.19 151.4 16.12 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 174.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 60.4 t -133.36 149.73 31.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -176.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 72.1 mtm -134.41 86.66 34.69 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 123.612 0.765 . . . . 0.0 109.284 -179.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.35 -11.55 30.26 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 123.061 2.507 . . . . 0.0 111.649 -177.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -81.11 -10.34 59.67 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.062 0.545 . . . . 0.0 110.7 176.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -128.88 3.18 5.36 Favored 'General case' 0 C--N 1.34 0.155 0 C-N-CA 123.73 0.812 . . . . 0.0 111.353 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.7 tpp85 53.05 34.05 16.29 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.335 1.054 . . . . 0.0 111.964 -176.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -137.84 168.55 19.47 Favored 'General case' 0 C--N 1.334 -0.08 0 C-N-CA 123.402 0.681 . . . . 0.0 110.282 -177.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.98 170.86 19.37 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 123.139 0.576 . . . . 0.0 110.262 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 14.1 tp -137.54 142.87 41.38 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 92.0 t -137.8 141.55 38.56 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -176.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -120.79 124.76 45.86 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.43 0.692 . . . . 0.0 109.219 177.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -89.16 153.23 21.12 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 120.919 0.39 . . . . 0.0 110.303 178.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -73.32 -14.39 61.29 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.409 -177.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -146.75 151.25 36.86 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 176.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -67.49 -20.65 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.302 0.241 . . . . 0.0 111.558 -175.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.4 tp -75.92 -25.79 56.32 Favored 'General case' 0 N--CA 1.456 -0.165 0 O-C-N 122.09 -0.381 . . . . 0.0 110.485 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.14 -30.31 65.41 Favored Glycine 0 C--N 1.339 0.722 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.69 -31.55 28.53 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.025 0.412 . . . . 0.0 110.34 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 47.5 t -73.75 -19.67 60.72 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 122.705 0.402 . . . . 0.0 110.974 179.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 122.694 0.398 . . . . 0.0 111.315 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.36 -31.52 22.92 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 122.169 -0.332 . . . . 0.0 111.386 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.4 t -85.06 -13.53 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -72.52 -1.95 17.87 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.295 0.638 . . . . 0.0 111.212 178.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 53.1 t80 -124.02 -36.75 2.66 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.827 0.451 . . . . 0.0 110.914 178.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.59 -8.7 59.35 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -176.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.41 -0.89 57.45 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.721 0.408 . . . . 0.0 111.986 178.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -138.73 -12.56 1.3 Allowed 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -151.88 163.21 39.71 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 9.3 pm0 -76.59 159.71 30.06 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 122.06 -0.4 . . . . 0.0 110.027 177.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -126.74 136.17 61.59 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -89.2 152.73 21.43 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.092 -0.38 . . . . 0.0 110.654 -178.161 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 47.2 mt -137.67 -39.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.177 -177.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.22 28.94 3.72 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 122.819 0.448 . . . . 0.0 110.986 -177.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.1 5.61 80.11 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 -176.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -131.35 152.98 81.49 Favored Pre-proline 0 N--CA 1.453 -0.319 0 C-N-CA 124.228 1.011 . . . . 0.0 109.01 177.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -71.44 145.34 47.52 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.357 2.705 . . . . 0.0 111.751 -176.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.38 -174.93 4.98 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.945 1.298 . . . . 0.0 108.668 177.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.35 160.42 39.87 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 120.989 0.423 . . . . 0.0 111.28 -178.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.13 144.66 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 C-N-CA 123.66 0.784 . . . . 0.0 109.415 178.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -155.32 166.28 34.05 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 123.163 0.585 . . . . 0.0 110.047 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 82.1 m-85 -61.26 165.69 4.34 Favored 'General case' 0 N--CA 1.457 -0.106 0 CA-C-O 121.038 0.446 . . . . 0.0 110.73 178.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 38.1 t -138.26 163.89 30.63 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.166 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 59.7 p -75.35 -7.25 53.49 Favored 'General case' 0 N--CA 1.457 -0.109 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 174.559 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 35.6 t -78.17 157.24 29.47 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 123.67 0.788 . . . . 0.0 110.371 176.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -141.3 -2.37 1.27 Allowed 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 123.386 0.674 . . . . 0.0 111.131 177.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -161.2 133.66 6.03 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 123.51 0.724 . . . . 0.0 109.333 -177.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 27.1 mm -76.36 150.49 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.143 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 175.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 61.6 p -83.71 132.47 34.86 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-O 120.917 0.389 . . . . 0.0 110.817 179.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 45.21 53.12 11.54 Favored Pre-proline 0 CA--C 1.536 0.405 0 C-N-CA 124.55 1.14 . . . . 0.0 113.527 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -76.86 -7.64 17.54 Favored 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 123.64 2.893 . . . . 0.0 111.775 -178.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 172.44 -1.78 0.03 OUTLIER Glycine 0 CA--C 1.529 0.957 0 CA-C-O 119.751 -0.472 . . . . 0.0 112.426 -178.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -146.21 164.06 33.46 Favored 'General case' 0 CA--C 1.53 0.212 0 CA-C-N 117.713 0.757 . . . . 0.0 109.758 178.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.2 m -66.07 143.03 57.58 Favored 'General case' 0 CA--C 1.528 0.11 0 CA-C-O 120.964 0.412 . . . . 0.0 110.886 -178.506 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -155.78 160.62 40.42 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.258 0.623 . . . . 0.0 110.233 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -142.13 23.33 2.03 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.116 0.566 . . . . 0.0 110.645 178.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 32.6 m 54.17 35.32 22.2 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 123.421 0.688 . . . . 0.0 112.327 -179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -124.98 177.39 6.08 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 123.427 0.691 . . . . 0.0 110.97 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.6 m -126.85 12.65 7.31 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 123.495 0.718 . . . . 0.0 111.857 -178.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 33.3 m -135.93 169.45 20.63 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 C-N-CA 123.616 0.766 . . . . 0.0 110.694 -177.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -135.43 17.87 3.37 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 122.904 0.481 . . . . 0.0 110.747 178.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 45.8 m . . . . . 0 C--O 1.251 1.143 0 CA-C-O 117.514 -1.231 . . . . 0.0 110.719 -179.629 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.166 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -146.48 149.85 34.46 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 122.937 0.495 . . . . 0.0 110.155 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -142.88 165.48 27.25 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.466 0.707 . . . . 0.0 109.573 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 77.8 m-85 -73.99 142.9 45.79 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 176.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 27.0 t0 57.55 170.31 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.351 1.06 . . . . 0.0 111.864 -173.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -76.81 132.61 71.25 Favored Pre-proline 0 N--CA 1.454 -0.24 0 O-C-N 121.524 -0.735 . . . . 0.0 111.001 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -83.83 157.24 13.73 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 123.834 3.023 . . . . 0.0 109.875 176.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.3 p-80 49.27 14.82 0.1 Allowed 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 115.926 1.824 . . . . 0.0 115.926 175.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 56.9 mttp -102.63 162.51 12.87 Favored 'General case' 0 C--N 1.338 0.094 0 CA-C-N 119.007 0.821 . . . . 0.0 110.383 176.177 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 39.1 p -133.51 153.86 80.54 Favored Pre-proline 0 C--O 1.232 0.146 0 C-N-CA 123.427 0.691 . . . . 0.0 110.462 -178.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -76.22 -4.61 15.31 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.813 3.009 . . . . 0.0 112.24 -179.357 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.29 35.42 10.6 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.162 0.585 . . . . 0.0 111.502 -177.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.407 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.3 p -68.04 160.52 74.03 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 124.128 0.971 . . . . 0.0 111.627 -176.789 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 81.8 Cg_endo -70.18 4.53 2.31 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 124.295 3.33 . . . . 0.0 112.373 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.8 t -117.95 142.63 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 178.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -131.55 151.59 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 CA-C-O 121.114 0.483 . . . . 0.0 110.635 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.3 t-80 -101.89 136.12 42.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.253 1.021 . . . . 0.0 109.993 178.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.13 145.02 17.17 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 C-N-CA 123.465 0.706 . . . . 0.0 109.116 -176.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -142.26 165.14 28.24 Favored 'General case' 0 CA--C 1.526 0.054 0 C-N-CA 123.543 0.737 . . . . 0.0 110.339 -176.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.61 24.08 63.45 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 119.37 -0.683 . . . . 0.0 113.499 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 73.0 mt -61.38 157.96 15.61 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.282 1.041 . . . . 0.0 109.977 177.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.21 -40.14 74.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 O-C-N 122.411 -0.181 . . . . 0.0 111.416 -175.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -171.52 -42.17 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.479 0.712 . . . . 0.0 109.961 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -172.72 54.33 0.16 Allowed Glycine 0 C--N 1.337 0.625 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -175.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.5 t -50.21 144.59 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.299 0.639 . . . . 0.0 109.567 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -91.94 164.03 2.16 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-O 121.092 0.472 . . . . 0.0 111.613 -175.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -61.76 -27.69 68.91 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.885 0.474 . . . . 0.0 110.858 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.1 -4.58 51.0 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -178.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -103.83 -30.37 10.41 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-N 118.379 0.536 . . . . 0.0 109.8 175.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 75.9 mt -71.48 -41.53 69.23 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.555 0.342 . . . . 0.0 110.368 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.84 -30.04 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 121.154 -0.218 . . . . 0.0 111.041 -177.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -84.67 -14.88 47.22 Favored 'General case' 0 N--CA 1.456 -0.16 0 O-C-N 122.116 -0.365 . . . . 0.0 111.777 -177.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.16 -15.66 16.61 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 178.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -110.92 -8.26 14.51 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -71.77 -6.17 39.45 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.736 0.698 . . . . 0.0 111.401 175.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -77.04 -13.82 59.91 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 122.591 0.356 . . . . 0.0 110.323 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -99.05 -17.57 18.18 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.518 0.327 . . . . 0.0 111.742 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.21 176.69 36.28 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.79 139.48 33.64 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 124.106 3.204 . . . . 0.0 110.464 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 75.1 mt -110.87 145.95 16.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 C-N-CA 122.735 0.414 . . . . 0.0 110.352 -177.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -105.62 -40.44 5.76 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.226 0.61 . . . . 0.0 111.287 -178.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -159.07 159.2 34.34 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-O 120.788 0.328 . . . . 0.0 110.895 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -144.05 145.71 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.755 0.822 . . . . 0.0 109.619 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.23 152.14 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.11 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.061 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 10.3 p -134.5 153.69 35.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 122.815 0.446 . . . . 0.0 111.105 -176.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 18.8 ptp -136.03 82.83 35.54 Favored Pre-proline 0 CA--C 1.532 0.267 0 C-N-CA 124.001 0.92 . . . . 0.0 109.606 179.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -58.45 -21.2 52.67 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 124.255 3.304 . . . . 0.0 113.131 -178.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.3 mtpt -78.78 -1.15 33.35 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.718 0.407 . . . . 0.0 111.293 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 22.6 tptm -131.66 -0.75 3.88 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.359 1.064 . . . . 0.0 110.481 179.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 57.75 28.95 16.64 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.947 0.899 . . . . 0.0 112.51 -177.004 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -134.32 169.98 16.4 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.808 0.443 . . . . 0.0 111.226 -175.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.63 171.25 18.46 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.211 0.604 . . . . 0.0 110.758 178.224 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.4 mt -132.96 146.04 51.43 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.917 0.887 . . . . 0.0 109.673 178.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.8 t -138.85 133.42 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -114.64 120.75 41.19 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 177.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -86.7 153.58 21.63 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 120.958 0.409 . . . . 0.0 110.598 -179.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -74.7 -13.34 60.6 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.517 -177.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -147.08 152.41 38.47 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 123.82 0.848 . . . . 0.0 108.995 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -67.71 -21.85 27.74 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -175.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.3 tp -72.75 -27.1 61.82 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.137 -0.352 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.59 -30.35 66.6 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.18 -34.36 25.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 117.105 0.452 . . . . 0.0 110.292 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -72.41 -20.94 61.34 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 122.487 0.315 . . . . 0.0 110.876 178.441 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -94.29 4.59 53.67 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 122.939 0.496 . . . . 0.0 111.475 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -108.46 -26.57 10.39 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 117.967 0.349 . . . . 0.0 111.87 179.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 45.3 t -89.43 -18.89 7.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 CA-C-N 117.8 0.273 . . . . 0.0 110.506 178.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -73.32 1.44 9.53 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.979 -0.451 . . . . 0.0 111.787 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 55.3 t80 -119.08 -34.67 3.82 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 123.045 0.538 . . . . 0.0 110.825 178.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.84 -3.18 58.96 Favored 'General case' 0 CA--C 1.533 0.314 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.94 -2.16 57.75 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.597 0.359 . . . . 0.0 111.417 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.14 -5.52 1.65 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.045 0.538 . . . . 0.0 111.528 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.56 173.93 15.64 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.841 0.856 . . . . 0.0 108.864 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.5 pt20 -93.07 155.58 17.41 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.53 135.18 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -178.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.48 151.7 21.85 Favored 'General case' 0 N--CA 1.455 -0.183 0 O-C-N 122.195 -0.316 . . . . 0.0 110.552 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.0 mt -137.71 -39.01 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.144 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.13 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.17 30.59 2.99 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.042 0.537 . . . . 0.0 110.823 -176.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.66 4.86 84.95 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -176.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -131.17 151.98 79.82 Favored Pre-proline 0 N--CA 1.455 -0.211 0 C-N-CA 123.994 0.918 . . . . 0.0 109.106 177.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -71.29 145.57 48.8 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 C-N-CA 123.694 2.929 . . . . 0.0 111.749 -177.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.67 -176.38 5.59 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.565 1.146 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -139.05 159.38 42.28 Favored 'General case' 0 CA--C 1.527 0.082 0 CA-C-O 120.969 0.414 . . . . 0.0 111.271 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.7 p -148.45 142.34 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.481 0.713 . . . . 0.0 109.483 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -155.64 163.05 40.44 Favored 'General case' 0 N--CA 1.455 -0.178 0 C-N-CA 123.2 0.6 . . . . 0.0 110.186 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -64.35 165.83 9.08 Favored 'General case' 0 N--CA 1.456 -0.144 0 O-C-N 122.205 -0.309 . . . . 0.0 110.376 176.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 95.9 p -145.94 177.15 9.16 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 122.763 0.425 . . . . 0.0 110.024 177.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 13.2 m -70.27 -9.2 55.25 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.264 0.225 . . . . 0.0 110.811 178.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 33.6 t -79.57 152.46 30.09 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 122.677 0.391 . . . . 0.0 110.867 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -139.97 -0.85 1.64 Allowed 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 123.166 0.586 . . . . 0.0 110.819 175.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -159.83 130.1 5.57 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.651 0.781 . . . . 0.0 109.065 -178.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 81.2 mt -84.39 144.42 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.141 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 174.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 46.6 m -81.38 139.03 35.55 Favored 'General case' 0 N--CA 1.457 -0.098 0 N-CA-C 112.003 0.372 . . . . 0.0 112.003 -174.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 25.1 mtp-105 42.48 56.36 10.62 Favored Pre-proline 0 CA--C 1.533 0.315 0 C-N-CA 124.876 1.27 . . . . 0.0 113.109 176.305 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -72.16 156.58 55.33 Favored 'Trans proline' 0 N--CA 1.451 -0.976 0 C-N-CA 123.05 2.5 . . . . 0.0 110.432 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 70.76 6.25 58.93 Favored Glycine 0 CA--C 1.53 0.998 0 CA-C-O 119.717 -0.49 . . . . 0.0 112.753 179.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -74.42 160.8 30.51 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 117.864 0.832 . . . . 0.0 111.228 -178.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 82.9 p -148.52 163.0 38.5 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 123.22 0.608 . . . . 0.0 110.587 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -98.95 -8.98 24.68 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 122.709 0.403 . . . . 0.0 111.356 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -149.62 153.28 36.81 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 122.859 0.463 . . . . 0.0 110.433 -178.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 67.0 m -142.08 159.34 42.42 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 123.586 0.754 . . . . 0.0 110.478 -179.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -132.37 162.99 29.7 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.228 0.611 . . . . 0.0 109.924 -178.138 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 28.2 m -78.3 5.98 9.27 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 122.991 0.516 . . . . 0.0 111.934 179.18 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.2 m -136.77 165.19 28.9 Favored 'Isoleucine or valine' 0 C--N 1.338 0.09 0 C-N-CA 123.386 0.675 . . . . 0.0 110.659 -178.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 65.6 m-20 -97.66 -2.6 41.08 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.965 0.506 . . . . 0.0 111.641 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 65.8 m . . . . . 0 C--O 1.25 1.115 0 CA-C-O 117.426 -1.273 . . . . 0.0 110.324 -179.104 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.276 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -147.8 146.89 29.32 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 123.275 0.63 . . . . 0.0 109.837 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -142.65 -6.86 0.88 Allowed 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 122.437 0.295 . . . . 0.0 111.344 -179.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -147.0 174.53 11.44 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 123.67 0.788 . . . . 0.0 109.453 -178.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -88.07 -7.12 57.45 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.464 0.305 . . . . 0.0 111.135 177.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -151.32 49.43 0.58 Allowed Pre-proline 0 CA--C 1.534 0.352 0 C-N-CA 123.22 0.608 . . . . 0.0 112.426 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -71.16 -15.22 31.96 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 123.366 2.711 . . . . 0.0 112.282 -175.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -149.23 14.61 0.89 Allowed 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 -177.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -91.21 161.98 14.84 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 122.732 0.413 . . . . 0.0 110.86 -178.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 14.2 p -82.58 154.42 68.51 Favored Pre-proline 0 C--O 1.231 0.124 0 C-N-CA 122.864 0.466 . . . . 0.0 110.875 178.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -78.19 -11.59 16.13 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.788 2.992 . . . . 0.0 112.069 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 48.97 35.01 6.06 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.399 0.679 . . . . 0.0 111.192 -176.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.401 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 57.8 p -73.35 160.68 81.95 Favored Pre-proline 0 CA--C 1.533 0.327 0 C-N-CA 123.936 0.894 . . . . 0.0 112.139 -174.236 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.401 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 91.2 Cg_endo -72.7 2.46 5.25 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 124.306 3.337 . . . . 0.0 112.649 179.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.2 t -121.88 140.92 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.137 0 CA-C-N 118.42 0.555 . . . . 0.0 109.655 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.21 154.37 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 CA-C-O 121.385 0.612 . . . . 0.0 110.728 178.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -105.73 141.81 36.53 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.208 1.003 . . . . 0.0 109.514 -179.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 20.7 mm -110.26 144.05 19.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 C-N-CA 123.04 0.536 . . . . 0.0 110.142 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 42.4 mtm105 -141.24 159.4 42.29 Favored 'General case' 0 CA--C 1.527 0.063 0 C-N-CA 123.492 0.717 . . . . 0.0 110.315 -178.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.41 25.03 59.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-O 119.552 -0.582 . . . . 0.0 113.366 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 53.9 mt -59.55 156.24 13.77 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 118.098 0.949 . . . . 0.0 109.482 176.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.8 pt -70.31 -37.96 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.135 0 N-CA-C 111.383 0.142 . . . . 0.0 111.383 -174.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.74 -35.53 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 123.954 0.901 . . . . 0.0 109.648 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 170.48 55.97 0.04 OUTLIER Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -176.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.8 m -53.21 151.72 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 117.236 0.518 . . . . 0.0 110.501 178.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -87.18 166.45 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.082 0 CA-C-O 121.314 0.578 . . . . 0.0 110.809 -177.232 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -60.3 -25.21 65.59 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.002 0.521 . . . . 0.0 110.698 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.89 -6.35 53.99 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 122.811 0.444 . . . . 0.0 112.038 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 79.4 m-20 -97.34 -33.11 11.55 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 118.371 0.532 . . . . 0.0 109.733 176.201 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.47 -40.76 66.71 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.308 0.243 . . . . 0.0 110.83 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.08 -30.06 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 O-C-N 122.158 -0.339 . . . . 0.0 110.855 -176.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.7 mm-40 -81.67 -18.22 45.28 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 117.822 0.283 . . . . 0.0 111.616 -178.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.35 -14.37 16.95 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -113.9 -7.43 13.17 Favored 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -178.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.0 pt20 -71.49 -5.84 36.01 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.666 0.666 . . . . 0.0 111.735 175.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -76.58 -14.3 60.01 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 122.962 0.505 . . . . 0.0 110.677 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -98.71 -17.01 18.77 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.56 0.344 . . . . 0.0 111.562 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.91 176.67 35.2 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -71.12 140.31 37.36 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 123.935 3.09 . . . . 0.0 110.631 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 72.4 mt -110.16 146.4 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.103 0 C-N-CA 122.863 0.465 . . . . 0.0 110.4 -178.006 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.8 t -108.26 -39.93 5.32 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 123.279 0.631 . . . . 0.0 111.62 -177.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -157.78 158.13 34.66 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 120.57 0.224 . . . . 0.0 111.04 178.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.5 t -145.01 146.36 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.079 0 C-N-CA 123.642 0.777 . . . . 0.0 109.507 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.28 153.24 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 175.352 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 11.1 p -133.7 151.74 33.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.118 0 CA-C-O 120.806 0.336 . . . . 0.0 111.191 -176.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 19.3 ptp -136.24 84.89 28.54 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.739 0.816 . . . . 0.0 109.159 179.691 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.5 -12.31 33.1 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.386 2.724 . . . . 0.0 111.666 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -77.93 -5.04 49.82 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 122.683 0.393 . . . . 0.0 111.018 176.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -132.79 5.17 3.92 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 123.645 0.778 . . . . 0.0 111.213 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 54.27 35.72 23.44 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.292 1.037 . . . . 0.0 112.343 -177.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -137.54 169.83 17.12 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.132 0.573 . . . . 0.0 111.039 -176.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.44 172.82 17.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.112 0.565 . . . . 0.0 110.494 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.4 mt -132.92 146.22 51.6 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.9 0.88 . . . . 0.0 109.374 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 89.8 t -138.36 133.03 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -116.26 121.68 42.74 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.578 0.751 . . . . 0.0 109.192 178.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 44.3 m-85 -88.5 155.52 19.61 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.052 0.453 . . . . 0.0 110.547 -178.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -75.77 -13.49 60.3 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.475 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -145.76 152.82 40.17 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.691 0.796 . . . . 0.0 109.097 177.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.8 p -69.55 -21.84 24.9 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 58.7 tp -77.44 -29.51 52.89 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.003 -0.436 . . . . 0.0 110.418 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.27 -31.09 73.94 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.15 -32.03 33.86 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 116.984 0.392 . . . . 0.0 110.534 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.6 t -70.6 -29.72 66.2 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 122.076 0.15 . . . . 0.0 110.628 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -75.84 -21.0 57.7 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.194 -0.316 . . . . 0.0 111.247 179.18 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -81.31 -28.19 34.7 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.971 0.35 . . . . 0.0 111.617 -177.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 33.3 t -92.16 -19.66 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 O-C-N 122.382 -0.199 . . . . 0.0 110.688 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -71.34 -11.69 61.04 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 122.117 -0.364 . . . . 0.0 110.888 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -104.88 -34.05 8.18 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 122.942 0.497 . . . . 0.0 110.764 178.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.71 -7.24 59.52 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -177.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -84.84 -2.51 57.84 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -141.47 -3.87 1.15 Allowed 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 122.829 0.452 . . . . 0.0 111.946 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 54.1 t30 -154.68 165.23 37.21 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 123.303 0.641 . . . . 0.0 109.456 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -85.14 158.3 20.43 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.04 135.72 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.058 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.2 m-85 -89.78 152.97 21.03 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.04 -0.413 . . . . 0.0 110.862 -178.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.2 mt -137.29 -41.0 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.227 -0.101 0 C-N-CA 122.669 0.388 . . . . 0.0 110.755 -177.137 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.92 29.91 3.73 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.817 0.447 . . . . 0.0 110.944 -177.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.05 4.24 81.96 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -176.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -130.31 151.81 79.14 Favored Pre-proline 0 N--CA 1.455 -0.223 0 C-N-CA 124.14 0.976 . . . . 0.0 109.053 177.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.69 146.04 53.4 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 123.526 2.817 . . . . 0.0 112.038 -176.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.35 -176.21 5.49 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.267 1.427 . . . . 0.0 108.902 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -138.99 161.51 37.17 Favored 'General case' 0 N--CA 1.457 -0.086 0 CA-C-O 120.943 0.402 . . . . 0.0 111.521 -179.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.0 p -150.09 141.55 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.842 0.857 . . . . 0.0 109.751 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -160.84 160.04 30.6 Favored 'General case' 0 N--CA 1.458 -0.074 0 C-N-CA 123.333 0.653 . . . . 0.0 109.747 178.373 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -63.76 159.84 18.5 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.061 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 10.7 t -149.51 47.13 0.96 Allowed 'General case' 0 CA--C 1.53 0.188 0 O-C-N 122.168 -0.333 . . . . 0.0 111.549 -178.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 63.3 p 49.84 23.96 1.17 Allowed 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 124.823 1.249 . . . . 0.0 113.835 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 42.7 t -106.17 154.07 21.22 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 123.376 0.67 . . . . 0.0 109.622 178.08 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -135.91 -3.54 2.27 Favored 'General case' 0 CA--C 1.528 0.103 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 178.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -157.7 132.98 8.87 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.246 0.618 . . . . 0.0 109.47 -178.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 78.2 mt -84.48 146.93 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 173.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 75.7 p -76.57 141.12 41.26 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 121.015 0.436 . . . . 0.0 111.943 -175.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 34.8 ttp-105 41.87 58.3 9.86 Favored Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 125.032 1.333 . . . . 0.0 112.93 176.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -75.78 -7.16 18.25 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 123.589 2.859 . . . . 0.0 111.304 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 78.64 4.91 88.12 Favored Glycine 0 CA--C 1.528 0.904 0 CA-C-O 119.61 -0.55 . . . . 0.0 113.158 176.029 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -137.81 -11.13 1.55 Allowed 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 118.352 1.076 . . . . 0.0 112.371 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 81.2 p -157.55 169.18 25.27 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 118.268 0.486 . . . . 0.0 111.304 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -152.13 157.35 41.44 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.665 0.786 . . . . 0.0 109.903 178.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -153.03 -7.03 0.18 Allowed 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 78.0 p -92.35 -11.47 34.95 Favored 'General case' 0 C--N 1.34 0.192 0 O-C-N 121.923 -0.486 . . . . 0.0 112.185 -177.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 13.3 tpp85 -157.61 170.35 22.6 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 123.079 0.552 . . . . 0.0 109.906 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 73.4 p -78.96 0.64 26.71 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.94 0.496 . . . . 0.0 111.4 176.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 33.6 m -138.47 174.3 10.55 Favored 'Isoleucine or valine' 0 C--O 1.231 0.102 0 C-N-CA 124.023 0.929 . . . . 0.0 110.423 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 52.3 p-10 -119.18 9.47 11.76 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.574 0.749 . . . . 0.0 111.608 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.3 m . . . . . 0 C--O 1.251 1.133 0 CA-C-O 117.741 -1.123 . . . . 0.0 111.062 -179.639 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -148.0 152.1 36.87 Favored 'General case' 0 N--CA 1.457 -0.122 0 C-N-CA 122.889 0.476 . . . . 0.0 109.821 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -69.12 -13.12 62.25 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -176.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 66.1 m-85 -95.31 5.73 50.91 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.114 0.566 . . . . 0.0 111.398 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -107.21 10.58 29.91 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 123.317 0.647 . . . . 0.0 110.993 179.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 52.3 m-20 48.67 54.64 16.36 Favored Pre-proline 0 CA--C 1.534 0.339 0 C-N-CA 124.263 1.025 . . . . 0.0 112.58 -179.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -67.59 -25.29 40.92 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 123.764 2.976 . . . . 0.0 111.967 -176.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 2.9 p-80 -155.77 13.47 0.34 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.469 0.707 . . . . 0.0 110.874 179.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 57.2 mtpt -93.61 166.48 12.22 Favored 'General case' 0 CA--C 1.528 0.122 0 C-N-CA 123.949 0.899 . . . . 0.0 110.441 -175.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 35.0 p -135.86 153.41 77.12 Favored Pre-proline 0 C--O 1.231 0.084 0 C-N-CA 123.2 0.6 . . . . 0.0 110.628 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -79.12 -7.54 15.24 Favored 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 124.031 3.154 . . . . 0.0 111.953 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.95 33.9 12.64 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 123.701 0.8 . . . . 0.0 112.008 -178.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.1 m -69.73 159.77 82.56 Favored Pre-proline 0 CA--C 1.529 0.16 0 C-N-CA 123.663 0.785 . . . . 0.0 112.224 -177.045 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -72.35 -1.52 10.3 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 123.92 3.08 . . . . 0.0 112.073 175.606 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.4 t -113.42 139.38 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 123.215 0.606 . . . . 0.0 109.707 178.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.2 m -125.17 159.49 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 C-N-CA 122.928 0.491 . . . . 0.0 110.316 178.417 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -114.55 135.65 53.89 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 123.834 0.854 . . . . 0.0 109.687 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.8 mm -106.74 143.88 16.76 Favored 'Isoleucine or valine' 0 C--O 1.23 0.068 0 C-N-CA 122.888 0.475 . . . . 0.0 110.365 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 72.1 mtm-85 -143.64 163.5 33.05 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 123.368 0.667 . . . . 0.0 110.523 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.84 22.27 66.69 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 119.572 -0.571 . . . . 0.0 113.148 174.046 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.48 156.08 16.95 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 118.173 0.986 . . . . 0.0 110.041 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.1 pt -70.97 -41.46 76.99 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.112 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -173.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.2 -35.9 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.228 0.611 . . . . 0.0 110.437 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.86 50.5 0.12 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.648 -0.581 . . . . 0.0 111.648 -177.329 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 88.1 t -50.16 143.09 2.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.419 0.688 . . . . 0.0 109.8 177.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 33.8 m -94.48 164.7 2.05 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 121.229 0.538 . . . . 0.0 111.73 -174.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -61.22 -25.87 67.35 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.431 0.692 . . . . 0.0 111.224 -178.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.42 -6.3 57.85 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -177.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -97.75 -29.06 13.59 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 118.222 0.465 . . . . 0.0 110.282 177.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 98.0 mt -74.02 -35.9 64.41 Favored 'General case' 0 N--CA 1.452 -0.325 0 O-C-N 122.401 -0.187 . . . . 0.0 110.93 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.05 -31.47 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.363 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -81.55 -16.56 51.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 119.565 -0.255 . . . . 0.0 111.596 -178.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.95 -13.36 15.51 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.4 mt -116.1 -6.13 11.92 Favored 'General case' 0 N--CA 1.461 0.094 0 CA-C-N 118.483 0.583 . . . . 0.0 112.479 -178.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -72.44 -6.41 43.4 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.678 0.672 . . . . 0.0 110.26 175.004 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -77.33 -3.89 42.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 123.923 0.889 . . . . 0.0 111.059 179.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -112.85 -16.49 12.71 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.006 0.522 . . . . 0.0 111.282 179.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.48 175.78 35.62 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -71.35 140.77 37.54 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 123.812 3.008 . . . . 0.0 110.564 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.3 mt -110.13 147.05 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.822 0.449 . . . . 0.0 110.572 -178.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -109.53 -41.15 4.66 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 123.206 0.603 . . . . 0.0 111.564 -176.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -158.06 158.03 34.0 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 117.666 0.212 . . . . 0.0 111.261 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.7 t -143.89 147.42 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 C-N-CA 123.932 0.893 . . . . 0.0 109.591 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -149.53 151.52 12.8 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.032 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 175.407 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.95 152.59 36.24 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 C-N-CA 122.437 0.295 . . . . 0.0 110.899 -175.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 21.2 ptp -138.58 78.76 31.07 Favored Pre-proline 0 CA--C 1.534 0.33 0 C-N-CA 123.675 0.79 . . . . 0.0 109.741 177.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.57 -18.43 47.15 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.89 3.06 . . . . 0.0 113.306 -177.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -71.66 -12.28 61.26 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 122.8 0.44 . . . . 0.0 110.873 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.69 4.55 6.73 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.703 0.801 . . . . 0.0 111.286 179.273 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 55.31 34.98 23.97 Favored 'General case' 0 CA--C 1.533 0.288 0 C-N-CA 124.095 0.958 . . . . 0.0 112.191 -176.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -134.03 169.02 17.75 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 123.054 0.541 . . . . 0.0 110.843 -177.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.81 171.8 19.01 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.167 176.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 43.2 mt -131.86 146.44 52.12 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.522 0.729 . . . . 0.0 109.825 178.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.6 t -138.28 131.75 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -114.92 122.84 47.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 177.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -87.26 155.35 20.11 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.41 -179.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -76.37 -11.65 59.93 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.246 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.73 152.92 38.58 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.928 0.891 . . . . 0.0 109.282 177.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -69.9 -21.33 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 O-C-N 122.224 -0.298 . . . . 0.0 111.702 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.2 tp -75.85 -28.97 58.42 Favored 'General case' 0 N--CA 1.454 -0.231 0 O-C-N 121.865 -0.522 . . . . 0.0 110.626 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.03 -29.51 73.52 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.12 -28.12 29.66 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.99 0.395 . . . . 0.0 110.74 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.6 t -74.06 -30.89 62.61 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.244 -0.285 . . . . 0.0 110.467 179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -76.24 -21.67 56.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.268 -0.27 . . . . 0.0 111.249 179.329 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -33.31 26.79 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 117.778 0.263 . . . . 0.0 111.396 -177.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.15 -22.67 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 O-C-N 122.308 -0.245 . . . . 0.0 110.535 179.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -68.79 -16.56 63.83 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.943 -0.473 . . . . 0.0 111.01 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -99.03 -34.79 10.27 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 122.695 0.398 . . . . 0.0 110.691 178.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.21 -10.76 59.02 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -177.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.54 -1.01 52.78 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 178.019 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -139.61 -7.48 1.29 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -155.02 165.39 36.88 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.257 0.623 . . . . 0.0 109.363 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.68 157.57 23.29 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 173.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.43 135.99 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 64.1 m-85 -90.29 151.11 21.64 Favored 'General case' 0 N--CA 1.457 -0.082 0 O-C-N 122.109 -0.369 . . . . 0.0 110.92 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.5 mt -137.14 -38.89 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.12 -176.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.65 29.07 3.25 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.149 0.58 . . . . 0.0 111.012 -176.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.82 4.66 82.18 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.53 151.98 79.64 Favored Pre-proline 0 C--O 1.234 0.253 0 C-N-CA 124.322 1.049 . . . . 0.0 109.322 177.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_endo -70.9 146.57 53.46 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 123.522 2.814 . . . . 0.0 111.702 -177.179 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.71 -177.72 6.28 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 125.205 1.402 . . . . 0.0 109.104 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -137.54 159.7 41.23 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.061 0.458 . . . . 0.0 111.792 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.5 p -151.23 139.98 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 123.347 0.659 . . . . 0.0 110.149 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -162.06 154.95 20.18 Favored 'General case' 0 CA--C 1.528 0.132 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -106.03 136.82 45.03 Favored 'General case' 0 CA--C 1.528 0.118 0 CA-C-O 121.351 0.596 . . . . 0.0 112.395 178.315 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 32.6 t -166.31 143.23 5.08 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.505 178.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 68.5 p 44.34 26.57 0.17 Allowed 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 125.894 1.677 . . . . 0.0 114.494 175.273 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 50.9 m -141.81 149.57 40.53 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 122.907 0.483 . . . . 0.0 109.886 -179.338 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -149.31 -5.59 0.38 Allowed 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 177.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -159.66 137.55 10.1 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.438 0.695 . . . . 0.0 109.136 -177.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 66.4 mt -88.27 143.52 11.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 173.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.2 m -80.64 139.55 36.15 Favored 'General case' 0 C--N 1.334 -0.109 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -174.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 20.8 tpp180 42.32 58.2 10.58 Favored Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 124.841 1.256 . . . . 0.0 112.844 175.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -74.36 -15.38 22.47 Favored 'Trans proline' 0 N--CA 1.454 -0.834 0 C-N-CA 123.01 2.474 . . . . 0.0 111.47 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 62.04 -136.22 45.97 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 178.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -155.45 -29.35 0.1 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.207 0.603 . . . . 0.0 111.631 -179.121 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 82.3 p -154.32 168.8 25.4 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.452 0.701 . . . . 0.0 110.396 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -145.79 152.79 40.11 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.278 0.631 . . . . 0.0 110.256 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -150.62 153.93 36.58 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.291 0.636 . . . . 0.0 110.533 -179.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 79.5 p -146.65 151.31 37.04 Favored 'General case' 0 C--O 1.232 0.165 0 C-N-CA 122.954 0.502 . . . . 0.0 110.009 177.239 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 20.0 ptp180 -156.54 168.31 27.77 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.105 0.562 . . . . 0.0 110.873 -178.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 48.8 m -74.69 133.03 42.12 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 122.603 0.361 . . . . 0.0 110.17 178.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 6.0 m -150.01 163.63 3.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 C-N-CA 124.149 0.98 . . . . 0.0 109.202 -179.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -76.8 137.36 39.2 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 110.338 -0.245 . . . . 0.0 110.338 179.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 49.0 m . . . . . 0 C--O 1.25 1.088 0 CA-C-O 117.074 -1.441 . . . . 0.0 110.171 179.068 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.198 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -142.09 13.29 2.03 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 122.693 0.397 . . . . 0.0 111.771 -178.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 68.8 m-20 -72.89 -15.0 61.6 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.34 0.256 . . . . 0.0 111.147 -179.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -146.06 166.73 25.23 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.606 0.762 . . . . 0.0 109.154 179.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -81.22 -22.88 38.47 Favored 'General case' 0 CA--C 1.53 0.194 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 -177.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -157.38 60.39 2.01 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 117.923 0.329 . . . . 0.0 111.632 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -74.58 -31.58 6.83 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.592 2.195 . . . . 0.0 111.792 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 6.5 p-80 -162.57 12.98 0.07 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.075 0.55 . . . . 0.0 111.693 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -73.18 161.64 30.34 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.982 -0.448 . . . . 0.0 110.905 -176.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 34.8 p -87.44 154.19 53.77 Favored Pre-proline 0 CA--C 1.528 0.124 0 C-N-CA 123.021 0.528 . . . . 0.0 110.873 -179.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -77.18 -9.24 17.76 Favored 'Trans proline' 0 N--CA 1.453 -0.877 0 C-N-CA 123.877 3.051 . . . . 0.0 111.744 178.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 49.44 33.95 6.14 Favored 'General case' 0 C--N 1.341 0.231 0 C-N-CA 123.622 0.769 . . . . 0.0 111.542 -176.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.426 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.7 p -82.84 161.77 57.23 Favored Pre-proline 0 CA--C 1.532 0.288 0 C-N-CA 123.828 0.851 . . . . 0.0 112.099 -173.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.426 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 98.9 Cg_endo -71.17 1.22 5.59 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 124.008 3.139 . . . . 0.0 112.758 178.229 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.57 139.05 37.62 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.094 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 178.277 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.3 154.22 37.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 122.928 0.491 . . . . 0.0 110.339 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 31.5 t-80 -110.65 138.18 47.37 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.993 0.917 . . . . 0.0 109.507 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.1 mm -107.49 144.77 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 C-N-CA 122.893 0.477 . . . . 0.0 110.33 -176.228 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -143.01 161.48 38.0 Favored 'General case' 0 C--N 1.338 0.088 0 C-N-CA 123.195 0.598 . . . . 0.0 110.553 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.36 23.51 62.85 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 119.498 -0.612 . . . . 0.0 113.488 173.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 76.4 mt -60.87 158.01 13.98 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 118.332 1.066 . . . . 0.0 110.523 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -72.31 -40.93 65.65 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -173.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -172.12 -38.22 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 C-N-CA 123.107 0.563 . . . . 0.0 110.079 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.33 51.91 0.11 Allowed Glycine 0 C--N 1.338 0.646 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -176.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 57.9 t -49.65 144.03 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 123.546 0.738 . . . . 0.0 110.153 178.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -90.0 161.95 2.57 Favored 'Isoleucine or valine' 0 C--N 1.338 0.072 0 CA-C-O 121.292 0.567 . . . . 0.0 111.655 -174.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -62.0 -24.05 66.8 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.259 0.624 . . . . 0.0 111.766 -176.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.48 -5.5 58.74 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -95.63 -31.55 13.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.312 0.505 . . . . 0.0 110.498 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.56 -34.07 60.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 O-C-N 121.921 -0.487 . . . . 0.0 110.752 -177.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.3 p -78.06 -30.64 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 120.709 -0.396 . . . . 0.0 109.979 -178.68 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -85.72 -12.03 52.17 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.274 -0.266 . . . . 0.0 111.558 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.84 -11.79 15.31 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 178.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -114.8 -9.37 12.52 Favored 'General case' 0 C--N 1.34 0.19 0 CA-C-N 118.457 0.571 . . . . 0.0 112.255 -179.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.64 -3.87 16.92 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 118.615 0.643 . . . . 0.0 111.71 176.696 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -78.49 -16.1 57.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.865 0.466 . . . . 0.0 110.511 178.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -96.67 -18.94 19.35 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.343 -0.223 . . . . 0.0 111.397 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.34 178.14 38.25 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.75 140.78 36.22 Favored 'Trans proline' 0 N--CA 1.451 -0.985 0 C-N-CA 124.061 3.174 . . . . 0.0 110.46 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.5 mt -110.05 148.44 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 C-N-CA 122.604 0.362 . . . . 0.0 110.449 -177.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -110.63 -39.78 4.78 Favored 'General case' 0 N--CA 1.457 -0.101 0 C-N-CA 123.247 0.619 . . . . 0.0 111.851 -177.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -158.68 158.06 33.02 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 117.76 0.255 . . . . 0.0 111.601 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 79.3 t -143.72 146.29 21.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 124.036 0.934 . . . . 0.0 109.586 179.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.9 p -147.53 153.49 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 174.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.8 t -128.75 150.8 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 CA-C-O 120.833 0.349 . . . . 0.0 110.659 -176.299 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -134.54 79.77 52.93 Favored Pre-proline 0 CA--C 1.531 0.237 0 C-N-CA 124.492 1.117 . . . . 0.0 109.195 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -68.96 -14.06 37.86 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.389 2.726 . . . . 0.0 111.778 -175.407 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -81.71 -1.88 48.56 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 122.824 0.45 . . . . 0.0 111.585 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -133.39 4.46 3.69 Favored 'General case' 0 C--N 1.339 0.14 0 C-N-CA 123.797 0.839 . . . . 0.0 111.113 175.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.4 tpp85 55.59 35.76 25.84 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.069 0.948 . . . . 0.0 111.667 -175.193 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -134.11 170.49 15.58 Favored 'General case' 0 N--CA 1.457 -0.076 0 C-N-CA 123.415 0.686 . . . . 0.0 110.929 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.88 170.94 20.5 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 176.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.7 tp -135.17 142.54 46.12 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.5 t -138.21 141.54 37.78 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.1 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -123.9 125.03 43.91 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.086 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -87.75 154.9 20.2 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.875 0.369 . . . . 0.0 110.341 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -74.97 -12.36 60.32 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.246 -178.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -147.8 152.49 37.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.988 0.915 . . . . 0.0 109.265 176.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.8 p -68.63 -21.85 26.37 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.0 tp -73.95 -26.08 60.3 Favored 'General case' 0 N--CA 1.453 -0.303 0 O-C-N 121.999 -0.438 . . . . 0.0 110.544 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.24 -29.13 68.92 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.042 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.66 -30.23 23.38 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 117.237 0.519 . . . . 0.0 110.513 178.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 36.8 t -75.55 -17.77 59.97 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 122.49 0.316 . . . . 0.0 110.484 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -93.35 -20.84 19.97 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.705 0.402 . . . . 0.0 110.723 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.35 -31.01 25.02 Favored 'General case' 0 N--CA 1.455 -0.177 0 O-C-N 122.112 -0.367 . . . . 0.0 111.501 -178.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.62 -19.4 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 O-C-N 122.04 -0.413 . . . . 0.0 110.698 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -70.5 -17.54 62.96 Favored 'General case' 0 CA--C 1.529 0.142 0 O-C-N 122.221 -0.3 . . . . 0.0 111.195 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.9 t80 -97.42 -36.79 10.24 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 122.686 0.394 . . . . 0.0 111.172 178.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.25 -6.61 59.42 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.22 -4.81 56.67 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.078 -0.389 . . . . 0.0 111.543 176.238 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -141.64 -4.99 1.07 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 23.9 m-80 -145.01 175.26 10.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.358 0.663 . . . . 0.0 109.615 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.1 pt20 -99.35 150.52 22.05 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 172.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -118.91 134.51 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -88.04 151.46 22.74 Favored 'General case' 0 N--CA 1.453 -0.278 0 O-C-N 122.183 -0.323 . . . . 0.0 110.853 -179.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 41.2 mt -138.22 -37.3 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.19 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.91 29.54 3.14 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.24 0.616 . . . . 0.0 111.087 -176.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.73 4.69 84.93 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -176.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.36 152.78 81.13 Favored Pre-proline 0 N--CA 1.454 -0.234 0 C-N-CA 124.24 1.016 . . . . 0.0 108.982 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -71.53 146.83 50.52 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 123.377 2.718 . . . . 0.0 111.792 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.67 -176.54 5.77 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 124.784 1.234 . . . . 0.0 109.011 178.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -137.83 159.79 41.05 Favored 'General case' 0 CA--C 1.527 0.081 0 CA-C-O 120.776 0.322 . . . . 0.0 111.428 -178.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.84 138.14 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.324 0.649 . . . . 0.0 110.23 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -159.04 151.79 21.88 Favored 'General case' 0 N--CA 1.456 -0.126 0 C-N-CA 123.502 0.721 . . . . 0.0 109.303 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -103.66 133.08 49.27 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-O 121.246 0.546 . . . . 0.0 112.425 178.52 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 42.1 t -167.89 145.14 4.28 Favored 'General case' 0 N--CA 1.456 -0.148 0 C-N-CA 123.068 0.547 . . . . 0.0 110.852 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 3.1 m 50.34 24.89 1.66 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.914 1.286 . . . . 0.0 114.003 172.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 33.5 t -152.71 153.46 33.28 Favored 'General case' 0 C--O 1.232 0.171 0 O-C-N 121.522 -0.736 . . . . 0.0 111.045 178.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -148.22 -4.91 0.46 Allowed 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 176.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 15.6 tppt? -159.72 136.65 9.38 Favored 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -178.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 38.6 mt -89.4 137.44 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 174.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.6 m -82.58 141.72 32.36 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.551 0.215 . . . . 0.0 111.359 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 90.5 mtt-85 44.91 54.73 13.29 Favored Pre-proline 0 CA--C 1.533 0.306 0 C-N-CA 124.335 1.054 . . . . 0.0 112.791 176.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -72.73 81.53 1.59 Allowed 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 123.199 2.599 . . . . 0.0 110.141 179.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 83.56 11.52 79.8 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.637 -0.535 . . . . 0.0 112.1 -177.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 51.3 m-20 -110.2 18.48 19.9 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.263 0.625 . . . . 0.0 111.839 -178.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.5 m -69.18 153.31 43.9 Favored 'General case' 0 CA--C 1.529 0.172 0 O-C-N 122.113 -0.367 . . . . 0.0 111.295 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -146.22 166.02 27.47 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 123.357 0.663 . . . . 0.0 110.69 178.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 19.4 t0 -147.93 142.73 26.75 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.131 0.572 . . . . 0.0 110.331 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 70.7 m -146.79 157.37 43.66 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 124.15 0.98 . . . . 0.0 109.87 179.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -123.57 160.79 26.3 Favored 'General case' 0 N--CA 1.457 -0.116 0 C-N-CA 122.38 0.272 . . . . 0.0 110.666 -176.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.6 p -86.63 5.86 33.82 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 123.384 0.674 . . . . 0.0 112.045 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 30.7 m -133.02 160.29 42.71 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 C-N-CA 122.986 0.514 . . . . 0.0 110.483 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 52.24 23.1 2.21 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.047 0.939 . . . . 0.0 112.622 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 45.1 m . . . . . 0 C--O 1.25 1.115 0 CA-C-O 117.447 -1.264 . . . . 0.0 110.057 -178.025 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.161 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -145.95 151.31 37.61 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.883 0.473 . . . . 0.0 110.084 179.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 48.9 t30 -150.63 167.2 28.02 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.156 0.583 . . . . 0.0 109.509 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -69.53 -22.61 63.56 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 122.488 0.315 . . . . 0.0 111.062 179.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.0 t0 -156.76 157.82 35.76 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.066 0.547 . . . . 0.0 109.855 176.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.404 ' N ' ' CD ' ' A' ' 90' ' ' PRO . 34.3 t0 47.73 45.99 3.2 Favored Pre-proline 0 CA--C 1.537 0.457 0 C-N-CA 124.473 1.109 . . . . 0.0 113.6 -179.059 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.404 ' CD ' ' N ' ' A' ' 89' ' ' ASP . 98.3 Cg_endo -73.14 -26.77 14.52 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.128 1.885 . . . . 0.0 110.901 176.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.2 p-80 -159.78 17.69 0.16 Allowed 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.349 0.659 . . . . 0.0 111.555 -178.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -78.26 3.32 15.71 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -174.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 23.6 p -71.37 151.04 94.2 Favored Pre-proline 0 CA--C 1.528 0.124 0 O-C-N 122.114 -0.366 . . . . 0.0 110.449 178.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -77.94 -10.91 16.7 Favored 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 123.602 2.868 . . . . 0.0 111.71 179.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 49.07 33.29 4.63 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.392 0.677 . . . . 0.0 111.257 -176.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.454 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 77.8 p -85.22 162.89 47.5 Favored Pre-proline 0 CA--C 1.529 0.147 0 C-N-CA 123.806 0.842 . . . . 0.0 112.016 -173.5 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.454 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 84.6 Cg_endo -70.5 2.15 4.23 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 123.89 3.06 . . . . 0.0 112.854 177.046 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.7 t -112.92 139.15 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 CA-C-N 118.327 0.512 . . . . 0.0 109.926 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.0 m -125.51 157.74 34.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 C-N-CA 122.908 0.483 . . . . 0.0 110.359 178.421 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.6 t-80 -115.39 137.63 51.84 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.179 0.991 . . . . 0.0 109.392 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.6 mm -107.67 145.69 14.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 C-N-CA 122.616 0.366 . . . . 0.0 110.044 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -142.64 157.74 44.38 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.418 0.687 . . . . 0.0 109.947 -178.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 24.98 57.51 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.314 174.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.3 mt -59.08 156.72 11.43 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 118.026 0.913 . . . . 0.0 109.812 177.562 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.1 pt -72.45 -39.07 61.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 O-C-N 122.181 -0.324 . . . . 0.0 111.773 -174.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -173.41 -36.2 0.01 OUTLIER 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 123.653 0.781 . . . . 0.0 110.033 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.31 54.75 0.05 OUTLIER Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -177.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.3 m -52.9 151.57 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 117.156 0.478 . . . . 0.0 110.271 177.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.1 m -88.34 165.74 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.039 0 CA-C-O 121.161 0.505 . . . . 0.0 111.36 -175.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.61 -23.92 66.35 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.132 0.573 . . . . 0.0 111.21 -178.173 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.2 -6.85 57.53 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 122.743 0.417 . . . . 0.0 111.867 -179.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -91.49 -34.96 14.59 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.236 0.471 . . . . 0.0 110.617 179.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.6 mp -75.87 -33.81 59.98 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 122.214 -0.304 . . . . 0.0 110.948 -176.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -76.57 -29.49 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.068 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 37.7 mm-40 -84.36 -14.26 50.02 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 122.206 0.202 . . . . 0.0 110.982 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.69 -21.79 16.24 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.8 mp -109.83 -10.68 14.75 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -177.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.36 -4.43 14.54 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.978 0.808 . . . . 0.0 111.956 177.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -83.6 -12.27 56.28 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.881 0.473 . . . . 0.0 110.413 178.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -103.97 -16.41 15.33 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 122.753 0.421 . . . . 0.0 111.425 -179.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.42 178.54 37.2 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -72.37 140.33 33.34 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 124.085 3.19 . . . . 0.0 110.671 179.268 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 79.4 mt -109.72 148.62 13.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.889 0.476 . . . . 0.0 110.684 -178.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 12.9 t -114.32 -36.39 4.67 Favored 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.384 0.673 . . . . 0.0 112.09 -177.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -155.96 156.06 33.86 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.626 0.25 . . . . 0.0 111.589 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.0 t -146.49 144.37 20.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.038 0.935 . . . . 0.0 109.183 179.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.7 p -151.33 152.82 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 175.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.8 150.59 34.07 Favored 'Isoleucine or valine' 0 C--N 1.335 -0.055 0 C-N-CA 122.587 0.355 . . . . 0.0 110.393 -175.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 70.0 mtm -132.74 84.74 49.18 Favored Pre-proline 0 N--CA 1.454 -0.237 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.57 -12.5 33.4 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.325 2.683 . . . . 0.0 111.964 -176.17 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -84.78 -1.75 56.77 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 122.842 0.457 . . . . 0.0 111.107 176.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -132.45 1.24 3.74 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 123.871 0.868 . . . . 0.0 111.157 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.2 tpp85 52.38 34.61 15.39 Favored 'General case' 0 C--N 1.341 0.197 0 C-N-CA 124.257 1.023 . . . . 0.0 111.846 -175.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.26 167.86 20.95 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.554 0.741 . . . . 0.0 110.354 -177.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.62 173.58 16.5 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.508 0.323 . . . . 0.0 110.792 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 45.0 mt -134.16 147.09 50.73 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.623 0.769 . . . . 0.0 110.14 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.6 t -140.06 135.28 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -116.75 122.63 45.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -84.77 156.02 21.58 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 120.974 0.416 . . . . 0.0 110.193 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -75.94 -12.29 60.12 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.325 -179.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -148.21 153.13 38.34 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 124.099 0.96 . . . . 0.0 109.362 177.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -70.5 -21.8 23.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.7 tp -74.34 -27.43 60.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 O-C-N 121.939 -0.476 . . . . 0.0 110.742 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.88 -30.63 67.86 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.88 -29.36 29.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 117.11 0.455 . . . . 0.0 111.028 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -77.58 -25.97 50.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.537 -0.171 . . . . 0.0 110.537 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -85.21 -17.22 37.75 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.135 0.174 . . . . 0.0 111.084 178.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.01 -28.56 25.66 Favored 'General case' 0 N--CA 1.456 -0.148 0 O-C-N 122.246 -0.284 . . . . 0.0 111.48 179.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.9 t -88.23 -21.91 6.88 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 O-C-N 122.196 -0.315 . . . . 0.0 110.618 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.16 -15.9 62.51 Favored 'General case' 0 CA--C 1.534 0.331 0 O-C-N 122.365 -0.209 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 58.0 t80 -93.76 -33.09 13.74 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.422 0.289 . . . . 0.0 110.927 178.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.99 -3.1 57.55 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 112.697 0.628 . . . . 0.0 112.697 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.81 -5.08 59.12 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 122.001 -0.437 . . . . 0.0 112.11 178.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -143.59 2.47 1.24 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 122.71 0.404 . . . . 0.0 111.52 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -155.27 173.72 16.23 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.032 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -98.48 156.34 16.82 Favored 'General case' 0 CA--C 1.527 0.094 0 CA-C-N 118.222 0.464 . . . . 0.0 110.276 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -119.56 136.49 56.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -177.607 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -92.89 147.65 22.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.98 -0.45 . . . . 0.0 110.384 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.8 mt -134.19 -40.15 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.131 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.83 29.78 3.78 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 123.012 0.525 . . . . 0.0 111.164 -177.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.11 5.14 83.51 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.394 -0.683 . . . . 0.0 111.394 -177.158 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -131.36 152.87 81.29 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 124.526 1.13 . . . . 0.0 108.84 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -71.1 146.23 51.44 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.531 2.821 . . . . 0.0 111.784 -177.212 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.5 -176.11 5.46 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.158 1.383 . . . . 0.0 108.772 177.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -138.98 159.43 42.16 Favored 'General case' 0 N--CA 1.456 -0.128 0 O-C-N 122.134 -0.353 . . . . 0.0 111.265 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.6 p -147.08 139.68 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 C-N-CA 123.237 0.615 . . . . 0.0 110.606 179.24 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -158.57 155.22 27.91 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.355 0.662 . . . . 0.0 109.582 176.24 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -97.66 127.68 43.8 Favored 'General case' 0 CA--C 1.527 0.069 0 CA-C-O 121.136 0.494 . . . . 0.0 111.375 177.429 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 41.6 m -158.95 144.08 16.07 Favored 'General case' 0 N--CA 1.457 -0.091 0 C-N-CA 123.205 0.602 . . . . 0.0 110.661 -177.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 82.1 p 44.44 26.86 0.19 Allowed 'General case' 0 N--CA 1.464 0.233 0 N-CA-C 115.508 1.67 . . . . 0.0 115.508 171.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 23.9 t -149.78 157.57 43.33 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 118.496 0.589 . . . . 0.0 110.807 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.85 -23.87 0.46 Allowed 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 179.714 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 15.7 tppt? -165.09 133.33 3.24 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -173.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 1.9 mp -82.67 136.95 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.079 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 172.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 77.4 p -94.39 143.41 26.43 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-O 120.613 0.244 . . . . 0.0 111.52 -176.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 69.8 ttt180 45.09 48.67 5.16 Favored Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 124.176 0.99 . . . . 0.0 112.797 177.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -76.26 -17.16 17.08 Favored 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 123.123 2.549 . . . . 0.0 112.264 -177.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -98.66 5.18 60.02 Favored Glycine 0 CA--C 1.529 0.92 0 CA-C-O 119.369 -0.684 . . . . 0.0 113.31 -175.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -145.79 165.04 29.99 Favored 'General case' 0 C--O 1.231 0.114 0 CA-C-N 118.292 1.046 . . . . 0.0 111.275 -176.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 82.2 p -120.56 163.47 17.94 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 123.845 0.858 . . . . 0.0 110.689 -179.262 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -130.68 5.31 4.65 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -175.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -75.31 159.95 30.88 Favored 'General case' 0 C--O 1.231 0.131 0 O-C-N 122.008 -0.433 . . . . 0.0 111.447 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 17.9 t -152.9 165.75 34.48 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 122.738 0.415 . . . . 0.0 110.229 -179.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -148.68 155.32 40.87 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.671 0.388 . . . . 0.0 110.176 178.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 20.3 m -86.24 31.74 0.64 Allowed 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 123.817 0.847 . . . . 0.0 112.688 -175.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 32.6 m -125.2 161.74 28.87 Favored 'Isoleucine or valine' 0 C--O 1.231 0.101 0 C-N-CA 123.125 0.57 . . . . 0.0 110.718 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 43.9 t30 52.81 32.08 11.69 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.466 0.706 . . . . 0.0 111.968 -177.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.9 m . . . . . 0 C--O 1.253 1.274 0 CA-C-O 117.357 -1.306 . . . . 0.0 111.073 -179.757 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.27 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -74.98 -14.67 60.65 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 122.883 0.473 . . . . 0.0 110.397 178.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -149.78 176.74 10.44 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.12 0.968 . . . . 0.0 108.704 179.208 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -70.59 -0.37 8.48 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.808 0.443 . . . . 0.0 111.451 177.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -141.88 160.09 40.9 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 124.244 1.018 . . . . 0.0 108.854 177.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 42.3 m-20 -67.63 131.13 92.94 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 117.654 0.207 . . . . 0.0 110.581 -177.449 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -73.83 -31.33 8.43 Favored 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 123.214 2.609 . . . . 0.0 111.848 -178.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 6.4 p-80 -158.18 -2.4 0.09 Allowed 'General case' 0 CA--C 1.53 0.202 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -179.174 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -84.56 162.62 19.76 Favored 'General case' 0 C--N 1.338 0.103 0 C-N-CA 122.673 0.389 . . . . 0.0 110.327 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 47.1 p -109.35 153.55 42.68 Favored Pre-proline 0 C--N 1.333 -0.135 0 C-N-CA 122.851 0.461 . . . . 0.0 111.02 -178.632 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -77.48 -1.99 12.17 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.967 3.111 . . . . 0.0 112.384 179.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.39 38.15 17.3 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.077 0.551 . . . . 0.0 111.315 -176.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.407 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 48.2 p -62.7 159.71 41.65 Favored Pre-proline 0 CA--C 1.532 0.262 0 C-N-CA 124.564 1.146 . . . . 0.0 112.03 -175.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 88.9 Cg_endo -70.11 4.79 2.14 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.583 3.522 . . . . 0.0 113.362 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.84 140.82 45.43 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.076 0 CA-C-N 118.579 0.627 . . . . 0.0 109.855 178.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.95 157.88 43.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 121.07 0.462 . . . . 0.0 110.643 179.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -107.84 142.63 37.61 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.908 0.883 . . . . 0.0 109.723 -179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.0 mm -111.42 144.88 18.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 123.006 0.523 . . . . 0.0 110.016 -176.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -141.36 160.12 40.78 Favored 'General case' 0 C--N 1.334 -0.068 0 C-N-CA 123.514 0.726 . . . . 0.0 110.068 -178.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.67 25.67 58.01 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.432 173.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 47.7 mt -59.07 154.87 14.8 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.388 1.094 . . . . 0.0 109.189 176.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.0 pt -69.95 -40.37 78.61 Favored 'Isoleucine or valine' 0 C--N 1.338 0.076 0 O-C-N 122.184 -0.322 . . . . 0.0 111.652 -172.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -172.91 -35.16 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.484 0.713 . . . . 0.0 109.979 -179.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.84 51.96 0.05 OUTLIER Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 -177.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.1 m -53.72 151.64 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 117.138 0.469 . . . . 0.0 110.087 177.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.3 m -88.46 163.88 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-O 120.881 0.372 . . . . 0.0 110.832 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.68 -22.33 63.8 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 122.819 0.448 . . . . 0.0 111.065 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.82 -8.04 58.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 122.868 0.467 . . . . 0.0 111.991 -179.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -91.12 -32.74 15.73 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 118.476 0.58 . . . . 0.0 110.48 178.007 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -71.41 -39.05 71.37 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.119 0.167 . . . . 0.0 110.601 -177.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.71 -31.28 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 C-N-CA 121.191 -0.203 . . . . 0.0 110.783 -175.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.7 mm-40 -81.26 -17.23 50.15 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 122.131 -0.356 . . . . 0.0 111.554 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.9 -12.47 16.21 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.3 mt -114.53 -9.11 12.71 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.491 0.587 . . . . 0.0 112.444 -179.059 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -70.06 -5.98 30.48 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.508 0.595 . . . . 0.0 111.778 176.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -76.28 -12.78 60.14 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 122.13 -0.356 . . . . 0.0 110.498 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -100.39 -16.9 17.46 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 122.455 0.302 . . . . 0.0 111.523 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.12 177.32 35.99 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.59 140.97 37.12 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.875 3.05 . . . . 0.0 110.451 -179.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.8 mt -111.07 146.73 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 122.675 0.39 . . . . 0.0 110.098 -178.125 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.2 t -108.26 -40.33 5.2 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.336 0.655 . . . . 0.0 111.436 -177.098 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -159.12 158.49 32.98 Favored 'General case' 0 N--CA 1.457 -0.078 0 CA-C-O 120.577 0.227 . . . . 0.0 111.355 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 65.1 t -145.23 147.92 18.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.801 0.84 . . . . 0.0 109.602 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.4 p -148.2 150.75 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 174.139 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 43.9 t -132.28 150.38 33.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.053 0 C-N-CA 122.628 0.371 . . . . 0.0 110.043 -174.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.7 mtm -135.62 80.59 43.98 Favored Pre-proline 0 N--CA 1.456 -0.171 0 C-N-CA 123.858 0.863 . . . . 0.0 109.486 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -58.88 -20.37 52.03 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.948 3.098 . . . . 0.0 113.041 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -76.09 -12.43 60.12 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.168 0.587 . . . . 0.0 111.139 179.334 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -124.06 3.57 8.65 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.644 0.778 . . . . 0.0 111.294 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.1 tpp85 52.83 32.84 13.03 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.473 1.109 . . . . 0.0 111.826 -176.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -136.93 166.74 22.94 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 123.435 0.694 . . . . 0.0 110.71 -177.044 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.03 172.18 17.25 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 122.748 0.419 . . . . 0.0 110.412 178.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 35.6 mt -132.09 146.52 52.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.728 0.811 . . . . 0.0 109.816 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 90.4 t -138.17 131.84 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.71 117.98 31.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.679 0.791 . . . . 0.0 109.169 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -86.26 155.36 20.71 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.012 0.434 . . . . 0.0 110.267 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -77.94 -11.04 59.86 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.497 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -146.47 152.02 38.34 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.522 0.729 . . . . 0.0 109.183 178.022 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -69.08 -21.48 25.42 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.76 -28.67 44.86 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 122.039 -0.413 . . . . 0.0 110.594 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.38 -28.73 73.11 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.82 -31.82 25.64 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.887 0.344 . . . . 0.0 110.66 178.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -69.95 -33.12 71.71 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 122.359 0.264 . . . . 0.0 110.578 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -73.72 -20.38 60.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 122.277 0.231 . . . . 0.0 111.447 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.44 -29.41 30.71 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 117.797 0.271 . . . . 0.0 111.585 -177.185 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.36 -21.96 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.096 0 O-C-N 122.312 -0.242 . . . . 0.0 110.648 178.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -68.41 -17.06 64.13 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 122.275 -0.266 . . . . 0.0 110.51 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 50.0 t80 -97.9 -36.0 10.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 122.426 0.29 . . . . 0.0 110.611 177.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.84 -15.06 59.82 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 122.648 0.379 . . . . 0.0 111.855 -177.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.24 52.4 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.982 0.513 . . . . 0.0 111.922 177.175 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -135.29 -18.33 1.75 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.129 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -151.33 166.21 31.67 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -81.12 154.25 26.86 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 175.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.588 HD11 ' H ' ' A' ' 158' ' ' TYR . 0.5 OUTLIER -110.04 164.52 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.173 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.588 ' H ' HD11 ' A' ' 157' ' ' ILE . 75.9 m-85 -119.52 154.64 33.53 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.094 -0.379 . . . . 0.0 110.3 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.6 mt -137.0 -42.28 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 O-C-N 123.165 0.291 . . . . 0.0 110.802 -177.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.08 29.83 3.69 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.268 0.627 . . . . 0.0 111.11 -177.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.48 6.75 80.3 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -176.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -129.7 153.67 80.83 Favored Pre-proline 0 C--O 1.233 0.203 0 C-N-CA 124.013 0.925 . . . . 0.0 109.245 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.97 144.18 52.09 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.184 2.589 . . . . 0.0 112.285 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.44 -177.59 6.31 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.473 1.509 . . . . 0.0 108.668 178.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -137.99 160.61 38.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.114 0.483 . . . . 0.0 111.471 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.4 p -150.25 140.86 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 123.888 0.875 . . . . 0.0 109.323 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -159.14 162.01 36.36 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.149 0.58 . . . . 0.0 109.893 178.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 15.1 m-85 -62.61 162.75 10.05 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 117.702 0.228 . . . . 0.0 110.388 176.601 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 14.7 t -145.48 25.27 1.36 Allowed 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 122.29 0.236 . . . . 0.0 111.279 -179.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 6.2 m 57.17 15.71 2.62 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.871 0.868 . . . . 0.0 112.178 -178.313 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 75.7 m -87.99 156.47 19.31 Favored 'General case' 0 N--CA 1.456 -0.168 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 177.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.8 pt20 -139.31 -6.26 1.39 Allowed 'General case' 0 CA--C 1.529 0.158 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 1.9 tmtm? -157.54 137.57 12.51 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 82.4 mt -85.6 149.17 4.33 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.08 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 173.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 45.0 m -78.62 141.58 37.91 Favored 'General case' 0 C--O 1.231 0.097 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -175.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 40.9 mtm180 41.15 53.1 6.49 Favored Pre-proline 0 CA--C 1.533 0.317 0 C-N-CA 125.112 1.365 . . . . 0.0 113.548 176.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -70.92 -8.81 24.43 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.677 2.251 . . . . 0.0 111.822 -175.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -121.85 7.04 10.25 Favored Glycine 0 CA--C 1.529 0.933 0 C-N-CA 123.516 0.579 . . . . 0.0 112.148 179.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -137.21 -12.03 1.65 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 117.849 0.825 . . . . 0.0 112.275 -176.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 29.2 t -79.79 149.87 30.94 Favored 'General case' 0 N--CA 1.455 -0.183 0 O-C-N 121.767 -0.583 . . . . 0.0 110.745 177.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 26.9 t70 51.89 24.42 2.54 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.893 0.877 . . . . 0.0 112.769 -178.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -73.82 155.45 38.8 Favored 'General case' 0 N--CA 1.455 -0.183 0 CA-C-O 120.906 0.384 . . . . 0.0 110.988 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 78.0 p -143.83 155.69 44.22 Favored 'General case' 0 C--O 1.231 0.079 0 C-N-CA 123.336 0.654 . . . . 0.0 109.387 178.004 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 14.6 ttm180 -151.94 164.06 37.95 Favored 'General case' 0 C--N 1.337 0.035 0 CA-C-O 120.647 0.261 . . . . 0.0 111.343 -174.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 36.4 m -80.72 4.15 19.83 Favored 'General case' 0 CA--C 1.529 0.136 0 C-N-CA 123.074 0.55 . . . . 0.0 111.761 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 32.9 m -134.17 158.7 42.25 Favored 'Isoleucine or valine' 0 C--O 1.231 0.109 0 C-N-CA 123.408 0.683 . . . . 0.0 110.423 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 45.5 t30 51.3 29.4 4.99 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.747 0.819 . . . . 0.0 112.177 -179.317 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 38.0 t . . . . . 0 C--O 1.25 1.122 0 CA-C-O 117.434 -1.27 . . . . 0.0 109.739 -178.998 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.273 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -134.15 -4.22 2.74 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 122.969 0.508 . . . . 0.0 110.87 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 58.21 173.03 0.06 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 125.202 1.401 . . . . 0.0 113.332 -177.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -89.39 -5.79 57.15 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 122.89 0.476 . . . . 0.0 111.225 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -152.21 150.76 30.18 Favored 'General case' 0 N--CA 1.455 -0.181 0 C-N-CA 124.322 1.049 . . . . 0.0 108.723 178.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 42.4 m-20 -79.91 127.28 77.83 Favored Pre-proline 0 N--CA 1.454 -0.23 0 O-C-N 122.275 -0.265 . . . . 0.0 110.842 -176.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -76.23 -18.42 16.2 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 123.621 2.881 . . . . 0.0 112.028 178.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 2.1 p-80 -151.11 -126.64 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 123.663 0.785 . . . . 0.0 109.287 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 82.9 mttt 62.71 179.16 0.14 Allowed 'General case' 0 C--N 1.341 0.196 0 C-N-CA 124.277 1.031 . . . . 0.0 111.346 -176.119 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 50.1 p -130.56 154.64 81.72 Favored Pre-proline 0 CA--C 1.53 0.196 0 C-N-CA 123.192 0.597 . . . . 0.0 110.572 -178.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -74.61 -2.56 12.6 Favored 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 124.025 3.15 . . . . 0.0 112.669 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.29 35.79 14.56 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.302 0.641 . . . . 0.0 111.545 -176.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.408 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 71.0 p -66.28 161.63 55.61 Favored Pre-proline 0 CA--C 1.532 0.254 0 C-N-CA 124.602 1.161 . . . . 0.0 111.484 -177.305 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 80.6 Cg_endo -69.78 4.27 2.3 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 124.098 3.198 . . . . 0.0 112.342 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.5 t -115.06 140.43 36.34 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 C-N-CA 123.076 0.55 . . . . 0.0 109.802 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.12 150.74 34.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.1 0 CA-C-O 121.035 0.445 . . . . 0.0 110.699 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.3 t-80 -99.39 136.21 39.67 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.249 1.019 . . . . 0.0 110.178 178.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.42 146.4 15.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.463 0.705 . . . . 0.0 109.168 -177.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -142.3 162.56 35.17 Favored 'General case' 0 N--CA 1.461 0.084 0 C-N-CA 123.573 0.749 . . . . 0.0 110.385 -176.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.27 26.99 53.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.66 -0.522 . . . . 0.0 113.239 172.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.4 mt -59.41 155.74 14.27 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 118.176 0.988 . . . . 0.0 109.798 177.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.2 pt -71.12 -39.5 74.08 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.111 0 O-C-N 122.189 -0.319 . . . . 0.0 111.308 -174.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -173.21 -37.05 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.882 0.873 . . . . 0.0 110.107 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.63 52.22 0.06 OUTLIER Glycine 0 C--N 1.337 0.612 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -176.44 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.1 m -54.04 154.4 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 CA-C-N 117.037 0.418 . . . . 0.0 110.203 177.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.9 m -90.84 166.11 1.85 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.063 0 CA-C-O 121.213 0.53 . . . . 0.0 111.091 -176.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -60.58 -24.2 65.25 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.24 0.616 . . . . 0.0 111.217 -178.663 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.5 -4.71 54.92 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 122.694 0.398 . . . . 0.0 112.015 -178.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -91.74 -35.76 13.96 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.256 0.48 . . . . 0.0 110.471 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.67 -31.9 52.86 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 122.225 -0.297 . . . . 0.0 111.105 -176.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.39 -31.5 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 O-C-N 122.057 -0.402 . . . . 0.0 110.184 -178.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.8 mm-40 -82.33 -18.55 41.77 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.244 -0.285 . . . . 0.0 111.054 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.01 -12.19 18.34 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.2 mt -117.6 -8.48 10.93 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.627 0.649 . . . . 0.0 112.525 -177.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.3 pt20 -68.8 -6.92 29.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 118.575 0.625 . . . . 0.0 111.563 176.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -76.47 -14.65 60.03 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.791 0.436 . . . . 0.0 110.607 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -99.41 -13.56 19.51 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 122.49 0.316 . . . . 0.0 111.613 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.62 176.32 32.59 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -71.27 140.35 36.97 Favored 'Trans proline' 0 N--CA 1.452 -0.93 0 C-N-CA 124.023 3.149 . . . . 0.0 110.51 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.6 mt -111.28 146.3 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.939 0.496 . . . . 0.0 110.519 -178.029 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -106.36 -41.26 5.36 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 123.433 0.693 . . . . 0.0 111.438 -177.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.0 t80 -159.29 158.89 33.32 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 122.225 0.21 . . . . 0.0 111.51 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -143.56 147.22 20.34 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 C-N-CA 123.827 0.851 . . . . 0.0 109.815 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.43 152.68 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.064 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 175.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 56.4 t -133.71 150.06 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 C-N-CA 122.852 0.461 . . . . 0.0 110.352 -176.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -133.79 86.47 38.58 Favored Pre-proline 0 N--CA 1.454 -0.262 0 C-N-CA 123.83 0.852 . . . . 0.0 109.318 -179.181 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -68.61 -14.64 39.98 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.463 2.776 . . . . 0.0 111.645 -176.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.0 tttp -79.24 -10.29 59.78 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.114 0.566 . . . . 0.0 110.91 177.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -126.76 1.22 6.73 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 123.683 0.793 . . . . 0.0 111.369 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.8 tpp85 53.05 32.33 12.75 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 124.358 1.063 . . . . 0.0 111.948 -176.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -135.77 166.56 22.99 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 123.551 0.74 . . . . 0.0 110.147 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.66 172.22 18.24 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-O 120.773 0.321 . . . . 0.0 110.921 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.5 mt -134.09 147.75 50.92 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.41 0.684 . . . . 0.0 109.929 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 81.6 t -138.24 133.61 43.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.8 tt0 -115.44 119.59 36.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 178.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 50.2 m-85 -86.13 155.0 20.96 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.987 0.422 . . . . 0.0 110.361 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -75.23 -14.41 60.52 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.379 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.29 153.03 39.25 Favored 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 123.697 0.799 . . . . 0.0 109.456 177.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -68.06 -22.0 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 52.5 tp -73.96 -25.45 59.95 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.184 -0.322 . . . . 0.0 110.494 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.25 -30.17 65.37 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 179.327 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.44 -31.17 22.99 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 122.864 0.466 . . . . 0.0 110.612 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.91 -19.98 60.53 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.601 0.36 . . . . 0.0 111.166 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -94.46 -15.48 24.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.45 0.3 . . . . 0.0 111.314 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.63 -32.6 25.61 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.31 -0.244 . . . . 0.0 111.491 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -84.86 -16.35 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -72.54 -4.39 30.34 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.656 0.382 . . . . 0.0 111.003 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -115.29 -35.78 4.55 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.806 0.442 . . . . 0.0 110.935 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -81.39 -7.77 59.63 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -177.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.7 -1.82 58.03 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.947 -0.471 . . . . 0.0 112.027 178.36 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.87 -6.7 1.45 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.678 0.391 . . . . 0.0 112.043 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -153.85 164.42 38.4 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.226 0.61 . . . . 0.0 109.563 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.26 158.18 23.6 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 174.161 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.96 135.45 64.01 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 -178.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -86.88 151.41 23.35 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.196 -0.315 . . . . 0.0 110.661 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.1 mt -137.09 -40.04 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 122.429 0.291 . . . . 0.0 111.095 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.34 29.12 4.0 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 122.842 0.457 . . . . 0.0 111.058 -178.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.96 78.1 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -177.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -131.58 152.4 80.36 Favored Pre-proline 0 N--CA 1.453 -0.32 0 C-N-CA 124.205 1.002 . . . . 0.0 108.774 177.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.68 145.26 57.06 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 123.147 2.565 . . . . 0.0 111.627 -177.101 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.09 -175.03 5.08 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 124.846 1.258 . . . . 0.0 108.905 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -138.35 162.01 35.48 Favored 'General case' 0 N--CA 1.456 -0.137 0 CA-C-O 120.915 0.388 . . . . 0.0 111.797 -178.067 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.14 144.05 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 C-N-CA 123.692 0.797 . . . . 0.0 109.378 178.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -157.18 166.22 33.82 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 122.966 0.506 . . . . 0.0 109.875 179.587 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -61.99 168.98 2.87 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-O 120.882 0.372 . . . . 0.0 111.056 177.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 35.5 t -145.6 165.97 27.14 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 123.175 0.59 . . . . 0.0 109.885 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 40.9 p -74.0 -7.62 53.08 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 175.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 68.8 m -73.8 152.14 40.38 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.869 0.868 . . . . 0.0 110.67 176.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.4 pt20 -137.29 -3.29 1.95 Allowed 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 122.626 0.37 . . . . 0.0 111.381 177.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -158.05 136.77 11.29 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.032 0.933 . . . . 0.0 108.608 -178.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 89.5 mt -87.39 137.56 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.212 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 174.12 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.5 m -78.67 141.25 38.1 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -174.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 69.9 ttt180 43.68 60.1 11.64 Favored Pre-proline 0 CA--C 1.533 0.29 0 C-N-CA 124.903 1.281 . . . . 0.0 112.751 174.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -72.02 -9.34 24.45 Favored 'Trans proline' 0 N--CA 1.455 -0.771 0 C-N-CA 123.23 2.62 . . . . 0.0 111.521 178.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 65.71 -134.76 35.35 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.516 -0.634 . . . . 0.0 111.516 176.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -152.73 163.42 39.72 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 123.357 0.663 . . . . 0.0 109.832 -176.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 95.3 p -144.83 162.68 36.2 Favored 'General case' 0 C--O 1.232 0.16 0 C-N-CA 123.357 0.663 . . . . 0.0 110.506 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -67.62 -16.46 64.18 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 122.284 -0.26 . . . . 0.0 111.117 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -85.53 -7.53 58.82 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.693 0.397 . . . . 0.0 110.758 178.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 46.5 m -113.06 0.16 14.91 Favored 'General case' 0 C--N 1.339 0.131 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -176.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 50.3 mtm180 -81.18 161.79 23.87 Favored 'General case' 0 C--N 1.34 0.171 0 CA-C-O 121.229 0.538 . . . . 0.0 111.309 179.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 62.7 m -71.94 -1.94 16.25 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.65 0.78 . . . . 0.0 111.665 178.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 40.3 t -88.16 -9.79 10.87 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 C-N-CA 123.655 0.782 . . . . 0.0 110.218 178.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -90.54 7.63 38.09 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 123.247 0.619 . . . . 0.0 111.386 -179.095 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 74.7 p . . . . . 0 C--O 1.254 1.291 0 CA-C-O 118.128 -0.939 . . . . 0.0 111.509 -178.406 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.244 0 N-CA-C 111.229 -0.749 . . . . 0.0 111.229 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -149.89 147.02 27.43 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.149 0.579 . . . . 0.0 110.121 179.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.6 p-10 -151.01 -177.43 6.01 Favored 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 122.755 0.422 . . . . 0.0 111.117 179.282 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -75.34 7.66 3.34 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.365 0.876 . . . . 0.0 113.365 -176.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -98.94 4.12 47.25 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -176.422 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 47.52 54.46 15.57 Favored Pre-proline 0 CA--C 1.534 0.335 0 C-N-CA 124.037 0.935 . . . . 0.0 112.774 177.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -71.9 -26.62 18.58 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 123.182 2.588 . . . . 0.0 112.106 -173.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . 0.576 ' CD2' ' H ' ' A' ' 92' ' ' LYS . 5.7 p-80 -158.49 -61.02 0.08 Allowed 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 122.377 0.271 . . . . 0.0 111.141 178.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.576 ' H ' ' CD2' ' A' ' 91' ' ' HIS . 97.7 mttt 44.28 33.25 0.81 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 124.433 1.093 . . . . 0.0 113.093 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 24.8 p -69.59 151.79 96.48 Favored Pre-proline 0 C--O 1.233 0.221 0 C-N-CA 122.614 0.366 . . . . 0.0 110.752 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -76.46 -7.33 17.77 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.675 2.917 . . . . 0.0 111.999 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.71 36.16 13.53 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.538 0.735 . . . . 0.0 112.044 -178.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 51.8 m -62.12 157.38 53.04 Favored Pre-proline 0 CA--C 1.531 0.243 0 C-N-CA 123.836 0.854 . . . . 0.0 112.225 -176.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -70.98 -1.33 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 124.114 3.209 . . . . 0.0 111.927 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.7 t -116.14 140.44 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 176.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.53 152.08 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.062 0.458 . . . . 0.0 110.761 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -102.48 136.38 42.41 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 123.982 0.913 . . . . 0.0 110.162 179.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.5 mp -111.95 145.87 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -177.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -141.39 162.95 34.24 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.692 0.797 . . . . 0.0 110.574 -177.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.83 27.22 54.31 Favored Glycine 0 CA--C 1.527 0.818 0 CA-C-O 119.469 -0.628 . . . . 0.0 113.185 174.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 54.0 mt -61.42 158.88 13.72 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 117.893 0.847 . . . . 0.0 110.415 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.87 -47.98 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -172.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -175.69 -35.86 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.208 0.603 . . . . 0.0 110.601 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -171.95 34.18 0.14 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.684 -0.509 . . . . 0.0 111.955 -175.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 8.8 p -52.32 148.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-N 117.425 0.612 . . . . 0.0 109.732 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.4 m -103.31 168.87 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.082 0 CA-C-O 121.364 0.602 . . . . 0.0 112.141 -172.202 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -57.99 -28.13 64.11 Favored 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 123.985 0.914 . . . . 0.0 111.602 -177.133 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.58 -2.31 38.27 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -176.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -104.17 -32.59 9.07 Favored 'General case' 0 N--CA 1.457 -0.121 0 CA-C-N 118.235 0.47 . . . . 0.0 110.415 177.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.75 -34.33 60.27 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.898 -0.501 . . . . 0.0 110.524 -179.325 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.0 p -76.5 -31.26 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.358 -179.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -83.0 -15.98 49.04 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 119.666 -0.207 . . . . 0.0 111.267 -178.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.72 -10.89 17.15 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -116.02 -9.15 11.78 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 118.632 0.651 . . . . 0.0 112.18 -179.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -68.9 -7.15 32.13 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 118.719 0.691 . . . . 0.0 111.523 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.67 -14.45 60.35 Favored 'General case' 0 CA--C 1.532 0.269 0 O-C-N 122.141 -0.35 . . . . 0.0 110.819 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.5 m-85 -97.13 -16.02 20.66 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 122.54 0.336 . . . . 0.0 111.591 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.78 178.56 35.8 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.85 139.5 33.48 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 124.046 3.164 . . . . 0.0 110.557 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 73.9 mt -110.94 145.76 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.688 0.395 . . . . 0.0 110.501 -177.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.1 t -106.73 -38.42 6.12 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 123.331 0.652 . . . . 0.0 111.463 -177.296 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -160.17 157.05 27.67 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.668 0.27 . . . . 0.0 111.23 179.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 94.4 t -144.14 146.23 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 C-N-CA 123.858 0.863 . . . . 0.0 109.666 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.83 153.79 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 C-N-CA 123.314 0.645 . . . . 0.0 109.513 176.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 46.0 t -127.34 150.66 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -177.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 68.2 mtm -132.27 77.85 69.77 Favored Pre-proline 0 CA--C 1.531 0.222 0 C-N-CA 124.3 1.04 . . . . 0.0 109.104 -177.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.8 -8.81 24.44 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 123.418 2.746 . . . . 0.0 111.72 -175.33 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -72.3 -17.11 61.89 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 122.656 0.382 . . . . 0.0 110.77 178.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 62.9 pttt -138.92 15.08 2.67 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 123.146 0.578 . . . . 0.0 111.91 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 57.53 39.68 27.63 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 124.079 0.952 . . . . 0.0 113.247 178.255 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.58 170.07 15.25 Favored 'General case' 0 CA--C 1.527 0.06 0 C-N-CA 123.043 0.537 . . . . 0.0 110.621 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.43 170.33 22.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 122.863 0.465 . . . . 0.0 110.564 177.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 34.1 mt -134.81 147.11 49.87 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.663 0.785 . . . . 0.0 110.179 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 85.0 t -139.08 132.07 38.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -114.15 119.79 38.31 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -86.97 154.79 20.51 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.426 -179.471 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -74.39 -14.63 60.89 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.507 -177.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -148.08 152.97 38.27 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.703 0.801 . . . . 0.0 109.108 176.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.1 p -66.72 -22.0 29.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -176.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.61 -26.11 60.64 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 122.031 -0.418 . . . . 0.0 110.629 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.03 -31.39 64.34 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.57 -32.12 25.98 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.047 0.423 . . . . 0.0 110.335 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.8 t -70.86 -15.64 62.65 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.198 0.599 . . . . 0.0 110.938 178.518 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 60.2 t30 -99.89 -14.03 18.92 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.029 0.532 . . . . 0.0 111.412 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -87.23 -31.65 20.18 Favored 'General case' 0 N--CA 1.456 -0.175 0 O-C-N 122.128 -0.358 . . . . 0.0 111.717 -177.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.6 t -86.82 -16.12 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.078 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -70.43 -4.69 23.78 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 122.913 0.485 . . . . 0.0 111.161 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -117.32 -32.21 5.03 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.969 0.508 . . . . 0.0 111.459 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.84 -0.93 55.52 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 113.083 0.771 . . . . 0.0 113.083 -176.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.67 -6.64 59.21 Favored 'General case' 0 CA--C 1.534 0.341 0 O-C-N 121.98 -0.45 . . . . 0.0 112.032 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -145.26 3.75 1.04 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.704 0.402 . . . . 0.0 111.88 179.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 49.0 t30 -151.52 171.3 17.79 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -178.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -95.61 155.88 16.56 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 118.38 0.536 . . . . 0.0 110.17 177.568 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -123.35 136.31 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -179.15 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -90.58 154.32 19.68 Favored 'General case' 0 N--CA 1.454 -0.235 0 O-C-N 122.047 -0.408 . . . . 0.0 110.851 -178.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.3 mt -137.33 -42.24 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.916 -177.337 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.49 30.88 3.47 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.936 0.494 . . . . 0.0 111.002 -177.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.7 5.94 80.82 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -130.59 151.21 78.3 Favored Pre-proline 0 N--CA 1.455 -0.207 0 C-N-CA 124.046 0.938 . . . . 0.0 109.01 177.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -72.17 145.97 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 123.375 2.717 . . . . 0.0 111.936 -176.219 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.0 -177.91 6.29 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.757 1.223 . . . . 0.0 108.845 177.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -137.34 158.78 43.66 Favored 'General case' 0 N--CA 1.457 -0.106 0 O-C-N 122.296 -0.253 . . . . 0.0 111.096 -178.552 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.01 142.09 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.23 0.612 . . . . 0.0 109.918 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 -152.59 167.55 28.51 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.187 0.595 . . . . 0.0 110.332 178.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -66.06 164.55 15.15 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 120.976 0.417 . . . . 0.0 110.842 177.384 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 98.2 p -144.56 174.34 11.03 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 176.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 59.7 p -76.26 1.76 15.12 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.675 0.39 . . . . 0.0 111.254 178.612 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 28.9 t -81.48 153.78 26.66 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 122.705 0.402 . . . . 0.0 110.758 179.147 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 19.3 pt20 -139.27 -5.17 1.44 Allowed 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 123.027 0.531 . . . . 0.0 111.08 176.287 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.4 tppt? -159.16 130.62 6.27 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 -178.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 69.5 mt -90.96 93.64 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.19 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 179.142 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 47.7 m 50.33 -114.31 0.74 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 123.515 0.726 . . . . 0.0 111.306 -178.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 14.9 tpp180 -140.98 82.78 14.69 Favored Pre-proline 0 N--CA 1.455 -0.187 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 -178.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -81.83 61.31 7.86 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 124.694 3.596 . . . . 0.0 110.842 -173.316 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 79.83 11.97 84.01 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -176.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 25.4 t0 61.86 169.01 0.11 Allowed 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 124.778 1.231 . . . . 0.0 113.012 -177.351 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 32.1 m -134.82 161.33 35.49 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.113 0.565 . . . . 0.0 110.847 -176.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -146.64 162.8 37.66 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 123.209 0.604 . . . . 0.0 110.138 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -143.21 154.91 44.34 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.096 0.558 . . . . 0.0 110.827 -178.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 54.8 m -138.82 161.97 35.94 Favored 'General case' 0 C--O 1.231 0.131 0 C-N-CA 123.238 0.615 . . . . 0.0 110.821 -177.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -91.81 12.12 22.49 Favored 'General case' 0 C--N 1.34 0.153 0 C-N-CA 123.399 0.68 . . . . 0.0 112.769 -178.211 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 43.7 m 61.92 7.17 1.93 Allowed 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 179.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 30.2 m -142.2 166.28 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 CA-C-N 118.426 0.557 . . . . 0.0 110.059 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 46.1 t30 -109.36 24.67 12.76 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.506 0.722 . . . . 0.0 110.942 -178.403 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 48.4 m . . . . . 0 C--O 1.251 1.149 0 CA-C-O 117.692 -1.147 . . . . 0.0 110.742 -178.711 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.427 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.2 p . . . . . 0 CA--C 1.531 0.237 0 N-CA-C 111.487 0.18 . . . . 0.0 111.487 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 77.7 Cg_endo -70.19 3.02 3.23 Favored 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 124.199 3.266 . . . . 0.0 112.452 178.332 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.3 t -115.64 141.31 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.087 0.555 . . . . 0.0 109.798 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.0 m -130.71 151.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-O 121.231 0.538 . . . . 0.0 110.898 177.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 22.9 t-80 -100.49 139.23 36.47 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.076 0.95 . . . . 0.0 110.03 179.702 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 29.7 mm -108.54 145.15 15.86 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 123.646 0.778 . . . . 0.0 110.089 -178.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -143.59 161.2 39.12 Favored 'General case' 0 C--N 1.337 0.044 0 C-N-CA 123.352 0.661 . . . . 0.0 110.376 -177.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.35 25.09 59.8 Favored Glycine 0 CA--C 1.528 0.845 0 CA-C-O 119.442 -0.644 . . . . 0.0 113.658 173.213 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 68.9 mt -61.21 157.56 15.94 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.398 1.099 . . . . 0.0 109.864 177.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.3 pt -73.08 -41.64 59.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -173.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -173.39 -35.08 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.277 0.631 . . . . 0.0 110.553 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.98 50.59 0.1 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -175.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.9 t -52.32 144.58 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.159 0 C-N-CA 123.5 0.72 . . . . 0.0 109.743 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.82 161.24 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.036 0 CA-C-O 121.084 0.469 . . . . 0.0 111.564 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -60.95 -25.05 66.52 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 123.288 0.635 . . . . 0.0 111.201 -177.183 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.23 -3.62 52.9 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -178.119 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -99.43 -31.22 11.76 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.369 0.531 . . . . 0.0 110.757 178.297 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.4 mp -75.18 -34.05 61.51 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.162 -0.336 . . . . 0.0 110.361 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -77.63 -30.63 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 118.099 0.409 . . . . 0.0 110.348 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -82.14 -17.02 47.84 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.369 -0.207 . . . . 0.0 111.433 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.1 -11.51 16.56 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.5 mt -115.97 -9.97 11.68 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.695 0.68 . . . . 0.0 112.404 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -68.45 -7.05 28.41 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 118.567 0.621 . . . . 0.0 111.637 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -76.01 -14.44 60.22 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 122.692 0.397 . . . . 0.0 110.859 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -98.68 -16.8 18.88 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 122.685 0.394 . . . . 0.0 111.639 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.05 177.05 35.72 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -71.5 141.21 37.91 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 123.775 2.984 . . . . 0.0 110.524 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.2 mt -110.65 147.05 15.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 C-N-CA 122.824 0.45 . . . . 0.0 110.356 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.0 t -107.31 -42.55 4.8 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.279 0.632 . . . . 0.0 111.348 -177.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 54.5 t80 -158.79 159.67 35.41 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 120.778 0.323 . . . . 0.0 111.076 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 76.7 t -143.35 146.85 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 124.008 0.923 . . . . 0.0 109.071 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -147.71 151.26 13.76 Favored 'Isoleucine or valine' 0 C--O 1.231 0.096 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 175.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 45.4 t -128.05 151.01 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.065 0 C-N-CA 122.503 0.321 . . . . 0.0 110.6 -175.093 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.7 mtm -133.7 81.19 54.04 Favored Pre-proline 0 N--CA 1.455 -0.192 0 C-N-CA 124.113 0.965 . . . . 0.0 108.732 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.43 -12.29 33.2 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.577 2.852 . . . . 0.0 111.729 -175.201 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -82.02 -5.14 58.12 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.676 0.39 . . . . 0.0 110.685 177.233 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 35.8 mmtp -130.4 3.83 4.69 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.245 1.018 . . . . 0.0 111.132 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 53.62 33.22 16.0 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.336 1.054 . . . . 0.0 112.087 -176.125 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -136.51 168.45 19.45 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.309 0.644 . . . . 0.0 110.413 -176.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.49 172.22 18.61 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.591 0.356 . . . . 0.0 110.457 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 36.8 mt -131.4 146.65 52.36 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.566 0.746 . . . . 0.0 110.219 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 84.7 t -137.83 131.75 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -115.37 121.21 42.1 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.055 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.56 153.61 21.69 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.984 0.421 . . . . 0.0 110.325 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -74.83 -13.38 60.56 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.936 0.398 . . . . 0.0 110.496 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -147.46 151.65 36.77 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.58 0.752 . . . . 0.0 109.412 177.228 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.01 -20.43 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 111.663 0.245 . . . . 0.0 111.663 -175.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.1 tp -74.13 -27.01 60.65 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.946 -0.471 . . . . 0.0 110.743 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.32 -30.44 69.31 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.58 -29.57 27.7 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 117.132 0.466 . . . . 0.0 110.189 178.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 32.0 t -71.97 -12.95 61.48 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.208 0.603 . . . . 0.0 111.366 179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -102.0 -17.71 15.97 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 122.623 0.369 . . . . 0.0 111.764 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.49 -30.43 25.19 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.135 0.425 . . . . 0.0 111.587 -176.482 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 25.9 t -88.06 -17.19 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -72.17 -3.75 25.22 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.448 0.299 . . . . 0.0 111.063 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -116.18 -33.43 5.01 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 122.925 0.49 . . . . 0.0 111.113 177.648 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.02 -7.77 58.4 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -177.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.03 -1.0 56.31 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 122.077 -0.389 . . . . 0.0 111.806 177.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -140.18 -5.94 1.25 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 122.821 0.448 . . . . 0.0 111.725 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.78 173.24 16.71 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -90.73 156.76 17.84 Favored 'General case' 0 CA--C 1.529 0.136 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 175.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.05 136.4 59.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -90.33 150.98 21.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 O-C-N 122.068 -0.395 . . . . 0.0 110.698 -178.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.1 mt -137.43 -38.79 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.932 -177.492 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -132.9 28.76 4.17 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.288 0.635 . . . . 0.0 111.126 -176.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.01 4.83 86.64 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -176.178 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -130.82 151.9 79.64 Favored Pre-proline 0 N--CA 1.453 -0.287 0 C-N-CA 124.303 1.041 . . . . 0.0 109.066 178.061 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -70.5 145.26 52.38 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 123.49 2.793 . . . . 0.0 111.905 -176.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.63 -175.79 5.34 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.852 1.261 . . . . 0.0 108.898 178.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -138.68 160.07 40.56 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-O 120.948 0.404 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.67 143.1 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.854 0.862 . . . . 0.0 109.647 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 N--CA 1.455 -0.195 0 C-N-CA 122.973 0.509 . . . . 0.0 110.089 179.022 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.0 m . . . . . 0 CA--C 1.532 0.27 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -70.87 2.61 3.98 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 124.184 3.256 . . . . 0.0 112.325 178.243 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.6 t -115.26 141.53 31.77 Favored 'Isoleucine or valine' 0 C--N 1.339 0.112 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.59 152.34 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.381 0.61 . . . . 0.0 111.025 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -100.65 141.07 34.02 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.307 1.043 . . . . 0.0 109.882 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.1 mm -110.37 144.92 17.51 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 C-N-CA 123.048 0.539 . . . . 0.0 109.801 -178.253 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -140.56 159.28 42.54 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 123.464 0.705 . . . . 0.0 110.21 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.66 24.64 60.05 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 119.322 -0.71 . . . . 0.0 113.615 173.398 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 51.3 mt -59.47 155.82 14.32 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.172 0.986 . . . . 0.0 109.533 177.341 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -70.58 -38.01 71.85 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.102 0 O-C-N 122.35 -0.219 . . . . 0.0 111.305 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -172.08 -37.19 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.908 0.883 . . . . 0.0 109.506 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.0 56.19 0.04 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 m -53.2 151.4 1.19 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 117.243 0.522 . . . . 0.0 110.422 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.2 m -86.68 166.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.122 0 CA-C-O 121.166 0.508 . . . . 0.0 110.855 -177.186 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.6 -26.72 68.16 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 122.871 0.468 . . . . 0.0 110.786 -178.601 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.62 -7.98 56.33 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -94.45 -34.65 12.65 Favored 'General case' 0 N--CA 1.457 -0.11 0 CA-C-N 118.248 0.476 . . . . 0.0 109.772 176.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.4 mt -72.73 -40.23 66.28 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 122.389 0.276 . . . . 0.0 110.93 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.1 p -77.3 -29.87 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 O-C-N 122.083 -0.385 . . . . 0.0 110.739 -176.483 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -85.88 -14.64 44.26 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 122.128 -0.357 . . . . 0.0 111.146 -178.022 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -101.52 -14.11 17.62 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 178.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.6 mt -115.12 -8.47 12.4 Favored 'General case' 0 CA--C 1.529 0.14 0 CA-C-N 118.566 0.621 . . . . 0.0 112.568 -178.405 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.3 pt20 -70.54 -6.09 33.78 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.849 0.749 . . . . 0.0 111.67 176.078 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -76.82 -16.39 59.45 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.53 0.332 . . . . 0.0 110.449 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -95.94 -18.79 20.02 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.529 0.332 . . . . 0.0 111.525 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.43 177.57 37.88 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.6 140.28 35.74 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 124.047 3.165 . . . . 0.0 110.576 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 70.1 mt -110.81 147.1 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.869 0.468 . . . . 0.0 110.258 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -108.48 -39.42 5.42 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.333 0.653 . . . . 0.0 111.494 -177.694 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -158.83 157.68 32.02 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 117.719 0.236 . . . . 0.0 111.167 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 63.7 t -145.08 146.57 19.74 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 C-N-CA 123.775 0.83 . . . . 0.0 110.091 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.0 p -150.68 151.8 12.14 Favored 'Isoleucine or valine' 0 C--O 1.231 0.102 0 C-N-CA 123.566 0.746 . . . . 0.0 109.24 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.8 p -134.13 150.29 31.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-O 120.736 0.303 . . . . 0.0 110.804 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.2 mpp? -130.55 83.73 61.29 Favored Pre-proline 0 CA--C 1.53 0.202 0 C-N-CA 123.567 0.747 . . . . 0.0 109.51 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -58.79 -18.88 43.77 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 123.938 3.092 . . . . 0.0 113.066 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -78.85 -6.27 55.63 Favored 'General case' 0 C--N 1.341 0.222 0 C-N-CA 122.944 0.498 . . . . 0.0 111.473 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -131.28 3.27 4.29 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.755 0.822 . . . . 0.0 111.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.0 tpp85 54.68 33.65 19.86 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.404 1.082 . . . . 0.0 111.977 -176.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -136.35 165.49 25.67 Favored 'General case' 0 C--O 1.23 0.078 0 C-N-CA 123.005 0.522 . . . . 0.0 110.78 -176.822 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.97 171.2 17.66 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 122.59 0.356 . . . . 0.0 110.582 178.475 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.3 mt -131.05 145.16 51.93 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.022 0.929 . . . . 0.0 109.688 178.067 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -137.9 131.92 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -113.36 121.29 43.92 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 177.623 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -87.74 154.86 20.24 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-O 120.816 0.341 . . . . 0.0 110.216 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -75.38 -13.24 60.39 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.189 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -147.87 150.25 33.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.72 0.808 . . . . 0.0 109.274 177.04 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -67.34 -21.98 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.7 tp -74.93 -28.78 60.74 Favored 'General case' 0 N--CA 1.455 -0.204 0 O-C-N 121.875 -0.516 . . . . 0.0 110.534 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.29 -30.46 69.36 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.42 -30.06 33.67 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.699 -0.295 . . . . 0.0 110.618 178.639 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.5 t -74.22 -32.97 63.21 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.669 0.271 . . . . 0.0 110.685 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -74.81 -17.52 60.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.211 -0.306 . . . . 0.0 110.906 -179.146 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.37 -30.17 23.86 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -176.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.0 t -89.17 -22.63 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 O-C-N 122.095 -0.378 . . . . 0.0 110.732 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -70.19 -1.67 10.91 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 122.132 -0.355 . . . . 0.0 111.535 179.093 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.2 t80 -112.75 -37.82 4.76 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 122.836 0.454 . . . . 0.0 110.969 176.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.81 -6.8 57.96 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -79.69 -4.99 54.23 Favored 'General case' 0 N--CA 1.453 -0.284 0 O-C-N 122.027 -0.42 . . . . 0.0 111.7 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -141.39 -4.84 1.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 122.654 0.382 . . . . 0.0 111.894 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 27.2 m-80 -145.53 174.53 11.08 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.505 0.722 . . . . 0.0 109.821 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' GLN . . . . . 0.455 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -94.73 151.72 19.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 173.972 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -121.96 134.98 63.57 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -88.54 152.19 22.02 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.136 -0.353 . . . . 0.0 110.576 -178.255 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.7 mt -136.56 -41.57 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.22 -177.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.75 30.09 3.77 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.098 0.559 . . . . 0.0 110.858 -178.157 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.9 4.99 78.15 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -131.7 152.72 80.87 Favored Pre-proline 0 N--CA 1.455 -0.214 0 C-N-CA 124.024 0.93 . . . . 0.0 109.399 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -70.77 144.82 49.69 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 123.408 2.739 . . . . 0.0 111.866 -175.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.99 -175.95 5.35 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.891 1.276 . . . . 0.0 108.929 178.37 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -140.53 160.46 39.95 Favored 'General case' 0 C--O 1.231 0.092 0 CA-C-O 120.995 0.426 . . . . 0.0 111.503 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -146.96 141.52 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 C-N-CA 123.772 0.829 . . . . 0.0 109.916 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.6 t30 . . . . . 0 N--CA 1.456 -0.151 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.578 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.408 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 71.3 p . . . . . 0 CA--C 1.533 0.317 0 N-CA-C 111.45 0.167 . . . . 0.0 111.45 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 92.7 Cg_endo -71.7 5.82 2.29 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 124.471 3.447 . . . . 0.0 112.179 177.5 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.8 t -120.57 141.67 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.124 0 C-N-CA 123.066 0.546 . . . . 0.0 109.57 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 31.6 m -130.28 149.86 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.115 0 CA-C-O 121.199 0.523 . . . . 0.0 111.063 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -98.14 142.08 30.27 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.338 1.055 . . . . 0.0 110.127 177.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.6 mm -111.56 145.5 17.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 C-N-CA 123.06 0.544 . . . . 0.0 109.723 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -142.11 161.21 38.57 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.254 0.622 . . . . 0.0 110.377 -179.484 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 81.67 24.23 56.44 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.592 -0.56 . . . . 0.0 113.641 173.151 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.5 mt -63.01 159.23 17.53 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.1 0.95 . . . . 0.0 110.072 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.3 pt -74.2 -42.45 51.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.529 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.93 -35.46 0.01 OUTLIER 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.074 0.55 . . . . 0.0 110.676 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -177.04 50.31 0.1 Allowed Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.1 t -50.61 146.19 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 123.565 0.746 . . . . 0.0 109.735 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.8 m -96.53 161.92 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.072 0 CA-C-O 121.182 0.515 . . . . 0.0 111.4 -176.079 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -60.1 -24.72 64.86 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.01 0.524 . . . . 0.0 111.376 -176.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.22 -6.17 56.0 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -99.43 -31.58 11.58 Favored 'General case' 0 CA--C 1.529 0.137 0 CA-C-N 118.155 0.434 . . . . 0.0 110.204 177.051 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -69.83 -39.11 76.67 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.1 p -78.44 -30.79 15.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 121.157 -0.217 . . . . 0.0 110.52 -176.481 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -82.2 -14.37 55.68 Favored 'General case' 0 N--CA 1.456 -0.14 0 O-C-N 122.072 -0.393 . . . . 0.0 111.715 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.67 -11.8 15.36 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 94.3 mt -115.95 -8.36 11.89 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.847 0.749 . . . . 0.0 112.481 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -70.42 -6.55 36.54 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.564 0.62 . . . . 0.0 111.9 176.216 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -76.42 -15.58 59.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 122.488 0.315 . . . . 0.0 110.518 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -96.33 -17.15 20.88 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 122.446 0.298 . . . . 0.0 111.355 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.72 176.35 35.56 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -71.46 140.4 36.44 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 124.186 3.257 . . . . 0.0 110.586 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.7 mt -111.63 145.69 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.091 0 C-N-CA 122.563 0.345 . . . . 0.0 110.232 -177.435 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.8 t -105.36 -41.96 5.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 123.287 0.635 . . . . 0.0 111.278 -177.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -158.92 159.55 35.06 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.742 0.306 . . . . 0.0 111.098 178.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 87.7 t -143.6 147.46 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.827 0.851 . . . . 0.0 109.692 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.1 p -148.5 149.74 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.094 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 175.596 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.87 149.35 33.53 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -130.54 82.02 66.2 Favored Pre-proline 0 N--CA 1.456 -0.137 0 C-N-CA 123.667 0.787 . . . . 0.0 109.32 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -58.82 -19.09 45.09 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.849 3.032 . . . . 0.0 112.838 -178.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -75.15 -13.47 60.47 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.905 0.482 . . . . 0.0 111.071 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -125.82 4.65 7.37 Favored 'General case' 0 CA--C 1.527 0.089 0 C-N-CA 123.541 0.737 . . . . 0.0 111.284 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.1 tpp85 55.18 32.08 17.72 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.128 0.971 . . . . 0.0 111.993 -177.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -135.87 166.32 23.57 Favored 'General case' 0 N--CA 1.457 -0.106 0 C-N-CA 123.059 0.544 . . . . 0.0 110.803 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.72 172.38 15.68 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 122.863 0.465 . . . . 0.0 110.725 179.251 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 30.6 mt -132.97 145.81 51.21 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.645 0.778 . . . . 0.0 109.772 177.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 86.2 t -137.26 132.42 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -114.53 117.72 31.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -85.2 153.5 22.59 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 120.99 0.424 . . . . 0.0 110.251 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -74.62 -13.15 60.61 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.388 -177.723 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -148.32 151.28 35.1 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.76 0.824 . . . . 0.0 108.965 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.9 p -66.42 -21.95 29.36 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.8 tp -73.31 -24.63 60.42 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 121.948 -0.47 . . . . 0.0 110.492 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.24 -31.16 64.04 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.22 -31.23 23.28 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-N 117.126 0.463 . . . . 0.0 110.133 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 t -71.54 -18.48 62.26 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.904 0.482 . . . . 0.0 110.913 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -96.68 -17.83 20.08 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 122.74 0.416 . . . . 0.0 111.127 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.82 -31.42 28.12 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.13 -0.356 . . . . 0.0 111.663 -177.571 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 32.1 t -85.74 -14.36 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 177.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -72.97 -2.79 22.41 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.137 0.575 . . . . 0.0 111.118 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -121.03 -34.85 3.44 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 122.701 0.401 . . . . 0.0 110.996 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.73 -9.59 58.06 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -176.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.72 -0.21 55.89 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 122.663 0.385 . . . . 0.0 111.654 176.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -136.51 -10.13 1.89 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.907 0.483 . . . . 0.0 111.726 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 50.0 t30 -154.12 170.62 20.74 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -86.88 155.63 20.17 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 175.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.73 136.15 61.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -178.614 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -89.04 151.21 22.39 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.121 -0.362 . . . . 0.0 110.758 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.8 mt -136.5 -38.46 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.839 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.37 29.43 3.0 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.28 0.632 . . . . 0.0 111.027 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.18 3.79 81.97 Favored Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.716 -0.554 . . . . 0.0 111.716 -176.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -130.56 151.8 79.29 Favored Pre-proline 0 N--CA 1.454 -0.24 0 C-N-CA 124.436 1.094 . . . . 0.0 109.03 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo -70.77 146.22 53.37 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 123.666 2.91 . . . . 0.0 112.143 -177.202 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.86 -175.55 5.37 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.193 1.397 . . . . 0.0 109.205 179.074 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -140.59 159.44 42.19 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.004 0.43 . . . . 0.0 111.759 -178.747 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.72 143.13 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 C-N-CA 123.903 0.881 . . . . 0.0 109.902 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.5 t30 . . . . . 0 N--CA 1.455 -0.218 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -179.868 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.0 m . . . . . 0 CA--C 1.53 0.189 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.51 0.06 5.99 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 124.229 3.286 . . . . 0.0 111.904 177.025 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 54.1 t -114.29 141.41 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 176.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.9 m -129.56 151.81 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.139 0 CA-C-O 121.332 0.587 . . . . 0.0 110.906 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.9 t-80 -98.72 136.21 39.1 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.201 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.3 mm -106.62 144.59 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.099 0.56 . . . . 0.0 109.752 -178.854 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -141.77 161.82 37.0 Favored 'General case' 0 C--N 1.338 0.074 0 C-N-CA 123.345 0.658 . . . . 0.0 110.584 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 77.3 24.93 64.69 Favored Glycine 0 CA--C 1.527 0.843 0 CA-C-O 119.642 -0.532 . . . . 0.0 113.086 174.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.6 mt -61.44 159.52 12.62 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 117.956 0.878 . . . . 0.0 110.638 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.1 pt -73.34 -41.52 57.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -173.392 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -173.94 -35.58 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 123.634 0.774 . . . . 0.0 109.97 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.45 49.65 0.06 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -176.517 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 14.5 p -52.83 148.49 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 122.897 0.479 . . . . 0.0 110.083 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -88.2 163.06 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 CA-C-O 121.324 0.583 . . . . 0.0 111.996 -171.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -62.24 -27.48 69.03 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.799 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.71 -3.07 49.41 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 123.087 0.555 . . . . 0.0 112.318 -178.024 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -104.29 -29.84 10.52 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.427 0.558 . . . . 0.0 109.711 177.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 49.8 mt -72.67 -38.97 67.46 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 122.546 0.339 . . . . 0.0 110.924 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.67 -30.23 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.442 -178.32 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -82.38 -16.01 50.68 Favored 'General case' 0 N--CA 1.453 -0.279 0 O-C-N 122.168 -0.332 . . . . 0.0 111.506 -178.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.44 -12.91 16.27 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 112.918 0.711 . . . . 0.0 112.918 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.9 mt -114.05 -7.62 13.08 Favored 'General case' 0 C--N 1.339 0.11 0 CA-C-N 118.516 0.598 . . . . 0.0 112.506 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.15 -6.07 31.56 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 118.731 0.696 . . . . 0.0 111.784 176.748 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -77.09 -13.62 59.93 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.801 0.44 . . . . 0.0 110.769 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -98.64 -18.16 18.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 122.531 0.332 . . . . 0.0 111.477 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.94 177.08 36.43 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -70.94 140.28 37.92 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 124.176 3.251 . . . . 0.0 110.3 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.1 mt -112.21 145.9 17.71 Favored 'Isoleucine or valine' 0 C--O 1.231 0.092 0 C-N-CA 122.746 0.419 . . . . 0.0 110.237 -177.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 t -105.88 -41.96 5.27 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.243 0.617 . . . . 0.0 111.395 -177.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -159.85 160.27 33.52 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-O 120.695 0.283 . . . . 0.0 111.035 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.8 t -145.24 147.01 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 123.906 0.882 . . . . 0.0 109.526 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.89 155.39 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.141 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 176.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 29.1 t -125.87 153.38 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.08 0 C-N-CA 122.503 0.321 . . . . 0.0 110.995 -177.268 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.5 mtm -135.56 77.13 53.35 Favored Pre-proline 0 CA--C 1.532 0.265 0 C-N-CA 124.237 1.015 . . . . 0.0 109.385 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -60.59 -16.68 44.33 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.972 3.115 . . . . 0.0 113.245 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -77.13 -6.56 53.34 Favored 'General case' 0 C--N 1.339 0.132 0 C-N-CA 123.009 0.524 . . . . 0.0 111.618 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -133.22 3.68 3.68 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.216 0.606 . . . . 0.0 111.386 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 13.4 tpp85 55.3 38.26 30.1 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.7 0.8 . . . . 0.0 111.152 -173.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 83.1 mt-30 -134.0 166.24 23.16 Favored 'General case' 0 N--CA 1.458 -0.05 0 C-N-CA 123.684 0.794 . . . . 0.0 110.608 -176.799 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.04 171.31 18.06 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 122.985 0.514 . . . . 0.0 109.871 176.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -132.18 146.01 51.74 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 123.407 0.683 . . . . 0.0 110.072 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 93.3 t -137.37 128.71 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 118.1 33.78 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.28 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.6 m-85 -85.85 154.87 21.24 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.348 -179.148 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -75.23 -12.24 60.24 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 120.704 0.287 . . . . 0.0 110.399 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -148.62 152.16 36.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 123.784 0.834 . . . . 0.0 109.14 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.49 -21.41 26.19 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 122.076 -0.39 . . . . 0.0 111.614 -175.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.6 tp -75.56 -28.87 59.17 Favored 'General case' 0 N--CA 1.452 -0.353 0 O-C-N 122.008 -0.433 . . . . 0.0 110.529 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.16 -30.92 71.71 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.37 -31.41 37.84 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.894 0.347 . . . . 0.0 110.301 178.086 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 44.2 t -70.81 -29.53 65.72 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 122.205 0.202 . . . . 0.0 110.983 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -78.07 -19.6 53.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 119.462 -0.304 . . . . 0.0 111.476 -179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.88 -32.06 23.4 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.108 0.413 . . . . 0.0 111.606 -176.721 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.5 t -86.76 -19.51 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -68.65 -14.1 62.79 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.102 -0.374 . . . . 0.0 110.99 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -104.4 -37.85 7.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.487 0.315 . . . . 0.0 111.256 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.65 -4.33 58.96 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -77.9 -9.15 58.93 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.228 0.467 . . . . 0.0 111.486 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -141.07 -1.86 1.34 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.681 0.392 . . . . 0.0 111.652 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.5 m-80 -144.41 175.7 9.92 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.131 0.572 . . . . 0.0 109.921 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' GLN . . . . . 0.476 ' CD ' ' H ' ' A' ' 156' ' ' GLN . 0.0 OUTLIER -98.48 155.86 17.05 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.714 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.95 135.59 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.094 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -89.38 155.94 19.01 Favored 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 122.045 -0.409 . . . . 0.0 111.085 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.9 mt -138.0 -42.51 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.786 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.84 32.2 2.99 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.236 0.614 . . . . 0.0 111.122 -177.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.07 4.84 81.32 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 -176.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -128.99 150.67 75.95 Favored Pre-proline 0 N--CA 1.455 -0.202 0 C-N-CA 123.83 0.852 . . . . 0.0 109.215 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -71.55 147.58 52.02 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.464 2.776 . . . . 0.0 111.702 -177.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -153.45 -174.6 5.01 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.072 1.349 . . . . 0.0 108.731 178.124 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -139.04 160.24 40.24 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-O 120.986 0.422 . . . . 0.0 111.345 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.7 p -147.23 140.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.575 0.75 . . . . 0.0 109.264 179.087 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 N--CA 1.454 -0.232 0 C-N-CA 122.91 0.484 . . . . 0.0 110.398 179.599 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 63.8 m . . . . . 0 CA--C 1.53 0.18 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -71.88 -3.76 13.81 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.831 3.021 . . . . 0.0 111.568 177.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 67.5 t -111.11 139.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.62 148.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 CA-C-O 121.319 0.58 . . . . 0.0 110.732 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -95.46 137.25 34.78 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.189 0.995 . . . . 0.0 110.35 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 26.0 mm -105.85 143.92 16.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 123.194 0.597 . . . . 0.0 109.787 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -142.56 160.53 40.11 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 123.132 0.573 . . . . 0.0 110.822 -178.025 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.81 26.09 56.86 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 119.457 -0.635 . . . . 0.0 113.523 173.132 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.9 mt -62.53 156.06 24.04 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.144 0.972 . . . . 0.0 109.814 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -70.57 -41.63 77.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -173.23 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -173.12 -34.78 0.01 OUTLIER 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.31 0.644 . . . . 0.0 110.676 -179.054 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.93 48.93 0.12 Allowed Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -176.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.7 t -51.56 143.21 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 C-N-CA 123.41 0.684 . . . . 0.0 109.697 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.8 m -95.72 164.98 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.119 0 CA-C-O 121.308 0.575 . . . . 0.0 111.637 -175.426 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -61.08 -26.02 67.36 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.538 0.735 . . . . 0.0 111.247 -178.264 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.45 -5.56 56.75 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 -177.523 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -98.11 -30.46 12.65 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.28 0.491 . . . . 0.0 109.922 177.324 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.2 mt -73.33 -38.8 65.65 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 122.556 0.342 . . . . 0.0 110.95 -178.058 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.6 p -77.27 -29.96 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.241 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.6 mm-40 -82.76 -15.14 52.92 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 119.445 -0.312 . . . . 0.0 111.643 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -108.31 -10.61 15.33 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -116.96 -9.61 11.1 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 118.501 0.591 . . . . 0.0 112.396 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -69.83 -7.34 39.13 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.7 0.682 . . . . 0.0 111.633 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -74.12 -18.47 60.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.508 0.323 . . . . 0.0 110.593 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -92.64 -19.07 22.25 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 122.369 0.268 . . . . 0.0 111.535 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.39 176.77 35.71 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 139.64 41.24 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.978 3.118 . . . . 0.0 110.93 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.9 mt -111.59 145.67 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.876 0.471 . . . . 0.0 110.226 -177.781 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.5 t -104.09 -41.28 5.88 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.193 0.597 . . . . 0.0 111.355 -177.526 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -161.42 161.18 30.16 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.563 0.22 . . . . 0.0 111.532 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 69.2 t -143.97 147.16 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 123.903 0.881 . . . . 0.0 109.625 179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -147.29 153.33 12.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 176.207 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 37.7 t -128.46 152.99 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.052 0 C-N-CA 122.42 0.288 . . . . 0.0 111.019 -174.67 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.6 mtm -134.28 79.17 56.1 Favored Pre-proline 0 CA--C 1.532 0.274 0 C-N-CA 124.21 1.004 . . . . 0.0 109.314 178.551 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.85 -21.54 57.81 Favored 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 123.598 2.866 . . . . 0.0 113.134 -177.175 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -83.48 1.89 39.5 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 122.939 0.495 . . . . 0.0 112.015 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -128.79 0.67 5.41 Favored 'General case' 0 C--N 1.338 0.086 0 C-N-CA 123.802 0.841 . . . . 0.0 111.158 176.342 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.5 tpp85 53.35 33.04 14.84 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.014 0.926 . . . . 0.0 111.116 -172.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -136.81 167.86 20.65 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.305 0.642 . . . . 0.0 110.825 -175.846 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.36 173.57 15.45 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.89 0.476 . . . . 0.0 110.175 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 40.4 mt -132.81 145.11 50.7 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 123.187 0.595 . . . . 0.0 109.837 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.2 t -135.44 131.33 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -114.83 117.74 31.58 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 60.8 m-85 -84.16 156.75 21.94 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.303 179.632 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -70.4 -18.41 63.03 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.284 -178.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -154.19 159.21 41.27 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 123.784 0.834 . . . . 0.0 109.579 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 27.2 m -65.42 -15.23 18.16 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.099 0 O-C-N 122.053 -0.405 . . . . 0.0 111.843 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 10.3 tt -67.61 -33.2 74.51 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.327 0.512 . . . . 0.0 110.384 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -76.14 -31.85 54.06 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.48 -32.46 32.49 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.372 0.586 . . . . 0.0 110.535 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.9 t -75.73 -8.08 55.95 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 123.101 0.56 . . . . 0.0 111.302 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -106.74 -16.31 14.52 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 122.409 0.283 . . . . 0.0 111.039 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -86.79 -34.93 19.41 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.063 -0.398 . . . . 0.0 111.33 -178.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.5 t -83.32 -15.78 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -71.37 -5.33 31.75 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 122.797 0.439 . . . . 0.0 111.265 179.419 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -116.52 -37.68 3.67 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 122.899 0.48 . . . . 0.0 110.911 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.68 -5.73 59.01 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -176.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.4 -4.36 58.4 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 122.069 -0.394 . . . . 0.0 111.441 177.039 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -142.07 -6.5 0.96 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 122.773 0.429 . . . . 0.0 111.686 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -144.76 175.13 10.4 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 123.387 0.675 . . . . 0.0 109.5 -179.196 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' GLN . . . . . 0.477 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -95.98 152.43 18.52 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 172.733 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.84 135.32 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.12 149.67 23.07 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 121.954 -0.466 . . . . 0.0 110.758 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 56.4 mt -137.38 -39.67 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.939 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.42 29.48 3.94 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.151 0.58 . . . . 0.0 111.033 -176.476 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.09 4.54 84.15 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -132.09 152.84 80.91 Favored Pre-proline 0 C--O 1.233 0.224 0 C-N-CA 124.102 0.961 . . . . 0.0 109.269 177.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -71.47 144.47 45.3 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 123.583 2.855 . . . . 0.0 111.764 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.74 -175.85 5.19 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.983 1.313 . . . . 0.0 108.765 177.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -138.5 160.26 40.0 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-O 120.927 0.394 . . . . 0.0 111.628 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.1 p -147.84 143.48 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.13 0 C-N-CA 123.785 0.834 . . . . 0.0 109.693 178.454 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 . . . . . 0 N--CA 1.457 -0.119 0 C-N-CA 123.259 0.624 . . . . 0.0 110.066 179.092 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 60.8 p . . . . . 0 CA--C 1.532 0.278 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -72.76 4.25 3.74 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 124.159 3.239 . . . . 0.0 112.358 178.306 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.5 140.43 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 123.279 0.631 . . . . 0.0 109.454 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.0 m -128.16 145.37 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 CA-C-O 121.199 0.523 . . . . 0.0 110.831 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -96.9 134.4 40.28 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.241 1.016 . . . . 0.0 109.932 177.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.415 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.1 mp -107.4 145.78 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.432 0.693 . . . . 0.0 109.408 -178.129 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.0 mtt180 -141.33 160.98 38.99 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.64 0.776 . . . . 0.0 109.892 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.84 28.49 50.54 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-O 119.545 -0.586 . . . . 0.0 113.438 175.122 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.9 mt -57.73 154.88 10.97 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 118.241 1.02 . . . . 0.0 109.877 177.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -68.19 -39.39 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.077 0 O-C-N 122.084 -0.385 . . . . 0.0 111.071 -176.831 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -171.62 -35.92 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.307 1.043 . . . . 0.0 109.742 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.48 55.92 0.04 OUTLIER Glycine 0 C--N 1.339 0.718 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -177.022 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.7 m -52.75 151.17 1.1 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-N 117.076 0.438 . . . . 0.0 110.511 178.265 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.7 m -87.46 166.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.953 0.406 . . . . 0.0 111.262 -177.004 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -61.99 -23.71 66.58 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.163 0.585 . . . . 0.0 111.242 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.31 -6.03 57.28 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -92.9 -35.14 13.5 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.565 0.62 . . . . 0.0 110.213 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 91.4 mt -73.25 -36.28 66.36 Favored 'General case' 0 N--CA 1.454 -0.274 0 O-C-N 122.385 -0.197 . . . . 0.0 111.266 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -76.97 -31.04 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.317 -177.232 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -82.14 -17.68 45.54 Favored 'General case' 0 N--CA 1.455 -0.219 0 O-C-N 122.185 -0.322 . . . . 0.0 111.167 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -9.13 18.31 Favored 'General case' 0 N--CA 1.455 -0.21 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.0 mt -120.82 -8.97 9.37 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -69.3 -7.19 34.79 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.866 0.757 . . . . 0.0 111.687 177.463 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -76.91 -14.99 59.81 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 122.025 -0.422 . . . . 0.0 110.731 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -96.08 -16.82 21.34 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.578 0.351 . . . . 0.0 111.592 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.4 176.55 34.6 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -70.59 140.75 40.24 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 123.889 3.06 . . . . 0.0 110.877 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 78.3 mt -110.81 146.63 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.083 0 C-N-CA 122.816 0.446 . . . . 0.0 110.487 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -106.43 -42.5 5.0 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.009 0.524 . . . . 0.0 111.478 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -159.11 159.28 34.32 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 120.837 0.351 . . . . 0.0 111.231 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.6 t -143.78 146.57 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.086 0 C-N-CA 124.001 0.92 . . . . 0.0 109.841 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.97 153.45 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.402 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 42.8 t -131.69 149.63 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.069 0 CA-C-O 120.717 0.294 . . . . 0.0 110.595 -176.233 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 81.55 67.52 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -60.29 -17.67 48.11 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.811 3.008 . . . . 0.0 112.877 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -82.9 -4.28 57.97 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.802 0.441 . . . . 0.0 111.484 179.03 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -129.23 4.04 5.22 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.861 0.864 . . . . 0.0 111.194 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 3.3 tpt180 54.58 30.44 13.16 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 123.847 0.859 . . . . 0.0 112.058 -177.348 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -138.89 166.59 24.05 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 123.119 0.568 . . . . 0.0 110.813 -174.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.98 172.17 16.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.213 0.605 . . . . 0.0 110.487 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.5 mt -134.14 146.48 50.26 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.443 0.697 . . . . 0.0 109.794 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.91 132.7 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.349 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -115.81 122.29 44.97 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.0 m-85 -87.89 156.03 19.57 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -178.619 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.3 -14.24 60.87 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.563 -178.08 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -149.49 153.47 37.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.68 0.792 . . . . 0.0 108.935 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.4 p -67.64 -20.92 26.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 O-C-N 122.175 -0.328 . . . . 0.0 111.717 -176.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.2 tp -74.52 -27.08 60.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 117.867 0.303 . . . . 0.0 110.997 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.91 -32.47 60.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.29 -29.39 34.31 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 117.018 0.409 . . . . 0.0 110.518 177.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -73.63 -19.28 60.9 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 122.681 0.392 . . . . 0.0 110.92 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -93.63 -17.27 23.46 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 122.191 -0.318 . . . . 0.0 111.03 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.33 -31.98 26.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 O-C-N 121.912 -0.492 . . . . 0.0 111.386 -178.07 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 37.0 t -85.75 -15.29 10.46 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 178.091 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -71.52 -7.67 49.06 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.784 0.434 . . . . 0.0 110.875 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 71.7 t80 -113.73 -36.93 4.71 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.621 0.369 . . . . 0.0 110.982 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.87 -7.17 59.68 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.44 -2.72 56.51 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 122.283 -0.261 . . . . 0.0 111.592 177.055 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -141.19 -7.88 1.02 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 122.73 0.412 . . . . 0.0 112.053 179.335 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -145.41 170.4 16.42 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.332 0.653 . . . . 0.0 109.982 -179.057 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -86.17 155.98 20.52 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -125.53 135.58 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -88.05 156.35 19.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 122.014 -0.429 . . . . 0.0 110.585 -178.094 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 62.9 mt -137.53 -43.79 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.536 -178.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.01 31.47 3.57 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.326 0.651 . . . . 0.0 111.185 -177.518 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.22 6.37 78.54 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.19 151.81 79.52 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.119 0.968 . . . . 0.0 109.142 177.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -71.86 143.61 41.6 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 123.558 2.839 . . . . 0.0 111.764 -176.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.76 -173.87 4.61 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 125.238 1.415 . . . . 0.0 108.395 177.548 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.01 160.12 40.53 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 121.042 0.448 . . . . 0.0 111.666 -178.22 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.6 p -149.74 144.98 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 C-N-CA 123.398 0.679 . . . . 0.0 110.064 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 . . . . . 0 N--CA 1.456 -0.148 0 C-N-CA 123.264 0.626 . . . . 0.0 110.148 179.5 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 65.5 m . . . . . 0 N--CA 1.455 -0.215 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -70.41 0.44 6.14 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 124.158 3.239 . . . . 0.0 111.773 176.404 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.1 t -112.4 139.9 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 123.6 0.76 . . . . 0.0 109.239 177.47 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.6 m -128.91 152.82 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 CA-C-O 121.08 0.467 . . . . 0.0 110.728 178.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -102.45 137.86 40.14 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.709 0.804 . . . . 0.0 110.112 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 18.8 mm -106.49 144.59 15.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 C-N-CA 123.527 0.731 . . . . 0.0 109.799 -178.228 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -143.14 160.95 39.46 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.07 0.548 . . . . 0.0 110.698 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.96 23.87 60.87 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-O 119.77 -0.461 . . . . 0.0 113.151 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 56.1 mt -60.34 157.55 13.48 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 117.952 0.876 . . . . 0.0 109.979 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 16.5 pt -72.34 -37.32 57.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 O-C-N 122.244 -0.285 . . . . 0.0 111.35 -176.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -172.92 -36.93 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 123.887 0.875 . . . . 0.0 109.7 -179.439 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 171.21 61.84 0.04 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -176.677 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.2 m -52.31 154.66 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 122.688 0.395 . . . . 0.0 110.608 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.45 HG12 ' H ' ' A' ' 111' ' ' ALA . 8.7 t -76.99 155.64 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 CA-C-O 120.936 0.398 . . . . 0.0 110.473 -175.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -59.4 -26.88 65.52 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.723 0.409 . . . . 0.0 110.239 174.778 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ALA . . . . . 0.45 ' H ' HG12 ' A' ' 109' ' ' VAL . . . -81.79 -6.83 59.41 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.513 0.725 . . . . 0.0 111.886 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -90.08 -34.11 16.04 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 118.341 0.519 . . . . 0.0 109.999 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.0 mt -73.52 -34.97 65.49 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 122.573 0.349 . . . . 0.0 111.373 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.89 -30.59 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.135 0 CA-C-N 118.041 0.382 . . . . 0.0 110.428 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -82.84 -15.81 50.13 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 119.526 -0.273 . . . . 0.0 111.155 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -11.15 16.96 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -119.26 -9.18 9.99 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 118.6 0.636 . . . . 0.0 112.535 -178.39 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -69.82 -6.9 35.49 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.156 0.889 . . . . 0.0 111.874 177.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -76.5 -12.64 60.07 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 122.117 -0.365 . . . . 0.0 110.695 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -100.1 -19.97 16.23 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 122.678 0.391 . . . . 0.0 111.337 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 166.05 175.97 36.93 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.396 -0.681 . . . . 0.0 111.396 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -71.33 141.42 38.96 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 123.918 3.079 . . . . 0.0 110.505 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 76.2 mt -112.61 146.26 17.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 122.875 0.47 . . . . 0.0 110.226 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.0 t -103.58 -44.81 5.01 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.009 0.523 . . . . 0.0 111.216 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.2 t80 -158.84 162.08 36.95 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-O 120.852 0.358 . . . . 0.0 111.465 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 95.2 t -142.55 144.81 24.15 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 124.167 0.987 . . . . 0.0 109.673 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.42 153.02 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.097 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 175.206 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 41.3 t -130.6 148.21 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.1 0 CA-C-O 120.604 0.24 . . . . 0.0 110.986 -175.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 84.0 60.52 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.808 0.843 . . . . 0.0 109.087 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.22 -12.32 33.64 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 123.489 2.793 . . . . 0.0 111.725 -176.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.9 tptt -76.94 -12.15 59.91 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 122.869 0.468 . . . . 0.0 110.9 177.279 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -129.29 6.92 5.36 Favored 'General case' 0 C--N 1.34 0.163 0 C-N-CA 123.636 0.775 . . . . 0.0 111.904 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 53.9 33.93 18.33 Favored 'General case' 0 N--CA 1.463 0.183 0 C-N-CA 124.449 1.1 . . . . 0.0 112.197 -177.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -136.66 166.26 23.98 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.175 0.59 . . . . 0.0 110.637 -177.078 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.91 172.36 16.34 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.673 0.389 . . . . 0.0 110.49 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 37.2 mt -131.32 149.05 52.71 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 123.406 0.682 . . . . 0.0 110.166 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -140.11 133.32 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.199 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -114.21 120.71 41.39 Favored 'General case' 0 N--CA 1.452 -0.325 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 177.249 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -85.83 152.22 23.18 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.041 0.448 . . . . 0.0 110.018 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -71.34 -15.15 62.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.349 -178.708 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.12 152.45 39.3 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.744 0.818 . . . . 0.0 109.469 177.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.0 p -68.89 -21.45 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 O-C-N 122.18 -0.325 . . . . 0.0 111.751 -175.279 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.6 tp -75.25 -28.89 60.02 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.83 -0.544 . . . . 0.0 110.334 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.68 -29.62 71.17 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.69 -30.28 36.46 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 117.029 0.414 . . . . 0.0 110.5 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.14 -28.17 62.09 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 122.501 0.32 . . . . 0.0 110.67 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -79.21 -19.43 50.79 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 119.541 -0.266 . . . . 0.0 111.532 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -32.67 27.03 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 118.157 0.435 . . . . 0.0 111.467 -177.208 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 30.0 t -85.73 -17.51 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -69.44 -11.63 60.98 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.539 0.336 . . . . 0.0 111.08 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -112.0 -36.85 5.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.635 0.374 . . . . 0.0 111.0 178.572 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.03 -11.67 59.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -176.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.48 -0.26 56.55 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -135.44 -10.85 2.16 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 117.921 0.328 . . . . 0.0 111.503 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.6 t30 -153.97 164.09 39.01 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.601 0.76 . . . . 0.0 109.065 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.6 pm0 -81.32 154.7 26.38 Favored 'General case' 0 CA--C 1.529 0.139 0 O-C-N 121.8 -0.563 . . . . 0.0 109.783 174.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.06 135.57 61.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.521 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -87.75 153.83 21.04 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.077 -0.389 . . . . 0.0 110.708 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.4 mt -136.99 -43.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.662 0.385 . . . . 0.0 110.802 -177.673 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.14 30.64 3.92 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.103 0.561 . . . . 0.0 111.333 -176.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 88.27 4.25 77.75 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.037 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -131.44 152.49 80.59 Favored Pre-proline 0 C--O 1.233 0.219 0 C-N-CA 124.013 0.925 . . . . 0.0 109.318 177.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.72 146.18 48.0 Favored 'Trans proline' 0 N--CA 1.453 -0.884 0 C-N-CA 123.438 2.759 . . . . 0.0 111.573 -176.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.43 -175.75 5.41 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.952 1.301 . . . . 0.0 109.021 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -139.42 160.76 39.08 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 121.174 0.511 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 2.9 p -147.76 141.18 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 123.962 0.905 . . . . 0.0 109.532 177.568 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.4 t30 . . . . . 0 CA--C 1.531 0.217 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.31 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 66.2 m . . . . . 0 CA--C 1.532 0.263 0 N-CA-C 111.509 0.189 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -69.53 1.36 4.35 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 124.138 3.225 . . . . 0.0 112.374 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.8 t -116.53 141.28 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.6 m -129.81 151.85 36.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-O 120.92 0.391 . . . . 0.0 110.958 178.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.4 t-80 -100.93 135.05 42.99 Favored 'General case' 0 N--CA 1.457 -0.086 0 C-N-CA 124.068 0.947 . . . . 0.0 109.974 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -109.93 145.18 16.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 -177.297 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -141.67 163.7 32.21 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 123.602 0.761 . . . . 0.0 110.481 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 25.56 56.15 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-O 119.452 -0.638 . . . . 0.0 113.611 172.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.8 mt -61.68 158.15 16.11 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.185 0.992 . . . . 0.0 110.186 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 12.4 pt -73.1 -39.94 57.74 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -173.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -172.78 -37.44 0.01 OUTLIER 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.243 0.617 . . . . 0.0 110.246 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.22 52.25 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -176.589 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 65.1 t -51.11 146.04 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.158 0.583 . . . . 0.0 110.082 178.381 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.4 m -95.74 163.69 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 CA-C-O 121.18 0.514 . . . . 0.0 111.47 -175.238 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -60.47 -28.02 68.01 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 123.27 0.628 . . . . 0.0 111.215 -178.47 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.79 -6.44 55.96 Favored 'General case' 0 CA--C 1.53 0.187 0 N-CA-C 112.294 0.479 . . . . 0.0 112.294 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -101.47 -31.03 11.09 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 176.026 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 76.5 mt -71.36 -41.21 70.01 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.515 0.326 . . . . 0.0 110.654 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.5 p -77.56 -29.63 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 121.278 -0.169 . . . . 0.0 110.915 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.2 mt-10 -85.87 -13.35 48.2 Favored 'General case' 0 N--CA 1.454 -0.225 0 O-C-N 122.006 -0.434 . . . . 0.0 111.365 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.21 -15.15 16.09 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.94 -7.21 13.17 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.522 0.601 . . . . 0.0 112.457 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -72.46 -5.55 37.51 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.662 0.665 . . . . 0.0 111.537 176.177 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -74.96 -16.13 60.65 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.493 0.317 . . . . 0.0 110.544 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.83 -17.21 21.32 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 122.537 0.335 . . . . 0.0 111.824 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.88 178.0 37.11 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.16 140.31 37.22 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 123.86 3.04 . . . . 0.0 110.821 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.5 mt -112.42 144.4 20.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 C-N-CA 122.993 0.517 . . . . 0.0 110.519 -178.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -102.77 -42.25 5.93 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.362 0.665 . . . . 0.0 111.05 -178.74 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -158.57 160.09 36.22 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.712 0.291 . . . . 0.0 111.275 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 84.9 t -143.97 147.6 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.053 0 C-N-CA 123.761 0.824 . . . . 0.0 109.841 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.3 p -148.0 154.57 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 176.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 9.5 p -136.93 151.45 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.07 0 CA-C-O 120.824 0.345 . . . . 0.0 110.948 -178.229 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -130.26 84.44 59.87 Favored Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.855 0.862 . . . . 0.0 109.004 179.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -59.54 -18.54 47.57 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.897 3.064 . . . . 0.0 112.779 -179.534 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -82.02 -5.8 58.65 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.08 0.552 . . . . 0.0 111.316 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -129.05 2.58 5.26 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.722 0.809 . . . . 0.0 111.461 178.918 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.4 tpp85 53.37 32.5 13.9 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.496 1.118 . . . . 0.0 112.0 -177.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -136.43 166.4 23.58 Favored 'General case' 0 CA--C 1.527 0.094 0 C-N-CA 123.144 0.578 . . . . 0.0 110.941 -176.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 171.4 17.3 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.88 0.472 . . . . 0.0 110.819 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.32 146.71 50.23 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 123.769 0.828 . . . . 0.0 109.797 178.696 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.8 t -136.64 131.96 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.231 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.45 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -112.23 116.11 29.9 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -84.54 152.6 23.8 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.835 0.35 . . . . 0.0 110.481 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -73.08 -14.5 61.41 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.409 -178.303 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -147.2 151.34 36.57 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.696 0.798 . . . . 0.0 109.103 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.2 p -67.39 -19.85 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 O-C-N 122.29 -0.256 . . . . 0.0 111.484 -175.65 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.9 tp -75.08 -27.24 59.85 Favored 'General case' 0 N--CA 1.454 -0.236 0 O-C-N 121.986 -0.446 . . . . 0.0 110.498 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.91 -31.2 69.85 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.36 -29.99 33.89 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 116.956 0.378 . . . . 0.0 110.395 177.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.46 -26.48 63.66 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 122.716 0.406 . . . . 0.0 110.825 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -84.05 -20.3 32.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.192 -0.318 . . . . 0.0 111.646 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.47 -29.1 26.31 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 118.125 0.42 . . . . 0.0 112.075 -175.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -89.63 -15.49 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.444 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -75.0 0.12 16.95 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.768 0.427 . . . . 0.0 111.038 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -120.17 -38.73 2.88 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.842 0.457 . . . . 0.0 110.852 177.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.29 -4.66 58.99 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.68 -4.13 58.34 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 122.103 -0.373 . . . . 0.0 111.506 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -141.66 -4.17 1.11 Allowed 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 122.609 0.364 . . . . 0.0 111.59 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -146.29 170.57 16.49 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.534 0.734 . . . . 0.0 109.972 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -90.84 153.16 20.42 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 172.657 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.48 135.18 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -88.55 150.61 23.0 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 122.01 -0.431 . . . . 0.0 110.749 -178.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.1 mt -136.97 -39.1 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.789 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.18 29.28 3.71 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 123.085 0.554 . . . . 0.0 110.937 -177.051 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.48 5.02 85.29 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -176.434 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -130.41 152.28 80.01 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 124.266 1.026 . . . . 0.0 109.144 177.834 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.52 144.21 44.45 Favored 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.076 2.518 . . . . 0.0 111.825 -176.557 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.96 -176.11 5.31 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 124.826 1.25 . . . . 0.0 109.024 177.679 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -139.46 161.13 38.24 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.949 0.404 . . . . 0.0 111.67 -178.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.6 p -150.04 143.27 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.411 0.684 . . . . 0.0 109.724 178.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 . . . . . 0 N--CA 1.456 -0.161 0 C-N-CA 123.055 0.542 . . . . 0.0 109.989 179.983 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.438 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.4 p . . . . . 0 N--CA 1.456 -0.164 0 N-CA-C 111.729 0.27 . . . . 0.0 111.729 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.438 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 96.4 Cg_endo -71.26 3.05 3.77 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.903 3.069 . . . . 0.0 112.504 177.623 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.7 t -115.02 141.39 31.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.116 0 C-N-CA 122.989 0.515 . . . . 0.0 109.877 178.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 20.9 m -126.69 152.57 34.59 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -107.7 141.01 39.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 124.079 0.952 . . . . 0.0 109.61 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 23.6 mm -111.23 143.82 20.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 122.883 0.473 . . . . 0.0 110.116 -175.796 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 -142.38 159.26 42.59 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 123.092 0.557 . . . . 0.0 110.176 -177.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.03 24.87 58.91 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.358 -0.69 . . . . 0.0 113.198 174.399 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.6 mt -60.52 157.87 13.36 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 118.234 1.017 . . . . 0.0 110.163 177.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.2 pt -70.88 -43.35 76.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -173.248 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -172.4 -34.5 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.375 0.67 . . . . 0.0 110.749 -179.111 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.9 49.07 0.11 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.704 -0.559 . . . . 0.0 111.704 -175.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.1 t -51.09 146.54 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 123.387 0.675 . . . . 0.0 110.026 178.386 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.2 m -101.33 166.41 2.42 Favored 'Isoleucine or valine' 0 C--N 1.337 0.045 0 CA-C-O 121.211 0.529 . . . . 0.0 111.584 -175.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.39 -27.48 67.47 Favored 'General case' 0 N--CA 1.456 -0.131 0 C-N-CA 123.196 0.598 . . . . 0.0 111.152 -177.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.46 -5.03 51.35 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -104.59 -30.86 9.72 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 175.369 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.6 mt -70.12 -38.41 75.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 122.506 0.322 . . . . 0.0 110.595 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -80.13 -29.63 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 CA-C-N 117.537 0.153 . . . . 0.0 110.731 -178.329 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.0 mm-40 -81.4 -13.91 57.75 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.28 -0.263 . . . . 0.0 111.321 -178.571 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -99.89 -25.97 14.16 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.2 mp -100.73 -9.76 21.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.921 0.711 . . . . 0.0 112.921 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -67.15 -8.63 32.55 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 118.604 0.638 . . . . 0.0 111.647 177.16 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.96 -14.62 59.1 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.663 0.385 . . . . 0.0 110.827 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -101.08 -18.31 16.29 Favored 'General case' 0 C--O 1.231 0.117 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -178.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.91 177.51 37.52 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -72.73 140.21 31.98 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 C-N-CA 124.268 3.312 . . . . 0.0 110.717 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 73.6 mt -110.07 146.69 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 C-N-CA 122.778 0.431 . . . . 0.0 110.3 -177.193 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -107.46 -40.16 5.43 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.158 0.583 . . . . 0.0 111.367 -177.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -159.52 158.44 31.83 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-O 120.739 0.304 . . . . 0.0 110.94 179.541 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 93.1 t -144.15 145.42 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.038 0 C-N-CA 123.924 0.89 . . . . 0.0 109.858 -178.741 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.3 p -148.31 152.74 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 12.4 p -130.22 156.58 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 CA-C-O 120.805 0.336 . . . . 0.0 111.156 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 48.6 mtt -130.45 78.14 74.73 Favored Pre-proline 0 C--O 1.232 0.168 0 C-N-CA 124.046 0.938 . . . . 0.0 109.54 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.62 -17.74 43.73 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 123.584 2.856 . . . . 0.0 113.048 -177.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.5 mtpt -89.52 -2.15 58.26 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.926 0.49 . . . . 0.0 111.807 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -130.84 0.39 4.3 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.652 0.781 . . . . 0.0 111.548 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 55.14 33.98 21.63 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.019 0.928 . . . . 0.0 111.861 -176.17 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -134.7 168.21 19.43 Favored 'General case' 0 C--O 1.232 0.14 0 C-N-CA 123.479 0.712 . . . . 0.0 110.602 -177.043 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.74 172.24 18.27 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.39 176.239 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.34 144.31 48.19 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.716 0.806 . . . . 0.0 109.468 177.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 77.9 t -137.0 131.29 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -113.44 120.26 40.44 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 58.7 m-85 -83.93 153.87 23.69 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.872 0.368 . . . . 0.0 110.361 -179.654 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -74.54 -12.58 60.51 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-O 120.907 0.384 . . . . 0.0 110.25 -178.526 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -149.54 152.48 35.62 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.843 0.857 . . . . 0.0 109.022 176.136 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.2 p -68.13 -20.43 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 O-C-N 122.031 -0.418 . . . . 0.0 111.657 -175.475 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.3 tp -71.96 -26.27 62.2 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.924 -0.485 . . . . 0.0 110.561 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.95 -31.47 64.45 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 178.516 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -84.42 -27.95 27.23 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 117.293 0.546 . . . . 0.0 110.555 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.1 t -77.89 -7.17 56.35 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 122.802 0.441 . . . . 0.0 110.602 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -107.14 -21.71 12.88 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.976 0.511 . . . . 0.0 110.754 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.42 -28.01 31.61 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 -178.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -91.01 -18.98 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -71.34 -14.24 62.13 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.36 0.264 . . . . 0.0 110.763 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -99.92 -36.79 9.28 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.568 0.347 . . . . 0.0 111.001 178.518 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -85.44 -6.43 59.21 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.832 0.678 . . . . 0.0 112.832 -176.021 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -78.64 -5.0 51.8 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 122.139 -0.351 . . . . 0.0 111.839 176.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -143.52 -3.59 0.91 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.58 0.352 . . . . 0.0 111.901 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 -145.42 175.09 10.58 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.455 0.702 . . . . 0.0 109.948 -178.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' GLN . . . . . 0.472 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.1 pm0 -96.94 152.68 18.47 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 173.162 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.17 134.44 63.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -89.55 148.91 23.11 Favored 'General case' 0 C--N 1.332 -0.17 0 O-C-N 122.193 -0.317 . . . . 0.0 110.71 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -136.01 -38.75 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.219 -176.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.37 29.45 3.63 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.112 0.565 . . . . 0.0 110.89 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.67 3.36 83.79 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -176.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -130.08 152.84 80.73 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 123.902 0.881 . . . . 0.0 108.968 177.738 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -72.11 145.97 45.45 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.306 2.671 . . . . 0.0 111.681 -176.259 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.48 -176.84 5.64 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.014 1.325 . . . . 0.0 108.475 177.443 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -137.84 160.02 40.43 Favored 'General case' 0 C--O 1.232 0.14 0 CA-C-O 120.885 0.374 . . . . 0.0 111.466 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.66 139.61 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 123.514 0.726 . . . . 0.0 110.174 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 . . . . . 0 CA--C 1.53 0.198 0 C-N-CA 123.445 0.698 . . . . 0.0 109.592 178.45 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.1 m . . . . . 0 CA--C 1.53 0.196 0 N-CA-C 112.368 0.507 . . . . 0.0 112.368 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.05 -0.98 9.84 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 124.024 3.149 . . . . 0.0 111.769 174.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.5 t -112.0 142.49 24.21 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 123.431 0.692 . . . . 0.0 109.461 178.154 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 21.3 m -128.29 152.41 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 C-N-CA 122.835 0.454 . . . . 0.0 110.171 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 -106.15 136.41 45.89 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.971 0.909 . . . . 0.0 109.359 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.7 mm -106.07 142.4 19.14 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 C-N-CA 122.859 0.464 . . . . 0.0 109.859 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -141.67 160.44 40.17 Favored 'General case' 0 C--O 1.231 0.1 0 C-N-CA 123.231 0.612 . . . . 0.0 110.334 -178.506 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.16 23.11 61.82 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.13 174.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 63.8 mt -60.02 158.45 10.97 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 118.151 0.975 . . . . 0.0 109.708 177.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 13.7 pt -73.37 -43.6 56.02 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.035 0 O-C-N 122.275 -0.266 . . . . 0.0 111.686 -174.544 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.72 -34.83 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.14 0.576 . . . . 0.0 110.371 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -173.82 48.46 0.15 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -176.437 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.2 t -49.48 141.34 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 C-N-CA 122.835 0.454 . . . . 0.0 109.809 177.523 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.4 m -92.21 163.44 2.25 Favored 'Isoleucine or valine' 0 C--O 1.23 0.04 0 CA-C-O 121.157 0.504 . . . . 0.0 111.624 -174.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -61.83 -26.31 68.04 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.224 -177.904 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.23 -6.39 57.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.661 0.384 . . . . 0.0 112.0 -178.195 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.8 -29.71 13.59 Favored 'General case' 0 CA--C 1.527 0.063 0 O-C-N 121.743 -0.598 . . . . 0.0 109.822 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.0 mt -74.01 -37.51 64.36 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.284 0.234 . . . . 0.0 110.92 -178.655 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.7 p -77.99 -29.96 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.323 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -85.55 -13.07 50.03 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 122.023 -0.423 . . . . 0.0 111.709 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -109.2 -9.18 15.03 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.8 mt -118.51 -7.4 10.63 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.815 0.734 . . . . 0.0 112.265 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.0 pt20 -74.0 -5.35 40.86 Favored 'General case' 0 C--N 1.34 0.157 0 CA-C-N 118.794 0.725 . . . . 0.0 110.342 175.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -77.6 -4.48 46.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.587 0.755 . . . . 0.0 111.095 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -111.53 -15.91 13.4 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.318 0.647 . . . . 0.0 111.272 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.84 176.73 36.02 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -72.14 140.19 33.83 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.0 3.133 . . . . 0.0 110.571 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.2 mt -109.86 148.92 13.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 122.844 0.457 . . . . 0.0 110.457 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.3 t -111.05 -41.26 4.25 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.251 0.62 . . . . 0.0 111.784 -177.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -158.1 158.09 34.05 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 117.839 0.291 . . . . 0.0 111.462 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 67.1 t -144.05 146.91 20.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.085 0.954 . . . . 0.0 109.699 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -148.95 151.42 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.9 t -128.07 149.5 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.073 0 CA-C-O 120.612 0.244 . . . . 0.0 111.32 -175.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.5 mpp? -130.44 83.07 63.54 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.982 0.913 . . . . 0.0 108.564 177.184 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -69.41 -11.7 31.89 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 123.482 2.788 . . . . 0.0 111.577 -175.063 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -81.58 -10.5 59.43 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 122.95 0.5 . . . . 0.0 110.81 177.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -126.35 6.47 7.01 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.576 0.75 . . . . 0.0 111.646 -178.689 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 55.19 31.0 15.56 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 123.982 0.913 . . . . 0.0 112.432 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -136.79 167.34 21.63 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.149 0.58 . . . . 0.0 111.103 -175.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.05 172.84 16.25 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.978 0.511 . . . . 0.0 110.319 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.0 mt -133.03 146.55 51.83 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 123.308 0.643 . . . . 0.0 110.054 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.82 133.15 41.23 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -117.08 121.88 42.56 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.297 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.7 m-85 -87.08 156.28 19.8 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 121.067 0.461 . . . . 0.0 110.555 -178.729 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -76.3 -13.57 60.15 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.14 -179.26 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -146.74 150.91 36.29 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.575 0.75 . . . . 0.0 109.319 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.7 p -69.33 -21.8 25.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.6 tp -75.91 -29.77 58.53 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.85 -0.531 . . . . 0.0 110.203 -179.475 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.83 -28.22 73.25 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 -25.77 33.48 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 117.05 0.425 . . . . 0.0 110.962 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.55 -34.09 41.31 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -68.69 -21.28 64.43 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 119.712 -0.185 . . . . 0.0 110.87 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.39 -27.62 27.51 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -178.4 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.3 t -92.58 -23.03 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.06 0 O-C-N 122.154 -0.342 . . . . 0.0 110.888 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -71.62 -7.77 49.91 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.105 -0.372 . . . . 0.0 111.472 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -106.29 -34.43 7.47 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.677 0.391 . . . . 0.0 110.477 176.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -10.39 59.07 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.313 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.91 -0.56 56.74 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -136.87 -11.4 1.76 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 122.677 0.391 . . . . 0.0 111.71 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -153.25 170.34 20.83 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -87.6 155.13 20.1 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 175.158 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.3 135.56 60.18 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -177.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -90.36 150.54 21.84 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 121.952 -0.467 . . . . 0.0 110.772 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.2 mt -137.43 -39.02 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.457 -0.076 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.869 -176.539 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.57 28.84 3.61 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 123.139 0.576 . . . . 0.0 110.908 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.9 5.64 83.43 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -176.555 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -131.21 153.14 81.61 Favored Pre-proline 0 N--CA 1.453 -0.275 0 C-N-CA 124.175 0.99 . . . . 0.0 109.152 177.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -72.26 145.9 44.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 123.251 2.634 . . . . 0.0 111.701 -176.63 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.11 -177.25 6.05 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 124.778 1.231 . . . . 0.0 108.839 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -139.64 160.39 39.97 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 120.976 0.417 . . . . 0.0 111.357 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -148.59 139.51 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 C-N-CA 123.339 0.655 . . . . 0.0 110.213 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.455 -0.21 0 C-N-CA 123.227 0.611 . . . . 0.0 109.858 178.836 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.2 m . . . . . 0 CA--C 1.531 0.244 0 N-CA-C 112.577 0.584 . . . . 0.0 112.577 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -65.4 -7.43 15.92 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.983 3.122 . . . . 0.0 113.382 177.869 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -109.85 141.43 25.17 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 123.032 0.533 . . . . 0.0 109.993 -178.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 28.0 m -125.61 156.29 35.12 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.242 0.617 . . . . 0.0 110.091 176.61 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -116.41 131.61 56.9 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.875 0.87 . . . . 0.0 109.421 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.442 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.8 mp -106.17 144.82 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -174.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -141.93 163.08 33.85 Favored 'General case' 0 N--CA 1.46 0.063 0 C-N-CA 123.557 0.743 . . . . 0.0 110.392 -177.634 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.32 23.27 61.19 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.213 -0.771 . . . . 0.0 113.017 174.508 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 70.9 mt -59.86 156.27 14.66 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.436 1.118 . . . . 0.0 110.141 178.599 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.6 pt -70.83 -41.23 77.32 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -172.627 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -173.92 -34.39 0.01 OUTLIER 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.413 0.685 . . . . 0.0 110.648 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.91 48.09 0.12 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.8 t -51.39 143.14 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 177.233 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -97.78 165.51 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.064 0 CA-C-O 121.35 0.595 . . . . 0.0 111.886 -174.378 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.16 -26.24 66.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.537 0.735 . . . . 0.0 111.334 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.88 -6.88 58.25 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.33 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -97.7 -28.98 13.65 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 118.181 0.446 . . . . 0.0 110.16 177.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 89.4 mt -74.35 -36.09 63.61 Favored 'General case' 0 N--CA 1.455 -0.191 0 O-C-N 122.255 -0.278 . . . . 0.0 110.979 -178.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.9 p -79.1 -30.28 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.189 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -82.59 -15.39 52.39 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 119.423 -0.322 . . . . 0.0 111.474 -178.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.87 -12.53 15.17 Favored 'General case' 0 C--N 1.339 0.132 0 N-CA-C 113.11 0.781 . . . . 0.0 113.11 -179.598 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.4 mt -116.46 -9.32 11.47 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -69.19 -6.88 31.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 118.809 0.731 . . . . 0.0 111.424 176.554 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -76.68 -15.13 59.88 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.089 -0.382 . . . . 0.0 110.649 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -97.24 -17.77 19.63 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 122.558 0.343 . . . . 0.0 111.454 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.68 177.05 36.21 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.688 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -70.54 139.91 38.59 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.077 3.185 . . . . 0.0 110.768 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 77.7 mt -110.33 146.31 15.71 Favored 'Isoleucine or valine' 0 C--O 1.232 0.133 0 C-N-CA 122.765 0.426 . . . . 0.0 110.205 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -107.73 -40.2 5.36 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.383 0.673 . . . . 0.0 111.348 -177.392 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -157.73 158.83 36.08 Favored 'General case' 0 C--N 1.338 0.096 0 CA-C-O 120.559 0.219 . . . . 0.0 111.342 -179.472 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 59.0 t -144.05 145.27 22.0 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 C-N-CA 124.175 0.99 . . . . 0.0 109.549 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.8 p -149.34 152.46 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 34.2 t -130.41 150.8 35.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 CA-C-O 120.675 0.274 . . . . 0.0 111.251 -175.655 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.4 81.36 68.3 Favored Pre-proline 0 CA--C 1.531 0.238 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 177.329 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -59.97 -17.88 46.98 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.945 3.097 . . . . 0.0 112.862 -177.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 mtmt -83.48 -5.82 59.27 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.876 0.47 . . . . 0.0 111.326 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -126.55 2.71 6.88 Favored 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.733 0.813 . . . . 0.0 111.112 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.3 tpp85 54.14 32.73 16.41 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 124.035 0.934 . . . . 0.0 111.865 -176.126 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -137.18 165.3 26.43 Favored 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 123.119 0.567 . . . . 0.0 110.956 -176.425 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 169.92 20.55 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 122.953 0.501 . . . . 0.0 110.569 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.8 mt -131.65 145.6 51.75 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.509 0.724 . . . . 0.0 109.824 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.74 134.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -116.16 121.8 43.17 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -86.39 155.85 20.42 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.027 0.442 . . . . 0.0 110.576 -179.049 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -74.86 -13.14 60.52 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.558 -178.263 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -147.73 152.87 38.5 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.883 0.873 . . . . 0.0 109.038 177.075 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.97 -21.61 25.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -175.608 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.8 tp -74.79 -29.85 61.24 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 122.108 -0.37 . . . . 0.0 110.692 -179.251 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.25 -28.58 71.25 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 179.711 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.17 -30.37 27.86 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 117.079 0.439 . . . . 0.0 110.898 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.8 t -75.21 -28.73 60.08 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.1 t30 -78.33 -21.21 49.91 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.321 0.248 . . . . 0.0 110.722 179.382 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.22 -31.25 30.38 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.301 -0.249 . . . . 0.0 111.505 -178.867 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 60.1 t -88.36 -21.97 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 O-C-N 122.252 -0.28 . . . . 0.0 110.556 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -66.9 -17.05 64.71 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 122.194 -0.316 . . . . 0.0 110.96 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -100.05 -36.54 9.32 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.189 0.196 . . . . 0.0 110.645 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.59 -11.04 59.95 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -176.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -89.29 1.42 55.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.578 0.351 . . . . 0.0 111.847 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -134.44 -15.64 2.15 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.76 0.424 . . . . 0.0 111.588 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -153.26 168.2 26.81 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.494 0.718 . . . . 0.0 109.186 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -82.78 155.54 24.17 Favored 'General case' 0 N--CA 1.457 -0.092 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 175.251 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -121.61 135.48 61.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -177.46 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -89.67 151.83 21.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.102 -0.374 . . . . 0.0 110.789 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -138.14 -39.06 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.894 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.69 29.41 3.53 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 122.876 0.47 . . . . 0.0 111.041 -176.817 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.87 4.86 84.42 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -176.254 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -131.59 152.08 79.8 Favored Pre-proline 0 N--CA 1.454 -0.231 0 C-N-CA 124.115 0.966 . . . . 0.0 108.95 177.491 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -71.54 146.55 49.84 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 123.58 2.854 . . . . 0.0 111.88 -176.396 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.8 -175.72 5.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.651 1.18 . . . . 0.0 108.811 178.057 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -138.82 159.44 42.12 Favored 'General case' 0 N--CA 1.457 -0.099 0 CA-C-O 120.644 0.259 . . . . 0.0 111.005 -179.085 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.9 p -149.26 139.11 16.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 C-N-CA 123.341 0.657 . . . . 0.0 110.247 178.736 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.1 t30 . . . . . 0 N--CA 1.456 -0.157 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.7 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.438 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.3 p . . . . . 0 CA--C 1.531 0.249 0 N-CA-C 111.586 0.217 . . . . 0.0 111.586 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.438 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 90.1 Cg_endo -70.49 5.7 1.87 Allowed 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 123.865 3.043 . . . . 0.0 112.119 177.377 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.3 t -117.85 139.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 C-N-CA 123.153 0.581 . . . . 0.0 109.864 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.2 m -131.37 146.83 33.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-O 120.911 0.386 . . . . 0.0 110.807 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.1 t-80 -96.58 137.41 35.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.845 0.858 . . . . 0.0 110.165 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.0 mp -111.77 145.82 17.45 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 123.552 0.741 . . . . 0.0 109.392 -177.716 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -142.56 164.94 28.75 Favored 'General case' 0 C--O 1.228 -0.04 0 C-N-CA 123.655 0.782 . . . . 0.0 110.724 -177.215 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.44 25.26 57.29 Favored Glycine 0 CA--C 1.525 0.711 0 CA-C-O 119.575 -0.569 . . . . 0.0 113.343 173.169 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.7 mt -60.33 156.5 15.61 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.987 0.894 . . . . 0.0 109.983 178.061 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.7 pt -71.84 -39.93 68.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 O-C-N 122.268 -0.27 . . . . 0.0 111.088 -175.277 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -172.92 -36.0 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.08 0 C-N-CA 123.612 0.765 . . . . 0.0 109.985 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 173.92 56.5 0.05 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -177.413 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.4 m -53.21 156.62 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 123.003 0.521 . . . . 0.0 110.782 178.361 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 111' ' ' ALA . 6.5 t -78.03 155.51 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 CA-C-O 121.032 0.444 . . . . 0.0 110.39 -176.341 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -60.76 -25.81 66.77 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.638 0.375 . . . . 0.0 110.265 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ALA . . . . . 0.42 ' H ' HG12 ' A' ' 109' ' ' VAL . . . -81.32 -8.27 59.71 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.079 0.551 . . . . 0.0 111.62 -179.15 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -85.7 -32.79 21.74 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.828 -0.545 . . . . 0.0 110.238 -179.397 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.1 mp -77.49 -30.94 53.28 Favored 'General case' 0 N--CA 1.456 -0.142 0 O-C-N 122.323 -0.236 . . . . 0.0 111.18 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.8 p -78.25 -31.76 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-N 118.18 0.445 . . . . 0.0 110.04 -178.55 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -82.23 -17.57 45.61 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 122.217 -0.302 . . . . 0.0 111.082 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.47 -10.34 18.62 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -117.6 -8.55 10.92 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.606 0.639 . . . . 0.0 112.21 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -67.54 -6.88 21.95 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 118.663 0.665 . . . . 0.0 111.874 175.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -76.59 -13.05 60.1 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.956 -0.465 . . . . 0.0 110.634 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -100.82 -16.9 17.13 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 122.567 0.347 . . . . 0.0 111.606 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.15 177.64 36.27 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -72.25 140.44 33.94 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.81 3.007 . . . . 0.0 110.52 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.2 mt -111.13 147.31 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.085 0 C-N-CA 122.75 0.42 . . . . 0.0 110.246 -177.519 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.8 t -107.63 -41.56 5.0 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.076 0.551 . . . . 0.0 111.656 -177.268 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 46.1 t80 -159.65 160.51 34.33 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 117.623 0.192 . . . . 0.0 111.258 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 88.9 t -143.65 146.51 21.04 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 C-N-CA 124.122 0.969 . . . . 0.0 109.829 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.8 p -144.19 151.4 16.12 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 174.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 60.4 t -133.36 149.73 31.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -176.676 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 72.1 mtm -134.41 86.66 34.69 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 123.612 0.765 . . . . 0.0 109.284 -179.25 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.35 -11.55 30.26 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 123.061 2.507 . . . . 0.0 111.649 -177.557 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -81.11 -10.34 59.67 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.062 0.545 . . . . 0.0 110.7 176.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -128.88 3.18 5.36 Favored 'General case' 0 C--N 1.34 0.155 0 C-N-CA 123.73 0.812 . . . . 0.0 111.353 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.7 tpp85 53.05 34.05 16.29 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.335 1.054 . . . . 0.0 111.964 -176.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -137.84 168.55 19.47 Favored 'General case' 0 C--N 1.334 -0.08 0 C-N-CA 123.402 0.681 . . . . 0.0 110.282 -177.4 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.98 170.86 19.37 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 123.139 0.576 . . . . 0.0 110.262 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 14.1 tp -137.54 142.87 41.38 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.169 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 92.0 t -137.8 141.55 38.56 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -176.875 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -120.79 124.76 45.86 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.43 0.692 . . . . 0.0 109.219 177.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -89.16 153.23 21.12 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 120.919 0.39 . . . . 0.0 110.303 178.886 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -73.32 -14.39 61.29 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.409 -177.768 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -146.75 151.25 36.86 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 176.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -67.49 -20.65 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.302 0.241 . . . . 0.0 111.558 -175.162 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.4 tp -75.92 -25.79 56.32 Favored 'General case' 0 N--CA 1.456 -0.165 0 O-C-N 122.09 -0.381 . . . . 0.0 110.485 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.14 -30.31 65.41 Favored Glycine 0 C--N 1.339 0.722 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.484 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.69 -31.55 28.53 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.025 0.412 . . . . 0.0 110.34 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 47.5 t -73.75 -19.67 60.72 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 122.705 0.402 . . . . 0.0 110.974 179.242 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 122.694 0.398 . . . . 0.0 111.315 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.36 -31.52 22.92 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 122.169 -0.332 . . . . 0.0 111.386 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.4 t -85.06 -13.53 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.128 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -72.52 -1.95 17.87 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.295 0.638 . . . . 0.0 111.212 178.873 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 53.1 t80 -124.02 -36.75 2.66 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.827 0.451 . . . . 0.0 110.914 178.692 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.59 -8.7 59.35 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -176.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.41 -0.89 57.45 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.721 0.408 . . . . 0.0 111.986 178.299 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -138.73 -12.56 1.3 Allowed 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -151.88 163.21 39.71 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 9.3 pm0 -76.59 159.71 30.06 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 122.06 -0.4 . . . . 0.0 110.027 177.028 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -126.74 136.17 61.59 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -89.2 152.73 21.43 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.092 -0.38 . . . . 0.0 110.654 -178.161 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 47.2 mt -137.67 -39.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.177 -177.652 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.22 28.94 3.72 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 122.819 0.448 . . . . 0.0 110.986 -177.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.1 5.61 80.11 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 -176.521 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -131.35 152.98 81.49 Favored Pre-proline 0 N--CA 1.453 -0.319 0 C-N-CA 124.228 1.011 . . . . 0.0 109.01 177.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -71.44 145.34 47.52 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.357 2.705 . . . . 0.0 111.751 -176.53 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.38 -174.93 4.98 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.945 1.298 . . . . 0.0 108.668 177.393 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.35 160.42 39.87 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 120.989 0.423 . . . . 0.0 111.28 -178.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.13 144.66 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 C-N-CA 123.66 0.784 . . . . 0.0 109.415 178.718 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 . . . . . 0 N--CA 1.455 -0.186 0 C-N-CA 123.163 0.585 . . . . 0.0 110.047 -179.342 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.433 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.3 p . . . . . 0 CA--C 1.533 0.292 0 N-CA-C 111.627 0.232 . . . . 0.0 111.627 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 81.8 Cg_endo -70.18 4.53 2.31 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 124.295 3.33 . . . . 0.0 112.373 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.8 t -117.95 142.63 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 178.732 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -131.55 151.59 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 CA-C-O 121.114 0.483 . . . . 0.0 110.635 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.3 t-80 -101.89 136.12 42.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.253 1.021 . . . . 0.0 109.993 178.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.13 145.02 17.17 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 C-N-CA 123.465 0.706 . . . . 0.0 109.116 -176.736 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -142.26 165.14 28.24 Favored 'General case' 0 CA--C 1.526 0.054 0 C-N-CA 123.543 0.737 . . . . 0.0 110.339 -176.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.61 24.08 63.45 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 119.37 -0.683 . . . . 0.0 113.499 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 73.0 mt -61.38 157.96 15.61 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.282 1.041 . . . . 0.0 109.977 177.802 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.21 -40.14 74.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 O-C-N 122.411 -0.181 . . . . 0.0 111.416 -175.458 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -171.52 -42.17 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.479 0.712 . . . . 0.0 109.961 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -172.72 54.33 0.16 Allowed Glycine 0 C--N 1.337 0.625 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -175.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.5 t -50.21 144.59 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.299 0.639 . . . . 0.0 109.567 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -91.94 164.03 2.16 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-O 121.092 0.472 . . . . 0.0 111.613 -175.294 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -61.76 -27.69 68.91 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.885 0.474 . . . . 0.0 110.858 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.1 -4.58 51.0 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -178.203 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -103.83 -30.37 10.41 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-N 118.379 0.536 . . . . 0.0 109.8 175.68 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 75.9 mt -71.48 -41.53 69.23 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.555 0.342 . . . . 0.0 110.368 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.84 -30.04 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 121.154 -0.218 . . . . 0.0 111.041 -177.346 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -84.67 -14.88 47.22 Favored 'General case' 0 N--CA 1.456 -0.16 0 O-C-N 122.116 -0.365 . . . . 0.0 111.777 -177.531 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.16 -15.66 16.61 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 178.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -110.92 -8.26 14.51 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -71.77 -6.17 39.45 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.736 0.698 . . . . 0.0 111.401 175.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -77.04 -13.82 59.91 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 122.591 0.356 . . . . 0.0 110.323 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -99.05 -17.57 18.18 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.518 0.327 . . . . 0.0 111.742 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.21 176.69 36.28 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.79 139.48 33.64 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 124.106 3.204 . . . . 0.0 110.464 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 75.1 mt -110.87 145.95 16.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 C-N-CA 122.735 0.414 . . . . 0.0 110.352 -177.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -105.62 -40.44 5.76 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.226 0.61 . . . . 0.0 111.287 -178.169 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -159.07 159.2 34.34 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-O 120.788 0.328 . . . . 0.0 110.895 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -144.05 145.71 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.755 0.822 . . . . 0.0 109.619 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.23 152.14 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.11 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.061 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 10.3 p -134.5 153.69 35.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 122.815 0.446 . . . . 0.0 111.105 -176.457 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 18.8 ptp -136.03 82.83 35.54 Favored Pre-proline 0 CA--C 1.532 0.267 0 C-N-CA 124.001 0.92 . . . . 0.0 109.606 179.283 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -58.45 -21.2 52.67 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 124.255 3.304 . . . . 0.0 113.131 -178.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.3 mtpt -78.78 -1.15 33.35 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.718 0.407 . . . . 0.0 111.293 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 22.6 tptm -131.66 -0.75 3.88 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.359 1.064 . . . . 0.0 110.481 179.508 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 57.75 28.95 16.64 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.947 0.899 . . . . 0.0 112.51 -177.004 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -134.32 169.98 16.4 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.808 0.443 . . . . 0.0 111.226 -175.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.63 171.25 18.46 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.211 0.604 . . . . 0.0 110.758 178.224 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.4 mt -132.96 146.04 51.43 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.917 0.887 . . . . 0.0 109.673 178.201 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.8 t -138.85 133.42 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -114.64 120.75 41.19 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 177.627 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -86.7 153.58 21.63 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 120.958 0.409 . . . . 0.0 110.598 -179.683 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -74.7 -13.34 60.6 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.517 -177.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -147.08 152.41 38.47 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 123.82 0.848 . . . . 0.0 108.995 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -67.71 -21.85 27.74 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -175.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.3 tp -72.75 -27.1 61.82 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.137 -0.352 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.59 -30.35 66.6 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.18 -34.36 25.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 117.105 0.452 . . . . 0.0 110.292 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -72.41 -20.94 61.34 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 122.487 0.315 . . . . 0.0 110.876 178.441 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -94.29 4.59 53.67 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 122.939 0.496 . . . . 0.0 111.475 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -108.46 -26.57 10.39 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 117.967 0.349 . . . . 0.0 111.87 179.698 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 45.3 t -89.43 -18.89 7.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 CA-C-N 117.8 0.273 . . . . 0.0 110.506 178.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -73.32 1.44 9.53 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.979 -0.451 . . . . 0.0 111.787 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 55.3 t80 -119.08 -34.67 3.82 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 123.045 0.538 . . . . 0.0 110.825 178.522 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.84 -3.18 58.96 Favored 'General case' 0 CA--C 1.533 0.314 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.265 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.94 -2.16 57.75 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.597 0.359 . . . . 0.0 111.417 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.14 -5.52 1.65 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.045 0.538 . . . . 0.0 111.528 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.56 173.93 15.64 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.841 0.856 . . . . 0.0 108.864 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.5 pt20 -93.07 155.58 17.41 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.53 135.18 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -178.399 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.48 151.7 21.85 Favored 'General case' 0 N--CA 1.455 -0.183 0 O-C-N 122.195 -0.316 . . . . 0.0 110.552 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.0 mt -137.71 -39.01 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.144 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.13 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.17 30.59 2.99 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.042 0.537 . . . . 0.0 110.823 -176.469 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.66 4.86 84.95 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -176.691 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -131.17 151.98 79.82 Favored Pre-proline 0 N--CA 1.455 -0.211 0 C-N-CA 123.994 0.918 . . . . 0.0 109.106 177.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -71.29 145.57 48.8 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 C-N-CA 123.694 2.929 . . . . 0.0 111.749 -177.169 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.67 -176.38 5.59 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.565 1.146 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -139.05 159.38 42.28 Favored 'General case' 0 CA--C 1.527 0.082 0 CA-C-O 120.969 0.414 . . . . 0.0 111.271 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.7 p -148.45 142.34 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.481 0.713 . . . . 0.0 109.483 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 . . . . . 0 N--CA 1.455 -0.178 0 C-N-CA 123.2 0.6 . . . . 0.0 110.186 -179.352 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.428 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 57.8 p . . . . . 0 CA--C 1.533 0.327 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 91.2 Cg_endo -72.7 2.46 5.25 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 124.306 3.337 . . . . 0.0 112.649 179.28 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.2 t -121.88 140.92 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.137 0 CA-C-N 118.42 0.555 . . . . 0.0 109.655 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.21 154.37 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 CA-C-O 121.385 0.612 . . . . 0.0 110.728 178.581 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -105.73 141.81 36.53 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.208 1.003 . . . . 0.0 109.514 -179.405 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 20.7 mm -110.26 144.05 19.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 C-N-CA 123.04 0.536 . . . . 0.0 110.142 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 42.4 mtm105 -141.24 159.4 42.29 Favored 'General case' 0 CA--C 1.527 0.063 0 C-N-CA 123.492 0.717 . . . . 0.0 110.315 -178.41 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.41 25.03 59.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-O 119.552 -0.582 . . . . 0.0 113.366 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 53.9 mt -59.55 156.24 13.77 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 118.098 0.949 . . . . 0.0 109.482 176.725 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.8 pt -70.31 -37.96 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.135 0 N-CA-C 111.383 0.142 . . . . 0.0 111.383 -174.241 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.74 -35.53 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 123.954 0.901 . . . . 0.0 109.648 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 170.48 55.97 0.04 OUTLIER Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -176.716 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.8 m -53.21 151.72 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 117.236 0.518 . . . . 0.0 110.501 178.425 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -87.18 166.45 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.082 0 CA-C-O 121.314 0.578 . . . . 0.0 110.809 -177.232 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -60.3 -25.21 65.59 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.002 0.521 . . . . 0.0 110.698 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.89 -6.35 53.99 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 122.811 0.444 . . . . 0.0 112.038 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 79.4 m-20 -97.34 -33.11 11.55 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 118.371 0.532 . . . . 0.0 109.733 176.201 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.47 -40.76 66.71 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.308 0.243 . . . . 0.0 110.83 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.08 -30.06 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 O-C-N 122.158 -0.339 . . . . 0.0 110.855 -176.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.7 mm-40 -81.67 -18.22 45.28 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 117.822 0.283 . . . . 0.0 111.616 -178.357 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.35 -14.37 16.95 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.507 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -113.9 -7.43 13.17 Favored 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -178.395 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.0 pt20 -71.49 -5.84 36.01 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.666 0.666 . . . . 0.0 111.735 175.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -76.58 -14.3 60.01 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 122.962 0.505 . . . . 0.0 110.677 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -98.71 -17.01 18.77 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.56 0.344 . . . . 0.0 111.562 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.91 176.67 35.2 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -71.12 140.31 37.36 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 123.935 3.09 . . . . 0.0 110.631 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 72.4 mt -110.16 146.4 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.103 0 C-N-CA 122.863 0.465 . . . . 0.0 110.4 -178.006 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.8 t -108.26 -39.93 5.32 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 123.279 0.631 . . . . 0.0 111.62 -177.128 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -157.78 158.13 34.66 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 120.57 0.224 . . . . 0.0 111.04 178.728 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.5 t -145.01 146.36 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.079 0 C-N-CA 123.642 0.777 . . . . 0.0 109.507 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.28 153.24 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 175.352 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 11.1 p -133.7 151.74 33.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.118 0 CA-C-O 120.806 0.336 . . . . 0.0 111.191 -176.737 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 19.3 ptp -136.24 84.89 28.54 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.739 0.816 . . . . 0.0 109.159 179.691 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.5 -12.31 33.1 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.386 2.724 . . . . 0.0 111.666 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -77.93 -5.04 49.82 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 122.683 0.393 . . . . 0.0 111.018 176.445 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -132.79 5.17 3.92 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 123.645 0.778 . . . . 0.0 111.213 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 54.27 35.72 23.44 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.292 1.037 . . . . 0.0 112.343 -177.193 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -137.54 169.83 17.12 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.132 0.573 . . . . 0.0 111.039 -176.487 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.44 172.82 17.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.112 0.565 . . . . 0.0 110.494 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.4 mt -132.92 146.22 51.6 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.9 0.88 . . . . 0.0 109.374 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 89.8 t -138.36 133.03 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -116.26 121.68 42.74 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.578 0.751 . . . . 0.0 109.192 178.462 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 44.3 m-85 -88.5 155.52 19.61 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.052 0.453 . . . . 0.0 110.547 -178.283 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -75.77 -13.49 60.3 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.475 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -145.76 152.82 40.17 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.691 0.796 . . . . 0.0 109.097 177.622 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.8 p -69.55 -21.84 24.9 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.45 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 58.7 tp -77.44 -29.51 52.89 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.003 -0.436 . . . . 0.0 110.418 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.27 -31.09 73.94 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.15 -32.03 33.86 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 116.984 0.392 . . . . 0.0 110.534 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.6 t -70.6 -29.72 66.2 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 122.076 0.15 . . . . 0.0 110.628 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -75.84 -21.0 57.7 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.194 -0.316 . . . . 0.0 111.247 179.18 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -81.31 -28.19 34.7 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.971 0.35 . . . . 0.0 111.617 -177.32 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 33.3 t -92.16 -19.66 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 O-C-N 122.382 -0.199 . . . . 0.0 110.688 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -71.34 -11.69 61.04 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 122.117 -0.364 . . . . 0.0 110.888 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -104.88 -34.05 8.18 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 122.942 0.497 . . . . 0.0 110.764 178.132 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.71 -7.24 59.52 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -177.601 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -84.84 -2.51 57.84 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -141.47 -3.87 1.15 Allowed 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 122.829 0.452 . . . . 0.0 111.946 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 54.1 t30 -154.68 165.23 37.21 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 123.303 0.641 . . . . 0.0 109.456 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -85.14 158.3 20.43 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.04 135.72 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.058 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.2 m-85 -89.78 152.97 21.03 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.04 -0.413 . . . . 0.0 110.862 -178.547 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.2 mt -137.29 -41.0 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.227 -0.101 0 C-N-CA 122.669 0.388 . . . . 0.0 110.755 -177.137 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.92 29.91 3.73 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.817 0.447 . . . . 0.0 110.944 -177.548 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.05 4.24 81.96 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -176.719 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -130.31 151.81 79.14 Favored Pre-proline 0 N--CA 1.455 -0.223 0 C-N-CA 124.14 0.976 . . . . 0.0 109.053 177.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.69 146.04 53.4 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 123.526 2.817 . . . . 0.0 112.038 -176.333 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.35 -176.21 5.49 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.267 1.427 . . . . 0.0 108.902 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -138.99 161.51 37.17 Favored 'General case' 0 N--CA 1.457 -0.086 0 CA-C-O 120.943 0.402 . . . . 0.0 111.521 -179.196 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.0 p -150.09 141.55 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.842 0.857 . . . . 0.0 109.751 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 . . . . . 0 N--CA 1.458 -0.074 0 C-N-CA 123.333 0.653 . . . . 0.0 109.747 178.373 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.1 m . . . . . 0 CA--C 1.529 0.16 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -72.35 -1.52 10.3 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 123.92 3.08 . . . . 0.0 112.073 175.606 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.4 t -113.42 139.38 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 123.215 0.606 . . . . 0.0 109.707 178.569 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.2 m -125.17 159.49 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 C-N-CA 122.928 0.491 . . . . 0.0 110.316 178.417 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -114.55 135.65 53.89 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 123.834 0.854 . . . . 0.0 109.687 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.8 mm -106.74 143.88 16.76 Favored 'Isoleucine or valine' 0 C--O 1.23 0.068 0 C-N-CA 122.888 0.475 . . . . 0.0 110.365 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 72.1 mtm-85 -143.64 163.5 33.05 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 123.368 0.667 . . . . 0.0 110.523 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.84 22.27 66.69 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 119.572 -0.571 . . . . 0.0 113.148 174.046 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.48 156.08 16.95 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 118.173 0.986 . . . . 0.0 110.041 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.1 pt -70.97 -41.46 76.99 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.112 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -173.276 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.2 -35.9 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.228 0.611 . . . . 0.0 110.437 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.86 50.5 0.12 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.648 -0.581 . . . . 0.0 111.648 -177.329 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 88.1 t -50.16 143.09 2.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.419 0.688 . . . . 0.0 109.8 177.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 33.8 m -94.48 164.7 2.05 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 121.229 0.538 . . . . 0.0 111.73 -174.739 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -61.22 -25.87 67.35 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.431 0.692 . . . . 0.0 111.224 -178.245 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.42 -6.3 57.85 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -177.795 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -97.75 -29.06 13.59 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 118.222 0.465 . . . . 0.0 110.282 177.136 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 98.0 mt -74.02 -35.9 64.41 Favored 'General case' 0 N--CA 1.452 -0.325 0 O-C-N 122.401 -0.187 . . . . 0.0 110.93 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.05 -31.47 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.363 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -81.55 -16.56 51.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 119.565 -0.255 . . . . 0.0 111.596 -178.423 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.95 -13.36 15.51 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.4 mt -116.1 -6.13 11.92 Favored 'General case' 0 N--CA 1.461 0.094 0 CA-C-N 118.483 0.583 . . . . 0.0 112.479 -178.189 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -72.44 -6.41 43.4 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.678 0.672 . . . . 0.0 110.26 175.004 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -77.33 -3.89 42.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 123.923 0.889 . . . . 0.0 111.059 179.433 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -112.85 -16.49 12.71 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.006 0.522 . . . . 0.0 111.282 179.618 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.48 175.78 35.62 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -71.35 140.77 37.54 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 123.812 3.008 . . . . 0.0 110.564 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 72.3 mt -110.13 147.05 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.822 0.449 . . . . 0.0 110.572 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -109.53 -41.15 4.66 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 123.206 0.603 . . . . 0.0 111.564 -176.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -158.06 158.03 34.0 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 117.666 0.212 . . . . 0.0 111.261 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.7 t -143.89 147.42 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 C-N-CA 123.932 0.893 . . . . 0.0 109.591 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -149.53 151.52 12.8 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.032 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 175.407 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.95 152.59 36.24 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 C-N-CA 122.437 0.295 . . . . 0.0 110.899 -175.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 21.2 ptp -138.58 78.76 31.07 Favored Pre-proline 0 CA--C 1.534 0.33 0 C-N-CA 123.675 0.79 . . . . 0.0 109.741 177.328 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.57 -18.43 47.15 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.89 3.06 . . . . 0.0 113.306 -177.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -71.66 -12.28 61.26 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 122.8 0.44 . . . . 0.0 110.873 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.69 4.55 6.73 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.703 0.801 . . . . 0.0 111.286 179.273 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 55.31 34.98 23.97 Favored 'General case' 0 CA--C 1.533 0.288 0 C-N-CA 124.095 0.958 . . . . 0.0 112.191 -176.357 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -134.03 169.02 17.75 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 123.054 0.541 . . . . 0.0 110.843 -177.001 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.81 171.8 19.01 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.167 176.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 43.2 mt -131.86 146.44 52.12 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.522 0.729 . . . . 0.0 109.825 178.861 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.6 t -138.28 131.75 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -114.92 122.84 47.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 177.619 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 47.1 m-85 -87.26 155.35 20.11 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.41 -179.26 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -76.37 -11.65 59.93 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.246 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.73 152.92 38.58 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.928 0.891 . . . . 0.0 109.282 177.024 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -69.9 -21.33 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 O-C-N 122.224 -0.298 . . . . 0.0 111.702 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.2 tp -75.85 -28.97 58.42 Favored 'General case' 0 N--CA 1.454 -0.231 0 O-C-N 121.865 -0.522 . . . . 0.0 110.626 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.03 -29.51 73.52 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.12 -28.12 29.66 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.99 0.395 . . . . 0.0 110.74 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.6 t -74.06 -30.89 62.61 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.244 -0.285 . . . . 0.0 110.467 179.397 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -76.24 -21.67 56.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.268 -0.27 . . . . 0.0 111.249 179.329 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -33.31 26.79 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 117.778 0.263 . . . . 0.0 111.396 -177.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.15 -22.67 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 O-C-N 122.308 -0.245 . . . . 0.0 110.535 179.736 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -68.79 -16.56 63.83 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.943 -0.473 . . . . 0.0 111.01 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -99.03 -34.79 10.27 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 122.695 0.398 . . . . 0.0 110.691 178.277 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.21 -10.76 59.02 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -177.638 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.54 -1.01 52.78 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 178.019 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -139.61 -7.48 1.29 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -155.02 165.39 36.88 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.257 0.623 . . . . 0.0 109.363 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.68 157.57 23.29 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 173.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.43 135.99 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.85 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 64.1 m-85 -90.29 151.11 21.64 Favored 'General case' 0 N--CA 1.457 -0.082 0 O-C-N 122.109 -0.369 . . . . 0.0 110.92 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.5 mt -137.14 -38.89 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.12 -176.388 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.65 29.07 3.25 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.149 0.58 . . . . 0.0 111.012 -176.197 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.82 4.66 82.18 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.53 151.98 79.64 Favored Pre-proline 0 C--O 1.234 0.253 0 C-N-CA 124.322 1.049 . . . . 0.0 109.322 177.649 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_endo -70.9 146.57 53.46 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 123.522 2.814 . . . . 0.0 111.702 -177.179 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.71 -177.72 6.28 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 125.205 1.402 . . . . 0.0 109.104 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -137.54 159.7 41.23 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.061 0.458 . . . . 0.0 111.792 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.5 p -151.23 139.98 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 123.347 0.659 . . . . 0.0 110.149 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.0 t30 . . . . . 0 CA--C 1.528 0.132 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.743 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.448 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.7 p . . . . . 0 CA--C 1.532 0.288 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 98.9 Cg_endo -71.17 1.22 5.59 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 124.008 3.139 . . . . 0.0 112.758 178.229 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.57 139.05 37.62 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.094 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 178.277 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.3 154.22 37.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 122.928 0.491 . . . . 0.0 110.339 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 31.5 t-80 -110.65 138.18 47.37 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.993 0.917 . . . . 0.0 109.507 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.1 mm -107.49 144.77 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 C-N-CA 122.893 0.477 . . . . 0.0 110.33 -176.228 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -143.01 161.48 38.0 Favored 'General case' 0 C--N 1.338 0.088 0 C-N-CA 123.195 0.598 . . . . 0.0 110.553 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.36 23.51 62.85 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 119.498 -0.612 . . . . 0.0 113.488 173.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 76.4 mt -60.87 158.01 13.98 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 118.332 1.066 . . . . 0.0 110.523 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -72.31 -40.93 65.65 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -173.76 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -172.12 -38.22 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 C-N-CA 123.107 0.563 . . . . 0.0 110.079 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.33 51.91 0.11 Allowed Glycine 0 C--N 1.338 0.646 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -176.916 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 57.9 t -49.65 144.03 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 123.546 0.738 . . . . 0.0 110.153 178.132 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -90.0 161.95 2.57 Favored 'Isoleucine or valine' 0 C--N 1.338 0.072 0 CA-C-O 121.292 0.567 . . . . 0.0 111.655 -174.694 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -62.0 -24.05 66.8 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.259 0.624 . . . . 0.0 111.766 -176.777 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.48 -5.5 58.74 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -95.63 -31.55 13.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.312 0.505 . . . . 0.0 110.498 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.56 -34.07 60.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 O-C-N 121.921 -0.487 . . . . 0.0 110.752 -177.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.3 p -78.06 -30.64 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 120.709 -0.396 . . . . 0.0 109.979 -178.68 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -85.72 -12.03 52.17 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.274 -0.266 . . . . 0.0 111.558 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.84 -11.79 15.31 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 178.44 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -114.8 -9.37 12.52 Favored 'General case' 0 C--N 1.34 0.19 0 CA-C-N 118.457 0.571 . . . . 0.0 112.255 -179.561 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.64 -3.87 16.92 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 118.615 0.643 . . . . 0.0 111.71 176.696 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -78.49 -16.1 57.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.865 0.466 . . . . 0.0 110.511 178.653 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -96.67 -18.94 19.35 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.343 -0.223 . . . . 0.0 111.397 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.34 178.14 38.25 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.75 140.78 36.22 Favored 'Trans proline' 0 N--CA 1.451 -0.985 0 C-N-CA 124.061 3.174 . . . . 0.0 110.46 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.5 mt -110.05 148.44 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 C-N-CA 122.604 0.362 . . . . 0.0 110.449 -177.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -110.63 -39.78 4.78 Favored 'General case' 0 N--CA 1.457 -0.101 0 C-N-CA 123.247 0.619 . . . . 0.0 111.851 -177.541 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -158.68 158.06 33.02 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 117.76 0.255 . . . . 0.0 111.601 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 79.3 t -143.72 146.29 21.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 124.036 0.934 . . . . 0.0 109.586 179.434 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.9 p -147.53 153.49 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 174.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.8 t -128.75 150.8 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 CA-C-O 120.833 0.349 . . . . 0.0 110.659 -176.299 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -134.54 79.77 52.93 Favored Pre-proline 0 CA--C 1.531 0.237 0 C-N-CA 124.492 1.117 . . . . 0.0 109.195 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -68.96 -14.06 37.86 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.389 2.726 . . . . 0.0 111.778 -175.407 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -81.71 -1.88 48.56 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 122.824 0.45 . . . . 0.0 111.585 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -133.39 4.46 3.69 Favored 'General case' 0 C--N 1.339 0.14 0 C-N-CA 123.797 0.839 . . . . 0.0 111.113 175.657 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.4 tpp85 55.59 35.76 25.84 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.069 0.948 . . . . 0.0 111.667 -175.193 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -134.11 170.49 15.58 Favored 'General case' 0 N--CA 1.457 -0.076 0 C-N-CA 123.415 0.686 . . . . 0.0 110.929 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.88 170.94 20.5 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 176.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.7 tp -135.17 142.54 46.12 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.5 t -138.21 141.54 37.78 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.1 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.222 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -123.9 125.03 43.91 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.086 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -87.75 154.9 20.2 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.875 0.369 . . . . 0.0 110.341 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -74.97 -12.36 60.32 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.246 -178.541 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -147.8 152.49 37.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.988 0.915 . . . . 0.0 109.265 176.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.8 p -68.63 -21.85 26.37 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.544 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.0 tp -73.95 -26.08 60.3 Favored 'General case' 0 N--CA 1.453 -0.303 0 O-C-N 121.999 -0.438 . . . . 0.0 110.544 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.24 -29.13 68.92 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.042 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.66 -30.23 23.38 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 117.237 0.519 . . . . 0.0 110.513 178.685 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 36.8 t -75.55 -17.77 59.97 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 122.49 0.316 . . . . 0.0 110.484 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -93.35 -20.84 19.97 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.705 0.402 . . . . 0.0 110.723 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.35 -31.01 25.02 Favored 'General case' 0 N--CA 1.455 -0.177 0 O-C-N 122.112 -0.367 . . . . 0.0 111.501 -178.081 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.62 -19.4 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 O-C-N 122.04 -0.413 . . . . 0.0 110.698 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -70.5 -17.54 62.96 Favored 'General case' 0 CA--C 1.529 0.142 0 O-C-N 122.221 -0.3 . . . . 0.0 111.195 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.9 t80 -97.42 -36.79 10.24 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 122.686 0.394 . . . . 0.0 111.172 178.664 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.25 -6.61 59.42 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.22 -4.81 56.67 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.078 -0.389 . . . . 0.0 111.543 176.238 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -141.64 -4.99 1.07 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 23.9 m-80 -145.01 175.26 10.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.358 0.663 . . . . 0.0 109.615 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.1 pt20 -99.35 150.52 22.05 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 172.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -118.91 134.51 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -88.04 151.46 22.74 Favored 'General case' 0 N--CA 1.453 -0.278 0 O-C-N 122.183 -0.323 . . . . 0.0 110.853 -179.051 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 41.2 mt -138.22 -37.3 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.19 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.91 29.54 3.14 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.24 0.616 . . . . 0.0 111.087 -176.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.73 4.69 84.93 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -176.683 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.36 152.78 81.13 Favored Pre-proline 0 N--CA 1.454 -0.234 0 C-N-CA 124.24 1.016 . . . . 0.0 108.982 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -71.53 146.83 50.52 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 123.377 2.718 . . . . 0.0 111.792 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.67 -176.54 5.77 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 124.784 1.234 . . . . 0.0 109.011 178.056 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -137.83 159.79 41.05 Favored 'General case' 0 CA--C 1.527 0.081 0 CA-C-O 120.776 0.322 . . . . 0.0 111.428 -178.768 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.84 138.14 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.324 0.649 . . . . 0.0 110.23 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.456 -0.126 0 C-N-CA 123.502 0.721 . . . . 0.0 109.303 179.594 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.481 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 77.8 p . . . . . 0 CA--C 1.529 0.147 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.481 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 84.6 Cg_endo -70.5 2.15 4.23 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 123.89 3.06 . . . . 0.0 112.854 177.046 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.7 t -112.92 139.15 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 CA-C-N 118.327 0.512 . . . . 0.0 109.926 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.0 m -125.51 157.74 34.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 C-N-CA 122.908 0.483 . . . . 0.0 110.359 178.421 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.6 t-80 -115.39 137.63 51.84 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.179 0.991 . . . . 0.0 109.392 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.6 mm -107.67 145.69 14.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 C-N-CA 122.616 0.366 . . . . 0.0 110.044 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -142.64 157.74 44.38 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.418 0.687 . . . . 0.0 109.947 -178.723 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 24.98 57.51 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.314 174.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.3 mt -59.08 156.72 11.43 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 118.026 0.913 . . . . 0.0 109.812 177.562 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.1 pt -72.45 -39.07 61.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 O-C-N 122.181 -0.324 . . . . 0.0 111.773 -174.616 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -173.41 -36.2 0.01 OUTLIER 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 123.653 0.781 . . . . 0.0 110.033 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.31 54.75 0.05 OUTLIER Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -177.185 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.3 m -52.9 151.57 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 117.156 0.478 . . . . 0.0 110.271 177.853 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.1 m -88.34 165.74 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.039 0 CA-C-O 121.161 0.505 . . . . 0.0 111.36 -175.853 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.61 -23.92 66.35 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.132 0.573 . . . . 0.0 111.21 -178.173 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.2 -6.85 57.53 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 122.743 0.417 . . . . 0.0 111.867 -179.124 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -91.49 -34.96 14.59 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.236 0.471 . . . . 0.0 110.617 179.124 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.6 mp -75.87 -33.81 59.98 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 122.214 -0.304 . . . . 0.0 110.948 -176.793 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -76.57 -29.49 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.068 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 37.7 mm-40 -84.36 -14.26 50.02 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 122.206 0.202 . . . . 0.0 110.982 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.69 -21.79 16.24 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.8 mp -109.83 -10.68 14.75 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -177.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.36 -4.43 14.54 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.978 0.808 . . . . 0.0 111.956 177.724 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -83.6 -12.27 56.28 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.881 0.473 . . . . 0.0 110.413 178.74 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -103.97 -16.41 15.33 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 122.753 0.421 . . . . 0.0 111.425 -179.236 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.42 178.54 37.2 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -72.37 140.33 33.34 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 124.085 3.19 . . . . 0.0 110.671 179.268 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 79.4 mt -109.72 148.62 13.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.889 0.476 . . . . 0.0 110.684 -178.368 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 12.9 t -114.32 -36.39 4.67 Favored 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.384 0.673 . . . . 0.0 112.09 -177.198 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -155.96 156.06 33.86 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.626 0.25 . . . . 0.0 111.589 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.0 t -146.49 144.37 20.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.038 0.935 . . . . 0.0 109.183 179.529 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.7 p -151.33 152.82 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 175.387 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.8 150.59 34.07 Favored 'Isoleucine or valine' 0 C--N 1.335 -0.055 0 C-N-CA 122.587 0.355 . . . . 0.0 110.393 -175.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 70.0 mtm -132.74 84.74 49.18 Favored Pre-proline 0 N--CA 1.454 -0.237 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.57 -12.5 33.4 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.325 2.683 . . . . 0.0 111.964 -176.17 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -84.78 -1.75 56.77 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 122.842 0.457 . . . . 0.0 111.107 176.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -132.45 1.24 3.74 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 123.871 0.868 . . . . 0.0 111.157 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.2 tpp85 52.38 34.61 15.39 Favored 'General case' 0 C--N 1.341 0.197 0 C-N-CA 124.257 1.023 . . . . 0.0 111.846 -175.343 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.26 167.86 20.95 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.554 0.741 . . . . 0.0 110.354 -177.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.62 173.58 16.5 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.508 0.323 . . . . 0.0 110.792 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 45.0 mt -134.16 147.09 50.73 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.623 0.769 . . . . 0.0 110.14 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.6 t -140.06 135.28 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -116.75 122.63 45.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -84.77 156.02 21.58 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 120.974 0.416 . . . . 0.0 110.193 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -75.94 -12.29 60.12 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.325 -179.387 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -148.21 153.13 38.34 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 124.099 0.96 . . . . 0.0 109.362 177.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -70.5 -21.8 23.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.478 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.7 tp -74.34 -27.43 60.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 O-C-N 121.939 -0.476 . . . . 0.0 110.742 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.88 -30.63 67.86 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.88 -29.36 29.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 117.11 0.455 . . . . 0.0 111.028 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -77.58 -25.97 50.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.537 -0.171 . . . . 0.0 110.537 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -85.21 -17.22 37.75 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.135 0.174 . . . . 0.0 111.084 178.214 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.01 -28.56 25.66 Favored 'General case' 0 N--CA 1.456 -0.148 0 O-C-N 122.246 -0.284 . . . . 0.0 111.48 179.65 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.9 t -88.23 -21.91 6.88 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 O-C-N 122.196 -0.315 . . . . 0.0 110.618 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.16 -15.9 62.51 Favored 'General case' 0 CA--C 1.534 0.331 0 O-C-N 122.365 -0.209 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 58.0 t80 -93.76 -33.09 13.74 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.422 0.289 . . . . 0.0 110.927 178.853 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.99 -3.1 57.55 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 112.697 0.628 . . . . 0.0 112.697 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.81 -5.08 59.12 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 122.001 -0.437 . . . . 0.0 112.11 178.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -143.59 2.47 1.24 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 122.71 0.404 . . . . 0.0 111.52 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -155.27 173.72 16.23 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.032 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -98.48 156.34 16.82 Favored 'General case' 0 CA--C 1.527 0.094 0 CA-C-N 118.222 0.464 . . . . 0.0 110.276 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -119.56 136.49 56.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -177.607 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -92.89 147.65 22.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.98 -0.45 . . . . 0.0 110.384 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.8 mt -134.19 -40.15 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.131 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.83 29.78 3.78 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 123.012 0.525 . . . . 0.0 111.164 -177.4 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.11 5.14 83.51 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.394 -0.683 . . . . 0.0 111.394 -177.158 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -131.36 152.87 81.29 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 124.526 1.13 . . . . 0.0 108.84 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -71.1 146.23 51.44 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.531 2.821 . . . . 0.0 111.784 -177.212 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.5 -176.11 5.46 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.158 1.383 . . . . 0.0 108.772 177.662 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -138.98 159.43 42.16 Favored 'General case' 0 N--CA 1.456 -0.128 0 O-C-N 122.134 -0.353 . . . . 0.0 111.265 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.6 p -147.08 139.68 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 C-N-CA 123.237 0.615 . . . . 0.0 110.606 179.24 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 . . . . . 0 N--CA 1.456 -0.144 0 C-N-CA 123.355 0.662 . . . . 0.0 109.582 176.24 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.433 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 48.2 p . . . . . 0 CA--C 1.532 0.262 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 88.9 Cg_endo -70.11 4.79 2.14 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.583 3.522 . . . . 0.0 113.362 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.84 140.82 45.43 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.076 0 CA-C-N 118.579 0.627 . . . . 0.0 109.855 178.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.95 157.88 43.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 121.07 0.462 . . . . 0.0 110.643 179.119 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -107.84 142.63 37.61 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.908 0.883 . . . . 0.0 109.723 -179.554 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.0 mm -111.42 144.88 18.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 123.006 0.523 . . . . 0.0 110.016 -176.774 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -141.36 160.12 40.78 Favored 'General case' 0 C--N 1.334 -0.068 0 C-N-CA 123.514 0.726 . . . . 0.0 110.068 -178.778 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.67 25.67 58.01 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.432 173.218 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 47.7 mt -59.07 154.87 14.8 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.388 1.094 . . . . 0.0 109.189 176.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.0 pt -69.95 -40.37 78.61 Favored 'Isoleucine or valine' 0 C--N 1.338 0.076 0 O-C-N 122.184 -0.322 . . . . 0.0 111.652 -172.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -172.91 -35.16 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.484 0.713 . . . . 0.0 109.979 -179.383 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.84 51.96 0.05 OUTLIER Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 -177.103 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.1 m -53.72 151.64 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 117.138 0.469 . . . . 0.0 110.087 177.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.3 m -88.46 163.88 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-O 120.881 0.372 . . . . 0.0 110.832 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.68 -22.33 63.8 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 122.819 0.448 . . . . 0.0 111.065 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.82 -8.04 58.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 122.868 0.467 . . . . 0.0 111.991 -179.247 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -91.12 -32.74 15.73 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 118.476 0.58 . . . . 0.0 110.48 178.007 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -71.41 -39.05 71.37 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.119 0.167 . . . . 0.0 110.601 -177.323 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.71 -31.28 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 C-N-CA 121.191 -0.203 . . . . 0.0 110.783 -175.607 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.7 mm-40 -81.26 -17.23 50.15 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 122.131 -0.356 . . . . 0.0 111.554 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.9 -12.47 16.21 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.3 mt -114.53 -9.11 12.71 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.491 0.587 . . . . 0.0 112.444 -179.059 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -70.06 -5.98 30.48 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.508 0.595 . . . . 0.0 111.778 176.29 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -76.28 -12.78 60.14 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 122.13 -0.356 . . . . 0.0 110.498 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -100.39 -16.9 17.46 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 122.455 0.302 . . . . 0.0 111.523 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.12 177.32 35.99 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.59 140.97 37.12 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.875 3.05 . . . . 0.0 110.451 -179.549 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.8 mt -111.07 146.73 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 122.675 0.39 . . . . 0.0 110.098 -178.125 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.2 t -108.26 -40.33 5.2 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.336 0.655 . . . . 0.0 111.436 -177.098 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -159.12 158.49 32.98 Favored 'General case' 0 N--CA 1.457 -0.078 0 CA-C-O 120.577 0.227 . . . . 0.0 111.355 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 65.1 t -145.23 147.92 18.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.801 0.84 . . . . 0.0 109.602 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.4 p -148.2 150.75 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 174.139 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 43.9 t -132.28 150.38 33.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.053 0 C-N-CA 122.628 0.371 . . . . 0.0 110.043 -174.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.7 mtm -135.62 80.59 43.98 Favored Pre-proline 0 N--CA 1.456 -0.171 0 C-N-CA 123.858 0.863 . . . . 0.0 109.486 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -58.88 -20.37 52.03 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.948 3.098 . . . . 0.0 113.041 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -76.09 -12.43 60.12 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.168 0.587 . . . . 0.0 111.139 179.334 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -124.06 3.57 8.65 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.644 0.778 . . . . 0.0 111.294 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.1 tpp85 52.83 32.84 13.03 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.473 1.109 . . . . 0.0 111.826 -176.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -136.93 166.74 22.94 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 123.435 0.694 . . . . 0.0 110.71 -177.044 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.03 172.18 17.25 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 122.748 0.419 . . . . 0.0 110.412 178.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 35.6 mt -132.09 146.52 52.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.728 0.811 . . . . 0.0 109.816 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 90.4 t -138.17 131.84 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.788 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.71 117.98 31.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.679 0.791 . . . . 0.0 109.169 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -86.26 155.36 20.71 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.012 0.434 . . . . 0.0 110.267 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -77.94 -11.04 59.86 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.497 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -146.47 152.02 38.34 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.522 0.729 . . . . 0.0 109.183 178.022 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -69.08 -21.48 25.42 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.76 -28.67 44.86 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 122.039 -0.413 . . . . 0.0 110.594 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.38 -28.73 73.11 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.82 -31.82 25.64 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.887 0.344 . . . . 0.0 110.66 178.665 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -69.95 -33.12 71.71 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 122.359 0.264 . . . . 0.0 110.578 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -73.72 -20.38 60.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 122.277 0.231 . . . . 0.0 111.447 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.44 -29.41 30.71 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 117.797 0.271 . . . . 0.0 111.585 -177.185 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.36 -21.96 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.096 0 O-C-N 122.312 -0.242 . . . . 0.0 110.648 178.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -68.41 -17.06 64.13 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 122.275 -0.266 . . . . 0.0 110.51 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 50.0 t80 -97.9 -36.0 10.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 122.426 0.29 . . . . 0.0 110.611 177.724 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.84 -15.06 59.82 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 122.648 0.379 . . . . 0.0 111.855 -177.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.24 52.4 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.982 0.513 . . . . 0.0 111.922 177.175 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -135.29 -18.33 1.75 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.129 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -151.33 166.21 31.67 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -81.12 154.25 26.86 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 175.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.638 HD13 ' H ' ' A' ' 158' ' ' TYR . 0.5 OUTLIER -110.04 164.52 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.173 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.638 ' H ' HD13 ' A' ' 157' ' ' ILE . 75.9 m-85 -119.52 154.64 33.53 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.094 -0.379 . . . . 0.0 110.3 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.6 mt -137.0 -42.28 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 O-C-N 123.165 0.291 . . . . 0.0 110.802 -177.388 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.08 29.83 3.69 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.268 0.627 . . . . 0.0 111.11 -177.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.48 6.75 80.3 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -176.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -129.7 153.67 80.83 Favored Pre-proline 0 C--O 1.233 0.203 0 C-N-CA 124.013 0.925 . . . . 0.0 109.245 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.97 144.18 52.09 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.184 2.589 . . . . 0.0 112.285 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.44 -177.59 6.31 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.473 1.509 . . . . 0.0 108.668 178.099 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -137.99 160.61 38.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.114 0.483 . . . . 0.0 111.471 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.4 p -150.25 140.86 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 123.888 0.875 . . . . 0.0 109.323 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 . . . . . 0 N--CA 1.455 -0.218 0 C-N-CA 123.149 0.58 . . . . 0.0 109.893 178.893 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.431 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 71.0 p . . . . . 0 CA--C 1.532 0.254 0 N-CA-C 111.484 0.179 . . . . 0.0 111.484 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.431 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 80.6 Cg_endo -69.78 4.27 2.3 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 124.098 3.198 . . . . 0.0 112.342 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.5 t -115.06 140.43 36.34 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 C-N-CA 123.076 0.55 . . . . 0.0 109.802 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.12 150.74 34.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.1 0 CA-C-O 121.035 0.445 . . . . 0.0 110.699 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.3 t-80 -99.39 136.21 39.67 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.249 1.019 . . . . 0.0 110.178 178.321 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.42 146.4 15.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.463 0.705 . . . . 0.0 109.168 -177.682 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -142.3 162.56 35.17 Favored 'General case' 0 N--CA 1.461 0.084 0 C-N-CA 123.573 0.749 . . . . 0.0 110.385 -176.835 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.27 26.99 53.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.66 -0.522 . . . . 0.0 113.239 172.749 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.4 mt -59.41 155.74 14.27 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 118.176 0.988 . . . . 0.0 109.798 177.305 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.2 pt -71.12 -39.5 74.08 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.111 0 O-C-N 122.189 -0.319 . . . . 0.0 111.308 -174.631 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -173.21 -37.05 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.882 0.873 . . . . 0.0 110.107 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.63 52.22 0.06 OUTLIER Glycine 0 C--N 1.337 0.612 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -176.44 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.1 m -54.04 154.4 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 CA-C-N 117.037 0.418 . . . . 0.0 110.203 177.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.9 m -90.84 166.11 1.85 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.063 0 CA-C-O 121.213 0.53 . . . . 0.0 111.091 -176.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -60.58 -24.2 65.25 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.24 0.616 . . . . 0.0 111.217 -178.663 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.5 -4.71 54.92 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 122.694 0.398 . . . . 0.0 112.015 -178.022 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -91.74 -35.76 13.96 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.256 0.48 . . . . 0.0 110.471 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.67 -31.9 52.86 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 122.225 -0.297 . . . . 0.0 111.105 -176.274 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.39 -31.5 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 O-C-N 122.057 -0.402 . . . . 0.0 110.184 -178.447 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.8 mm-40 -82.33 -18.55 41.77 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.244 -0.285 . . . . 0.0 111.054 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.01 -12.19 18.34 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.2 mt -117.6 -8.48 10.93 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.627 0.649 . . . . 0.0 112.525 -177.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.3 pt20 -68.8 -6.92 29.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 118.575 0.625 . . . . 0.0 111.563 176.308 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -76.47 -14.65 60.03 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.791 0.436 . . . . 0.0 110.607 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -99.41 -13.56 19.51 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 122.49 0.316 . . . . 0.0 111.613 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.62 176.32 32.59 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -71.27 140.35 36.97 Favored 'Trans proline' 0 N--CA 1.452 -0.93 0 C-N-CA 124.023 3.149 . . . . 0.0 110.51 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.6 mt -111.28 146.3 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.939 0.496 . . . . 0.0 110.519 -178.029 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -106.36 -41.26 5.36 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 123.433 0.693 . . . . 0.0 111.438 -177.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.0 t80 -159.29 158.89 33.32 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 122.225 0.21 . . . . 0.0 111.51 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -143.56 147.22 20.34 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 C-N-CA 123.827 0.851 . . . . 0.0 109.815 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.43 152.68 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.064 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 175.246 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 56.4 t -133.71 150.06 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 C-N-CA 122.852 0.461 . . . . 0.0 110.352 -176.317 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -133.79 86.47 38.58 Favored Pre-proline 0 N--CA 1.454 -0.262 0 C-N-CA 123.83 0.852 . . . . 0.0 109.318 -179.181 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -68.61 -14.64 39.98 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.463 2.776 . . . . 0.0 111.645 -176.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.0 tttp -79.24 -10.29 59.78 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.114 0.566 . . . . 0.0 110.91 177.217 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -126.76 1.22 6.73 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 123.683 0.793 . . . . 0.0 111.369 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.8 tpp85 53.05 32.33 12.75 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 124.358 1.063 . . . . 0.0 111.948 -176.022 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -135.77 166.56 22.99 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 123.551 0.74 . . . . 0.0 110.147 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.66 172.22 18.24 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-O 120.773 0.321 . . . . 0.0 110.921 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.5 mt -134.09 147.75 50.92 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.41 0.684 . . . . 0.0 109.929 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 81.6 t -138.24 133.61 43.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.8 tt0 -115.44 119.59 36.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 178.183 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 50.2 m-85 -86.13 155.0 20.96 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.987 0.422 . . . . 0.0 110.361 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -75.23 -14.41 60.52 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.379 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.29 153.03 39.25 Favored 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 123.697 0.799 . . . . 0.0 109.456 177.261 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -68.06 -22.0 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 52.5 tp -73.96 -25.45 59.95 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.184 -0.322 . . . . 0.0 110.494 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.25 -30.17 65.37 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 179.327 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.44 -31.17 22.99 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 122.864 0.466 . . . . 0.0 110.612 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.91 -19.98 60.53 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.601 0.36 . . . . 0.0 111.166 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -94.46 -15.48 24.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.45 0.3 . . . . 0.0 111.314 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.63 -32.6 25.61 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.31 -0.244 . . . . 0.0 111.491 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -84.86 -16.35 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -72.54 -4.39 30.34 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.656 0.382 . . . . 0.0 111.003 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -115.29 -35.78 4.55 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.806 0.442 . . . . 0.0 110.935 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -81.39 -7.77 59.63 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -177.833 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.7 -1.82 58.03 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.947 -0.471 . . . . 0.0 112.027 178.36 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.87 -6.7 1.45 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.678 0.391 . . . . 0.0 112.043 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -153.85 164.42 38.4 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.226 0.61 . . . . 0.0 109.563 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.26 158.18 23.6 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 174.161 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.96 135.45 64.01 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 -178.919 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -86.88 151.41 23.35 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.196 -0.315 . . . . 0.0 110.661 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.1 mt -137.09 -40.04 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 122.429 0.291 . . . . 0.0 111.095 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.34 29.12 4.0 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 122.842 0.457 . . . . 0.0 111.058 -178.158 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.96 78.1 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -177.376 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -131.58 152.4 80.36 Favored Pre-proline 0 N--CA 1.453 -0.32 0 C-N-CA 124.205 1.002 . . . . 0.0 108.774 177.762 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.68 145.26 57.06 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 123.147 2.565 . . . . 0.0 111.627 -177.101 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.09 -175.03 5.08 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 124.846 1.258 . . . . 0.0 108.905 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -138.35 162.01 35.48 Favored 'General case' 0 N--CA 1.456 -0.137 0 CA-C-O 120.915 0.388 . . . . 0.0 111.797 -178.067 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.14 144.05 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 C-N-CA 123.692 0.797 . . . . 0.0 109.378 178.734 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.454 -0.226 0 C-N-CA 122.966 0.506 . . . . 0.0 109.875 179.587 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 51.8 m . . . . . 0 CA--C 1.531 0.243 0 N-CA-C 112.225 0.454 . . . . 0.0 112.225 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -70.98 -1.33 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 124.114 3.209 . . . . 0.0 111.927 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.7 t -116.14 140.44 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 176.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.53 152.08 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.062 0.458 . . . . 0.0 110.761 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -102.48 136.38 42.41 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 123.982 0.913 . . . . 0.0 110.162 179.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.5 mp -111.95 145.87 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -177.174 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -141.39 162.95 34.24 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.692 0.797 . . . . 0.0 110.574 -177.661 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.83 27.22 54.31 Favored Glycine 0 CA--C 1.527 0.818 0 CA-C-O 119.469 -0.628 . . . . 0.0 113.185 174.888 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 54.0 mt -61.42 158.88 13.72 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 117.893 0.847 . . . . 0.0 110.415 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.87 -47.98 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -172.798 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -175.69 -35.86 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.208 0.603 . . . . 0.0 110.601 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -171.95 34.18 0.14 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.684 -0.509 . . . . 0.0 111.955 -175.117 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 8.8 p -52.32 148.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-N 117.425 0.612 . . . . 0.0 109.732 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.4 m -103.31 168.87 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.082 0 CA-C-O 121.364 0.602 . . . . 0.0 112.141 -172.202 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -57.99 -28.13 64.11 Favored 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 123.985 0.914 . . . . 0.0 111.602 -177.133 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.58 -2.31 38.27 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -176.446 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -104.17 -32.59 9.07 Favored 'General case' 0 N--CA 1.457 -0.121 0 CA-C-N 118.235 0.47 . . . . 0.0 110.415 177.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.75 -34.33 60.27 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.898 -0.501 . . . . 0.0 110.524 -179.325 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.0 p -76.5 -31.26 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.358 -179.052 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -83.0 -15.98 49.04 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 119.666 -0.207 . . . . 0.0 111.267 -178.241 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.72 -10.89 17.15 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -116.02 -9.15 11.78 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 118.632 0.651 . . . . 0.0 112.18 -179.5 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -68.9 -7.15 32.13 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 118.719 0.691 . . . . 0.0 111.523 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.67 -14.45 60.35 Favored 'General case' 0 CA--C 1.532 0.269 0 O-C-N 122.141 -0.35 . . . . 0.0 110.819 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.5 m-85 -97.13 -16.02 20.66 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 122.54 0.336 . . . . 0.0 111.591 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.78 178.56 35.8 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.85 139.5 33.48 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 124.046 3.164 . . . . 0.0 110.557 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 73.9 mt -110.94 145.76 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.688 0.395 . . . . 0.0 110.501 -177.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.1 t -106.73 -38.42 6.12 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 123.331 0.652 . . . . 0.0 111.463 -177.296 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -160.17 157.05 27.67 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.668 0.27 . . . . 0.0 111.23 179.597 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 94.4 t -144.14 146.23 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 C-N-CA 123.858 0.863 . . . . 0.0 109.666 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.83 153.79 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 C-N-CA 123.314 0.645 . . . . 0.0 109.513 176.561 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 46.0 t -127.34 150.66 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -177.465 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 68.2 mtm -132.27 77.85 69.77 Favored Pre-proline 0 CA--C 1.531 0.222 0 C-N-CA 124.3 1.04 . . . . 0.0 109.104 -177.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.8 -8.81 24.44 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 123.418 2.746 . . . . 0.0 111.72 -175.33 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -72.3 -17.11 61.89 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 122.656 0.382 . . . . 0.0 110.77 178.311 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 62.9 pttt -138.92 15.08 2.67 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 123.146 0.578 . . . . 0.0 111.91 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 57.53 39.68 27.63 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 124.079 0.952 . . . . 0.0 113.247 178.255 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.58 170.07 15.25 Favored 'General case' 0 CA--C 1.527 0.06 0 C-N-CA 123.043 0.537 . . . . 0.0 110.621 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.43 170.33 22.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 122.863 0.465 . . . . 0.0 110.564 177.003 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 34.1 mt -134.81 147.11 49.87 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.663 0.785 . . . . 0.0 110.179 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 85.0 t -139.08 132.07 38.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -114.15 119.79 38.31 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -86.97 154.79 20.51 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.426 -179.471 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -74.39 -14.63 60.89 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.507 -177.707 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -148.08 152.97 38.27 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.703 0.801 . . . . 0.0 109.108 176.468 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.1 p -66.72 -22.0 29.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -176.048 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.61 -26.11 60.64 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 122.031 -0.418 . . . . 0.0 110.629 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.03 -31.39 64.34 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.57 -32.12 25.98 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.047 0.423 . . . . 0.0 110.335 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.8 t -70.86 -15.64 62.65 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.198 0.599 . . . . 0.0 110.938 178.518 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 60.2 t30 -99.89 -14.03 18.92 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.029 0.532 . . . . 0.0 111.412 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -87.23 -31.65 20.18 Favored 'General case' 0 N--CA 1.456 -0.175 0 O-C-N 122.128 -0.358 . . . . 0.0 111.717 -177.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.6 t -86.82 -16.12 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.078 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -70.43 -4.69 23.78 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 122.913 0.485 . . . . 0.0 111.161 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -117.32 -32.21 5.03 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.969 0.508 . . . . 0.0 111.459 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.84 -0.93 55.52 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 113.083 0.771 . . . . 0.0 113.083 -176.302 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.67 -6.64 59.21 Favored 'General case' 0 CA--C 1.534 0.341 0 O-C-N 121.98 -0.45 . . . . 0.0 112.032 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -145.26 3.75 1.04 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.704 0.402 . . . . 0.0 111.88 179.075 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 49.0 t30 -151.52 171.3 17.79 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -178.581 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -95.61 155.88 16.56 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 118.38 0.536 . . . . 0.0 110.17 177.568 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -123.35 136.31 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -179.15 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -90.58 154.32 19.68 Favored 'General case' 0 N--CA 1.454 -0.235 0 O-C-N 122.047 -0.408 . . . . 0.0 110.851 -178.615 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.3 mt -137.33 -42.24 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.916 -177.337 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.49 30.88 3.47 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.936 0.494 . . . . 0.0 111.002 -177.381 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.7 5.94 80.82 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -130.59 151.21 78.3 Favored Pre-proline 0 N--CA 1.455 -0.207 0 C-N-CA 124.046 0.938 . . . . 0.0 109.01 177.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -72.17 145.97 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 123.375 2.717 . . . . 0.0 111.936 -176.219 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.0 -177.91 6.29 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.757 1.223 . . . . 0.0 108.845 177.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -137.34 158.78 43.66 Favored 'General case' 0 N--CA 1.457 -0.106 0 O-C-N 122.296 -0.253 . . . . 0.0 111.096 -178.552 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.01 142.09 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.23 0.612 . . . . 0.0 109.918 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 . . . . . 0 N--CA 1.456 -0.15 0 C-N-CA 123.187 0.595 . . . . 0.0 110.332 178.15 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.299 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -149.17 166.68 28.1 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 123.087 0.555 . . . . 0.0 110.627 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -148.86 166.93 27.07 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.844 0.458 . . . . 0.0 110.012 -179.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -73.0 -11.48 60.58 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 123.279 0.632 . . . . 0.0 112.163 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -147.14 159.43 43.62 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 123.497 0.719 . . . . 0.0 109.687 178.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 38.5 m-20 -73.87 139.81 77.15 Favored Pre-proline 0 N--CA 1.454 -0.232 0 O-C-N 122.127 -0.358 . . . . 0.0 110.892 -177.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_endo -75.33 -27.59 9.37 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 123.58 2.853 . . . . 0.0 112.83 -177.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.9 p-80 -158.65 2.26 0.1 Allowed 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -178.101 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -84.82 163.96 18.75 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 118.577 0.626 . . . . 0.0 110.762 -178.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.6 p -135.07 156.0 78.64 Favored Pre-proline 0 C--O 1.231 0.13 0 C-N-CA 123.404 0.682 . . . . 0.0 110.599 -178.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -75.77 -5.04 16.01 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 123.881 3.054 . . . . 0.0 112.543 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.26 35.08 9.77 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.146 0.578 . . . . 0.0 111.656 -177.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.427 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.2 p -66.22 160.51 64.22 Favored Pre-proline 0 CA--C 1.531 0.237 0 C-N-CA 124.08 0.952 . . . . 0.0 111.487 -177.024 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 77.7 Cg_endo -70.19 3.02 3.23 Favored 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 124.199 3.266 . . . . 0.0 112.452 178.332 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.3 t -115.64 141.31 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.087 0.555 . . . . 0.0 109.798 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.0 m -130.71 151.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-O 121.231 0.538 . . . . 0.0 110.898 177.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 22.9 t-80 -100.49 139.23 36.47 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.076 0.95 . . . . 0.0 110.03 179.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 29.7 mm -108.54 145.15 15.86 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 123.646 0.778 . . . . 0.0 110.089 -178.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -143.59 161.2 39.12 Favored 'General case' 0 C--N 1.337 0.044 0 C-N-CA 123.352 0.661 . . . . 0.0 110.376 -177.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.35 25.09 59.8 Favored Glycine 0 CA--C 1.528 0.845 0 CA-C-O 119.442 -0.644 . . . . 0.0 113.658 173.213 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 68.9 mt -61.21 157.56 15.94 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.398 1.099 . . . . 0.0 109.864 177.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.3 pt -73.08 -41.64 59.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -173.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -173.39 -35.08 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.277 0.631 . . . . 0.0 110.553 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.98 50.59 0.1 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -175.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.9 t -52.32 144.58 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.159 0 C-N-CA 123.5 0.72 . . . . 0.0 109.743 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.82 161.24 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.036 0 CA-C-O 121.084 0.469 . . . . 0.0 111.564 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -60.95 -25.05 66.52 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 123.288 0.635 . . . . 0.0 111.201 -177.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.23 -3.62 52.9 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -178.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -99.43 -31.22 11.76 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.369 0.531 . . . . 0.0 110.757 178.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.4 mp -75.18 -34.05 61.51 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.162 -0.336 . . . . 0.0 110.361 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -77.63 -30.63 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 118.099 0.409 . . . . 0.0 110.348 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -82.14 -17.02 47.84 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.369 -0.207 . . . . 0.0 111.433 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.1 -11.51 16.56 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.5 mt -115.97 -9.97 11.68 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.695 0.68 . . . . 0.0 112.404 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -68.45 -7.05 28.41 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 118.567 0.621 . . . . 0.0 111.637 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -76.01 -14.44 60.22 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 122.692 0.397 . . . . 0.0 110.859 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -98.68 -16.8 18.88 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 122.685 0.394 . . . . 0.0 111.639 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.05 177.05 35.72 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -71.5 141.21 37.91 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 123.775 2.984 . . . . 0.0 110.524 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.2 mt -110.65 147.05 15.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 C-N-CA 122.824 0.45 . . . . 0.0 110.356 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.0 t -107.31 -42.55 4.8 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.279 0.632 . . . . 0.0 111.348 -177.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 54.5 t80 -158.79 159.67 35.41 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 120.778 0.323 . . . . 0.0 111.076 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 76.7 t -143.35 146.85 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 124.008 0.923 . . . . 0.0 109.071 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -147.71 151.26 13.76 Favored 'Isoleucine or valine' 0 C--O 1.231 0.096 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 175.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 45.4 t -128.05 151.01 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.065 0 C-N-CA 122.503 0.321 . . . . 0.0 110.6 -175.093 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.7 mtm -133.7 81.19 54.04 Favored Pre-proline 0 N--CA 1.455 -0.192 0 C-N-CA 124.113 0.965 . . . . 0.0 108.732 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.43 -12.29 33.2 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.577 2.852 . . . . 0.0 111.729 -175.201 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -82.02 -5.14 58.12 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.676 0.39 . . . . 0.0 110.685 177.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 35.8 mmtp -130.4 3.83 4.69 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.245 1.018 . . . . 0.0 111.132 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 53.62 33.22 16.0 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.336 1.054 . . . . 0.0 112.087 -176.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -136.51 168.45 19.45 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.309 0.644 . . . . 0.0 110.413 -176.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.49 172.22 18.61 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.591 0.356 . . . . 0.0 110.457 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 36.8 mt -131.4 146.65 52.36 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.566 0.746 . . . . 0.0 110.219 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 84.7 t -137.83 131.75 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -115.37 121.21 42.1 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.055 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.56 153.61 21.69 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.984 0.421 . . . . 0.0 110.325 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -74.83 -13.38 60.56 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.936 0.398 . . . . 0.0 110.496 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -147.46 151.65 36.77 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.58 0.752 . . . . 0.0 109.412 177.228 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.01 -20.43 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 111.663 0.245 . . . . 0.0 111.663 -175.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.1 tp -74.13 -27.01 60.65 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.946 -0.471 . . . . 0.0 110.743 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.32 -30.44 69.31 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.58 -29.57 27.7 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 117.132 0.466 . . . . 0.0 110.189 178.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 32.0 t -71.97 -12.95 61.48 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.208 0.603 . . . . 0.0 111.366 179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -102.0 -17.71 15.97 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 122.623 0.369 . . . . 0.0 111.764 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.49 -30.43 25.19 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.135 0.425 . . . . 0.0 111.587 -176.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 25.9 t -88.06 -17.19 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -72.17 -3.75 25.22 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.448 0.299 . . . . 0.0 111.063 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -116.18 -33.43 5.01 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 122.925 0.49 . . . . 0.0 111.113 177.648 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.02 -7.77 58.4 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -177.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.03 -1.0 56.31 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 122.077 -0.389 . . . . 0.0 111.806 177.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -140.18 -5.94 1.25 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 122.821 0.448 . . . . 0.0 111.725 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.78 173.24 16.71 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -90.73 156.76 17.84 Favored 'General case' 0 CA--C 1.529 0.136 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 175.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.05 136.4 59.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -90.33 150.98 21.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 O-C-N 122.068 -0.395 . . . . 0.0 110.698 -178.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.1 mt -137.43 -38.79 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.932 -177.492 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -132.9 28.76 4.17 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.288 0.635 . . . . 0.0 111.126 -176.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.01 4.83 86.64 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -176.178 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -130.82 151.9 79.64 Favored Pre-proline 0 N--CA 1.453 -0.287 0 C-N-CA 124.303 1.041 . . . . 0.0 109.066 178.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -70.5 145.26 52.38 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 123.49 2.793 . . . . 0.0 111.905 -176.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.63 -175.79 5.34 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.852 1.261 . . . . 0.0 108.898 178.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -138.68 160.07 40.56 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-O 120.948 0.404 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.67 143.1 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.854 0.862 . . . . 0.0 109.647 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -156.93 162.69 39.63 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 122.973 0.509 . . . . 0.0 110.089 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 34.3 m-85 -65.1 166.38 9.63 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-O 120.817 0.342 . . . . 0.0 110.278 177.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 88.4 p -147.16 176.39 9.99 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 122.956 0.502 . . . . 0.0 109.833 178.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 62.4 p -72.4 -4.18 28.53 Favored 'General case' 0 CA--C 1.529 0.146 0 C-N-CA 122.301 0.24 . . . . 0.0 111.015 178.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 59.7 m -79.07 150.18 31.92 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 122.913 0.485 . . . . 0.0 110.477 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -139.04 -3.76 1.57 Allowed 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 122.706 0.402 . . . . 0.0 111.326 176.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -159.27 135.27 8.83 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 124.005 0.922 . . . . 0.0 108.593 -178.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 78.8 mt -89.23 142.35 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 174.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 46.1 m -78.47 139.56 38.69 Favored 'General case' 0 N--CA 1.457 -0.113 0 N-CA-C 111.627 0.232 . . . . 0.0 111.627 -175.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 54.7 mtp180 40.54 58.87 7.88 Favored Pre-proline 0 CA--C 1.532 0.251 0 C-N-CA 124.851 1.26 . . . . 0.0 112.712 176.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -73.06 137.83 27.12 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 122.821 2.347 . . . . 0.0 110.19 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 79.4 3.57 88.72 Favored Glycine 0 CA--C 1.529 0.928 0 CA-C-O 119.215 -0.769 . . . . 0.0 113.491 177.015 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -147.05 172.95 12.94 Favored 'General case' 0 CA--C 1.528 0.116 0 CA-C-N 118.681 1.24 . . . . 0.0 111.404 178.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 29.0 t -144.03 162.6 35.81 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.27 0.628 . . . . 0.0 109.803 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -79.51 -8.22 59.0 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 111.685 0.254 . . . . 0.0 111.685 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -151.48 144.83 24.78 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 122.899 0.48 . . . . 0.0 110.027 177.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 25.0 t -156.41 -22.64 0.1 Allowed 'General case' 0 C--O 1.233 0.23 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 21.8 tpp85 -154.39 153.32 31.39 Favored 'General case' 0 N--CA 1.456 -0.132 0 C-N-CA 122.657 0.383 . . . . 0.0 110.628 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 48.8 m -132.97 135.64 45.61 Favored 'General case' 0 N--CA 1.456 -0.129 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 176.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 17.0 m -146.32 167.08 7.66 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 C-N-CA 123.911 0.885 . . . . 0.0 109.721 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 48.2 t30 53.73 28.59 8.33 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 123.84 0.856 . . . . 0.0 112.134 -178.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 33.0 t . . . . . 0 C--O 1.251 1.158 0 CA-C-O 117.609 -1.186 . . . . 0.0 110.004 -178.756 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.059 0 N-CA-C 110.558 -1.017 . . . . 0.0 110.558 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.4 167.93 28.76 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 122.975 0.51 . . . . 0.0 110.818 -177.26 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -150.71 162.95 39.72 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 122.983 0.513 . . . . 0.0 110.088 177.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -68.31 -11.38 59.38 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.621 0.768 . . . . 0.0 112.535 -177.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -95.81 7.13 47.17 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 117.934 0.334 . . . . 0.0 111.607 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 55.3 m-20 47.27 61.85 12.91 Favored Pre-proline 0 CA--C 1.533 0.308 0 C-N-CA 123.665 0.786 . . . . 0.0 111.995 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -64.68 -21.21 65.38 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 123.448 2.766 . . . . 0.0 112.657 -176.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 4.3 p-80 -155.52 27.17 0.39 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.072 0.549 . . . . 0.0 110.784 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 28.2 mtpp -129.06 23.06 5.67 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.896 0.878 . . . . 0.0 111.139 -178.397 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 70.5 p -70.38 154.73 94.28 Favored Pre-proline 0 C--O 1.234 0.242 0 C-N-CA 123.188 0.595 . . . . 0.0 112.149 -175.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.92 -1.74 11.92 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 124.365 3.377 . . . . 0.0 112.327 177.39 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 53.38 33.59 16.15 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.703 0.801 . . . . 0.0 112.468 -178.187 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.0 m -63.36 158.66 55.85 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 123.797 0.839 . . . . 0.0 112.018 -178.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -70.87 2.61 3.98 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 124.184 3.256 . . . . 0.0 112.325 178.243 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.6 t -115.26 141.53 31.77 Favored 'Isoleucine or valine' 0 C--N 1.339 0.112 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.59 152.34 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.381 0.61 . . . . 0.0 111.025 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -100.65 141.07 34.02 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.307 1.043 . . . . 0.0 109.882 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.1 mm -110.37 144.92 17.51 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 C-N-CA 123.048 0.539 . . . . 0.0 109.801 -178.253 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -140.56 159.28 42.54 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 123.464 0.705 . . . . 0.0 110.21 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.66 24.64 60.05 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 119.322 -0.71 . . . . 0.0 113.615 173.398 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 51.3 mt -59.47 155.82 14.32 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.172 0.986 . . . . 0.0 109.533 177.341 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -70.58 -38.01 71.85 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.102 0 O-C-N 122.35 -0.219 . . . . 0.0 111.305 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -172.08 -37.19 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.908 0.883 . . . . 0.0 109.506 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.0 56.19 0.04 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 m -53.2 151.4 1.19 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 117.243 0.522 . . . . 0.0 110.422 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.2 m -86.68 166.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.122 0 CA-C-O 121.166 0.508 . . . . 0.0 110.855 -177.186 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.6 -26.72 68.16 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 122.871 0.468 . . . . 0.0 110.786 -178.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.62 -7.98 56.33 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -94.45 -34.65 12.65 Favored 'General case' 0 N--CA 1.457 -0.11 0 CA-C-N 118.248 0.476 . . . . 0.0 109.772 176.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.4 mt -72.73 -40.23 66.28 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 122.389 0.276 . . . . 0.0 110.93 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.1 p -77.3 -29.87 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 O-C-N 122.083 -0.385 . . . . 0.0 110.739 -176.483 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -85.88 -14.64 44.26 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 122.128 -0.357 . . . . 0.0 111.146 -178.022 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -101.52 -14.11 17.62 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 178.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.6 mt -115.12 -8.47 12.4 Favored 'General case' 0 CA--C 1.529 0.14 0 CA-C-N 118.566 0.621 . . . . 0.0 112.568 -178.405 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.3 pt20 -70.54 -6.09 33.78 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.849 0.749 . . . . 0.0 111.67 176.078 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -76.82 -16.39 59.45 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.53 0.332 . . . . 0.0 110.449 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -95.94 -18.79 20.02 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.529 0.332 . . . . 0.0 111.525 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.43 177.57 37.88 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.6 140.28 35.74 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 124.047 3.165 . . . . 0.0 110.576 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 70.1 mt -110.81 147.1 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.869 0.468 . . . . 0.0 110.258 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -108.48 -39.42 5.42 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.333 0.653 . . . . 0.0 111.494 -177.694 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -158.83 157.68 32.02 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 117.719 0.236 . . . . 0.0 111.167 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 63.7 t -145.08 146.57 19.74 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 C-N-CA 123.775 0.83 . . . . 0.0 110.091 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.0 p -150.68 151.8 12.14 Favored 'Isoleucine or valine' 0 C--O 1.231 0.102 0 C-N-CA 123.566 0.746 . . . . 0.0 109.24 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.8 p -134.13 150.29 31.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-O 120.736 0.303 . . . . 0.0 110.804 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.2 mpp? -130.55 83.73 61.29 Favored Pre-proline 0 CA--C 1.53 0.202 0 C-N-CA 123.567 0.747 . . . . 0.0 109.51 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -58.79 -18.88 43.77 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 123.938 3.092 . . . . 0.0 113.066 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -78.85 -6.27 55.63 Favored 'General case' 0 C--N 1.341 0.222 0 C-N-CA 122.944 0.498 . . . . 0.0 111.473 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -131.28 3.27 4.29 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.755 0.822 . . . . 0.0 111.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.0 tpp85 54.68 33.65 19.86 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.404 1.082 . . . . 0.0 111.977 -176.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -136.35 165.49 25.67 Favored 'General case' 0 C--O 1.23 0.078 0 C-N-CA 123.005 0.522 . . . . 0.0 110.78 -176.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.97 171.2 17.66 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 122.59 0.356 . . . . 0.0 110.582 178.475 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.3 mt -131.05 145.16 51.93 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.022 0.929 . . . . 0.0 109.688 178.067 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -137.9 131.92 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -113.36 121.29 43.92 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 177.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -87.74 154.86 20.24 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-O 120.816 0.341 . . . . 0.0 110.216 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -75.38 -13.24 60.39 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.189 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -147.87 150.25 33.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.72 0.808 . . . . 0.0 109.274 177.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -67.34 -21.98 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.7 tp -74.93 -28.78 60.74 Favored 'General case' 0 N--CA 1.455 -0.204 0 O-C-N 121.875 -0.516 . . . . 0.0 110.534 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.29 -30.46 69.36 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.42 -30.06 33.67 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.699 -0.295 . . . . 0.0 110.618 178.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.5 t -74.22 -32.97 63.21 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.669 0.271 . . . . 0.0 110.685 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -74.81 -17.52 60.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.211 -0.306 . . . . 0.0 110.906 -179.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.37 -30.17 23.86 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -176.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.0 t -89.17 -22.63 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 O-C-N 122.095 -0.378 . . . . 0.0 110.732 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -70.19 -1.67 10.91 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 122.132 -0.355 . . . . 0.0 111.535 179.093 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.2 t80 -112.75 -37.82 4.76 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 122.836 0.454 . . . . 0.0 110.969 176.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.81 -6.8 57.96 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -79.69 -4.99 54.23 Favored 'General case' 0 N--CA 1.453 -0.284 0 O-C-N 122.027 -0.42 . . . . 0.0 111.7 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -141.39 -4.84 1.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 122.654 0.382 . . . . 0.0 111.894 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 27.2 m-80 -145.53 174.53 11.08 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.505 0.722 . . . . 0.0 109.821 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' GLN . . . . . 0.455 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -94.73 151.72 19.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 173.972 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -121.96 134.98 63.57 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -88.54 152.19 22.02 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.136 -0.353 . . . . 0.0 110.576 -178.255 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.7 mt -136.56 -41.57 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.22 -177.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.75 30.09 3.77 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.098 0.559 . . . . 0.0 110.858 -178.157 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.9 4.99 78.15 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -131.7 152.72 80.87 Favored Pre-proline 0 N--CA 1.455 -0.214 0 C-N-CA 124.024 0.93 . . . . 0.0 109.399 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -70.77 144.82 49.69 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 123.408 2.739 . . . . 0.0 111.866 -175.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.99 -175.95 5.35 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.891 1.276 . . . . 0.0 108.929 178.37 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -140.53 160.46 39.95 Favored 'General case' 0 C--O 1.231 0.092 0 CA-C-O 120.995 0.426 . . . . 0.0 111.503 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -146.96 141.52 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 C-N-CA 123.772 0.829 . . . . 0.0 109.916 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -155.43 160.2 40.45 Favored 'General case' 0 N--CA 1.456 -0.151 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 29.3 m-85 -62.22 170.41 2.29 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 121.114 0.483 . . . . 0.0 111.073 178.145 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 35.1 t -146.46 172.67 13.18 Favored 'General case' 0 N--CA 1.455 -0.208 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 179.06 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 52.0 p -72.19 -7.84 51.45 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 122.475 0.31 . . . . 0.0 110.252 176.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 71.2 m -74.55 146.5 42.56 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.638 0.775 . . . . 0.0 110.395 176.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -137.86 -5.19 1.72 Allowed 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 122.958 0.503 . . . . 0.0 111.21 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -160.17 131.25 5.74 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.962 0.905 . . . . 0.0 109.108 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 8.8 tp -76.18 148.66 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 43.8 t -90.24 131.6 35.97 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 122.375 -0.203 . . . . 0.0 111.453 -177.204 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 45.18 55.52 14.32 Favored Pre-proline 0 CA--C 1.534 0.359 0 C-N-CA 124.501 1.12 . . . . 0.0 113.336 173.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -71.99 -10.25 25.83 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 123.208 2.605 . . . . 0.0 112.465 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 176.56 -2.22 0.03 OUTLIER Glycine 0 CA--C 1.529 0.944 0 CA-C-O 119.732 -0.482 . . . . 0.0 112.725 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -146.29 156.51 43.41 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-N 117.928 0.864 . . . . 0.0 110.014 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 79.6 p -151.44 163.92 37.91 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 122.525 0.33 . . . . 0.0 110.835 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -151.26 156.87 41.75 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.462 0.705 . . . . 0.0 110.028 179.154 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -147.86 169.98 18.63 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-O 120.994 0.426 . . . . 0.0 110.768 -179.219 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 77.5 p -130.72 175.51 8.96 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.432 0.693 . . . . 0.0 110.587 179.354 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 8.7 tpp85 -147.2 163.41 36.43 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-O 120.688 0.28 . . . . 0.0 111.095 -178.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 35.6 m -84.92 9.44 14.39 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.913 0.485 . . . . 0.0 112.174 -179.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 33.7 m -138.51 164.14 27.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.143 0 C-N-CA 123.644 0.778 . . . . 0.0 109.783 -178.637 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.6 t30 -76.49 132.03 39.36 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.25 1.11 0 CA-C-O 116.809 -1.567 . . . . 0.0 111.129 179.324 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.186 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -148.49 166.01 29.48 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.077 0.551 . . . . 0.0 110.693 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 56.8 t30 -148.91 169.71 19.94 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.031 0.533 . . . . 0.0 110.114 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -77.32 -9.72 59.0 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 123.704 0.802 . . . . 0.0 111.819 178.683 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -150.96 158.5 44.22 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.548 0.739 . . . . 0.0 109.371 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -70.73 140.52 86.67 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 122.218 -0.301 . . . . 0.0 110.825 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -74.87 -31.34 6.52 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 123.27 2.647 . . . . 0.0 112.124 -177.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -160.71 0.18 0.06 Allowed 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -178.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -80.79 156.81 26.0 Favored 'General case' 0 C--N 1.338 0.075 0 CA-C-N 118.341 0.519 . . . . 0.0 110.578 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 43.7 p -86.47 154.0 56.32 Favored Pre-proline 0 CA--C 1.53 0.196 0 C-N-CA 122.834 0.454 . . . . 0.0 111.058 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -76.67 -4.02 14.48 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 123.742 2.961 . . . . 0.0 112.379 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.17 35.55 13.58 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 123.36 0.664 . . . . 0.0 111.724 -178.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.408 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 71.3 p -67.92 160.53 73.46 Favored Pre-proline 0 CA--C 1.533 0.317 0 C-N-CA 123.772 0.829 . . . . 0.0 111.45 -177.571 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 92.7 Cg_endo -71.7 5.82 2.29 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 124.471 3.447 . . . . 0.0 112.179 177.5 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.8 t -120.57 141.67 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.124 0 C-N-CA 123.066 0.546 . . . . 0.0 109.57 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 31.6 m -130.28 149.86 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.115 0 CA-C-O 121.199 0.523 . . . . 0.0 111.063 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -98.14 142.08 30.27 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.338 1.055 . . . . 0.0 110.127 177.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.6 mm -111.56 145.5 17.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 C-N-CA 123.06 0.544 . . . . 0.0 109.723 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -142.11 161.21 38.57 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.254 0.622 . . . . 0.0 110.377 -179.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 81.67 24.23 56.44 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.592 -0.56 . . . . 0.0 113.641 173.151 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.5 mt -63.01 159.23 17.53 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.1 0.95 . . . . 0.0 110.072 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.3 pt -74.2 -42.45 51.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.529 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.93 -35.46 0.01 OUTLIER 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.074 0.55 . . . . 0.0 110.676 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -177.04 50.31 0.1 Allowed Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.1 t -50.61 146.19 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 123.565 0.746 . . . . 0.0 109.735 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.8 m -96.53 161.92 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.072 0 CA-C-O 121.182 0.515 . . . . 0.0 111.4 -176.079 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -60.1 -24.72 64.86 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.01 0.524 . . . . 0.0 111.376 -176.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.22 -6.17 56.0 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -99.43 -31.58 11.58 Favored 'General case' 0 CA--C 1.529 0.137 0 CA-C-N 118.155 0.434 . . . . 0.0 110.204 177.051 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -69.83 -39.11 76.67 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.1 p -78.44 -30.79 15.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 121.157 -0.217 . . . . 0.0 110.52 -176.481 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -82.2 -14.37 55.68 Favored 'General case' 0 N--CA 1.456 -0.14 0 O-C-N 122.072 -0.393 . . . . 0.0 111.715 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.67 -11.8 15.36 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 94.3 mt -115.95 -8.36 11.89 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.847 0.749 . . . . 0.0 112.481 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -70.42 -6.55 36.54 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.564 0.62 . . . . 0.0 111.9 176.216 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -76.42 -15.58 59.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 122.488 0.315 . . . . 0.0 110.518 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -96.33 -17.15 20.88 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 122.446 0.298 . . . . 0.0 111.355 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.72 176.35 35.56 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -71.46 140.4 36.44 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 124.186 3.257 . . . . 0.0 110.586 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.7 mt -111.63 145.69 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.091 0 C-N-CA 122.563 0.345 . . . . 0.0 110.232 -177.435 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.8 t -105.36 -41.96 5.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 123.287 0.635 . . . . 0.0 111.278 -177.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -158.92 159.55 35.06 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.742 0.306 . . . . 0.0 111.098 178.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 87.7 t -143.6 147.46 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.827 0.851 . . . . 0.0 109.692 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.1 p -148.5 149.74 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.094 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 175.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.87 149.35 33.53 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -130.54 82.02 66.2 Favored Pre-proline 0 N--CA 1.456 -0.137 0 C-N-CA 123.667 0.787 . . . . 0.0 109.32 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -58.82 -19.09 45.09 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.849 3.032 . . . . 0.0 112.838 -178.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -75.15 -13.47 60.47 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.905 0.482 . . . . 0.0 111.071 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -125.82 4.65 7.37 Favored 'General case' 0 CA--C 1.527 0.089 0 C-N-CA 123.541 0.737 . . . . 0.0 111.284 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.1 tpp85 55.18 32.08 17.72 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.128 0.971 . . . . 0.0 111.993 -177.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -135.87 166.32 23.57 Favored 'General case' 0 N--CA 1.457 -0.106 0 C-N-CA 123.059 0.544 . . . . 0.0 110.803 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.72 172.38 15.68 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 122.863 0.465 . . . . 0.0 110.725 179.251 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 30.6 mt -132.97 145.81 51.21 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.645 0.778 . . . . 0.0 109.772 177.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 86.2 t -137.26 132.42 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -114.53 117.72 31.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -85.2 153.5 22.59 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 120.99 0.424 . . . . 0.0 110.251 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -74.62 -13.15 60.61 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.388 -177.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -148.32 151.28 35.1 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.76 0.824 . . . . 0.0 108.965 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.9 p -66.42 -21.95 29.36 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.8 tp -73.31 -24.63 60.42 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 121.948 -0.47 . . . . 0.0 110.492 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.24 -31.16 64.04 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.22 -31.23 23.28 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-N 117.126 0.463 . . . . 0.0 110.133 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 t -71.54 -18.48 62.26 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.904 0.482 . . . . 0.0 110.913 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -96.68 -17.83 20.08 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 122.74 0.416 . . . . 0.0 111.127 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.82 -31.42 28.12 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.13 -0.356 . . . . 0.0 111.663 -177.571 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 32.1 t -85.74 -14.36 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 177.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -72.97 -2.79 22.41 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.137 0.575 . . . . 0.0 111.118 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -121.03 -34.85 3.44 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 122.701 0.401 . . . . 0.0 110.996 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.73 -9.59 58.06 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -176.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.72 -0.21 55.89 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 122.663 0.385 . . . . 0.0 111.654 176.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -136.51 -10.13 1.89 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.907 0.483 . . . . 0.0 111.726 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 50.0 t30 -154.12 170.62 20.74 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -86.88 155.63 20.17 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 175.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.73 136.15 61.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -178.614 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -89.04 151.21 22.39 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.121 -0.362 . . . . 0.0 110.758 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.8 mt -136.5 -38.46 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.839 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.37 29.43 3.0 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.28 0.632 . . . . 0.0 111.027 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.18 3.79 81.97 Favored Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.716 -0.554 . . . . 0.0 111.716 -176.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -130.56 151.8 79.29 Favored Pre-proline 0 N--CA 1.454 -0.24 0 C-N-CA 124.436 1.094 . . . . 0.0 109.03 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo -70.77 146.22 53.37 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 123.666 2.91 . . . . 0.0 112.143 -177.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.86 -175.55 5.37 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.193 1.397 . . . . 0.0 109.205 179.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -140.59 159.44 42.19 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.004 0.43 . . . . 0.0 111.759 -178.747 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.72 143.13 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 C-N-CA 123.903 0.881 . . . . 0.0 109.902 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -156.91 162.96 39.64 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -60.86 168.45 2.34 Favored 'General case' 0 N--CA 1.455 -0.206 0 O-C-N 122.078 -0.389 . . . . 0.0 111.284 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 41.3 t -140.66 164.35 30.43 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 123.117 0.567 . . . . 0.0 110.377 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 23.9 m -68.65 -12.76 61.77 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 174.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 35.5 t -73.04 152.74 41.16 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.664 0.786 . . . . 0.0 110.986 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.3 pt20 -138.74 -1.0 1.87 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.159 0.584 . . . . 0.0 110.743 175.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -160.86 129.81 4.71 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 123.854 0.861 . . . . 0.0 108.948 -177.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 77.2 mt -83.25 148.2 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 175.104 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.2 m -79.3 139.5 37.82 Favored 'General case' 0 N--CA 1.457 -0.101 0 CA-C-O 120.676 0.275 . . . . 0.0 111.741 -177.265 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 44.97 52.63 10.61 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 124.651 1.18 . . . . 0.0 113.132 176.231 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -76.06 166.38 28.02 Favored 'Trans proline' 0 N--CA 1.451 -1.008 0 C-N-CA 123.35 2.7 . . . . 0.0 111.072 -177.657 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 62.81 -130.87 43.01 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -147.76 165.08 31.6 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 123.397 0.679 . . . . 0.0 110.516 -178.763 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 30.9 t -150.23 158.14 43.84 Favored 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 122.796 0.438 . . . . 0.0 110.638 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -150.2 154.83 38.66 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.219 0.608 . . . . 0.0 110.043 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -148.93 155.97 41.62 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 122.775 0.43 . . . . 0.0 110.933 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 51.1 m -134.7 148.15 50.25 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 123.913 0.885 . . . . 0.0 109.267 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 17.1 ttm180 -151.97 163.61 38.9 Favored 'General case' 0 CA--C 1.528 0.134 0 O-C-N 122.414 -0.179 . . . . 0.0 110.926 -174.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.4 m -99.59 6.22 45.79 Favored 'General case' 0 CA--C 1.528 0.108 0 N-CA-C 112.738 0.644 . . . . 0.0 112.738 -176.211 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.8 m -80.18 164.94 2.96 Favored 'Isoleucine or valine' 0 C--O 1.23 0.034 0 CA-C-N 117.982 0.356 . . . . 0.0 110.946 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -90.72 5.46 48.1 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 122.917 0.487 . . . . 0.0 111.718 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 28.0 m . . . . . 0 C--O 1.251 1.179 0 CA-C-O 117.27 -1.348 . . . . 0.0 111.196 -179.821 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.134 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -147.4 164.46 33.23 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 122.892 0.477 . . . . 0.0 110.726 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -149.83 170.96 17.55 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.156 0.582 . . . . 0.0 109.746 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -69.28 147.33 51.34 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 176.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 40.9 m-20 54.98 -179.66 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.156 0.982 . . . . 0.0 112.124 -176.059 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -86.99 136.53 33.93 Favored Pre-proline 0 CA--C 1.531 0.243 0 O-C-N 121.904 -0.498 . . . . 0.0 110.44 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -83.79 157.34 13.83 Favored 'Trans proline' 0 N--CA 1.451 -0.985 0 C-N-CA 123.956 3.104 . . . . 0.0 110.401 176.585 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 7.4 p80 48.83 15.48 0.09 Allowed 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 116.369 1.988 . . . . 0.0 116.369 173.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -101.5 158.72 15.87 Favored 'General case' 0 N--CA 1.461 0.093 0 CA-C-N 118.925 0.784 . . . . 0.0 110.093 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 49.1 p -139.93 156.98 70.36 Favored Pre-proline 0 C--O 1.232 0.178 0 C-N-CA 123.419 0.688 . . . . 0.0 110.048 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -74.64 -3.51 13.98 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 123.584 2.856 . . . . 0.0 112.35 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.34 35.74 14.6 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.474 0.71 . . . . 0.0 112.057 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.0 m -61.43 158.79 36.2 Favored Pre-proline 0 CA--C 1.53 0.189 0 C-N-CA 124.091 0.956 . . . . 0.0 112.207 -177.445 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.51 0.06 5.99 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 124.229 3.286 . . . . 0.0 111.904 177.025 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 54.1 t -114.29 141.41 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 176.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.9 m -129.56 151.81 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.139 0 CA-C-O 121.332 0.587 . . . . 0.0 110.906 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.9 t-80 -98.72 136.21 39.1 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.201 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.3 mm -106.62 144.59 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.099 0.56 . . . . 0.0 109.752 -178.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -141.77 161.82 37.0 Favored 'General case' 0 C--N 1.338 0.074 0 C-N-CA 123.345 0.658 . . . . 0.0 110.584 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 77.3 24.93 64.69 Favored Glycine 0 CA--C 1.527 0.843 0 CA-C-O 119.642 -0.532 . . . . 0.0 113.086 174.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.6 mt -61.44 159.52 12.62 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 117.956 0.878 . . . . 0.0 110.638 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.1 pt -73.34 -41.52 57.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -173.392 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -173.94 -35.58 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 123.634 0.774 . . . . 0.0 109.97 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.45 49.65 0.06 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -176.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 14.5 p -52.83 148.49 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 122.897 0.479 . . . . 0.0 110.083 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -88.2 163.06 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 CA-C-O 121.324 0.583 . . . . 0.0 111.996 -171.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -62.24 -27.48 69.03 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.799 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.71 -3.07 49.41 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 123.087 0.555 . . . . 0.0 112.318 -178.024 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -104.29 -29.84 10.52 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.427 0.558 . . . . 0.0 109.711 177.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 49.8 mt -72.67 -38.97 67.46 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 122.546 0.339 . . . . 0.0 110.924 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.67 -30.23 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.442 -178.32 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -82.38 -16.01 50.68 Favored 'General case' 0 N--CA 1.453 -0.279 0 O-C-N 122.168 -0.332 . . . . 0.0 111.506 -178.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.44 -12.91 16.27 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 112.918 0.711 . . . . 0.0 112.918 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.9 mt -114.05 -7.62 13.08 Favored 'General case' 0 C--N 1.339 0.11 0 CA-C-N 118.516 0.598 . . . . 0.0 112.506 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.15 -6.07 31.56 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 118.731 0.696 . . . . 0.0 111.784 176.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -77.09 -13.62 59.93 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.801 0.44 . . . . 0.0 110.769 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -98.64 -18.16 18.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 122.531 0.332 . . . . 0.0 111.477 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.94 177.08 36.43 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -70.94 140.28 37.92 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 124.176 3.251 . . . . 0.0 110.3 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.1 mt -112.21 145.9 17.71 Favored 'Isoleucine or valine' 0 C--O 1.231 0.092 0 C-N-CA 122.746 0.419 . . . . 0.0 110.237 -177.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 t -105.88 -41.96 5.27 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.243 0.617 . . . . 0.0 111.395 -177.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -159.85 160.27 33.52 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-O 120.695 0.283 . . . . 0.0 111.035 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.8 t -145.24 147.01 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 123.906 0.882 . . . . 0.0 109.526 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.89 155.39 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.141 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 176.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 29.1 t -125.87 153.38 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.08 0 C-N-CA 122.503 0.321 . . . . 0.0 110.995 -177.268 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.5 mtm -135.56 77.13 53.35 Favored Pre-proline 0 CA--C 1.532 0.265 0 C-N-CA 124.237 1.015 . . . . 0.0 109.385 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -60.59 -16.68 44.33 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.972 3.115 . . . . 0.0 113.245 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -77.13 -6.56 53.34 Favored 'General case' 0 C--N 1.339 0.132 0 C-N-CA 123.009 0.524 . . . . 0.0 111.618 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -133.22 3.68 3.68 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.216 0.606 . . . . 0.0 111.386 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 13.4 tpp85 55.3 38.26 30.1 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.7 0.8 . . . . 0.0 111.152 -173.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 83.1 mt-30 -134.0 166.24 23.16 Favored 'General case' 0 N--CA 1.458 -0.05 0 C-N-CA 123.684 0.794 . . . . 0.0 110.608 -176.799 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.04 171.31 18.06 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 122.985 0.514 . . . . 0.0 109.871 176.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -132.18 146.01 51.74 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 123.407 0.683 . . . . 0.0 110.072 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 93.3 t -137.37 128.71 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 118.1 33.78 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.28 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.6 m-85 -85.85 154.87 21.24 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.348 -179.148 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -75.23 -12.24 60.24 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 120.704 0.287 . . . . 0.0 110.399 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -148.62 152.16 36.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 123.784 0.834 . . . . 0.0 109.14 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.49 -21.41 26.19 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 122.076 -0.39 . . . . 0.0 111.614 -175.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.6 tp -75.56 -28.87 59.17 Favored 'General case' 0 N--CA 1.452 -0.353 0 O-C-N 122.008 -0.433 . . . . 0.0 110.529 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.16 -30.92 71.71 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.37 -31.41 37.84 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.894 0.347 . . . . 0.0 110.301 178.086 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 44.2 t -70.81 -29.53 65.72 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 122.205 0.202 . . . . 0.0 110.983 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -78.07 -19.6 53.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 119.462 -0.304 . . . . 0.0 111.476 -179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.88 -32.06 23.4 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.108 0.413 . . . . 0.0 111.606 -176.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.5 t -86.76 -19.51 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -68.65 -14.1 62.79 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.102 -0.374 . . . . 0.0 110.99 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -104.4 -37.85 7.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.487 0.315 . . . . 0.0 111.256 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.65 -4.33 58.96 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -77.9 -9.15 58.93 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.228 0.467 . . . . 0.0 111.486 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -141.07 -1.86 1.34 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.681 0.392 . . . . 0.0 111.652 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.5 m-80 -144.41 175.7 9.92 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.131 0.572 . . . . 0.0 109.921 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' GLN . . . . . 0.476 ' CD ' ' H ' ' A' ' 156' ' ' GLN . 0.0 OUTLIER -98.48 155.86 17.05 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.714 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.95 135.59 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.094 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -89.38 155.94 19.01 Favored 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 122.045 -0.409 . . . . 0.0 111.085 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.9 mt -138.0 -42.51 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.786 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.84 32.2 2.99 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.236 0.614 . . . . 0.0 111.122 -177.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.07 4.84 81.32 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 -176.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -128.99 150.67 75.95 Favored Pre-proline 0 N--CA 1.455 -0.202 0 C-N-CA 123.83 0.852 . . . . 0.0 109.215 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -71.55 147.58 52.02 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.464 2.776 . . . . 0.0 111.702 -177.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -153.45 -174.6 5.01 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.072 1.349 . . . . 0.0 108.731 178.124 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -139.04 160.24 40.24 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-O 120.986 0.422 . . . . 0.0 111.345 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.7 p -147.23 140.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.575 0.75 . . . . 0.0 109.264 179.087 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -157.26 161.12 39.19 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 122.91 0.484 . . . . 0.0 110.398 179.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -66.19 163.78 17.04 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 175.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 94.3 p -149.86 -175.8 5.18 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 176.743 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 58.7 p -72.97 1.95 7.87 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 122.614 0.366 . . . . 0.0 111.33 177.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 91.4 p -73.35 155.28 39.56 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 122.868 0.467 . . . . 0.0 110.771 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -145.55 -9.78 0.55 Allowed 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 175.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -161.46 136.7 7.54 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.748 0.819 . . . . 0.0 108.844 -178.16 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 73.5 mt -86.72 143.41 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.122 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 174.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.9 m -72.94 134.68 44.85 Favored 'General case' 0 C--N 1.334 -0.085 0 C-N-CA 122.183 0.193 . . . . 0.0 110.993 -177.01 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 71.5 ttt180 40.16 66.0 3.53 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 124.767 1.227 . . . . 0.0 112.199 179.148 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -77.03 62.49 7.46 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 124.34 3.36 . . . . 0.0 111.13 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 82.33 0.77 90.11 Favored Glycine 0 CA--C 1.527 0.823 0 C-N-CA 123.304 0.478 . . . . 0.0 112.144 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -83.28 159.17 21.98 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 117.435 0.618 . . . . 0.0 110.364 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 66.3 m -146.42 160.65 41.79 Favored 'General case' 0 C--O 1.23 0.077 0 C-N-CA 123.273 0.629 . . . . 0.0 110.012 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -147.24 154.39 40.95 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 123.03 0.532 . . . . 0.0 110.262 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 26.8 t0 -142.8 9.33 1.74 Allowed 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.363 0.665 . . . . 0.0 110.952 179.107 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 33.6 t -61.8 144.27 55.04 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.579 -0.701 . . . . 0.0 109.86 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 18.3 ptp180 -152.1 170.7 19.31 Favored 'General case' 0 CA--C 1.528 0.116 0 C-N-CA 122.947 0.499 . . . . 0.0 111.033 -175.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.8 m -82.24 8.33 11.4 Favored 'General case' 0 C--O 1.232 0.155 0 C-N-CA 124.113 0.965 . . . . 0.0 113.166 -175.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 31.3 m -136.35 165.61 28.58 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 C-N-CA 122.948 0.499 . . . . 0.0 110.888 -177.443 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 30.9 m120 -80.82 -15.3 56.75 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 122.25 0.22 . . . . 0.0 111.032 178.685 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 33.0 t . . . . . 0 C--O 1.252 1.201 0 CA-C-O 117.694 -1.146 . . . . 0.0 109.855 178.099 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.054 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -136.91 154.91 50.34 Favored 'General case' 0 CA--C 1.527 0.077 0 C-N-CA 123.467 0.707 . . . . 0.0 109.39 179.325 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 -146.83 -5.58 0.53 Allowed 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -176.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 85.0 m-85 -142.12 180.0 6.57 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 123.283 0.633 . . . . 0.0 109.717 -177.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -89.23 133.63 34.36 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 177.082 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 44.42 47.99 4.09 Favored Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 113.963 1.098 . . . . 0.0 113.963 -178.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.36 -23.22 24.17 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 122.184 1.923 . . . . 0.0 111.563 -179.075 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -157.12 9.15 0.19 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.481 0.713 . . . . 0.0 111.542 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -76.33 163.99 26.47 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 122.961 0.504 . . . . 0.0 110.517 -178.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 33.2 p -136.5 152.47 74.83 Favored Pre-proline 0 CA--C 1.528 0.121 0 C-N-CA 122.96 0.504 . . . . 0.0 110.359 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -76.57 -5.3 15.95 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 123.893 3.062 . . . . 0.0 112.749 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.09 33.12 8.65 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 123.487 0.715 . . . . 0.0 111.918 -177.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 63.8 m -63.41 157.55 63.72 Favored Pre-proline 0 CA--C 1.53 0.18 0 C-N-CA 123.805 0.842 . . . . 0.0 111.757 -177.527 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -71.88 -3.76 13.81 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.831 3.021 . . . . 0.0 111.568 177.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 67.5 t -111.11 139.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.62 148.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 CA-C-O 121.319 0.58 . . . . 0.0 110.732 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -95.46 137.25 34.78 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.189 0.995 . . . . 0.0 110.35 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 26.0 mm -105.85 143.92 16.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 123.194 0.597 . . . . 0.0 109.787 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -142.56 160.53 40.11 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 123.132 0.573 . . . . 0.0 110.822 -178.025 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.81 26.09 56.86 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 119.457 -0.635 . . . . 0.0 113.523 173.132 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.9 mt -62.53 156.06 24.04 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.144 0.972 . . . . 0.0 109.814 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -70.57 -41.63 77.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -173.23 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -173.12 -34.78 0.01 OUTLIER 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.31 0.644 . . . . 0.0 110.676 -179.054 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.93 48.93 0.12 Allowed Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -176.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.7 t -51.56 143.21 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 C-N-CA 123.41 0.684 . . . . 0.0 109.697 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.8 m -95.72 164.98 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.119 0 CA-C-O 121.308 0.575 . . . . 0.0 111.637 -175.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -61.08 -26.02 67.36 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.538 0.735 . . . . 0.0 111.247 -178.264 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.45 -5.56 56.75 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 -177.523 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -98.11 -30.46 12.65 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.28 0.491 . . . . 0.0 109.922 177.324 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.2 mt -73.33 -38.8 65.65 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 122.556 0.342 . . . . 0.0 110.95 -178.058 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.6 p -77.27 -29.96 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.241 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.6 mm-40 -82.76 -15.14 52.92 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 119.445 -0.312 . . . . 0.0 111.643 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -108.31 -10.61 15.33 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -116.96 -9.61 11.1 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 118.501 0.591 . . . . 0.0 112.396 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -69.83 -7.34 39.13 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.7 0.682 . . . . 0.0 111.633 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -74.12 -18.47 60.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.508 0.323 . . . . 0.0 110.593 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -92.64 -19.07 22.25 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 122.369 0.268 . . . . 0.0 111.535 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.39 176.77 35.71 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 139.64 41.24 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.978 3.118 . . . . 0.0 110.93 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.9 mt -111.59 145.67 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.876 0.471 . . . . 0.0 110.226 -177.781 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.5 t -104.09 -41.28 5.88 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.193 0.597 . . . . 0.0 111.355 -177.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' TYR . . . . . 0.405 ' CG ' ' HA ' ' A' ' 177' ' ' PRO . 55.5 t80 -161.42 161.18 30.16 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.563 0.22 . . . . 0.0 111.532 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 69.2 t -143.97 147.16 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 123.903 0.881 . . . . 0.0 109.625 179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -147.29 153.33 12.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 176.207 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 37.7 t -128.46 152.99 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.052 0 C-N-CA 122.42 0.288 . . . . 0.0 111.019 -174.67 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.6 mtm -134.28 79.17 56.1 Favored Pre-proline 0 CA--C 1.532 0.274 0 C-N-CA 124.21 1.004 . . . . 0.0 109.314 178.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.85 -21.54 57.81 Favored 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 123.598 2.866 . . . . 0.0 113.134 -177.175 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -83.48 1.89 39.5 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 122.939 0.495 . . . . 0.0 112.015 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -128.79 0.67 5.41 Favored 'General case' 0 C--N 1.338 0.086 0 C-N-CA 123.802 0.841 . . . . 0.0 111.158 176.342 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.5 tpp85 53.35 33.04 14.84 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.014 0.926 . . . . 0.0 111.116 -172.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -136.81 167.86 20.65 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.305 0.642 . . . . 0.0 110.825 -175.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.36 173.57 15.45 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.89 0.476 . . . . 0.0 110.175 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 40.4 mt -132.81 145.11 50.7 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 123.187 0.595 . . . . 0.0 109.837 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.2 t -135.44 131.33 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -114.83 117.74 31.58 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 60.8 m-85 -84.16 156.75 21.94 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.303 179.632 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -70.4 -18.41 63.03 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.284 -178.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -154.19 159.21 41.27 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 123.784 0.834 . . . . 0.0 109.579 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 27.2 m -65.42 -15.23 18.16 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.099 0 O-C-N 122.053 -0.405 . . . . 0.0 111.843 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 10.3 tt -67.61 -33.2 74.51 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.327 0.512 . . . . 0.0 110.384 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -76.14 -31.85 54.06 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.48 -32.46 32.49 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.372 0.586 . . . . 0.0 110.535 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.9 t -75.73 -8.08 55.95 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 123.101 0.56 . . . . 0.0 111.302 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -106.74 -16.31 14.52 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 122.409 0.283 . . . . 0.0 111.039 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -86.79 -34.93 19.41 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.063 -0.398 . . . . 0.0 111.33 -178.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.5 t -83.32 -15.78 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -71.37 -5.33 31.75 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 122.797 0.439 . . . . 0.0 111.265 179.419 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -116.52 -37.68 3.67 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 122.899 0.48 . . . . 0.0 110.911 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.68 -5.73 59.01 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -176.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.4 -4.36 58.4 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 122.069 -0.394 . . . . 0.0 111.441 177.039 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -142.07 -6.5 0.96 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 122.773 0.429 . . . . 0.0 111.686 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -144.76 175.13 10.4 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 123.387 0.675 . . . . 0.0 109.5 -179.196 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' GLN . . . . . 0.477 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -95.98 152.43 18.52 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 172.733 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.84 135.32 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.12 149.67 23.07 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 121.954 -0.466 . . . . 0.0 110.758 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 56.4 mt -137.38 -39.67 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.939 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.42 29.48 3.94 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.151 0.58 . . . . 0.0 111.033 -176.476 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.09 4.54 84.15 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -132.09 152.84 80.91 Favored Pre-proline 0 C--O 1.233 0.224 0 C-N-CA 124.102 0.961 . . . . 0.0 109.269 177.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -71.47 144.47 45.3 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 123.583 2.855 . . . . 0.0 111.764 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.74 -175.85 5.19 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.983 1.313 . . . . 0.0 108.765 177.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -138.5 160.26 40.0 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-O 120.927 0.394 . . . . 0.0 111.628 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.1 p -147.84 143.48 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.13 0 C-N-CA 123.785 0.834 . . . . 0.0 109.693 178.454 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -156.04 161.45 40.43 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.259 0.624 . . . . 0.0 110.066 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -64.64 162.91 14.76 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.725 0.298 . . . . 0.0 110.648 177.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 44.3 t -147.98 159.87 43.43 Favored 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.147 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 59.1 p -74.69 8.32 2.47 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 122.69 0.396 . . . . 0.0 110.253 176.51 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.401 ' C ' ' H ' ' A' ' 173' ' ' LYS . 83.5 p -59.46 -43.85 93.12 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 124.369 1.068 . . . . 0.0 110.901 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 48.86 -10.72 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 128.906 2.882 . . . . 0.0 116.898 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' LYS . . . . . 0.401 ' H ' ' C ' ' A' ' 171' ' ' SER . 16.5 tppt? -165.15 138.3 4.58 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 123.556 0.743 . . . . 0.0 109.526 -177.252 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 81.5 mt -84.34 156.99 3.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 174.675 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 80.8 p -81.18 -8.28 59.73 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 114.339 1.237 . . . . 0.0 114.339 -172.083 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 176' ' ' ARG . . . . . 0.446 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 37.7 ptt180 -154.89 36.49 0.07 OUTLIER Pre-proline 0 CA--C 1.535 0.383 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -177.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' PRO . . . . . 0.446 ' CD ' ' N ' ' A' ' 176' ' ' ARG . 87.6 Cg_endo -72.66 111.67 3.3 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.62 2.213 . . . . 0.0 111.123 -176.243 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 70.45 -9.81 3.13 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 123.958 0.79 . . . . 0.0 114.021 176.67 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -157.81 158.88 36.03 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.094 0.947 . . . . 0.0 110.051 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.2 m -133.31 153.33 51.66 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 123.073 0.549 . . . . 0.0 110.422 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -150.36 155.17 39.11 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 122.691 0.396 . . . . 0.0 110.752 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -140.62 154.12 46.32 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.688 0.795 . . . . 0.0 109.816 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 49.5 m -67.5 137.34 55.72 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 120.665 0.269 . . . . 0.0 110.321 -178.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 31.4 ptt-85 -160.38 167.19 27.9 Favored 'General case' 0 N--CA 1.458 -0.072 0 C-N-CA 123.594 0.758 . . . . 0.0 110.115 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.4 m -78.63 130.26 35.68 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 122.401 0.281 . . . . 0.0 110.25 178.268 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 11.2 m -149.38 163.09 4.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 C-N-CA 124.272 1.029 . . . . 0.0 109.159 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.6 t30 -79.06 134.14 36.77 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 178.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 60.5 m . . . . . 0 C--O 1.251 1.156 0 CA-C-O 117.527 -1.225 . . . . 0.0 110.075 179.878 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 111.141 -0.783 . . . . 0.0 111.141 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -149.41 162.16 40.65 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.896 0.478 . . . . 0.0 110.988 179.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 45.9 t30 -151.98 163.53 39.09 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.638 0.775 . . . . 0.0 108.943 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 53.82 -163.92 0.1 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.689 0.796 . . . . 0.0 111.695 -177.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -115.23 2.13 13.98 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.007 0.523 . . . . 0.0 111.458 178.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.422 ' N ' ' CD ' ' A' ' 90' ' ' PRO . 14.9 p-10 -144.09 43.34 0.42 Allowed Pre-proline 0 CA--C 1.537 0.478 0 N-CA-C 113.17 0.804 . . . . 0.0 113.17 -177.691 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.422 ' CD ' ' N ' ' A' ' 89' ' ' ASP . 73.6 Cg_endo -69.71 -14.83 36.82 Favored 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 122.735 2.29 . . . . 0.0 112.324 -177.759 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -147.52 11.0 0.98 Allowed 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -177.422 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -83.6 158.57 21.87 Favored 'General case' 0 C--O 1.231 0.108 0 O-C-N 122.154 -0.341 . . . . 0.0 110.673 -179.252 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 22.2 p -80.31 153.42 74.11 Favored Pre-proline 0 C--N 1.333 -0.118 0 C-N-CA 122.806 0.442 . . . . 0.0 111.121 -178.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -76.03 -8.05 18.62 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.574 2.849 . . . . 0.0 112.299 -178.532 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.32 34.89 9.6 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.48 0.712 . . . . 0.0 111.42 -177.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 60.8 p -72.2 159.38 85.58 Favored Pre-proline 0 CA--C 1.532 0.278 0 C-N-CA 123.956 0.902 . . . . 0.0 112.486 -175.228 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -72.76 4.25 3.74 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 124.159 3.239 . . . . 0.0 112.358 178.306 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.5 140.43 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 123.279 0.631 . . . . 0.0 109.454 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.0 m -128.16 145.37 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 CA-C-O 121.199 0.523 . . . . 0.0 110.831 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -96.9 134.4 40.28 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.241 1.016 . . . . 0.0 109.932 177.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.415 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.1 mp -107.4 145.78 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.432 0.693 . . . . 0.0 109.408 -178.129 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.0 mtt180 -141.33 160.98 38.99 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.64 0.776 . . . . 0.0 109.892 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.84 28.49 50.54 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-O 119.545 -0.586 . . . . 0.0 113.438 175.122 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.9 mt -57.73 154.88 10.97 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 118.241 1.02 . . . . 0.0 109.877 177.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -68.19 -39.39 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.077 0 O-C-N 122.084 -0.385 . . . . 0.0 111.071 -176.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -171.62 -35.92 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.307 1.043 . . . . 0.0 109.742 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.48 55.92 0.04 OUTLIER Glycine 0 C--N 1.339 0.718 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -177.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.7 m -52.75 151.17 1.1 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-N 117.076 0.438 . . . . 0.0 110.511 178.265 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.7 m -87.46 166.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.953 0.406 . . . . 0.0 111.262 -177.004 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -61.99 -23.71 66.58 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.163 0.585 . . . . 0.0 111.242 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.31 -6.03 57.28 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -92.9 -35.14 13.5 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.565 0.62 . . . . 0.0 110.213 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 91.4 mt -73.25 -36.28 66.36 Favored 'General case' 0 N--CA 1.454 -0.274 0 O-C-N 122.385 -0.197 . . . . 0.0 111.266 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -76.97 -31.04 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.317 -177.232 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -82.14 -17.68 45.54 Favored 'General case' 0 N--CA 1.455 -0.219 0 O-C-N 122.185 -0.322 . . . . 0.0 111.167 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -9.13 18.31 Favored 'General case' 0 N--CA 1.455 -0.21 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.0 mt -120.82 -8.97 9.37 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -69.3 -7.19 34.79 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.866 0.757 . . . . 0.0 111.687 177.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -76.91 -14.99 59.81 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 122.025 -0.422 . . . . 0.0 110.731 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -96.08 -16.82 21.34 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.578 0.351 . . . . 0.0 111.592 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.4 176.55 34.6 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -70.59 140.75 40.24 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 123.889 3.06 . . . . 0.0 110.877 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 78.3 mt -110.81 146.63 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.083 0 C-N-CA 122.816 0.446 . . . . 0.0 110.487 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -106.43 -42.5 5.0 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.009 0.524 . . . . 0.0 111.478 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -159.11 159.28 34.32 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 120.837 0.351 . . . . 0.0 111.231 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.6 t -143.78 146.57 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.086 0 C-N-CA 124.001 0.92 . . . . 0.0 109.841 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.97 153.45 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.402 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 42.8 t -131.69 149.63 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.069 0 CA-C-O 120.717 0.294 . . . . 0.0 110.595 -176.233 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 81.55 67.52 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -60.29 -17.67 48.11 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.811 3.008 . . . . 0.0 112.877 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -82.9 -4.28 57.97 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.802 0.441 . . . . 0.0 111.484 179.03 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -129.23 4.04 5.22 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.861 0.864 . . . . 0.0 111.194 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 3.3 tpt180 54.58 30.44 13.16 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 123.847 0.859 . . . . 0.0 112.058 -177.348 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -138.89 166.59 24.05 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 123.119 0.568 . . . . 0.0 110.813 -174.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.98 172.17 16.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.213 0.605 . . . . 0.0 110.487 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.5 mt -134.14 146.48 50.26 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.443 0.697 . . . . 0.0 109.794 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.91 132.7 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.349 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -115.81 122.29 44.97 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.0 m-85 -87.89 156.03 19.57 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -178.619 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.3 -14.24 60.87 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.563 -178.08 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -149.49 153.47 37.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.68 0.792 . . . . 0.0 108.935 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.4 p -67.64 -20.92 26.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 O-C-N 122.175 -0.328 . . . . 0.0 111.717 -176.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.2 tp -74.52 -27.08 60.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 117.867 0.303 . . . . 0.0 110.997 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.91 -32.47 60.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.29 -29.39 34.31 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 117.018 0.409 . . . . 0.0 110.518 177.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -73.63 -19.28 60.9 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 122.681 0.392 . . . . 0.0 110.92 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -93.63 -17.27 23.46 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 122.191 -0.318 . . . . 0.0 111.03 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.33 -31.98 26.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 O-C-N 121.912 -0.492 . . . . 0.0 111.386 -178.07 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 37.0 t -85.75 -15.29 10.46 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 178.091 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -71.52 -7.67 49.06 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.784 0.434 . . . . 0.0 110.875 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 71.7 t80 -113.73 -36.93 4.71 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.621 0.369 . . . . 0.0 110.982 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.87 -7.17 59.68 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.44 -2.72 56.51 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 122.283 -0.261 . . . . 0.0 111.592 177.055 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -141.19 -7.88 1.02 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 122.73 0.412 . . . . 0.0 112.053 179.335 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -145.41 170.4 16.42 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.332 0.653 . . . . 0.0 109.982 -179.057 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -86.17 155.98 20.52 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -125.53 135.58 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -88.05 156.35 19.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 122.014 -0.429 . . . . 0.0 110.585 -178.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 62.9 mt -137.53 -43.79 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.536 -178.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.01 31.47 3.57 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.326 0.651 . . . . 0.0 111.185 -177.518 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.22 6.37 78.54 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.19 151.81 79.52 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.119 0.968 . . . . 0.0 109.142 177.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -71.86 143.61 41.6 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 123.558 2.839 . . . . 0.0 111.764 -176.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.76 -173.87 4.61 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 125.238 1.415 . . . . 0.0 108.395 177.548 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.01 160.12 40.53 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 121.042 0.448 . . . . 0.0 111.666 -178.22 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.6 p -149.74 144.98 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 C-N-CA 123.398 0.679 . . . . 0.0 110.064 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -156.43 163.99 38.79 Favored 'General case' 0 N--CA 1.456 -0.148 0 C-N-CA 123.264 0.626 . . . . 0.0 110.148 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -61.95 164.26 6.75 Favored 'General case' 0 C--O 1.231 0.086 0 CA-C-O 120.556 0.217 . . . . 0.0 110.618 177.689 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 47.2 t -148.38 152.57 37.24 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 120.731 0.301 . . . . 0.0 110.461 177.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 60.1 p -75.75 -1.63 25.87 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 122.558 0.343 . . . . 0.0 111.097 178.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 68.4 m -59.69 -36.18 75.97 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 122.975 0.51 . . . . 0.0 110.827 179.004 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 47.72 -1.51 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 128.001 2.52 . . . . 0.0 116.157 177.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 15.9 tppt? -163.64 142.66 8.04 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 124.312 1.045 . . . . 0.0 109.003 -177.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 69.2 mt -98.22 148.05 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.264 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 173.176 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 34.2 t -80.82 142.32 33.81 Favored 'General case' 0 N--CA 1.455 -0.177 0 O-C-N 122.272 -0.268 . . . . 0.0 111.35 -177.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 85.0 mtm180 46.43 51.22 9.56 Favored Pre-proline 0 CA--C 1.534 0.343 0 C-N-CA 124.665 1.186 . . . . 0.0 113.208 177.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -79.07 -5.15 14.35 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 123.42 2.746 . . . . 0.0 112.151 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -168.54 7.03 0.05 OUTLIER Glycine 0 CA--C 1.529 0.913 0 CA-C-O 119.661 -0.521 . . . . 0.0 112.986 -178.007 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -143.88 151.03 39.32 Favored 'General case' 0 N--CA 1.456 -0.129 0 CA-C-N 117.779 0.789 . . . . 0.0 110.029 -178.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 17.8 t -151.78 167.71 27.38 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.096 0.559 . . . . 0.0 110.202 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -141.75 155.73 45.62 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.298 0.639 . . . . 0.0 110.768 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -138.87 164.53 29.41 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 123.588 0.755 . . . . 0.0 110.512 -178.145 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 75.8 p -69.19 156.09 39.3 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.795 0.331 . . . . 0.0 111.086 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.7 mpt_? -84.13 163.71 19.63 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 122.872 0.469 . . . . 0.0 110.8 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 17.5 t -139.0 24.96 2.54 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.453 0.701 . . . . 0.0 110.548 -177.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.37 165.93 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.135 0 C-N-CA 124.019 0.928 . . . . 0.0 110.086 -177.281 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -71.12 131.51 43.69 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 32.3 t . . . . . 0 C--O 1.251 1.147 0 CA-C-O 117.251 -1.357 . . . . 0.0 110.178 179.874 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.194 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -149.82 167.22 27.18 Favored 'General case' 0 C--N 1.334 -0.09 0 C-N-CA 122.993 0.517 . . . . 0.0 110.921 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -90.48 36.47 0.89 Allowed 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.178 0.591 . . . . 0.0 110.432 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 56.21 28.4 13.12 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.536 0.734 . . . . 0.0 111.944 -176.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -144.51 163.47 33.76 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.972 0.909 . . . . 0.0 109.815 -178.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -121.83 64.78 18.06 Favored Pre-proline 0 CA--C 1.535 0.366 0 C-N-CA 123.857 0.863 . . . . 0.0 110.891 -178.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -72.6 -16.62 26.93 Favored 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.674 2.916 . . . . 0.0 112.776 -174.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -149.57 8.88 0.7 Allowed 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 -177.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -89.23 165.1 14.65 Favored 'General case' 0 C--O 1.231 0.095 0 O-C-N 121.944 -0.473 . . . . 0.0 110.556 178.065 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 58.5 p -136.46 155.06 77.25 Favored Pre-proline 0 C--O 1.231 0.098 0 C-N-CA 123.202 0.601 . . . . 0.0 110.344 -179.151 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -74.88 -4.25 15.13 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 124.058 3.172 . . . . 0.0 112.481 178.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.29 35.44 13.71 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.274 0.63 . . . . 0.0 112.208 -178.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 65.5 m -60.88 158.65 31.91 Favored Pre-proline 0 N--CA 1.455 -0.215 0 C-N-CA 123.9 0.88 . . . . 0.0 111.883 -178.27 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -70.41 0.44 6.14 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 124.158 3.239 . . . . 0.0 111.773 176.404 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.1 t -112.4 139.9 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 123.6 0.76 . . . . 0.0 109.239 177.47 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.6 m -128.91 152.82 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 CA-C-O 121.08 0.467 . . . . 0.0 110.728 178.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -102.45 137.86 40.14 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.709 0.804 . . . . 0.0 110.112 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 18.8 mm -106.49 144.59 15.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 C-N-CA 123.527 0.731 . . . . 0.0 109.799 -178.228 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -143.14 160.95 39.46 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.07 0.548 . . . . 0.0 110.698 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.96 23.87 60.87 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-O 119.77 -0.461 . . . . 0.0 113.151 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 56.1 mt -60.34 157.55 13.48 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 117.952 0.876 . . . . 0.0 109.979 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 16.5 pt -72.34 -37.32 57.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 O-C-N 122.244 -0.285 . . . . 0.0 111.35 -176.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -172.92 -36.93 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 123.887 0.875 . . . . 0.0 109.7 -179.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 171.21 61.84 0.04 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -176.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.2 m -52.31 154.66 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 122.688 0.395 . . . . 0.0 110.608 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.45 HG12 ' H ' ' A' ' 111' ' ' ALA . 8.7 t -76.99 155.64 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 CA-C-O 120.936 0.398 . . . . 0.0 110.473 -175.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -59.4 -26.88 65.52 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.723 0.409 . . . . 0.0 110.239 174.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.45 ' H ' HG12 ' A' ' 109' ' ' VAL . . . -81.79 -6.83 59.41 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.513 0.725 . . . . 0.0 111.886 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -90.08 -34.11 16.04 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 118.341 0.519 . . . . 0.0 109.999 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.0 mt -73.52 -34.97 65.49 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 122.573 0.349 . . . . 0.0 111.373 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.89 -30.59 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.135 0 CA-C-N 118.041 0.382 . . . . 0.0 110.428 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -82.84 -15.81 50.13 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 119.526 -0.273 . . . . 0.0 111.155 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -11.15 16.96 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -119.26 -9.18 9.99 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 118.6 0.636 . . . . 0.0 112.535 -178.39 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -69.82 -6.9 35.49 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.156 0.889 . . . . 0.0 111.874 177.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -76.5 -12.64 60.07 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 122.117 -0.365 . . . . 0.0 110.695 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -100.1 -19.97 16.23 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 122.678 0.391 . . . . 0.0 111.337 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 166.05 175.97 36.93 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.396 -0.681 . . . . 0.0 111.396 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -71.33 141.42 38.96 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 123.918 3.079 . . . . 0.0 110.505 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 76.2 mt -112.61 146.26 17.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 122.875 0.47 . . . . 0.0 110.226 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.0 t -103.58 -44.81 5.01 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.009 0.523 . . . . 0.0 111.216 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' TYR . . . . . 0.462 ' CE2' ' HA ' ' A' ' 177' ' ' PRO . 58.2 t80 -158.84 162.08 36.95 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-O 120.852 0.358 . . . . 0.0 111.465 178.582 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 95.2 t -142.55 144.81 24.15 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 124.167 0.987 . . . . 0.0 109.673 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.42 153.02 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.097 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 175.206 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 41.3 t -130.6 148.21 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.1 0 CA-C-O 120.604 0.24 . . . . 0.0 110.986 -175.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 84.0 60.52 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.808 0.843 . . . . 0.0 109.087 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.22 -12.32 33.64 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 123.489 2.793 . . . . 0.0 111.725 -176.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.9 tptt -76.94 -12.15 59.91 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 122.869 0.468 . . . . 0.0 110.9 177.279 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -129.29 6.92 5.36 Favored 'General case' 0 C--N 1.34 0.163 0 C-N-CA 123.636 0.775 . . . . 0.0 111.904 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 53.9 33.93 18.33 Favored 'General case' 0 N--CA 1.463 0.183 0 C-N-CA 124.449 1.1 . . . . 0.0 112.197 -177.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -136.66 166.26 23.98 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.175 0.59 . . . . 0.0 110.637 -177.078 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.91 172.36 16.34 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.673 0.389 . . . . 0.0 110.49 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 37.2 mt -131.32 149.05 52.71 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 123.406 0.682 . . . . 0.0 110.166 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -140.11 133.32 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.199 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -114.21 120.71 41.39 Favored 'General case' 0 N--CA 1.452 -0.325 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 177.249 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -85.83 152.22 23.18 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.041 0.448 . . . . 0.0 110.018 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -71.34 -15.15 62.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.349 -178.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.12 152.45 39.3 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.744 0.818 . . . . 0.0 109.469 177.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.0 p -68.89 -21.45 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 O-C-N 122.18 -0.325 . . . . 0.0 111.751 -175.279 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.6 tp -75.25 -28.89 60.02 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.83 -0.544 . . . . 0.0 110.334 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.68 -29.62 71.17 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.69 -30.28 36.46 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 117.029 0.414 . . . . 0.0 110.5 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.14 -28.17 62.09 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 122.501 0.32 . . . . 0.0 110.67 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -79.21 -19.43 50.79 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 119.541 -0.266 . . . . 0.0 111.532 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -32.67 27.03 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 118.157 0.435 . . . . 0.0 111.467 -177.208 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 30.0 t -85.73 -17.51 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -69.44 -11.63 60.98 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.539 0.336 . . . . 0.0 111.08 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -112.0 -36.85 5.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.635 0.374 . . . . 0.0 111.0 178.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.03 -11.67 59.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -176.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.48 -0.26 56.55 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -135.44 -10.85 2.16 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 117.921 0.328 . . . . 0.0 111.503 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.6 t30 -153.97 164.09 39.01 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.601 0.76 . . . . 0.0 109.065 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.6 pm0 -81.32 154.7 26.38 Favored 'General case' 0 CA--C 1.529 0.139 0 O-C-N 121.8 -0.563 . . . . 0.0 109.783 174.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.06 135.57 61.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.521 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -87.75 153.83 21.04 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.077 -0.389 . . . . 0.0 110.708 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.4 mt -136.99 -43.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.662 0.385 . . . . 0.0 110.802 -177.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.14 30.64 3.92 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.103 0.561 . . . . 0.0 111.333 -176.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 88.27 4.25 77.75 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.037 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -131.44 152.49 80.59 Favored Pre-proline 0 C--O 1.233 0.219 0 C-N-CA 124.013 0.925 . . . . 0.0 109.318 177.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.72 146.18 48.0 Favored 'Trans proline' 0 N--CA 1.453 -0.884 0 C-N-CA 123.438 2.759 . . . . 0.0 111.573 -176.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.43 -175.75 5.41 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.952 1.301 . . . . 0.0 109.021 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -139.42 160.76 39.08 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 121.174 0.511 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 2.9 p -147.76 141.18 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 123.962 0.905 . . . . 0.0 109.532 177.568 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -156.81 161.93 39.73 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -64.27 168.06 6.02 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-O 121.025 0.44 . . . . 0.0 110.541 177.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 93.5 p -146.35 178.9 7.9 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 123.152 0.581 . . . . 0.0 109.856 176.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 54.5 p -75.52 2.15 12.38 Favored 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 122.274 0.23 . . . . 0.0 111.212 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 70.9 m -81.51 152.23 27.41 Favored 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 123.012 0.525 . . . . 0.0 110.988 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 18.6 pt20 -133.2 0.27 3.39 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 123.32 0.648 . . . . 0.0 110.643 176.322 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 3.3 tppp? -152.88 136.29 15.86 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.48 1.112 . . . . 0.0 108.689 -178.227 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 19.4 tt -82.38 153.87 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 123.012 0.525 . . . . 0.0 110.18 178.242 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.7 m -74.75 130.99 40.46 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -174.029 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 40.37 65.3 4.09 Favored Pre-proline 0 CA--C 1.532 0.259 0 C-N-CA 125.313 1.445 . . . . 0.0 112.799 172.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' PRO . . . . . 0.462 ' HA ' ' CE2' ' A' ' 125' ' ' TYR . 86.1 Cg_endo -73.85 -7.1 19.6 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 123.23 2.62 . . . . 0.0 112.335 179.282 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 64.4 -130.19 37.55 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 176.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -126.98 178.71 5.81 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.838 0.855 . . . . 0.0 110.466 -177.03 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.4 m -71.49 2.36 5.14 Favored 'General case' 0 CA--C 1.529 0.136 0 C-N-CA 123.155 0.582 . . . . 0.0 112.458 -178.461 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -145.57 147.72 32.39 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.311 0.645 . . . . 0.0 110.21 177.395 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -151.73 143.66 23.8 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.345 0.658 . . . . 0.0 109.845 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 38.4 t -78.86 122.67 26.39 Favored 'General case' 0 C--O 1.232 0.155 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 94.9 mtt180 -146.87 167.75 23.16 Favored 'General case' 0 CA--C 1.523 -0.081 0 C-N-CA 123.453 0.701 . . . . 0.0 110.509 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 66.2 m -68.26 -0.33 4.62 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.292 1.037 . . . . 0.0 111.994 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 4.0 t -124.52 11.75 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 C-N-CA 123.734 0.813 . . . . 0.0 109.753 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -134.54 22.92 3.68 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 123.125 0.57 . . . . 0.0 110.45 -178.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 C--O 1.249 1.069 0 CA-C-O 116.914 -1.517 . . . . 0.0 111.577 -179.444 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.113 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -73.46 -20.44 60.7 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 116.925 0.363 . . . . 0.0 110.52 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -150.14 139.12 21.01 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 174.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.409 ' CG ' ' N ' ' A' ' 88' ' ' ASP . 25.1 t80 51.09 -160.9 0.08 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 123.357 0.411 . . . . 0.0 111.216 -179.536 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ASP . . . . . 0.409 ' N ' ' CG ' ' A' ' 87' ' ' TYR . 38.0 t70 -69.47 -26.44 64.57 Favored 'General case' 0 N--CA 1.454 -0.226 0 O-C-N 121.745 -0.597 . . . . 0.0 109.59 175.101 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -155.89 143.99 14.34 Favored Pre-proline 0 CA--C 1.532 0.268 0 C-N-CA 124.142 0.977 . . . . 0.0 109.08 174.499 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -78.79 -30.6 2.85 Favored 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.945 2.43 . . . . 0.0 113.36 -176.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 4.7 p-80 -161.01 10.62 0.09 Allowed 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 113.197 0.814 . . . . 0.0 113.197 -175.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -77.45 171.29 15.12 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.273 0.488 . . . . 0.0 111.343 -176.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.4 p -138.0 154.88 74.66 Favored Pre-proline 0 C--O 1.232 0.139 0 C-N-CA 123.4 0.68 . . . . 0.0 109.879 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -76.09 -5.82 16.68 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 123.658 2.906 . . . . 0.0 112.119 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.41 34.89 9.85 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.332 0.653 . . . . 0.0 111.986 -178.106 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 66.2 m -61.9 158.24 44.75 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 124.088 0.955 . . . . 0.0 111.509 -177.084 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -69.53 1.36 4.35 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 124.138 3.225 . . . . 0.0 112.374 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.8 t -116.53 141.28 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.6 m -129.81 151.85 36.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-O 120.92 0.391 . . . . 0.0 110.958 178.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.4 t-80 -100.93 135.05 42.99 Favored 'General case' 0 N--CA 1.457 -0.086 0 C-N-CA 124.068 0.947 . . . . 0.0 109.974 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -109.93 145.18 16.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 -177.297 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -141.67 163.7 32.21 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 123.602 0.761 . . . . 0.0 110.481 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 25.56 56.15 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-O 119.452 -0.638 . . . . 0.0 113.611 172.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.8 mt -61.68 158.15 16.11 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.185 0.992 . . . . 0.0 110.186 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 12.4 pt -73.1 -39.94 57.74 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -173.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -172.78 -37.44 0.01 OUTLIER 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.243 0.617 . . . . 0.0 110.246 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.22 52.25 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -176.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 65.1 t -51.11 146.04 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.158 0.583 . . . . 0.0 110.082 178.381 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.4 m -95.74 163.69 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 CA-C-O 121.18 0.514 . . . . 0.0 111.47 -175.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -60.47 -28.02 68.01 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 123.27 0.628 . . . . 0.0 111.215 -178.47 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.79 -6.44 55.96 Favored 'General case' 0 CA--C 1.53 0.187 0 N-CA-C 112.294 0.479 . . . . 0.0 112.294 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -101.47 -31.03 11.09 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 176.026 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 76.5 mt -71.36 -41.21 70.01 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.515 0.326 . . . . 0.0 110.654 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.5 p -77.56 -29.63 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 121.278 -0.169 . . . . 0.0 110.915 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.2 mt-10 -85.87 -13.35 48.2 Favored 'General case' 0 N--CA 1.454 -0.225 0 O-C-N 122.006 -0.434 . . . . 0.0 111.365 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.21 -15.15 16.09 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.94 -7.21 13.17 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.522 0.601 . . . . 0.0 112.457 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -72.46 -5.55 37.51 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.662 0.665 . . . . 0.0 111.537 176.177 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -74.96 -16.13 60.65 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.493 0.317 . . . . 0.0 110.544 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.83 -17.21 21.32 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 122.537 0.335 . . . . 0.0 111.824 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.88 178.0 37.11 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.16 140.31 37.22 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 123.86 3.04 . . . . 0.0 110.821 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.5 mt -112.42 144.4 20.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 C-N-CA 122.993 0.517 . . . . 0.0 110.519 -178.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -102.77 -42.25 5.93 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.362 0.665 . . . . 0.0 111.05 -178.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -158.57 160.09 36.22 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.712 0.291 . . . . 0.0 111.275 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 84.9 t -143.97 147.6 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.053 0 C-N-CA 123.761 0.824 . . . . 0.0 109.841 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.3 p -148.0 154.57 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 176.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 9.5 p -136.93 151.45 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.07 0 CA-C-O 120.824 0.345 . . . . 0.0 110.948 -178.229 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -130.26 84.44 59.87 Favored Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.855 0.862 . . . . 0.0 109.004 179.738 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -59.54 -18.54 47.57 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.897 3.064 . . . . 0.0 112.779 -179.534 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -82.02 -5.8 58.65 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.08 0.552 . . . . 0.0 111.316 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -129.05 2.58 5.26 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.722 0.809 . . . . 0.0 111.461 178.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.4 tpp85 53.37 32.5 13.9 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.496 1.118 . . . . 0.0 112.0 -177.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -136.43 166.4 23.58 Favored 'General case' 0 CA--C 1.527 0.094 0 C-N-CA 123.144 0.578 . . . . 0.0 110.941 -176.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 171.4 17.3 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.88 0.472 . . . . 0.0 110.819 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.32 146.71 50.23 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 123.769 0.828 . . . . 0.0 109.797 178.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.8 t -136.64 131.96 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.231 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.45 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -112.23 116.11 29.9 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -84.54 152.6 23.8 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.835 0.35 . . . . 0.0 110.481 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -73.08 -14.5 61.41 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.409 -178.303 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -147.2 151.34 36.57 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.696 0.798 . . . . 0.0 109.103 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.2 p -67.39 -19.85 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 O-C-N 122.29 -0.256 . . . . 0.0 111.484 -175.65 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.9 tp -75.08 -27.24 59.85 Favored 'General case' 0 N--CA 1.454 -0.236 0 O-C-N 121.986 -0.446 . . . . 0.0 110.498 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.91 -31.2 69.85 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.36 -29.99 33.89 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 116.956 0.378 . . . . 0.0 110.395 177.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.46 -26.48 63.66 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 122.716 0.406 . . . . 0.0 110.825 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -84.05 -20.3 32.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.192 -0.318 . . . . 0.0 111.646 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.47 -29.1 26.31 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 118.125 0.42 . . . . 0.0 112.075 -175.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -89.63 -15.49 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.444 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -75.0 0.12 16.95 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.768 0.427 . . . . 0.0 111.038 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -120.17 -38.73 2.88 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.842 0.457 . . . . 0.0 110.852 177.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.29 -4.66 58.99 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.68 -4.13 58.34 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 122.103 -0.373 . . . . 0.0 111.506 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -141.66 -4.17 1.11 Allowed 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 122.609 0.364 . . . . 0.0 111.59 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -146.29 170.57 16.49 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.534 0.734 . . . . 0.0 109.972 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -90.84 153.16 20.42 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 172.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.48 135.18 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -88.55 150.61 23.0 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 122.01 -0.431 . . . . 0.0 110.749 -178.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.1 mt -136.97 -39.1 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.789 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.18 29.28 3.71 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 123.085 0.554 . . . . 0.0 110.937 -177.051 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.48 5.02 85.29 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -176.434 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -130.41 152.28 80.01 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 124.266 1.026 . . . . 0.0 109.144 177.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.52 144.21 44.45 Favored 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.076 2.518 . . . . 0.0 111.825 -176.557 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.96 -176.11 5.31 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 124.826 1.25 . . . . 0.0 109.024 177.679 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -139.46 161.13 38.24 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.949 0.404 . . . . 0.0 111.67 -178.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.6 p -150.04 143.27 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.411 0.684 . . . . 0.0 109.724 178.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -154.29 163.13 40.62 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.055 0.542 . . . . 0.0 109.989 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -63.31 164.31 9.15 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 120.904 0.383 . . . . 0.0 110.601 177.023 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 87.8 p -145.78 174.52 11.15 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 123.201 0.6 . . . . 0.0 109.766 176.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 57.8 p -77.35 -0.71 26.64 Favored 'General case' 0 C--O 1.232 0.152 0 C-N-CA 122.562 0.345 . . . . 0.0 111.132 178.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 49.4 m -77.31 150.1 35.26 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.285 0.634 . . . . 0.0 110.215 179.266 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -138.19 -3.85 1.74 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 122.795 0.438 . . . . 0.0 111.202 177.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -158.24 135.51 10.1 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.932 0.893 . . . . 0.0 108.857 -178.611 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 73.1 mt -93.15 147.85 5.15 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 175.377 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 39.6 m -75.45 141.31 43.16 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-O 120.429 0.157 . . . . 0.0 111.401 -176.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 70.0 ttt180 45.17 56.04 14.65 Favored Pre-proline 0 CA--C 1.535 0.394 0 C-N-CA 124.745 1.218 . . . . 0.0 112.539 177.207 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -80.45 5.04 6.36 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 123.605 2.87 . . . . 0.0 112.007 -177.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 80.55 6.16 89.48 Favored Glycine 0 CA--C 1.531 1.045 0 O-C-N 122.085 -0.384 . . . . 0.0 112.32 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -74.93 161.58 29.39 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 117.428 0.614 . . . . 0.0 110.683 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 88.7 p -140.21 163.67 32.13 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 123.093 0.557 . . . . 0.0 110.998 -178.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -109.58 7.62 24.68 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.214 0.606 . . . . 0.0 111.887 -178.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -145.35 157.99 43.92 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 122.845 0.458 . . . . 0.0 110.443 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 51.0 m -134.22 166.93 21.64 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 123.301 0.64 . . . . 0.0 110.591 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 11.4 tpp85 -148.98 163.32 37.84 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-O 120.523 0.201 . . . . 0.0 110.634 -178.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 25.4 m -82.13 7.54 13.25 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.161 0.584 . . . . 0.0 112.285 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 34.1 m -135.42 161.02 39.9 Favored 'Isoleucine or valine' 0 C--N 1.34 0.164 0 C-N-CA 123.082 0.553 . . . . 0.0 110.395 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 45.8 t30 -144.03 15.0 1.7 Allowed 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 122.836 0.454 . . . . 0.0 110.529 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 49.4 m . . . . . 0 C--O 1.252 1.198 0 CA-C-O 117.628 -1.177 . . . . 0.0 110.441 -178.534 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.178 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -86.49 -6.29 58.94 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 117.124 0.462 . . . . 0.0 111.647 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -70.06 -11.2 60.71 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.111 0.564 . . . . 0.0 111.414 -177.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -92.92 3.41 55.76 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.152 0.581 . . . . 0.0 111.256 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -105.06 11.34 33.43 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.671 0.789 . . . . 0.0 110.638 178.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 49.05 49.92 8.33 Favored Pre-proline 0 CA--C 1.533 0.316 0 C-N-CA 124.764 1.225 . . . . 0.0 113.128 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -73.43 -20.03 21.32 Favored 'Trans proline' 0 N--CA 1.452 -0.934 0 C-N-CA 123.527 2.818 . . . . 0.0 112.079 -176.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -147.9 10.96 0.93 Allowed 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.167 0.587 . . . . 0.0 111.262 -178.556 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.7 mtpt -91.26 167.14 12.53 Favored 'General case' 0 N--CA 1.456 -0.127 0 C-N-CA 123.161 0.584 . . . . 0.0 110.574 -179.068 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 53.1 p -133.29 153.12 80.47 Favored Pre-proline 0 C--N 1.334 -0.098 0 C-N-CA 123.345 0.658 . . . . 0.0 110.437 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -75.94 -7.76 18.52 Favored 'Trans proline' 0 N--CA 1.453 -0.91 0 C-N-CA 123.838 3.026 . . . . 0.0 111.855 178.329 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.08 34.75 8.76 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.343 0.657 . . . . 0.0 111.31 -177.059 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.438 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.4 p -78.23 161.39 70.57 Favored Pre-proline 0 N--CA 1.456 -0.164 0 C-N-CA 123.938 0.895 . . . . 0.0 111.729 -174.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.438 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 96.4 Cg_endo -71.26 3.05 3.77 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.903 3.069 . . . . 0.0 112.504 177.623 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.7 t -115.02 141.39 31.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.116 0 C-N-CA 122.989 0.515 . . . . 0.0 109.877 178.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 20.9 m -126.69 152.57 34.59 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -107.7 141.01 39.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 124.079 0.952 . . . . 0.0 109.61 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 23.6 mm -111.23 143.82 20.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 122.883 0.473 . . . . 0.0 110.116 -175.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 -142.38 159.26 42.59 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 123.092 0.557 . . . . 0.0 110.176 -177.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.03 24.87 58.91 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.358 -0.69 . . . . 0.0 113.198 174.399 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.6 mt -60.52 157.87 13.36 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 118.234 1.017 . . . . 0.0 110.163 177.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.2 pt -70.88 -43.35 76.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -173.248 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -172.4 -34.5 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.375 0.67 . . . . 0.0 110.749 -179.111 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.9 49.07 0.11 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.704 -0.559 . . . . 0.0 111.704 -175.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.1 t -51.09 146.54 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 123.387 0.675 . . . . 0.0 110.026 178.386 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.2 m -101.33 166.41 2.42 Favored 'Isoleucine or valine' 0 C--N 1.337 0.045 0 CA-C-O 121.211 0.529 . . . . 0.0 111.584 -175.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.39 -27.48 67.47 Favored 'General case' 0 N--CA 1.456 -0.131 0 C-N-CA 123.196 0.598 . . . . 0.0 111.152 -177.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.46 -5.03 51.35 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -104.59 -30.86 9.72 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 175.369 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.6 mt -70.12 -38.41 75.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 122.506 0.322 . . . . 0.0 110.595 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -80.13 -29.63 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 CA-C-N 117.537 0.153 . . . . 0.0 110.731 -178.329 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.0 mm-40 -81.4 -13.91 57.75 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.28 -0.263 . . . . 0.0 111.321 -178.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -99.89 -25.97 14.16 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.2 mp -100.73 -9.76 21.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.921 0.711 . . . . 0.0 112.921 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -67.15 -8.63 32.55 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 118.604 0.638 . . . . 0.0 111.647 177.16 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.96 -14.62 59.1 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.663 0.385 . . . . 0.0 110.827 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -101.08 -18.31 16.29 Favored 'General case' 0 C--O 1.231 0.117 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -178.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.91 177.51 37.52 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -72.73 140.21 31.98 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 C-N-CA 124.268 3.312 . . . . 0.0 110.717 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 73.6 mt -110.07 146.69 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 C-N-CA 122.778 0.431 . . . . 0.0 110.3 -177.193 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -107.46 -40.16 5.43 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.158 0.583 . . . . 0.0 111.367 -177.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -159.52 158.44 31.83 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-O 120.739 0.304 . . . . 0.0 110.94 179.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 93.1 t -144.15 145.42 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.038 0 C-N-CA 123.924 0.89 . . . . 0.0 109.858 -178.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.3 p -148.31 152.74 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 12.4 p -130.22 156.58 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 CA-C-O 120.805 0.336 . . . . 0.0 111.156 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 48.6 mtt -130.45 78.14 74.73 Favored Pre-proline 0 C--O 1.232 0.168 0 C-N-CA 124.046 0.938 . . . . 0.0 109.54 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.62 -17.74 43.73 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 123.584 2.856 . . . . 0.0 113.048 -177.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.5 mtpt -89.52 -2.15 58.26 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.926 0.49 . . . . 0.0 111.807 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -130.84 0.39 4.3 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.652 0.781 . . . . 0.0 111.548 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 55.14 33.98 21.63 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.019 0.928 . . . . 0.0 111.861 -176.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -134.7 168.21 19.43 Favored 'General case' 0 C--O 1.232 0.14 0 C-N-CA 123.479 0.712 . . . . 0.0 110.602 -177.043 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.74 172.24 18.27 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.39 176.239 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.34 144.31 48.19 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.716 0.806 . . . . 0.0 109.468 177.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 77.9 t -137.0 131.29 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -113.44 120.26 40.44 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 58.7 m-85 -83.93 153.87 23.69 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.872 0.368 . . . . 0.0 110.361 -179.654 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -74.54 -12.58 60.51 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-O 120.907 0.384 . . . . 0.0 110.25 -178.526 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -149.54 152.48 35.62 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.843 0.857 . . . . 0.0 109.022 176.136 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.2 p -68.13 -20.43 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 O-C-N 122.031 -0.418 . . . . 0.0 111.657 -175.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.3 tp -71.96 -26.27 62.2 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.924 -0.485 . . . . 0.0 110.561 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.95 -31.47 64.45 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 178.516 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -84.42 -27.95 27.23 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 117.293 0.546 . . . . 0.0 110.555 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.1 t -77.89 -7.17 56.35 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 122.802 0.441 . . . . 0.0 110.602 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -107.14 -21.71 12.88 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.976 0.511 . . . . 0.0 110.754 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.42 -28.01 31.61 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 -178.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -91.01 -18.98 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -71.34 -14.24 62.13 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.36 0.264 . . . . 0.0 110.763 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -99.92 -36.79 9.28 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.568 0.347 . . . . 0.0 111.001 178.518 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -85.44 -6.43 59.21 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.832 0.678 . . . . 0.0 112.832 -176.021 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -78.64 -5.0 51.8 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 122.139 -0.351 . . . . 0.0 111.839 176.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -143.52 -3.59 0.91 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.58 0.352 . . . . 0.0 111.901 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 -145.42 175.09 10.58 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.455 0.702 . . . . 0.0 109.948 -178.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' GLN . . . . . 0.472 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.1 pm0 -96.94 152.68 18.47 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 173.162 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.17 134.44 63.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -89.55 148.91 23.11 Favored 'General case' 0 C--N 1.332 -0.17 0 O-C-N 122.193 -0.317 . . . . 0.0 110.71 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -136.01 -38.75 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.219 -176.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.37 29.45 3.63 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.112 0.565 . . . . 0.0 110.89 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.67 3.36 83.79 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -176.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -130.08 152.84 80.73 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 123.902 0.881 . . . . 0.0 108.968 177.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -72.11 145.97 45.45 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.306 2.671 . . . . 0.0 111.681 -176.259 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.48 -176.84 5.64 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.014 1.325 . . . . 0.0 108.475 177.443 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -137.84 160.02 40.43 Favored 'General case' 0 C--O 1.232 0.14 0 CA-C-O 120.885 0.374 . . . . 0.0 111.466 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.66 139.61 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 123.514 0.726 . . . . 0.0 110.174 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -159.98 150.7 18.98 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.445 0.698 . . . . 0.0 109.592 178.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -98.54 124.51 43.33 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 121.321 0.581 . . . . 0.0 111.801 178.008 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 27.5 t -166.46 150.04 7.25 Favored 'General case' 0 C--O 1.231 0.131 0 C-N-CA 122.926 0.49 . . . . 0.0 110.049 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 80.6 p 44.06 26.04 0.13 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.19 1.396 . . . . 0.0 114.291 177.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 67.1 p -149.48 149.63 31.08 Favored 'General case' 0 N--CA 1.456 -0.128 0 CA-C-O 120.914 0.388 . . . . 0.0 110.818 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.1 pt20 -150.36 -6.83 0.3 Allowed 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 116.187 -0.46 . . . . 0.0 112.215 176.178 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -158.96 137.36 10.77 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.752 0.821 . . . . 0.0 109.164 -178.106 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 66.2 mt -91.09 145.18 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 174.388 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.3 m -77.71 139.81 39.45 Favored 'General case' 0 C--N 1.335 -0.061 0 N-CA-C 111.56 0.208 . . . . 0.0 111.56 -177.118 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 28.5 mmt85 42.68 56.86 11.2 Favored Pre-proline 0 CA--C 1.534 0.346 0 C-N-CA 124.312 1.045 . . . . 0.0 112.625 177.66 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -77.75 56.88 5.81 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 124.316 3.344 . . . . 0.0 111.32 -177.354 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 81.49 9.73 85.4 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.511 -0.636 . . . . 0.0 111.511 -177.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -139.89 165.16 28.06 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.782 0.833 . . . . 0.0 109.505 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 80.1 p -119.85 164.8 15.48 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 123.058 0.543 . . . . 0.0 111.459 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -74.04 154.02 39.41 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 122.71 0.404 . . . . 0.0 111.121 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -86.83 -2.19 58.38 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.009 0.524 . . . . 0.0 111.25 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 63.6 m -90.22 8.73 31.64 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 123.37 0.668 . . . . 0.0 111.73 -179.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.6 tpt180 -140.74 148.19 40.31 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.215 0.606 . . . . 0.0 110.303 -178.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 57.9 m -139.07 138.32 37.01 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 177.024 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 10.4 m -148.8 163.33 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 C-N-CA 123.697 0.799 . . . . 0.0 108.999 -177.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -76.36 138.2 40.29 Favored 'General case' 0 N--CA 1.454 -0.271 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.7 m . . . . . 0 C--O 1.25 1.109 0 C-N-CA 124.422 1.089 . . . . 0.0 111.966 -179.882 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.096 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -145.91 149.88 35.06 Favored 'General case' 0 N--CA 1.456 -0.131 0 C-N-CA 123.239 0.615 . . . . 0.0 109.753 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -67.94 -15.27 63.54 Favored 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 111.748 0.277 . . . . 0.0 111.748 -174.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 -86.97 4.19 42.75 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.804 0.441 . . . . 0.0 111.471 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -108.35 10.22 27.63 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.495 0.718 . . . . 0.0 110.414 177.418 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 23.9 m-20 48.33 49.1 6.84 Favored Pre-proline 0 CA--C 1.533 0.29 0 C-N-CA 124.644 1.178 . . . . 0.0 112.775 -178.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -76.62 -12.99 18.31 Favored 'Trans proline' 0 N--CA 1.457 -0.663 0 C-N-CA 123.926 3.084 . . . . 0.0 113.538 -172.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -146.74 18.81 1.3 Allowed 'General case' 0 C--O 1.231 0.1 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -174.18 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -93.17 6.0 49.54 Favored 'General case' 0 CA--C 1.529 0.167 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -176.503 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 30.1 p -74.75 152.03 86.96 Favored Pre-proline 0 CA--C 1.529 0.139 0 O-C-N 122.121 -0.362 . . . . 0.0 110.693 178.751 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -78.78 -6.19 15.08 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 124.086 3.19 . . . . 0.0 112.314 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.41 34.47 12.04 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.564 0.746 . . . . 0.0 112.112 -177.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.1 m -70.97 159.0 86.92 Favored Pre-proline 0 CA--C 1.53 0.196 0 C-N-CA 123.446 0.698 . . . . 0.0 112.368 -176.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.05 -0.98 9.84 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 124.024 3.149 . . . . 0.0 111.769 174.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.5 t -112.0 142.49 24.21 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 123.431 0.692 . . . . 0.0 109.461 178.154 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 21.3 m -128.29 152.41 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 C-N-CA 122.835 0.454 . . . . 0.0 110.171 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 -106.15 136.41 45.89 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.971 0.909 . . . . 0.0 109.359 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.7 mm -106.07 142.4 19.14 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 C-N-CA 122.859 0.464 . . . . 0.0 109.859 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -141.67 160.44 40.17 Favored 'General case' 0 C--O 1.231 0.1 0 C-N-CA 123.231 0.612 . . . . 0.0 110.334 -178.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.16 23.11 61.82 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.13 174.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 63.8 mt -60.02 158.45 10.97 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 118.151 0.975 . . . . 0.0 109.708 177.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 13.7 pt -73.37 -43.6 56.02 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.035 0 O-C-N 122.275 -0.266 . . . . 0.0 111.686 -174.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.72 -34.83 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.14 0.576 . . . . 0.0 110.371 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -173.82 48.46 0.15 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -176.437 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.2 t -49.48 141.34 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 C-N-CA 122.835 0.454 . . . . 0.0 109.809 177.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.4 m -92.21 163.44 2.25 Favored 'Isoleucine or valine' 0 C--O 1.23 0.04 0 CA-C-O 121.157 0.504 . . . . 0.0 111.624 -174.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -61.83 -26.31 68.04 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.224 -177.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.23 -6.39 57.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.661 0.384 . . . . 0.0 112.0 -178.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.8 -29.71 13.59 Favored 'General case' 0 CA--C 1.527 0.063 0 O-C-N 121.743 -0.598 . . . . 0.0 109.822 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.0 mt -74.01 -37.51 64.36 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.284 0.234 . . . . 0.0 110.92 -178.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.7 p -77.99 -29.96 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.323 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -85.55 -13.07 50.03 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 122.023 -0.423 . . . . 0.0 111.709 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -109.2 -9.18 15.03 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.8 mt -118.51 -7.4 10.63 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.815 0.734 . . . . 0.0 112.265 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.0 pt20 -74.0 -5.35 40.86 Favored 'General case' 0 C--N 1.34 0.157 0 CA-C-N 118.794 0.725 . . . . 0.0 110.342 175.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -77.6 -4.48 46.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.587 0.755 . . . . 0.0 111.095 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -111.53 -15.91 13.4 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.318 0.647 . . . . 0.0 111.272 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.84 176.73 36.02 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -72.14 140.19 33.83 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.0 3.133 . . . . 0.0 110.571 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.2 mt -109.86 148.92 13.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 122.844 0.457 . . . . 0.0 110.457 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.3 t -111.05 -41.26 4.25 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.251 0.62 . . . . 0.0 111.784 -177.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -158.1 158.09 34.05 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 117.839 0.291 . . . . 0.0 111.462 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 67.1 t -144.05 146.91 20.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.085 0.954 . . . . 0.0 109.699 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -148.95 151.42 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.9 t -128.07 149.5 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.073 0 CA-C-O 120.612 0.244 . . . . 0.0 111.32 -175.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.5 mpp? -130.44 83.07 63.54 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.982 0.913 . . . . 0.0 108.564 177.184 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -69.41 -11.7 31.89 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 123.482 2.788 . . . . 0.0 111.577 -175.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -81.58 -10.5 59.43 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 122.95 0.5 . . . . 0.0 110.81 177.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -126.35 6.47 7.01 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.576 0.75 . . . . 0.0 111.646 -178.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 55.19 31.0 15.56 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 123.982 0.913 . . . . 0.0 112.432 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -136.79 167.34 21.63 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.149 0.58 . . . . 0.0 111.103 -175.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.05 172.84 16.25 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.978 0.511 . . . . 0.0 110.319 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.0 mt -133.03 146.55 51.83 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 123.308 0.643 . . . . 0.0 110.054 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.82 133.15 41.23 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -117.08 121.88 42.56 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.297 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.7 m-85 -87.08 156.28 19.8 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 121.067 0.461 . . . . 0.0 110.555 -178.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -76.3 -13.57 60.15 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.14 -179.26 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -146.74 150.91 36.29 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.575 0.75 . . . . 0.0 109.319 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.7 p -69.33 -21.8 25.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.6 tp -75.91 -29.77 58.53 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.85 -0.531 . . . . 0.0 110.203 -179.475 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.83 -28.22 73.25 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 -25.77 33.48 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 117.05 0.425 . . . . 0.0 110.962 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.55 -34.09 41.31 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -68.69 -21.28 64.43 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 119.712 -0.185 . . . . 0.0 110.87 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.39 -27.62 27.51 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -178.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.3 t -92.58 -23.03 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.06 0 O-C-N 122.154 -0.342 . . . . 0.0 110.888 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -71.62 -7.77 49.91 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.105 -0.372 . . . . 0.0 111.472 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -106.29 -34.43 7.47 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.677 0.391 . . . . 0.0 110.477 176.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -10.39 59.07 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.313 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.91 -0.56 56.74 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -136.87 -11.4 1.76 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 122.677 0.391 . . . . 0.0 111.71 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -153.25 170.34 20.83 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -87.6 155.13 20.1 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 175.158 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.3 135.56 60.18 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -177.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -90.36 150.54 21.84 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 121.952 -0.467 . . . . 0.0 110.772 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.2 mt -137.43 -39.02 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.457 -0.076 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.869 -176.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.57 28.84 3.61 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 123.139 0.576 . . . . 0.0 110.908 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.9 5.64 83.43 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -176.555 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -131.21 153.14 81.61 Favored Pre-proline 0 N--CA 1.453 -0.275 0 C-N-CA 124.175 0.99 . . . . 0.0 109.152 177.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -72.26 145.9 44.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 123.251 2.634 . . . . 0.0 111.701 -176.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.11 -177.25 6.05 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 124.778 1.231 . . . . 0.0 108.839 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -139.64 160.39 39.97 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 120.976 0.417 . . . . 0.0 111.357 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -148.59 139.51 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 C-N-CA 123.339 0.655 . . . . 0.0 110.213 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -159.05 150.97 20.86 Favored 'General case' 0 N--CA 1.455 -0.21 0 C-N-CA 123.227 0.611 . . . . 0.0 109.858 178.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -98.04 124.57 42.59 Favored 'General case' 0 N--CA 1.457 -0.117 0 CA-C-O 121.193 0.52 . . . . 0.0 111.918 177.181 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 28.4 t -165.75 148.53 7.57 Favored 'General case' 0 N--CA 1.456 -0.156 0 C-N-CA 122.841 0.457 . . . . 0.0 110.374 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 81.8 p 45.27 25.0 0.17 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 125.407 1.483 . . . . 0.0 114.324 176.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 71.2 p -148.95 149.91 32.01 Favored 'General case' 0 N--CA 1.457 -0.124 0 O-C-N 121.909 -0.495 . . . . 0.0 111.185 -179.088 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -149.72 -6.49 0.34 Allowed 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 176.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -159.87 137.38 9.75 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 123.543 0.737 . . . . 0.0 109.045 -177.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 66.9 mt -89.07 145.06 7.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.197 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 174.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.5 m -80.9 141.15 34.85 Favored 'General case' 0 C--O 1.231 0.106 0 N-CA-C 111.749 0.278 . . . . 0.0 111.749 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 82.5 mtp180 44.71 52.74 10.45 Favored Pre-proline 0 CA--C 1.533 0.291 0 C-N-CA 124.577 1.151 . . . . 0.0 113.181 177.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -75.81 176.58 9.83 Favored 'Trans proline' 0 N--CA 1.451 -1.004 0 C-N-CA 123.133 2.556 . . . . 0.0 110.918 -179.292 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 84.17 134.86 2.81 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 24.6 m-20 -72.84 164.34 26.75 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 123.319 0.648 . . . . 0.0 111.122 178.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 88.4 p -77.71 167.75 21.06 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 122.944 0.497 . . . . 0.0 110.954 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -125.7 1.8 7.49 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.106 0.562 . . . . 0.0 111.711 -178.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -150.59 155.52 39.58 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.102 0.561 . . . . 0.0 110.112 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 78.6 p -144.4 152.88 41.31 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.619 0.768 . . . . 0.0 109.255 177.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.0 ttm180 -152.43 164.86 36.69 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 120.719 0.295 . . . . 0.0 111.257 -175.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 41.4 m -92.08 10.48 29.01 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.183 0.593 . . . . 0.0 111.9 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 28.0 m -139.25 166.63 21.43 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 C-N-CA 123.41 0.684 . . . . 0.0 109.901 -178.018 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -74.09 133.37 42.85 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 63.6 m . . . . . 0 C--O 1.252 1.191 0 CA-C-O 117.642 -1.17 . . . . 0.0 110.531 -178.62 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.158 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -150.02 165.36 32.95 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.193 0.597 . . . . 0.0 110.812 -177.665 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.5 t30 -149.06 169.37 20.82 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 123.285 0.634 . . . . 0.0 109.894 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -75.11 -12.3 60.28 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 123.673 0.789 . . . . 0.0 111.711 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -150.15 155.26 39.48 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 123.416 0.686 . . . . 0.0 109.653 178.053 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -75.38 136.36 71.94 Favored Pre-proline 0 CA--C 1.533 0.313 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 -176.607 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -69.64 -24.05 30.64 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 123.604 2.869 . . . . 0.0 114.708 -174.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 2.8 p-80 -157.16 -3.69 0.1 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 115.672 1.73 . . . . 0.0 115.672 -174.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -81.61 157.23 24.78 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 119.585 1.084 . . . . 0.0 110.996 178.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.2 p -84.22 153.76 62.92 Favored Pre-proline 0 C--O 1.231 0.13 0 C-N-CA 123.13 0.572 . . . . 0.0 111.011 -178.363 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -79.55 -8.76 14.86 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 124.142 3.228 . . . . 0.0 111.556 177.63 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.79 35.03 14.34 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 123.711 0.804 . . . . 0.0 112.293 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.2 m -76.01 163.47 66.52 Favored Pre-proline 0 CA--C 1.531 0.244 0 C-N-CA 123.289 0.636 . . . . 0.0 112.577 -175.605 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -65.4 -7.43 15.92 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.983 3.122 . . . . 0.0 113.382 177.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -109.85 141.43 25.17 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 123.032 0.533 . . . . 0.0 109.993 -178.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 28.0 m -125.61 156.29 35.12 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.242 0.617 . . . . 0.0 110.091 176.61 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -116.41 131.61 56.9 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.875 0.87 . . . . 0.0 109.421 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.442 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.8 mp -106.17 144.82 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -174.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -141.93 163.08 33.85 Favored 'General case' 0 N--CA 1.46 0.063 0 C-N-CA 123.557 0.743 . . . . 0.0 110.392 -177.634 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.32 23.27 61.19 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.213 -0.771 . . . . 0.0 113.017 174.508 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 70.9 mt -59.86 156.27 14.66 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.436 1.118 . . . . 0.0 110.141 178.599 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.6 pt -70.83 -41.23 77.32 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -172.627 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -173.92 -34.39 0.01 OUTLIER 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.413 0.685 . . . . 0.0 110.648 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.91 48.09 0.12 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.8 t -51.39 143.14 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 177.233 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -97.78 165.51 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.064 0 CA-C-O 121.35 0.595 . . . . 0.0 111.886 -174.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.16 -26.24 66.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.537 0.735 . . . . 0.0 111.334 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.88 -6.88 58.25 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -97.7 -28.98 13.65 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 118.181 0.446 . . . . 0.0 110.16 177.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 89.4 mt -74.35 -36.09 63.61 Favored 'General case' 0 N--CA 1.455 -0.191 0 O-C-N 122.255 -0.278 . . . . 0.0 110.979 -178.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.9 p -79.1 -30.28 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.189 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -82.59 -15.39 52.39 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 119.423 -0.322 . . . . 0.0 111.474 -178.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.87 -12.53 15.17 Favored 'General case' 0 C--N 1.339 0.132 0 N-CA-C 113.11 0.781 . . . . 0.0 113.11 -179.598 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.4 mt -116.46 -9.32 11.47 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -69.19 -6.88 31.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 118.809 0.731 . . . . 0.0 111.424 176.554 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -76.68 -15.13 59.88 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.089 -0.382 . . . . 0.0 110.649 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -97.24 -17.77 19.63 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 122.558 0.343 . . . . 0.0 111.454 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.68 177.05 36.21 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.688 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -70.54 139.91 38.59 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.077 3.185 . . . . 0.0 110.768 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 77.7 mt -110.33 146.31 15.71 Favored 'Isoleucine or valine' 0 C--O 1.232 0.133 0 C-N-CA 122.765 0.426 . . . . 0.0 110.205 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -107.73 -40.2 5.36 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.383 0.673 . . . . 0.0 111.348 -177.392 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -157.73 158.83 36.08 Favored 'General case' 0 C--N 1.338 0.096 0 CA-C-O 120.559 0.219 . . . . 0.0 111.342 -179.472 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 59.0 t -144.05 145.27 22.0 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 C-N-CA 124.175 0.99 . . . . 0.0 109.549 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.8 p -149.34 152.46 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 34.2 t -130.41 150.8 35.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 CA-C-O 120.675 0.274 . . . . 0.0 111.251 -175.655 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.4 81.36 68.3 Favored Pre-proline 0 CA--C 1.531 0.238 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 177.329 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -59.97 -17.88 46.98 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.945 3.097 . . . . 0.0 112.862 -177.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 mtmt -83.48 -5.82 59.27 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.876 0.47 . . . . 0.0 111.326 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -126.55 2.71 6.88 Favored 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.733 0.813 . . . . 0.0 111.112 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.3 tpp85 54.14 32.73 16.41 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 124.035 0.934 . . . . 0.0 111.865 -176.126 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -137.18 165.3 26.43 Favored 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 123.119 0.567 . . . . 0.0 110.956 -176.425 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 169.92 20.55 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 122.953 0.501 . . . . 0.0 110.569 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.8 mt -131.65 145.6 51.75 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.509 0.724 . . . . 0.0 109.824 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.74 134.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -116.16 121.8 43.17 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -86.39 155.85 20.42 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.027 0.442 . . . . 0.0 110.576 -179.049 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -74.86 -13.14 60.52 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.558 -178.263 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -147.73 152.87 38.5 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.883 0.873 . . . . 0.0 109.038 177.075 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.97 -21.61 25.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -175.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.8 tp -74.79 -29.85 61.24 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 122.108 -0.37 . . . . 0.0 110.692 -179.251 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.25 -28.58 71.25 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 179.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.17 -30.37 27.86 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 117.079 0.439 . . . . 0.0 110.898 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.8 t -75.21 -28.73 60.08 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.1 t30 -78.33 -21.21 49.91 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.321 0.248 . . . . 0.0 110.722 179.382 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.22 -31.25 30.38 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.301 -0.249 . . . . 0.0 111.505 -178.867 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 60.1 t -88.36 -21.97 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 O-C-N 122.252 -0.28 . . . . 0.0 110.556 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -66.9 -17.05 64.71 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 122.194 -0.316 . . . . 0.0 110.96 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -100.05 -36.54 9.32 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.189 0.196 . . . . 0.0 110.645 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.59 -11.04 59.95 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -176.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -89.29 1.42 55.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.578 0.351 . . . . 0.0 111.847 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -134.44 -15.64 2.15 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.76 0.424 . . . . 0.0 111.588 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -153.26 168.2 26.81 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.494 0.718 . . . . 0.0 109.186 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -82.78 155.54 24.17 Favored 'General case' 0 N--CA 1.457 -0.092 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 175.251 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -121.61 135.48 61.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -177.46 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -89.67 151.83 21.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.102 -0.374 . . . . 0.0 110.789 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -138.14 -39.06 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.894 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.69 29.41 3.53 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 122.876 0.47 . . . . 0.0 111.041 -176.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.87 4.86 84.42 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -176.254 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -131.59 152.08 79.8 Favored Pre-proline 0 N--CA 1.454 -0.231 0 C-N-CA 124.115 0.966 . . . . 0.0 108.95 177.491 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -71.54 146.55 49.84 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 123.58 2.854 . . . . 0.0 111.88 -176.396 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.8 -175.72 5.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.651 1.18 . . . . 0.0 108.811 178.057 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -138.82 159.44 42.12 Favored 'General case' 0 N--CA 1.457 -0.099 0 CA-C-O 120.644 0.259 . . . . 0.0 111.005 -179.085 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.9 p -149.26 139.11 16.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 C-N-CA 123.341 0.657 . . . . 0.0 110.247 178.736 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -159.9 152.94 21.77 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.7 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -103.5 132.37 49.82 Favored 'General case' 0 CA--C 1.527 0.089 0 CA-C-O 121.385 0.612 . . . . 0.0 112.607 178.468 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 38.1 t -166.09 145.63 6.12 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.639 178.045 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 3.1 m 49.44 28.25 2.34 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.81 1.244 . . . . 0.0 113.457 173.802 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 34.6 t -151.36 152.11 32.67 Favored 'General case' 0 N--CA 1.458 -0.068 0 O-C-N 121.632 -0.668 . . . . 0.0 111.037 179.13 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -149.11 -3.73 0.43 Allowed 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 123.395 0.678 . . . . 0.0 111.752 176.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -160.57 133.76 6.64 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -176.435 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 70.8 mt -82.68 150.36 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.112 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 176.567 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 44.6 m -74.45 132.14 41.66 Favored 'General case' 0 N--CA 1.457 -0.096 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 -176.091 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' ARG . . . . . 0.447 ' N ' ' HD3' ' A' ' 177' ' ' PRO . 98.8 mtt180 39.44 56.75 6.31 Favored Pre-proline 0 CA--C 1.534 0.364 0 C-N-CA 125.495 1.518 . . . . 0.0 114.101 175.695 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 177' ' ' PRO . . . . . 0.447 ' HD3' ' N ' ' A' ' 176' ' ' ARG . 23.3 Cg_exo -68.18 -13.77 38.83 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.518 2.145 . . . . 0.0 112.237 -179.344 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -81.0 3.06 78.4 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-O 119.611 -0.549 . . . . 0.0 112.727 -178.288 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -66.88 146.92 53.89 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 118.059 0.93 . . . . 0.0 110.817 -179.428 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.4 m -141.35 14.89 2.2 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 123.652 0.781 . . . . 0.0 111.34 -177.03 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -73.47 150.25 41.77 Favored 'General case' 0 N--CA 1.455 -0.206 0 O-C-N 122.097 -0.377 . . . . 0.0 111.009 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -142.53 165.72 26.63 Favored 'General case' 0 N--CA 1.457 -0.121 0 C-N-CA 123.594 0.758 . . . . 0.0 110.324 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 65.6 p -79.8 -3.17 46.53 Favored 'General case' 0 C--O 1.232 0.169 0 C-N-CA 123.129 0.572 . . . . 0.0 112.151 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 24.0 tpt180 -148.2 148.26 30.34 Favored 'General case' 0 CA--C 1.523 -0.071 0 C-N-CA 123.077 0.551 . . . . 0.0 109.835 -178.021 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 51.1 m -82.58 132.55 35.19 Favored 'General case' 0 N--CA 1.456 -0.171 0 N-CA-C 110.0 -0.371 . . . . 0.0 110.0 177.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 17.7 m -146.36 161.29 10.35 Favored 'Isoleucine or valine' 0 C--O 1.231 0.124 0 C-N-CA 123.496 0.719 . . . . 0.0 110.238 -178.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -142.86 15.04 1.93 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 122.788 0.435 . . . . 0.0 110.791 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.5 m . . . . . 0 C--O 1.251 1.133 0 CA-C-O 117.278 -1.344 . . . . 0.0 109.887 -178.184 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.261 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -138.95 154.95 48.37 Favored 'General case' 0 C--O 1.23 0.078 0 C-N-CA 123.213 0.605 . . . . 0.0 110.538 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 56.53 176.85 0.04 OUTLIER 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.614 1.165 . . . . 0.0 113.186 -179.479 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -91.81 0.2 57.5 Favored 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 123.252 0.621 . . . . 0.0 111.087 178.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -150.12 162.19 40.9 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.149 0.98 . . . . 0.0 108.619 178.332 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 50.7 m-20 -62.41 120.7 61.36 Favored Pre-proline 0 CA--C 1.533 0.295 0 O-C-N 122.181 -0.325 . . . . 0.0 110.651 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -75.81 -28.26 8.04 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.364 2.709 . . . . 0.0 112.239 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 4.0 p-80 -157.41 0.72 0.11 Allowed 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -178.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -87.06 167.42 14.21 Favored 'General case' 0 C--O 1.23 0.064 0 CA-C-N 118.286 0.494 . . . . 0.0 110.558 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 54.9 p -124.51 154.63 69.65 Favored Pre-proline 0 C--O 1.231 0.096 0 C-N-CA 123.283 0.633 . . . . 0.0 110.63 -178.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -74.28 -4.0 14.72 Favored 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 123.734 2.956 . . . . 0.0 112.434 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.16 36.02 11.48 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.218 0.607 . . . . 0.0 111.446 -177.075 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.438 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.3 p -67.92 161.13 69.87 Favored Pre-proline 0 CA--C 1.531 0.249 0 C-N-CA 123.799 0.84 . . . . 0.0 111.586 -177.177 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.438 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 90.1 Cg_endo -70.49 5.7 1.87 Allowed 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 123.865 3.043 . . . . 0.0 112.119 177.377 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.3 t -117.85 139.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 C-N-CA 123.153 0.581 . . . . 0.0 109.864 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.2 m -131.37 146.83 33.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-O 120.911 0.386 . . . . 0.0 110.807 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.1 t-80 -96.58 137.41 35.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.845 0.858 . . . . 0.0 110.165 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.0 mp -111.77 145.82 17.45 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 123.552 0.741 . . . . 0.0 109.392 -177.716 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -142.56 164.94 28.75 Favored 'General case' 0 C--O 1.228 -0.04 0 C-N-CA 123.655 0.782 . . . . 0.0 110.724 -177.215 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.44 25.26 57.29 Favored Glycine 0 CA--C 1.525 0.711 0 CA-C-O 119.575 -0.569 . . . . 0.0 113.343 173.169 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.7 mt -60.33 156.5 15.61 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.987 0.894 . . . . 0.0 109.983 178.061 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.7 pt -71.84 -39.93 68.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 O-C-N 122.268 -0.27 . . . . 0.0 111.088 -175.277 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -172.92 -36.0 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.08 0 C-N-CA 123.612 0.765 . . . . 0.0 109.985 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 173.92 56.5 0.05 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -177.413 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.4 m -53.21 156.62 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 123.003 0.521 . . . . 0.0 110.782 178.361 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 111' ' ' ALA . 6.5 t -78.03 155.51 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 CA-C-O 121.032 0.444 . . . . 0.0 110.39 -176.341 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -60.76 -25.81 66.77 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.638 0.375 . . . . 0.0 110.265 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.42 ' H ' HG12 ' A' ' 109' ' ' VAL . . . -81.32 -8.27 59.71 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.079 0.551 . . . . 0.0 111.62 -179.15 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -85.7 -32.79 21.74 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.828 -0.545 . . . . 0.0 110.238 -179.397 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.1 mp -77.49 -30.94 53.28 Favored 'General case' 0 N--CA 1.456 -0.142 0 O-C-N 122.323 -0.236 . . . . 0.0 111.18 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.8 p -78.25 -31.76 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-N 118.18 0.445 . . . . 0.0 110.04 -178.55 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -82.23 -17.57 45.61 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 122.217 -0.302 . . . . 0.0 111.082 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.47 -10.34 18.62 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -117.6 -8.55 10.92 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.606 0.639 . . . . 0.0 112.21 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -67.54 -6.88 21.95 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 118.663 0.665 . . . . 0.0 111.874 175.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -76.59 -13.05 60.1 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.956 -0.465 . . . . 0.0 110.634 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -100.82 -16.9 17.13 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 122.567 0.347 . . . . 0.0 111.606 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.15 177.64 36.27 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -72.25 140.44 33.94 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.81 3.007 . . . . 0.0 110.52 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.2 mt -111.13 147.31 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.085 0 C-N-CA 122.75 0.42 . . . . 0.0 110.246 -177.519 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.8 t -107.63 -41.56 5.0 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.076 0.551 . . . . 0.0 111.656 -177.268 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 46.1 t80 -159.65 160.51 34.33 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 117.623 0.192 . . . . 0.0 111.258 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 88.9 t -143.65 146.51 21.04 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 C-N-CA 124.122 0.969 . . . . 0.0 109.829 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.8 p -144.19 151.4 16.12 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 174.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 60.4 t -133.36 149.73 31.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -176.676 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 72.1 mtm -134.41 86.66 34.69 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 123.612 0.765 . . . . 0.0 109.284 -179.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.35 -11.55 30.26 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 123.061 2.507 . . . . 0.0 111.649 -177.557 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -81.11 -10.34 59.67 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.062 0.545 . . . . 0.0 110.7 176.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -128.88 3.18 5.36 Favored 'General case' 0 C--N 1.34 0.155 0 C-N-CA 123.73 0.812 . . . . 0.0 111.353 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.7 tpp85 53.05 34.05 16.29 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.335 1.054 . . . . 0.0 111.964 -176.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -137.84 168.55 19.47 Favored 'General case' 0 C--N 1.334 -0.08 0 C-N-CA 123.402 0.681 . . . . 0.0 110.282 -177.4 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.98 170.86 19.37 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 123.139 0.576 . . . . 0.0 110.262 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 14.1 tp -137.54 142.87 41.38 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.169 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 92.0 t -137.8 141.55 38.56 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -176.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -120.79 124.76 45.86 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.43 0.692 . . . . 0.0 109.219 177.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -89.16 153.23 21.12 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 120.919 0.39 . . . . 0.0 110.303 178.886 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -73.32 -14.39 61.29 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.409 -177.768 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -146.75 151.25 36.86 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 176.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -67.49 -20.65 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.302 0.241 . . . . 0.0 111.558 -175.162 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.4 tp -75.92 -25.79 56.32 Favored 'General case' 0 N--CA 1.456 -0.165 0 O-C-N 122.09 -0.381 . . . . 0.0 110.485 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.14 -30.31 65.41 Favored Glycine 0 C--N 1.339 0.722 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.484 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.69 -31.55 28.53 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.025 0.412 . . . . 0.0 110.34 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 47.5 t -73.75 -19.67 60.72 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 122.705 0.402 . . . . 0.0 110.974 179.242 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 122.694 0.398 . . . . 0.0 111.315 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.36 -31.52 22.92 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 122.169 -0.332 . . . . 0.0 111.386 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.4 t -85.06 -13.53 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -72.52 -1.95 17.87 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.295 0.638 . . . . 0.0 111.212 178.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 53.1 t80 -124.02 -36.75 2.66 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.827 0.451 . . . . 0.0 110.914 178.692 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.59 -8.7 59.35 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -176.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.41 -0.89 57.45 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.721 0.408 . . . . 0.0 111.986 178.299 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -138.73 -12.56 1.3 Allowed 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -151.88 163.21 39.71 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 9.3 pm0 -76.59 159.71 30.06 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 122.06 -0.4 . . . . 0.0 110.027 177.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -126.74 136.17 61.59 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -89.2 152.73 21.43 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.092 -0.38 . . . . 0.0 110.654 -178.161 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 47.2 mt -137.67 -39.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.177 -177.652 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.22 28.94 3.72 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 122.819 0.448 . . . . 0.0 110.986 -177.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.1 5.61 80.11 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 -176.521 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -131.35 152.98 81.49 Favored Pre-proline 0 N--CA 1.453 -0.319 0 C-N-CA 124.228 1.011 . . . . 0.0 109.01 177.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -71.44 145.34 47.52 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.357 2.705 . . . . 0.0 111.751 -176.53 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.38 -174.93 4.98 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.945 1.298 . . . . 0.0 108.668 177.393 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.35 160.42 39.87 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 120.989 0.423 . . . . 0.0 111.28 -178.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.13 144.66 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 C-N-CA 123.66 0.784 . . . . 0.0 109.415 178.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -155.32 166.28 34.05 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 123.163 0.585 . . . . 0.0 110.047 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 82.1 m-85 -61.26 165.69 4.34 Favored 'General case' 0 N--CA 1.457 -0.106 0 CA-C-O 121.038 0.446 . . . . 0.0 110.73 178.101 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 38.1 t -138.26 163.89 30.63 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.166 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 59.7 p -75.35 -7.25 53.49 Favored 'General case' 0 N--CA 1.457 -0.109 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 174.559 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 35.6 t -78.17 157.24 29.47 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 123.67 0.788 . . . . 0.0 110.371 176.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -141.3 -2.37 1.27 Allowed 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 123.386 0.674 . . . . 0.0 111.131 177.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -161.2 133.66 6.03 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 123.51 0.724 . . . . 0.0 109.333 -177.475 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 27.1 mm -76.36 150.49 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.143 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 175.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 61.6 p -83.71 132.47 34.86 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-O 120.917 0.389 . . . . 0.0 110.817 179.496 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 45.21 53.12 11.54 Favored Pre-proline 0 CA--C 1.536 0.405 0 C-N-CA 124.55 1.14 . . . . 0.0 113.527 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -76.86 -7.64 17.54 Favored 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 123.64 2.893 . . . . 0.0 111.775 -178.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 172.44 -1.78 0.03 OUTLIER Glycine 0 CA--C 1.529 0.957 0 CA-C-O 119.751 -0.472 . . . . 0.0 112.426 -178.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -146.21 164.06 33.46 Favored 'General case' 0 CA--C 1.53 0.212 0 CA-C-N 117.713 0.757 . . . . 0.0 109.758 178.324 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.2 m -66.07 143.03 57.58 Favored 'General case' 0 CA--C 1.528 0.11 0 CA-C-O 120.964 0.412 . . . . 0.0 110.886 -178.506 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -155.78 160.62 40.42 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.258 0.623 . . . . 0.0 110.233 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -142.13 23.33 2.03 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.116 0.566 . . . . 0.0 110.645 178.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 32.6 m 54.17 35.32 22.2 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 123.421 0.688 . . . . 0.0 112.327 -179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -124.98 177.39 6.08 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 123.427 0.691 . . . . 0.0 110.97 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.6 m -126.85 12.65 7.31 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 123.495 0.718 . . . . 0.0 111.857 -178.294 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 33.3 m -135.93 169.45 20.63 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 C-N-CA 123.616 0.766 . . . . 0.0 110.694 -177.236 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -135.43 17.87 3.37 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 122.904 0.481 . . . . 0.0 110.747 178.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 45.8 m . . . . . 0 C--O 1.251 1.143 0 CA-C-O 117.514 -1.231 . . . . 0.0 110.719 -179.629 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.166 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -146.48 149.85 34.46 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 122.937 0.495 . . . . 0.0 110.155 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -142.88 165.48 27.25 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.466 0.707 . . . . 0.0 109.573 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 77.8 m-85 -73.99 142.9 45.79 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 176.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 27.0 t0 57.55 170.31 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.351 1.06 . . . . 0.0 111.864 -173.559 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -76.81 132.61 71.25 Favored Pre-proline 0 N--CA 1.454 -0.24 0 O-C-N 121.524 -0.735 . . . . 0.0 111.001 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -83.83 157.24 13.73 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 123.834 3.023 . . . . 0.0 109.875 176.104 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 6.9 p80 49.27 14.82 0.1 Allowed 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 115.926 1.824 . . . . 0.0 115.926 175.288 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 56.9 mttp -102.63 162.51 12.87 Favored 'General case' 0 C--N 1.338 0.094 0 CA-C-N 119.007 0.821 . . . . 0.0 110.383 176.177 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 39.1 p -133.51 153.86 80.54 Favored Pre-proline 0 C--O 1.232 0.146 0 C-N-CA 123.427 0.691 . . . . 0.0 110.462 -178.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -76.22 -4.61 15.31 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.813 3.009 . . . . 0.0 112.24 -179.357 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.29 35.42 10.6 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.162 0.585 . . . . 0.0 111.502 -177.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.433 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.3 p -68.04 160.52 74.03 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 124.128 0.971 . . . . 0.0 111.627 -176.789 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 81.8 Cg_endo -70.18 4.53 2.31 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 124.295 3.33 . . . . 0.0 112.373 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.8 t -117.95 142.63 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 178.732 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -131.55 151.59 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 CA-C-O 121.114 0.483 . . . . 0.0 110.635 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.3 t-80 -101.89 136.12 42.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.253 1.021 . . . . 0.0 109.993 178.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.13 145.02 17.17 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 C-N-CA 123.465 0.706 . . . . 0.0 109.116 -176.736 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -142.26 165.14 28.24 Favored 'General case' 0 CA--C 1.526 0.054 0 C-N-CA 123.543 0.737 . . . . 0.0 110.339 -176.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.61 24.08 63.45 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 119.37 -0.683 . . . . 0.0 113.499 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 73.0 mt -61.38 157.96 15.61 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.282 1.041 . . . . 0.0 109.977 177.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.21 -40.14 74.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 O-C-N 122.411 -0.181 . . . . 0.0 111.416 -175.458 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -171.52 -42.17 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.479 0.712 . . . . 0.0 109.961 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -172.72 54.33 0.16 Allowed Glycine 0 C--N 1.337 0.625 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -175.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.5 t -50.21 144.59 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.299 0.639 . . . . 0.0 109.567 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -91.94 164.03 2.16 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-O 121.092 0.472 . . . . 0.0 111.613 -175.294 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -61.76 -27.69 68.91 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.885 0.474 . . . . 0.0 110.858 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.1 -4.58 51.0 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -178.203 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -103.83 -30.37 10.41 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-N 118.379 0.536 . . . . 0.0 109.8 175.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 75.9 mt -71.48 -41.53 69.23 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.555 0.342 . . . . 0.0 110.368 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.84 -30.04 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 121.154 -0.218 . . . . 0.0 111.041 -177.346 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -84.67 -14.88 47.22 Favored 'General case' 0 N--CA 1.456 -0.16 0 O-C-N 122.116 -0.365 . . . . 0.0 111.777 -177.531 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.16 -15.66 16.61 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 178.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -110.92 -8.26 14.51 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -71.77 -6.17 39.45 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.736 0.698 . . . . 0.0 111.401 175.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -77.04 -13.82 59.91 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 122.591 0.356 . . . . 0.0 110.323 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -99.05 -17.57 18.18 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.518 0.327 . . . . 0.0 111.742 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.21 176.69 36.28 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.79 139.48 33.64 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 124.106 3.204 . . . . 0.0 110.464 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 75.1 mt -110.87 145.95 16.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 C-N-CA 122.735 0.414 . . . . 0.0 110.352 -177.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -105.62 -40.44 5.76 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.226 0.61 . . . . 0.0 111.287 -178.169 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -159.07 159.2 34.34 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-O 120.788 0.328 . . . . 0.0 110.895 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -144.05 145.71 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.755 0.822 . . . . 0.0 109.619 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.23 152.14 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.11 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.061 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 10.3 p -134.5 153.69 35.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 122.815 0.446 . . . . 0.0 111.105 -176.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 18.8 ptp -136.03 82.83 35.54 Favored Pre-proline 0 CA--C 1.532 0.267 0 C-N-CA 124.001 0.92 . . . . 0.0 109.606 179.283 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -58.45 -21.2 52.67 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 124.255 3.304 . . . . 0.0 113.131 -178.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.3 mtpt -78.78 -1.15 33.35 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.718 0.407 . . . . 0.0 111.293 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 22.6 tptm -131.66 -0.75 3.88 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.359 1.064 . . . . 0.0 110.481 179.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 57.75 28.95 16.64 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.947 0.899 . . . . 0.0 112.51 -177.004 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -134.32 169.98 16.4 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.808 0.443 . . . . 0.0 111.226 -175.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.63 171.25 18.46 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.211 0.604 . . . . 0.0 110.758 178.224 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.4 mt -132.96 146.04 51.43 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.917 0.887 . . . . 0.0 109.673 178.201 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.8 t -138.85 133.42 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -114.64 120.75 41.19 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 177.627 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -86.7 153.58 21.63 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 120.958 0.409 . . . . 0.0 110.598 -179.683 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -74.7 -13.34 60.6 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.517 -177.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -147.08 152.41 38.47 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 123.82 0.848 . . . . 0.0 108.995 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -67.71 -21.85 27.74 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -175.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.3 tp -72.75 -27.1 61.82 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.137 -0.352 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.59 -30.35 66.6 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.18 -34.36 25.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 117.105 0.452 . . . . 0.0 110.292 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -72.41 -20.94 61.34 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 122.487 0.315 . . . . 0.0 110.876 178.441 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -94.29 4.59 53.67 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 122.939 0.496 . . . . 0.0 111.475 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -108.46 -26.57 10.39 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 117.967 0.349 . . . . 0.0 111.87 179.698 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 45.3 t -89.43 -18.89 7.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 CA-C-N 117.8 0.273 . . . . 0.0 110.506 178.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -73.32 1.44 9.53 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.979 -0.451 . . . . 0.0 111.787 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 55.3 t80 -119.08 -34.67 3.82 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 123.045 0.538 . . . . 0.0 110.825 178.522 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.84 -3.18 58.96 Favored 'General case' 0 CA--C 1.533 0.314 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.265 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.94 -2.16 57.75 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.597 0.359 . . . . 0.0 111.417 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.14 -5.52 1.65 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.045 0.538 . . . . 0.0 111.528 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.56 173.93 15.64 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.841 0.856 . . . . 0.0 108.864 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.5 pt20 -93.07 155.58 17.41 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.53 135.18 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -178.399 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.48 151.7 21.85 Favored 'General case' 0 N--CA 1.455 -0.183 0 O-C-N 122.195 -0.316 . . . . 0.0 110.552 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.0 mt -137.71 -39.01 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.144 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.13 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.17 30.59 2.99 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.042 0.537 . . . . 0.0 110.823 -176.469 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.66 4.86 84.95 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -176.691 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -131.17 151.98 79.82 Favored Pre-proline 0 N--CA 1.455 -0.211 0 C-N-CA 123.994 0.918 . . . . 0.0 109.106 177.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -71.29 145.57 48.8 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 C-N-CA 123.694 2.929 . . . . 0.0 111.749 -177.169 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.67 -176.38 5.59 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.565 1.146 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -139.05 159.38 42.28 Favored 'General case' 0 CA--C 1.527 0.082 0 CA-C-O 120.969 0.414 . . . . 0.0 111.271 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.7 p -148.45 142.34 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.481 0.713 . . . . 0.0 109.483 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -155.64 163.05 40.44 Favored 'General case' 0 N--CA 1.455 -0.178 0 C-N-CA 123.2 0.6 . . . . 0.0 110.186 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -64.35 165.83 9.08 Favored 'General case' 0 N--CA 1.456 -0.144 0 O-C-N 122.205 -0.309 . . . . 0.0 110.376 176.098 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 95.9 p -145.94 177.15 9.16 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 122.763 0.425 . . . . 0.0 110.024 177.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 13.2 m -70.27 -9.2 55.25 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.264 0.225 . . . . 0.0 110.811 178.379 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 33.6 t -79.57 152.46 30.09 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 122.677 0.391 . . . . 0.0 110.867 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -139.97 -0.85 1.64 Allowed 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 123.166 0.586 . . . . 0.0 110.819 175.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -159.83 130.1 5.57 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.651 0.781 . . . . 0.0 109.065 -178.058 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 81.2 mt -84.39 144.42 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.141 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 174.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 46.6 m -81.38 139.03 35.55 Favored 'General case' 0 N--CA 1.457 -0.098 0 N-CA-C 112.003 0.372 . . . . 0.0 112.003 -174.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 25.1 mtp-105 42.48 56.36 10.62 Favored Pre-proline 0 CA--C 1.533 0.315 0 C-N-CA 124.876 1.27 . . . . 0.0 113.109 176.305 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -72.16 156.58 55.33 Favored 'Trans proline' 0 N--CA 1.451 -0.976 0 C-N-CA 123.05 2.5 . . . . 0.0 110.432 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 70.76 6.25 58.93 Favored Glycine 0 CA--C 1.53 0.998 0 CA-C-O 119.717 -0.49 . . . . 0.0 112.753 179.283 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -74.42 160.8 30.51 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 117.864 0.832 . . . . 0.0 111.228 -178.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 82.9 p -148.52 163.0 38.5 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 123.22 0.608 . . . . 0.0 110.587 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -98.95 -8.98 24.68 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 122.709 0.403 . . . . 0.0 111.356 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -149.62 153.28 36.81 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 122.859 0.463 . . . . 0.0 110.433 -178.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 67.0 m -142.08 159.34 42.42 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 123.586 0.754 . . . . 0.0 110.478 -179.527 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -132.37 162.99 29.7 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.228 0.611 . . . . 0.0 109.924 -178.138 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 28.2 m -78.3 5.98 9.27 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 122.991 0.516 . . . . 0.0 111.934 179.18 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.2 m -136.77 165.19 28.9 Favored 'Isoleucine or valine' 0 C--N 1.338 0.09 0 C-N-CA 123.386 0.675 . . . . 0.0 110.659 -178.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 65.6 m-20 -97.66 -2.6 41.08 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.965 0.506 . . . . 0.0 111.641 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 65.8 m . . . . . 0 C--O 1.25 1.115 0 CA-C-O 117.426 -1.273 . . . . 0.0 110.324 -179.104 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.276 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -147.8 146.89 29.32 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 123.275 0.63 . . . . 0.0 109.837 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -142.65 -6.86 0.88 Allowed 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 122.437 0.295 . . . . 0.0 111.344 -179.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -147.0 174.53 11.44 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 123.67 0.788 . . . . 0.0 109.453 -178.426 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -88.07 -7.12 57.45 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.464 0.305 . . . . 0.0 111.135 177.228 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -151.32 49.43 0.58 Allowed Pre-proline 0 CA--C 1.534 0.352 0 C-N-CA 123.22 0.608 . . . . 0.0 112.426 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -71.16 -15.22 31.96 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 123.366 2.711 . . . . 0.0 112.282 -175.65 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -149.23 14.61 0.89 Allowed 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 -177.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -91.21 161.98 14.84 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 122.732 0.413 . . . . 0.0 110.86 -178.23 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 14.2 p -82.58 154.42 68.51 Favored Pre-proline 0 C--O 1.231 0.124 0 C-N-CA 122.864 0.466 . . . . 0.0 110.875 178.419 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -78.19 -11.59 16.13 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.788 2.992 . . . . 0.0 112.069 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 48.97 35.01 6.06 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.399 0.679 . . . . 0.0 111.192 -176.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.428 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 57.8 p -73.35 160.68 81.95 Favored Pre-proline 0 CA--C 1.533 0.327 0 C-N-CA 123.936 0.894 . . . . 0.0 112.139 -174.236 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 91.2 Cg_endo -72.7 2.46 5.25 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 124.306 3.337 . . . . 0.0 112.649 179.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.2 t -121.88 140.92 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.137 0 CA-C-N 118.42 0.555 . . . . 0.0 109.655 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.21 154.37 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 CA-C-O 121.385 0.612 . . . . 0.0 110.728 178.581 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -105.73 141.81 36.53 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.208 1.003 . . . . 0.0 109.514 -179.405 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 20.7 mm -110.26 144.05 19.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 C-N-CA 123.04 0.536 . . . . 0.0 110.142 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 42.4 mtm105 -141.24 159.4 42.29 Favored 'General case' 0 CA--C 1.527 0.063 0 C-N-CA 123.492 0.717 . . . . 0.0 110.315 -178.41 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.41 25.03 59.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-O 119.552 -0.582 . . . . 0.0 113.366 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 53.9 mt -59.55 156.24 13.77 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 118.098 0.949 . . . . 0.0 109.482 176.725 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.8 pt -70.31 -37.96 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.135 0 N-CA-C 111.383 0.142 . . . . 0.0 111.383 -174.241 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.74 -35.53 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 123.954 0.901 . . . . 0.0 109.648 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 170.48 55.97 0.04 OUTLIER Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -176.716 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.8 m -53.21 151.72 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 117.236 0.518 . . . . 0.0 110.501 178.425 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -87.18 166.45 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.082 0 CA-C-O 121.314 0.578 . . . . 0.0 110.809 -177.232 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -60.3 -25.21 65.59 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.002 0.521 . . . . 0.0 110.698 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.89 -6.35 53.99 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 122.811 0.444 . . . . 0.0 112.038 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 79.4 m-20 -97.34 -33.11 11.55 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 118.371 0.532 . . . . 0.0 109.733 176.201 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.47 -40.76 66.71 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.308 0.243 . . . . 0.0 110.83 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.08 -30.06 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 O-C-N 122.158 -0.339 . . . . 0.0 110.855 -176.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.7 mm-40 -81.67 -18.22 45.28 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 117.822 0.283 . . . . 0.0 111.616 -178.357 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.35 -14.37 16.95 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.507 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -113.9 -7.43 13.17 Favored 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -178.395 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.0 pt20 -71.49 -5.84 36.01 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.666 0.666 . . . . 0.0 111.735 175.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -76.58 -14.3 60.01 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 122.962 0.505 . . . . 0.0 110.677 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -98.71 -17.01 18.77 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.56 0.344 . . . . 0.0 111.562 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.91 176.67 35.2 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -71.12 140.31 37.36 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 123.935 3.09 . . . . 0.0 110.631 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 72.4 mt -110.16 146.4 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.103 0 C-N-CA 122.863 0.465 . . . . 0.0 110.4 -178.006 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.8 t -108.26 -39.93 5.32 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 123.279 0.631 . . . . 0.0 111.62 -177.128 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -157.78 158.13 34.66 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 120.57 0.224 . . . . 0.0 111.04 178.728 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.5 t -145.01 146.36 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.079 0 C-N-CA 123.642 0.777 . . . . 0.0 109.507 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.28 153.24 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 175.352 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 11.1 p -133.7 151.74 33.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.118 0 CA-C-O 120.806 0.336 . . . . 0.0 111.191 -176.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 19.3 ptp -136.24 84.89 28.54 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.739 0.816 . . . . 0.0 109.159 179.691 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.5 -12.31 33.1 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.386 2.724 . . . . 0.0 111.666 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -77.93 -5.04 49.82 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 122.683 0.393 . . . . 0.0 111.018 176.445 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -132.79 5.17 3.92 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 123.645 0.778 . . . . 0.0 111.213 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 54.27 35.72 23.44 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.292 1.037 . . . . 0.0 112.343 -177.193 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -137.54 169.83 17.12 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.132 0.573 . . . . 0.0 111.039 -176.487 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.44 172.82 17.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.112 0.565 . . . . 0.0 110.494 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.4 mt -132.92 146.22 51.6 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.9 0.88 . . . . 0.0 109.374 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 89.8 t -138.36 133.03 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -116.26 121.68 42.74 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.578 0.751 . . . . 0.0 109.192 178.462 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 44.3 m-85 -88.5 155.52 19.61 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.052 0.453 . . . . 0.0 110.547 -178.283 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -75.77 -13.49 60.3 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.475 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -145.76 152.82 40.17 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.691 0.796 . . . . 0.0 109.097 177.622 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.8 p -69.55 -21.84 24.9 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.45 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 58.7 tp -77.44 -29.51 52.89 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.003 -0.436 . . . . 0.0 110.418 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.27 -31.09 73.94 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.15 -32.03 33.86 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 116.984 0.392 . . . . 0.0 110.534 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.6 t -70.6 -29.72 66.2 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 122.076 0.15 . . . . 0.0 110.628 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -75.84 -21.0 57.7 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.194 -0.316 . . . . 0.0 111.247 179.18 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -81.31 -28.19 34.7 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.971 0.35 . . . . 0.0 111.617 -177.32 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 33.3 t -92.16 -19.66 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 O-C-N 122.382 -0.199 . . . . 0.0 110.688 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -71.34 -11.69 61.04 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 122.117 -0.364 . . . . 0.0 110.888 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -104.88 -34.05 8.18 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 122.942 0.497 . . . . 0.0 110.764 178.132 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.71 -7.24 59.52 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -177.601 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -84.84 -2.51 57.84 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -141.47 -3.87 1.15 Allowed 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 122.829 0.452 . . . . 0.0 111.946 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 54.1 t30 -154.68 165.23 37.21 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 123.303 0.641 . . . . 0.0 109.456 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -85.14 158.3 20.43 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.04 135.72 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.058 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.2 m-85 -89.78 152.97 21.03 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.04 -0.413 . . . . 0.0 110.862 -178.547 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.2 mt -137.29 -41.0 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.227 -0.101 0 C-N-CA 122.669 0.388 . . . . 0.0 110.755 -177.137 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.92 29.91 3.73 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.817 0.447 . . . . 0.0 110.944 -177.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.05 4.24 81.96 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -176.719 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -130.31 151.81 79.14 Favored Pre-proline 0 N--CA 1.455 -0.223 0 C-N-CA 124.14 0.976 . . . . 0.0 109.053 177.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.69 146.04 53.4 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 123.526 2.817 . . . . 0.0 112.038 -176.333 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.35 -176.21 5.49 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.267 1.427 . . . . 0.0 108.902 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -138.99 161.51 37.17 Favored 'General case' 0 N--CA 1.457 -0.086 0 CA-C-O 120.943 0.402 . . . . 0.0 111.521 -179.196 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.0 p -150.09 141.55 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.842 0.857 . . . . 0.0 109.751 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -160.84 160.04 30.6 Favored 'General case' 0 N--CA 1.458 -0.074 0 C-N-CA 123.333 0.653 . . . . 0.0 109.747 178.373 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -63.76 159.84 18.5 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.061 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 10.7 t -149.51 47.13 0.96 Allowed 'General case' 0 CA--C 1.53 0.188 0 O-C-N 122.168 -0.333 . . . . 0.0 111.549 -178.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 63.3 p 49.84 23.96 1.17 Allowed 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 124.823 1.249 . . . . 0.0 113.835 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 42.7 t -106.17 154.07 21.22 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 123.376 0.67 . . . . 0.0 109.622 178.08 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -135.91 -3.54 2.27 Favored 'General case' 0 CA--C 1.528 0.103 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 178.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -157.7 132.98 8.87 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.246 0.618 . . . . 0.0 109.47 -178.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 78.2 mt -84.48 146.93 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 173.712 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 75.7 p -76.57 141.12 41.26 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 121.015 0.436 . . . . 0.0 111.943 -175.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 34.8 ttp-105 41.87 58.3 9.86 Favored Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 125.032 1.333 . . . . 0.0 112.93 176.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -75.78 -7.16 18.25 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 123.589 2.859 . . . . 0.0 111.304 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 78.64 4.91 88.12 Favored Glycine 0 CA--C 1.528 0.904 0 CA-C-O 119.61 -0.55 . . . . 0.0 113.158 176.029 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -137.81 -11.13 1.55 Allowed 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 118.352 1.076 . . . . 0.0 112.371 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 81.2 p -157.55 169.18 25.27 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 118.268 0.486 . . . . 0.0 111.304 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -152.13 157.35 41.44 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.665 0.786 . . . . 0.0 109.903 178.613 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -153.03 -7.03 0.18 Allowed 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 78.0 p -92.35 -11.47 34.95 Favored 'General case' 0 C--N 1.34 0.192 0 O-C-N 121.923 -0.486 . . . . 0.0 112.185 -177.062 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 13.3 tpp85 -157.61 170.35 22.6 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 123.079 0.552 . . . . 0.0 109.906 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 73.4 p -78.96 0.64 26.71 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.94 0.496 . . . . 0.0 111.4 176.66 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 33.6 m -138.47 174.3 10.55 Favored 'Isoleucine or valine' 0 C--O 1.231 0.102 0 C-N-CA 124.023 0.929 . . . . 0.0 110.423 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 52.3 p-10 -119.18 9.47 11.76 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.574 0.749 . . . . 0.0 111.608 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.3 m . . . . . 0 C--O 1.251 1.133 0 CA-C-O 117.741 -1.123 . . . . 0.0 111.062 -179.639 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -148.0 152.1 36.87 Favored 'General case' 0 N--CA 1.457 -0.122 0 C-N-CA 122.889 0.476 . . . . 0.0 109.821 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -69.12 -13.12 62.25 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -176.415 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 66.1 m-85 -95.31 5.73 50.91 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.114 0.566 . . . . 0.0 111.398 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -107.21 10.58 29.91 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 123.317 0.647 . . . . 0.0 110.993 179.308 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 52.3 m-20 48.67 54.64 16.36 Favored Pre-proline 0 CA--C 1.534 0.339 0 C-N-CA 124.263 1.025 . . . . 0.0 112.58 -179.188 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -67.59 -25.29 40.92 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 123.764 2.976 . . . . 0.0 111.967 -176.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 8.0 p80 -155.77 13.47 0.34 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.469 0.707 . . . . 0.0 110.874 179.328 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 57.2 mtpt -93.61 166.48 12.22 Favored 'General case' 0 CA--C 1.528 0.122 0 C-N-CA 123.949 0.899 . . . . 0.0 110.441 -175.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 35.0 p -135.86 153.41 77.12 Favored Pre-proline 0 C--O 1.231 0.084 0 C-N-CA 123.2 0.6 . . . . 0.0 110.628 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -79.12 -7.54 15.24 Favored 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 124.031 3.154 . . . . 0.0 111.953 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.95 33.9 12.64 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 123.701 0.8 . . . . 0.0 112.008 -178.284 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.1 m -69.73 159.77 82.56 Favored Pre-proline 0 CA--C 1.529 0.16 0 C-N-CA 123.663 0.785 . . . . 0.0 112.224 -177.045 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -72.35 -1.52 10.3 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 123.92 3.08 . . . . 0.0 112.073 175.606 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.4 t -113.42 139.38 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 123.215 0.606 . . . . 0.0 109.707 178.569 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.2 m -125.17 159.49 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 C-N-CA 122.928 0.491 . . . . 0.0 110.316 178.417 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -114.55 135.65 53.89 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 123.834 0.854 . . . . 0.0 109.687 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.8 mm -106.74 143.88 16.76 Favored 'Isoleucine or valine' 0 C--O 1.23 0.068 0 C-N-CA 122.888 0.475 . . . . 0.0 110.365 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 72.1 mtm-85 -143.64 163.5 33.05 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 123.368 0.667 . . . . 0.0 110.523 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.84 22.27 66.69 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 119.572 -0.571 . . . . 0.0 113.148 174.046 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.48 156.08 16.95 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 118.173 0.986 . . . . 0.0 110.041 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.1 pt -70.97 -41.46 76.99 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.112 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -173.276 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.2 -35.9 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.228 0.611 . . . . 0.0 110.437 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.86 50.5 0.12 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.648 -0.581 . . . . 0.0 111.648 -177.329 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 88.1 t -50.16 143.09 2.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.419 0.688 . . . . 0.0 109.8 177.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 33.8 m -94.48 164.7 2.05 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 121.229 0.538 . . . . 0.0 111.73 -174.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -61.22 -25.87 67.35 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.431 0.692 . . . . 0.0 111.224 -178.245 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.42 -6.3 57.85 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -177.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -97.75 -29.06 13.59 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 118.222 0.465 . . . . 0.0 110.282 177.136 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 98.0 mt -74.02 -35.9 64.41 Favored 'General case' 0 N--CA 1.452 -0.325 0 O-C-N 122.401 -0.187 . . . . 0.0 110.93 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.05 -31.47 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.363 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -81.55 -16.56 51.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 119.565 -0.255 . . . . 0.0 111.596 -178.423 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.95 -13.36 15.51 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.4 mt -116.1 -6.13 11.92 Favored 'General case' 0 N--CA 1.461 0.094 0 CA-C-N 118.483 0.583 . . . . 0.0 112.479 -178.189 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -72.44 -6.41 43.4 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.678 0.672 . . . . 0.0 110.26 175.004 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -77.33 -3.89 42.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 123.923 0.889 . . . . 0.0 111.059 179.433 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -112.85 -16.49 12.71 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.006 0.522 . . . . 0.0 111.282 179.618 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.48 175.78 35.62 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -71.35 140.77 37.54 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 123.812 3.008 . . . . 0.0 110.564 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 72.3 mt -110.13 147.05 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.822 0.449 . . . . 0.0 110.572 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -109.53 -41.15 4.66 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 123.206 0.603 . . . . 0.0 111.564 -176.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -158.06 158.03 34.0 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 117.666 0.212 . . . . 0.0 111.261 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.7 t -143.89 147.42 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 C-N-CA 123.932 0.893 . . . . 0.0 109.591 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -149.53 151.52 12.8 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.032 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 175.407 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.95 152.59 36.24 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 C-N-CA 122.437 0.295 . . . . 0.0 110.899 -175.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 21.2 ptp -138.58 78.76 31.07 Favored Pre-proline 0 CA--C 1.534 0.33 0 C-N-CA 123.675 0.79 . . . . 0.0 109.741 177.328 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.57 -18.43 47.15 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.89 3.06 . . . . 0.0 113.306 -177.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -71.66 -12.28 61.26 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 122.8 0.44 . . . . 0.0 110.873 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.69 4.55 6.73 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.703 0.801 . . . . 0.0 111.286 179.273 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 55.31 34.98 23.97 Favored 'General case' 0 CA--C 1.533 0.288 0 C-N-CA 124.095 0.958 . . . . 0.0 112.191 -176.357 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -134.03 169.02 17.75 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 123.054 0.541 . . . . 0.0 110.843 -177.001 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.81 171.8 19.01 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.167 176.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 43.2 mt -131.86 146.44 52.12 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.522 0.729 . . . . 0.0 109.825 178.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.6 t -138.28 131.75 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -114.92 122.84 47.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 177.619 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 47.1 m-85 -87.26 155.35 20.11 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.41 -179.26 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -76.37 -11.65 59.93 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.246 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.73 152.92 38.58 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.928 0.891 . . . . 0.0 109.282 177.024 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -69.9 -21.33 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 O-C-N 122.224 -0.298 . . . . 0.0 111.702 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.2 tp -75.85 -28.97 58.42 Favored 'General case' 0 N--CA 1.454 -0.231 0 O-C-N 121.865 -0.522 . . . . 0.0 110.626 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.03 -29.51 73.52 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.12 -28.12 29.66 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.99 0.395 . . . . 0.0 110.74 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.6 t -74.06 -30.89 62.61 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.244 -0.285 . . . . 0.0 110.467 179.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -76.24 -21.67 56.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.268 -0.27 . . . . 0.0 111.249 179.329 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -33.31 26.79 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 117.778 0.263 . . . . 0.0 111.396 -177.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.15 -22.67 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 O-C-N 122.308 -0.245 . . . . 0.0 110.535 179.736 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -68.79 -16.56 63.83 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.943 -0.473 . . . . 0.0 111.01 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -99.03 -34.79 10.27 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 122.695 0.398 . . . . 0.0 110.691 178.277 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.21 -10.76 59.02 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -177.638 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.54 -1.01 52.78 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 178.019 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -139.61 -7.48 1.29 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -155.02 165.39 36.88 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.257 0.623 . . . . 0.0 109.363 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.68 157.57 23.29 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 173.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.43 135.99 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.85 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 64.1 m-85 -90.29 151.11 21.64 Favored 'General case' 0 N--CA 1.457 -0.082 0 O-C-N 122.109 -0.369 . . . . 0.0 110.92 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.5 mt -137.14 -38.89 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.12 -176.388 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.65 29.07 3.25 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.149 0.58 . . . . 0.0 111.012 -176.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.82 4.66 82.18 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.53 151.98 79.64 Favored Pre-proline 0 C--O 1.234 0.253 0 C-N-CA 124.322 1.049 . . . . 0.0 109.322 177.649 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_endo -70.9 146.57 53.46 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 123.522 2.814 . . . . 0.0 111.702 -177.179 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.71 -177.72 6.28 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 125.205 1.402 . . . . 0.0 109.104 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -137.54 159.7 41.23 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.061 0.458 . . . . 0.0 111.792 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.5 p -151.23 139.98 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 123.347 0.659 . . . . 0.0 110.149 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -162.06 154.95 20.18 Favored 'General case' 0 CA--C 1.528 0.132 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.743 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -106.03 136.82 45.03 Favored 'General case' 0 CA--C 1.528 0.118 0 CA-C-O 121.351 0.596 . . . . 0.0 112.395 178.315 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 32.6 t -166.31 143.23 5.08 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.505 178.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 68.5 p 44.34 26.57 0.17 Allowed 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 125.894 1.677 . . . . 0.0 114.494 175.273 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 50.9 m -141.81 149.57 40.53 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 122.907 0.483 . . . . 0.0 109.886 -179.338 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -149.31 -5.59 0.38 Allowed 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 177.638 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -159.66 137.55 10.1 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.438 0.695 . . . . 0.0 109.136 -177.086 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 66.4 mt -88.27 143.52 11.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 173.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.2 m -80.64 139.55 36.15 Favored 'General case' 0 C--N 1.334 -0.109 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -174.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 20.8 tpp180 42.32 58.2 10.58 Favored Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 124.841 1.256 . . . . 0.0 112.844 175.066 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -74.36 -15.38 22.47 Favored 'Trans proline' 0 N--CA 1.454 -0.834 0 C-N-CA 123.01 2.474 . . . . 0.0 111.47 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 62.04 -136.22 45.97 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 178.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -155.45 -29.35 0.1 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.207 0.603 . . . . 0.0 111.631 -179.121 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 82.3 p -154.32 168.8 25.4 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.452 0.701 . . . . 0.0 110.396 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -145.79 152.79 40.11 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.278 0.631 . . . . 0.0 110.256 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -150.62 153.93 36.58 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.291 0.636 . . . . 0.0 110.533 -179.686 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 79.5 p -146.65 151.31 37.04 Favored 'General case' 0 C--O 1.232 0.165 0 C-N-CA 122.954 0.502 . . . . 0.0 110.009 177.239 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 20.0 ptp180 -156.54 168.31 27.77 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.105 0.562 . . . . 0.0 110.873 -178.036 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 48.8 m -74.69 133.03 42.12 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 122.603 0.361 . . . . 0.0 110.17 178.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 6.0 m -150.01 163.63 3.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 C-N-CA 124.149 0.98 . . . . 0.0 109.202 -179.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -76.8 137.36 39.2 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 110.338 -0.245 . . . . 0.0 110.338 179.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 49.0 m . . . . . 0 C--O 1.25 1.088 0 CA-C-O 117.074 -1.441 . . . . 0.0 110.171 179.068 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.198 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -142.09 13.29 2.03 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 122.693 0.397 . . . . 0.0 111.771 -178.709 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 68.8 m-20 -72.89 -15.0 61.6 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.34 0.256 . . . . 0.0 111.147 -179.63 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -146.06 166.73 25.23 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.606 0.762 . . . . 0.0 109.154 179.02 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -81.22 -22.88 38.47 Favored 'General case' 0 CA--C 1.53 0.194 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 -177.58 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -157.38 60.39 2.01 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 117.923 0.329 . . . . 0.0 111.632 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -74.58 -31.58 6.83 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.592 2.195 . . . . 0.0 111.792 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 6.5 p-80 -162.57 12.98 0.07 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.075 0.55 . . . . 0.0 111.693 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -73.18 161.64 30.34 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.982 -0.448 . . . . 0.0 110.905 -176.053 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 34.8 p -87.44 154.19 53.77 Favored Pre-proline 0 CA--C 1.528 0.124 0 C-N-CA 123.021 0.528 . . . . 0.0 110.873 -179.523 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -77.18 -9.24 17.76 Favored 'Trans proline' 0 N--CA 1.453 -0.877 0 C-N-CA 123.877 3.051 . . . . 0.0 111.744 178.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 49.44 33.95 6.14 Favored 'General case' 0 C--N 1.341 0.231 0 C-N-CA 123.622 0.769 . . . . 0.0 111.542 -176.773 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.448 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.7 p -82.84 161.77 57.23 Favored Pre-proline 0 CA--C 1.532 0.288 0 C-N-CA 123.828 0.851 . . . . 0.0 112.099 -173.764 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 98.9 Cg_endo -71.17 1.22 5.59 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 124.008 3.139 . . . . 0.0 112.758 178.229 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.57 139.05 37.62 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.094 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 178.277 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.3 154.22 37.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 122.928 0.491 . . . . 0.0 110.339 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 31.5 t-80 -110.65 138.18 47.37 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.993 0.917 . . . . 0.0 109.507 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.1 mm -107.49 144.77 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 C-N-CA 122.893 0.477 . . . . 0.0 110.33 -176.228 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -143.01 161.48 38.0 Favored 'General case' 0 C--N 1.338 0.088 0 C-N-CA 123.195 0.598 . . . . 0.0 110.553 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.36 23.51 62.85 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 119.498 -0.612 . . . . 0.0 113.488 173.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 76.4 mt -60.87 158.01 13.98 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 118.332 1.066 . . . . 0.0 110.523 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -72.31 -40.93 65.65 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -173.76 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -172.12 -38.22 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 C-N-CA 123.107 0.563 . . . . 0.0 110.079 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.33 51.91 0.11 Allowed Glycine 0 C--N 1.338 0.646 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -176.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 57.9 t -49.65 144.03 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 123.546 0.738 . . . . 0.0 110.153 178.132 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -90.0 161.95 2.57 Favored 'Isoleucine or valine' 0 C--N 1.338 0.072 0 CA-C-O 121.292 0.567 . . . . 0.0 111.655 -174.694 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -62.0 -24.05 66.8 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.259 0.624 . . . . 0.0 111.766 -176.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.48 -5.5 58.74 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -95.63 -31.55 13.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.312 0.505 . . . . 0.0 110.498 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.56 -34.07 60.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 O-C-N 121.921 -0.487 . . . . 0.0 110.752 -177.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.3 p -78.06 -30.64 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 120.709 -0.396 . . . . 0.0 109.979 -178.68 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -85.72 -12.03 52.17 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.274 -0.266 . . . . 0.0 111.558 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.84 -11.79 15.31 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 178.44 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -114.8 -9.37 12.52 Favored 'General case' 0 C--N 1.34 0.19 0 CA-C-N 118.457 0.571 . . . . 0.0 112.255 -179.561 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.64 -3.87 16.92 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 118.615 0.643 . . . . 0.0 111.71 176.696 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -78.49 -16.1 57.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.865 0.466 . . . . 0.0 110.511 178.653 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -96.67 -18.94 19.35 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.343 -0.223 . . . . 0.0 111.397 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.34 178.14 38.25 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.75 140.78 36.22 Favored 'Trans proline' 0 N--CA 1.451 -0.985 0 C-N-CA 124.061 3.174 . . . . 0.0 110.46 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.5 mt -110.05 148.44 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 C-N-CA 122.604 0.362 . . . . 0.0 110.449 -177.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -110.63 -39.78 4.78 Favored 'General case' 0 N--CA 1.457 -0.101 0 C-N-CA 123.247 0.619 . . . . 0.0 111.851 -177.541 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -158.68 158.06 33.02 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 117.76 0.255 . . . . 0.0 111.601 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 79.3 t -143.72 146.29 21.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 124.036 0.934 . . . . 0.0 109.586 179.434 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.9 p -147.53 153.49 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 174.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.8 t -128.75 150.8 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 CA-C-O 120.833 0.349 . . . . 0.0 110.659 -176.299 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -134.54 79.77 52.93 Favored Pre-proline 0 CA--C 1.531 0.237 0 C-N-CA 124.492 1.117 . . . . 0.0 109.195 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -68.96 -14.06 37.86 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.389 2.726 . . . . 0.0 111.778 -175.407 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -81.71 -1.88 48.56 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 122.824 0.45 . . . . 0.0 111.585 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -133.39 4.46 3.69 Favored 'General case' 0 C--N 1.339 0.14 0 C-N-CA 123.797 0.839 . . . . 0.0 111.113 175.657 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.4 tpp85 55.59 35.76 25.84 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.069 0.948 . . . . 0.0 111.667 -175.193 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -134.11 170.49 15.58 Favored 'General case' 0 N--CA 1.457 -0.076 0 C-N-CA 123.415 0.686 . . . . 0.0 110.929 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.88 170.94 20.5 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 176.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.7 tp -135.17 142.54 46.12 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.5 t -138.21 141.54 37.78 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.1 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.222 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -123.9 125.03 43.91 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.086 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -87.75 154.9 20.2 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.875 0.369 . . . . 0.0 110.341 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -74.97 -12.36 60.32 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.246 -178.541 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -147.8 152.49 37.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.988 0.915 . . . . 0.0 109.265 176.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.8 p -68.63 -21.85 26.37 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.544 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.0 tp -73.95 -26.08 60.3 Favored 'General case' 0 N--CA 1.453 -0.303 0 O-C-N 121.999 -0.438 . . . . 0.0 110.544 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.24 -29.13 68.92 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.042 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.66 -30.23 23.38 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 117.237 0.519 . . . . 0.0 110.513 178.685 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 36.8 t -75.55 -17.77 59.97 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 122.49 0.316 . . . . 0.0 110.484 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -93.35 -20.84 19.97 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.705 0.402 . . . . 0.0 110.723 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.35 -31.01 25.02 Favored 'General case' 0 N--CA 1.455 -0.177 0 O-C-N 122.112 -0.367 . . . . 0.0 111.501 -178.081 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.62 -19.4 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 O-C-N 122.04 -0.413 . . . . 0.0 110.698 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -70.5 -17.54 62.96 Favored 'General case' 0 CA--C 1.529 0.142 0 O-C-N 122.221 -0.3 . . . . 0.0 111.195 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.9 t80 -97.42 -36.79 10.24 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 122.686 0.394 . . . . 0.0 111.172 178.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.25 -6.61 59.42 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.22 -4.81 56.67 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.078 -0.389 . . . . 0.0 111.543 176.238 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -141.64 -4.99 1.07 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 23.9 m-80 -145.01 175.26 10.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.358 0.663 . . . . 0.0 109.615 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.1 pt20 -99.35 150.52 22.05 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 172.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -118.91 134.51 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -88.04 151.46 22.74 Favored 'General case' 0 N--CA 1.453 -0.278 0 O-C-N 122.183 -0.323 . . . . 0.0 110.853 -179.051 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 41.2 mt -138.22 -37.3 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.19 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.91 29.54 3.14 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.24 0.616 . . . . 0.0 111.087 -176.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.73 4.69 84.93 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -176.683 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.36 152.78 81.13 Favored Pre-proline 0 N--CA 1.454 -0.234 0 C-N-CA 124.24 1.016 . . . . 0.0 108.982 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -71.53 146.83 50.52 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 123.377 2.718 . . . . 0.0 111.792 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.67 -176.54 5.77 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 124.784 1.234 . . . . 0.0 109.011 178.056 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -137.83 159.79 41.05 Favored 'General case' 0 CA--C 1.527 0.081 0 CA-C-O 120.776 0.322 . . . . 0.0 111.428 -178.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.84 138.14 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.324 0.649 . . . . 0.0 110.23 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -159.04 151.79 21.88 Favored 'General case' 0 N--CA 1.456 -0.126 0 C-N-CA 123.502 0.721 . . . . 0.0 109.303 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -103.66 133.08 49.27 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-O 121.246 0.546 . . . . 0.0 112.425 178.52 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 42.1 t -167.89 145.14 4.28 Favored 'General case' 0 N--CA 1.456 -0.148 0 C-N-CA 123.068 0.547 . . . . 0.0 110.852 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 3.1 m 50.34 24.89 1.66 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.914 1.286 . . . . 0.0 114.003 172.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 33.5 t -152.71 153.46 33.28 Favored 'General case' 0 C--O 1.232 0.171 0 O-C-N 121.522 -0.736 . . . . 0.0 111.045 178.094 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -148.22 -4.91 0.46 Allowed 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 176.42 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 15.6 tppt? -159.72 136.65 9.38 Favored 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -178.093 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 38.6 mt -89.4 137.44 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 174.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.6 m -82.58 141.72 32.36 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.551 0.215 . . . . 0.0 111.359 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 90.5 mtt-85 44.91 54.73 13.29 Favored Pre-proline 0 CA--C 1.533 0.306 0 C-N-CA 124.335 1.054 . . . . 0.0 112.791 176.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -72.73 81.53 1.59 Allowed 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 123.199 2.599 . . . . 0.0 110.141 179.437 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 83.56 11.52 79.8 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.637 -0.535 . . . . 0.0 112.1 -177.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 51.3 m-20 -110.2 18.48 19.9 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.263 0.625 . . . . 0.0 111.839 -178.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.5 m -69.18 153.31 43.9 Favored 'General case' 0 CA--C 1.529 0.172 0 O-C-N 122.113 -0.367 . . . . 0.0 111.295 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -146.22 166.02 27.47 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 123.357 0.663 . . . . 0.0 110.69 178.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 19.4 t0 -147.93 142.73 26.75 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.131 0.572 . . . . 0.0 110.331 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 70.7 m -146.79 157.37 43.66 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 124.15 0.98 . . . . 0.0 109.87 179.653 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -123.57 160.79 26.3 Favored 'General case' 0 N--CA 1.457 -0.116 0 C-N-CA 122.38 0.272 . . . . 0.0 110.666 -176.53 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.6 p -86.63 5.86 33.82 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 123.384 0.674 . . . . 0.0 112.045 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 30.7 m -133.02 160.29 42.71 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 C-N-CA 122.986 0.514 . . . . 0.0 110.483 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 52.24 23.1 2.21 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.047 0.939 . . . . 0.0 112.622 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 45.1 m . . . . . 0 C--O 1.25 1.115 0 CA-C-O 117.447 -1.264 . . . . 0.0 110.057 -178.025 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.161 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -145.95 151.31 37.61 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.883 0.473 . . . . 0.0 110.084 179.524 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 48.9 t30 -150.63 167.2 28.02 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.156 0.583 . . . . 0.0 109.509 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -69.53 -22.61 63.56 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 122.488 0.315 . . . . 0.0 111.062 179.344 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.0 t0 -156.76 157.82 35.76 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.066 0.547 . . . . 0.0 109.855 176.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.404 ' N ' ' CD ' ' A' ' 90' ' ' PRO . 34.3 t0 47.73 45.99 3.2 Favored Pre-proline 0 CA--C 1.537 0.457 0 C-N-CA 124.473 1.109 . . . . 0.0 113.6 -179.059 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.404 ' CD ' ' N ' ' A' ' 89' ' ' ASP . 98.3 Cg_endo -73.14 -26.77 14.52 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.128 1.885 . . . . 0.0 110.901 176.721 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.2 p-80 -159.78 17.69 0.16 Allowed 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.349 0.659 . . . . 0.0 111.555 -178.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -78.26 3.32 15.71 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -174.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 23.6 p -71.37 151.04 94.2 Favored Pre-proline 0 CA--C 1.528 0.124 0 O-C-N 122.114 -0.366 . . . . 0.0 110.449 178.099 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -77.94 -10.91 16.7 Favored 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 123.602 2.868 . . . . 0.0 111.71 179.115 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 49.07 33.29 4.63 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.392 0.677 . . . . 0.0 111.257 -176.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.481 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 77.8 p -85.22 162.89 47.5 Favored Pre-proline 0 CA--C 1.529 0.147 0 C-N-CA 123.806 0.842 . . . . 0.0 112.016 -173.5 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.481 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 84.6 Cg_endo -70.5 2.15 4.23 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 123.89 3.06 . . . . 0.0 112.854 177.046 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.7 t -112.92 139.15 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 CA-C-N 118.327 0.512 . . . . 0.0 109.926 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.0 m -125.51 157.74 34.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 C-N-CA 122.908 0.483 . . . . 0.0 110.359 178.421 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.6 t-80 -115.39 137.63 51.84 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.179 0.991 . . . . 0.0 109.392 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.6 mm -107.67 145.69 14.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 C-N-CA 122.616 0.366 . . . . 0.0 110.044 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -142.64 157.74 44.38 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.418 0.687 . . . . 0.0 109.947 -178.723 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 24.98 57.51 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.314 174.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.3 mt -59.08 156.72 11.43 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 118.026 0.913 . . . . 0.0 109.812 177.562 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.1 pt -72.45 -39.07 61.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 O-C-N 122.181 -0.324 . . . . 0.0 111.773 -174.616 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -173.41 -36.2 0.01 OUTLIER 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 123.653 0.781 . . . . 0.0 110.033 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.31 54.75 0.05 OUTLIER Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -177.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.3 m -52.9 151.57 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 117.156 0.478 . . . . 0.0 110.271 177.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.1 m -88.34 165.74 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.039 0 CA-C-O 121.161 0.505 . . . . 0.0 111.36 -175.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.61 -23.92 66.35 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.132 0.573 . . . . 0.0 111.21 -178.173 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.2 -6.85 57.53 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 122.743 0.417 . . . . 0.0 111.867 -179.124 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -91.49 -34.96 14.59 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.236 0.471 . . . . 0.0 110.617 179.124 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.6 mp -75.87 -33.81 59.98 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 122.214 -0.304 . . . . 0.0 110.948 -176.793 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -76.57 -29.49 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.068 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 37.7 mm-40 -84.36 -14.26 50.02 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 122.206 0.202 . . . . 0.0 110.982 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.69 -21.79 16.24 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.8 mp -109.83 -10.68 14.75 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -177.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.36 -4.43 14.54 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.978 0.808 . . . . 0.0 111.956 177.724 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -83.6 -12.27 56.28 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.881 0.473 . . . . 0.0 110.413 178.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -103.97 -16.41 15.33 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 122.753 0.421 . . . . 0.0 111.425 -179.236 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.42 178.54 37.2 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -72.37 140.33 33.34 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 124.085 3.19 . . . . 0.0 110.671 179.268 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 79.4 mt -109.72 148.62 13.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.889 0.476 . . . . 0.0 110.684 -178.368 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 12.9 t -114.32 -36.39 4.67 Favored 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.384 0.673 . . . . 0.0 112.09 -177.198 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -155.96 156.06 33.86 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.626 0.25 . . . . 0.0 111.589 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.0 t -146.49 144.37 20.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.038 0.935 . . . . 0.0 109.183 179.529 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.7 p -151.33 152.82 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 175.387 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.8 150.59 34.07 Favored 'Isoleucine or valine' 0 C--N 1.335 -0.055 0 C-N-CA 122.587 0.355 . . . . 0.0 110.393 -175.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 70.0 mtm -132.74 84.74 49.18 Favored Pre-proline 0 N--CA 1.454 -0.237 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.57 -12.5 33.4 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.325 2.683 . . . . 0.0 111.964 -176.17 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -84.78 -1.75 56.77 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 122.842 0.457 . . . . 0.0 111.107 176.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -132.45 1.24 3.74 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 123.871 0.868 . . . . 0.0 111.157 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.2 tpp85 52.38 34.61 15.39 Favored 'General case' 0 C--N 1.341 0.197 0 C-N-CA 124.257 1.023 . . . . 0.0 111.846 -175.343 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.26 167.86 20.95 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.554 0.741 . . . . 0.0 110.354 -177.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.62 173.58 16.5 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.508 0.323 . . . . 0.0 110.792 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 45.0 mt -134.16 147.09 50.73 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.623 0.769 . . . . 0.0 110.14 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.6 t -140.06 135.28 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -116.75 122.63 45.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -84.77 156.02 21.58 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 120.974 0.416 . . . . 0.0 110.193 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -75.94 -12.29 60.12 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.325 -179.387 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -148.21 153.13 38.34 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 124.099 0.96 . . . . 0.0 109.362 177.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -70.5 -21.8 23.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.478 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.7 tp -74.34 -27.43 60.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 O-C-N 121.939 -0.476 . . . . 0.0 110.742 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.88 -30.63 67.86 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.88 -29.36 29.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 117.11 0.455 . . . . 0.0 111.028 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -77.58 -25.97 50.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.537 -0.171 . . . . 0.0 110.537 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -85.21 -17.22 37.75 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.135 0.174 . . . . 0.0 111.084 178.214 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.01 -28.56 25.66 Favored 'General case' 0 N--CA 1.456 -0.148 0 O-C-N 122.246 -0.284 . . . . 0.0 111.48 179.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.9 t -88.23 -21.91 6.88 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 O-C-N 122.196 -0.315 . . . . 0.0 110.618 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.16 -15.9 62.51 Favored 'General case' 0 CA--C 1.534 0.331 0 O-C-N 122.365 -0.209 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 58.0 t80 -93.76 -33.09 13.74 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.422 0.289 . . . . 0.0 110.927 178.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.99 -3.1 57.55 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 112.697 0.628 . . . . 0.0 112.697 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.81 -5.08 59.12 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 122.001 -0.437 . . . . 0.0 112.11 178.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -143.59 2.47 1.24 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 122.71 0.404 . . . . 0.0 111.52 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -155.27 173.72 16.23 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.032 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -98.48 156.34 16.82 Favored 'General case' 0 CA--C 1.527 0.094 0 CA-C-N 118.222 0.464 . . . . 0.0 110.276 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -119.56 136.49 56.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -177.607 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -92.89 147.65 22.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.98 -0.45 . . . . 0.0 110.384 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.8 mt -134.19 -40.15 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.131 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.83 29.78 3.78 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 123.012 0.525 . . . . 0.0 111.164 -177.4 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.11 5.14 83.51 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.394 -0.683 . . . . 0.0 111.394 -177.158 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -131.36 152.87 81.29 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 124.526 1.13 . . . . 0.0 108.84 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -71.1 146.23 51.44 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.531 2.821 . . . . 0.0 111.784 -177.212 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.5 -176.11 5.46 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.158 1.383 . . . . 0.0 108.772 177.662 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -138.98 159.43 42.16 Favored 'General case' 0 N--CA 1.456 -0.128 0 O-C-N 122.134 -0.353 . . . . 0.0 111.265 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.6 p -147.08 139.68 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 C-N-CA 123.237 0.615 . . . . 0.0 110.606 179.24 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -158.57 155.22 27.91 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.355 0.662 . . . . 0.0 109.582 176.24 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -97.66 127.68 43.8 Favored 'General case' 0 CA--C 1.527 0.069 0 CA-C-O 121.136 0.494 . . . . 0.0 111.375 177.429 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 41.6 m -158.95 144.08 16.07 Favored 'General case' 0 N--CA 1.457 -0.091 0 C-N-CA 123.205 0.602 . . . . 0.0 110.661 -177.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 82.1 p 44.44 26.86 0.19 Allowed 'General case' 0 N--CA 1.464 0.233 0 N-CA-C 115.508 1.67 . . . . 0.0 115.508 171.741 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 23.9 t -149.78 157.57 43.33 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 118.496 0.589 . . . . 0.0 110.807 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.85 -23.87 0.46 Allowed 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 179.714 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 15.7 tppt? -165.09 133.33 3.24 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -173.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 174' ' ' ILE . 1.9 mp -82.67 136.95 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.079 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 172.614 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 77.4 p -94.39 143.41 26.43 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-O 120.613 0.244 . . . . 0.0 111.52 -176.433 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 69.8 ttt180 45.09 48.67 5.16 Favored Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 124.176 0.99 . . . . 0.0 112.797 177.699 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -76.26 -17.16 17.08 Favored 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 123.123 2.549 . . . . 0.0 112.264 -177.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -98.66 5.18 60.02 Favored Glycine 0 CA--C 1.529 0.92 0 CA-C-O 119.369 -0.684 . . . . 0.0 113.31 -175.295 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -145.79 165.04 29.99 Favored 'General case' 0 C--O 1.231 0.114 0 CA-C-N 118.292 1.046 . . . . 0.0 111.275 -176.154 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 82.2 p -120.56 163.47 17.94 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 123.845 0.858 . . . . 0.0 110.689 -179.262 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -130.68 5.31 4.65 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -175.113 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -75.31 159.95 30.88 Favored 'General case' 0 C--O 1.231 0.131 0 O-C-N 122.008 -0.433 . . . . 0.0 111.447 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 17.9 t -152.9 165.75 34.48 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 122.738 0.415 . . . . 0.0 110.229 -179.015 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -148.68 155.32 40.87 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.671 0.388 . . . . 0.0 110.176 178.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 20.3 m -86.24 31.74 0.64 Allowed 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 123.817 0.847 . . . . 0.0 112.688 -175.454 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 32.6 m -125.2 161.74 28.87 Favored 'Isoleucine or valine' 0 C--O 1.231 0.101 0 C-N-CA 123.125 0.57 . . . . 0.0 110.718 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 43.9 t30 52.81 32.08 11.69 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.466 0.706 . . . . 0.0 111.968 -177.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.9 m . . . . . 0 C--O 1.253 1.274 0 CA-C-O 117.357 -1.306 . . . . 0.0 111.073 -179.757 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.27 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -74.98 -14.67 60.65 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 122.883 0.473 . . . . 0.0 110.397 178.307 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -149.78 176.74 10.44 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.12 0.968 . . . . 0.0 108.704 179.208 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -70.59 -0.37 8.48 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.808 0.443 . . . . 0.0 111.451 177.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -141.88 160.09 40.9 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 124.244 1.018 . . . . 0.0 108.854 177.547 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 42.3 m-20 -67.63 131.13 92.94 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 117.654 0.207 . . . . 0.0 110.581 -177.449 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -73.83 -31.33 8.43 Favored 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 123.214 2.609 . . . . 0.0 111.848 -178.72 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 6.4 p-80 -158.18 -2.4 0.09 Allowed 'General case' 0 CA--C 1.53 0.202 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -179.174 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -84.56 162.62 19.76 Favored 'General case' 0 C--N 1.338 0.103 0 C-N-CA 122.673 0.389 . . . . 0.0 110.327 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 47.1 p -109.35 153.55 42.68 Favored Pre-proline 0 C--N 1.333 -0.135 0 C-N-CA 122.851 0.461 . . . . 0.0 111.02 -178.632 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -77.48 -1.99 12.17 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.967 3.111 . . . . 0.0 112.384 179.541 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.39 38.15 17.3 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.077 0.551 . . . . 0.0 111.315 -176.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.433 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 48.2 p -62.7 159.71 41.65 Favored Pre-proline 0 CA--C 1.532 0.262 0 C-N-CA 124.564 1.146 . . . . 0.0 112.03 -175.805 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 88.9 Cg_endo -70.11 4.79 2.14 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.583 3.522 . . . . 0.0 113.362 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.84 140.82 45.43 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.076 0 CA-C-N 118.579 0.627 . . . . 0.0 109.855 178.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.95 157.88 43.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 121.07 0.462 . . . . 0.0 110.643 179.119 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -107.84 142.63 37.61 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.908 0.883 . . . . 0.0 109.723 -179.554 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.0 mm -111.42 144.88 18.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 123.006 0.523 . . . . 0.0 110.016 -176.774 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -141.36 160.12 40.78 Favored 'General case' 0 C--N 1.334 -0.068 0 C-N-CA 123.514 0.726 . . . . 0.0 110.068 -178.778 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.67 25.67 58.01 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.432 173.218 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 47.7 mt -59.07 154.87 14.8 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.388 1.094 . . . . 0.0 109.189 176.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.0 pt -69.95 -40.37 78.61 Favored 'Isoleucine or valine' 0 C--N 1.338 0.076 0 O-C-N 122.184 -0.322 . . . . 0.0 111.652 -172.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -172.91 -35.16 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.484 0.713 . . . . 0.0 109.979 -179.383 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.84 51.96 0.05 OUTLIER Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 -177.103 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.1 m -53.72 151.64 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 117.138 0.469 . . . . 0.0 110.087 177.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.3 m -88.46 163.88 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-O 120.881 0.372 . . . . 0.0 110.832 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.68 -22.33 63.8 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 122.819 0.448 . . . . 0.0 111.065 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.82 -8.04 58.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 122.868 0.467 . . . . 0.0 111.991 -179.247 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -91.12 -32.74 15.73 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 118.476 0.58 . . . . 0.0 110.48 178.007 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -71.41 -39.05 71.37 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.119 0.167 . . . . 0.0 110.601 -177.323 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.71 -31.28 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 C-N-CA 121.191 -0.203 . . . . 0.0 110.783 -175.607 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.7 mm-40 -81.26 -17.23 50.15 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 122.131 -0.356 . . . . 0.0 111.554 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.9 -12.47 16.21 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.3 mt -114.53 -9.11 12.71 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.491 0.587 . . . . 0.0 112.444 -179.059 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -70.06 -5.98 30.48 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.508 0.595 . . . . 0.0 111.778 176.29 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -76.28 -12.78 60.14 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 122.13 -0.356 . . . . 0.0 110.498 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -100.39 -16.9 17.46 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 122.455 0.302 . . . . 0.0 111.523 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.12 177.32 35.99 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.59 140.97 37.12 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.875 3.05 . . . . 0.0 110.451 -179.549 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.8 mt -111.07 146.73 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 122.675 0.39 . . . . 0.0 110.098 -178.125 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.2 t -108.26 -40.33 5.2 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.336 0.655 . . . . 0.0 111.436 -177.098 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -159.12 158.49 32.98 Favored 'General case' 0 N--CA 1.457 -0.078 0 CA-C-O 120.577 0.227 . . . . 0.0 111.355 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 65.1 t -145.23 147.92 18.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.801 0.84 . . . . 0.0 109.602 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.4 p -148.2 150.75 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 174.139 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 43.9 t -132.28 150.38 33.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.053 0 C-N-CA 122.628 0.371 . . . . 0.0 110.043 -174.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.7 mtm -135.62 80.59 43.98 Favored Pre-proline 0 N--CA 1.456 -0.171 0 C-N-CA 123.858 0.863 . . . . 0.0 109.486 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -58.88 -20.37 52.03 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.948 3.098 . . . . 0.0 113.041 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -76.09 -12.43 60.12 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.168 0.587 . . . . 0.0 111.139 179.334 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -124.06 3.57 8.65 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.644 0.778 . . . . 0.0 111.294 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.1 tpp85 52.83 32.84 13.03 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.473 1.109 . . . . 0.0 111.826 -176.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -136.93 166.74 22.94 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 123.435 0.694 . . . . 0.0 110.71 -177.044 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.03 172.18 17.25 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 122.748 0.419 . . . . 0.0 110.412 178.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 35.6 mt -132.09 146.52 52.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.728 0.811 . . . . 0.0 109.816 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 90.4 t -138.17 131.84 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.788 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.71 117.98 31.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.679 0.791 . . . . 0.0 109.169 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -86.26 155.36 20.71 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.012 0.434 . . . . 0.0 110.267 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -77.94 -11.04 59.86 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.497 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -146.47 152.02 38.34 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.522 0.729 . . . . 0.0 109.183 178.022 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -69.08 -21.48 25.42 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.76 -28.67 44.86 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 122.039 -0.413 . . . . 0.0 110.594 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.38 -28.73 73.11 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.82 -31.82 25.64 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.887 0.344 . . . . 0.0 110.66 178.665 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -69.95 -33.12 71.71 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 122.359 0.264 . . . . 0.0 110.578 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -73.72 -20.38 60.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 122.277 0.231 . . . . 0.0 111.447 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.44 -29.41 30.71 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 117.797 0.271 . . . . 0.0 111.585 -177.185 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.36 -21.96 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.096 0 O-C-N 122.312 -0.242 . . . . 0.0 110.648 178.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -68.41 -17.06 64.13 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 122.275 -0.266 . . . . 0.0 110.51 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 50.0 t80 -97.9 -36.0 10.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 122.426 0.29 . . . . 0.0 110.611 177.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.84 -15.06 59.82 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 122.648 0.379 . . . . 0.0 111.855 -177.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.24 52.4 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.982 0.513 . . . . 0.0 111.922 177.175 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -135.29 -18.33 1.75 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.129 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -151.33 166.21 31.67 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -81.12 154.25 26.86 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 175.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.638 HD13 ' H ' ' A' ' 158' ' ' TYR . 0.5 OUTLIER -110.04 164.52 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.173 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.638 ' H ' HD13 ' A' ' 157' ' ' ILE . 75.9 m-85 -119.52 154.64 33.53 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.094 -0.379 . . . . 0.0 110.3 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.6 mt -137.0 -42.28 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 O-C-N 123.165 0.291 . . . . 0.0 110.802 -177.388 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.08 29.83 3.69 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.268 0.627 . . . . 0.0 111.11 -177.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.48 6.75 80.3 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -176.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -129.7 153.67 80.83 Favored Pre-proline 0 C--O 1.233 0.203 0 C-N-CA 124.013 0.925 . . . . 0.0 109.245 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.97 144.18 52.09 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.184 2.589 . . . . 0.0 112.285 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.44 -177.59 6.31 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.473 1.509 . . . . 0.0 108.668 178.099 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -137.99 160.61 38.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.114 0.483 . . . . 0.0 111.471 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.4 p -150.25 140.86 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 123.888 0.875 . . . . 0.0 109.323 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -159.14 162.01 36.36 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.149 0.58 . . . . 0.0 109.893 178.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 15.1 m-85 -62.61 162.75 10.05 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 117.702 0.228 . . . . 0.0 110.388 176.601 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 14.7 t -145.48 25.27 1.36 Allowed 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 122.29 0.236 . . . . 0.0 111.279 -179.056 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 6.2 m 57.17 15.71 2.62 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.871 0.868 . . . . 0.0 112.178 -178.313 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 75.7 m -87.99 156.47 19.31 Favored 'General case' 0 N--CA 1.456 -0.168 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 177.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.8 pt20 -139.31 -6.26 1.39 Allowed 'General case' 0 CA--C 1.529 0.158 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 1.9 tmtm? -157.54 137.57 12.51 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.019 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 82.4 mt -85.6 149.17 4.33 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.08 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 173.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 45.0 m -78.62 141.58 37.91 Favored 'General case' 0 C--O 1.231 0.097 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -175.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 40.9 mtm180 41.15 53.1 6.49 Favored Pre-proline 0 CA--C 1.533 0.317 0 C-N-CA 125.112 1.365 . . . . 0.0 113.548 176.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -70.92 -8.81 24.43 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.677 2.251 . . . . 0.0 111.822 -175.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -121.85 7.04 10.25 Favored Glycine 0 CA--C 1.529 0.933 0 C-N-CA 123.516 0.579 . . . . 0.0 112.148 179.281 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -137.21 -12.03 1.65 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 117.849 0.825 . . . . 0.0 112.275 -176.467 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 29.2 t -79.79 149.87 30.94 Favored 'General case' 0 N--CA 1.455 -0.183 0 O-C-N 121.767 -0.583 . . . . 0.0 110.745 177.76 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 26.9 t70 51.89 24.42 2.54 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.893 0.877 . . . . 0.0 112.769 -178.121 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -73.82 155.45 38.8 Favored 'General case' 0 N--CA 1.455 -0.183 0 CA-C-O 120.906 0.384 . . . . 0.0 110.988 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 78.0 p -143.83 155.69 44.22 Favored 'General case' 0 C--O 1.231 0.079 0 C-N-CA 123.336 0.654 . . . . 0.0 109.387 178.004 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 14.6 ttm180 -151.94 164.06 37.95 Favored 'General case' 0 C--N 1.337 0.035 0 CA-C-O 120.647 0.261 . . . . 0.0 111.343 -174.549 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 36.4 m -80.72 4.15 19.83 Favored 'General case' 0 CA--C 1.529 0.136 0 C-N-CA 123.074 0.55 . . . . 0.0 111.761 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 32.9 m -134.17 158.7 42.25 Favored 'Isoleucine or valine' 0 C--O 1.231 0.109 0 C-N-CA 123.408 0.683 . . . . 0.0 110.423 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 45.5 t30 51.3 29.4 4.99 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.747 0.819 . . . . 0.0 112.177 -179.317 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 38.0 t . . . . . 0 C--O 1.25 1.122 0 CA-C-O 117.434 -1.27 . . . . 0.0 109.739 -178.998 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.273 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -134.15 -4.22 2.74 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 122.969 0.508 . . . . 0.0 110.87 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 58.21 173.03 0.06 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 125.202 1.401 . . . . 0.0 113.332 -177.529 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -89.39 -5.79 57.15 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 122.89 0.476 . . . . 0.0 111.225 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -152.21 150.76 30.18 Favored 'General case' 0 N--CA 1.455 -0.181 0 C-N-CA 124.322 1.049 . . . . 0.0 108.723 178.755 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 42.4 m-20 -79.91 127.28 77.83 Favored Pre-proline 0 N--CA 1.454 -0.23 0 O-C-N 122.275 -0.265 . . . . 0.0 110.842 -176.603 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -76.23 -18.42 16.2 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 123.621 2.881 . . . . 0.0 112.028 178.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 2.1 p-80 -151.11 -126.64 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 123.663 0.785 . . . . 0.0 109.287 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 82.9 mttt 62.71 179.16 0.14 Allowed 'General case' 0 C--N 1.341 0.196 0 C-N-CA 124.277 1.031 . . . . 0.0 111.346 -176.119 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 50.1 p -130.56 154.64 81.72 Favored Pre-proline 0 CA--C 1.53 0.196 0 C-N-CA 123.192 0.597 . . . . 0.0 110.572 -178.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -74.61 -2.56 12.6 Favored 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 124.025 3.15 . . . . 0.0 112.669 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.29 35.79 14.56 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.302 0.641 . . . . 0.0 111.545 -176.727 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.431 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 71.0 p -66.28 161.63 55.61 Favored Pre-proline 0 CA--C 1.532 0.254 0 C-N-CA 124.602 1.161 . . . . 0.0 111.484 -177.305 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.431 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 80.6 Cg_endo -69.78 4.27 2.3 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 124.098 3.198 . . . . 0.0 112.342 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.5 t -115.06 140.43 36.34 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 C-N-CA 123.076 0.55 . . . . 0.0 109.802 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.12 150.74 34.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.1 0 CA-C-O 121.035 0.445 . . . . 0.0 110.699 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.3 t-80 -99.39 136.21 39.67 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.249 1.019 . . . . 0.0 110.178 178.321 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.42 146.4 15.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.463 0.705 . . . . 0.0 109.168 -177.682 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -142.3 162.56 35.17 Favored 'General case' 0 N--CA 1.461 0.084 0 C-N-CA 123.573 0.749 . . . . 0.0 110.385 -176.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.27 26.99 53.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.66 -0.522 . . . . 0.0 113.239 172.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.4 mt -59.41 155.74 14.27 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 118.176 0.988 . . . . 0.0 109.798 177.305 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.2 pt -71.12 -39.5 74.08 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.111 0 O-C-N 122.189 -0.319 . . . . 0.0 111.308 -174.631 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -173.21 -37.05 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.882 0.873 . . . . 0.0 110.107 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.63 52.22 0.06 OUTLIER Glycine 0 C--N 1.337 0.612 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -176.44 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.1 m -54.04 154.4 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 CA-C-N 117.037 0.418 . . . . 0.0 110.203 177.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.9 m -90.84 166.11 1.85 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.063 0 CA-C-O 121.213 0.53 . . . . 0.0 111.091 -176.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -60.58 -24.2 65.25 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.24 0.616 . . . . 0.0 111.217 -178.663 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.5 -4.71 54.92 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 122.694 0.398 . . . . 0.0 112.015 -178.022 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -91.74 -35.76 13.96 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.256 0.48 . . . . 0.0 110.471 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.67 -31.9 52.86 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 122.225 -0.297 . . . . 0.0 111.105 -176.274 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.39 -31.5 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 O-C-N 122.057 -0.402 . . . . 0.0 110.184 -178.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.8 mm-40 -82.33 -18.55 41.77 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.244 -0.285 . . . . 0.0 111.054 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.01 -12.19 18.34 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.2 mt -117.6 -8.48 10.93 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.627 0.649 . . . . 0.0 112.525 -177.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.3 pt20 -68.8 -6.92 29.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 118.575 0.625 . . . . 0.0 111.563 176.308 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -76.47 -14.65 60.03 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.791 0.436 . . . . 0.0 110.607 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -99.41 -13.56 19.51 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 122.49 0.316 . . . . 0.0 111.613 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.62 176.32 32.59 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -71.27 140.35 36.97 Favored 'Trans proline' 0 N--CA 1.452 -0.93 0 C-N-CA 124.023 3.149 . . . . 0.0 110.51 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.6 mt -111.28 146.3 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.939 0.496 . . . . 0.0 110.519 -178.029 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -106.36 -41.26 5.36 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 123.433 0.693 . . . . 0.0 111.438 -177.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.0 t80 -159.29 158.89 33.32 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 122.225 0.21 . . . . 0.0 111.51 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -143.56 147.22 20.34 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 C-N-CA 123.827 0.851 . . . . 0.0 109.815 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.43 152.68 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.064 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 175.246 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 56.4 t -133.71 150.06 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 C-N-CA 122.852 0.461 . . . . 0.0 110.352 -176.317 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -133.79 86.47 38.58 Favored Pre-proline 0 N--CA 1.454 -0.262 0 C-N-CA 123.83 0.852 . . . . 0.0 109.318 -179.181 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -68.61 -14.64 39.98 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.463 2.776 . . . . 0.0 111.645 -176.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.0 tttp -79.24 -10.29 59.78 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.114 0.566 . . . . 0.0 110.91 177.217 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -126.76 1.22 6.73 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 123.683 0.793 . . . . 0.0 111.369 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.8 tpp85 53.05 32.33 12.75 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 124.358 1.063 . . . . 0.0 111.948 -176.022 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -135.77 166.56 22.99 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 123.551 0.74 . . . . 0.0 110.147 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.66 172.22 18.24 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-O 120.773 0.321 . . . . 0.0 110.921 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.5 mt -134.09 147.75 50.92 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.41 0.684 . . . . 0.0 109.929 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 81.6 t -138.24 133.61 43.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.8 tt0 -115.44 119.59 36.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 178.183 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 50.2 m-85 -86.13 155.0 20.96 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.987 0.422 . . . . 0.0 110.361 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -75.23 -14.41 60.52 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.379 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.29 153.03 39.25 Favored 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 123.697 0.799 . . . . 0.0 109.456 177.261 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -68.06 -22.0 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 52.5 tp -73.96 -25.45 59.95 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.184 -0.322 . . . . 0.0 110.494 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.25 -30.17 65.37 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 179.327 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.44 -31.17 22.99 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 122.864 0.466 . . . . 0.0 110.612 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.91 -19.98 60.53 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.601 0.36 . . . . 0.0 111.166 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -94.46 -15.48 24.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.45 0.3 . . . . 0.0 111.314 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.63 -32.6 25.61 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.31 -0.244 . . . . 0.0 111.491 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -84.86 -16.35 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -72.54 -4.39 30.34 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.656 0.382 . . . . 0.0 111.003 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -115.29 -35.78 4.55 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.806 0.442 . . . . 0.0 110.935 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -81.39 -7.77 59.63 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -177.833 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.7 -1.82 58.03 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.947 -0.471 . . . . 0.0 112.027 178.36 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.87 -6.7 1.45 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.678 0.391 . . . . 0.0 112.043 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -153.85 164.42 38.4 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.226 0.61 . . . . 0.0 109.563 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.26 158.18 23.6 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 174.161 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.96 135.45 64.01 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 -178.919 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -86.88 151.41 23.35 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.196 -0.315 . . . . 0.0 110.661 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.1 mt -137.09 -40.04 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 122.429 0.291 . . . . 0.0 111.095 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.34 29.12 4.0 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 122.842 0.457 . . . . 0.0 111.058 -178.158 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.96 78.1 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -177.376 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -131.58 152.4 80.36 Favored Pre-proline 0 N--CA 1.453 -0.32 0 C-N-CA 124.205 1.002 . . . . 0.0 108.774 177.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.68 145.26 57.06 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 123.147 2.565 . . . . 0.0 111.627 -177.101 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.09 -175.03 5.08 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 124.846 1.258 . . . . 0.0 108.905 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -138.35 162.01 35.48 Favored 'General case' 0 N--CA 1.456 -0.137 0 CA-C-O 120.915 0.388 . . . . 0.0 111.797 -178.067 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.14 144.05 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 C-N-CA 123.692 0.797 . . . . 0.0 109.378 178.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -157.18 166.22 33.82 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 122.966 0.506 . . . . 0.0 109.875 179.587 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -61.99 168.98 2.87 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-O 120.882 0.372 . . . . 0.0 111.056 177.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 35.5 t -145.6 165.97 27.14 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 123.175 0.59 . . . . 0.0 109.885 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 40.9 p -74.0 -7.62 53.08 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 175.473 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 68.8 m -73.8 152.14 40.38 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.869 0.868 . . . . 0.0 110.67 176.455 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.4 pt20 -137.29 -3.29 1.95 Allowed 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 122.626 0.37 . . . . 0.0 111.381 177.054 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -158.05 136.77 11.29 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.032 0.933 . . . . 0.0 108.608 -178.401 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 89.5 mt -87.39 137.56 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.212 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 174.12 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.5 m -78.67 141.25 38.1 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -174.24 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 69.9 ttt180 43.68 60.1 11.64 Favored Pre-proline 0 CA--C 1.533 0.29 0 C-N-CA 124.903 1.281 . . . . 0.0 112.751 174.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -72.02 -9.34 24.45 Favored 'Trans proline' 0 N--CA 1.455 -0.771 0 C-N-CA 123.23 2.62 . . . . 0.0 111.521 178.405 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 65.71 -134.76 35.35 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.516 -0.634 . . . . 0.0 111.516 176.571 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -152.73 163.42 39.72 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 123.357 0.663 . . . . 0.0 109.832 -176.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 95.3 p -144.83 162.68 36.2 Favored 'General case' 0 C--O 1.232 0.16 0 C-N-CA 123.357 0.663 . . . . 0.0 110.506 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -67.62 -16.46 64.18 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 122.284 -0.26 . . . . 0.0 111.117 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -85.53 -7.53 58.82 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.693 0.397 . . . . 0.0 110.758 178.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 46.5 m -113.06 0.16 14.91 Favored 'General case' 0 C--N 1.339 0.131 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -176.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 50.3 mtm180 -81.18 161.79 23.87 Favored 'General case' 0 C--N 1.34 0.171 0 CA-C-O 121.229 0.538 . . . . 0.0 111.309 179.065 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 62.7 m -71.94 -1.94 16.25 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.65 0.78 . . . . 0.0 111.665 178.41 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 40.3 t -88.16 -9.79 10.87 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 C-N-CA 123.655 0.782 . . . . 0.0 110.218 178.047 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -90.54 7.63 38.09 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 123.247 0.619 . . . . 0.0 111.386 -179.095 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 74.7 p . . . . . 0 C--O 1.254 1.291 0 CA-C-O 118.128 -0.939 . . . . 0.0 111.509 -178.406 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.244 0 N-CA-C 111.229 -0.749 . . . . 0.0 111.229 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -149.89 147.02 27.43 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.149 0.579 . . . . 0.0 110.121 179.34 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.6 p-10 -151.01 -177.43 6.01 Favored 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 122.755 0.422 . . . . 0.0 111.117 179.282 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -75.34 7.66 3.34 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.365 0.876 . . . . 0.0 113.365 -176.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -98.94 4.12 47.25 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -176.422 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 47.52 54.46 15.57 Favored Pre-proline 0 CA--C 1.534 0.335 0 C-N-CA 124.037 0.935 . . . . 0.0 112.774 177.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -71.9 -26.62 18.58 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 123.182 2.588 . . . . 0.0 112.106 -173.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 5.9 p80 -158.49 -61.02 0.08 Allowed 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 122.377 0.271 . . . . 0.0 111.141 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 97.7 mttt 44.28 33.25 0.81 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 124.433 1.093 . . . . 0.0 113.093 -179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 24.8 p -69.59 151.79 96.48 Favored Pre-proline 0 C--O 1.233 0.221 0 C-N-CA 122.614 0.366 . . . . 0.0 110.752 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -76.46 -7.33 17.77 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.675 2.917 . . . . 0.0 111.999 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.71 36.16 13.53 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.538 0.735 . . . . 0.0 112.044 -178.633 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 51.8 m -62.12 157.38 53.04 Favored Pre-proline 0 CA--C 1.531 0.243 0 C-N-CA 123.836 0.854 . . . . 0.0 112.225 -176.112 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -70.98 -1.33 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 124.114 3.209 . . . . 0.0 111.927 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.7 t -116.14 140.44 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 176.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.53 152.08 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.062 0.458 . . . . 0.0 110.761 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -102.48 136.38 42.41 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 123.982 0.913 . . . . 0.0 110.162 179.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.5 mp -111.95 145.87 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -177.174 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -141.39 162.95 34.24 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.692 0.797 . . . . 0.0 110.574 -177.661 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.83 27.22 54.31 Favored Glycine 0 CA--C 1.527 0.818 0 CA-C-O 119.469 -0.628 . . . . 0.0 113.185 174.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 54.0 mt -61.42 158.88 13.72 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 117.893 0.847 . . . . 0.0 110.415 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.87 -47.98 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -172.798 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -175.69 -35.86 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.208 0.603 . . . . 0.0 110.601 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -171.95 34.18 0.14 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.684 -0.509 . . . . 0.0 111.955 -175.117 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 8.8 p -52.32 148.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-N 117.425 0.612 . . . . 0.0 109.732 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.4 m -103.31 168.87 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.082 0 CA-C-O 121.364 0.602 . . . . 0.0 112.141 -172.202 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -57.99 -28.13 64.11 Favored 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 123.985 0.914 . . . . 0.0 111.602 -177.133 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.58 -2.31 38.27 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -176.446 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -104.17 -32.59 9.07 Favored 'General case' 0 N--CA 1.457 -0.121 0 CA-C-N 118.235 0.47 . . . . 0.0 110.415 177.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.75 -34.33 60.27 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.898 -0.501 . . . . 0.0 110.524 -179.325 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.0 p -76.5 -31.26 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.358 -179.052 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -83.0 -15.98 49.04 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 119.666 -0.207 . . . . 0.0 111.267 -178.241 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.72 -10.89 17.15 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -116.02 -9.15 11.78 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 118.632 0.651 . . . . 0.0 112.18 -179.5 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -68.9 -7.15 32.13 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 118.719 0.691 . . . . 0.0 111.523 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.67 -14.45 60.35 Favored 'General case' 0 CA--C 1.532 0.269 0 O-C-N 122.141 -0.35 . . . . 0.0 110.819 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.5 m-85 -97.13 -16.02 20.66 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 122.54 0.336 . . . . 0.0 111.591 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.78 178.56 35.8 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.85 139.5 33.48 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 124.046 3.164 . . . . 0.0 110.557 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 73.9 mt -110.94 145.76 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.688 0.395 . . . . 0.0 110.501 -177.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.1 t -106.73 -38.42 6.12 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 123.331 0.652 . . . . 0.0 111.463 -177.296 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -160.17 157.05 27.67 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.668 0.27 . . . . 0.0 111.23 179.597 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 94.4 t -144.14 146.23 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 C-N-CA 123.858 0.863 . . . . 0.0 109.666 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.83 153.79 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 C-N-CA 123.314 0.645 . . . . 0.0 109.513 176.561 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 46.0 t -127.34 150.66 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -177.465 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 68.2 mtm -132.27 77.85 69.77 Favored Pre-proline 0 CA--C 1.531 0.222 0 C-N-CA 124.3 1.04 . . . . 0.0 109.104 -177.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.8 -8.81 24.44 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 123.418 2.746 . . . . 0.0 111.72 -175.33 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -72.3 -17.11 61.89 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 122.656 0.382 . . . . 0.0 110.77 178.311 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 62.9 pttt -138.92 15.08 2.67 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 123.146 0.578 . . . . 0.0 111.91 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 57.53 39.68 27.63 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 124.079 0.952 . . . . 0.0 113.247 178.255 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.58 170.07 15.25 Favored 'General case' 0 CA--C 1.527 0.06 0 C-N-CA 123.043 0.537 . . . . 0.0 110.621 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.43 170.33 22.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 122.863 0.465 . . . . 0.0 110.564 177.003 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 34.1 mt -134.81 147.11 49.87 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.663 0.785 . . . . 0.0 110.179 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 85.0 t -139.08 132.07 38.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -114.15 119.79 38.31 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -86.97 154.79 20.51 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.426 -179.471 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -74.39 -14.63 60.89 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.507 -177.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -148.08 152.97 38.27 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.703 0.801 . . . . 0.0 109.108 176.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.1 p -66.72 -22.0 29.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -176.048 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.61 -26.11 60.64 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 122.031 -0.418 . . . . 0.0 110.629 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.03 -31.39 64.34 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.57 -32.12 25.98 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.047 0.423 . . . . 0.0 110.335 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.8 t -70.86 -15.64 62.65 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.198 0.599 . . . . 0.0 110.938 178.518 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 60.2 t30 -99.89 -14.03 18.92 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.029 0.532 . . . . 0.0 111.412 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -87.23 -31.65 20.18 Favored 'General case' 0 N--CA 1.456 -0.175 0 O-C-N 122.128 -0.358 . . . . 0.0 111.717 -177.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.6 t -86.82 -16.12 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.078 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -70.43 -4.69 23.78 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 122.913 0.485 . . . . 0.0 111.161 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -117.32 -32.21 5.03 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.969 0.508 . . . . 0.0 111.459 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.84 -0.93 55.52 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 113.083 0.771 . . . . 0.0 113.083 -176.302 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.67 -6.64 59.21 Favored 'General case' 0 CA--C 1.534 0.341 0 O-C-N 121.98 -0.45 . . . . 0.0 112.032 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -145.26 3.75 1.04 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.704 0.402 . . . . 0.0 111.88 179.075 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 49.0 t30 -151.52 171.3 17.79 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -178.581 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -95.61 155.88 16.56 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 118.38 0.536 . . . . 0.0 110.17 177.568 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -123.35 136.31 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -179.15 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -90.58 154.32 19.68 Favored 'General case' 0 N--CA 1.454 -0.235 0 O-C-N 122.047 -0.408 . . . . 0.0 110.851 -178.615 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.3 mt -137.33 -42.24 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.916 -177.337 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.49 30.88 3.47 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.936 0.494 . . . . 0.0 111.002 -177.381 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.7 5.94 80.82 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -130.59 151.21 78.3 Favored Pre-proline 0 N--CA 1.455 -0.207 0 C-N-CA 124.046 0.938 . . . . 0.0 109.01 177.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -72.17 145.97 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 123.375 2.717 . . . . 0.0 111.936 -176.219 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.0 -177.91 6.29 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.757 1.223 . . . . 0.0 108.845 177.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -137.34 158.78 43.66 Favored 'General case' 0 N--CA 1.457 -0.106 0 O-C-N 122.296 -0.253 . . . . 0.0 111.096 -178.552 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.01 142.09 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.23 0.612 . . . . 0.0 109.918 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 -152.59 167.55 28.51 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.187 0.595 . . . . 0.0 110.332 178.15 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -66.06 164.55 15.15 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 120.976 0.417 . . . . 0.0 110.842 177.384 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 98.2 p -144.56 174.34 11.03 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 176.692 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 59.7 p -76.26 1.76 15.12 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.675 0.39 . . . . 0.0 111.254 178.612 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 28.9 t -81.48 153.78 26.66 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 122.705 0.402 . . . . 0.0 110.758 179.147 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 19.3 pt20 -139.27 -5.17 1.44 Allowed 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 123.027 0.531 . . . . 0.0 111.08 176.287 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.4 tppt? -159.16 130.62 6.27 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 -178.47 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 69.5 mt -90.96 93.64 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.19 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 179.142 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 47.7 m 50.33 -114.31 0.74 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 123.515 0.726 . . . . 0.0 111.306 -178.548 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 14.9 tpp180 -140.98 82.78 14.69 Favored Pre-proline 0 N--CA 1.455 -0.187 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 -178.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -81.83 61.31 7.86 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 124.694 3.596 . . . . 0.0 110.842 -173.316 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 79.83 11.97 84.01 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -176.565 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 25.4 t0 61.86 169.01 0.11 Allowed 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 124.778 1.231 . . . . 0.0 113.012 -177.351 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 32.1 m -134.82 161.33 35.49 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.113 0.565 . . . . 0.0 110.847 -176.779 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -146.64 162.8 37.66 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 123.209 0.604 . . . . 0.0 110.138 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -143.21 154.91 44.34 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.096 0.558 . . . . 0.0 110.827 -178.449 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 54.8 m -138.82 161.97 35.94 Favored 'General case' 0 C--O 1.231 0.131 0 C-N-CA 123.238 0.615 . . . . 0.0 110.821 -177.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -91.81 12.12 22.49 Favored 'General case' 0 C--N 1.34 0.153 0 C-N-CA 123.399 0.68 . . . . 0.0 112.769 -178.211 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 43.7 m 61.92 7.17 1.93 Allowed 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 179.453 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 30.2 m -142.2 166.28 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 CA-C-N 118.426 0.557 . . . . 0.0 110.059 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 46.1 t30 -109.36 24.67 12.76 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.506 0.722 . . . . 0.0 110.942 -178.403 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 48.4 m . . . . . 0 C--O 1.251 1.149 0 CA-C-O 117.692 -1.147 . . . . 0.0 110.742 -178.711 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.427 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.2 p . . . . . 0 CA--C 1.531 0.237 0 N-CA-C 111.487 0.18 . . . . 0.0 111.487 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 77.7 Cg_endo -70.19 3.02 3.23 Favored 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 124.199 3.266 . . . . 0.0 112.452 178.332 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.3 t -115.64 141.31 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.087 0.555 . . . . 0.0 109.798 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.0 m -130.71 151.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-O 121.231 0.538 . . . . 0.0 110.898 177.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 22.9 t-80 -100.49 139.23 36.47 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.076 0.95 . . . . 0.0 110.03 179.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 29.7 mm -108.54 145.15 15.86 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 123.646 0.778 . . . . 0.0 110.089 -178.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -143.59 161.2 39.12 Favored 'General case' 0 C--N 1.337 0.044 0 C-N-CA 123.352 0.661 . . . . 0.0 110.376 -177.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.35 25.09 59.8 Favored Glycine 0 CA--C 1.528 0.845 0 CA-C-O 119.442 -0.644 . . . . 0.0 113.658 173.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 68.9 mt -61.21 157.56 15.94 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.398 1.099 . . . . 0.0 109.864 177.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.3 pt -73.08 -41.64 59.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -173.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -173.39 -35.08 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.277 0.631 . . . . 0.0 110.553 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.98 50.59 0.1 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -175.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.9 t -52.32 144.58 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.159 0 C-N-CA 123.5 0.72 . . . . 0.0 109.743 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.82 161.24 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.036 0 CA-C-O 121.084 0.469 . . . . 0.0 111.564 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -60.95 -25.05 66.52 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 123.288 0.635 . . . . 0.0 111.201 -177.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.23 -3.62 52.9 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -178.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -99.43 -31.22 11.76 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.369 0.531 . . . . 0.0 110.757 178.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.4 mp -75.18 -34.05 61.51 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.162 -0.336 . . . . 0.0 110.361 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -77.63 -30.63 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 118.099 0.409 . . . . 0.0 110.348 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -82.14 -17.02 47.84 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.369 -0.207 . . . . 0.0 111.433 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.1 -11.51 16.56 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.5 mt -115.97 -9.97 11.68 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.695 0.68 . . . . 0.0 112.404 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -68.45 -7.05 28.41 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 118.567 0.621 . . . . 0.0 111.637 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -76.01 -14.44 60.22 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 122.692 0.397 . . . . 0.0 110.859 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -98.68 -16.8 18.88 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 122.685 0.394 . . . . 0.0 111.639 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.05 177.05 35.72 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -71.5 141.21 37.91 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 123.775 2.984 . . . . 0.0 110.524 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.2 mt -110.65 147.05 15.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 C-N-CA 122.824 0.45 . . . . 0.0 110.356 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.0 t -107.31 -42.55 4.8 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.279 0.632 . . . . 0.0 111.348 -177.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 54.5 t80 -158.79 159.67 35.41 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 120.778 0.323 . . . . 0.0 111.076 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 76.7 t -143.35 146.85 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 124.008 0.923 . . . . 0.0 109.071 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -147.71 151.26 13.76 Favored 'Isoleucine or valine' 0 C--O 1.231 0.096 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 175.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 45.4 t -128.05 151.01 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.065 0 C-N-CA 122.503 0.321 . . . . 0.0 110.6 -175.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.7 mtm -133.7 81.19 54.04 Favored Pre-proline 0 N--CA 1.455 -0.192 0 C-N-CA 124.113 0.965 . . . . 0.0 108.732 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.43 -12.29 33.2 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.577 2.852 . . . . 0.0 111.729 -175.201 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -82.02 -5.14 58.12 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.676 0.39 . . . . 0.0 110.685 177.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 35.8 mmtp -130.4 3.83 4.69 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.245 1.018 . . . . 0.0 111.132 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 53.62 33.22 16.0 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.336 1.054 . . . . 0.0 112.087 -176.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -136.51 168.45 19.45 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.309 0.644 . . . . 0.0 110.413 -176.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.49 172.22 18.61 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.591 0.356 . . . . 0.0 110.457 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 36.8 mt -131.4 146.65 52.36 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.566 0.746 . . . . 0.0 110.219 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 84.7 t -137.83 131.75 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -115.37 121.21 42.1 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.055 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.56 153.61 21.69 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.984 0.421 . . . . 0.0 110.325 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -74.83 -13.38 60.56 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.936 0.398 . . . . 0.0 110.496 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -147.46 151.65 36.77 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.58 0.752 . . . . 0.0 109.412 177.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.01 -20.43 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 111.663 0.245 . . . . 0.0 111.663 -175.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.1 tp -74.13 -27.01 60.65 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.946 -0.471 . . . . 0.0 110.743 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.32 -30.44 69.31 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.58 -29.57 27.7 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 117.132 0.466 . . . . 0.0 110.189 178.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 32.0 t -71.97 -12.95 61.48 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.208 0.603 . . . . 0.0 111.366 179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -102.0 -17.71 15.97 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 122.623 0.369 . . . . 0.0 111.764 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.49 -30.43 25.19 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.135 0.425 . . . . 0.0 111.587 -176.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 25.9 t -88.06 -17.19 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -72.17 -3.75 25.22 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.448 0.299 . . . . 0.0 111.063 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -116.18 -33.43 5.01 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 122.925 0.49 . . . . 0.0 111.113 177.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.02 -7.77 58.4 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -177.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.03 -1.0 56.31 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 122.077 -0.389 . . . . 0.0 111.806 177.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -140.18 -5.94 1.25 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 122.821 0.448 . . . . 0.0 111.725 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.78 173.24 16.71 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -90.73 156.76 17.84 Favored 'General case' 0 CA--C 1.529 0.136 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 175.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.05 136.4 59.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -90.33 150.98 21.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 O-C-N 122.068 -0.395 . . . . 0.0 110.698 -178.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.1 mt -137.43 -38.79 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.932 -177.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -132.9 28.76 4.17 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.288 0.635 . . . . 0.0 111.126 -176.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.01 4.83 86.64 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -176.178 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -130.82 151.9 79.64 Favored Pre-proline 0 N--CA 1.453 -0.287 0 C-N-CA 124.303 1.041 . . . . 0.0 109.066 178.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -70.5 145.26 52.38 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 123.49 2.793 . . . . 0.0 111.905 -176.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.63 -175.79 5.34 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.852 1.261 . . . . 0.0 108.898 178.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -138.68 160.07 40.56 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-O 120.948 0.404 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.67 143.1 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.854 0.862 . . . . 0.0 109.647 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 N--CA 1.455 -0.195 0 C-N-CA 122.973 0.509 . . . . 0.0 110.089 179.022 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.0 m . . . . . 0 CA--C 1.532 0.27 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -70.87 2.61 3.98 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 124.184 3.256 . . . . 0.0 112.325 178.243 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.6 t -115.26 141.53 31.77 Favored 'Isoleucine or valine' 0 C--N 1.339 0.112 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.59 152.34 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.381 0.61 . . . . 0.0 111.025 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -100.65 141.07 34.02 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.307 1.043 . . . . 0.0 109.882 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.1 mm -110.37 144.92 17.51 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 C-N-CA 123.048 0.539 . . . . 0.0 109.801 -178.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -140.56 159.28 42.54 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 123.464 0.705 . . . . 0.0 110.21 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.66 24.64 60.05 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 119.322 -0.71 . . . . 0.0 113.615 173.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 51.3 mt -59.47 155.82 14.32 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.172 0.986 . . . . 0.0 109.533 177.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -70.58 -38.01 71.85 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.102 0 O-C-N 122.35 -0.219 . . . . 0.0 111.305 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -172.08 -37.19 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.908 0.883 . . . . 0.0 109.506 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.0 56.19 0.04 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 m -53.2 151.4 1.19 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 117.243 0.522 . . . . 0.0 110.422 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.2 m -86.68 166.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.122 0 CA-C-O 121.166 0.508 . . . . 0.0 110.855 -177.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.6 -26.72 68.16 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 122.871 0.468 . . . . 0.0 110.786 -178.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.62 -7.98 56.33 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -94.45 -34.65 12.65 Favored 'General case' 0 N--CA 1.457 -0.11 0 CA-C-N 118.248 0.476 . . . . 0.0 109.772 176.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.4 mt -72.73 -40.23 66.28 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 122.389 0.276 . . . . 0.0 110.93 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.1 p -77.3 -29.87 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 O-C-N 122.083 -0.385 . . . . 0.0 110.739 -176.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -85.88 -14.64 44.26 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 122.128 -0.357 . . . . 0.0 111.146 -178.022 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -101.52 -14.11 17.62 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 178.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.6 mt -115.12 -8.47 12.4 Favored 'General case' 0 CA--C 1.529 0.14 0 CA-C-N 118.566 0.621 . . . . 0.0 112.568 -178.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.3 pt20 -70.54 -6.09 33.78 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.849 0.749 . . . . 0.0 111.67 176.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -76.82 -16.39 59.45 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.53 0.332 . . . . 0.0 110.449 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -95.94 -18.79 20.02 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.529 0.332 . . . . 0.0 111.525 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.43 177.57 37.88 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.6 140.28 35.74 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 124.047 3.165 . . . . 0.0 110.576 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 70.1 mt -110.81 147.1 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.869 0.468 . . . . 0.0 110.258 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -108.48 -39.42 5.42 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.333 0.653 . . . . 0.0 111.494 -177.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -158.83 157.68 32.02 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 117.719 0.236 . . . . 0.0 111.167 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 63.7 t -145.08 146.57 19.74 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 C-N-CA 123.775 0.83 . . . . 0.0 110.091 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.0 p -150.68 151.8 12.14 Favored 'Isoleucine or valine' 0 C--O 1.231 0.102 0 C-N-CA 123.566 0.746 . . . . 0.0 109.24 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.8 p -134.13 150.29 31.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-O 120.736 0.303 . . . . 0.0 110.804 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.2 mpp? -130.55 83.73 61.29 Favored Pre-proline 0 CA--C 1.53 0.202 0 C-N-CA 123.567 0.747 . . . . 0.0 109.51 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -58.79 -18.88 43.77 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 123.938 3.092 . . . . 0.0 113.066 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -78.85 -6.27 55.63 Favored 'General case' 0 C--N 1.341 0.222 0 C-N-CA 122.944 0.498 . . . . 0.0 111.473 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -131.28 3.27 4.29 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.755 0.822 . . . . 0.0 111.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.0 tpp85 54.68 33.65 19.86 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.404 1.082 . . . . 0.0 111.977 -176.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -136.35 165.49 25.67 Favored 'General case' 0 C--O 1.23 0.078 0 C-N-CA 123.005 0.522 . . . . 0.0 110.78 -176.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.97 171.2 17.66 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 122.59 0.356 . . . . 0.0 110.582 178.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.3 mt -131.05 145.16 51.93 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.022 0.929 . . . . 0.0 109.688 178.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -137.9 131.92 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -113.36 121.29 43.92 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 177.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -87.74 154.86 20.24 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-O 120.816 0.341 . . . . 0.0 110.216 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -75.38 -13.24 60.39 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.189 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -147.87 150.25 33.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.72 0.808 . . . . 0.0 109.274 177.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -67.34 -21.98 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.7 tp -74.93 -28.78 60.74 Favored 'General case' 0 N--CA 1.455 -0.204 0 O-C-N 121.875 -0.516 . . . . 0.0 110.534 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.29 -30.46 69.36 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.42 -30.06 33.67 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.699 -0.295 . . . . 0.0 110.618 178.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.5 t -74.22 -32.97 63.21 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.669 0.271 . . . . 0.0 110.685 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -74.81 -17.52 60.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.211 -0.306 . . . . 0.0 110.906 -179.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.37 -30.17 23.86 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -176.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.0 t -89.17 -22.63 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 O-C-N 122.095 -0.378 . . . . 0.0 110.732 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -70.19 -1.67 10.91 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 122.132 -0.355 . . . . 0.0 111.535 179.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.2 t80 -112.75 -37.82 4.76 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 122.836 0.454 . . . . 0.0 110.969 176.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.81 -6.8 57.96 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -79.69 -4.99 54.23 Favored 'General case' 0 N--CA 1.453 -0.284 0 O-C-N 122.027 -0.42 . . . . 0.0 111.7 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -141.39 -4.84 1.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 122.654 0.382 . . . . 0.0 111.894 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 27.2 m-80 -145.53 174.53 11.08 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.505 0.722 . . . . 0.0 109.821 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . 0.455 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -94.73 151.72 19.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 173.972 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -121.96 134.98 63.57 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -88.54 152.19 22.02 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.136 -0.353 . . . . 0.0 110.576 -178.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.7 mt -136.56 -41.57 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.22 -177.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.75 30.09 3.77 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.098 0.559 . . . . 0.0 110.858 -178.157 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.9 4.99 78.15 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -131.7 152.72 80.87 Favored Pre-proline 0 N--CA 1.455 -0.214 0 C-N-CA 124.024 0.93 . . . . 0.0 109.399 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -70.77 144.82 49.69 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 123.408 2.739 . . . . 0.0 111.866 -175.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.99 -175.95 5.35 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.891 1.276 . . . . 0.0 108.929 178.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -140.53 160.46 39.95 Favored 'General case' 0 C--O 1.231 0.092 0 CA-C-O 120.995 0.426 . . . . 0.0 111.503 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -146.96 141.52 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 C-N-CA 123.772 0.829 . . . . 0.0 109.916 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.6 t30 . . . . . 0 N--CA 1.456 -0.151 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.578 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.408 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 71.3 p . . . . . 0 CA--C 1.533 0.317 0 N-CA-C 111.45 0.167 . . . . 0.0 111.45 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 92.7 Cg_endo -71.7 5.82 2.29 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 124.471 3.447 . . . . 0.0 112.179 177.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.8 t -120.57 141.67 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.124 0 C-N-CA 123.066 0.546 . . . . 0.0 109.57 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 31.6 m -130.28 149.86 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.115 0 CA-C-O 121.199 0.523 . . . . 0.0 111.063 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -98.14 142.08 30.27 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.338 1.055 . . . . 0.0 110.127 177.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.6 mm -111.56 145.5 17.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 C-N-CA 123.06 0.544 . . . . 0.0 109.723 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -142.11 161.21 38.57 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.254 0.622 . . . . 0.0 110.377 -179.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 81.67 24.23 56.44 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.592 -0.56 . . . . 0.0 113.641 173.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.5 mt -63.01 159.23 17.53 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.1 0.95 . . . . 0.0 110.072 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.3 pt -74.2 -42.45 51.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.93 -35.46 0.01 OUTLIER 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.074 0.55 . . . . 0.0 110.676 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -177.04 50.31 0.1 Allowed Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.1 t -50.61 146.19 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 123.565 0.746 . . . . 0.0 109.735 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.8 m -96.53 161.92 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.072 0 CA-C-O 121.182 0.515 . . . . 0.0 111.4 -176.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -60.1 -24.72 64.86 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.01 0.524 . . . . 0.0 111.376 -176.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.22 -6.17 56.0 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -99.43 -31.58 11.58 Favored 'General case' 0 CA--C 1.529 0.137 0 CA-C-N 118.155 0.434 . . . . 0.0 110.204 177.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -69.83 -39.11 76.67 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.1 p -78.44 -30.79 15.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 121.157 -0.217 . . . . 0.0 110.52 -176.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -82.2 -14.37 55.68 Favored 'General case' 0 N--CA 1.456 -0.14 0 O-C-N 122.072 -0.393 . . . . 0.0 111.715 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.67 -11.8 15.36 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 94.3 mt -115.95 -8.36 11.89 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.847 0.749 . . . . 0.0 112.481 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -70.42 -6.55 36.54 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.564 0.62 . . . . 0.0 111.9 176.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -76.42 -15.58 59.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 122.488 0.315 . . . . 0.0 110.518 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -96.33 -17.15 20.88 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 122.446 0.298 . . . . 0.0 111.355 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.72 176.35 35.56 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -71.46 140.4 36.44 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 124.186 3.257 . . . . 0.0 110.586 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.7 mt -111.63 145.69 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.091 0 C-N-CA 122.563 0.345 . . . . 0.0 110.232 -177.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.8 t -105.36 -41.96 5.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 123.287 0.635 . . . . 0.0 111.278 -177.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -158.92 159.55 35.06 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.742 0.306 . . . . 0.0 111.098 178.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 87.7 t -143.6 147.46 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.827 0.851 . . . . 0.0 109.692 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.1 p -148.5 149.74 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.094 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 175.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.87 149.35 33.53 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -130.54 82.02 66.2 Favored Pre-proline 0 N--CA 1.456 -0.137 0 C-N-CA 123.667 0.787 . . . . 0.0 109.32 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -58.82 -19.09 45.09 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.849 3.032 . . . . 0.0 112.838 -178.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -75.15 -13.47 60.47 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.905 0.482 . . . . 0.0 111.071 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -125.82 4.65 7.37 Favored 'General case' 0 CA--C 1.527 0.089 0 C-N-CA 123.541 0.737 . . . . 0.0 111.284 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.1 tpp85 55.18 32.08 17.72 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.128 0.971 . . . . 0.0 111.993 -177.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -135.87 166.32 23.57 Favored 'General case' 0 N--CA 1.457 -0.106 0 C-N-CA 123.059 0.544 . . . . 0.0 110.803 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.72 172.38 15.68 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 122.863 0.465 . . . . 0.0 110.725 179.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 30.6 mt -132.97 145.81 51.21 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.645 0.778 . . . . 0.0 109.772 177.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 86.2 t -137.26 132.42 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -114.53 117.72 31.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -85.2 153.5 22.59 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 120.99 0.424 . . . . 0.0 110.251 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -74.62 -13.15 60.61 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.388 -177.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -148.32 151.28 35.1 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.76 0.824 . . . . 0.0 108.965 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.9 p -66.42 -21.95 29.36 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.8 tp -73.31 -24.63 60.42 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 121.948 -0.47 . . . . 0.0 110.492 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.24 -31.16 64.04 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.22 -31.23 23.28 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-N 117.126 0.463 . . . . 0.0 110.133 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 t -71.54 -18.48 62.26 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.904 0.482 . . . . 0.0 110.913 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -96.68 -17.83 20.08 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 122.74 0.416 . . . . 0.0 111.127 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.82 -31.42 28.12 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.13 -0.356 . . . . 0.0 111.663 -177.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 32.1 t -85.74 -14.36 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 177.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -72.97 -2.79 22.41 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.137 0.575 . . . . 0.0 111.118 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -121.03 -34.85 3.44 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 122.701 0.401 . . . . 0.0 110.996 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.73 -9.59 58.06 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -176.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.72 -0.21 55.89 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 122.663 0.385 . . . . 0.0 111.654 176.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -136.51 -10.13 1.89 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.907 0.483 . . . . 0.0 111.726 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 50.0 t30 -154.12 170.62 20.74 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -86.88 155.63 20.17 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 175.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.73 136.15 61.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -178.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -89.04 151.21 22.39 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.121 -0.362 . . . . 0.0 110.758 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.8 mt -136.5 -38.46 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.839 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.37 29.43 3.0 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.28 0.632 . . . . 0.0 111.027 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.18 3.79 81.97 Favored Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.716 -0.554 . . . . 0.0 111.716 -176.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -130.56 151.8 79.29 Favored Pre-proline 0 N--CA 1.454 -0.24 0 C-N-CA 124.436 1.094 . . . . 0.0 109.03 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo -70.77 146.22 53.37 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 123.666 2.91 . . . . 0.0 112.143 -177.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.86 -175.55 5.37 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.193 1.397 . . . . 0.0 109.205 179.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -140.59 159.44 42.19 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.004 0.43 . . . . 0.0 111.759 -178.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.72 143.13 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 C-N-CA 123.903 0.881 . . . . 0.0 109.902 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.5 t30 . . . . . 0 N--CA 1.455 -0.218 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -179.868 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.0 m . . . . . 0 CA--C 1.53 0.189 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.51 0.06 5.99 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 124.229 3.286 . . . . 0.0 111.904 177.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 54.1 t -114.29 141.41 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 176.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.9 m -129.56 151.81 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.139 0 CA-C-O 121.332 0.587 . . . . 0.0 110.906 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.9 t-80 -98.72 136.21 39.1 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.201 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.3 mm -106.62 144.59 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.099 0.56 . . . . 0.0 109.752 -178.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -141.77 161.82 37.0 Favored 'General case' 0 C--N 1.338 0.074 0 C-N-CA 123.345 0.658 . . . . 0.0 110.584 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 77.3 24.93 64.69 Favored Glycine 0 CA--C 1.527 0.843 0 CA-C-O 119.642 -0.532 . . . . 0.0 113.086 174.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.6 mt -61.44 159.52 12.62 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 117.956 0.878 . . . . 0.0 110.638 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.1 pt -73.34 -41.52 57.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -173.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -173.94 -35.58 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 123.634 0.774 . . . . 0.0 109.97 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.45 49.65 0.06 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -176.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 14.5 p -52.83 148.49 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 122.897 0.479 . . . . 0.0 110.083 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -88.2 163.06 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 CA-C-O 121.324 0.583 . . . . 0.0 111.996 -171.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -62.24 -27.48 69.03 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.799 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.71 -3.07 49.41 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 123.087 0.555 . . . . 0.0 112.318 -178.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -104.29 -29.84 10.52 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.427 0.558 . . . . 0.0 109.711 177.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 49.8 mt -72.67 -38.97 67.46 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 122.546 0.339 . . . . 0.0 110.924 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.67 -30.23 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.442 -178.32 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -82.38 -16.01 50.68 Favored 'General case' 0 N--CA 1.453 -0.279 0 O-C-N 122.168 -0.332 . . . . 0.0 111.506 -178.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.44 -12.91 16.27 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 112.918 0.711 . . . . 0.0 112.918 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.9 mt -114.05 -7.62 13.08 Favored 'General case' 0 C--N 1.339 0.11 0 CA-C-N 118.516 0.598 . . . . 0.0 112.506 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.15 -6.07 31.56 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 118.731 0.696 . . . . 0.0 111.784 176.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -77.09 -13.62 59.93 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.801 0.44 . . . . 0.0 110.769 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -98.64 -18.16 18.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 122.531 0.332 . . . . 0.0 111.477 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.94 177.08 36.43 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -70.94 140.28 37.92 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 124.176 3.251 . . . . 0.0 110.3 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.1 mt -112.21 145.9 17.71 Favored 'Isoleucine or valine' 0 C--O 1.231 0.092 0 C-N-CA 122.746 0.419 . . . . 0.0 110.237 -177.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 t -105.88 -41.96 5.27 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.243 0.617 . . . . 0.0 111.395 -177.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -159.85 160.27 33.52 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-O 120.695 0.283 . . . . 0.0 111.035 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.8 t -145.24 147.01 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 123.906 0.882 . . . . 0.0 109.526 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.89 155.39 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.141 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 176.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 29.1 t -125.87 153.38 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.08 0 C-N-CA 122.503 0.321 . . . . 0.0 110.995 -177.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.5 mtm -135.56 77.13 53.35 Favored Pre-proline 0 CA--C 1.532 0.265 0 C-N-CA 124.237 1.015 . . . . 0.0 109.385 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -60.59 -16.68 44.33 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.972 3.115 . . . . 0.0 113.245 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -77.13 -6.56 53.34 Favored 'General case' 0 C--N 1.339 0.132 0 C-N-CA 123.009 0.524 . . . . 0.0 111.618 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -133.22 3.68 3.68 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.216 0.606 . . . . 0.0 111.386 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 13.4 tpp85 55.3 38.26 30.1 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.7 0.8 . . . . 0.0 111.152 -173.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 83.1 mt-30 -134.0 166.24 23.16 Favored 'General case' 0 N--CA 1.458 -0.05 0 C-N-CA 123.684 0.794 . . . . 0.0 110.608 -176.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.04 171.31 18.06 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 122.985 0.514 . . . . 0.0 109.871 176.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -132.18 146.01 51.74 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 123.407 0.683 . . . . 0.0 110.072 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 93.3 t -137.37 128.71 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 118.1 33.78 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.6 m-85 -85.85 154.87 21.24 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.348 -179.148 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -75.23 -12.24 60.24 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 120.704 0.287 . . . . 0.0 110.399 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -148.62 152.16 36.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 123.784 0.834 . . . . 0.0 109.14 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.49 -21.41 26.19 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 122.076 -0.39 . . . . 0.0 111.614 -175.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.6 tp -75.56 -28.87 59.17 Favored 'General case' 0 N--CA 1.452 -0.353 0 O-C-N 122.008 -0.433 . . . . 0.0 110.529 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.16 -30.92 71.71 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.37 -31.41 37.84 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.894 0.347 . . . . 0.0 110.301 178.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 44.2 t -70.81 -29.53 65.72 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 122.205 0.202 . . . . 0.0 110.983 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -78.07 -19.6 53.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 119.462 -0.304 . . . . 0.0 111.476 -179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.88 -32.06 23.4 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.108 0.413 . . . . 0.0 111.606 -176.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.5 t -86.76 -19.51 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -68.65 -14.1 62.79 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.102 -0.374 . . . . 0.0 110.99 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -104.4 -37.85 7.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.487 0.315 . . . . 0.0 111.256 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.65 -4.33 58.96 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -77.9 -9.15 58.93 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.228 0.467 . . . . 0.0 111.486 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -141.07 -1.86 1.34 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.681 0.392 . . . . 0.0 111.652 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.5 m-80 -144.41 175.7 9.92 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.131 0.572 . . . . 0.0 109.921 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . 0.476 ' CD ' ' H ' ' A' ' 156' ' ' GLN . 0.0 OUTLIER -98.48 155.86 17.05 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.714 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.95 135.59 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -89.38 155.94 19.01 Favored 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 122.045 -0.409 . . . . 0.0 111.085 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.9 mt -138.0 -42.51 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.786 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.84 32.2 2.99 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.236 0.614 . . . . 0.0 111.122 -177.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.07 4.84 81.32 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 -176.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -128.99 150.67 75.95 Favored Pre-proline 0 N--CA 1.455 -0.202 0 C-N-CA 123.83 0.852 . . . . 0.0 109.215 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -71.55 147.58 52.02 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.464 2.776 . . . . 0.0 111.702 -177.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -153.45 -174.6 5.01 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.072 1.349 . . . . 0.0 108.731 178.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -139.04 160.24 40.24 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-O 120.986 0.422 . . . . 0.0 111.345 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.7 p -147.23 140.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.575 0.75 . . . . 0.0 109.264 179.087 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 N--CA 1.454 -0.232 0 C-N-CA 122.91 0.484 . . . . 0.0 110.398 179.599 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 63.8 m . . . . . 0 CA--C 1.53 0.18 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -71.88 -3.76 13.81 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.831 3.021 . . . . 0.0 111.568 177.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 67.5 t -111.11 139.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.62 148.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 CA-C-O 121.319 0.58 . . . . 0.0 110.732 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -95.46 137.25 34.78 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.189 0.995 . . . . 0.0 110.35 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 26.0 mm -105.85 143.92 16.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 123.194 0.597 . . . . 0.0 109.787 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -142.56 160.53 40.11 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 123.132 0.573 . . . . 0.0 110.822 -178.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.81 26.09 56.86 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 119.457 -0.635 . . . . 0.0 113.523 173.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.9 mt -62.53 156.06 24.04 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.144 0.972 . . . . 0.0 109.814 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -70.57 -41.63 77.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -173.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -173.12 -34.78 0.01 OUTLIER 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.31 0.644 . . . . 0.0 110.676 -179.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.93 48.93 0.12 Allowed Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -176.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.7 t -51.56 143.21 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 C-N-CA 123.41 0.684 . . . . 0.0 109.697 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.8 m -95.72 164.98 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.119 0 CA-C-O 121.308 0.575 . . . . 0.0 111.637 -175.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -61.08 -26.02 67.36 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.538 0.735 . . . . 0.0 111.247 -178.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.45 -5.56 56.75 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 -177.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -98.11 -30.46 12.65 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.28 0.491 . . . . 0.0 109.922 177.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.2 mt -73.33 -38.8 65.65 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 122.556 0.342 . . . . 0.0 110.95 -178.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.6 p -77.27 -29.96 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.241 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.6 mm-40 -82.76 -15.14 52.92 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 119.445 -0.312 . . . . 0.0 111.643 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -108.31 -10.61 15.33 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -116.96 -9.61 11.1 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 118.501 0.591 . . . . 0.0 112.396 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -69.83 -7.34 39.13 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.7 0.682 . . . . 0.0 111.633 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -74.12 -18.47 60.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.508 0.323 . . . . 0.0 110.593 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -92.64 -19.07 22.25 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 122.369 0.268 . . . . 0.0 111.535 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.39 176.77 35.71 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 139.64 41.24 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.978 3.118 . . . . 0.0 110.93 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.9 mt -111.59 145.67 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.876 0.471 . . . . 0.0 110.226 -177.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.5 t -104.09 -41.28 5.88 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.193 0.597 . . . . 0.0 111.355 -177.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -161.42 161.18 30.16 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.563 0.22 . . . . 0.0 111.532 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 69.2 t -143.97 147.16 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 123.903 0.881 . . . . 0.0 109.625 179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -147.29 153.33 12.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 176.207 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 37.7 t -128.46 152.99 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.052 0 C-N-CA 122.42 0.288 . . . . 0.0 111.019 -174.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.6 mtm -134.28 79.17 56.1 Favored Pre-proline 0 CA--C 1.532 0.274 0 C-N-CA 124.21 1.004 . . . . 0.0 109.314 178.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.85 -21.54 57.81 Favored 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 123.598 2.866 . . . . 0.0 113.134 -177.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -83.48 1.89 39.5 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 122.939 0.495 . . . . 0.0 112.015 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -128.79 0.67 5.41 Favored 'General case' 0 C--N 1.338 0.086 0 C-N-CA 123.802 0.841 . . . . 0.0 111.158 176.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.5 tpp85 53.35 33.04 14.84 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.014 0.926 . . . . 0.0 111.116 -172.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -136.81 167.86 20.65 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.305 0.642 . . . . 0.0 110.825 -175.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.36 173.57 15.45 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.89 0.476 . . . . 0.0 110.175 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 40.4 mt -132.81 145.11 50.7 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 123.187 0.595 . . . . 0.0 109.837 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.2 t -135.44 131.33 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -114.83 117.74 31.58 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 60.8 m-85 -84.16 156.75 21.94 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.303 179.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -70.4 -18.41 63.03 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.284 -178.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -154.19 159.21 41.27 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 123.784 0.834 . . . . 0.0 109.579 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 27.2 m -65.42 -15.23 18.16 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.099 0 O-C-N 122.053 -0.405 . . . . 0.0 111.843 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 10.3 tt -67.61 -33.2 74.51 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.327 0.512 . . . . 0.0 110.384 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -76.14 -31.85 54.06 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.48 -32.46 32.49 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.372 0.586 . . . . 0.0 110.535 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.9 t -75.73 -8.08 55.95 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 123.101 0.56 . . . . 0.0 111.302 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -106.74 -16.31 14.52 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 122.409 0.283 . . . . 0.0 111.039 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -86.79 -34.93 19.41 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.063 -0.398 . . . . 0.0 111.33 -178.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.5 t -83.32 -15.78 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -71.37 -5.33 31.75 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 122.797 0.439 . . . . 0.0 111.265 179.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -116.52 -37.68 3.67 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 122.899 0.48 . . . . 0.0 110.911 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.68 -5.73 59.01 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -176.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.4 -4.36 58.4 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 122.069 -0.394 . . . . 0.0 111.441 177.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -142.07 -6.5 0.96 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 122.773 0.429 . . . . 0.0 111.686 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -144.76 175.13 10.4 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 123.387 0.675 . . . . 0.0 109.5 -179.196 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . 0.477 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -95.98 152.43 18.52 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 172.733 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.84 135.32 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.12 149.67 23.07 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 121.954 -0.466 . . . . 0.0 110.758 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 56.4 mt -137.38 -39.67 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.939 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.42 29.48 3.94 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.151 0.58 . . . . 0.0 111.033 -176.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.09 4.54 84.15 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -132.09 152.84 80.91 Favored Pre-proline 0 C--O 1.233 0.224 0 C-N-CA 124.102 0.961 . . . . 0.0 109.269 177.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -71.47 144.47 45.3 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 123.583 2.855 . . . . 0.0 111.764 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.74 -175.85 5.19 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.983 1.313 . . . . 0.0 108.765 177.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -138.5 160.26 40.0 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-O 120.927 0.394 . . . . 0.0 111.628 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.1 p -147.84 143.48 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.13 0 C-N-CA 123.785 0.834 . . . . 0.0 109.693 178.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 . . . . . 0 N--CA 1.457 -0.119 0 C-N-CA 123.259 0.624 . . . . 0.0 110.066 179.092 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 60.8 p . . . . . 0 CA--C 1.532 0.278 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -72.76 4.25 3.74 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 124.159 3.239 . . . . 0.0 112.358 178.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.5 140.43 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 123.279 0.631 . . . . 0.0 109.454 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.0 m -128.16 145.37 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 CA-C-O 121.199 0.523 . . . . 0.0 110.831 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -96.9 134.4 40.28 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.241 1.016 . . . . 0.0 109.932 177.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.415 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.1 mp -107.4 145.78 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.432 0.693 . . . . 0.0 109.408 -178.129 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.0 mtt180 -141.33 160.98 38.99 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.64 0.776 . . . . 0.0 109.892 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.84 28.49 50.54 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-O 119.545 -0.586 . . . . 0.0 113.438 175.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.9 mt -57.73 154.88 10.97 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 118.241 1.02 . . . . 0.0 109.877 177.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -68.19 -39.39 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.077 0 O-C-N 122.084 -0.385 . . . . 0.0 111.071 -176.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -171.62 -35.92 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.307 1.043 . . . . 0.0 109.742 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.48 55.92 0.04 OUTLIER Glycine 0 C--N 1.339 0.718 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -177.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.7 m -52.75 151.17 1.1 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-N 117.076 0.438 . . . . 0.0 110.511 178.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.7 m -87.46 166.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.953 0.406 . . . . 0.0 111.262 -177.004 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -61.99 -23.71 66.58 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.163 0.585 . . . . 0.0 111.242 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.31 -6.03 57.28 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -92.9 -35.14 13.5 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.565 0.62 . . . . 0.0 110.213 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 91.4 mt -73.25 -36.28 66.36 Favored 'General case' 0 N--CA 1.454 -0.274 0 O-C-N 122.385 -0.197 . . . . 0.0 111.266 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -76.97 -31.04 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.317 -177.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -82.14 -17.68 45.54 Favored 'General case' 0 N--CA 1.455 -0.219 0 O-C-N 122.185 -0.322 . . . . 0.0 111.167 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -9.13 18.31 Favored 'General case' 0 N--CA 1.455 -0.21 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.0 mt -120.82 -8.97 9.37 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -69.3 -7.19 34.79 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.866 0.757 . . . . 0.0 111.687 177.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -76.91 -14.99 59.81 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 122.025 -0.422 . . . . 0.0 110.731 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -96.08 -16.82 21.34 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.578 0.351 . . . . 0.0 111.592 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.4 176.55 34.6 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -70.59 140.75 40.24 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 123.889 3.06 . . . . 0.0 110.877 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 78.3 mt -110.81 146.63 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.083 0 C-N-CA 122.816 0.446 . . . . 0.0 110.487 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -106.43 -42.5 5.0 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.009 0.524 . . . . 0.0 111.478 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -159.11 159.28 34.32 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 120.837 0.351 . . . . 0.0 111.231 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.6 t -143.78 146.57 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.086 0 C-N-CA 124.001 0.92 . . . . 0.0 109.841 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.97 153.45 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 42.8 t -131.69 149.63 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.069 0 CA-C-O 120.717 0.294 . . . . 0.0 110.595 -176.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 81.55 67.52 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -60.29 -17.67 48.11 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.811 3.008 . . . . 0.0 112.877 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -82.9 -4.28 57.97 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.802 0.441 . . . . 0.0 111.484 179.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -129.23 4.04 5.22 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.861 0.864 . . . . 0.0 111.194 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 3.3 tpt180 54.58 30.44 13.16 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 123.847 0.859 . . . . 0.0 112.058 -177.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -138.89 166.59 24.05 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 123.119 0.568 . . . . 0.0 110.813 -174.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.98 172.17 16.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.213 0.605 . . . . 0.0 110.487 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.5 mt -134.14 146.48 50.26 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.443 0.697 . . . . 0.0 109.794 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.91 132.7 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -115.81 122.29 44.97 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.0 m-85 -87.89 156.03 19.57 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -178.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.3 -14.24 60.87 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.563 -178.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -149.49 153.47 37.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.68 0.792 . . . . 0.0 108.935 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.4 p -67.64 -20.92 26.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 O-C-N 122.175 -0.328 . . . . 0.0 111.717 -176.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.2 tp -74.52 -27.08 60.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 117.867 0.303 . . . . 0.0 110.997 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.91 -32.47 60.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.29 -29.39 34.31 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 117.018 0.409 . . . . 0.0 110.518 177.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -73.63 -19.28 60.9 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 122.681 0.392 . . . . 0.0 110.92 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -93.63 -17.27 23.46 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 122.191 -0.318 . . . . 0.0 111.03 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.33 -31.98 26.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 O-C-N 121.912 -0.492 . . . . 0.0 111.386 -178.07 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 37.0 t -85.75 -15.29 10.46 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 178.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -71.52 -7.67 49.06 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.784 0.434 . . . . 0.0 110.875 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 71.7 t80 -113.73 -36.93 4.71 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.621 0.369 . . . . 0.0 110.982 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.87 -7.17 59.68 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.44 -2.72 56.51 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 122.283 -0.261 . . . . 0.0 111.592 177.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -141.19 -7.88 1.02 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 122.73 0.412 . . . . 0.0 112.053 179.335 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -145.41 170.4 16.42 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.332 0.653 . . . . 0.0 109.982 -179.057 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -86.17 155.98 20.52 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -125.53 135.58 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -88.05 156.35 19.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 122.014 -0.429 . . . . 0.0 110.585 -178.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 62.9 mt -137.53 -43.79 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.536 -178.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.01 31.47 3.57 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.326 0.651 . . . . 0.0 111.185 -177.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.22 6.37 78.54 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.19 151.81 79.52 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.119 0.968 . . . . 0.0 109.142 177.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -71.86 143.61 41.6 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 123.558 2.839 . . . . 0.0 111.764 -176.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.76 -173.87 4.61 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 125.238 1.415 . . . . 0.0 108.395 177.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.01 160.12 40.53 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 121.042 0.448 . . . . 0.0 111.666 -178.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.6 p -149.74 144.98 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 C-N-CA 123.398 0.679 . . . . 0.0 110.064 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 . . . . . 0 N--CA 1.456 -0.148 0 C-N-CA 123.264 0.626 . . . . 0.0 110.148 179.5 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 65.5 m . . . . . 0 N--CA 1.455 -0.215 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -70.41 0.44 6.14 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 124.158 3.239 . . . . 0.0 111.773 176.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.1 t -112.4 139.9 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 123.6 0.76 . . . . 0.0 109.239 177.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.6 m -128.91 152.82 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 CA-C-O 121.08 0.467 . . . . 0.0 110.728 178.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -102.45 137.86 40.14 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.709 0.804 . . . . 0.0 110.112 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 18.8 mm -106.49 144.59 15.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 C-N-CA 123.527 0.731 . . . . 0.0 109.799 -178.228 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -143.14 160.95 39.46 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.07 0.548 . . . . 0.0 110.698 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.96 23.87 60.87 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-O 119.77 -0.461 . . . . 0.0 113.151 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 56.1 mt -60.34 157.55 13.48 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 117.952 0.876 . . . . 0.0 109.979 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 16.5 pt -72.34 -37.32 57.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 O-C-N 122.244 -0.285 . . . . 0.0 111.35 -176.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -172.92 -36.93 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 123.887 0.875 . . . . 0.0 109.7 -179.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 171.21 61.84 0.04 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -176.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.2 m -52.31 154.66 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 122.688 0.395 . . . . 0.0 110.608 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.45 HG12 ' H ' ' A' ' 111' ' ' ALA . 8.7 t -76.99 155.64 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 CA-C-O 120.936 0.398 . . . . 0.0 110.473 -175.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -59.4 -26.88 65.52 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.723 0.409 . . . . 0.0 110.239 174.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . 0.45 ' H ' HG12 ' A' ' 109' ' ' VAL . . . -81.79 -6.83 59.41 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.513 0.725 . . . . 0.0 111.886 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -90.08 -34.11 16.04 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 118.341 0.519 . . . . 0.0 109.999 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.0 mt -73.52 -34.97 65.49 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 122.573 0.349 . . . . 0.0 111.373 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.89 -30.59 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.135 0 CA-C-N 118.041 0.382 . . . . 0.0 110.428 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -82.84 -15.81 50.13 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 119.526 -0.273 . . . . 0.0 111.155 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -11.15 16.96 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -119.26 -9.18 9.99 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 118.6 0.636 . . . . 0.0 112.535 -178.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -69.82 -6.9 35.49 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.156 0.889 . . . . 0.0 111.874 177.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -76.5 -12.64 60.07 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 122.117 -0.365 . . . . 0.0 110.695 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -100.1 -19.97 16.23 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 122.678 0.391 . . . . 0.0 111.337 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 166.05 175.97 36.93 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.396 -0.681 . . . . 0.0 111.396 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -71.33 141.42 38.96 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 123.918 3.079 . . . . 0.0 110.505 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 76.2 mt -112.61 146.26 17.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 122.875 0.47 . . . . 0.0 110.226 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.0 t -103.58 -44.81 5.01 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.009 0.523 . . . . 0.0 111.216 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.2 t80 -158.84 162.08 36.95 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-O 120.852 0.358 . . . . 0.0 111.465 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 95.2 t -142.55 144.81 24.15 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 124.167 0.987 . . . . 0.0 109.673 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.42 153.02 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.097 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 175.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 41.3 t -130.6 148.21 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.1 0 CA-C-O 120.604 0.24 . . . . 0.0 110.986 -175.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 84.0 60.52 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.808 0.843 . . . . 0.0 109.087 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.22 -12.32 33.64 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 123.489 2.793 . . . . 0.0 111.725 -176.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.9 tptt -76.94 -12.15 59.91 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 122.869 0.468 . . . . 0.0 110.9 177.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -129.29 6.92 5.36 Favored 'General case' 0 C--N 1.34 0.163 0 C-N-CA 123.636 0.775 . . . . 0.0 111.904 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 53.9 33.93 18.33 Favored 'General case' 0 N--CA 1.463 0.183 0 C-N-CA 124.449 1.1 . . . . 0.0 112.197 -177.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -136.66 166.26 23.98 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.175 0.59 . . . . 0.0 110.637 -177.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.91 172.36 16.34 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.673 0.389 . . . . 0.0 110.49 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 37.2 mt -131.32 149.05 52.71 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 123.406 0.682 . . . . 0.0 110.166 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -140.11 133.32 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.199 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -114.21 120.71 41.39 Favored 'General case' 0 N--CA 1.452 -0.325 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 177.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -85.83 152.22 23.18 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.041 0.448 . . . . 0.0 110.018 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -71.34 -15.15 62.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.349 -178.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.12 152.45 39.3 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.744 0.818 . . . . 0.0 109.469 177.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.0 p -68.89 -21.45 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 O-C-N 122.18 -0.325 . . . . 0.0 111.751 -175.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.6 tp -75.25 -28.89 60.02 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.83 -0.544 . . . . 0.0 110.334 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.68 -29.62 71.17 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.69 -30.28 36.46 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 117.029 0.414 . . . . 0.0 110.5 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.14 -28.17 62.09 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 122.501 0.32 . . . . 0.0 110.67 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -79.21 -19.43 50.79 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 119.541 -0.266 . . . . 0.0 111.532 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -32.67 27.03 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 118.157 0.435 . . . . 0.0 111.467 -177.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 30.0 t -85.73 -17.51 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -69.44 -11.63 60.98 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.539 0.336 . . . . 0.0 111.08 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -112.0 -36.85 5.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.635 0.374 . . . . 0.0 111.0 178.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.03 -11.67 59.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -176.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.48 -0.26 56.55 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -135.44 -10.85 2.16 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 117.921 0.328 . . . . 0.0 111.503 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.6 t30 -153.97 164.09 39.01 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.601 0.76 . . . . 0.0 109.065 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.6 pm0 -81.32 154.7 26.38 Favored 'General case' 0 CA--C 1.529 0.139 0 O-C-N 121.8 -0.563 . . . . 0.0 109.783 174.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.06 135.57 61.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -87.75 153.83 21.04 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.077 -0.389 . . . . 0.0 110.708 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.4 mt -136.99 -43.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.662 0.385 . . . . 0.0 110.802 -177.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.14 30.64 3.92 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.103 0.561 . . . . 0.0 111.333 -176.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 88.27 4.25 77.75 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.037 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -131.44 152.49 80.59 Favored Pre-proline 0 C--O 1.233 0.219 0 C-N-CA 124.013 0.925 . . . . 0.0 109.318 177.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.72 146.18 48.0 Favored 'Trans proline' 0 N--CA 1.453 -0.884 0 C-N-CA 123.438 2.759 . . . . 0.0 111.573 -176.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.43 -175.75 5.41 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.952 1.301 . . . . 0.0 109.021 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -139.42 160.76 39.08 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 121.174 0.511 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 2.9 p -147.76 141.18 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 123.962 0.905 . . . . 0.0 109.532 177.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.4 t30 . . . . . 0 CA--C 1.531 0.217 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.31 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 66.2 m . . . . . 0 CA--C 1.532 0.263 0 N-CA-C 111.509 0.189 . . . . 0.0 111.509 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -69.53 1.36 4.35 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 124.138 3.225 . . . . 0.0 112.374 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.8 t -116.53 141.28 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.6 m -129.81 151.85 36.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-O 120.92 0.391 . . . . 0.0 110.958 178.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.4 t-80 -100.93 135.05 42.99 Favored 'General case' 0 N--CA 1.457 -0.086 0 C-N-CA 124.068 0.947 . . . . 0.0 109.974 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -109.93 145.18 16.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 -177.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -141.67 163.7 32.21 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 123.602 0.761 . . . . 0.0 110.481 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 25.56 56.15 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-O 119.452 -0.638 . . . . 0.0 113.611 172.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.8 mt -61.68 158.15 16.11 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.185 0.992 . . . . 0.0 110.186 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 12.4 pt -73.1 -39.94 57.74 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -173.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -172.78 -37.44 0.01 OUTLIER 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.243 0.617 . . . . 0.0 110.246 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.22 52.25 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -176.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 65.1 t -51.11 146.04 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.158 0.583 . . . . 0.0 110.082 178.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.4 m -95.74 163.69 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 CA-C-O 121.18 0.514 . . . . 0.0 111.47 -175.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -60.47 -28.02 68.01 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 123.27 0.628 . . . . 0.0 111.215 -178.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.79 -6.44 55.96 Favored 'General case' 0 CA--C 1.53 0.187 0 N-CA-C 112.294 0.479 . . . . 0.0 112.294 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -101.47 -31.03 11.09 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 176.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 76.5 mt -71.36 -41.21 70.01 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.515 0.326 . . . . 0.0 110.654 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.5 p -77.56 -29.63 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 121.278 -0.169 . . . . 0.0 110.915 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.2 mt-10 -85.87 -13.35 48.2 Favored 'General case' 0 N--CA 1.454 -0.225 0 O-C-N 122.006 -0.434 . . . . 0.0 111.365 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.21 -15.15 16.09 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.94 -7.21 13.17 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.522 0.601 . . . . 0.0 112.457 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -72.46 -5.55 37.51 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.662 0.665 . . . . 0.0 111.537 176.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -74.96 -16.13 60.65 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.493 0.317 . . . . 0.0 110.544 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.83 -17.21 21.32 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 122.537 0.335 . . . . 0.0 111.824 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.88 178.0 37.11 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.16 140.31 37.22 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 123.86 3.04 . . . . 0.0 110.821 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.5 mt -112.42 144.4 20.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 C-N-CA 122.993 0.517 . . . . 0.0 110.519 -178.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -102.77 -42.25 5.93 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.362 0.665 . . . . 0.0 111.05 -178.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -158.57 160.09 36.22 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.712 0.291 . . . . 0.0 111.275 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 84.9 t -143.97 147.6 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.053 0 C-N-CA 123.761 0.824 . . . . 0.0 109.841 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.3 p -148.0 154.57 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 176.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 9.5 p -136.93 151.45 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.07 0 CA-C-O 120.824 0.345 . . . . 0.0 110.948 -178.229 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -130.26 84.44 59.87 Favored Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.855 0.862 . . . . 0.0 109.004 179.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -59.54 -18.54 47.57 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.897 3.064 . . . . 0.0 112.779 -179.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -82.02 -5.8 58.65 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.08 0.552 . . . . 0.0 111.316 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -129.05 2.58 5.26 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.722 0.809 . . . . 0.0 111.461 178.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.4 tpp85 53.37 32.5 13.9 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.496 1.118 . . . . 0.0 112.0 -177.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -136.43 166.4 23.58 Favored 'General case' 0 CA--C 1.527 0.094 0 C-N-CA 123.144 0.578 . . . . 0.0 110.941 -176.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 171.4 17.3 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.88 0.472 . . . . 0.0 110.819 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.32 146.71 50.23 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 123.769 0.828 . . . . 0.0 109.797 178.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.8 t -136.64 131.96 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.231 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -112.23 116.11 29.9 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -84.54 152.6 23.8 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.835 0.35 . . . . 0.0 110.481 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -73.08 -14.5 61.41 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.409 -178.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -147.2 151.34 36.57 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.696 0.798 . . . . 0.0 109.103 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.2 p -67.39 -19.85 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 O-C-N 122.29 -0.256 . . . . 0.0 111.484 -175.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.9 tp -75.08 -27.24 59.85 Favored 'General case' 0 N--CA 1.454 -0.236 0 O-C-N 121.986 -0.446 . . . . 0.0 110.498 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.91 -31.2 69.85 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.36 -29.99 33.89 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 116.956 0.378 . . . . 0.0 110.395 177.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.46 -26.48 63.66 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 122.716 0.406 . . . . 0.0 110.825 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -84.05 -20.3 32.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.192 -0.318 . . . . 0.0 111.646 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.47 -29.1 26.31 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 118.125 0.42 . . . . 0.0 112.075 -175.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -89.63 -15.49 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -75.0 0.12 16.95 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.768 0.427 . . . . 0.0 111.038 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -120.17 -38.73 2.88 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.842 0.457 . . . . 0.0 110.852 177.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.29 -4.66 58.99 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.68 -4.13 58.34 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 122.103 -0.373 . . . . 0.0 111.506 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -141.66 -4.17 1.11 Allowed 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 122.609 0.364 . . . . 0.0 111.59 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -146.29 170.57 16.49 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.534 0.734 . . . . 0.0 109.972 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -90.84 153.16 20.42 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 172.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.48 135.18 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -88.55 150.61 23.0 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 122.01 -0.431 . . . . 0.0 110.749 -178.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.1 mt -136.97 -39.1 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.789 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.18 29.28 3.71 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 123.085 0.554 . . . . 0.0 110.937 -177.051 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.48 5.02 85.29 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -176.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -130.41 152.28 80.01 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 124.266 1.026 . . . . 0.0 109.144 177.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.52 144.21 44.45 Favored 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.076 2.518 . . . . 0.0 111.825 -176.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.96 -176.11 5.31 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 124.826 1.25 . . . . 0.0 109.024 177.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -139.46 161.13 38.24 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.949 0.404 . . . . 0.0 111.67 -178.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.6 p -150.04 143.27 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.411 0.684 . . . . 0.0 109.724 178.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 . . . . . 0 N--CA 1.456 -0.161 0 C-N-CA 123.055 0.542 . . . . 0.0 109.989 179.983 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.438 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.4 p . . . . . 0 N--CA 1.456 -0.164 0 N-CA-C 111.729 0.27 . . . . 0.0 111.729 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.438 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 96.4 Cg_endo -71.26 3.05 3.77 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.903 3.069 . . . . 0.0 112.504 177.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.7 t -115.02 141.39 31.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.116 0 C-N-CA 122.989 0.515 . . . . 0.0 109.877 178.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 20.9 m -126.69 152.57 34.59 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -107.7 141.01 39.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 124.079 0.952 . . . . 0.0 109.61 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 23.6 mm -111.23 143.82 20.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 122.883 0.473 . . . . 0.0 110.116 -175.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 -142.38 159.26 42.59 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 123.092 0.557 . . . . 0.0 110.176 -177.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.03 24.87 58.91 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.358 -0.69 . . . . 0.0 113.198 174.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.6 mt -60.52 157.87 13.36 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 118.234 1.017 . . . . 0.0 110.163 177.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.2 pt -70.88 -43.35 76.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -173.248 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -172.4 -34.5 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.375 0.67 . . . . 0.0 110.749 -179.111 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.9 49.07 0.11 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.704 -0.559 . . . . 0.0 111.704 -175.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.1 t -51.09 146.54 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 123.387 0.675 . . . . 0.0 110.026 178.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.2 m -101.33 166.41 2.42 Favored 'Isoleucine or valine' 0 C--N 1.337 0.045 0 CA-C-O 121.211 0.529 . . . . 0.0 111.584 -175.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.39 -27.48 67.47 Favored 'General case' 0 N--CA 1.456 -0.131 0 C-N-CA 123.196 0.598 . . . . 0.0 111.152 -177.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.46 -5.03 51.35 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -104.59 -30.86 9.72 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 175.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.6 mt -70.12 -38.41 75.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 122.506 0.322 . . . . 0.0 110.595 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -80.13 -29.63 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 CA-C-N 117.537 0.153 . . . . 0.0 110.731 -178.329 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.0 mm-40 -81.4 -13.91 57.75 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.28 -0.263 . . . . 0.0 111.321 -178.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -99.89 -25.97 14.16 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.2 mp -100.73 -9.76 21.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.921 0.711 . . . . 0.0 112.921 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -67.15 -8.63 32.55 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 118.604 0.638 . . . . 0.0 111.647 177.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.96 -14.62 59.1 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.663 0.385 . . . . 0.0 110.827 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -101.08 -18.31 16.29 Favored 'General case' 0 C--O 1.231 0.117 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -178.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.91 177.51 37.52 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -72.73 140.21 31.98 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 C-N-CA 124.268 3.312 . . . . 0.0 110.717 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 73.6 mt -110.07 146.69 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 C-N-CA 122.778 0.431 . . . . 0.0 110.3 -177.193 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -107.46 -40.16 5.43 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.158 0.583 . . . . 0.0 111.367 -177.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -159.52 158.44 31.83 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-O 120.739 0.304 . . . . 0.0 110.94 179.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 93.1 t -144.15 145.42 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.038 0 C-N-CA 123.924 0.89 . . . . 0.0 109.858 -178.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.3 p -148.31 152.74 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 12.4 p -130.22 156.58 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 CA-C-O 120.805 0.336 . . . . 0.0 111.156 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 48.6 mtt -130.45 78.14 74.73 Favored Pre-proline 0 C--O 1.232 0.168 0 C-N-CA 124.046 0.938 . . . . 0.0 109.54 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.62 -17.74 43.73 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 123.584 2.856 . . . . 0.0 113.048 -177.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.5 mtpt -89.52 -2.15 58.26 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.926 0.49 . . . . 0.0 111.807 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -130.84 0.39 4.3 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.652 0.781 . . . . 0.0 111.548 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 55.14 33.98 21.63 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.019 0.928 . . . . 0.0 111.861 -176.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -134.7 168.21 19.43 Favored 'General case' 0 C--O 1.232 0.14 0 C-N-CA 123.479 0.712 . . . . 0.0 110.602 -177.043 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.74 172.24 18.27 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.39 176.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.34 144.31 48.19 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.716 0.806 . . . . 0.0 109.468 177.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 77.9 t -137.0 131.29 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -113.44 120.26 40.44 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 58.7 m-85 -83.93 153.87 23.69 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.872 0.368 . . . . 0.0 110.361 -179.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -74.54 -12.58 60.51 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-O 120.907 0.384 . . . . 0.0 110.25 -178.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -149.54 152.48 35.62 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.843 0.857 . . . . 0.0 109.022 176.136 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.2 p -68.13 -20.43 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 O-C-N 122.031 -0.418 . . . . 0.0 111.657 -175.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.3 tp -71.96 -26.27 62.2 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.924 -0.485 . . . . 0.0 110.561 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.95 -31.47 64.45 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 178.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -84.42 -27.95 27.23 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 117.293 0.546 . . . . 0.0 110.555 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.1 t -77.89 -7.17 56.35 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 122.802 0.441 . . . . 0.0 110.602 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -107.14 -21.71 12.88 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.976 0.511 . . . . 0.0 110.754 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.42 -28.01 31.61 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 -178.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -91.01 -18.98 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -71.34 -14.24 62.13 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.36 0.264 . . . . 0.0 110.763 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -99.92 -36.79 9.28 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.568 0.347 . . . . 0.0 111.001 178.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -85.44 -6.43 59.21 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.832 0.678 . . . . 0.0 112.832 -176.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -78.64 -5.0 51.8 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 122.139 -0.351 . . . . 0.0 111.839 176.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -143.52 -3.59 0.91 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.58 0.352 . . . . 0.0 111.901 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 -145.42 175.09 10.58 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.455 0.702 . . . . 0.0 109.948 -178.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . 0.472 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.1 pm0 -96.94 152.68 18.47 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 173.162 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.17 134.44 63.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -89.55 148.91 23.11 Favored 'General case' 0 C--N 1.332 -0.17 0 O-C-N 122.193 -0.317 . . . . 0.0 110.71 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -136.01 -38.75 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.219 -176.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.37 29.45 3.63 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.112 0.565 . . . . 0.0 110.89 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.67 3.36 83.79 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -176.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -130.08 152.84 80.73 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 123.902 0.881 . . . . 0.0 108.968 177.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -72.11 145.97 45.45 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.306 2.671 . . . . 0.0 111.681 -176.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.48 -176.84 5.64 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.014 1.325 . . . . 0.0 108.475 177.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -137.84 160.02 40.43 Favored 'General case' 0 C--O 1.232 0.14 0 CA-C-O 120.885 0.374 . . . . 0.0 111.466 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.66 139.61 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 123.514 0.726 . . . . 0.0 110.174 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 . . . . . 0 CA--C 1.53 0.198 0 C-N-CA 123.445 0.698 . . . . 0.0 109.592 178.45 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.1 m . . . . . 0 CA--C 1.53 0.196 0 N-CA-C 112.368 0.507 . . . . 0.0 112.368 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.05 -0.98 9.84 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 124.024 3.149 . . . . 0.0 111.769 174.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.5 t -112.0 142.49 24.21 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 123.431 0.692 . . . . 0.0 109.461 178.154 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 21.3 m -128.29 152.41 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 C-N-CA 122.835 0.454 . . . . 0.0 110.171 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 -106.15 136.41 45.89 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.971 0.909 . . . . 0.0 109.359 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.7 mm -106.07 142.4 19.14 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 C-N-CA 122.859 0.464 . . . . 0.0 109.859 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -141.67 160.44 40.17 Favored 'General case' 0 C--O 1.231 0.1 0 C-N-CA 123.231 0.612 . . . . 0.0 110.334 -178.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.16 23.11 61.82 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.13 174.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 63.8 mt -60.02 158.45 10.97 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 118.151 0.975 . . . . 0.0 109.708 177.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 13.7 pt -73.37 -43.6 56.02 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.035 0 O-C-N 122.275 -0.266 . . . . 0.0 111.686 -174.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.72 -34.83 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.14 0.576 . . . . 0.0 110.371 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -173.82 48.46 0.15 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -176.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.2 t -49.48 141.34 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 C-N-CA 122.835 0.454 . . . . 0.0 109.809 177.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.4 m -92.21 163.44 2.25 Favored 'Isoleucine or valine' 0 C--O 1.23 0.04 0 CA-C-O 121.157 0.504 . . . . 0.0 111.624 -174.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -61.83 -26.31 68.04 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.224 -177.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.23 -6.39 57.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.661 0.384 . . . . 0.0 112.0 -178.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.8 -29.71 13.59 Favored 'General case' 0 CA--C 1.527 0.063 0 O-C-N 121.743 -0.598 . . . . 0.0 109.822 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.0 mt -74.01 -37.51 64.36 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.284 0.234 . . . . 0.0 110.92 -178.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.7 p -77.99 -29.96 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.323 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -85.55 -13.07 50.03 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 122.023 -0.423 . . . . 0.0 111.709 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -109.2 -9.18 15.03 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.8 mt -118.51 -7.4 10.63 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.815 0.734 . . . . 0.0 112.265 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.0 pt20 -74.0 -5.35 40.86 Favored 'General case' 0 C--N 1.34 0.157 0 CA-C-N 118.794 0.725 . . . . 0.0 110.342 175.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -77.6 -4.48 46.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.587 0.755 . . . . 0.0 111.095 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -111.53 -15.91 13.4 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.318 0.647 . . . . 0.0 111.272 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.84 176.73 36.02 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -72.14 140.19 33.83 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.0 3.133 . . . . 0.0 110.571 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.2 mt -109.86 148.92 13.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 122.844 0.457 . . . . 0.0 110.457 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.3 t -111.05 -41.26 4.25 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.251 0.62 . . . . 0.0 111.784 -177.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -158.1 158.09 34.05 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 117.839 0.291 . . . . 0.0 111.462 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 67.1 t -144.05 146.91 20.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.085 0.954 . . . . 0.0 109.699 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -148.95 151.42 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.9 t -128.07 149.5 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.073 0 CA-C-O 120.612 0.244 . . . . 0.0 111.32 -175.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.5 mpp? -130.44 83.07 63.54 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.982 0.913 . . . . 0.0 108.564 177.184 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -69.41 -11.7 31.89 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 123.482 2.788 . . . . 0.0 111.577 -175.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -81.58 -10.5 59.43 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 122.95 0.5 . . . . 0.0 110.81 177.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -126.35 6.47 7.01 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.576 0.75 . . . . 0.0 111.646 -178.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 55.19 31.0 15.56 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 123.982 0.913 . . . . 0.0 112.432 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -136.79 167.34 21.63 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.149 0.58 . . . . 0.0 111.103 -175.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.05 172.84 16.25 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.978 0.511 . . . . 0.0 110.319 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.0 mt -133.03 146.55 51.83 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 123.308 0.643 . . . . 0.0 110.054 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.82 133.15 41.23 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -117.08 121.88 42.56 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.7 m-85 -87.08 156.28 19.8 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 121.067 0.461 . . . . 0.0 110.555 -178.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -76.3 -13.57 60.15 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.14 -179.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -146.74 150.91 36.29 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.575 0.75 . . . . 0.0 109.319 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.7 p -69.33 -21.8 25.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.6 tp -75.91 -29.77 58.53 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.85 -0.531 . . . . 0.0 110.203 -179.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.83 -28.22 73.25 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 -25.77 33.48 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 117.05 0.425 . . . . 0.0 110.962 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.55 -34.09 41.31 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -68.69 -21.28 64.43 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 119.712 -0.185 . . . . 0.0 110.87 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.39 -27.62 27.51 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -178.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.3 t -92.58 -23.03 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.06 0 O-C-N 122.154 -0.342 . . . . 0.0 110.888 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -71.62 -7.77 49.91 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.105 -0.372 . . . . 0.0 111.472 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -106.29 -34.43 7.47 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.677 0.391 . . . . 0.0 110.477 176.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -10.39 59.07 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.91 -0.56 56.74 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -136.87 -11.4 1.76 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 122.677 0.391 . . . . 0.0 111.71 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -153.25 170.34 20.83 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -87.6 155.13 20.1 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 175.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.3 135.56 60.18 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -177.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -90.36 150.54 21.84 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 121.952 -0.467 . . . . 0.0 110.772 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.2 mt -137.43 -39.02 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.457 -0.076 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.869 -176.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.57 28.84 3.61 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 123.139 0.576 . . . . 0.0 110.908 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.9 5.64 83.43 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -176.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -131.21 153.14 81.61 Favored Pre-proline 0 N--CA 1.453 -0.275 0 C-N-CA 124.175 0.99 . . . . 0.0 109.152 177.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -72.26 145.9 44.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 123.251 2.634 . . . . 0.0 111.701 -176.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.11 -177.25 6.05 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 124.778 1.231 . . . . 0.0 108.839 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -139.64 160.39 39.97 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 120.976 0.417 . . . . 0.0 111.357 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -148.59 139.51 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 C-N-CA 123.339 0.655 . . . . 0.0 110.213 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.455 -0.21 0 C-N-CA 123.227 0.611 . . . . 0.0 109.858 178.836 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.2 m . . . . . 0 CA--C 1.531 0.244 0 N-CA-C 112.577 0.584 . . . . 0.0 112.577 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -65.4 -7.43 15.92 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.983 3.122 . . . . 0.0 113.382 177.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -109.85 141.43 25.17 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 123.032 0.533 . . . . 0.0 109.993 -178.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 28.0 m -125.61 156.29 35.12 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.242 0.617 . . . . 0.0 110.091 176.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -116.41 131.61 56.9 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.875 0.87 . . . . 0.0 109.421 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.442 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.8 mp -106.17 144.82 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -174.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -141.93 163.08 33.85 Favored 'General case' 0 N--CA 1.46 0.063 0 C-N-CA 123.557 0.743 . . . . 0.0 110.392 -177.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.32 23.27 61.19 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.213 -0.771 . . . . 0.0 113.017 174.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 70.9 mt -59.86 156.27 14.66 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.436 1.118 . . . . 0.0 110.141 178.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.6 pt -70.83 -41.23 77.32 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -172.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -173.92 -34.39 0.01 OUTLIER 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.413 0.685 . . . . 0.0 110.648 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.91 48.09 0.12 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.8 t -51.39 143.14 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 177.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -97.78 165.51 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.064 0 CA-C-O 121.35 0.595 . . . . 0.0 111.886 -174.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.16 -26.24 66.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.537 0.735 . . . . 0.0 111.334 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.88 -6.88 58.25 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -97.7 -28.98 13.65 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 118.181 0.446 . . . . 0.0 110.16 177.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 89.4 mt -74.35 -36.09 63.61 Favored 'General case' 0 N--CA 1.455 -0.191 0 O-C-N 122.255 -0.278 . . . . 0.0 110.979 -178.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.9 p -79.1 -30.28 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.189 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -82.59 -15.39 52.39 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 119.423 -0.322 . . . . 0.0 111.474 -178.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.87 -12.53 15.17 Favored 'General case' 0 C--N 1.339 0.132 0 N-CA-C 113.11 0.781 . . . . 0.0 113.11 -179.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.4 mt -116.46 -9.32 11.47 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -69.19 -6.88 31.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 118.809 0.731 . . . . 0.0 111.424 176.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -76.68 -15.13 59.88 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.089 -0.382 . . . . 0.0 110.649 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -97.24 -17.77 19.63 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 122.558 0.343 . . . . 0.0 111.454 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.68 177.05 36.21 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.688 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -70.54 139.91 38.59 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.077 3.185 . . . . 0.0 110.768 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 77.7 mt -110.33 146.31 15.71 Favored 'Isoleucine or valine' 0 C--O 1.232 0.133 0 C-N-CA 122.765 0.426 . . . . 0.0 110.205 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -107.73 -40.2 5.36 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.383 0.673 . . . . 0.0 111.348 -177.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -157.73 158.83 36.08 Favored 'General case' 0 C--N 1.338 0.096 0 CA-C-O 120.559 0.219 . . . . 0.0 111.342 -179.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 59.0 t -144.05 145.27 22.0 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 C-N-CA 124.175 0.99 . . . . 0.0 109.549 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.8 p -149.34 152.46 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 34.2 t -130.41 150.8 35.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 CA-C-O 120.675 0.274 . . . . 0.0 111.251 -175.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.4 81.36 68.3 Favored Pre-proline 0 CA--C 1.531 0.238 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 177.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -59.97 -17.88 46.98 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.945 3.097 . . . . 0.0 112.862 -177.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 mtmt -83.48 -5.82 59.27 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.876 0.47 . . . . 0.0 111.326 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -126.55 2.71 6.88 Favored 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.733 0.813 . . . . 0.0 111.112 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.3 tpp85 54.14 32.73 16.41 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 124.035 0.934 . . . . 0.0 111.865 -176.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -137.18 165.3 26.43 Favored 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 123.119 0.567 . . . . 0.0 110.956 -176.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 169.92 20.55 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 122.953 0.501 . . . . 0.0 110.569 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.8 mt -131.65 145.6 51.75 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.509 0.724 . . . . 0.0 109.824 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.74 134.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -116.16 121.8 43.17 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -86.39 155.85 20.42 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.027 0.442 . . . . 0.0 110.576 -179.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -74.86 -13.14 60.52 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.558 -178.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -147.73 152.87 38.5 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.883 0.873 . . . . 0.0 109.038 177.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.97 -21.61 25.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -175.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.8 tp -74.79 -29.85 61.24 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 122.108 -0.37 . . . . 0.0 110.692 -179.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.25 -28.58 71.25 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 179.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.17 -30.37 27.86 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 117.079 0.439 . . . . 0.0 110.898 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.8 t -75.21 -28.73 60.08 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.1 t30 -78.33 -21.21 49.91 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.321 0.248 . . . . 0.0 110.722 179.382 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.22 -31.25 30.38 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.301 -0.249 . . . . 0.0 111.505 -178.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 60.1 t -88.36 -21.97 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 O-C-N 122.252 -0.28 . . . . 0.0 110.556 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -66.9 -17.05 64.71 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 122.194 -0.316 . . . . 0.0 110.96 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -100.05 -36.54 9.32 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.189 0.196 . . . . 0.0 110.645 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.59 -11.04 59.95 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -176.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -89.29 1.42 55.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.578 0.351 . . . . 0.0 111.847 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -134.44 -15.64 2.15 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.76 0.424 . . . . 0.0 111.588 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -153.26 168.2 26.81 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.494 0.718 . . . . 0.0 109.186 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -82.78 155.54 24.17 Favored 'General case' 0 N--CA 1.457 -0.092 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 175.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -121.61 135.48 61.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -177.46 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -89.67 151.83 21.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.102 -0.374 . . . . 0.0 110.789 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -138.14 -39.06 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.894 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.69 29.41 3.53 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 122.876 0.47 . . . . 0.0 111.041 -176.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.87 4.86 84.42 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -176.254 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -131.59 152.08 79.8 Favored Pre-proline 0 N--CA 1.454 -0.231 0 C-N-CA 124.115 0.966 . . . . 0.0 108.95 177.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -71.54 146.55 49.84 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 123.58 2.854 . . . . 0.0 111.88 -176.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.8 -175.72 5.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.651 1.18 . . . . 0.0 108.811 178.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -138.82 159.44 42.12 Favored 'General case' 0 N--CA 1.457 -0.099 0 CA-C-O 120.644 0.259 . . . . 0.0 111.005 -179.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.9 p -149.26 139.11 16.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 C-N-CA 123.341 0.657 . . . . 0.0 110.247 178.736 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.1 t30 . . . . . 0 N--CA 1.456 -0.157 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.7 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.438 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.3 p . . . . . 0 CA--C 1.531 0.249 0 N-CA-C 111.586 0.217 . . . . 0.0 111.586 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.438 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 90.1 Cg_endo -70.49 5.7 1.87 Allowed 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 123.865 3.043 . . . . 0.0 112.119 177.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.3 t -117.85 139.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 C-N-CA 123.153 0.581 . . . . 0.0 109.864 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.2 m -131.37 146.83 33.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-O 120.911 0.386 . . . . 0.0 110.807 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.1 t-80 -96.58 137.41 35.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.845 0.858 . . . . 0.0 110.165 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.0 mp -111.77 145.82 17.45 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 123.552 0.741 . . . . 0.0 109.392 -177.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -142.56 164.94 28.75 Favored 'General case' 0 C--O 1.228 -0.04 0 C-N-CA 123.655 0.782 . . . . 0.0 110.724 -177.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.44 25.26 57.29 Favored Glycine 0 CA--C 1.525 0.711 0 CA-C-O 119.575 -0.569 . . . . 0.0 113.343 173.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.7 mt -60.33 156.5 15.61 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.987 0.894 . . . . 0.0 109.983 178.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.7 pt -71.84 -39.93 68.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 O-C-N 122.268 -0.27 . . . . 0.0 111.088 -175.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -172.92 -36.0 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.08 0 C-N-CA 123.612 0.765 . . . . 0.0 109.985 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 173.92 56.5 0.05 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -177.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.4 m -53.21 156.62 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 123.003 0.521 . . . . 0.0 110.782 178.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 111' ' ' ALA . 6.5 t -78.03 155.51 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 CA-C-O 121.032 0.444 . . . . 0.0 110.39 -176.341 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -60.76 -25.81 66.77 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.638 0.375 . . . . 0.0 110.265 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . 0.42 ' H ' HG12 ' A' ' 109' ' ' VAL . . . -81.32 -8.27 59.71 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.079 0.551 . . . . 0.0 111.62 -179.15 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -85.7 -32.79 21.74 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.828 -0.545 . . . . 0.0 110.238 -179.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.1 mp -77.49 -30.94 53.28 Favored 'General case' 0 N--CA 1.456 -0.142 0 O-C-N 122.323 -0.236 . . . . 0.0 111.18 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.8 p -78.25 -31.76 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-N 118.18 0.445 . . . . 0.0 110.04 -178.55 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -82.23 -17.57 45.61 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 122.217 -0.302 . . . . 0.0 111.082 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.47 -10.34 18.62 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -117.6 -8.55 10.92 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.606 0.639 . . . . 0.0 112.21 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -67.54 -6.88 21.95 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 118.663 0.665 . . . . 0.0 111.874 175.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -76.59 -13.05 60.1 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.956 -0.465 . . . . 0.0 110.634 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -100.82 -16.9 17.13 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 122.567 0.347 . . . . 0.0 111.606 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.15 177.64 36.27 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -72.25 140.44 33.94 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.81 3.007 . . . . 0.0 110.52 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.2 mt -111.13 147.31 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.085 0 C-N-CA 122.75 0.42 . . . . 0.0 110.246 -177.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.8 t -107.63 -41.56 5.0 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.076 0.551 . . . . 0.0 111.656 -177.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 46.1 t80 -159.65 160.51 34.33 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 117.623 0.192 . . . . 0.0 111.258 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 88.9 t -143.65 146.51 21.04 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 C-N-CA 124.122 0.969 . . . . 0.0 109.829 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.8 p -144.19 151.4 16.12 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 174.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 60.4 t -133.36 149.73 31.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -176.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 72.1 mtm -134.41 86.66 34.69 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 123.612 0.765 . . . . 0.0 109.284 -179.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.35 -11.55 30.26 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 123.061 2.507 . . . . 0.0 111.649 -177.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -81.11 -10.34 59.67 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.062 0.545 . . . . 0.0 110.7 176.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -128.88 3.18 5.36 Favored 'General case' 0 C--N 1.34 0.155 0 C-N-CA 123.73 0.812 . . . . 0.0 111.353 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.7 tpp85 53.05 34.05 16.29 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.335 1.054 . . . . 0.0 111.964 -176.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -137.84 168.55 19.47 Favored 'General case' 0 C--N 1.334 -0.08 0 C-N-CA 123.402 0.681 . . . . 0.0 110.282 -177.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.98 170.86 19.37 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 123.139 0.576 . . . . 0.0 110.262 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 14.1 tp -137.54 142.87 41.38 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 92.0 t -137.8 141.55 38.56 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -176.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -120.79 124.76 45.86 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.43 0.692 . . . . 0.0 109.219 177.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -89.16 153.23 21.12 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 120.919 0.39 . . . . 0.0 110.303 178.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -73.32 -14.39 61.29 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.409 -177.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -146.75 151.25 36.86 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 176.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -67.49 -20.65 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.302 0.241 . . . . 0.0 111.558 -175.162 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.4 tp -75.92 -25.79 56.32 Favored 'General case' 0 N--CA 1.456 -0.165 0 O-C-N 122.09 -0.381 . . . . 0.0 110.485 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.14 -30.31 65.41 Favored Glycine 0 C--N 1.339 0.722 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.484 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.69 -31.55 28.53 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.025 0.412 . . . . 0.0 110.34 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 47.5 t -73.75 -19.67 60.72 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 122.705 0.402 . . . . 0.0 110.974 179.242 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 122.694 0.398 . . . . 0.0 111.315 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.36 -31.52 22.92 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 122.169 -0.332 . . . . 0.0 111.386 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.4 t -85.06 -13.53 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -72.52 -1.95 17.87 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.295 0.638 . . . . 0.0 111.212 178.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 53.1 t80 -124.02 -36.75 2.66 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.827 0.451 . . . . 0.0 110.914 178.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.59 -8.7 59.35 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -176.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.41 -0.89 57.45 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.721 0.408 . . . . 0.0 111.986 178.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -138.73 -12.56 1.3 Allowed 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -151.88 163.21 39.71 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 9.3 pm0 -76.59 159.71 30.06 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 122.06 -0.4 . . . . 0.0 110.027 177.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -126.74 136.17 61.59 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -89.2 152.73 21.43 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.092 -0.38 . . . . 0.0 110.654 -178.161 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 47.2 mt -137.67 -39.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.177 -177.652 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.22 28.94 3.72 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 122.819 0.448 . . . . 0.0 110.986 -177.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.1 5.61 80.11 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 -176.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -131.35 152.98 81.49 Favored Pre-proline 0 N--CA 1.453 -0.319 0 C-N-CA 124.228 1.011 . . . . 0.0 109.01 177.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -71.44 145.34 47.52 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.357 2.705 . . . . 0.0 111.751 -176.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.38 -174.93 4.98 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.945 1.298 . . . . 0.0 108.668 177.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.35 160.42 39.87 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 120.989 0.423 . . . . 0.0 111.28 -178.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.13 144.66 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 C-N-CA 123.66 0.784 . . . . 0.0 109.415 178.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 . . . . . 0 N--CA 1.455 -0.186 0 C-N-CA 123.163 0.585 . . . . 0.0 110.047 -179.342 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.433 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.3 p . . . . . 0 CA--C 1.533 0.292 0 N-CA-C 111.627 0.232 . . . . 0.0 111.627 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 81.8 Cg_endo -70.18 4.53 2.31 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 124.295 3.33 . . . . 0.0 112.373 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.8 t -117.95 142.63 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 178.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -131.55 151.59 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 CA-C-O 121.114 0.483 . . . . 0.0 110.635 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.3 t-80 -101.89 136.12 42.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.253 1.021 . . . . 0.0 109.993 178.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.13 145.02 17.17 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 C-N-CA 123.465 0.706 . . . . 0.0 109.116 -176.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -142.26 165.14 28.24 Favored 'General case' 0 CA--C 1.526 0.054 0 C-N-CA 123.543 0.737 . . . . 0.0 110.339 -176.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.61 24.08 63.45 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 119.37 -0.683 . . . . 0.0 113.499 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 73.0 mt -61.38 157.96 15.61 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.282 1.041 . . . . 0.0 109.977 177.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.21 -40.14 74.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 O-C-N 122.411 -0.181 . . . . 0.0 111.416 -175.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -171.52 -42.17 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.479 0.712 . . . . 0.0 109.961 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -172.72 54.33 0.16 Allowed Glycine 0 C--N 1.337 0.625 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -175.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.5 t -50.21 144.59 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.299 0.639 . . . . 0.0 109.567 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -91.94 164.03 2.16 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-O 121.092 0.472 . . . . 0.0 111.613 -175.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -61.76 -27.69 68.91 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.885 0.474 . . . . 0.0 110.858 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.1 -4.58 51.0 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -178.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -103.83 -30.37 10.41 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-N 118.379 0.536 . . . . 0.0 109.8 175.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 75.9 mt -71.48 -41.53 69.23 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.555 0.342 . . . . 0.0 110.368 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.84 -30.04 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 121.154 -0.218 . . . . 0.0 111.041 -177.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -84.67 -14.88 47.22 Favored 'General case' 0 N--CA 1.456 -0.16 0 O-C-N 122.116 -0.365 . . . . 0.0 111.777 -177.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.16 -15.66 16.61 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 178.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -110.92 -8.26 14.51 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -71.77 -6.17 39.45 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.736 0.698 . . . . 0.0 111.401 175.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -77.04 -13.82 59.91 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 122.591 0.356 . . . . 0.0 110.323 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -99.05 -17.57 18.18 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.518 0.327 . . . . 0.0 111.742 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.21 176.69 36.28 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.79 139.48 33.64 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 124.106 3.204 . . . . 0.0 110.464 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 75.1 mt -110.87 145.95 16.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 C-N-CA 122.735 0.414 . . . . 0.0 110.352 -177.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -105.62 -40.44 5.76 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.226 0.61 . . . . 0.0 111.287 -178.169 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -159.07 159.2 34.34 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-O 120.788 0.328 . . . . 0.0 110.895 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -144.05 145.71 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.755 0.822 . . . . 0.0 109.619 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.23 152.14 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.11 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.061 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 10.3 p -134.5 153.69 35.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 122.815 0.446 . . . . 0.0 111.105 -176.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 18.8 ptp -136.03 82.83 35.54 Favored Pre-proline 0 CA--C 1.532 0.267 0 C-N-CA 124.001 0.92 . . . . 0.0 109.606 179.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -58.45 -21.2 52.67 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 124.255 3.304 . . . . 0.0 113.131 -178.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.3 mtpt -78.78 -1.15 33.35 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.718 0.407 . . . . 0.0 111.293 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 22.6 tptm -131.66 -0.75 3.88 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.359 1.064 . . . . 0.0 110.481 179.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 57.75 28.95 16.64 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.947 0.899 . . . . 0.0 112.51 -177.004 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -134.32 169.98 16.4 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.808 0.443 . . . . 0.0 111.226 -175.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.63 171.25 18.46 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.211 0.604 . . . . 0.0 110.758 178.224 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.4 mt -132.96 146.04 51.43 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.917 0.887 . . . . 0.0 109.673 178.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.8 t -138.85 133.42 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -114.64 120.75 41.19 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 177.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -86.7 153.58 21.63 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 120.958 0.409 . . . . 0.0 110.598 -179.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -74.7 -13.34 60.6 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.517 -177.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -147.08 152.41 38.47 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 123.82 0.848 . . . . 0.0 108.995 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -67.71 -21.85 27.74 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -175.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.3 tp -72.75 -27.1 61.82 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.137 -0.352 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.59 -30.35 66.6 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.18 -34.36 25.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 117.105 0.452 . . . . 0.0 110.292 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -72.41 -20.94 61.34 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 122.487 0.315 . . . . 0.0 110.876 178.441 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -94.29 4.59 53.67 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 122.939 0.496 . . . . 0.0 111.475 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -108.46 -26.57 10.39 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 117.967 0.349 . . . . 0.0 111.87 179.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 45.3 t -89.43 -18.89 7.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 CA-C-N 117.8 0.273 . . . . 0.0 110.506 178.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -73.32 1.44 9.53 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.979 -0.451 . . . . 0.0 111.787 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 55.3 t80 -119.08 -34.67 3.82 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 123.045 0.538 . . . . 0.0 110.825 178.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.84 -3.18 58.96 Favored 'General case' 0 CA--C 1.533 0.314 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.94 -2.16 57.75 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.597 0.359 . . . . 0.0 111.417 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.14 -5.52 1.65 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.045 0.538 . . . . 0.0 111.528 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.56 173.93 15.64 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.841 0.856 . . . . 0.0 108.864 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.5 pt20 -93.07 155.58 17.41 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.53 135.18 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -178.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.48 151.7 21.85 Favored 'General case' 0 N--CA 1.455 -0.183 0 O-C-N 122.195 -0.316 . . . . 0.0 110.552 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.0 mt -137.71 -39.01 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.144 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.13 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.17 30.59 2.99 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.042 0.537 . . . . 0.0 110.823 -176.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.66 4.86 84.95 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -176.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -131.17 151.98 79.82 Favored Pre-proline 0 N--CA 1.455 -0.211 0 C-N-CA 123.994 0.918 . . . . 0.0 109.106 177.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -71.29 145.57 48.8 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 C-N-CA 123.694 2.929 . . . . 0.0 111.749 -177.169 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.67 -176.38 5.59 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.565 1.146 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -139.05 159.38 42.28 Favored 'General case' 0 CA--C 1.527 0.082 0 CA-C-O 120.969 0.414 . . . . 0.0 111.271 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.7 p -148.45 142.34 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.481 0.713 . . . . 0.0 109.483 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 . . . . . 0 N--CA 1.455 -0.178 0 C-N-CA 123.2 0.6 . . . . 0.0 110.186 -179.352 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.428 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 57.8 p . . . . . 0 CA--C 1.533 0.327 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 91.2 Cg_endo -72.7 2.46 5.25 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 124.306 3.337 . . . . 0.0 112.649 179.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.2 t -121.88 140.92 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.137 0 CA-C-N 118.42 0.555 . . . . 0.0 109.655 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.21 154.37 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 CA-C-O 121.385 0.612 . . . . 0.0 110.728 178.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -105.73 141.81 36.53 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.208 1.003 . . . . 0.0 109.514 -179.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 20.7 mm -110.26 144.05 19.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 C-N-CA 123.04 0.536 . . . . 0.0 110.142 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 42.4 mtm105 -141.24 159.4 42.29 Favored 'General case' 0 CA--C 1.527 0.063 0 C-N-CA 123.492 0.717 . . . . 0.0 110.315 -178.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.41 25.03 59.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-O 119.552 -0.582 . . . . 0.0 113.366 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 53.9 mt -59.55 156.24 13.77 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 118.098 0.949 . . . . 0.0 109.482 176.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.8 pt -70.31 -37.96 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.135 0 N-CA-C 111.383 0.142 . . . . 0.0 111.383 -174.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.74 -35.53 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 123.954 0.901 . . . . 0.0 109.648 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 170.48 55.97 0.04 OUTLIER Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -176.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.8 m -53.21 151.72 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 117.236 0.518 . . . . 0.0 110.501 178.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -87.18 166.45 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.082 0 CA-C-O 121.314 0.578 . . . . 0.0 110.809 -177.232 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -60.3 -25.21 65.59 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.002 0.521 . . . . 0.0 110.698 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.89 -6.35 53.99 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 122.811 0.444 . . . . 0.0 112.038 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 79.4 m-20 -97.34 -33.11 11.55 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 118.371 0.532 . . . . 0.0 109.733 176.201 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.47 -40.76 66.71 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.308 0.243 . . . . 0.0 110.83 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.08 -30.06 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 O-C-N 122.158 -0.339 . . . . 0.0 110.855 -176.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.7 mm-40 -81.67 -18.22 45.28 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 117.822 0.283 . . . . 0.0 111.616 -178.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.35 -14.37 16.95 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -113.9 -7.43 13.17 Favored 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -178.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.0 pt20 -71.49 -5.84 36.01 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.666 0.666 . . . . 0.0 111.735 175.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -76.58 -14.3 60.01 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 122.962 0.505 . . . . 0.0 110.677 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -98.71 -17.01 18.77 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.56 0.344 . . . . 0.0 111.562 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.91 176.67 35.2 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -71.12 140.31 37.36 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 123.935 3.09 . . . . 0.0 110.631 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 72.4 mt -110.16 146.4 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.103 0 C-N-CA 122.863 0.465 . . . . 0.0 110.4 -178.006 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.8 t -108.26 -39.93 5.32 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 123.279 0.631 . . . . 0.0 111.62 -177.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -157.78 158.13 34.66 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 120.57 0.224 . . . . 0.0 111.04 178.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.5 t -145.01 146.36 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.079 0 C-N-CA 123.642 0.777 . . . . 0.0 109.507 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.28 153.24 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 175.352 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 11.1 p -133.7 151.74 33.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.118 0 CA-C-O 120.806 0.336 . . . . 0.0 111.191 -176.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 19.3 ptp -136.24 84.89 28.54 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.739 0.816 . . . . 0.0 109.159 179.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.5 -12.31 33.1 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.386 2.724 . . . . 0.0 111.666 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -77.93 -5.04 49.82 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 122.683 0.393 . . . . 0.0 111.018 176.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -132.79 5.17 3.92 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 123.645 0.778 . . . . 0.0 111.213 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 54.27 35.72 23.44 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.292 1.037 . . . . 0.0 112.343 -177.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -137.54 169.83 17.12 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.132 0.573 . . . . 0.0 111.039 -176.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.44 172.82 17.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.112 0.565 . . . . 0.0 110.494 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.4 mt -132.92 146.22 51.6 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.9 0.88 . . . . 0.0 109.374 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 89.8 t -138.36 133.03 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -116.26 121.68 42.74 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.578 0.751 . . . . 0.0 109.192 178.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 44.3 m-85 -88.5 155.52 19.61 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.052 0.453 . . . . 0.0 110.547 -178.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -75.77 -13.49 60.3 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.475 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -145.76 152.82 40.17 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.691 0.796 . . . . 0.0 109.097 177.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.8 p -69.55 -21.84 24.9 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 58.7 tp -77.44 -29.51 52.89 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.003 -0.436 . . . . 0.0 110.418 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.27 -31.09 73.94 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.15 -32.03 33.86 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 116.984 0.392 . . . . 0.0 110.534 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.6 t -70.6 -29.72 66.2 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 122.076 0.15 . . . . 0.0 110.628 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -75.84 -21.0 57.7 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.194 -0.316 . . . . 0.0 111.247 179.18 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -81.31 -28.19 34.7 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.971 0.35 . . . . 0.0 111.617 -177.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 33.3 t -92.16 -19.66 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 O-C-N 122.382 -0.199 . . . . 0.0 110.688 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -71.34 -11.69 61.04 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 122.117 -0.364 . . . . 0.0 110.888 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -104.88 -34.05 8.18 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 122.942 0.497 . . . . 0.0 110.764 178.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.71 -7.24 59.52 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -177.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -84.84 -2.51 57.84 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -141.47 -3.87 1.15 Allowed 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 122.829 0.452 . . . . 0.0 111.946 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 54.1 t30 -154.68 165.23 37.21 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 123.303 0.641 . . . . 0.0 109.456 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -85.14 158.3 20.43 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.04 135.72 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.058 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.2 m-85 -89.78 152.97 21.03 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.04 -0.413 . . . . 0.0 110.862 -178.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.2 mt -137.29 -41.0 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.227 -0.101 0 C-N-CA 122.669 0.388 . . . . 0.0 110.755 -177.137 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.92 29.91 3.73 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.817 0.447 . . . . 0.0 110.944 -177.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.05 4.24 81.96 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -176.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -130.31 151.81 79.14 Favored Pre-proline 0 N--CA 1.455 -0.223 0 C-N-CA 124.14 0.976 . . . . 0.0 109.053 177.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.69 146.04 53.4 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 123.526 2.817 . . . . 0.0 112.038 -176.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.35 -176.21 5.49 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.267 1.427 . . . . 0.0 108.902 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -138.99 161.51 37.17 Favored 'General case' 0 N--CA 1.457 -0.086 0 CA-C-O 120.943 0.402 . . . . 0.0 111.521 -179.196 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.0 p -150.09 141.55 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.842 0.857 . . . . 0.0 109.751 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 . . . . . 0 N--CA 1.458 -0.074 0 C-N-CA 123.333 0.653 . . . . 0.0 109.747 178.373 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.1 m . . . . . 0 CA--C 1.529 0.16 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -72.35 -1.52 10.3 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 123.92 3.08 . . . . 0.0 112.073 175.606 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.4 t -113.42 139.38 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 123.215 0.606 . . . . 0.0 109.707 178.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.2 m -125.17 159.49 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 C-N-CA 122.928 0.491 . . . . 0.0 110.316 178.417 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -114.55 135.65 53.89 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 123.834 0.854 . . . . 0.0 109.687 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.8 mm -106.74 143.88 16.76 Favored 'Isoleucine or valine' 0 C--O 1.23 0.068 0 C-N-CA 122.888 0.475 . . . . 0.0 110.365 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 72.1 mtm-85 -143.64 163.5 33.05 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 123.368 0.667 . . . . 0.0 110.523 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.84 22.27 66.69 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 119.572 -0.571 . . . . 0.0 113.148 174.046 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.48 156.08 16.95 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 118.173 0.986 . . . . 0.0 110.041 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.1 pt -70.97 -41.46 76.99 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.112 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -173.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.2 -35.9 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.228 0.611 . . . . 0.0 110.437 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.86 50.5 0.12 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.648 -0.581 . . . . 0.0 111.648 -177.329 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 88.1 t -50.16 143.09 2.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.419 0.688 . . . . 0.0 109.8 177.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 33.8 m -94.48 164.7 2.05 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 121.229 0.538 . . . . 0.0 111.73 -174.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -61.22 -25.87 67.35 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.431 0.692 . . . . 0.0 111.224 -178.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.42 -6.3 57.85 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -177.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -97.75 -29.06 13.59 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 118.222 0.465 . . . . 0.0 110.282 177.136 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 98.0 mt -74.02 -35.9 64.41 Favored 'General case' 0 N--CA 1.452 -0.325 0 O-C-N 122.401 -0.187 . . . . 0.0 110.93 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.05 -31.47 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.363 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -81.55 -16.56 51.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 119.565 -0.255 . . . . 0.0 111.596 -178.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.95 -13.36 15.51 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.4 mt -116.1 -6.13 11.92 Favored 'General case' 0 N--CA 1.461 0.094 0 CA-C-N 118.483 0.583 . . . . 0.0 112.479 -178.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -72.44 -6.41 43.4 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.678 0.672 . . . . 0.0 110.26 175.004 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -77.33 -3.89 42.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 123.923 0.889 . . . . 0.0 111.059 179.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -112.85 -16.49 12.71 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.006 0.522 . . . . 0.0 111.282 179.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.48 175.78 35.62 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -71.35 140.77 37.54 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 123.812 3.008 . . . . 0.0 110.564 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 72.3 mt -110.13 147.05 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.822 0.449 . . . . 0.0 110.572 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -109.53 -41.15 4.66 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 123.206 0.603 . . . . 0.0 111.564 -176.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -158.06 158.03 34.0 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 117.666 0.212 . . . . 0.0 111.261 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.7 t -143.89 147.42 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 C-N-CA 123.932 0.893 . . . . 0.0 109.591 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -149.53 151.52 12.8 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.032 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 175.407 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.95 152.59 36.24 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 C-N-CA 122.437 0.295 . . . . 0.0 110.899 -175.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 21.2 ptp -138.58 78.76 31.07 Favored Pre-proline 0 CA--C 1.534 0.33 0 C-N-CA 123.675 0.79 . . . . 0.0 109.741 177.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.57 -18.43 47.15 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.89 3.06 . . . . 0.0 113.306 -177.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -71.66 -12.28 61.26 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 122.8 0.44 . . . . 0.0 110.873 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.69 4.55 6.73 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.703 0.801 . . . . 0.0 111.286 179.273 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 55.31 34.98 23.97 Favored 'General case' 0 CA--C 1.533 0.288 0 C-N-CA 124.095 0.958 . . . . 0.0 112.191 -176.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -134.03 169.02 17.75 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 123.054 0.541 . . . . 0.0 110.843 -177.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.81 171.8 19.01 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.167 176.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 43.2 mt -131.86 146.44 52.12 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.522 0.729 . . . . 0.0 109.825 178.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.6 t -138.28 131.75 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -114.92 122.84 47.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 177.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 47.1 m-85 -87.26 155.35 20.11 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.41 -179.26 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -76.37 -11.65 59.93 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.246 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.73 152.92 38.58 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.928 0.891 . . . . 0.0 109.282 177.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -69.9 -21.33 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 O-C-N 122.224 -0.298 . . . . 0.0 111.702 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.2 tp -75.85 -28.97 58.42 Favored 'General case' 0 N--CA 1.454 -0.231 0 O-C-N 121.865 -0.522 . . . . 0.0 110.626 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.03 -29.51 73.52 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.12 -28.12 29.66 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.99 0.395 . . . . 0.0 110.74 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.6 t -74.06 -30.89 62.61 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.244 -0.285 . . . . 0.0 110.467 179.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -76.24 -21.67 56.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.268 -0.27 . . . . 0.0 111.249 179.329 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -33.31 26.79 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 117.778 0.263 . . . . 0.0 111.396 -177.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.15 -22.67 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 O-C-N 122.308 -0.245 . . . . 0.0 110.535 179.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -68.79 -16.56 63.83 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.943 -0.473 . . . . 0.0 111.01 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -99.03 -34.79 10.27 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 122.695 0.398 . . . . 0.0 110.691 178.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.21 -10.76 59.02 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -177.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.54 -1.01 52.78 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 178.019 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -139.61 -7.48 1.29 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -155.02 165.39 36.88 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.257 0.623 . . . . 0.0 109.363 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.68 157.57 23.29 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 173.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.43 135.99 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 64.1 m-85 -90.29 151.11 21.64 Favored 'General case' 0 N--CA 1.457 -0.082 0 O-C-N 122.109 -0.369 . . . . 0.0 110.92 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.5 mt -137.14 -38.89 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.12 -176.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.65 29.07 3.25 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.149 0.58 . . . . 0.0 111.012 -176.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.82 4.66 82.18 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.53 151.98 79.64 Favored Pre-proline 0 C--O 1.234 0.253 0 C-N-CA 124.322 1.049 . . . . 0.0 109.322 177.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_endo -70.9 146.57 53.46 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 123.522 2.814 . . . . 0.0 111.702 -177.179 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.71 -177.72 6.28 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 125.205 1.402 . . . . 0.0 109.104 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -137.54 159.7 41.23 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.061 0.458 . . . . 0.0 111.792 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.5 p -151.23 139.98 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 123.347 0.659 . . . . 0.0 110.149 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.0 t30 . . . . . 0 CA--C 1.528 0.132 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.743 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.448 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.7 p . . . . . 0 CA--C 1.532 0.288 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 98.9 Cg_endo -71.17 1.22 5.59 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 124.008 3.139 . . . . 0.0 112.758 178.229 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.57 139.05 37.62 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.094 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 178.277 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.3 154.22 37.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 122.928 0.491 . . . . 0.0 110.339 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 31.5 t-80 -110.65 138.18 47.37 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.993 0.917 . . . . 0.0 109.507 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.1 mm -107.49 144.77 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 C-N-CA 122.893 0.477 . . . . 0.0 110.33 -176.228 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -143.01 161.48 38.0 Favored 'General case' 0 C--N 1.338 0.088 0 C-N-CA 123.195 0.598 . . . . 0.0 110.553 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.36 23.51 62.85 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 119.498 -0.612 . . . . 0.0 113.488 173.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 76.4 mt -60.87 158.01 13.98 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 118.332 1.066 . . . . 0.0 110.523 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -72.31 -40.93 65.65 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -173.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -172.12 -38.22 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 C-N-CA 123.107 0.563 . . . . 0.0 110.079 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.33 51.91 0.11 Allowed Glycine 0 C--N 1.338 0.646 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -176.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 57.9 t -49.65 144.03 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 123.546 0.738 . . . . 0.0 110.153 178.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -90.0 161.95 2.57 Favored 'Isoleucine or valine' 0 C--N 1.338 0.072 0 CA-C-O 121.292 0.567 . . . . 0.0 111.655 -174.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -62.0 -24.05 66.8 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.259 0.624 . . . . 0.0 111.766 -176.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.48 -5.5 58.74 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -95.63 -31.55 13.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.312 0.505 . . . . 0.0 110.498 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.56 -34.07 60.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 O-C-N 121.921 -0.487 . . . . 0.0 110.752 -177.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.3 p -78.06 -30.64 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 120.709 -0.396 . . . . 0.0 109.979 -178.68 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -85.72 -12.03 52.17 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.274 -0.266 . . . . 0.0 111.558 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.84 -11.79 15.31 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 178.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -114.8 -9.37 12.52 Favored 'General case' 0 C--N 1.34 0.19 0 CA-C-N 118.457 0.571 . . . . 0.0 112.255 -179.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.64 -3.87 16.92 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 118.615 0.643 . . . . 0.0 111.71 176.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -78.49 -16.1 57.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.865 0.466 . . . . 0.0 110.511 178.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -96.67 -18.94 19.35 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.343 -0.223 . . . . 0.0 111.397 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.34 178.14 38.25 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.75 140.78 36.22 Favored 'Trans proline' 0 N--CA 1.451 -0.985 0 C-N-CA 124.061 3.174 . . . . 0.0 110.46 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.5 mt -110.05 148.44 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 C-N-CA 122.604 0.362 . . . . 0.0 110.449 -177.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -110.63 -39.78 4.78 Favored 'General case' 0 N--CA 1.457 -0.101 0 C-N-CA 123.247 0.619 . . . . 0.0 111.851 -177.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -158.68 158.06 33.02 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 117.76 0.255 . . . . 0.0 111.601 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 79.3 t -143.72 146.29 21.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 124.036 0.934 . . . . 0.0 109.586 179.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.9 p -147.53 153.49 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 174.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.8 t -128.75 150.8 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 CA-C-O 120.833 0.349 . . . . 0.0 110.659 -176.299 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -134.54 79.77 52.93 Favored Pre-proline 0 CA--C 1.531 0.237 0 C-N-CA 124.492 1.117 . . . . 0.0 109.195 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -68.96 -14.06 37.86 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.389 2.726 . . . . 0.0 111.778 -175.407 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -81.71 -1.88 48.56 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 122.824 0.45 . . . . 0.0 111.585 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -133.39 4.46 3.69 Favored 'General case' 0 C--N 1.339 0.14 0 C-N-CA 123.797 0.839 . . . . 0.0 111.113 175.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.4 tpp85 55.59 35.76 25.84 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.069 0.948 . . . . 0.0 111.667 -175.193 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -134.11 170.49 15.58 Favored 'General case' 0 N--CA 1.457 -0.076 0 C-N-CA 123.415 0.686 . . . . 0.0 110.929 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.88 170.94 20.5 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 176.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.7 tp -135.17 142.54 46.12 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.5 t -138.21 141.54 37.78 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.1 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -123.9 125.03 43.91 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.086 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -87.75 154.9 20.2 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.875 0.369 . . . . 0.0 110.341 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -74.97 -12.36 60.32 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.246 -178.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -147.8 152.49 37.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.988 0.915 . . . . 0.0 109.265 176.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.8 p -68.63 -21.85 26.37 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.0 tp -73.95 -26.08 60.3 Favored 'General case' 0 N--CA 1.453 -0.303 0 O-C-N 121.999 -0.438 . . . . 0.0 110.544 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.24 -29.13 68.92 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.042 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.66 -30.23 23.38 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 117.237 0.519 . . . . 0.0 110.513 178.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 36.8 t -75.55 -17.77 59.97 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 122.49 0.316 . . . . 0.0 110.484 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -93.35 -20.84 19.97 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.705 0.402 . . . . 0.0 110.723 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.35 -31.01 25.02 Favored 'General case' 0 N--CA 1.455 -0.177 0 O-C-N 122.112 -0.367 . . . . 0.0 111.501 -178.081 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.62 -19.4 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 O-C-N 122.04 -0.413 . . . . 0.0 110.698 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -70.5 -17.54 62.96 Favored 'General case' 0 CA--C 1.529 0.142 0 O-C-N 122.221 -0.3 . . . . 0.0 111.195 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.9 t80 -97.42 -36.79 10.24 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 122.686 0.394 . . . . 0.0 111.172 178.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.25 -6.61 59.42 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.22 -4.81 56.67 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.078 -0.389 . . . . 0.0 111.543 176.238 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -141.64 -4.99 1.07 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 23.9 m-80 -145.01 175.26 10.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.358 0.663 . . . . 0.0 109.615 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.1 pt20 -99.35 150.52 22.05 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 172.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -118.91 134.51 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -88.04 151.46 22.74 Favored 'General case' 0 N--CA 1.453 -0.278 0 O-C-N 122.183 -0.323 . . . . 0.0 110.853 -179.051 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 41.2 mt -138.22 -37.3 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.19 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.91 29.54 3.14 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.24 0.616 . . . . 0.0 111.087 -176.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.73 4.69 84.93 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -176.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.36 152.78 81.13 Favored Pre-proline 0 N--CA 1.454 -0.234 0 C-N-CA 124.24 1.016 . . . . 0.0 108.982 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -71.53 146.83 50.52 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 123.377 2.718 . . . . 0.0 111.792 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.67 -176.54 5.77 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 124.784 1.234 . . . . 0.0 109.011 178.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -137.83 159.79 41.05 Favored 'General case' 0 CA--C 1.527 0.081 0 CA-C-O 120.776 0.322 . . . . 0.0 111.428 -178.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.84 138.14 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.324 0.649 . . . . 0.0 110.23 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.456 -0.126 0 C-N-CA 123.502 0.721 . . . . 0.0 109.303 179.594 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.481 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 77.8 p . . . . . 0 CA--C 1.529 0.147 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.481 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 84.6 Cg_endo -70.5 2.15 4.23 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 123.89 3.06 . . . . 0.0 112.854 177.046 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.7 t -112.92 139.15 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 CA-C-N 118.327 0.512 . . . . 0.0 109.926 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.0 m -125.51 157.74 34.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 C-N-CA 122.908 0.483 . . . . 0.0 110.359 178.421 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.6 t-80 -115.39 137.63 51.84 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.179 0.991 . . . . 0.0 109.392 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.6 mm -107.67 145.69 14.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 C-N-CA 122.616 0.366 . . . . 0.0 110.044 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -142.64 157.74 44.38 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.418 0.687 . . . . 0.0 109.947 -178.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 24.98 57.51 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.314 174.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.3 mt -59.08 156.72 11.43 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 118.026 0.913 . . . . 0.0 109.812 177.562 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.1 pt -72.45 -39.07 61.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 O-C-N 122.181 -0.324 . . . . 0.0 111.773 -174.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -173.41 -36.2 0.01 OUTLIER 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 123.653 0.781 . . . . 0.0 110.033 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.31 54.75 0.05 OUTLIER Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -177.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.3 m -52.9 151.57 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 117.156 0.478 . . . . 0.0 110.271 177.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.1 m -88.34 165.74 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.039 0 CA-C-O 121.161 0.505 . . . . 0.0 111.36 -175.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.61 -23.92 66.35 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.132 0.573 . . . . 0.0 111.21 -178.173 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.2 -6.85 57.53 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 122.743 0.417 . . . . 0.0 111.867 -179.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -91.49 -34.96 14.59 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.236 0.471 . . . . 0.0 110.617 179.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.6 mp -75.87 -33.81 59.98 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 122.214 -0.304 . . . . 0.0 110.948 -176.793 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -76.57 -29.49 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.068 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 37.7 mm-40 -84.36 -14.26 50.02 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 122.206 0.202 . . . . 0.0 110.982 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.69 -21.79 16.24 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.8 mp -109.83 -10.68 14.75 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -177.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.36 -4.43 14.54 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.978 0.808 . . . . 0.0 111.956 177.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -83.6 -12.27 56.28 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.881 0.473 . . . . 0.0 110.413 178.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -103.97 -16.41 15.33 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 122.753 0.421 . . . . 0.0 111.425 -179.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.42 178.54 37.2 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -72.37 140.33 33.34 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 124.085 3.19 . . . . 0.0 110.671 179.268 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 79.4 mt -109.72 148.62 13.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.889 0.476 . . . . 0.0 110.684 -178.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 12.9 t -114.32 -36.39 4.67 Favored 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.384 0.673 . . . . 0.0 112.09 -177.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -155.96 156.06 33.86 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.626 0.25 . . . . 0.0 111.589 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.0 t -146.49 144.37 20.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.038 0.935 . . . . 0.0 109.183 179.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.7 p -151.33 152.82 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 175.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.8 150.59 34.07 Favored 'Isoleucine or valine' 0 C--N 1.335 -0.055 0 C-N-CA 122.587 0.355 . . . . 0.0 110.393 -175.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 70.0 mtm -132.74 84.74 49.18 Favored Pre-proline 0 N--CA 1.454 -0.237 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.57 -12.5 33.4 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.325 2.683 . . . . 0.0 111.964 -176.17 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -84.78 -1.75 56.77 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 122.842 0.457 . . . . 0.0 111.107 176.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -132.45 1.24 3.74 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 123.871 0.868 . . . . 0.0 111.157 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.2 tpp85 52.38 34.61 15.39 Favored 'General case' 0 C--N 1.341 0.197 0 C-N-CA 124.257 1.023 . . . . 0.0 111.846 -175.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.26 167.86 20.95 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.554 0.741 . . . . 0.0 110.354 -177.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.62 173.58 16.5 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.508 0.323 . . . . 0.0 110.792 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 45.0 mt -134.16 147.09 50.73 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.623 0.769 . . . . 0.0 110.14 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.6 t -140.06 135.28 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -116.75 122.63 45.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -84.77 156.02 21.58 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 120.974 0.416 . . . . 0.0 110.193 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -75.94 -12.29 60.12 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.325 -179.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -148.21 153.13 38.34 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 124.099 0.96 . . . . 0.0 109.362 177.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -70.5 -21.8 23.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.7 tp -74.34 -27.43 60.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 O-C-N 121.939 -0.476 . . . . 0.0 110.742 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.88 -30.63 67.86 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.88 -29.36 29.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 117.11 0.455 . . . . 0.0 111.028 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -77.58 -25.97 50.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.537 -0.171 . . . . 0.0 110.537 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -85.21 -17.22 37.75 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.135 0.174 . . . . 0.0 111.084 178.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.01 -28.56 25.66 Favored 'General case' 0 N--CA 1.456 -0.148 0 O-C-N 122.246 -0.284 . . . . 0.0 111.48 179.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.9 t -88.23 -21.91 6.88 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 O-C-N 122.196 -0.315 . . . . 0.0 110.618 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.16 -15.9 62.51 Favored 'General case' 0 CA--C 1.534 0.331 0 O-C-N 122.365 -0.209 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 58.0 t80 -93.76 -33.09 13.74 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.422 0.289 . . . . 0.0 110.927 178.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.99 -3.1 57.55 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 112.697 0.628 . . . . 0.0 112.697 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.81 -5.08 59.12 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 122.001 -0.437 . . . . 0.0 112.11 178.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -143.59 2.47 1.24 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 122.71 0.404 . . . . 0.0 111.52 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -155.27 173.72 16.23 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.032 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -98.48 156.34 16.82 Favored 'General case' 0 CA--C 1.527 0.094 0 CA-C-N 118.222 0.464 . . . . 0.0 110.276 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -119.56 136.49 56.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -177.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -92.89 147.65 22.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.98 -0.45 . . . . 0.0 110.384 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.8 mt -134.19 -40.15 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.131 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.83 29.78 3.78 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 123.012 0.525 . . . . 0.0 111.164 -177.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.11 5.14 83.51 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.394 -0.683 . . . . 0.0 111.394 -177.158 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -131.36 152.87 81.29 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 124.526 1.13 . . . . 0.0 108.84 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -71.1 146.23 51.44 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.531 2.821 . . . . 0.0 111.784 -177.212 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.5 -176.11 5.46 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.158 1.383 . . . . 0.0 108.772 177.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -138.98 159.43 42.16 Favored 'General case' 0 N--CA 1.456 -0.128 0 O-C-N 122.134 -0.353 . . . . 0.0 111.265 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.6 p -147.08 139.68 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 C-N-CA 123.237 0.615 . . . . 0.0 110.606 179.24 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 . . . . . 0 N--CA 1.456 -0.144 0 C-N-CA 123.355 0.662 . . . . 0.0 109.582 176.24 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.433 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 48.2 p . . . . . 0 CA--C 1.532 0.262 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 88.9 Cg_endo -70.11 4.79 2.14 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.583 3.522 . . . . 0.0 113.362 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.84 140.82 45.43 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.076 0 CA-C-N 118.579 0.627 . . . . 0.0 109.855 178.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.95 157.88 43.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 121.07 0.462 . . . . 0.0 110.643 179.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -107.84 142.63 37.61 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.908 0.883 . . . . 0.0 109.723 -179.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.0 mm -111.42 144.88 18.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 123.006 0.523 . . . . 0.0 110.016 -176.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -141.36 160.12 40.78 Favored 'General case' 0 C--N 1.334 -0.068 0 C-N-CA 123.514 0.726 . . . . 0.0 110.068 -178.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.67 25.67 58.01 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.432 173.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 47.7 mt -59.07 154.87 14.8 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.388 1.094 . . . . 0.0 109.189 176.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.0 pt -69.95 -40.37 78.61 Favored 'Isoleucine or valine' 0 C--N 1.338 0.076 0 O-C-N 122.184 -0.322 . . . . 0.0 111.652 -172.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -172.91 -35.16 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.484 0.713 . . . . 0.0 109.979 -179.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.84 51.96 0.05 OUTLIER Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 -177.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.1 m -53.72 151.64 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 117.138 0.469 . . . . 0.0 110.087 177.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.3 m -88.46 163.88 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-O 120.881 0.372 . . . . 0.0 110.832 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.68 -22.33 63.8 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 122.819 0.448 . . . . 0.0 111.065 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.82 -8.04 58.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 122.868 0.467 . . . . 0.0 111.991 -179.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -91.12 -32.74 15.73 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 118.476 0.58 . . . . 0.0 110.48 178.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -71.41 -39.05 71.37 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.119 0.167 . . . . 0.0 110.601 -177.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.71 -31.28 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 C-N-CA 121.191 -0.203 . . . . 0.0 110.783 -175.607 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.7 mm-40 -81.26 -17.23 50.15 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 122.131 -0.356 . . . . 0.0 111.554 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.9 -12.47 16.21 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.3 mt -114.53 -9.11 12.71 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.491 0.587 . . . . 0.0 112.444 -179.059 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -70.06 -5.98 30.48 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.508 0.595 . . . . 0.0 111.778 176.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -76.28 -12.78 60.14 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 122.13 -0.356 . . . . 0.0 110.498 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -100.39 -16.9 17.46 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 122.455 0.302 . . . . 0.0 111.523 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.12 177.32 35.99 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.59 140.97 37.12 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.875 3.05 . . . . 0.0 110.451 -179.549 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.8 mt -111.07 146.73 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 122.675 0.39 . . . . 0.0 110.098 -178.125 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.2 t -108.26 -40.33 5.2 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.336 0.655 . . . . 0.0 111.436 -177.098 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -159.12 158.49 32.98 Favored 'General case' 0 N--CA 1.457 -0.078 0 CA-C-O 120.577 0.227 . . . . 0.0 111.355 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 65.1 t -145.23 147.92 18.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.801 0.84 . . . . 0.0 109.602 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.4 p -148.2 150.75 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 174.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 43.9 t -132.28 150.38 33.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.053 0 C-N-CA 122.628 0.371 . . . . 0.0 110.043 -174.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.7 mtm -135.62 80.59 43.98 Favored Pre-proline 0 N--CA 1.456 -0.171 0 C-N-CA 123.858 0.863 . . . . 0.0 109.486 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -58.88 -20.37 52.03 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.948 3.098 . . . . 0.0 113.041 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -76.09 -12.43 60.12 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.168 0.587 . . . . 0.0 111.139 179.334 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -124.06 3.57 8.65 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.644 0.778 . . . . 0.0 111.294 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.1 tpp85 52.83 32.84 13.03 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.473 1.109 . . . . 0.0 111.826 -176.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -136.93 166.74 22.94 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 123.435 0.694 . . . . 0.0 110.71 -177.044 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.03 172.18 17.25 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 122.748 0.419 . . . . 0.0 110.412 178.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 35.6 mt -132.09 146.52 52.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.728 0.811 . . . . 0.0 109.816 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 90.4 t -138.17 131.84 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.71 117.98 31.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.679 0.791 . . . . 0.0 109.169 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -86.26 155.36 20.71 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.012 0.434 . . . . 0.0 110.267 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -77.94 -11.04 59.86 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.497 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -146.47 152.02 38.34 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.522 0.729 . . . . 0.0 109.183 178.022 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -69.08 -21.48 25.42 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.76 -28.67 44.86 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 122.039 -0.413 . . . . 0.0 110.594 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.38 -28.73 73.11 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.82 -31.82 25.64 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.887 0.344 . . . . 0.0 110.66 178.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -69.95 -33.12 71.71 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 122.359 0.264 . . . . 0.0 110.578 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -73.72 -20.38 60.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 122.277 0.231 . . . . 0.0 111.447 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.44 -29.41 30.71 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 117.797 0.271 . . . . 0.0 111.585 -177.185 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.36 -21.96 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.096 0 O-C-N 122.312 -0.242 . . . . 0.0 110.648 178.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -68.41 -17.06 64.13 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 122.275 -0.266 . . . . 0.0 110.51 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 50.0 t80 -97.9 -36.0 10.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 122.426 0.29 . . . . 0.0 110.611 177.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.84 -15.06 59.82 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 122.648 0.379 . . . . 0.0 111.855 -177.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.24 52.4 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.982 0.513 . . . . 0.0 111.922 177.175 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -135.29 -18.33 1.75 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.129 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -151.33 166.21 31.67 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -81.12 154.25 26.86 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 175.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.638 HD13 ' H ' ' A' ' 158' ' ' TYR . 0.5 OUTLIER -110.04 164.52 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.173 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.638 ' H ' HD13 ' A' ' 157' ' ' ILE . 75.9 m-85 -119.52 154.64 33.53 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.094 -0.379 . . . . 0.0 110.3 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.6 mt -137.0 -42.28 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 O-C-N 123.165 0.291 . . . . 0.0 110.802 -177.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.08 29.83 3.69 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.268 0.627 . . . . 0.0 111.11 -177.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.48 6.75 80.3 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -176.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -129.7 153.67 80.83 Favored Pre-proline 0 C--O 1.233 0.203 0 C-N-CA 124.013 0.925 . . . . 0.0 109.245 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.97 144.18 52.09 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.184 2.589 . . . . 0.0 112.285 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.44 -177.59 6.31 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.473 1.509 . . . . 0.0 108.668 178.099 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -137.99 160.61 38.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.114 0.483 . . . . 0.0 111.471 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.4 p -150.25 140.86 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 123.888 0.875 . . . . 0.0 109.323 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 . . . . . 0 N--CA 1.455 -0.218 0 C-N-CA 123.149 0.58 . . . . 0.0 109.893 178.893 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.431 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 71.0 p . . . . . 0 CA--C 1.532 0.254 0 N-CA-C 111.484 0.179 . . . . 0.0 111.484 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.431 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 80.6 Cg_endo -69.78 4.27 2.3 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 124.098 3.198 . . . . 0.0 112.342 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.5 t -115.06 140.43 36.34 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 C-N-CA 123.076 0.55 . . . . 0.0 109.802 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.12 150.74 34.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.1 0 CA-C-O 121.035 0.445 . . . . 0.0 110.699 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.3 t-80 -99.39 136.21 39.67 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.249 1.019 . . . . 0.0 110.178 178.321 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.42 146.4 15.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.463 0.705 . . . . 0.0 109.168 -177.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -142.3 162.56 35.17 Favored 'General case' 0 N--CA 1.461 0.084 0 C-N-CA 123.573 0.749 . . . . 0.0 110.385 -176.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.27 26.99 53.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.66 -0.522 . . . . 0.0 113.239 172.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.4 mt -59.41 155.74 14.27 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 118.176 0.988 . . . . 0.0 109.798 177.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.2 pt -71.12 -39.5 74.08 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.111 0 O-C-N 122.189 -0.319 . . . . 0.0 111.308 -174.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -173.21 -37.05 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.882 0.873 . . . . 0.0 110.107 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.63 52.22 0.06 OUTLIER Glycine 0 C--N 1.337 0.612 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -176.44 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.1 m -54.04 154.4 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 CA-C-N 117.037 0.418 . . . . 0.0 110.203 177.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.9 m -90.84 166.11 1.85 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.063 0 CA-C-O 121.213 0.53 . . . . 0.0 111.091 -176.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -60.58 -24.2 65.25 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.24 0.616 . . . . 0.0 111.217 -178.663 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.5 -4.71 54.92 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 122.694 0.398 . . . . 0.0 112.015 -178.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -91.74 -35.76 13.96 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.256 0.48 . . . . 0.0 110.471 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.67 -31.9 52.86 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 122.225 -0.297 . . . . 0.0 111.105 -176.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.39 -31.5 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 O-C-N 122.057 -0.402 . . . . 0.0 110.184 -178.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.8 mm-40 -82.33 -18.55 41.77 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.244 -0.285 . . . . 0.0 111.054 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.01 -12.19 18.34 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.2 mt -117.6 -8.48 10.93 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.627 0.649 . . . . 0.0 112.525 -177.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.3 pt20 -68.8 -6.92 29.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 118.575 0.625 . . . . 0.0 111.563 176.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -76.47 -14.65 60.03 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.791 0.436 . . . . 0.0 110.607 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -99.41 -13.56 19.51 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 122.49 0.316 . . . . 0.0 111.613 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.62 176.32 32.59 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -71.27 140.35 36.97 Favored 'Trans proline' 0 N--CA 1.452 -0.93 0 C-N-CA 124.023 3.149 . . . . 0.0 110.51 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.6 mt -111.28 146.3 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.939 0.496 . . . . 0.0 110.519 -178.029 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -106.36 -41.26 5.36 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 123.433 0.693 . . . . 0.0 111.438 -177.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.0 t80 -159.29 158.89 33.32 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 122.225 0.21 . . . . 0.0 111.51 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -143.56 147.22 20.34 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 C-N-CA 123.827 0.851 . . . . 0.0 109.815 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.43 152.68 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.064 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 175.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 56.4 t -133.71 150.06 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 C-N-CA 122.852 0.461 . . . . 0.0 110.352 -176.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -133.79 86.47 38.58 Favored Pre-proline 0 N--CA 1.454 -0.262 0 C-N-CA 123.83 0.852 . . . . 0.0 109.318 -179.181 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -68.61 -14.64 39.98 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.463 2.776 . . . . 0.0 111.645 -176.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.0 tttp -79.24 -10.29 59.78 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.114 0.566 . . . . 0.0 110.91 177.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -126.76 1.22 6.73 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 123.683 0.793 . . . . 0.0 111.369 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.8 tpp85 53.05 32.33 12.75 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 124.358 1.063 . . . . 0.0 111.948 -176.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -135.77 166.56 22.99 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 123.551 0.74 . . . . 0.0 110.147 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.66 172.22 18.24 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-O 120.773 0.321 . . . . 0.0 110.921 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.5 mt -134.09 147.75 50.92 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.41 0.684 . . . . 0.0 109.929 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 81.6 t -138.24 133.61 43.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.8 tt0 -115.44 119.59 36.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 178.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 50.2 m-85 -86.13 155.0 20.96 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.987 0.422 . . . . 0.0 110.361 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -75.23 -14.41 60.52 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.379 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.29 153.03 39.25 Favored 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 123.697 0.799 . . . . 0.0 109.456 177.261 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -68.06 -22.0 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 52.5 tp -73.96 -25.45 59.95 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.184 -0.322 . . . . 0.0 110.494 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.25 -30.17 65.37 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 179.327 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.44 -31.17 22.99 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 122.864 0.466 . . . . 0.0 110.612 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.91 -19.98 60.53 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.601 0.36 . . . . 0.0 111.166 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -94.46 -15.48 24.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.45 0.3 . . . . 0.0 111.314 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.63 -32.6 25.61 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.31 -0.244 . . . . 0.0 111.491 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -84.86 -16.35 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -72.54 -4.39 30.34 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.656 0.382 . . . . 0.0 111.003 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -115.29 -35.78 4.55 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.806 0.442 . . . . 0.0 110.935 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -81.39 -7.77 59.63 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -177.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.7 -1.82 58.03 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.947 -0.471 . . . . 0.0 112.027 178.36 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.87 -6.7 1.45 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.678 0.391 . . . . 0.0 112.043 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -153.85 164.42 38.4 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.226 0.61 . . . . 0.0 109.563 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.26 158.18 23.6 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 174.161 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.96 135.45 64.01 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 -178.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -86.88 151.41 23.35 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.196 -0.315 . . . . 0.0 110.661 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.1 mt -137.09 -40.04 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 122.429 0.291 . . . . 0.0 111.095 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.34 29.12 4.0 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 122.842 0.457 . . . . 0.0 111.058 -178.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.96 78.1 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -177.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -131.58 152.4 80.36 Favored Pre-proline 0 N--CA 1.453 -0.32 0 C-N-CA 124.205 1.002 . . . . 0.0 108.774 177.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.68 145.26 57.06 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 123.147 2.565 . . . . 0.0 111.627 -177.101 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.09 -175.03 5.08 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 124.846 1.258 . . . . 0.0 108.905 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -138.35 162.01 35.48 Favored 'General case' 0 N--CA 1.456 -0.137 0 CA-C-O 120.915 0.388 . . . . 0.0 111.797 -178.067 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.14 144.05 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 C-N-CA 123.692 0.797 . . . . 0.0 109.378 178.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.454 -0.226 0 C-N-CA 122.966 0.506 . . . . 0.0 109.875 179.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 51.8 m . . . . . 0 CA--C 1.531 0.243 0 N-CA-C 112.225 0.454 . . . . 0.0 112.225 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -70.98 -1.33 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 124.114 3.209 . . . . 0.0 111.927 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.7 t -116.14 140.44 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 176.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.53 152.08 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.062 0.458 . . . . 0.0 110.761 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -102.48 136.38 42.41 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 123.982 0.913 . . . . 0.0 110.162 179.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.5 mp -111.95 145.87 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -177.174 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -141.39 162.95 34.24 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.692 0.797 . . . . 0.0 110.574 -177.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.83 27.22 54.31 Favored Glycine 0 CA--C 1.527 0.818 0 CA-C-O 119.469 -0.628 . . . . 0.0 113.185 174.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 54.0 mt -61.42 158.88 13.72 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 117.893 0.847 . . . . 0.0 110.415 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.87 -47.98 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -172.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -175.69 -35.86 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.208 0.603 . . . . 0.0 110.601 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -171.95 34.18 0.14 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.684 -0.509 . . . . 0.0 111.955 -175.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 8.8 p -52.32 148.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-N 117.425 0.612 . . . . 0.0 109.732 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.4 m -103.31 168.87 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.082 0 CA-C-O 121.364 0.602 . . . . 0.0 112.141 -172.202 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -57.99 -28.13 64.11 Favored 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 123.985 0.914 . . . . 0.0 111.602 -177.133 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.58 -2.31 38.27 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -176.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -104.17 -32.59 9.07 Favored 'General case' 0 N--CA 1.457 -0.121 0 CA-C-N 118.235 0.47 . . . . 0.0 110.415 177.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.75 -34.33 60.27 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.898 -0.501 . . . . 0.0 110.524 -179.325 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.0 p -76.5 -31.26 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.358 -179.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -83.0 -15.98 49.04 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 119.666 -0.207 . . . . 0.0 111.267 -178.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.72 -10.89 17.15 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -116.02 -9.15 11.78 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 118.632 0.651 . . . . 0.0 112.18 -179.5 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -68.9 -7.15 32.13 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 118.719 0.691 . . . . 0.0 111.523 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.67 -14.45 60.35 Favored 'General case' 0 CA--C 1.532 0.269 0 O-C-N 122.141 -0.35 . . . . 0.0 110.819 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.5 m-85 -97.13 -16.02 20.66 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 122.54 0.336 . . . . 0.0 111.591 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.78 178.56 35.8 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.85 139.5 33.48 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 124.046 3.164 . . . . 0.0 110.557 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 73.9 mt -110.94 145.76 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.688 0.395 . . . . 0.0 110.501 -177.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.1 t -106.73 -38.42 6.12 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 123.331 0.652 . . . . 0.0 111.463 -177.296 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -160.17 157.05 27.67 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.668 0.27 . . . . 0.0 111.23 179.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 94.4 t -144.14 146.23 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 C-N-CA 123.858 0.863 . . . . 0.0 109.666 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.83 153.79 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 C-N-CA 123.314 0.645 . . . . 0.0 109.513 176.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 46.0 t -127.34 150.66 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -177.465 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 68.2 mtm -132.27 77.85 69.77 Favored Pre-proline 0 CA--C 1.531 0.222 0 C-N-CA 124.3 1.04 . . . . 0.0 109.104 -177.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.8 -8.81 24.44 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 123.418 2.746 . . . . 0.0 111.72 -175.33 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -72.3 -17.11 61.89 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 122.656 0.382 . . . . 0.0 110.77 178.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 62.9 pttt -138.92 15.08 2.67 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 123.146 0.578 . . . . 0.0 111.91 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 57.53 39.68 27.63 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 124.079 0.952 . . . . 0.0 113.247 178.255 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.58 170.07 15.25 Favored 'General case' 0 CA--C 1.527 0.06 0 C-N-CA 123.043 0.537 . . . . 0.0 110.621 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.43 170.33 22.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 122.863 0.465 . . . . 0.0 110.564 177.003 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 34.1 mt -134.81 147.11 49.87 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.663 0.785 . . . . 0.0 110.179 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 85.0 t -139.08 132.07 38.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -114.15 119.79 38.31 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -86.97 154.79 20.51 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.426 -179.471 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -74.39 -14.63 60.89 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.507 -177.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -148.08 152.97 38.27 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.703 0.801 . . . . 0.0 109.108 176.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.1 p -66.72 -22.0 29.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -176.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.61 -26.11 60.64 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 122.031 -0.418 . . . . 0.0 110.629 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.03 -31.39 64.34 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.57 -32.12 25.98 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.047 0.423 . . . . 0.0 110.335 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.8 t -70.86 -15.64 62.65 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.198 0.599 . . . . 0.0 110.938 178.518 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 60.2 t30 -99.89 -14.03 18.92 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.029 0.532 . . . . 0.0 111.412 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -87.23 -31.65 20.18 Favored 'General case' 0 N--CA 1.456 -0.175 0 O-C-N 122.128 -0.358 . . . . 0.0 111.717 -177.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.6 t -86.82 -16.12 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.078 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -70.43 -4.69 23.78 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 122.913 0.485 . . . . 0.0 111.161 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -117.32 -32.21 5.03 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.969 0.508 . . . . 0.0 111.459 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.84 -0.93 55.52 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 113.083 0.771 . . . . 0.0 113.083 -176.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.67 -6.64 59.21 Favored 'General case' 0 CA--C 1.534 0.341 0 O-C-N 121.98 -0.45 . . . . 0.0 112.032 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -145.26 3.75 1.04 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.704 0.402 . . . . 0.0 111.88 179.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 49.0 t30 -151.52 171.3 17.79 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -178.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -95.61 155.88 16.56 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 118.38 0.536 . . . . 0.0 110.17 177.568 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -123.35 136.31 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -179.15 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -90.58 154.32 19.68 Favored 'General case' 0 N--CA 1.454 -0.235 0 O-C-N 122.047 -0.408 . . . . 0.0 110.851 -178.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.3 mt -137.33 -42.24 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.916 -177.337 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.49 30.88 3.47 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.936 0.494 . . . . 0.0 111.002 -177.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.7 5.94 80.82 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -130.59 151.21 78.3 Favored Pre-proline 0 N--CA 1.455 -0.207 0 C-N-CA 124.046 0.938 . . . . 0.0 109.01 177.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -72.17 145.97 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 123.375 2.717 . . . . 0.0 111.936 -176.219 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.0 -177.91 6.29 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.757 1.223 . . . . 0.0 108.845 177.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -137.34 158.78 43.66 Favored 'General case' 0 N--CA 1.457 -0.106 0 O-C-N 122.296 -0.253 . . . . 0.0 111.096 -178.552 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.01 142.09 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.23 0.612 . . . . 0.0 109.918 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 . . . . . 0 N--CA 1.456 -0.15 0 C-N-CA 123.187 0.595 . . . . 0.0 110.332 178.15 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.299 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -149.17 166.68 28.1 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 123.087 0.555 . . . . 0.0 110.627 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -148.86 166.93 27.07 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.844 0.458 . . . . 0.0 110.012 -179.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -73.0 -11.48 60.58 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 123.279 0.632 . . . . 0.0 112.163 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -147.14 159.43 43.62 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 123.497 0.719 . . . . 0.0 109.687 178.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 38.5 m-20 -73.87 139.81 77.15 Favored Pre-proline 0 N--CA 1.454 -0.232 0 O-C-N 122.127 -0.358 . . . . 0.0 110.892 -177.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_endo -75.33 -27.59 9.37 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 123.58 2.853 . . . . 0.0 112.83 -177.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.9 p-80 -158.65 2.26 0.1 Allowed 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -178.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -84.82 163.96 18.75 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 118.577 0.626 . . . . 0.0 110.762 -178.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.6 p -135.07 156.0 78.64 Favored Pre-proline 0 C--O 1.231 0.13 0 C-N-CA 123.404 0.682 . . . . 0.0 110.599 -178.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -75.77 -5.04 16.01 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 123.881 3.054 . . . . 0.0 112.543 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.26 35.08 9.77 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.146 0.578 . . . . 0.0 111.656 -177.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.427 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.2 p -66.22 160.51 64.22 Favored Pre-proline 0 CA--C 1.531 0.237 0 C-N-CA 124.08 0.952 . . . . 0.0 111.487 -177.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 77.7 Cg_endo -70.19 3.02 3.23 Favored 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 124.199 3.266 . . . . 0.0 112.452 178.332 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.3 t -115.64 141.31 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.087 0.555 . . . . 0.0 109.798 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.0 m -130.71 151.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.191 0 CA-C-O 121.231 0.538 . . . . 0.0 110.898 177.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 22.9 t-80 -100.49 139.23 36.47 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.076 0.95 . . . . 0.0 110.03 179.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 29.7 mm -108.54 145.15 15.86 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 123.646 0.778 . . . . 0.0 110.089 -178.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -143.59 161.2 39.12 Favored 'General case' 0 C--N 1.337 0.044 0 C-N-CA 123.352 0.661 . . . . 0.0 110.376 -177.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.35 25.09 59.8 Favored Glycine 0 CA--C 1.528 0.845 0 CA-C-O 119.442 -0.644 . . . . 0.0 113.658 173.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 68.9 mt -61.21 157.56 15.94 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.398 1.099 . . . . 0.0 109.864 177.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.3 pt -73.08 -41.64 59.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -173.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -173.39 -35.08 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.277 0.631 . . . . 0.0 110.553 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.98 50.59 0.1 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -175.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.9 t -52.32 144.58 3.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.159 0 C-N-CA 123.5 0.72 . . . . 0.0 109.743 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.82 161.24 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.036 0 CA-C-O 121.084 0.469 . . . . 0.0 111.564 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -60.95 -25.05 66.52 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 123.288 0.635 . . . . 0.0 111.201 -177.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.23 -3.62 52.9 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -178.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -99.43 -31.22 11.76 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.369 0.531 . . . . 0.0 110.757 178.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.4 mp -75.18 -34.05 61.51 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.162 -0.336 . . . . 0.0 110.361 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -77.63 -30.63 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 118.099 0.409 . . . . 0.0 110.348 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -82.14 -17.02 47.84 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.369 -0.207 . . . . 0.0 111.433 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.1 -11.51 16.56 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.5 mt -115.97 -9.97 11.68 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.695 0.68 . . . . 0.0 112.404 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -68.45 -7.05 28.41 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 118.567 0.621 . . . . 0.0 111.637 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -76.01 -14.44 60.22 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 122.692 0.397 . . . . 0.0 110.859 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -98.68 -16.8 18.88 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 122.685 0.394 . . . . 0.0 111.639 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.05 177.05 35.72 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -71.5 141.21 37.91 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 123.775 2.984 . . . . 0.0 110.524 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.2 mt -110.65 147.05 15.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.171 0 C-N-CA 122.824 0.45 . . . . 0.0 110.356 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.0 t -107.31 -42.55 4.8 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.279 0.632 . . . . 0.0 111.348 -177.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 54.5 t80 -158.79 159.67 35.41 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-O 120.778 0.323 . . . . 0.0 111.076 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 76.7 t -143.35 146.85 20.92 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 124.008 0.923 . . . . 0.0 109.071 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -147.71 151.26 13.76 Favored 'Isoleucine or valine' 0 C--O 1.231 0.096 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 175.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 45.4 t -128.05 151.01 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.065 0 C-N-CA 122.503 0.321 . . . . 0.0 110.6 -175.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.7 mtm -133.7 81.19 54.04 Favored Pre-proline 0 N--CA 1.455 -0.192 0 C-N-CA 124.113 0.965 . . . . 0.0 108.732 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.43 -12.29 33.2 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.577 2.852 . . . . 0.0 111.729 -175.201 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -82.02 -5.14 58.12 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.676 0.39 . . . . 0.0 110.685 177.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 35.8 mmtp -130.4 3.83 4.69 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 124.245 1.018 . . . . 0.0 111.132 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 53.62 33.22 16.0 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 124.336 1.054 . . . . 0.0 112.087 -176.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -136.51 168.45 19.45 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.309 0.644 . . . . 0.0 110.413 -176.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.49 172.22 18.61 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 122.591 0.356 . . . . 0.0 110.457 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 36.8 mt -131.4 146.65 52.36 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 123.566 0.746 . . . . 0.0 110.219 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 84.7 t -137.83 131.75 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -115.37 121.21 42.1 Favored 'General case' 0 N--CA 1.453 -0.314 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.055 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -86.56 153.61 21.69 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.984 0.421 . . . . 0.0 110.325 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -74.83 -13.38 60.56 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-O 120.936 0.398 . . . . 0.0 110.496 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -147.46 151.65 36.77 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.58 0.752 . . . . 0.0 109.412 177.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.9 p -67.01 -20.43 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 111.663 0.245 . . . . 0.0 111.663 -175.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.1 tp -74.13 -27.01 60.65 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.946 -0.471 . . . . 0.0 110.743 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.32 -30.44 69.31 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.58 -29.57 27.7 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 117.132 0.466 . . . . 0.0 110.189 178.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 32.0 t -71.97 -12.95 61.48 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.208 0.603 . . . . 0.0 111.366 179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -102.0 -17.71 15.97 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 122.623 0.369 . . . . 0.0 111.764 -179.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.49 -30.43 25.19 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 118.135 0.425 . . . . 0.0 111.587 -176.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 25.9 t -88.06 -17.19 8.64 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -72.17 -3.75 25.22 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.448 0.299 . . . . 0.0 111.063 179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -116.18 -33.43 5.01 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 122.925 0.49 . . . . 0.0 111.113 177.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -86.02 -7.77 58.4 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -177.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.03 -1.0 56.31 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 122.077 -0.389 . . . . 0.0 111.806 177.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -140.18 -5.94 1.25 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 122.821 0.448 . . . . 0.0 111.725 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.78 173.24 16.71 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -90.73 156.76 17.84 Favored 'General case' 0 CA--C 1.529 0.136 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 175.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.05 136.4 59.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -177.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -90.33 150.98 21.68 Favored 'General case' 0 N--CA 1.455 -0.213 0 O-C-N 122.068 -0.395 . . . . 0.0 110.698 -178.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.1 mt -137.43 -38.79 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.932 -177.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -132.9 28.76 4.17 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.288 0.635 . . . . 0.0 111.126 -176.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.01 4.83 86.64 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -176.178 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -130.82 151.9 79.64 Favored Pre-proline 0 N--CA 1.453 -0.287 0 C-N-CA 124.303 1.041 . . . . 0.0 109.066 178.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -70.5 145.26 52.38 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 123.49 2.793 . . . . 0.0 111.905 -176.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.63 -175.79 5.34 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.852 1.261 . . . . 0.0 108.898 178.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -138.68 160.07 40.56 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-O 120.948 0.404 . . . . 0.0 111.764 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.67 143.1 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.854 0.862 . . . . 0.0 109.647 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -156.93 162.69 39.63 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 122.973 0.509 . . . . 0.0 110.089 179.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 34.3 m-85 -65.1 166.38 9.63 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-O 120.817 0.342 . . . . 0.0 110.278 177.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 88.4 p -147.16 176.39 9.99 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 122.956 0.502 . . . . 0.0 109.833 178.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 62.4 p -72.4 -4.18 28.53 Favored 'General case' 0 CA--C 1.529 0.146 0 C-N-CA 122.301 0.24 . . . . 0.0 111.015 178.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 59.7 m -79.07 150.18 31.92 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 122.913 0.485 . . . . 0.0 110.477 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -139.04 -3.76 1.57 Allowed 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 122.706 0.402 . . . . 0.0 111.326 176.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -159.27 135.27 8.83 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 124.005 0.922 . . . . 0.0 108.593 -178.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 78.8 mt -89.23 142.35 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 174.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 46.1 m -78.47 139.56 38.69 Favored 'General case' 0 N--CA 1.457 -0.113 0 N-CA-C 111.627 0.232 . . . . 0.0 111.627 -175.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 54.7 mtp180 40.54 58.87 7.88 Favored Pre-proline 0 CA--C 1.532 0.251 0 C-N-CA 124.851 1.26 . . . . 0.0 112.712 176.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -73.06 137.83 27.12 Favored 'Trans proline' 0 N--CA 1.447 -1.218 0 C-N-CA 122.821 2.347 . . . . 0.0 110.19 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 79.4 3.57 88.72 Favored Glycine 0 CA--C 1.529 0.928 0 CA-C-O 119.215 -0.769 . . . . 0.0 113.491 177.015 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -147.05 172.95 12.94 Favored 'General case' 0 CA--C 1.528 0.116 0 CA-C-N 118.681 1.24 . . . . 0.0 111.404 178.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 29.0 t -144.03 162.6 35.81 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.27 0.628 . . . . 0.0 109.803 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -79.51 -8.22 59.0 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 111.685 0.254 . . . . 0.0 111.685 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -151.48 144.83 24.78 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 122.899 0.48 . . . . 0.0 110.027 177.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 25.0 t -156.41 -22.64 0.1 Allowed 'General case' 0 C--O 1.233 0.23 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 21.8 tpp85 -154.39 153.32 31.39 Favored 'General case' 0 N--CA 1.456 -0.132 0 C-N-CA 122.657 0.383 . . . . 0.0 110.628 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 48.8 m -132.97 135.64 45.61 Favored 'General case' 0 N--CA 1.456 -0.129 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 176.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 17.0 m -146.32 167.08 7.66 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 C-N-CA 123.911 0.885 . . . . 0.0 109.721 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 48.2 t30 53.73 28.59 8.33 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 123.84 0.856 . . . . 0.0 112.134 -178.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 33.0 t . . . . . 0 C--O 1.251 1.158 0 CA-C-O 117.609 -1.186 . . . . 0.0 110.004 -178.756 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.059 0 N-CA-C 110.558 -1.017 . . . . 0.0 110.558 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.4 167.93 28.76 Favored 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 122.975 0.51 . . . . 0.0 110.818 -177.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -150.71 162.95 39.72 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 122.983 0.513 . . . . 0.0 110.088 177.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -68.31 -11.38 59.38 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.621 0.768 . . . . 0.0 112.535 -177.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -95.81 7.13 47.17 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 117.934 0.334 . . . . 0.0 111.607 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 55.3 m-20 47.27 61.85 12.91 Favored Pre-proline 0 CA--C 1.533 0.308 0 C-N-CA 123.665 0.786 . . . . 0.0 111.995 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -64.68 -21.21 65.38 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 123.448 2.766 . . . . 0.0 112.657 -176.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 4.3 p-80 -155.52 27.17 0.39 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.072 0.549 . . . . 0.0 110.784 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 28.2 mtpp -129.06 23.06 5.67 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.896 0.878 . . . . 0.0 111.139 -178.397 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 70.5 p -70.38 154.73 94.28 Favored Pre-proline 0 C--O 1.234 0.242 0 C-N-CA 123.188 0.595 . . . . 0.0 112.149 -175.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.92 -1.74 11.92 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 124.365 3.377 . . . . 0.0 112.327 177.39 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 53.38 33.59 16.15 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.703 0.801 . . . . 0.0 112.468 -178.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.0 m -63.36 158.66 55.85 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 123.797 0.839 . . . . 0.0 112.018 -178.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -70.87 2.61 3.98 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 124.184 3.256 . . . . 0.0 112.325 178.243 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.6 t -115.26 141.53 31.77 Favored 'Isoleucine or valine' 0 C--N 1.339 0.112 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.59 152.34 37.16 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.381 0.61 . . . . 0.0 111.025 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -100.65 141.07 34.02 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.307 1.043 . . . . 0.0 109.882 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.1 mm -110.37 144.92 17.51 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 C-N-CA 123.048 0.539 . . . . 0.0 109.801 -178.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -140.56 159.28 42.54 Favored 'General case' 0 C--O 1.23 0.033 0 C-N-CA 123.464 0.705 . . . . 0.0 110.21 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.66 24.64 60.05 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-O 119.322 -0.71 . . . . 0.0 113.615 173.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 51.3 mt -59.47 155.82 14.32 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.172 0.986 . . . . 0.0 109.533 177.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -70.58 -38.01 71.85 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.102 0 O-C-N 122.35 -0.219 . . . . 0.0 111.305 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -172.08 -37.19 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.908 0.883 . . . . 0.0 109.506 -179.074 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.0 56.19 0.04 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -176.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 m -53.2 151.4 1.19 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 117.243 0.522 . . . . 0.0 110.422 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.2 m -86.68 166.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.122 0 CA-C-O 121.166 0.508 . . . . 0.0 110.855 -177.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.6 -26.72 68.16 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 122.871 0.468 . . . . 0.0 110.786 -178.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.62 -7.98 56.33 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 86.1 m-20 -94.45 -34.65 12.65 Favored 'General case' 0 N--CA 1.457 -0.11 0 CA-C-N 118.248 0.476 . . . . 0.0 109.772 176.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.4 mt -72.73 -40.23 66.28 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 122.389 0.276 . . . . 0.0 110.93 -177.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.1 p -77.3 -29.87 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 O-C-N 122.083 -0.385 . . . . 0.0 110.739 -176.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -85.88 -14.64 44.26 Favored 'General case' 0 N--CA 1.456 -0.136 0 O-C-N 122.128 -0.357 . . . . 0.0 111.146 -178.022 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -101.52 -14.11 17.62 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 178.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.6 mt -115.12 -8.47 12.4 Favored 'General case' 0 CA--C 1.529 0.14 0 CA-C-N 118.566 0.621 . . . . 0.0 112.568 -178.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.3 pt20 -70.54 -6.09 33.78 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.849 0.749 . . . . 0.0 111.67 176.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -76.82 -16.39 59.45 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.53 0.332 . . . . 0.0 110.449 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -95.94 -18.79 20.02 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 122.529 0.332 . . . . 0.0 111.525 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.43 177.57 37.88 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.6 140.28 35.74 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 124.047 3.165 . . . . 0.0 110.576 179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 70.1 mt -110.81 147.1 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.869 0.468 . . . . 0.0 110.258 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -108.48 -39.42 5.42 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.333 0.653 . . . . 0.0 111.494 -177.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.5 t80 -158.83 157.68 32.02 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 117.719 0.236 . . . . 0.0 111.167 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 63.7 t -145.08 146.57 19.74 Favored 'Isoleucine or valine' 0 C--N 1.339 0.129 0 C-N-CA 123.775 0.83 . . . . 0.0 110.091 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.0 p -150.68 151.8 12.14 Favored 'Isoleucine or valine' 0 C--O 1.231 0.102 0 C-N-CA 123.566 0.746 . . . . 0.0 109.24 175.022 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.8 p -134.13 150.29 31.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-O 120.736 0.303 . . . . 0.0 110.804 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.2 mpp? -130.55 83.73 61.29 Favored Pre-proline 0 CA--C 1.53 0.202 0 C-N-CA 123.567 0.747 . . . . 0.0 109.51 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -58.79 -18.88 43.77 Favored 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 123.938 3.092 . . . . 0.0 113.066 -179.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -78.85 -6.27 55.63 Favored 'General case' 0 C--N 1.341 0.222 0 C-N-CA 122.944 0.498 . . . . 0.0 111.473 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -131.28 3.27 4.29 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.755 0.822 . . . . 0.0 111.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.0 tpp85 54.68 33.65 19.86 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.404 1.082 . . . . 0.0 111.977 -176.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -136.35 165.49 25.67 Favored 'General case' 0 C--O 1.23 0.078 0 C-N-CA 123.005 0.522 . . . . 0.0 110.78 -176.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.97 171.2 17.66 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 122.59 0.356 . . . . 0.0 110.582 178.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.3 mt -131.05 145.16 51.93 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.022 0.929 . . . . 0.0 109.688 178.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -137.9 131.92 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.188 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -113.36 121.29 43.92 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 177.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -87.74 154.86 20.24 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-O 120.816 0.341 . . . . 0.0 110.216 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -75.38 -13.24 60.39 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.189 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -147.87 150.25 33.78 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.72 0.808 . . . . 0.0 109.274 177.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -67.34 -21.98 28.42 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.7 tp -74.93 -28.78 60.74 Favored 'General case' 0 N--CA 1.455 -0.204 0 O-C-N 121.875 -0.516 . . . . 0.0 110.534 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.29 -30.46 69.36 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.42 -30.06 33.67 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.699 -0.295 . . . . 0.0 110.618 178.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.5 t -74.22 -32.97 63.21 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 120.669 0.271 . . . . 0.0 110.685 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -74.81 -17.52 60.6 Favored 'General case' 0 N--CA 1.453 -0.316 0 O-C-N 122.211 -0.306 . . . . 0.0 110.906 -179.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.37 -30.17 23.86 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -176.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.0 t -89.17 -22.63 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 O-C-N 122.095 -0.378 . . . . 0.0 110.732 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -70.19 -1.67 10.91 Favored 'General case' 0 CA--C 1.53 0.193 0 O-C-N 122.132 -0.355 . . . . 0.0 111.535 179.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.2 t80 -112.75 -37.82 4.76 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 122.836 0.454 . . . . 0.0 110.969 176.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.81 -6.8 57.96 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -79.69 -4.99 54.23 Favored 'General case' 0 N--CA 1.453 -0.284 0 O-C-N 122.027 -0.42 . . . . 0.0 111.7 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -141.39 -4.84 1.11 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 122.654 0.382 . . . . 0.0 111.894 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 27.2 m-80 -145.53 174.53 11.08 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.505 0.722 . . . . 0.0 109.821 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . 0.455 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -94.73 151.72 19.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 173.972 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -121.96 134.98 63.57 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -88.54 152.19 22.02 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.136 -0.353 . . . . 0.0 110.576 -178.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.7 mt -136.56 -41.57 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.154 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.22 -177.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.75 30.09 3.77 Favored 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 123.098 0.559 . . . . 0.0 110.858 -178.157 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.9 4.99 78.15 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 -177.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -131.7 152.72 80.87 Favored Pre-proline 0 N--CA 1.455 -0.214 0 C-N-CA 124.024 0.93 . . . . 0.0 109.399 177.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -70.77 144.82 49.69 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 123.408 2.739 . . . . 0.0 111.866 -175.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.99 -175.95 5.35 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 124.891 1.276 . . . . 0.0 108.929 178.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -140.53 160.46 39.95 Favored 'General case' 0 C--O 1.231 0.092 0 CA-C-O 120.995 0.426 . . . . 0.0 111.503 -178.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -146.96 141.52 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 C-N-CA 123.772 0.829 . . . . 0.0 109.916 178.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -155.43 160.2 40.45 Favored 'General case' 0 N--CA 1.456 -0.151 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 29.3 m-85 -62.22 170.41 2.29 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 121.114 0.483 . . . . 0.0 111.073 178.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 35.1 t -146.46 172.67 13.18 Favored 'General case' 0 N--CA 1.455 -0.208 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 179.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 52.0 p -72.19 -7.84 51.45 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 122.475 0.31 . . . . 0.0 110.252 176.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 71.2 m -74.55 146.5 42.56 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.638 0.775 . . . . 0.0 110.395 176.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -137.86 -5.19 1.72 Allowed 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 122.958 0.503 . . . . 0.0 111.21 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -160.17 131.25 5.74 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.962 0.905 . . . . 0.0 109.108 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 8.8 tp -76.18 148.66 7.0 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 175.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 43.8 t -90.24 131.6 35.97 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 122.375 -0.203 . . . . 0.0 111.453 -177.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 45.18 55.52 14.32 Favored Pre-proline 0 CA--C 1.534 0.359 0 C-N-CA 124.501 1.12 . . . . 0.0 113.336 173.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -71.99 -10.25 25.83 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 123.208 2.605 . . . . 0.0 112.465 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 176.56 -2.22 0.03 OUTLIER Glycine 0 CA--C 1.529 0.944 0 CA-C-O 119.732 -0.482 . . . . 0.0 112.725 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -146.29 156.51 43.41 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-N 117.928 0.864 . . . . 0.0 110.014 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 79.6 p -151.44 163.92 37.91 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 122.525 0.33 . . . . 0.0 110.835 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -151.26 156.87 41.75 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.462 0.705 . . . . 0.0 110.028 179.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -147.86 169.98 18.63 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-O 120.994 0.426 . . . . 0.0 110.768 -179.219 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 77.5 p -130.72 175.51 8.96 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.432 0.693 . . . . 0.0 110.587 179.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 8.7 tpp85 -147.2 163.41 36.43 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-O 120.688 0.28 . . . . 0.0 111.095 -178.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 35.6 m -84.92 9.44 14.39 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.913 0.485 . . . . 0.0 112.174 -179.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 33.7 m -138.51 164.14 27.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.143 0 C-N-CA 123.644 0.778 . . . . 0.0 109.783 -178.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.6 t30 -76.49 132.03 39.36 Favored 'General case' 0 N--CA 1.453 -0.277 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.25 1.11 0 CA-C-O 116.809 -1.567 . . . . 0.0 111.129 179.324 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.186 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -148.49 166.01 29.48 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.077 0.551 . . . . 0.0 110.693 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 56.8 t30 -148.91 169.71 19.94 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.031 0.533 . . . . 0.0 110.114 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -77.32 -9.72 59.0 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 123.704 0.802 . . . . 0.0 111.819 178.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.9 t0 -150.96 158.5 44.22 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.548 0.739 . . . . 0.0 109.371 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -70.73 140.52 86.67 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 122.218 -0.301 . . . . 0.0 110.825 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -74.87 -31.34 6.52 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 123.27 2.647 . . . . 0.0 112.124 -177.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -160.71 0.18 0.06 Allowed 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -178.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -80.79 156.81 26.0 Favored 'General case' 0 C--N 1.338 0.075 0 CA-C-N 118.341 0.519 . . . . 0.0 110.578 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 43.7 p -86.47 154.0 56.32 Favored Pre-proline 0 CA--C 1.53 0.196 0 C-N-CA 122.834 0.454 . . . . 0.0 111.058 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -76.67 -4.02 14.48 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 123.742 2.961 . . . . 0.0 112.379 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.17 35.55 13.58 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 123.36 0.664 . . . . 0.0 111.724 -178.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.408 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 71.3 p -67.92 160.53 73.46 Favored Pre-proline 0 CA--C 1.533 0.317 0 C-N-CA 123.772 0.829 . . . . 0.0 111.45 -177.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 92.7 Cg_endo -71.7 5.82 2.29 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 124.471 3.447 . . . . 0.0 112.179 177.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.8 t -120.57 141.67 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.124 0 C-N-CA 123.066 0.546 . . . . 0.0 109.57 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 31.6 m -130.28 149.86 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.115 0 CA-C-O 121.199 0.523 . . . . 0.0 111.063 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.9 t-80 -98.14 142.08 30.27 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.338 1.055 . . . . 0.0 110.127 177.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.6 mm -111.56 145.5 17.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 C-N-CA 123.06 0.544 . . . . 0.0 109.723 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.5 mtt180 -142.11 161.21 38.57 Favored 'General case' 0 C--O 1.231 0.11 0 C-N-CA 123.254 0.622 . . . . 0.0 110.377 -179.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 81.67 24.23 56.44 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.592 -0.56 . . . . 0.0 113.641 173.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.5 mt -63.01 159.23 17.53 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 118.1 0.95 . . . . 0.0 110.072 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.3 pt -74.2 -42.45 51.32 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -172.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.93 -35.46 0.01 OUTLIER 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.074 0.55 . . . . 0.0 110.676 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -177.04 50.31 0.1 Allowed Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -176.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.1 t -50.61 146.19 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 123.565 0.746 . . . . 0.0 109.735 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.8 m -96.53 161.92 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.072 0 CA-C-O 121.182 0.515 . . . . 0.0 111.4 -176.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -60.1 -24.72 64.86 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.01 0.524 . . . . 0.0 111.376 -176.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.22 -6.17 56.0 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -178.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -99.43 -31.58 11.58 Favored 'General case' 0 CA--C 1.529 0.137 0 CA-C-N 118.155 0.434 . . . . 0.0 110.204 177.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -69.83 -39.11 76.67 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.1 p -78.44 -30.79 15.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 121.157 -0.217 . . . . 0.0 110.52 -176.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -82.2 -14.37 55.68 Favored 'General case' 0 N--CA 1.456 -0.14 0 O-C-N 122.072 -0.393 . . . . 0.0 111.715 -178.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.67 -11.8 15.36 Favored 'General case' 0 CA--C 1.53 0.192 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 94.3 mt -115.95 -8.36 11.89 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.847 0.749 . . . . 0.0 112.481 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -70.42 -6.55 36.54 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.564 0.62 . . . . 0.0 111.9 176.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -76.42 -15.58 59.9 Favored 'General case' 0 CA--C 1.531 0.249 0 C-N-CA 122.488 0.315 . . . . 0.0 110.518 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -96.33 -17.15 20.88 Favored 'General case' 0 N--CA 1.456 -0.17 0 C-N-CA 122.446 0.298 . . . . 0.0 111.355 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.72 176.35 35.56 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -71.46 140.4 36.44 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 124.186 3.257 . . . . 0.0 110.586 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.7 mt -111.63 145.69 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.091 0 C-N-CA 122.563 0.345 . . . . 0.0 110.232 -177.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.8 t -105.36 -41.96 5.38 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 123.287 0.635 . . . . 0.0 111.278 -177.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -158.92 159.55 35.06 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.742 0.306 . . . . 0.0 111.098 178.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 87.7 t -143.6 147.46 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 C-N-CA 123.827 0.851 . . . . 0.0 109.692 -179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.1 p -148.5 149.74 14.82 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.094 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 175.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 50.1 t -129.87 149.35 33.53 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -177.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -130.54 82.02 66.2 Favored Pre-proline 0 N--CA 1.456 -0.137 0 C-N-CA 123.667 0.787 . . . . 0.0 109.32 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -58.82 -19.09 45.09 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 123.849 3.032 . . . . 0.0 112.838 -178.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -75.15 -13.47 60.47 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 122.905 0.482 . . . . 0.0 111.071 -179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -125.82 4.65 7.37 Favored 'General case' 0 CA--C 1.527 0.089 0 C-N-CA 123.541 0.737 . . . . 0.0 111.284 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.1 tpp85 55.18 32.08 17.72 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.128 0.971 . . . . 0.0 111.993 -177.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -135.87 166.32 23.57 Favored 'General case' 0 N--CA 1.457 -0.106 0 C-N-CA 123.059 0.544 . . . . 0.0 110.803 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.72 172.38 15.68 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 122.863 0.465 . . . . 0.0 110.725 179.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 30.6 mt -132.97 145.81 51.21 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 123.645 0.778 . . . . 0.0 109.772 177.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 86.2 t -137.26 132.42 46.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -114.53 117.72 31.72 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -85.2 153.5 22.59 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 120.99 0.424 . . . . 0.0 110.251 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -74.62 -13.15 60.61 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.388 -177.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -148.32 151.28 35.1 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.76 0.824 . . . . 0.0 108.965 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.9 p -66.42 -21.95 29.36 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.8 tp -73.31 -24.63 60.42 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 121.948 -0.47 . . . . 0.0 110.492 -179.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.24 -31.16 64.04 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.22 -31.23 23.28 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-N 117.126 0.463 . . . . 0.0 110.133 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 41.3 t -71.54 -18.48 62.26 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 122.904 0.482 . . . . 0.0 110.913 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -96.68 -17.83 20.08 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 122.74 0.416 . . . . 0.0 111.127 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.82 -31.42 28.12 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.13 -0.356 . . . . 0.0 111.663 -177.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 32.1 t -85.74 -14.36 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 177.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -72.97 -2.79 22.41 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.137 0.575 . . . . 0.0 111.118 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -121.03 -34.85 3.44 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 122.701 0.401 . . . . 0.0 110.996 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.73 -9.59 58.06 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 112.721 0.637 . . . . 0.0 112.721 -176.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.72 -0.21 55.89 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 122.663 0.385 . . . . 0.0 111.654 176.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -136.51 -10.13 1.89 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.907 0.483 . . . . 0.0 111.726 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 50.0 t30 -154.12 170.62 20.74 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -86.88 155.63 20.17 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 175.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -123.73 136.15 61.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -178.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -89.04 151.21 22.39 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.121 -0.362 . . . . 0.0 110.758 -179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.8 mt -136.5 -38.46 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.163 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.839 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.37 29.43 3.0 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.28 0.632 . . . . 0.0 111.027 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.18 3.79 81.97 Favored Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.716 -0.554 . . . . 0.0 111.716 -176.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -130.56 151.8 79.29 Favored Pre-proline 0 N--CA 1.454 -0.24 0 C-N-CA 124.436 1.094 . . . . 0.0 109.03 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_endo -70.77 146.22 53.37 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 123.666 2.91 . . . . 0.0 112.143 -177.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.86 -175.55 5.37 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.193 1.397 . . . . 0.0 109.205 179.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -140.59 159.44 42.19 Favored 'General case' 0 N--CA 1.456 -0.171 0 CA-C-O 121.004 0.43 . . . . 0.0 111.759 -178.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.72 143.13 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.145 0 C-N-CA 123.903 0.881 . . . . 0.0 109.902 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -156.91 162.96 39.64 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -60.86 168.45 2.34 Favored 'General case' 0 N--CA 1.455 -0.206 0 O-C-N 122.078 -0.389 . . . . 0.0 111.284 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 41.3 t -140.66 164.35 30.43 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 123.117 0.567 . . . . 0.0 110.377 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 23.9 m -68.65 -12.76 61.77 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 174.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 35.5 t -73.04 152.74 41.16 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.664 0.786 . . . . 0.0 110.986 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.3 pt20 -138.74 -1.0 1.87 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.159 0.584 . . . . 0.0 110.743 175.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -160.86 129.81 4.71 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 123.854 0.861 . . . . 0.0 108.948 -177.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 77.2 mt -83.25 148.2 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 175.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.2 m -79.3 139.5 37.82 Favored 'General case' 0 N--CA 1.457 -0.101 0 CA-C-O 120.676 0.275 . . . . 0.0 111.741 -177.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 44.97 52.63 10.61 Favored Pre-proline 0 CA--C 1.535 0.373 0 C-N-CA 124.651 1.18 . . . . 0.0 113.132 176.231 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -76.06 166.38 28.02 Favored 'Trans proline' 0 N--CA 1.451 -1.008 0 C-N-CA 123.35 2.7 . . . . 0.0 111.072 -177.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 62.81 -130.87 43.01 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -147.76 165.08 31.6 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 123.397 0.679 . . . . 0.0 110.516 -178.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 30.9 t -150.23 158.14 43.84 Favored 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 122.796 0.438 . . . . 0.0 110.638 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -150.2 154.83 38.66 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.219 0.608 . . . . 0.0 110.043 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -148.93 155.97 41.62 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 122.775 0.43 . . . . 0.0 110.933 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 51.1 m -134.7 148.15 50.25 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 123.913 0.885 . . . . 0.0 109.267 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 17.1 ttm180 -151.97 163.61 38.9 Favored 'General case' 0 CA--C 1.528 0.134 0 O-C-N 122.414 -0.179 . . . . 0.0 110.926 -174.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.4 m -99.59 6.22 45.79 Favored 'General case' 0 CA--C 1.528 0.108 0 N-CA-C 112.738 0.644 . . . . 0.0 112.738 -176.211 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.8 m -80.18 164.94 2.96 Favored 'Isoleucine or valine' 0 C--O 1.23 0.034 0 CA-C-N 117.982 0.356 . . . . 0.0 110.946 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -90.72 5.46 48.1 Favored 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 122.917 0.487 . . . . 0.0 111.718 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 28.0 m . . . . . 0 C--O 1.251 1.179 0 CA-C-O 117.27 -1.348 . . . . 0.0 111.196 -179.821 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.134 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -147.4 164.46 33.23 Favored 'General case' 0 C--O 1.231 0.122 0 C-N-CA 122.892 0.477 . . . . 0.0 110.726 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -149.83 170.96 17.55 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.156 0.582 . . . . 0.0 109.746 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -69.28 147.33 51.34 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 176.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 40.9 m-20 54.98 -179.66 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.156 0.982 . . . . 0.0 112.124 -176.059 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -86.99 136.53 33.93 Favored Pre-proline 0 CA--C 1.531 0.243 0 O-C-N 121.904 -0.498 . . . . 0.0 110.44 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -83.79 157.34 13.83 Favored 'Trans proline' 0 N--CA 1.451 -0.985 0 C-N-CA 123.956 3.104 . . . . 0.0 110.401 176.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.4 p-80 48.83 15.48 0.09 Allowed 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 116.369 1.988 . . . . 0.0 116.369 173.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -101.5 158.72 15.87 Favored 'General case' 0 N--CA 1.461 0.093 0 CA-C-N 118.925 0.784 . . . . 0.0 110.093 175.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 49.1 p -139.93 156.98 70.36 Favored Pre-proline 0 C--O 1.232 0.178 0 C-N-CA 123.419 0.688 . . . . 0.0 110.048 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -74.64 -3.51 13.98 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 123.584 2.856 . . . . 0.0 112.35 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.34 35.74 14.6 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.474 0.71 . . . . 0.0 112.057 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.0 m -61.43 158.79 36.2 Favored Pre-proline 0 CA--C 1.53 0.189 0 C-N-CA 124.091 0.956 . . . . 0.0 112.207 -177.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.51 0.06 5.99 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 124.229 3.286 . . . . 0.0 111.904 177.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 54.1 t -114.29 141.41 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 176.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.9 m -129.56 151.81 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.139 0 CA-C-O 121.332 0.587 . . . . 0.0 110.906 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.9 t-80 -98.72 136.21 39.1 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.201 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.3 mm -106.62 144.59 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 123.099 0.56 . . . . 0.0 109.752 -178.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -141.77 161.82 37.0 Favored 'General case' 0 C--N 1.338 0.074 0 C-N-CA 123.345 0.658 . . . . 0.0 110.584 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 77.3 24.93 64.69 Favored Glycine 0 CA--C 1.527 0.843 0 CA-C-O 119.642 -0.532 . . . . 0.0 113.086 174.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.6 mt -61.44 159.52 12.62 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 117.956 0.878 . . . . 0.0 110.638 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.1 pt -73.34 -41.52 57.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -173.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -173.94 -35.58 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.133 0 C-N-CA 123.634 0.774 . . . . 0.0 109.97 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.45 49.65 0.06 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -176.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 14.5 p -52.83 148.49 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 C-N-CA 122.897 0.479 . . . . 0.0 110.083 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -88.2 163.06 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 CA-C-O 121.324 0.583 . . . . 0.0 111.996 -171.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -62.24 -27.48 69.03 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.799 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.71 -3.07 49.41 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 123.087 0.555 . . . . 0.0 112.318 -178.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -104.29 -29.84 10.52 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.427 0.558 . . . . 0.0 109.711 177.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 49.8 mt -72.67 -38.97 67.46 Favored 'General case' 0 N--CA 1.455 -0.197 0 C-N-CA 122.546 0.339 . . . . 0.0 110.924 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -77.67 -30.23 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.442 -178.32 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -82.38 -16.01 50.68 Favored 'General case' 0 N--CA 1.453 -0.279 0 O-C-N 122.168 -0.332 . . . . 0.0 111.506 -178.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.44 -12.91 16.27 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 112.918 0.711 . . . . 0.0 112.918 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.9 mt -114.05 -7.62 13.08 Favored 'General case' 0 C--N 1.339 0.11 0 CA-C-N 118.516 0.598 . . . . 0.0 112.506 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.15 -6.07 31.56 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 118.731 0.696 . . . . 0.0 111.784 176.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -77.09 -13.62 59.93 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.801 0.44 . . . . 0.0 110.769 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -98.64 -18.16 18.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 122.531 0.332 . . . . 0.0 111.477 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.94 177.08 36.43 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -70.94 140.28 37.92 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 124.176 3.251 . . . . 0.0 110.3 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.1 mt -112.21 145.9 17.71 Favored 'Isoleucine or valine' 0 C--O 1.231 0.092 0 C-N-CA 122.746 0.419 . . . . 0.0 110.237 -177.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 t -105.88 -41.96 5.27 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.243 0.617 . . . . 0.0 111.395 -177.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -159.85 160.27 33.52 Favored 'General case' 0 CA--C 1.529 0.149 0 CA-C-O 120.695 0.283 . . . . 0.0 111.035 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.8 t -145.24 147.01 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.136 0 C-N-CA 123.906 0.882 . . . . 0.0 109.526 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.5 p -147.89 155.39 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.141 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 176.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 29.1 t -125.87 153.38 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.08 0 C-N-CA 122.503 0.321 . . . . 0.0 110.995 -177.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.5 mtm -135.56 77.13 53.35 Favored Pre-proline 0 CA--C 1.532 0.265 0 C-N-CA 124.237 1.015 . . . . 0.0 109.385 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -60.59 -16.68 44.33 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.972 3.115 . . . . 0.0 113.245 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -77.13 -6.56 53.34 Favored 'General case' 0 C--N 1.339 0.132 0 C-N-CA 123.009 0.524 . . . . 0.0 111.618 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -133.22 3.68 3.68 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.216 0.606 . . . . 0.0 111.386 179.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 13.4 tpp85 55.3 38.26 30.1 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.7 0.8 . . . . 0.0 111.152 -173.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 83.1 mt-30 -134.0 166.24 23.16 Favored 'General case' 0 N--CA 1.458 -0.05 0 C-N-CA 123.684 0.794 . . . . 0.0 110.608 -176.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.04 171.31 18.06 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 122.985 0.514 . . . . 0.0 109.871 176.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -132.18 146.01 51.74 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 123.407 0.683 . . . . 0.0 110.072 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 93.3 t -137.37 128.71 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 118.1 33.78 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.404 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.6 m-85 -85.85 154.87 21.24 Favored 'General case' 0 N--CA 1.452 -0.355 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.348 -179.148 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -75.23 -12.24 60.24 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 120.704 0.287 . . . . 0.0 110.399 -178.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -148.62 152.16 36.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 123.784 0.834 . . . . 0.0 109.14 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.49 -21.41 26.19 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 122.076 -0.39 . . . . 0.0 111.614 -175.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.6 tp -75.56 -28.87 59.17 Favored 'General case' 0 N--CA 1.452 -0.353 0 O-C-N 122.008 -0.433 . . . . 0.0 110.529 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.16 -30.92 71.71 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.37 -31.41 37.84 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.894 0.347 . . . . 0.0 110.301 178.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 44.2 t -70.81 -29.53 65.72 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 122.205 0.202 . . . . 0.0 110.983 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -78.07 -19.6 53.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 119.462 -0.304 . . . . 0.0 111.476 -179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.88 -32.06 23.4 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.108 0.413 . . . . 0.0 111.606 -176.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.5 t -86.76 -19.51 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -68.65 -14.1 62.79 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.102 -0.374 . . . . 0.0 110.99 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -104.4 -37.85 7.05 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.487 0.315 . . . . 0.0 111.256 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.65 -4.33 58.96 Favored 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -77.9 -9.15 58.93 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.228 0.467 . . . . 0.0 111.486 177.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -141.07 -1.86 1.34 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 122.681 0.392 . . . . 0.0 111.652 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.5 m-80 -144.41 175.7 9.92 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.131 0.572 . . . . 0.0 109.921 -178.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . 0.476 ' CD ' ' H ' ' A' ' 156' ' ' GLN . 0.0 OUTLIER -98.48 155.86 17.05 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.714 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.95 135.59 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -89.38 155.94 19.01 Favored 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 122.045 -0.409 . . . . 0.0 111.085 -178.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.9 mt -138.0 -42.51 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.786 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.84 32.2 2.99 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.236 0.614 . . . . 0.0 111.122 -177.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.07 4.84 81.32 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 -176.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -128.99 150.67 75.95 Favored Pre-proline 0 N--CA 1.455 -0.202 0 C-N-CA 123.83 0.852 . . . . 0.0 109.215 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -71.55 147.58 52.02 Favored 'Trans proline' 0 N--CA 1.451 -1.0 0 C-N-CA 123.464 2.776 . . . . 0.0 111.702 -177.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -153.45 -174.6 5.01 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 125.072 1.349 . . . . 0.0 108.731 178.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -139.04 160.24 40.24 Favored 'General case' 0 N--CA 1.456 -0.173 0 CA-C-O 120.986 0.422 . . . . 0.0 111.345 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.7 p -147.23 140.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 C-N-CA 123.575 0.75 . . . . 0.0 109.264 179.087 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -157.26 161.12 39.19 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 122.91 0.484 . . . . 0.0 110.398 179.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -66.19 163.78 17.04 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 175.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 94.3 p -149.86 -175.8 5.18 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 176.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 58.7 p -72.97 1.95 7.87 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 122.614 0.366 . . . . 0.0 111.33 177.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 91.4 p -73.35 155.28 39.56 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 122.868 0.467 . . . . 0.0 110.771 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -145.55 -9.78 0.55 Allowed 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 175.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -161.46 136.7 7.54 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.748 0.819 . . . . 0.0 108.844 -178.16 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 73.5 mt -86.72 143.41 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.122 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 174.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.9 m -72.94 134.68 44.85 Favored 'General case' 0 C--N 1.334 -0.085 0 C-N-CA 122.183 0.193 . . . . 0.0 110.993 -177.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 71.5 ttt180 40.16 66.0 3.53 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 124.767 1.227 . . . . 0.0 112.199 179.148 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -77.03 62.49 7.46 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 124.34 3.36 . . . . 0.0 111.13 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 82.33 0.77 90.11 Favored Glycine 0 CA--C 1.527 0.823 0 C-N-CA 123.304 0.478 . . . . 0.0 112.144 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -83.28 159.17 21.98 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 117.435 0.618 . . . . 0.0 110.364 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 66.3 m -146.42 160.65 41.79 Favored 'General case' 0 C--O 1.23 0.077 0 C-N-CA 123.273 0.629 . . . . 0.0 110.012 178.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -147.24 154.39 40.95 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 123.03 0.532 . . . . 0.0 110.262 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 26.8 t0 -142.8 9.33 1.74 Allowed 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.363 0.665 . . . . 0.0 110.952 179.107 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 33.6 t -61.8 144.27 55.04 Favored 'General case' 0 CA--C 1.53 0.174 0 O-C-N 121.579 -0.701 . . . . 0.0 109.86 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 18.3 ptp180 -152.1 170.7 19.31 Favored 'General case' 0 CA--C 1.528 0.116 0 C-N-CA 122.947 0.499 . . . . 0.0 111.033 -175.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.8 m -82.24 8.33 11.4 Favored 'General case' 0 C--O 1.232 0.155 0 C-N-CA 124.113 0.965 . . . . 0.0 113.166 -175.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 31.3 m -136.35 165.61 28.58 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 C-N-CA 122.948 0.499 . . . . 0.0 110.888 -177.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 30.9 m120 -80.82 -15.3 56.75 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 122.25 0.22 . . . . 0.0 111.032 178.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 33.0 t . . . . . 0 C--O 1.252 1.201 0 CA-C-O 117.694 -1.146 . . . . 0.0 109.855 178.099 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.054 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -136.91 154.91 50.34 Favored 'General case' 0 CA--C 1.527 0.077 0 C-N-CA 123.467 0.707 . . . . 0.0 109.39 179.325 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 -146.83 -5.58 0.53 Allowed 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -176.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 85.0 m-85 -142.12 180.0 6.57 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 123.283 0.633 . . . . 0.0 109.717 -177.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -89.23 133.63 34.36 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 177.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 44.42 47.99 4.09 Favored Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 113.963 1.098 . . . . 0.0 113.963 -178.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -71.36 -23.22 24.17 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 122.184 1.923 . . . . 0.0 111.563 -179.075 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -157.12 9.15 0.19 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.481 0.713 . . . . 0.0 111.542 178.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -76.33 163.99 26.47 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 122.961 0.504 . . . . 0.0 110.517 -178.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 33.2 p -136.5 152.47 74.83 Favored Pre-proline 0 CA--C 1.528 0.121 0 C-N-CA 122.96 0.504 . . . . 0.0 110.359 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -76.57 -5.3 15.95 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 123.893 3.062 . . . . 0.0 112.749 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.09 33.12 8.65 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 123.487 0.715 . . . . 0.0 111.918 -177.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 63.8 m -63.41 157.55 63.72 Favored Pre-proline 0 CA--C 1.53 0.18 0 C-N-CA 123.805 0.842 . . . . 0.0 111.757 -177.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -71.88 -3.76 13.81 Favored 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.831 3.021 . . . . 0.0 111.568 177.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 67.5 t -111.11 139.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.2 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 177.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.62 148.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 CA-C-O 121.319 0.58 . . . . 0.0 110.732 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -95.46 137.25 34.78 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 124.189 0.995 . . . . 0.0 110.35 178.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 26.0 mm -105.85 143.92 16.12 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 123.194 0.597 . . . . 0.0 109.787 -178.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -142.56 160.53 40.11 Favored 'General case' 0 N--CA 1.458 -0.066 0 C-N-CA 123.132 0.573 . . . . 0.0 110.822 -178.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.81 26.09 56.86 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-O 119.457 -0.635 . . . . 0.0 113.523 173.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.9 mt -62.53 156.06 24.04 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.144 0.972 . . . . 0.0 109.814 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -70.57 -41.63 77.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -173.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -173.12 -34.78 0.01 OUTLIER 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.31 0.644 . . . . 0.0 110.676 -179.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.93 48.93 0.12 Allowed Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -176.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.7 t -51.56 143.21 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 C-N-CA 123.41 0.684 . . . . 0.0 109.697 178.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.8 m -95.72 164.98 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.119 0 CA-C-O 121.308 0.575 . . . . 0.0 111.637 -175.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -61.08 -26.02 67.36 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.538 0.735 . . . . 0.0 111.247 -178.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.45 -5.56 56.75 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 -177.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -98.11 -30.46 12.65 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.28 0.491 . . . . 0.0 109.922 177.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.2 mt -73.33 -38.8 65.65 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 122.556 0.342 . . . . 0.0 110.95 -178.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.6 p -77.27 -29.96 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.241 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.6 mm-40 -82.76 -15.14 52.92 Favored 'General case' 0 N--CA 1.455 -0.176 0 CA-C-O 119.445 -0.312 . . . . 0.0 111.643 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -108.31 -10.61 15.33 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -116.96 -9.61 11.1 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 118.501 0.591 . . . . 0.0 112.396 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -69.83 -7.34 39.13 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.7 0.682 . . . . 0.0 111.633 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -74.12 -18.47 60.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.508 0.323 . . . . 0.0 110.593 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -92.64 -19.07 22.25 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 122.369 0.268 . . . . 0.0 111.535 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.39 176.77 35.71 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.494 -0.642 . . . . 0.0 111.494 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 139.64 41.24 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.978 3.118 . . . . 0.0 110.93 -179.187 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.9 mt -111.59 145.67 17.5 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.876 0.471 . . . . 0.0 110.226 -177.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.5 t -104.09 -41.28 5.88 Favored 'General case' 0 N--CA 1.455 -0.221 0 C-N-CA 123.193 0.597 . . . . 0.0 111.355 -177.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . 0.405 ' CG ' ' HA ' ' A' ' 177' ' ' PRO . 55.5 t80 -161.42 161.18 30.16 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.563 0.22 . . . . 0.0 111.532 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 69.2 t -143.97 147.16 20.07 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 123.903 0.881 . . . . 0.0 109.625 179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -147.29 153.33 12.33 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 176.207 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 37.7 t -128.46 152.99 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.052 0 C-N-CA 122.42 0.288 . . . . 0.0 111.019 -174.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 69.6 mtm -134.28 79.17 56.1 Favored Pre-proline 0 CA--C 1.532 0.274 0 C-N-CA 124.21 1.004 . . . . 0.0 109.314 178.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -58.85 -21.54 57.81 Favored 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 123.598 2.866 . . . . 0.0 113.134 -177.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -83.48 1.89 39.5 Favored 'General case' 0 C--N 1.34 0.157 0 C-N-CA 122.939 0.495 . . . . 0.0 112.015 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -128.79 0.67 5.41 Favored 'General case' 0 C--N 1.338 0.086 0 C-N-CA 123.802 0.841 . . . . 0.0 111.158 176.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.5 tpp85 53.35 33.04 14.84 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.014 0.926 . . . . 0.0 111.116 -172.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -136.81 167.86 20.65 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.305 0.642 . . . . 0.0 110.825 -175.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.36 173.57 15.45 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.89 0.476 . . . . 0.0 110.175 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 40.4 mt -132.81 145.11 50.7 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 123.187 0.595 . . . . 0.0 109.837 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.2 t -135.44 131.33 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -114.83 117.74 31.58 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.41 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 60.8 m-85 -84.16 156.75 21.94 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.303 179.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -70.4 -18.41 63.03 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.284 -178.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -154.19 159.21 41.27 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 123.784 0.834 . . . . 0.0 109.579 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 27.2 m -65.42 -15.23 18.16 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.099 0 O-C-N 122.053 -0.405 . . . . 0.0 111.843 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 10.3 tt -67.61 -33.2 74.51 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 118.327 0.512 . . . . 0.0 110.384 179.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -76.14 -31.85 54.06 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.363 -0.695 . . . . 0.0 111.363 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.48 -32.46 32.49 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.372 0.586 . . . . 0.0 110.535 179.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 34.9 t -75.73 -8.08 55.95 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 123.101 0.56 . . . . 0.0 111.302 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -106.74 -16.31 14.52 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 122.409 0.283 . . . . 0.0 111.039 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -86.79 -34.93 19.41 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 122.063 -0.398 . . . . 0.0 111.33 -178.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.5 t -83.32 -15.78 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -71.37 -5.33 31.75 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 122.797 0.439 . . . . 0.0 111.265 179.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -116.52 -37.68 3.67 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 122.899 0.48 . . . . 0.0 110.911 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.68 -5.73 59.01 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -176.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.4 -4.36 58.4 Favored 'General case' 0 CA--C 1.531 0.226 0 O-C-N 122.069 -0.394 . . . . 0.0 111.441 177.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -142.07 -6.5 0.96 Allowed 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 122.773 0.429 . . . . 0.0 111.686 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 26.3 m-80 -144.76 175.13 10.4 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 123.387 0.675 . . . . 0.0 109.5 -179.196 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . 0.477 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.0 OUTLIER -95.98 152.43 18.52 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 172.733 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.84 135.32 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.12 149.67 23.07 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 121.954 -0.466 . . . . 0.0 110.758 -179.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 56.4 mt -137.38 -39.67 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.939 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.42 29.48 3.94 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.151 0.58 . . . . 0.0 111.033 -176.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.09 4.54 84.15 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -132.09 152.84 80.91 Favored Pre-proline 0 C--O 1.233 0.224 0 C-N-CA 124.102 0.961 . . . . 0.0 109.269 177.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -71.47 144.47 45.3 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 123.583 2.855 . . . . 0.0 111.764 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.74 -175.85 5.19 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 124.983 1.313 . . . . 0.0 108.765 177.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -138.5 160.26 40.0 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-O 120.927 0.394 . . . . 0.0 111.628 -178.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.1 p -147.84 143.48 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.13 0 C-N-CA 123.785 0.834 . . . . 0.0 109.693 178.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -156.04 161.45 40.43 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.259 0.624 . . . . 0.0 110.066 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -64.64 162.91 14.76 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.725 0.298 . . . . 0.0 110.648 177.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 44.3 t -147.98 159.87 43.43 Favored 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 59.1 p -74.69 8.32 2.47 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 122.69 0.396 . . . . 0.0 110.253 176.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.401 ' C ' ' H ' ' A' ' 173' ' ' LYS . 83.5 p -59.46 -43.85 93.12 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 124.369 1.068 . . . . 0.0 110.901 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 48.86 -10.72 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 128.906 2.882 . . . . 0.0 116.898 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . 0.401 ' H ' ' C ' ' A' ' 171' ' ' SER . 16.5 tppt? -165.15 138.3 4.58 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 123.556 0.743 . . . . 0.0 109.526 -177.252 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 81.5 mt -84.34 156.99 3.62 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 174.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 80.8 p -81.18 -8.28 59.73 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 114.339 1.237 . . . . 0.0 114.339 -172.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . 0.446 ' N ' ' CD ' ' A' ' 177' ' ' PRO . 37.7 ptt180 -154.89 36.49 0.07 OUTLIER Pre-proline 0 CA--C 1.535 0.383 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -177.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . 0.446 ' CD ' ' N ' ' A' ' 176' ' ' ARG . 87.6 Cg_endo -72.66 111.67 3.3 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.62 2.213 . . . . 0.0 111.123 -176.243 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 70.45 -9.81 3.13 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 123.958 0.79 . . . . 0.0 114.021 176.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -157.81 158.88 36.03 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.094 0.947 . . . . 0.0 110.051 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.2 m -133.31 153.33 51.66 Favored 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 123.073 0.549 . . . . 0.0 110.422 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -150.36 155.17 39.11 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 122.691 0.396 . . . . 0.0 110.752 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -140.62 154.12 46.32 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.688 0.795 . . . . 0.0 109.816 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 49.5 m -67.5 137.34 55.72 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 120.665 0.269 . . . . 0.0 110.321 -178.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 31.4 ptt-85 -160.38 167.19 27.9 Favored 'General case' 0 N--CA 1.458 -0.072 0 C-N-CA 123.594 0.758 . . . . 0.0 110.115 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.4 m -78.63 130.26 35.68 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 122.401 0.281 . . . . 0.0 110.25 178.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 11.2 m -149.38 163.09 4.32 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 C-N-CA 124.272 1.029 . . . . 0.0 109.159 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.6 t30 -79.06 134.14 36.77 Favored 'General case' 0 N--CA 1.455 -0.211 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 178.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 60.5 m . . . . . 0 C--O 1.251 1.156 0 CA-C-O 117.527 -1.225 . . . . 0.0 110.075 179.878 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 111.141 -0.783 . . . . 0.0 111.141 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -149.41 162.16 40.65 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 122.896 0.478 . . . . 0.0 110.988 179.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 45.9 t30 -151.98 163.53 39.09 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.638 0.775 . . . . 0.0 108.943 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 53.82 -163.92 0.1 Allowed 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.689 0.796 . . . . 0.0 111.695 -177.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -115.23 2.13 13.98 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 123.007 0.523 . . . . 0.0 111.458 178.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.422 ' N ' ' CD ' ' A' ' 90' ' ' PRO . 14.9 p-10 -144.09 43.34 0.42 Allowed Pre-proline 0 CA--C 1.537 0.478 0 N-CA-C 113.17 0.804 . . . . 0.0 113.17 -177.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.422 ' CD ' ' N ' ' A' ' 89' ' ' ASP . 73.6 Cg_endo -69.71 -14.83 36.82 Favored 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 122.735 2.29 . . . . 0.0 112.324 -177.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -147.52 11.0 0.98 Allowed 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -177.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -83.6 158.57 21.87 Favored 'General case' 0 C--O 1.231 0.108 0 O-C-N 122.154 -0.341 . . . . 0.0 110.673 -179.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 22.2 p -80.31 153.42 74.11 Favored Pre-proline 0 C--N 1.333 -0.118 0 C-N-CA 122.806 0.442 . . . . 0.0 111.121 -178.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -76.03 -8.05 18.62 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.574 2.849 . . . . 0.0 112.299 -178.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.32 34.89 9.6 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.48 0.712 . . . . 0.0 111.42 -177.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 60.8 p -72.2 159.38 85.58 Favored Pre-proline 0 CA--C 1.532 0.278 0 C-N-CA 123.956 0.902 . . . . 0.0 112.486 -175.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -72.76 4.25 3.74 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 124.159 3.239 . . . . 0.0 112.358 178.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.7 t -123.5 140.43 47.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.217 0 C-N-CA 123.279 0.631 . . . . 0.0 109.454 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.0 m -128.16 145.37 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 CA-C-O 121.199 0.523 . . . . 0.0 110.831 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -96.9 134.4 40.28 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.241 1.016 . . . . 0.0 109.932 177.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.415 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.1 mp -107.4 145.78 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.432 0.693 . . . . 0.0 109.408 -178.129 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.0 mtt180 -141.33 160.98 38.99 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.64 0.776 . . . . 0.0 109.892 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.84 28.49 50.54 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-O 119.545 -0.586 . . . . 0.0 113.438 175.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.9 mt -57.73 154.88 10.97 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 118.241 1.02 . . . . 0.0 109.877 177.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.9 pt -68.19 -39.39 81.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.077 0 O-C-N 122.084 -0.385 . . . . 0.0 111.071 -176.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -171.62 -35.92 0.02 OUTLIER 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.307 1.043 . . . . 0.0 109.742 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 172.48 55.92 0.04 OUTLIER Glycine 0 C--N 1.339 0.718 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 -177.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 20.7 m -52.75 151.17 1.1 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-N 117.076 0.438 . . . . 0.0 110.511 178.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.7 m -87.46 166.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.953 0.406 . . . . 0.0 111.262 -177.004 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -61.99 -23.71 66.58 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.163 0.585 . . . . 0.0 111.242 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.31 -6.03 57.28 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -92.9 -35.14 13.5 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 118.565 0.62 . . . . 0.0 110.213 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 91.4 mt -73.25 -36.28 66.36 Favored 'General case' 0 N--CA 1.454 -0.274 0 O-C-N 122.385 -0.197 . . . . 0.0 111.266 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -76.97 -31.04 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.317 -177.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -82.14 -17.68 45.54 Favored 'General case' 0 N--CA 1.455 -0.219 0 O-C-N 122.185 -0.322 . . . . 0.0 111.167 -178.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -9.13 18.31 Favored 'General case' 0 N--CA 1.455 -0.21 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.0 mt -120.82 -8.97 9.37 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -69.3 -7.19 34.79 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.866 0.757 . . . . 0.0 111.687 177.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -76.91 -14.99 59.81 Favored 'General case' 0 CA--C 1.531 0.24 0 O-C-N 122.025 -0.422 . . . . 0.0 110.731 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -96.08 -16.82 21.34 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 122.578 0.351 . . . . 0.0 111.592 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.4 176.55 34.6 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -70.59 140.75 40.24 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 123.889 3.06 . . . . 0.0 110.877 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 78.3 mt -110.81 146.63 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.083 0 C-N-CA 122.816 0.446 . . . . 0.0 110.487 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -106.43 -42.5 5.0 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.009 0.524 . . . . 0.0 111.478 -177.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -159.11 159.28 34.32 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-O 120.837 0.351 . . . . 0.0 111.231 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 89.6 t -143.78 146.57 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.086 0 C-N-CA 124.001 0.92 . . . . 0.0 109.841 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.97 153.45 11.73 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 42.8 t -131.69 149.63 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.069 0 CA-C-O 120.717 0.294 . . . . 0.0 110.595 -176.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 81.55 67.52 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -60.29 -17.67 48.11 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.811 3.008 . . . . 0.0 112.877 -178.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -82.9 -4.28 57.97 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.802 0.441 . . . . 0.0 111.484 179.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -129.23 4.04 5.22 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.861 0.864 . . . . 0.0 111.194 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 3.3 tpt180 54.58 30.44 13.16 Favored 'General case' 0 C--N 1.341 0.202 0 C-N-CA 123.847 0.859 . . . . 0.0 112.058 -177.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -138.89 166.59 24.05 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 123.119 0.568 . . . . 0.0 110.813 -174.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.98 172.17 16.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.213 0.605 . . . . 0.0 110.487 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.5 mt -134.14 146.48 50.26 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 123.443 0.697 . . . . 0.0 109.794 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.91 132.7 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -115.81 122.29 44.97 Favored 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.4 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.0 m-85 -87.89 156.03 19.57 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -178.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.3 -14.24 60.87 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.563 -178.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -149.49 153.47 37.29 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.68 0.792 . . . . 0.0 108.935 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.4 p -67.64 -20.92 26.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 O-C-N 122.175 -0.328 . . . . 0.0 111.717 -176.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.2 tp -74.52 -27.08 60.38 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 117.867 0.303 . . . . 0.0 110.997 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.91 -32.47 60.93 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.29 -29.39 34.31 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 117.018 0.409 . . . . 0.0 110.518 177.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -73.63 -19.28 60.9 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 122.681 0.392 . . . . 0.0 110.92 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -93.63 -17.27 23.46 Favored 'General case' 0 CA--C 1.532 0.276 0 O-C-N 122.191 -0.318 . . . . 0.0 111.03 -179.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.33 -31.98 26.52 Favored 'General case' 0 N--CA 1.455 -0.179 0 O-C-N 121.912 -0.492 . . . . 0.0 111.386 -178.07 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 37.0 t -85.75 -15.29 10.46 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 178.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -71.52 -7.67 49.06 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.784 0.434 . . . . 0.0 110.875 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 71.7 t80 -113.73 -36.93 4.71 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.621 0.369 . . . . 0.0 110.982 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.87 -7.17 59.68 Favored 'General case' 0 CA--C 1.53 0.195 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.44 -2.72 56.51 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 122.283 -0.261 . . . . 0.0 111.592 177.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -141.19 -7.88 1.02 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 122.73 0.412 . . . . 0.0 112.053 179.335 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 28.6 m-80 -145.41 170.4 16.42 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.332 0.653 . . . . 0.0 109.982 -179.057 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -86.17 155.98 20.52 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -125.53 135.58 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -88.05 156.35 19.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 O-C-N 122.014 -0.429 . . . . 0.0 110.585 -178.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 62.9 mt -137.53 -43.79 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.536 -178.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.01 31.47 3.57 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.326 0.651 . . . . 0.0 111.185 -177.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.22 6.37 78.54 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.19 151.81 79.52 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.119 0.968 . . . . 0.0 109.142 177.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -71.86 143.61 41.6 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 123.558 2.839 . . . . 0.0 111.764 -176.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.76 -173.87 4.61 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 125.238 1.415 . . . . 0.0 108.395 177.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.01 160.12 40.53 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 121.042 0.448 . . . . 0.0 111.666 -178.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.6 p -149.74 144.98 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 C-N-CA 123.398 0.679 . . . . 0.0 110.064 179.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -156.43 163.99 38.79 Favored 'General case' 0 N--CA 1.456 -0.148 0 C-N-CA 123.264 0.626 . . . . 0.0 110.148 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -61.95 164.26 6.75 Favored 'General case' 0 C--O 1.231 0.086 0 CA-C-O 120.556 0.217 . . . . 0.0 110.618 177.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 47.2 t -148.38 152.57 37.24 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 120.731 0.301 . . . . 0.0 110.461 177.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 60.1 p -75.75 -1.63 25.87 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 122.558 0.343 . . . . 0.0 111.097 178.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 68.4 m -59.69 -36.18 75.97 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 122.975 0.51 . . . . 0.0 110.827 179.004 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 47.72 -1.51 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 128.001 2.52 . . . . 0.0 116.157 177.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 15.9 tppt? -163.64 142.66 8.04 Favored 'General case' 0 N--CA 1.454 -0.228 0 C-N-CA 124.312 1.045 . . . . 0.0 109.003 -177.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 69.2 mt -98.22 148.05 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.264 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 173.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 34.2 t -80.82 142.32 33.81 Favored 'General case' 0 N--CA 1.455 -0.177 0 O-C-N 122.272 -0.268 . . . . 0.0 111.35 -177.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 85.0 mtm180 46.43 51.22 9.56 Favored Pre-proline 0 CA--C 1.534 0.343 0 C-N-CA 124.665 1.186 . . . . 0.0 113.208 177.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -79.07 -5.15 14.35 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 123.42 2.746 . . . . 0.0 112.151 -178.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -168.54 7.03 0.05 OUTLIER Glycine 0 CA--C 1.529 0.913 0 CA-C-O 119.661 -0.521 . . . . 0.0 112.986 -178.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -143.88 151.03 39.32 Favored 'General case' 0 N--CA 1.456 -0.129 0 CA-C-N 117.779 0.789 . . . . 0.0 110.029 -178.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 17.8 t -151.78 167.71 27.38 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.096 0.559 . . . . 0.0 110.202 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -141.75 155.73 45.62 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.298 0.639 . . . . 0.0 110.768 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -138.87 164.53 29.41 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 123.588 0.755 . . . . 0.0 110.512 -178.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 75.8 p -69.19 156.09 39.3 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.795 0.331 . . . . 0.0 111.086 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.7 mpt_? -84.13 163.71 19.63 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 122.872 0.469 . . . . 0.0 110.8 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 17.5 t -139.0 24.96 2.54 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.453 0.701 . . . . 0.0 110.548 -177.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.37 165.93 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.135 0 C-N-CA 124.019 0.928 . . . . 0.0 110.086 -177.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -71.12 131.51 43.69 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 32.3 t . . . . . 0 C--O 1.251 1.147 0 CA-C-O 117.251 -1.357 . . . . 0.0 110.178 179.874 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.194 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -149.82 167.22 27.18 Favored 'General case' 0 C--N 1.334 -0.09 0 C-N-CA 122.993 0.517 . . . . 0.0 110.921 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -90.48 36.47 0.89 Allowed 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.178 0.591 . . . . 0.0 110.432 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 56.21 28.4 13.12 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.536 0.734 . . . . 0.0 111.944 -176.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -144.51 163.47 33.76 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.972 0.909 . . . . 0.0 109.815 -178.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 13.1 p-10 -121.83 64.78 18.06 Favored Pre-proline 0 CA--C 1.535 0.366 0 C-N-CA 123.857 0.863 . . . . 0.0 110.891 -178.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -72.6 -16.62 26.93 Favored 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.674 2.916 . . . . 0.0 112.776 -174.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -149.57 8.88 0.7 Allowed 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 -177.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -89.23 165.1 14.65 Favored 'General case' 0 C--O 1.231 0.095 0 O-C-N 121.944 -0.473 . . . . 0.0 110.556 178.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 58.5 p -136.46 155.06 77.25 Favored Pre-proline 0 C--O 1.231 0.098 0 C-N-CA 123.202 0.601 . . . . 0.0 110.344 -179.151 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -74.88 -4.25 15.13 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 124.058 3.172 . . . . 0.0 112.481 178.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.29 35.44 13.71 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 123.274 0.63 . . . . 0.0 112.208 -178.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 65.5 m -60.88 158.65 31.91 Favored Pre-proline 0 N--CA 1.455 -0.215 0 C-N-CA 123.9 0.88 . . . . 0.0 111.883 -178.27 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -70.41 0.44 6.14 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 124.158 3.239 . . . . 0.0 111.773 176.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.1 t -112.4 139.9 34.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 C-N-CA 123.6 0.76 . . . . 0.0 109.239 177.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 32.6 m -128.91 152.82 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 CA-C-O 121.08 0.467 . . . . 0.0 110.728 178.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -102.45 137.86 40.14 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.709 0.804 . . . . 0.0 110.112 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 18.8 mm -106.49 144.59 15.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 C-N-CA 123.527 0.731 . . . . 0.0 109.799 -178.228 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.7 mtt180 -143.14 160.95 39.46 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.07 0.548 . . . . 0.0 110.698 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.96 23.87 60.87 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-O 119.77 -0.461 . . . . 0.0 113.151 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 56.1 mt -60.34 157.55 13.48 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 117.952 0.876 . . . . 0.0 109.979 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 16.5 pt -72.34 -37.32 57.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 O-C-N 122.244 -0.285 . . . . 0.0 111.35 -176.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -172.92 -36.93 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.176 0 C-N-CA 123.887 0.875 . . . . 0.0 109.7 -179.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 171.21 61.84 0.04 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -176.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.2 m -52.31 154.66 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 122.688 0.395 . . . . 0.0 110.608 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.45 HG12 ' H ' ' A' ' 111' ' ' ALA . 8.7 t -76.99 155.64 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.101 0 CA-C-O 120.936 0.398 . . . . 0.0 110.473 -175.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -59.4 -26.88 65.52 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.723 0.409 . . . . 0.0 110.239 174.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.45 ' H ' HG12 ' A' ' 109' ' ' VAL . . . -81.79 -6.83 59.41 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 123.513 0.725 . . . . 0.0 111.886 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -90.08 -34.11 16.04 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 118.341 0.519 . . . . 0.0 109.999 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 90.0 mt -73.52 -34.97 65.49 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 122.573 0.349 . . . . 0.0 111.373 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.89 -30.59 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.135 0 CA-C-N 118.041 0.382 . . . . 0.0 110.428 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -82.84 -15.81 50.13 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-O 119.526 -0.273 . . . . 0.0 111.155 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.77 -11.15 16.96 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -119.26 -9.18 9.99 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 118.6 0.636 . . . . 0.0 112.535 -178.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -69.82 -6.9 35.49 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 119.156 0.889 . . . . 0.0 111.874 177.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -76.5 -12.64 60.07 Favored 'General case' 0 CA--C 1.532 0.251 0 O-C-N 122.117 -0.365 . . . . 0.0 110.695 178.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -100.1 -19.97 16.23 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 122.678 0.391 . . . . 0.0 111.337 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 166.05 175.97 36.93 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.396 -0.681 . . . . 0.0 111.396 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -71.33 141.42 38.96 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 123.918 3.079 . . . . 0.0 110.505 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 76.2 mt -112.61 146.26 17.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 C-N-CA 122.875 0.47 . . . . 0.0 110.226 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.0 t -103.58 -44.81 5.01 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.009 0.523 . . . . 0.0 111.216 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . 0.462 ' CE2' ' HA ' ' A' ' 177' ' ' PRO . 58.2 t80 -158.84 162.08 36.95 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-O 120.852 0.358 . . . . 0.0 111.465 178.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 95.2 t -142.55 144.81 24.15 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 C-N-CA 124.167 0.987 . . . . 0.0 109.673 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.42 153.02 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.097 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 175.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 41.3 t -130.6 148.21 33.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.1 0 CA-C-O 120.604 0.24 . . . . 0.0 110.986 -175.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.53 84.0 60.52 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.808 0.843 . . . . 0.0 109.087 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.22 -12.32 33.64 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 123.489 2.793 . . . . 0.0 111.725 -176.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.9 tptt -76.94 -12.15 59.91 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 122.869 0.468 . . . . 0.0 110.9 177.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -129.29 6.92 5.36 Favored 'General case' 0 C--N 1.34 0.163 0 C-N-CA 123.636 0.775 . . . . 0.0 111.904 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 53.9 33.93 18.33 Favored 'General case' 0 N--CA 1.463 0.183 0 C-N-CA 124.449 1.1 . . . . 0.0 112.197 -177.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -136.66 166.26 23.98 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.175 0.59 . . . . 0.0 110.637 -177.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -151.91 172.36 16.34 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.673 0.389 . . . . 0.0 110.49 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 37.2 mt -131.32 149.05 52.71 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 123.406 0.682 . . . . 0.0 110.166 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.2 t -140.11 133.32 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.199 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -114.21 120.71 41.39 Favored 'General case' 0 N--CA 1.452 -0.325 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 177.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -85.83 152.22 23.18 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.041 0.448 . . . . 0.0 110.018 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -71.34 -15.15 62.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.349 -178.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.12 152.45 39.3 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 123.744 0.818 . . . . 0.0 109.469 177.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.0 p -68.89 -21.45 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 O-C-N 122.18 -0.325 . . . . 0.0 111.751 -175.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.6 tp -75.25 -28.89 60.02 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.83 -0.544 . . . . 0.0 110.334 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.68 -29.62 71.17 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.69 -30.28 36.46 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 117.029 0.414 . . . . 0.0 110.5 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.7 t -73.14 -28.17 62.09 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 122.501 0.32 . . . . 0.0 110.67 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -79.21 -19.43 50.79 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-O 119.541 -0.266 . . . . 0.0 111.532 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -32.67 27.03 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-N 118.157 0.435 . . . . 0.0 111.467 -177.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 30.0 t -85.73 -17.51 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -69.44 -11.63 60.98 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.539 0.336 . . . . 0.0 111.08 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -112.0 -36.85 5.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.635 0.374 . . . . 0.0 111.0 178.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -80.03 -11.67 59.76 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -176.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.48 -0.26 56.55 Favored 'General case' 0 CA--C 1.534 0.335 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 177.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -135.44 -10.85 2.16 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 117.921 0.328 . . . . 0.0 111.503 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.6 t30 -153.97 164.09 39.01 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.601 0.76 . . . . 0.0 109.065 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.6 pm0 -81.32 154.7 26.38 Favored 'General case' 0 CA--C 1.529 0.139 0 O-C-N 121.8 -0.563 . . . . 0.0 109.783 174.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.06 135.57 61.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -87.75 153.83 21.04 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.077 -0.389 . . . . 0.0 110.708 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 61.4 mt -136.99 -43.36 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.662 0.385 . . . . 0.0 110.802 -177.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.14 30.64 3.92 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.103 0.561 . . . . 0.0 111.333 -176.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 88.27 4.25 77.75 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.037 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -131.44 152.49 80.59 Favored Pre-proline 0 C--O 1.233 0.219 0 C-N-CA 124.013 0.925 . . . . 0.0 109.318 177.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.72 146.18 48.0 Favored 'Trans proline' 0 N--CA 1.453 -0.884 0 C-N-CA 123.438 2.759 . . . . 0.0 111.573 -176.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.43 -175.75 5.41 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.952 1.301 . . . . 0.0 109.021 178.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -139.42 160.76 39.08 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 121.174 0.511 . . . . 0.0 111.712 -178.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 2.9 p -147.76 141.18 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 123.962 0.905 . . . . 0.0 109.532 177.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -156.81 161.93 39.73 Favored 'General case' 0 CA--C 1.531 0.217 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -64.27 168.06 6.02 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-O 121.025 0.44 . . . . 0.0 110.541 177.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 93.5 p -146.35 178.9 7.9 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 123.152 0.581 . . . . 0.0 109.856 176.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 54.5 p -75.52 2.15 12.38 Favored 'General case' 0 N--CA 1.456 -0.145 0 C-N-CA 122.274 0.23 . . . . 0.0 111.212 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 70.9 m -81.51 152.23 27.41 Favored 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 123.012 0.525 . . . . 0.0 110.988 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 18.6 pt20 -133.2 0.27 3.39 Favored 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 123.32 0.648 . . . . 0.0 110.643 176.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 3.3 tppp? -152.88 136.29 15.86 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.48 1.112 . . . . 0.0 108.689 -178.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 19.4 tt -82.38 153.87 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 123.012 0.525 . . . . 0.0 110.18 178.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.7 m -74.75 130.99 40.46 Favored 'General case' 0 N--CA 1.455 -0.18 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -174.029 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 40.37 65.3 4.09 Favored Pre-proline 0 CA--C 1.532 0.259 0 C-N-CA 125.313 1.445 . . . . 0.0 112.799 172.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . 0.462 ' HA ' ' CE2' ' A' ' 125' ' ' TYR . 86.1 Cg_endo -73.85 -7.1 19.6 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 123.23 2.62 . . . . 0.0 112.335 179.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 64.4 -130.19 37.55 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 176.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -126.98 178.71 5.81 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.838 0.855 . . . . 0.0 110.466 -177.03 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.4 m -71.49 2.36 5.14 Favored 'General case' 0 CA--C 1.529 0.136 0 C-N-CA 123.155 0.582 . . . . 0.0 112.458 -178.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -145.57 147.72 32.39 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.311 0.645 . . . . 0.0 110.21 177.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -151.73 143.66 23.8 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.345 0.658 . . . . 0.0 109.845 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 38.4 t -78.86 122.67 26.39 Favored 'General case' 0 C--O 1.232 0.155 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 94.9 mtt180 -146.87 167.75 23.16 Favored 'General case' 0 CA--C 1.523 -0.081 0 C-N-CA 123.453 0.701 . . . . 0.0 110.509 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 66.2 m -68.26 -0.33 4.62 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 124.292 1.037 . . . . 0.0 111.994 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 4.0 t -124.52 11.75 4.72 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 C-N-CA 123.734 0.813 . . . . 0.0 109.753 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -134.54 22.92 3.68 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 123.125 0.57 . . . . 0.0 110.45 -178.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 C--O 1.249 1.069 0 CA-C-O 116.914 -1.517 . . . . 0.0 111.577 -179.444 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.113 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -73.46 -20.44 60.7 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 116.925 0.363 . . . . 0.0 110.52 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -150.14 139.12 21.01 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 174.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.409 ' CG ' ' N ' ' A' ' 88' ' ' ASP . 25.1 t80 51.09 -160.9 0.08 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 123.357 0.411 . . . . 0.0 111.216 -179.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . 0.409 ' N ' ' CG ' ' A' ' 87' ' ' TYR . 38.0 t70 -69.47 -26.44 64.57 Favored 'General case' 0 N--CA 1.454 -0.226 0 O-C-N 121.745 -0.597 . . . . 0.0 109.59 175.101 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -155.89 143.99 14.34 Favored Pre-proline 0 CA--C 1.532 0.268 0 C-N-CA 124.142 0.977 . . . . 0.0 109.08 174.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -78.79 -30.6 2.85 Favored 'Trans proline' 0 N--CA 1.455 -0.781 0 C-N-CA 122.945 2.43 . . . . 0.0 113.36 -176.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 4.7 p-80 -161.01 10.62 0.09 Allowed 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 113.197 0.814 . . . . 0.0 113.197 -175.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -77.45 171.29 15.12 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.273 0.488 . . . . 0.0 111.343 -176.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.4 p -138.0 154.88 74.66 Favored Pre-proline 0 C--O 1.232 0.139 0 C-N-CA 123.4 0.68 . . . . 0.0 109.879 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -76.09 -5.82 16.68 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 123.658 2.906 . . . . 0.0 112.119 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.41 34.89 9.85 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.332 0.653 . . . . 0.0 111.986 -178.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 66.2 m -61.9 158.24 44.75 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 124.088 0.955 . . . . 0.0 111.509 -177.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -69.53 1.36 4.35 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 124.138 3.225 . . . . 0.0 112.374 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.8 t -116.53 141.28 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.6 m -129.81 151.85 36.46 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 CA-C-O 120.92 0.391 . . . . 0.0 110.958 178.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.4 t-80 -100.93 135.05 42.99 Favored 'General case' 0 N--CA 1.457 -0.086 0 C-N-CA 124.068 0.947 . . . . 0.0 109.974 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -109.93 145.18 16.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.108 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 -177.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -141.67 163.7 32.21 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 123.602 0.761 . . . . 0.0 110.481 -177.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 25.56 56.15 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-O 119.452 -0.638 . . . . 0.0 113.611 172.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 67.8 mt -61.68 158.15 16.11 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.185 0.992 . . . . 0.0 110.186 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 12.4 pt -73.1 -39.94 57.74 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.104 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -173.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -172.78 -37.44 0.01 OUTLIER 'General case' 0 C--O 1.231 0.08 0 C-N-CA 123.243 0.617 . . . . 0.0 110.246 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.22 52.25 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -176.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 65.1 t -51.11 146.04 1.67 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.158 0.583 . . . . 0.0 110.082 178.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.4 m -95.74 163.69 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.131 0 CA-C-O 121.18 0.514 . . . . 0.0 111.47 -175.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -60.47 -28.02 68.01 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 123.27 0.628 . . . . 0.0 111.215 -178.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.79 -6.44 55.96 Favored 'General case' 0 CA--C 1.53 0.187 0 N-CA-C 112.294 0.479 . . . . 0.0 112.294 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -101.47 -31.03 11.09 Favored 'General case' 0 N--CA 1.457 -0.099 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 176.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 76.5 mt -71.36 -41.21 70.01 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.515 0.326 . . . . 0.0 110.654 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.5 p -77.56 -29.63 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 C-N-CA 121.278 -0.169 . . . . 0.0 110.915 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.2 mt-10 -85.87 -13.35 48.2 Favored 'General case' 0 N--CA 1.454 -0.225 0 O-C-N 122.006 -0.434 . . . . 0.0 111.365 -177.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.21 -15.15 16.09 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.463 0.542 . . . . 0.0 112.463 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.94 -7.21 13.17 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.522 0.601 . . . . 0.0 112.457 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -72.46 -5.55 37.51 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 118.662 0.665 . . . . 0.0 111.537 176.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -74.96 -16.13 60.65 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.493 0.317 . . . . 0.0 110.544 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.83 -17.21 21.32 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 122.537 0.335 . . . . 0.0 111.824 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.88 178.0 37.11 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.16 140.31 37.22 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 123.86 3.04 . . . . 0.0 110.821 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 71.5 mt -112.42 144.4 20.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 C-N-CA 122.993 0.517 . . . . 0.0 110.519 -178.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -102.77 -42.25 5.93 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.362 0.665 . . . . 0.0 111.05 -178.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -158.57 160.09 36.22 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-O 120.712 0.291 . . . . 0.0 111.275 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 84.9 t -143.97 147.6 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.053 0 C-N-CA 123.761 0.824 . . . . 0.0 109.841 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 7.3 p -148.0 154.57 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.134 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 176.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 9.5 p -136.93 151.45 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.07 0 CA-C-O 120.824 0.345 . . . . 0.0 110.948 -178.229 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -130.26 84.44 59.87 Favored Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.855 0.862 . . . . 0.0 109.004 179.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -59.54 -18.54 47.57 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.897 3.064 . . . . 0.0 112.779 -179.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -82.02 -5.8 58.65 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.08 0.552 . . . . 0.0 111.316 179.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -129.05 2.58 5.26 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 123.722 0.809 . . . . 0.0 111.461 178.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.4 tpp85 53.37 32.5 13.9 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 124.496 1.118 . . . . 0.0 112.0 -177.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -136.43 166.4 23.58 Favored 'General case' 0 CA--C 1.527 0.094 0 C-N-CA 123.144 0.578 . . . . 0.0 110.941 -176.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 171.4 17.3 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.88 0.472 . . . . 0.0 110.819 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.32 146.71 50.23 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 123.769 0.828 . . . . 0.0 109.797 178.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.8 t -136.64 131.96 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.231 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -112.23 116.11 29.9 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 56.8 m-85 -84.54 152.6 23.8 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.835 0.35 . . . . 0.0 110.481 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -73.08 -14.5 61.41 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.409 -178.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -147.2 151.34 36.57 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.696 0.798 . . . . 0.0 109.103 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.2 p -67.39 -19.85 25.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 O-C-N 122.29 -0.256 . . . . 0.0 111.484 -175.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 54.9 tp -75.08 -27.24 59.85 Favored 'General case' 0 N--CA 1.454 -0.236 0 O-C-N 121.986 -0.446 . . . . 0.0 110.498 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.91 -31.2 69.85 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.36 -29.99 33.89 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 116.956 0.378 . . . . 0.0 110.395 177.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.9 t -70.46 -26.48 63.66 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 122.716 0.406 . . . . 0.0 110.825 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -84.05 -20.3 32.92 Favored 'General case' 0 N--CA 1.454 -0.268 0 O-C-N 122.192 -0.318 . . . . 0.0 111.646 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.47 -29.1 26.31 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 118.125 0.42 . . . . 0.0 112.075 -175.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -89.63 -15.49 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -75.0 0.12 16.95 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.768 0.427 . . . . 0.0 111.038 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -120.17 -38.73 2.88 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.842 0.457 . . . . 0.0 110.852 177.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.29 -4.66 58.99 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.68 -4.13 58.34 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 122.103 -0.373 . . . . 0.0 111.506 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -141.66 -4.17 1.11 Allowed 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 122.609 0.364 . . . . 0.0 111.59 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 29.8 m-80 -146.29 170.57 16.49 Favored 'General case' 0 CA--C 1.528 0.118 0 C-N-CA 123.534 0.734 . . . . 0.0 109.972 -179.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -90.84 153.16 20.42 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 172.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.48 135.18 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -88.55 150.61 23.0 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 122.01 -0.431 . . . . 0.0 110.749 -178.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.1 mt -136.97 -39.1 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.789 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.18 29.28 3.71 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 123.085 0.554 . . . . 0.0 110.937 -177.051 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.48 5.02 85.29 Favored Glycine 0 CA--C 1.529 0.916 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 -176.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -130.41 152.28 80.01 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 124.266 1.026 . . . . 0.0 109.144 177.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -71.52 144.21 44.45 Favored 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.076 2.518 . . . . 0.0 111.825 -176.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -149.96 -176.11 5.31 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 124.826 1.25 . . . . 0.0 109.024 177.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -139.46 161.13 38.24 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.949 0.404 . . . . 0.0 111.67 -178.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.6 p -150.04 143.27 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.102 0 C-N-CA 123.411 0.684 . . . . 0.0 109.724 178.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -154.29 163.13 40.62 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.055 0.542 . . . . 0.0 109.989 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -63.31 164.31 9.15 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-O 120.904 0.383 . . . . 0.0 110.601 177.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 87.8 p -145.78 174.52 11.15 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 123.201 0.6 . . . . 0.0 109.766 176.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 57.8 p -77.35 -0.71 26.64 Favored 'General case' 0 C--O 1.232 0.152 0 C-N-CA 122.562 0.345 . . . . 0.0 111.132 178.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 49.4 m -77.31 150.1 35.26 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.285 0.634 . . . . 0.0 110.215 179.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -138.19 -3.85 1.74 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 122.795 0.438 . . . . 0.0 111.202 177.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -158.24 135.51 10.1 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.932 0.893 . . . . 0.0 108.857 -178.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 73.1 mt -93.15 147.85 5.15 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 175.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 39.6 m -75.45 141.31 43.16 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-O 120.429 0.157 . . . . 0.0 111.401 -176.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 70.0 ttt180 45.17 56.04 14.65 Favored Pre-proline 0 CA--C 1.535 0.394 0 C-N-CA 124.745 1.218 . . . . 0.0 112.539 177.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -80.45 5.04 6.36 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 123.605 2.87 . . . . 0.0 112.007 -177.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 80.55 6.16 89.48 Favored Glycine 0 CA--C 1.531 1.045 0 O-C-N 122.085 -0.384 . . . . 0.0 112.32 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -74.93 161.58 29.39 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 117.428 0.614 . . . . 0.0 110.683 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 88.7 p -140.21 163.67 32.13 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 123.093 0.557 . . . . 0.0 110.998 -178.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -109.58 7.62 24.68 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 123.214 0.606 . . . . 0.0 111.887 -178.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -145.35 157.99 43.92 Favored 'General case' 0 C--O 1.233 0.221 0 C-N-CA 122.845 0.458 . . . . 0.0 110.443 -179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 51.0 m -134.22 166.93 21.64 Favored 'General case' 0 C--O 1.232 0.167 0 C-N-CA 123.301 0.64 . . . . 0.0 110.591 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 11.4 tpp85 -148.98 163.32 37.84 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-O 120.523 0.201 . . . . 0.0 110.634 -178.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 25.4 m -82.13 7.54 13.25 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.161 0.584 . . . . 0.0 112.285 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 34.1 m -135.42 161.02 39.9 Favored 'Isoleucine or valine' 0 C--N 1.34 0.164 0 C-N-CA 123.082 0.553 . . . . 0.0 110.395 -179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 45.8 t30 -144.03 15.0 1.7 Allowed 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 122.836 0.454 . . . . 0.0 110.529 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 49.4 m . . . . . 0 C--O 1.252 1.198 0 CA-C-O 117.628 -1.177 . . . . 0.0 110.441 -178.534 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.178 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -86.49 -6.29 58.94 Favored 'General case' 0 CA--C 1.529 0.16 0 CA-C-N 117.124 0.462 . . . . 0.0 111.647 -178.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -70.06 -11.2 60.71 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.111 0.564 . . . . 0.0 111.414 -177.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -92.92 3.41 55.76 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.152 0.581 . . . . 0.0 111.256 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -105.06 11.34 33.43 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 123.671 0.789 . . . . 0.0 110.638 178.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 49.05 49.92 8.33 Favored Pre-proline 0 CA--C 1.533 0.316 0 C-N-CA 124.764 1.225 . . . . 0.0 113.128 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -73.43 -20.03 21.32 Favored 'Trans proline' 0 N--CA 1.452 -0.934 0 C-N-CA 123.527 2.818 . . . . 0.0 112.079 -176.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -147.9 10.96 0.93 Allowed 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 123.167 0.587 . . . . 0.0 111.262 -178.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.7 mtpt -91.26 167.14 12.53 Favored 'General case' 0 N--CA 1.456 -0.127 0 C-N-CA 123.161 0.584 . . . . 0.0 110.574 -179.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 53.1 p -133.29 153.12 80.47 Favored Pre-proline 0 C--N 1.334 -0.098 0 C-N-CA 123.345 0.658 . . . . 0.0 110.437 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -75.94 -7.76 18.52 Favored 'Trans proline' 0 N--CA 1.453 -0.91 0 C-N-CA 123.838 3.026 . . . . 0.0 111.855 178.329 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.08 34.75 8.76 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.343 0.657 . . . . 0.0 111.31 -177.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.438 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.4 p -78.23 161.39 70.57 Favored Pre-proline 0 N--CA 1.456 -0.164 0 C-N-CA 123.938 0.895 . . . . 0.0 111.729 -174.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.438 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 96.4 Cg_endo -71.26 3.05 3.77 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.903 3.069 . . . . 0.0 112.504 177.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.7 t -115.02 141.39 31.89 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.116 0 C-N-CA 122.989 0.515 . . . . 0.0 109.877 178.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 20.9 m -126.69 152.57 34.59 Favored 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 120.973 0.416 . . . . 0.0 110.241 177.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -107.7 141.01 39.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 124.079 0.952 . . . . 0.0 109.61 179.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 23.6 mm -111.23 143.82 20.34 Favored 'Isoleucine or valine' 0 C--O 1.232 0.146 0 C-N-CA 122.883 0.473 . . . . 0.0 110.116 -175.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 -142.38 159.26 42.59 Favored 'General case' 0 N--CA 1.457 -0.093 0 C-N-CA 123.092 0.557 . . . . 0.0 110.176 -177.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.03 24.87 58.91 Favored Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.358 -0.69 . . . . 0.0 113.198 174.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 72.6 mt -60.52 157.87 13.36 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 118.234 1.017 . . . . 0.0 110.163 177.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.2 pt -70.88 -43.35 76.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -173.248 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -172.4 -34.5 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.375 0.67 . . . . 0.0 110.749 -179.111 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.9 49.07 0.11 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.704 -0.559 . . . . 0.0 111.704 -175.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.1 t -51.09 146.54 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 123.387 0.675 . . . . 0.0 110.026 178.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.2 m -101.33 166.41 2.42 Favored 'Isoleucine or valine' 0 C--N 1.337 0.045 0 CA-C-O 121.211 0.529 . . . . 0.0 111.584 -175.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.39 -27.48 67.47 Favored 'General case' 0 N--CA 1.456 -0.131 0 C-N-CA 123.196 0.598 . . . . 0.0 111.152 -177.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.46 -5.03 51.35 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -177.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 77.7 m-20 -104.59 -30.86 9.72 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 175.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.6 mt -70.12 -38.41 75.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 122.506 0.322 . . . . 0.0 110.595 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.0 p -80.13 -29.63 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 CA-C-N 117.537 0.153 . . . . 0.0 110.731 -178.329 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.0 mm-40 -81.4 -13.91 57.75 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.28 -0.263 . . . . 0.0 111.321 -178.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -99.89 -25.97 14.16 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.2 mp -100.73 -9.76 21.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.921 0.711 . . . . 0.0 112.921 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -67.15 -8.63 32.55 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 118.604 0.638 . . . . 0.0 111.647 177.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -78.96 -14.62 59.1 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 122.663 0.385 . . . . 0.0 110.827 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -101.08 -18.31 16.29 Favored 'General case' 0 C--O 1.231 0.117 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -178.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.91 177.51 37.52 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -72.73 140.21 31.98 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 C-N-CA 124.268 3.312 . . . . 0.0 110.717 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 73.6 mt -110.07 146.69 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.194 0 C-N-CA 122.778 0.431 . . . . 0.0 110.3 -177.193 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.2 t -107.46 -40.16 5.43 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.158 0.583 . . . . 0.0 111.367 -177.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -159.52 158.44 31.83 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-O 120.739 0.304 . . . . 0.0 110.94 179.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 93.1 t -144.15 145.42 21.74 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.038 0 C-N-CA 123.924 0.89 . . . . 0.0 109.858 -178.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.3 p -148.31 152.74 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 175.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 12.4 p -130.22 156.58 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 CA-C-O 120.805 0.336 . . . . 0.0 111.156 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 48.6 mtt -130.45 78.14 74.73 Favored Pre-proline 0 C--O 1.232 0.168 0 C-N-CA 124.046 0.938 . . . . 0.0 109.54 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -59.62 -17.74 43.73 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 123.584 2.856 . . . . 0.0 113.048 -177.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.5 mtpt -89.52 -2.15 58.26 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 122.926 0.49 . . . . 0.0 111.807 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -130.84 0.39 4.3 Favored 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.652 0.781 . . . . 0.0 111.548 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.3 tpp85 55.14 33.98 21.63 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.019 0.928 . . . . 0.0 111.861 -176.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -134.7 168.21 19.43 Favored 'General case' 0 C--O 1.232 0.14 0 C-N-CA 123.479 0.712 . . . . 0.0 110.602 -177.043 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.74 172.24 18.27 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.39 176.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 41.3 mt -134.34 144.31 48.19 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.716 0.806 . . . . 0.0 109.468 177.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 77.9 t -137.0 131.29 46.24 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 177.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -113.44 120.26 40.44 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 58.7 m-85 -83.93 153.87 23.69 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.872 0.368 . . . . 0.0 110.361 -179.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -74.54 -12.58 60.51 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-O 120.907 0.384 . . . . 0.0 110.25 -178.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -149.54 152.48 35.62 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 123.843 0.857 . . . . 0.0 109.022 176.136 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.2 p -68.13 -20.43 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 O-C-N 122.031 -0.418 . . . . 0.0 111.657 -175.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.3 tp -71.96 -26.27 62.2 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.924 -0.485 . . . . 0.0 110.561 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.95 -31.47 64.45 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 178.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -84.42 -27.95 27.23 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 117.293 0.546 . . . . 0.0 110.555 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 30.1 t -77.89 -7.17 56.35 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 122.802 0.441 . . . . 0.0 110.602 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -107.14 -21.71 12.88 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 122.976 0.511 . . . . 0.0 110.754 179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.42 -28.01 31.61 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 -178.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -91.01 -18.98 7.27 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.138 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.7 t30 -71.34 -14.24 62.13 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.36 0.264 . . . . 0.0 110.763 -178.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -99.92 -36.79 9.28 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.568 0.347 . . . . 0.0 111.001 178.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -85.44 -6.43 59.21 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 112.832 0.678 . . . . 0.0 112.832 -176.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -78.64 -5.0 51.8 Favored 'General case' 0 CA--C 1.532 0.288 0 O-C-N 122.139 -0.351 . . . . 0.0 111.839 176.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -143.52 -3.59 0.91 Allowed 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.58 0.352 . . . . 0.0 111.901 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 -145.42 175.09 10.58 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.455 0.702 . . . . 0.0 109.948 -178.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . 0.472 ' H ' ' NE2' ' A' ' 156' ' ' GLN . 1.1 pm0 -96.94 152.68 18.47 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 173.162 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.17 134.44 63.65 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -178.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -89.55 148.91 23.11 Favored 'General case' 0 C--N 1.332 -0.17 0 O-C-N 122.193 -0.317 . . . . 0.0 110.71 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -136.01 -38.75 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.219 -176.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.37 29.45 3.63 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.112 0.565 . . . . 0.0 110.89 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.67 3.36 83.79 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -176.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -130.08 152.84 80.73 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 123.902 0.881 . . . . 0.0 108.968 177.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -72.11 145.97 45.45 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.306 2.671 . . . . 0.0 111.681 -176.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -150.48 -176.84 5.64 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 125.014 1.325 . . . . 0.0 108.475 177.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -137.84 160.02 40.43 Favored 'General case' 0 C--O 1.232 0.14 0 CA-C-O 120.885 0.374 . . . . 0.0 111.466 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.66 139.61 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 123.514 0.726 . . . . 0.0 110.174 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -159.98 150.7 18.98 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.445 0.698 . . . . 0.0 109.592 178.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -98.54 124.51 43.33 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 121.321 0.581 . . . . 0.0 111.801 178.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 27.5 t -166.46 150.04 7.25 Favored 'General case' 0 C--O 1.231 0.131 0 C-N-CA 122.926 0.49 . . . . 0.0 110.049 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 80.6 p 44.06 26.04 0.13 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 125.19 1.396 . . . . 0.0 114.291 177.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 67.1 p -149.48 149.63 31.08 Favored 'General case' 0 N--CA 1.456 -0.128 0 CA-C-O 120.914 0.388 . . . . 0.0 110.818 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.1 pt20 -150.36 -6.83 0.3 Allowed 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 116.187 -0.46 . . . . 0.0 112.215 176.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -158.96 137.36 10.77 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.752 0.821 . . . . 0.0 109.164 -178.106 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 66.2 mt -91.09 145.18 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 174.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.3 m -77.71 139.81 39.45 Favored 'General case' 0 C--N 1.335 -0.061 0 N-CA-C 111.56 0.208 . . . . 0.0 111.56 -177.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 28.5 mmt85 42.68 56.86 11.2 Favored Pre-proline 0 CA--C 1.534 0.346 0 C-N-CA 124.312 1.045 . . . . 0.0 112.625 177.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -77.75 56.88 5.81 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 124.316 3.344 . . . . 0.0 111.32 -177.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 81.49 9.73 85.4 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.511 -0.636 . . . . 0.0 111.511 -177.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -139.89 165.16 28.06 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.782 0.833 . . . . 0.0 109.505 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 80.1 p -119.85 164.8 15.48 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 123.058 0.543 . . . . 0.0 111.459 -177.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -74.04 154.02 39.41 Favored 'General case' 0 C--O 1.232 0.147 0 C-N-CA 122.71 0.404 . . . . 0.0 111.121 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -86.83 -2.19 58.38 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.009 0.524 . . . . 0.0 111.25 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 63.6 m -90.22 8.73 31.64 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 123.37 0.668 . . . . 0.0 111.73 -179.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 32.6 tpt180 -140.74 148.19 40.31 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.215 0.606 . . . . 0.0 110.303 -178.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 57.9 m -139.07 138.32 37.01 Favored 'General case' 0 N--CA 1.455 -0.218 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 177.024 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 10.4 m -148.8 163.33 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 C-N-CA 123.697 0.799 . . . . 0.0 108.999 -177.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -76.36 138.2 40.29 Favored 'General case' 0 N--CA 1.454 -0.271 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.7 m . . . . . 0 C--O 1.25 1.109 0 C-N-CA 124.422 1.089 . . . . 0.0 111.966 -179.882 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.096 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -145.91 149.88 35.06 Favored 'General case' 0 N--CA 1.456 -0.131 0 C-N-CA 123.239 0.615 . . . . 0.0 109.753 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 58.1 t30 -67.94 -15.27 63.54 Favored 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 111.748 0.277 . . . . 0.0 111.748 -174.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 -86.97 4.19 42.75 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.804 0.441 . . . . 0.0 111.471 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -108.35 10.22 27.63 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.495 0.718 . . . . 0.0 110.414 177.418 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 23.9 m-20 48.33 49.1 6.84 Favored Pre-proline 0 CA--C 1.533 0.29 0 C-N-CA 124.644 1.178 . . . . 0.0 112.775 -178.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -76.62 -12.99 18.31 Favored 'Trans proline' 0 N--CA 1.457 -0.663 0 C-N-CA 123.926 3.084 . . . . 0.0 113.538 -172.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -146.74 18.81 1.3 Allowed 'General case' 0 C--O 1.231 0.1 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -174.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -93.17 6.0 49.54 Favored 'General case' 0 CA--C 1.529 0.167 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -176.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 30.1 p -74.75 152.03 86.96 Favored Pre-proline 0 CA--C 1.529 0.139 0 O-C-N 122.121 -0.362 . . . . 0.0 110.693 178.751 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -78.78 -6.19 15.08 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 124.086 3.19 . . . . 0.0 112.314 -179.472 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.41 34.47 12.04 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.564 0.746 . . . . 0.0 112.112 -177.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.1 m -70.97 159.0 86.92 Favored Pre-proline 0 CA--C 1.53 0.196 0 C-N-CA 123.446 0.698 . . . . 0.0 112.368 -176.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -73.05 -0.98 9.84 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 124.024 3.149 . . . . 0.0 111.769 174.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.5 t -112.0 142.49 24.21 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.181 0 C-N-CA 123.431 0.692 . . . . 0.0 109.461 178.154 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 21.3 m -128.29 152.41 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 C-N-CA 122.835 0.454 . . . . 0.0 110.171 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 19.7 t-80 -106.15 136.41 45.89 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.971 0.909 . . . . 0.0 109.359 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.7 mm -106.07 142.4 19.14 Favored 'Isoleucine or valine' 0 C--O 1.232 0.139 0 C-N-CA 122.859 0.464 . . . . 0.0 109.859 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -141.67 160.44 40.17 Favored 'General case' 0 C--O 1.231 0.1 0 C-N-CA 123.231 0.612 . . . . 0.0 110.334 -178.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.16 23.11 61.82 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-O 119.455 -0.636 . . . . 0.0 113.13 174.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 63.8 mt -60.02 158.45 10.97 Favored 'General case' 0 CA--C 1.529 0.158 0 CA-C-N 118.151 0.975 . . . . 0.0 109.708 177.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 13.7 pt -73.37 -43.6 56.02 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.035 0 O-C-N 122.275 -0.266 . . . . 0.0 111.686 -174.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.72 -34.83 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.14 0.576 . . . . 0.0 110.371 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -173.82 48.46 0.15 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -176.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.2 t -49.48 141.34 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 C-N-CA 122.835 0.454 . . . . 0.0 109.809 177.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 34.4 m -92.21 163.44 2.25 Favored 'Isoleucine or valine' 0 C--O 1.23 0.04 0 CA-C-O 121.157 0.504 . . . . 0.0 111.624 -174.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -61.83 -26.31 68.04 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.224 -177.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.23 -6.39 57.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 122.661 0.384 . . . . 0.0 112.0 -178.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -96.8 -29.71 13.59 Favored 'General case' 0 CA--C 1.527 0.063 0 O-C-N 121.743 -0.598 . . . . 0.0 109.822 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 93.0 mt -74.01 -37.51 64.36 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.284 0.234 . . . . 0.0 110.92 -178.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.7 p -77.99 -29.96 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.323 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 89.6 mt-10 -85.55 -13.07 50.03 Favored 'General case' 0 CA--C 1.53 0.206 0 O-C-N 122.023 -0.423 . . . . 0.0 111.709 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -109.2 -9.18 15.03 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.8 mt -118.51 -7.4 10.63 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 118.815 0.734 . . . . 0.0 112.265 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.0 pt20 -74.0 -5.35 40.86 Favored 'General case' 0 C--N 1.34 0.157 0 CA-C-N 118.794 0.725 . . . . 0.0 110.342 175.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.2 mm-40 -77.6 -4.48 46.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.587 0.755 . . . . 0.0 111.095 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -111.53 -15.91 13.4 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.318 0.647 . . . . 0.0 111.272 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.84 176.73 36.02 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -72.14 140.19 33.83 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.0 3.133 . . . . 0.0 110.571 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 69.2 mt -109.86 148.92 13.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 122.844 0.457 . . . . 0.0 110.457 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.3 t -111.05 -41.26 4.25 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.251 0.62 . . . . 0.0 111.784 -177.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -158.1 158.09 34.05 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 117.839 0.291 . . . . 0.0 111.462 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 67.1 t -144.05 146.91 20.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.085 0.954 . . . . 0.0 109.699 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -148.95 151.42 13.09 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.9 t -128.07 149.5 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.073 0 CA-C-O 120.612 0.244 . . . . 0.0 111.32 -175.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.5 mpp? -130.44 83.07 63.54 Favored Pre-proline 0 CA--C 1.531 0.234 0 C-N-CA 123.982 0.913 . . . . 0.0 108.564 177.184 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -69.41 -11.7 31.89 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 123.482 2.788 . . . . 0.0 111.577 -175.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -81.58 -10.5 59.43 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 122.95 0.5 . . . . 0.0 110.81 177.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -126.35 6.47 7.01 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.576 0.75 . . . . 0.0 111.646 -178.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 55.19 31.0 15.56 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 123.982 0.913 . . . . 0.0 112.432 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -136.79 167.34 21.63 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 123.149 0.58 . . . . 0.0 111.103 -175.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.05 172.84 16.25 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.978 0.511 . . . . 0.0 110.319 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 33.0 mt -133.03 146.55 51.83 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 123.308 0.643 . . . . 0.0 110.054 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.82 133.15 41.23 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -117.08 121.88 42.56 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 46.7 m-85 -87.08 156.28 19.8 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 121.067 0.461 . . . . 0.0 110.555 -178.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -76.3 -13.57 60.15 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.14 -179.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -146.74 150.91 36.29 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.575 0.75 . . . . 0.0 109.319 177.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.7 p -69.33 -21.8 25.24 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -174.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.6 tp -75.91 -29.77 58.53 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.85 -0.531 . . . . 0.0 110.203 -179.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.83 -28.22 73.25 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 -25.77 33.48 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 117.05 0.425 . . . . 0.0 110.962 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.8 t -79.55 -34.09 41.31 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -68.69 -21.28 64.43 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-O 119.712 -0.185 . . . . 0.0 110.87 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.39 -27.62 27.51 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -178.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.3 t -92.58 -23.03 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.06 0 O-C-N 122.154 -0.342 . . . . 0.0 110.888 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 79.2 m-20 -71.62 -7.77 49.91 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.105 -0.372 . . . . 0.0 111.472 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -106.29 -34.43 7.47 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.677 0.391 . . . . 0.0 110.477 176.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.41 -10.39 59.07 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.91 -0.56 56.74 Favored 'General case' 0 CA--C 1.532 0.276 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -136.87 -11.4 1.76 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 122.677 0.391 . . . . 0.0 111.71 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -153.25 170.34 20.83 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -87.6 155.13 20.1 Favored 'General case' 0 N--CA 1.456 -0.159 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 175.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.3 135.56 60.18 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -177.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -90.36 150.54 21.84 Favored 'General case' 0 N--CA 1.455 -0.2 0 O-C-N 121.952 -0.467 . . . . 0.0 110.772 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.2 mt -137.43 -39.02 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.457 -0.076 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.869 -176.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.57 28.84 3.61 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 123.139 0.576 . . . . 0.0 110.908 -177.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.9 5.64 83.43 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -176.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -131.21 153.14 81.61 Favored Pre-proline 0 N--CA 1.453 -0.275 0 C-N-CA 124.175 0.99 . . . . 0.0 109.152 177.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -72.26 145.9 44.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 123.251 2.634 . . . . 0.0 111.701 -176.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.11 -177.25 6.05 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 124.778 1.231 . . . . 0.0 108.839 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -139.64 160.39 39.97 Favored 'General case' 0 CA--C 1.528 0.109 0 CA-C-O 120.976 0.417 . . . . 0.0 111.357 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.5 p -148.59 139.51 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 C-N-CA 123.339 0.655 . . . . 0.0 110.213 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -159.05 150.97 20.86 Favored 'General case' 0 N--CA 1.455 -0.21 0 C-N-CA 123.227 0.611 . . . . 0.0 109.858 178.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -98.04 124.57 42.59 Favored 'General case' 0 N--CA 1.457 -0.117 0 CA-C-O 121.193 0.52 . . . . 0.0 111.918 177.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 28.4 t -165.75 148.53 7.57 Favored 'General case' 0 N--CA 1.456 -0.156 0 C-N-CA 122.841 0.457 . . . . 0.0 110.374 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 81.8 p 45.27 25.0 0.17 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 125.407 1.483 . . . . 0.0 114.324 176.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 71.2 p -148.95 149.91 32.01 Favored 'General case' 0 N--CA 1.457 -0.124 0 O-C-N 121.909 -0.495 . . . . 0.0 111.185 -179.088 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -149.72 -6.49 0.34 Allowed 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 176.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -159.87 137.38 9.75 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 123.543 0.737 . . . . 0.0 109.045 -177.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 66.9 mt -89.07 145.06 7.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.197 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 174.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.5 m -80.9 141.15 34.85 Favored 'General case' 0 C--O 1.231 0.106 0 N-CA-C 111.749 0.278 . . . . 0.0 111.749 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 82.5 mtp180 44.71 52.74 10.45 Favored Pre-proline 0 CA--C 1.533 0.291 0 C-N-CA 124.577 1.151 . . . . 0.0 113.181 177.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -75.81 176.58 9.83 Favored 'Trans proline' 0 N--CA 1.451 -1.004 0 C-N-CA 123.133 2.556 . . . . 0.0 110.918 -179.292 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 84.17 134.86 2.81 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 24.6 m-20 -72.84 164.34 26.75 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 123.319 0.648 . . . . 0.0 111.122 178.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 88.4 p -77.71 167.75 21.06 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 122.944 0.497 . . . . 0.0 110.954 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -125.7 1.8 7.49 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.106 0.562 . . . . 0.0 111.711 -178.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -150.59 155.52 39.58 Favored 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.102 0.561 . . . . 0.0 110.112 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 78.6 p -144.4 152.88 41.31 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.619 0.768 . . . . 0.0 109.255 177.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 10.0 ttm180 -152.43 164.86 36.69 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 120.719 0.295 . . . . 0.0 111.257 -175.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 41.4 m -92.08 10.48 29.01 Favored 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 123.183 0.593 . . . . 0.0 111.9 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 28.0 m -139.25 166.63 21.43 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 C-N-CA 123.41 0.684 . . . . 0.0 109.901 -178.018 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -74.09 133.37 42.85 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 63.6 m . . . . . 0 C--O 1.252 1.191 0 CA-C-O 117.642 -1.17 . . . . 0.0 110.531 -178.62 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.158 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -150.02 165.36 32.95 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.193 0.597 . . . . 0.0 110.812 -177.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.5 t30 -149.06 169.37 20.82 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 123.285 0.634 . . . . 0.0 109.894 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -75.11 -12.3 60.28 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 123.673 0.789 . . . . 0.0 111.711 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -150.15 155.26 39.48 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 123.416 0.686 . . . . 0.0 109.653 178.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -75.38 136.36 71.94 Favored Pre-proline 0 CA--C 1.533 0.313 0 N-CA-C 110.404 -0.221 . . . . 0.0 110.404 -176.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -69.64 -24.05 30.64 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 123.604 2.869 . . . . 0.0 114.708 -174.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 2.8 p-80 -157.16 -3.69 0.1 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 115.672 1.73 . . . . 0.0 115.672 -174.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -81.61 157.23 24.78 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 119.585 1.084 . . . . 0.0 110.996 178.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 40.2 p -84.22 153.76 62.92 Favored Pre-proline 0 C--O 1.231 0.13 0 C-N-CA 123.13 0.572 . . . . 0.0 111.011 -178.363 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -79.55 -8.76 14.86 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 124.142 3.228 . . . . 0.0 111.556 177.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.79 35.03 14.34 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 123.711 0.804 . . . . 0.0 112.293 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.2 m -76.01 163.47 66.52 Favored Pre-proline 0 CA--C 1.531 0.244 0 C-N-CA 123.289 0.636 . . . . 0.0 112.577 -175.605 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -65.4 -7.43 15.92 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.983 3.122 . . . . 0.0 113.382 177.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -109.85 141.43 25.17 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 123.032 0.533 . . . . 0.0 109.993 -178.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 28.0 m -125.61 156.29 35.12 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.242 0.617 . . . . 0.0 110.091 176.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.3 t-80 -116.41 131.61 56.9 Favored 'General case' 0 N--CA 1.455 -0.184 0 C-N-CA 123.875 0.87 . . . . 0.0 109.421 -178.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.442 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.8 mp -106.17 144.82 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -174.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 92.5 mtt180 -141.93 163.08 33.85 Favored 'General case' 0 N--CA 1.46 0.063 0 C-N-CA 123.557 0.743 . . . . 0.0 110.392 -177.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.32 23.27 61.19 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-O 119.213 -0.771 . . . . 0.0 113.017 174.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 70.9 mt -59.86 156.27 14.66 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.436 1.118 . . . . 0.0 110.141 178.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.6 pt -70.83 -41.23 77.32 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -172.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -173.92 -34.39 0.01 OUTLIER 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.413 0.685 . . . . 0.0 110.648 -179.056 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.91 48.09 0.12 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.8 t -51.39 143.14 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 177.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -97.78 165.51 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.064 0 CA-C-O 121.35 0.595 . . . . 0.0 111.886 -174.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -60.16 -26.24 66.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.537 0.735 . . . . 0.0 111.334 -178.289 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.88 -6.88 58.25 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -177.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -97.7 -28.98 13.65 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 118.181 0.446 . . . . 0.0 110.16 177.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 89.4 mt -74.35 -36.09 63.61 Favored 'General case' 0 N--CA 1.455 -0.191 0 O-C-N 122.255 -0.278 . . . . 0.0 110.979 -178.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 10.9 p -79.1 -30.28 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.275 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.189 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -82.59 -15.39 52.39 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 119.423 -0.322 . . . . 0.0 111.474 -178.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.87 -12.53 15.17 Favored 'General case' 0 C--N 1.339 0.132 0 N-CA-C 113.11 0.781 . . . . 0.0 113.11 -179.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.4 mt -116.46 -9.32 11.47 Favored 'General case' 0 C--O 1.231 0.115 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -69.19 -6.88 31.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 118.809 0.731 . . . . 0.0 111.424 176.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -76.68 -15.13 59.88 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.089 -0.382 . . . . 0.0 110.649 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -97.24 -17.77 19.63 Favored 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 122.558 0.343 . . . . 0.0 111.454 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.68 177.05 36.21 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.688 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -70.54 139.91 38.59 Favored 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 124.077 3.185 . . . . 0.0 110.768 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 77.7 mt -110.33 146.31 15.71 Favored 'Isoleucine or valine' 0 C--O 1.232 0.133 0 C-N-CA 122.765 0.426 . . . . 0.0 110.205 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -107.73 -40.2 5.36 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.383 0.673 . . . . 0.0 111.348 -177.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -157.73 158.83 36.08 Favored 'General case' 0 C--N 1.338 0.096 0 CA-C-O 120.559 0.219 . . . . 0.0 111.342 -179.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 59.0 t -144.05 145.27 22.0 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.128 0 C-N-CA 124.175 0.99 . . . . 0.0 109.549 179.241 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 10.8 p -149.34 152.46 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 34.2 t -130.41 150.8 35.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 CA-C-O 120.675 0.274 . . . . 0.0 111.251 -175.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -130.4 81.36 68.3 Favored Pre-proline 0 CA--C 1.531 0.238 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 177.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -59.97 -17.88 46.98 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.945 3.097 . . . . 0.0 112.862 -177.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 mtmt -83.48 -5.82 59.27 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.876 0.47 . . . . 0.0 111.326 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -126.55 2.71 6.88 Favored 'General case' 0 C--N 1.338 0.068 0 C-N-CA 123.733 0.813 . . . . 0.0 111.112 179.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.3 tpp85 54.14 32.73 16.41 Favored 'General case' 0 CA--C 1.531 0.238 0 C-N-CA 124.035 0.934 . . . . 0.0 111.865 -176.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -137.18 165.3 26.43 Favored 'General case' 0 CA--C 1.528 0.108 0 C-N-CA 123.119 0.567 . . . . 0.0 110.956 -176.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -150.89 169.92 20.55 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 122.953 0.501 . . . . 0.0 110.569 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.8 mt -131.65 145.6 51.75 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.509 0.724 . . . . 0.0 109.824 179.32 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 95.4 t -138.74 134.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -116.16 121.8 43.17 Favored 'General case' 0 N--CA 1.452 -0.374 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -86.39 155.85 20.42 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.027 0.442 . . . . 0.0 110.576 -179.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -74.86 -13.14 60.52 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.558 -178.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -147.73 152.87 38.5 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 123.883 0.873 . . . . 0.0 109.038 177.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.97 -21.61 25.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -175.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.8 tp -74.79 -29.85 61.24 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 122.108 -0.37 . . . . 0.0 110.692 -179.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.25 -28.58 71.25 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 179.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.17 -30.37 27.86 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 117.079 0.439 . . . . 0.0 110.898 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.8 t -75.21 -28.73 60.08 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 57.1 t30 -78.33 -21.21 49.91 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 122.321 0.248 . . . . 0.0 110.722 179.382 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.22 -31.25 30.38 Favored 'General case' 0 N--CA 1.455 -0.196 0 O-C-N 122.301 -0.249 . . . . 0.0 111.505 -178.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 60.1 t -88.36 -21.97 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.072 0 O-C-N 122.252 -0.28 . . . . 0.0 110.556 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -66.9 -17.05 64.71 Favored 'General case' 0 CA--C 1.532 0.262 0 O-C-N 122.194 -0.316 . . . . 0.0 110.96 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 48.6 t80 -100.05 -36.54 9.32 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 122.189 0.196 . . . . 0.0 110.645 177.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -78.59 -11.04 59.95 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 -176.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -89.29 1.42 55.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.578 0.351 . . . . 0.0 111.847 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -134.44 -15.64 2.15 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.76 0.424 . . . . 0.0 111.588 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -153.26 168.2 26.81 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.494 0.718 . . . . 0.0 109.186 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -82.78 155.54 24.17 Favored 'General case' 0 N--CA 1.457 -0.092 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 175.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -121.61 135.48 61.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -177.46 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -89.67 151.83 21.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.102 -0.374 . . . . 0.0 110.789 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 50.0 mt -138.14 -39.06 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.11 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.894 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.69 29.41 3.53 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 122.876 0.47 . . . . 0.0 111.041 -176.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.87 4.86 84.42 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -176.254 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -131.59 152.08 79.8 Favored Pre-proline 0 N--CA 1.454 -0.231 0 C-N-CA 124.115 0.966 . . . . 0.0 108.95 177.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -71.54 146.55 49.84 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 123.58 2.854 . . . . 0.0 111.88 -176.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.8 -175.72 5.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 124.651 1.18 . . . . 0.0 108.811 178.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -138.82 159.44 42.12 Favored 'General case' 0 N--CA 1.457 -0.099 0 CA-C-O 120.644 0.259 . . . . 0.0 111.005 -179.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.9 p -149.26 139.11 16.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 C-N-CA 123.341 0.657 . . . . 0.0 110.247 178.736 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -159.9 152.94 21.77 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -103.5 132.37 49.82 Favored 'General case' 0 CA--C 1.527 0.089 0 CA-C-O 121.385 0.612 . . . . 0.0 112.607 178.468 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 38.1 t -166.09 145.63 6.12 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.639 178.045 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 3.1 m 49.44 28.25 2.34 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.81 1.244 . . . . 0.0 113.457 173.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 34.6 t -151.36 152.11 32.67 Favored 'General case' 0 N--CA 1.458 -0.068 0 O-C-N 121.632 -0.668 . . . . 0.0 111.037 179.13 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -149.11 -3.73 0.43 Allowed 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 123.395 0.678 . . . . 0.0 111.752 176.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -160.57 133.76 6.64 Favored 'General case' 0 N--CA 1.456 -0.169 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -176.435 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 70.8 mt -82.68 150.36 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.112 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 176.567 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 44.6 m -74.45 132.14 41.66 Favored 'General case' 0 N--CA 1.457 -0.096 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 -176.091 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . 0.447 ' N ' ' HD3' ' A' ' 177' ' ' PRO . 98.8 mtt180 39.44 56.75 6.31 Favored Pre-proline 0 CA--C 1.534 0.364 0 C-N-CA 125.495 1.518 . . . . 0.0 114.101 175.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . 0.447 ' HD3' ' N ' ' A' ' 176' ' ' ARG . 23.3 Cg_exo -68.18 -13.77 38.83 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.518 2.145 . . . . 0.0 112.237 -179.344 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -81.0 3.06 78.4 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-O 119.611 -0.549 . . . . 0.0 112.727 -178.288 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -66.88 146.92 53.89 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 118.059 0.93 . . . . 0.0 110.817 -179.428 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.4 m -141.35 14.89 2.2 Favored 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 123.652 0.781 . . . . 0.0 111.34 -177.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -73.47 150.25 41.77 Favored 'General case' 0 N--CA 1.455 -0.206 0 O-C-N 122.097 -0.377 . . . . 0.0 111.009 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -142.53 165.72 26.63 Favored 'General case' 0 N--CA 1.457 -0.121 0 C-N-CA 123.594 0.758 . . . . 0.0 110.324 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 65.6 p -79.8 -3.17 46.53 Favored 'General case' 0 C--O 1.232 0.169 0 C-N-CA 123.129 0.572 . . . . 0.0 112.151 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 24.0 tpt180 -148.2 148.26 30.34 Favored 'General case' 0 CA--C 1.523 -0.071 0 C-N-CA 123.077 0.551 . . . . 0.0 109.835 -178.021 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 51.1 m -82.58 132.55 35.19 Favored 'General case' 0 N--CA 1.456 -0.171 0 N-CA-C 110.0 -0.371 . . . . 0.0 110.0 177.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 17.7 m -146.36 161.29 10.35 Favored 'Isoleucine or valine' 0 C--O 1.231 0.124 0 C-N-CA 123.496 0.719 . . . . 0.0 110.238 -178.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -142.86 15.04 1.93 Allowed 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 122.788 0.435 . . . . 0.0 110.791 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.5 m . . . . . 0 C--O 1.251 1.133 0 CA-C-O 117.278 -1.344 . . . . 0.0 109.887 -178.184 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.261 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -138.95 154.95 48.37 Favored 'General case' 0 C--O 1.23 0.078 0 C-N-CA 123.213 0.605 . . . . 0.0 110.538 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 56.53 176.85 0.04 OUTLIER 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 124.614 1.165 . . . . 0.0 113.186 -179.479 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -91.81 0.2 57.5 Favored 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 123.252 0.621 . . . . 0.0 111.087 178.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -150.12 162.19 40.9 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.149 0.98 . . . . 0.0 108.619 178.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 50.7 m-20 -62.41 120.7 61.36 Favored Pre-proline 0 CA--C 1.533 0.295 0 O-C-N 122.181 -0.325 . . . . 0.0 110.651 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -75.81 -28.26 8.04 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.364 2.709 . . . . 0.0 112.239 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 4.0 p-80 -157.41 0.72 0.11 Allowed 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -178.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -87.06 167.42 14.21 Favored 'General case' 0 C--O 1.23 0.064 0 CA-C-N 118.286 0.494 . . . . 0.0 110.558 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 54.9 p -124.51 154.63 69.65 Favored Pre-proline 0 C--O 1.231 0.096 0 C-N-CA 123.283 0.633 . . . . 0.0 110.63 -178.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -74.28 -4.0 14.72 Favored 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 123.734 2.956 . . . . 0.0 112.434 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.16 36.02 11.48 Favored 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.218 0.607 . . . . 0.0 111.446 -177.075 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.438 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.3 p -67.92 161.13 69.87 Favored Pre-proline 0 CA--C 1.531 0.249 0 C-N-CA 123.799 0.84 . . . . 0.0 111.586 -177.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.438 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 90.1 Cg_endo -70.49 5.7 1.87 Allowed 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 123.865 3.043 . . . . 0.0 112.119 177.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 88.3 t -117.85 139.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.117 0 C-N-CA 123.153 0.581 . . . . 0.0 109.864 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.2 m -131.37 146.83 33.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-O 120.911 0.386 . . . . 0.0 110.807 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 23.1 t-80 -96.58 137.41 35.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.845 0.858 . . . . 0.0 110.165 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.0 mp -111.77 145.82 17.45 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 123.552 0.741 . . . . 0.0 109.392 -177.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.3 mtt180 -142.56 164.94 28.75 Favored 'General case' 0 C--O 1.228 -0.04 0 C-N-CA 123.655 0.782 . . . . 0.0 110.724 -177.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.44 25.26 57.29 Favored Glycine 0 CA--C 1.525 0.711 0 CA-C-O 119.575 -0.569 . . . . 0.0 113.343 173.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 44.7 mt -60.33 156.5 15.61 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.987 0.894 . . . . 0.0 109.983 178.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 10.7 pt -71.84 -39.93 68.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 O-C-N 122.268 -0.27 . . . . 0.0 111.088 -175.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -172.92 -36.0 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.08 0 C-N-CA 123.612 0.765 . . . . 0.0 109.985 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 173.92 56.5 0.05 OUTLIER Glycine 0 C--N 1.336 0.582 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -177.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.4 m -53.21 156.62 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 123.003 0.521 . . . . 0.0 110.782 178.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 111' ' ' ALA . 6.5 t -78.03 155.51 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.16 0 CA-C-O 121.032 0.444 . . . . 0.0 110.39 -176.341 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -60.76 -25.81 66.77 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 122.638 0.375 . . . . 0.0 110.265 175.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.42 ' H ' HG12 ' A' ' 109' ' ' VAL . . . -81.32 -8.27 59.71 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.079 0.551 . . . . 0.0 111.62 -179.15 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -85.7 -32.79 21.74 Favored 'General case' 0 CA--C 1.531 0.233 0 O-C-N 121.828 -0.545 . . . . 0.0 110.238 -179.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.1 mp -77.49 -30.94 53.28 Favored 'General case' 0 N--CA 1.456 -0.142 0 O-C-N 122.323 -0.236 . . . . 0.0 111.18 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.8 p -78.25 -31.76 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-N 118.18 0.445 . . . . 0.0 110.04 -178.55 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -82.23 -17.57 45.61 Favored 'General case' 0 N--CA 1.454 -0.258 0 O-C-N 122.217 -0.302 . . . . 0.0 111.082 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -103.47 -10.34 18.62 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 113.363 0.875 . . . . 0.0 113.363 -179.29 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -117.6 -8.55 10.92 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.606 0.639 . . . . 0.0 112.21 -179.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -67.54 -6.88 21.95 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 118.663 0.665 . . . . 0.0 111.874 175.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -76.59 -13.05 60.1 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.956 -0.465 . . . . 0.0 110.634 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.8 m-85 -100.82 -16.9 17.13 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 122.567 0.347 . . . . 0.0 111.606 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.15 177.64 36.27 Favored Glycine 0 CA--C 1.527 0.834 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -72.25 140.44 33.94 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.81 3.007 . . . . 0.0 110.52 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.2 mt -111.13 147.31 15.23 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.085 0 C-N-CA 122.75 0.42 . . . . 0.0 110.246 -177.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 26.8 t -107.63 -41.56 5.0 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.076 0.551 . . . . 0.0 111.656 -177.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 46.1 t80 -159.65 160.51 34.33 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 117.623 0.192 . . . . 0.0 111.258 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 88.9 t -143.65 146.51 21.04 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 C-N-CA 124.122 0.969 . . . . 0.0 109.829 -178.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.8 p -144.19 151.4 16.12 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 174.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 60.4 t -133.36 149.73 31.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.088 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -176.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 72.1 mtm -134.41 86.66 34.69 Favored Pre-proline 0 N--CA 1.454 -0.245 0 C-N-CA 123.612 0.765 . . . . 0.0 109.284 -179.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -70.35 -11.55 30.26 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 123.061 2.507 . . . . 0.0 111.649 -177.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -81.11 -10.34 59.67 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 123.062 0.545 . . . . 0.0 110.7 176.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -128.88 3.18 5.36 Favored 'General case' 0 C--N 1.34 0.155 0 C-N-CA 123.73 0.812 . . . . 0.0 111.353 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.7 tpp85 53.05 34.05 16.29 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.335 1.054 . . . . 0.0 111.964 -176.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -137.84 168.55 19.47 Favored 'General case' 0 C--N 1.334 -0.08 0 C-N-CA 123.402 0.681 . . . . 0.0 110.282 -177.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.98 170.86 19.37 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 123.139 0.576 . . . . 0.0 110.262 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 14.1 tp -137.54 142.87 41.38 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 92.0 t -137.8 141.55 38.56 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.103 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -176.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -120.79 124.76 45.86 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 123.43 0.692 . . . . 0.0 109.219 177.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -89.16 153.23 21.12 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 120.919 0.39 . . . . 0.0 110.303 178.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -73.32 -14.39 61.29 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.409 -177.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -146.75 151.25 36.86 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 176.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -67.49 -20.65 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 C-N-CA 122.302 0.241 . . . . 0.0 111.558 -175.162 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 53.4 tp -75.92 -25.79 56.32 Favored 'General case' 0 N--CA 1.456 -0.165 0 O-C-N 122.09 -0.381 . . . . 0.0 110.485 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.14 -30.31 65.41 Favored Glycine 0 C--N 1.339 0.722 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.484 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.69 -31.55 28.53 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.025 0.412 . . . . 0.0 110.34 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 47.5 t -73.75 -19.67 60.72 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 122.705 0.402 . . . . 0.0 110.974 179.242 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 61.8 t30 -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 122.694 0.398 . . . . 0.0 111.315 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.36 -31.52 22.92 Favored 'General case' 0 N--CA 1.456 -0.17 0 O-C-N 122.169 -0.332 . . . . 0.0 111.386 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.4 t -85.06 -13.53 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.161 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -72.52 -1.95 17.87 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.295 0.638 . . . . 0.0 111.212 178.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 53.1 t80 -124.02 -36.75 2.66 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 122.827 0.451 . . . . 0.0 110.914 178.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -79.59 -8.7 59.35 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -176.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -87.41 -0.89 57.45 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.721 0.408 . . . . 0.0 111.986 178.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -138.73 -12.56 1.3 Allowed 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.606 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -151.88 163.21 39.71 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 9.3 pm0 -76.59 159.71 30.06 Favored 'General case' 0 N--CA 1.455 -0.207 0 O-C-N 122.06 -0.4 . . . . 0.0 110.027 177.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -126.74 136.17 61.59 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.057 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -89.2 152.73 21.43 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.092 -0.38 . . . . 0.0 110.654 -178.161 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 47.2 mt -137.67 -39.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.177 -177.652 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.22 28.94 3.72 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 122.819 0.448 . . . . 0.0 110.986 -177.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.1 5.61 80.11 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 -176.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -131.35 152.98 81.49 Favored Pre-proline 0 N--CA 1.453 -0.319 0 C-N-CA 124.228 1.011 . . . . 0.0 109.01 177.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -71.44 145.34 47.52 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.357 2.705 . . . . 0.0 111.751 -176.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.38 -174.93 4.98 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.945 1.298 . . . . 0.0 108.668 177.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -139.35 160.42 39.87 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 120.989 0.423 . . . . 0.0 111.28 -178.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 6.1 p -149.13 144.66 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.178 0 C-N-CA 123.66 0.784 . . . . 0.0 109.415 178.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -155.32 166.28 34.05 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 123.163 0.585 . . . . 0.0 110.047 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 82.1 m-85 -61.26 165.69 4.34 Favored 'General case' 0 N--CA 1.457 -0.106 0 CA-C-O 121.038 0.446 . . . . 0.0 110.73 178.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 38.1 t -138.26 163.89 30.63 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.166 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 59.7 p -75.35 -7.25 53.49 Favored 'General case' 0 N--CA 1.457 -0.109 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 174.559 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 35.6 t -78.17 157.24 29.47 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 123.67 0.788 . . . . 0.0 110.371 176.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -141.3 -2.37 1.27 Allowed 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 123.386 0.674 . . . . 0.0 111.131 177.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -161.2 133.66 6.03 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 123.51 0.724 . . . . 0.0 109.333 -177.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 27.1 mm -76.36 150.49 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.143 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 175.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 61.6 p -83.71 132.47 34.86 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-O 120.917 0.389 . . . . 0.0 110.817 179.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 45.21 53.12 11.54 Favored Pre-proline 0 CA--C 1.536 0.405 0 C-N-CA 124.55 1.14 . . . . 0.0 113.527 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -76.86 -7.64 17.54 Favored 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 123.64 2.893 . . . . 0.0 111.775 -178.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 172.44 -1.78 0.03 OUTLIER Glycine 0 CA--C 1.529 0.957 0 CA-C-O 119.751 -0.472 . . . . 0.0 112.426 -178.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -146.21 164.06 33.46 Favored 'General case' 0 CA--C 1.53 0.212 0 CA-C-N 117.713 0.757 . . . . 0.0 109.758 178.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.2 m -66.07 143.03 57.58 Favored 'General case' 0 CA--C 1.528 0.11 0 CA-C-O 120.964 0.412 . . . . 0.0 110.886 -178.506 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -155.78 160.62 40.42 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 123.258 0.623 . . . . 0.0 110.233 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -142.13 23.33 2.03 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.116 0.566 . . . . 0.0 110.645 178.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 32.6 m 54.17 35.32 22.2 Favored 'General case' 0 C--O 1.232 0.176 0 C-N-CA 123.421 0.688 . . . . 0.0 112.327 -179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -124.98 177.39 6.08 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 123.427 0.691 . . . . 0.0 110.97 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.6 m -126.85 12.65 7.31 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 123.495 0.718 . . . . 0.0 111.857 -178.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 33.3 m -135.93 169.45 20.63 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 C-N-CA 123.616 0.766 . . . . 0.0 110.694 -177.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -135.43 17.87 3.37 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 122.904 0.481 . . . . 0.0 110.747 178.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 45.8 m . . . . . 0 C--O 1.251 1.143 0 CA-C-O 117.514 -1.231 . . . . 0.0 110.719 -179.629 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.166 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -146.48 149.85 34.46 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 122.937 0.495 . . . . 0.0 110.155 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -142.88 165.48 27.25 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 123.466 0.707 . . . . 0.0 109.573 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 77.8 m-85 -73.99 142.9 45.79 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 176.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 27.0 t0 57.55 170.31 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.351 1.06 . . . . 0.0 111.864 -173.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -76.81 132.61 71.25 Favored Pre-proline 0 N--CA 1.454 -0.24 0 O-C-N 121.524 -0.735 . . . . 0.0 111.001 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -83.83 157.24 13.73 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 123.834 3.023 . . . . 0.0 109.875 176.104 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.3 p-80 49.27 14.82 0.1 Allowed 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 115.926 1.824 . . . . 0.0 115.926 175.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 56.9 mttp -102.63 162.51 12.87 Favored 'General case' 0 C--N 1.338 0.094 0 CA-C-N 119.007 0.821 . . . . 0.0 110.383 176.177 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 39.1 p -133.51 153.86 80.54 Favored Pre-proline 0 C--O 1.232 0.146 0 C-N-CA 123.427 0.691 . . . . 0.0 110.462 -178.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -76.22 -4.61 15.31 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.813 3.009 . . . . 0.0 112.24 -179.357 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.29 35.42 10.6 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.162 0.585 . . . . 0.0 111.502 -177.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.433 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 78.3 p -68.04 160.52 74.03 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 124.128 0.971 . . . . 0.0 111.627 -176.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 81.8 Cg_endo -70.18 4.53 2.31 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 124.295 3.33 . . . . 0.0 112.373 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 84.8 t -117.95 142.63 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 178.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 34.2 m -131.55 151.59 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.164 0 CA-C-O 121.114 0.483 . . . . 0.0 110.635 178.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 17.3 t-80 -101.89 136.12 42.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.253 1.021 . . . . 0.0 109.993 178.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.13 145.02 17.17 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 C-N-CA 123.465 0.706 . . . . 0.0 109.116 -176.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -142.26 165.14 28.24 Favored 'General case' 0 CA--C 1.526 0.054 0 C-N-CA 123.543 0.737 . . . . 0.0 110.339 -176.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.61 24.08 63.45 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 119.37 -0.683 . . . . 0.0 113.499 173.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 73.0 mt -61.38 157.96 15.61 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.282 1.041 . . . . 0.0 109.977 177.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.21 -40.14 74.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 O-C-N 122.411 -0.181 . . . . 0.0 111.416 -175.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -171.52 -42.17 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.479 0.712 . . . . 0.0 109.961 179.177 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -172.72 54.33 0.16 Allowed Glycine 0 C--N 1.337 0.625 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -175.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.5 t -50.21 144.59 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 C-N-CA 123.299 0.639 . . . . 0.0 109.567 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.5 m -91.94 164.03 2.16 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-O 121.092 0.472 . . . . 0.0 111.613 -175.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -61.76 -27.69 68.91 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 122.885 0.474 . . . . 0.0 110.858 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.1 -4.58 51.0 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -178.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -103.83 -30.37 10.41 Favored 'General case' 0 CA--C 1.528 0.105 0 CA-C-N 118.379 0.536 . . . . 0.0 109.8 175.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 75.9 mt -71.48 -41.53 69.23 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.555 0.342 . . . . 0.0 110.368 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.84 -30.04 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 121.154 -0.218 . . . . 0.0 111.041 -177.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -84.67 -14.88 47.22 Favored 'General case' 0 N--CA 1.456 -0.16 0 O-C-N 122.116 -0.365 . . . . 0.0 111.777 -177.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.16 -15.66 16.61 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 178.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.2 mt -110.92 -8.26 14.51 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -71.77 -6.17 39.45 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 118.736 0.698 . . . . 0.0 111.401 175.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -77.04 -13.82 59.91 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 122.591 0.356 . . . . 0.0 110.323 178.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -99.05 -17.57 18.18 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 122.518 0.327 . . . . 0.0 111.742 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.21 176.69 36.28 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.79 139.48 33.64 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 124.106 3.204 . . . . 0.0 110.464 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 75.1 mt -110.87 145.95 16.56 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 C-N-CA 122.735 0.414 . . . . 0.0 110.352 -177.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -105.62 -40.44 5.76 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.226 0.61 . . . . 0.0 111.287 -178.169 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -159.07 159.2 34.34 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-O 120.788 0.328 . . . . 0.0 110.895 178.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -144.05 145.71 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 C-N-CA 123.755 0.822 . . . . 0.0 109.619 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.23 152.14 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.11 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.061 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 10.3 p -134.5 153.69 35.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 122.815 0.446 . . . . 0.0 111.105 -176.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 18.8 ptp -136.03 82.83 35.54 Favored Pre-proline 0 CA--C 1.532 0.267 0 C-N-CA 124.001 0.92 . . . . 0.0 109.606 179.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -58.45 -21.2 52.67 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 124.255 3.304 . . . . 0.0 113.131 -178.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.3 mtpt -78.78 -1.15 33.35 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.718 0.407 . . . . 0.0 111.293 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 22.6 tptm -131.66 -0.75 3.88 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.359 1.064 . . . . 0.0 110.481 179.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 2.1 tpp180 57.75 28.95 16.64 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.947 0.899 . . . . 0.0 112.51 -177.004 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -134.32 169.98 16.4 Favored 'General case' 0 C--N 1.339 0.143 0 C-N-CA 122.808 0.443 . . . . 0.0 111.226 -175.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -152.63 171.25 18.46 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.211 0.604 . . . . 0.0 110.758 178.224 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 29.4 mt -132.96 146.04 51.43 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.917 0.887 . . . . 0.0 109.673 178.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.8 t -138.85 133.42 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -114.64 120.75 41.19 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 177.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -86.7 153.58 21.63 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 120.958 0.409 . . . . 0.0 110.598 -179.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -74.7 -13.34 60.6 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.517 -177.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -147.08 152.41 38.47 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 123.82 0.848 . . . . 0.0 108.995 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -67.71 -21.85 27.74 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -175.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.3 tp -72.75 -27.1 61.82 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.137 -0.352 . . . . 0.0 110.414 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.59 -30.35 66.6 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.18 -34.36 25.97 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 117.105 0.452 . . . . 0.0 110.292 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.1 t -72.41 -20.94 61.34 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 122.487 0.315 . . . . 0.0 110.876 178.441 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -94.29 4.59 53.67 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 122.939 0.496 . . . . 0.0 111.475 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -108.46 -26.57 10.39 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 117.967 0.349 . . . . 0.0 111.87 179.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 45.3 t -89.43 -18.89 7.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 CA-C-N 117.8 0.273 . . . . 0.0 110.506 178.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -73.32 1.44 9.53 Favored 'General case' 0 CA--C 1.532 0.277 0 O-C-N 121.979 -0.451 . . . . 0.0 111.787 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 55.3 t80 -119.08 -34.67 3.82 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 123.045 0.538 . . . . 0.0 110.825 178.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -87.84 -3.18 58.96 Favored 'General case' 0 CA--C 1.533 0.314 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -90.94 -2.16 57.75 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.597 0.359 . . . . 0.0 111.417 177.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.14 -5.52 1.65 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.045 0.538 . . . . 0.0 111.528 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -154.56 173.93 15.64 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.841 0.856 . . . . 0.0 108.864 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 16.5 pt20 -93.07 155.58 17.41 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 175.121 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -122.53 135.18 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -178.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 71.0 m-85 -89.48 151.7 21.85 Favored 'General case' 0 N--CA 1.455 -0.183 0 O-C-N 122.195 -0.316 . . . . 0.0 110.552 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 46.0 mt -137.71 -39.01 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.144 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.13 -176.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -136.17 30.59 2.99 Favored 'General case' 0 CA--C 1.53 0.179 0 C-N-CA 123.042 0.537 . . . . 0.0 110.823 -176.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.66 4.86 84.95 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -176.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -131.17 151.98 79.82 Favored Pre-proline 0 N--CA 1.455 -0.211 0 C-N-CA 123.994 0.918 . . . . 0.0 109.106 177.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_endo -71.29 145.57 48.8 Favored 'Trans proline' 0 N--CA 1.45 -1.072 0 C-N-CA 123.694 2.929 . . . . 0.0 111.749 -177.169 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.67 -176.38 5.59 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.565 1.146 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -139.05 159.38 42.28 Favored 'General case' 0 CA--C 1.527 0.082 0 CA-C-O 120.969 0.414 . . . . 0.0 111.271 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 5.7 p -148.45 142.34 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.481 0.713 . . . . 0.0 109.483 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -155.64 163.05 40.44 Favored 'General case' 0 N--CA 1.455 -0.178 0 C-N-CA 123.2 0.6 . . . . 0.0 110.186 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -64.35 165.83 9.08 Favored 'General case' 0 N--CA 1.456 -0.144 0 O-C-N 122.205 -0.309 . . . . 0.0 110.376 176.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 95.9 p -145.94 177.15 9.16 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 122.763 0.425 . . . . 0.0 110.024 177.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 13.2 m -70.27 -9.2 55.25 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.264 0.225 . . . . 0.0 110.811 178.379 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 33.6 t -79.57 152.46 30.09 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 122.677 0.391 . . . . 0.0 110.867 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -139.97 -0.85 1.64 Allowed 'General case' 0 CA--C 1.529 0.144 0 C-N-CA 123.166 0.586 . . . . 0.0 110.819 175.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -159.83 130.1 5.57 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.651 0.781 . . . . 0.0 109.065 -178.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 81.2 mt -84.39 144.42 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.141 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 174.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 46.6 m -81.38 139.03 35.55 Favored 'General case' 0 N--CA 1.457 -0.098 0 N-CA-C 112.003 0.372 . . . . 0.0 112.003 -174.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 25.1 mtp-105 42.48 56.36 10.62 Favored Pre-proline 0 CA--C 1.533 0.315 0 C-N-CA 124.876 1.27 . . . . 0.0 113.109 176.305 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -72.16 156.58 55.33 Favored 'Trans proline' 0 N--CA 1.451 -0.976 0 C-N-CA 123.05 2.5 . . . . 0.0 110.432 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 70.76 6.25 58.93 Favored Glycine 0 CA--C 1.53 0.998 0 CA-C-O 119.717 -0.49 . . . . 0.0 112.753 179.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -74.42 160.8 30.51 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 117.864 0.832 . . . . 0.0 111.228 -178.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 82.9 p -148.52 163.0 38.5 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 123.22 0.608 . . . . 0.0 110.587 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -98.95 -8.98 24.68 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 122.709 0.403 . . . . 0.0 111.356 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -149.62 153.28 36.81 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 122.859 0.463 . . . . 0.0 110.433 -178.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 67.0 m -142.08 159.34 42.42 Favored 'General case' 0 C--O 1.231 0.124 0 C-N-CA 123.586 0.754 . . . . 0.0 110.478 -179.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -132.37 162.99 29.7 Favored 'General case' 0 CA--C 1.528 0.113 0 C-N-CA 123.228 0.611 . . . . 0.0 109.924 -178.138 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 28.2 m -78.3 5.98 9.27 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 122.991 0.516 . . . . 0.0 111.934 179.18 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 35.2 m -136.77 165.19 28.9 Favored 'Isoleucine or valine' 0 C--N 1.338 0.09 0 C-N-CA 123.386 0.675 . . . . 0.0 110.659 -178.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 65.6 m-20 -97.66 -2.6 41.08 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.965 0.506 . . . . 0.0 111.641 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 65.8 m . . . . . 0 C--O 1.25 1.115 0 CA-C-O 117.426 -1.273 . . . . 0.0 110.324 -179.104 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.276 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -147.8 146.89 29.32 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 123.275 0.63 . . . . 0.0 109.837 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -142.65 -6.86 0.88 Allowed 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 122.437 0.295 . . . . 0.0 111.344 -179.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -147.0 174.53 11.44 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 123.67 0.788 . . . . 0.0 109.453 -178.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -88.07 -7.12 57.45 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.464 0.305 . . . . 0.0 111.135 177.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -151.32 49.43 0.58 Allowed Pre-proline 0 CA--C 1.534 0.352 0 C-N-CA 123.22 0.608 . . . . 0.0 112.426 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -71.16 -15.22 31.96 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 123.366 2.711 . . . . 0.0 112.282 -175.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -149.23 14.61 0.89 Allowed 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 111.897 0.332 . . . . 0.0 111.897 -177.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -91.21 161.98 14.84 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 122.732 0.413 . . . . 0.0 110.86 -178.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 14.2 p -82.58 154.42 68.51 Favored Pre-proline 0 C--O 1.231 0.124 0 C-N-CA 122.864 0.466 . . . . 0.0 110.875 178.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -78.19 -11.59 16.13 Favored 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.788 2.992 . . . . 0.0 112.069 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 48.97 35.01 6.06 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.399 0.679 . . . . 0.0 111.192 -176.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.428 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 57.8 p -73.35 160.68 81.95 Favored Pre-proline 0 CA--C 1.533 0.327 0 C-N-CA 123.936 0.894 . . . . 0.0 112.139 -174.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 91.2 Cg_endo -72.7 2.46 5.25 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 124.306 3.337 . . . . 0.0 112.649 179.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.2 t -121.88 140.92 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.137 0 CA-C-N 118.42 0.555 . . . . 0.0 109.655 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.21 154.37 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 CA-C-O 121.385 0.612 . . . . 0.0 110.728 178.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -105.73 141.81 36.53 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.208 1.003 . . . . 0.0 109.514 -179.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 20.7 mm -110.26 144.05 19.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 C-N-CA 123.04 0.536 . . . . 0.0 110.142 -176.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 42.4 mtm105 -141.24 159.4 42.29 Favored 'General case' 0 CA--C 1.527 0.063 0 C-N-CA 123.492 0.717 . . . . 0.0 110.315 -178.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.41 25.03 59.79 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-O 119.552 -0.582 . . . . 0.0 113.366 173.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 53.9 mt -59.55 156.24 13.77 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 118.098 0.949 . . . . 0.0 109.482 176.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.8 pt -70.31 -37.96 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.135 0 N-CA-C 111.383 0.142 . . . . 0.0 111.383 -174.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -172.74 -35.53 0.01 OUTLIER 'General case' 0 N--CA 1.457 -0.081 0 C-N-CA 123.954 0.901 . . . . 0.0 109.648 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 170.48 55.97 0.04 OUTLIER Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -176.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 17.8 m -53.21 151.72 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 117.236 0.518 . . . . 0.0 110.501 178.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 26.8 m -87.18 166.45 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.082 0 CA-C-O 121.314 0.578 . . . . 0.0 110.809 -177.232 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -60.3 -25.21 65.59 Favored 'General case' 0 CA--C 1.528 0.124 0 C-N-CA 123.002 0.521 . . . . 0.0 110.698 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.89 -6.35 53.99 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 122.811 0.444 . . . . 0.0 112.038 -178.745 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 79.4 m-20 -97.34 -33.11 11.55 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 118.371 0.532 . . . . 0.0 109.733 176.201 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.47 -40.76 66.71 Favored 'General case' 0 N--CA 1.453 -0.298 0 C-N-CA 122.308 0.243 . . . . 0.0 110.83 -177.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.08 -30.06 15.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 O-C-N 122.158 -0.339 . . . . 0.0 110.855 -176.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.7 mm-40 -81.67 -18.22 45.28 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 117.822 0.283 . . . . 0.0 111.616 -178.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.35 -14.37 16.95 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -179.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -113.9 -7.43 13.17 Favored 'General case' 0 CA--C 1.53 0.174 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -178.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.0 pt20 -71.49 -5.84 36.01 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 118.666 0.666 . . . . 0.0 111.735 175.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 12.6 tp10 -76.58 -14.3 60.01 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 122.962 0.505 . . . . 0.0 110.677 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -98.71 -17.01 18.77 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.56 0.344 . . . . 0.0 111.562 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 162.91 176.67 35.2 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -71.12 140.31 37.36 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 123.935 3.09 . . . . 0.0 110.631 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 72.4 mt -110.16 146.4 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.103 0 C-N-CA 122.863 0.465 . . . . 0.0 110.4 -178.006 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.8 t -108.26 -39.93 5.32 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 123.279 0.631 . . . . 0.0 111.62 -177.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -157.78 158.13 34.66 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 120.57 0.224 . . . . 0.0 111.04 178.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.5 t -145.01 146.36 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.079 0 C-N-CA 123.642 0.777 . . . . 0.0 109.507 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.28 153.24 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 175.352 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 11.1 p -133.7 151.74 33.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.118 0 CA-C-O 120.806 0.336 . . . . 0.0 111.191 -176.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 19.3 ptp -136.24 84.89 28.54 Favored Pre-proline 0 CA--C 1.529 0.149 0 C-N-CA 123.739 0.816 . . . . 0.0 109.159 179.691 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -69.5 -12.31 33.1 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.386 2.724 . . . . 0.0 111.666 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -77.93 -5.04 49.82 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 122.683 0.393 . . . . 0.0 111.018 176.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -132.79 5.17 3.92 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 123.645 0.778 . . . . 0.0 111.213 179.13 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 10.5 tpp85 54.27 35.72 23.44 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.292 1.037 . . . . 0.0 112.343 -177.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -137.54 169.83 17.12 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.132 0.573 . . . . 0.0 111.039 -176.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.44 172.82 17.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.112 0.565 . . . . 0.0 110.494 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.4 mt -132.92 146.22 51.6 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.9 0.88 . . . . 0.0 109.374 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 89.8 t -138.36 133.03 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -116.26 121.68 42.74 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 123.578 0.751 . . . . 0.0 109.192 178.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 44.3 m-85 -88.5 155.52 19.61 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.052 0.453 . . . . 0.0 110.547 -178.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -75.77 -13.49 60.3 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.475 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -145.76 152.82 40.17 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.691 0.796 . . . . 0.0 109.097 177.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.8 p -69.55 -21.84 24.9 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.115 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -175.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 58.7 tp -77.44 -29.51 52.89 Favored 'General case' 0 N--CA 1.455 -0.223 0 O-C-N 122.003 -0.436 . . . . 0.0 110.418 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.27 -31.09 73.94 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.15 -32.03 33.86 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 116.984 0.392 . . . . 0.0 110.534 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 46.6 t -70.6 -29.72 66.2 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 122.076 0.15 . . . . 0.0 110.628 178.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -75.84 -21.0 57.7 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.194 -0.316 . . . . 0.0 111.247 179.18 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -81.31 -28.19 34.7 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 117.971 0.35 . . . . 0.0 111.617 -177.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 33.3 t -92.16 -19.66 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 O-C-N 122.382 -0.199 . . . . 0.0 110.688 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -71.34 -11.69 61.04 Favored 'General case' 0 CA--C 1.534 0.327 0 O-C-N 122.117 -0.364 . . . . 0.0 110.888 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -104.88 -34.05 8.18 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 122.942 0.497 . . . . 0.0 110.764 178.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -83.71 -7.24 59.52 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.651 0.611 . . . . 0.0 112.651 -177.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -84.84 -2.51 57.84 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 178.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -141.47 -3.87 1.15 Allowed 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 122.829 0.452 . . . . 0.0 111.946 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 54.1 t30 -154.68 165.23 37.21 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 123.303 0.641 . . . . 0.0 109.456 -178.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.5 pm0 -85.14 158.3 20.43 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.04 135.72 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.142 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.058 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 75.2 m-85 -89.78 152.97 21.03 Favored 'General case' 0 N--CA 1.457 -0.123 0 O-C-N 122.04 -0.413 . . . . 0.0 110.862 -178.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.2 mt -137.29 -41.0 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.227 -0.101 0 C-N-CA 122.669 0.388 . . . . 0.0 110.755 -177.137 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.92 29.91 3.73 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.817 0.447 . . . . 0.0 110.944 -177.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.05 4.24 81.96 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 -176.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -130.31 151.81 79.14 Favored Pre-proline 0 N--CA 1.455 -0.223 0 C-N-CA 124.14 0.976 . . . . 0.0 109.053 177.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -70.69 146.04 53.4 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 123.526 2.817 . . . . 0.0 112.038 -176.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.35 -176.21 5.49 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.267 1.427 . . . . 0.0 108.902 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -138.99 161.51 37.17 Favored 'General case' 0 N--CA 1.457 -0.086 0 CA-C-O 120.943 0.402 . . . . 0.0 111.521 -179.196 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.0 p -150.09 141.55 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.842 0.857 . . . . 0.0 109.751 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -160.84 160.04 30.6 Favored 'General case' 0 N--CA 1.458 -0.074 0 C-N-CA 123.333 0.653 . . . . 0.0 109.747 178.373 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -63.76 159.84 18.5 Favored 'General case' 0 CA--C 1.53 0.18 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.061 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 10.7 t -149.51 47.13 0.96 Allowed 'General case' 0 CA--C 1.53 0.188 0 O-C-N 122.168 -0.333 . . . . 0.0 111.549 -178.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 63.3 p 49.84 23.96 1.17 Allowed 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 124.823 1.249 . . . . 0.0 113.835 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 42.7 t -106.17 154.07 21.22 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 123.376 0.67 . . . . 0.0 109.622 178.08 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -135.91 -3.54 2.27 Favored 'General case' 0 CA--C 1.528 0.103 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 178.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -157.7 132.98 8.87 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.246 0.618 . . . . 0.0 109.47 -178.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 78.2 mt -84.48 146.93 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 173.712 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 75.7 p -76.57 141.12 41.26 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 121.015 0.436 . . . . 0.0 111.943 -175.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 34.8 ttp-105 41.87 58.3 9.86 Favored Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 125.032 1.333 . . . . 0.0 112.93 176.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -75.78 -7.16 18.25 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 123.589 2.859 . . . . 0.0 111.304 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 78.64 4.91 88.12 Favored Glycine 0 CA--C 1.528 0.904 0 CA-C-O 119.61 -0.55 . . . . 0.0 113.158 176.029 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -137.81 -11.13 1.55 Allowed 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 118.352 1.076 . . . . 0.0 112.371 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 81.2 p -157.55 169.18 25.27 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 118.268 0.486 . . . . 0.0 111.304 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -152.13 157.35 41.44 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.665 0.786 . . . . 0.0 109.903 178.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -153.03 -7.03 0.18 Allowed 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 78.0 p -92.35 -11.47 34.95 Favored 'General case' 0 C--N 1.34 0.192 0 O-C-N 121.923 -0.486 . . . . 0.0 112.185 -177.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 13.3 tpp85 -157.61 170.35 22.6 Favored 'General case' 0 CA--C 1.528 0.106 0 C-N-CA 123.079 0.552 . . . . 0.0 109.906 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 73.4 p -78.96 0.64 26.71 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.94 0.496 . . . . 0.0 111.4 176.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 33.6 m -138.47 174.3 10.55 Favored 'Isoleucine or valine' 0 C--O 1.231 0.102 0 C-N-CA 124.023 0.929 . . . . 0.0 110.423 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 52.3 p-10 -119.18 9.47 11.76 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.574 0.749 . . . . 0.0 111.608 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.3 m . . . . . 0 C--O 1.251 1.133 0 CA-C-O 117.741 -1.123 . . . . 0.0 111.062 -179.639 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.118 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -148.0 152.1 36.87 Favored 'General case' 0 N--CA 1.457 -0.122 0 C-N-CA 122.889 0.476 . . . . 0.0 109.821 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -69.12 -13.12 62.25 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -176.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 66.1 m-85 -95.31 5.73 50.91 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.114 0.566 . . . . 0.0 111.398 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -107.21 10.58 29.91 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 123.317 0.647 . . . . 0.0 110.993 179.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 52.3 m-20 48.67 54.64 16.36 Favored Pre-proline 0 CA--C 1.534 0.339 0 C-N-CA 124.263 1.025 . . . . 0.0 112.58 -179.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -67.59 -25.29 40.92 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 123.764 2.976 . . . . 0.0 111.967 -176.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 2.9 p-80 -155.77 13.47 0.34 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.469 0.707 . . . . 0.0 110.874 179.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 57.2 mtpt -93.61 166.48 12.22 Favored 'General case' 0 CA--C 1.528 0.122 0 C-N-CA 123.949 0.899 . . . . 0.0 110.441 -175.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 35.0 p -135.86 153.41 77.12 Favored Pre-proline 0 C--O 1.231 0.084 0 C-N-CA 123.2 0.6 . . . . 0.0 110.628 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -79.12 -7.54 15.24 Favored 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 124.031 3.154 . . . . 0.0 111.953 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.95 33.9 12.64 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 123.701 0.8 . . . . 0.0 112.008 -178.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.1 m -69.73 159.77 82.56 Favored Pre-proline 0 CA--C 1.529 0.16 0 C-N-CA 123.663 0.785 . . . . 0.0 112.224 -177.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -72.35 -1.52 10.3 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 123.92 3.08 . . . . 0.0 112.073 175.606 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 95.4 t -113.42 139.38 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 123.215 0.606 . . . . 0.0 109.707 178.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.2 m -125.17 159.49 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 C-N-CA 122.928 0.491 . . . . 0.0 110.316 178.417 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -114.55 135.65 53.89 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 123.834 0.854 . . . . 0.0 109.687 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 21.8 mm -106.74 143.88 16.76 Favored 'Isoleucine or valine' 0 C--O 1.23 0.068 0 C-N-CA 122.888 0.475 . . . . 0.0 110.365 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 72.1 mtm-85 -143.64 163.5 33.05 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 123.368 0.667 . . . . 0.0 110.523 -178.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 78.84 22.27 66.69 Favored Glycine 0 CA--C 1.527 0.794 0 CA-C-O 119.572 -0.571 . . . . 0.0 113.148 174.046 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.48 156.08 16.95 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 118.173 0.986 . . . . 0.0 110.041 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.1 pt -70.97 -41.46 76.99 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.112 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -173.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -172.2 -35.9 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.228 0.611 . . . . 0.0 110.437 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -175.86 50.5 0.12 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.648 -0.581 . . . . 0.0 111.648 -177.329 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 88.1 t -50.16 143.09 2.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.419 0.688 . . . . 0.0 109.8 177.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 33.8 m -94.48 164.7 2.05 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 121.229 0.538 . . . . 0.0 111.73 -174.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -61.22 -25.87 67.35 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.431 0.692 . . . . 0.0 111.224 -178.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.42 -6.3 57.85 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -177.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -97.75 -29.06 13.59 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 118.222 0.465 . . . . 0.0 110.282 177.136 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 98.0 mt -74.02 -35.9 64.41 Favored 'General case' 0 N--CA 1.452 -0.325 0 O-C-N 122.401 -0.187 . . . . 0.0 110.93 -179.094 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.05 -31.47 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.203 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.363 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.6 mm-40 -81.55 -16.56 51.34 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 119.565 -0.255 . . . . 0.0 111.596 -178.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -105.95 -13.36 15.51 Favored 'General case' 0 CA--C 1.53 0.205 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.4 mt -116.1 -6.13 11.92 Favored 'General case' 0 N--CA 1.461 0.094 0 CA-C-N 118.483 0.583 . . . . 0.0 112.479 -178.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -72.44 -6.41 43.4 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.678 0.672 . . . . 0.0 110.26 175.004 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -77.33 -3.89 42.33 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 123.923 0.889 . . . . 0.0 111.059 179.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -112.85 -16.49 12.71 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.006 0.522 . . . . 0.0 111.282 179.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 164.48 175.78 35.62 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -71.35 140.77 37.54 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 123.812 3.008 . . . . 0.0 110.564 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 72.3 mt -110.13 147.05 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 122.822 0.449 . . . . 0.0 110.572 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.7 t -109.53 -41.15 4.66 Favored 'General case' 0 N--CA 1.456 -0.173 0 C-N-CA 123.206 0.603 . . . . 0.0 111.564 -176.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -158.06 158.03 34.0 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 117.666 0.212 . . . . 0.0 111.261 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.7 t -143.89 147.42 19.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 C-N-CA 123.932 0.893 . . . . 0.0 109.591 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 12.0 p -149.53 151.52 12.8 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.032 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 175.407 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.95 152.59 36.24 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 C-N-CA 122.437 0.295 . . . . 0.0 110.899 -175.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 21.2 ptp -138.58 78.76 31.07 Favored Pre-proline 0 CA--C 1.534 0.33 0 C-N-CA 123.675 0.79 . . . . 0.0 109.741 177.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.57 -18.43 47.15 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.89 3.06 . . . . 0.0 113.306 -177.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 22.9 tptm -71.66 -12.28 61.26 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 122.8 0.44 . . . . 0.0 110.873 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -126.69 4.55 6.73 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.703 0.801 . . . . 0.0 111.286 179.273 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 55.31 34.98 23.97 Favored 'General case' 0 CA--C 1.533 0.288 0 C-N-CA 124.095 0.958 . . . . 0.0 112.191 -176.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -134.03 169.02 17.75 Favored 'General case' 0 N--CA 1.457 -0.113 0 C-N-CA 123.054 0.541 . . . . 0.0 110.843 -177.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.81 171.8 19.01 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.167 176.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 43.2 mt -131.86 146.44 52.12 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 123.522 0.729 . . . . 0.0 109.825 178.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 97.6 t -138.28 131.75 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -114.92 122.84 47.53 Favored 'General case' 0 N--CA 1.454 -0.275 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 177.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 47.1 m-85 -87.26 155.35 20.11 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.41 -179.26 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -76.37 -11.65 59.93 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.246 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.73 152.92 38.58 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 123.928 0.891 . . . . 0.0 109.282 177.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -69.9 -21.33 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 O-C-N 122.224 -0.298 . . . . 0.0 111.702 -175.106 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 57.2 tp -75.85 -28.97 58.42 Favored 'General case' 0 N--CA 1.454 -0.231 0 O-C-N 121.865 -0.522 . . . . 0.0 110.626 -179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.03 -29.51 73.52 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.12 -28.12 29.66 Favored 'General case' 0 N--CA 1.453 -0.324 0 CA-C-N 116.99 0.395 . . . . 0.0 110.74 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.6 t -74.06 -30.89 62.61 Favored 'General case' 0 N--CA 1.454 -0.251 0 O-C-N 122.244 -0.285 . . . . 0.0 110.467 179.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -76.24 -21.67 56.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 O-C-N 122.268 -0.27 . . . . 0.0 111.249 179.329 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.94 -33.31 26.79 Favored 'General case' 0 N--CA 1.456 -0.14 0 CA-C-N 117.778 0.263 . . . . 0.0 111.396 -177.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.15 -22.67 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 O-C-N 122.308 -0.245 . . . . 0.0 110.535 179.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -68.79 -16.56 63.83 Favored 'General case' 0 CA--C 1.531 0.234 0 O-C-N 121.943 -0.473 . . . . 0.0 111.01 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -99.03 -34.79 10.27 Favored 'General case' 0 N--CA 1.456 -0.159 0 C-N-CA 122.695 0.398 . . . . 0.0 110.691 178.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -82.21 -10.76 59.02 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 112.656 0.613 . . . . 0.0 112.656 -177.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.54 -1.01 52.78 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 178.019 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -139.61 -7.48 1.29 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 57.0 t30 -155.02 165.39 36.88 Favored 'General case' 0 CA--C 1.53 0.203 0 C-N-CA 123.257 0.623 . . . . 0.0 109.363 -178.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.68 157.57 23.29 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 173.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -122.43 135.99 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -178.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 64.1 m-85 -90.29 151.11 21.64 Favored 'General case' 0 N--CA 1.457 -0.082 0 O-C-N 122.109 -0.369 . . . . 0.0 110.92 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 52.5 mt -137.14 -38.89 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.12 -176.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.65 29.07 3.25 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.149 0.58 . . . . 0.0 111.012 -176.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.82 4.66 82.18 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 -176.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.0 m-70 -131.53 151.98 79.64 Favored Pre-proline 0 C--O 1.234 0.253 0 C-N-CA 124.322 1.049 . . . . 0.0 109.322 177.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_endo -70.9 146.57 53.46 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 123.522 2.814 . . . . 0.0 111.702 -177.179 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.71 -177.72 6.28 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 125.205 1.402 . . . . 0.0 109.104 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -137.54 159.7 41.23 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.061 0.458 . . . . 0.0 111.792 -177.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.5 p -151.23 139.98 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 123.347 0.659 . . . . 0.0 110.149 179.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 47.0 t30 -162.06 154.95 20.18 Favored 'General case' 0 CA--C 1.528 0.132 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -106.03 136.82 45.03 Favored 'General case' 0 CA--C 1.528 0.118 0 CA-C-O 121.351 0.596 . . . . 0.0 112.395 178.315 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 32.6 t -166.31 143.23 5.08 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.505 178.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 68.5 p 44.34 26.57 0.17 Allowed 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 125.894 1.677 . . . . 0.0 114.494 175.273 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 50.9 m -141.81 149.57 40.53 Favored 'General case' 0 N--CA 1.456 -0.139 0 C-N-CA 122.907 0.483 . . . . 0.0 109.886 -179.338 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -149.31 -5.59 0.38 Allowed 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 177.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -159.66 137.55 10.1 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.438 0.695 . . . . 0.0 109.136 -177.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 66.4 mt -88.27 143.52 11.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 173.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.2 m -80.64 139.55 36.15 Favored 'General case' 0 C--N 1.334 -0.109 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -174.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 20.8 tpp180 42.32 58.2 10.58 Favored Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 124.841 1.256 . . . . 0.0 112.844 175.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -74.36 -15.38 22.47 Favored 'Trans proline' 0 N--CA 1.454 -0.834 0 C-N-CA 123.01 2.474 . . . . 0.0 111.47 179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 62.04 -136.22 45.97 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 178.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -155.45 -29.35 0.1 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 123.207 0.603 . . . . 0.0 111.631 -179.121 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 82.3 p -154.32 168.8 25.4 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.452 0.701 . . . . 0.0 110.396 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -145.79 152.79 40.11 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.278 0.631 . . . . 0.0 110.256 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -150.62 153.93 36.58 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.291 0.636 . . . . 0.0 110.533 -179.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 79.5 p -146.65 151.31 37.04 Favored 'General case' 0 C--O 1.232 0.165 0 C-N-CA 122.954 0.502 . . . . 0.0 110.009 177.239 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 20.0 ptp180 -156.54 168.31 27.77 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.105 0.562 . . . . 0.0 110.873 -178.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 48.8 m -74.69 133.03 42.12 Favored 'General case' 0 N--CA 1.456 -0.146 0 C-N-CA 122.603 0.361 . . . . 0.0 110.17 178.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 6.0 m -150.01 163.63 3.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 C-N-CA 124.149 0.98 . . . . 0.0 109.202 -179.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -76.8 137.36 39.2 Favored 'General case' 0 N--CA 1.454 -0.228 0 N-CA-C 110.338 -0.245 . . . . 0.0 110.338 179.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 49.0 m . . . . . 0 C--O 1.25 1.088 0 CA-C-O 117.074 -1.441 . . . . 0.0 110.171 179.068 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.198 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -142.09 13.29 2.03 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 122.693 0.397 . . . . 0.0 111.771 -178.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 68.8 m-20 -72.89 -15.0 61.6 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.34 0.256 . . . . 0.0 111.147 -179.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -146.06 166.73 25.23 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.606 0.762 . . . . 0.0 109.154 179.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -81.22 -22.88 38.47 Favored 'General case' 0 CA--C 1.53 0.194 0 N-CA-C 111.768 0.285 . . . . 0.0 111.768 -177.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -157.38 60.39 2.01 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 117.923 0.329 . . . . 0.0 111.632 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -74.58 -31.58 6.83 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.592 2.195 . . . . 0.0 111.792 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 6.5 p-80 -162.57 12.98 0.07 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.075 0.55 . . . . 0.0 111.693 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -73.18 161.64 30.34 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.982 -0.448 . . . . 0.0 110.905 -176.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 34.8 p -87.44 154.19 53.77 Favored Pre-proline 0 CA--C 1.528 0.124 0 C-N-CA 123.021 0.528 . . . . 0.0 110.873 -179.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -77.18 -9.24 17.76 Favored 'Trans proline' 0 N--CA 1.453 -0.877 0 C-N-CA 123.877 3.051 . . . . 0.0 111.744 178.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 49.44 33.95 6.14 Favored 'General case' 0 C--N 1.341 0.231 0 C-N-CA 123.622 0.769 . . . . 0.0 111.542 -176.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.448 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 79.7 p -82.84 161.77 57.23 Favored Pre-proline 0 CA--C 1.532 0.288 0 C-N-CA 123.828 0.851 . . . . 0.0 112.099 -173.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 98.9 Cg_endo -71.17 1.22 5.59 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 124.008 3.139 . . . . 0.0 112.758 178.229 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.57 139.05 37.62 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.094 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 178.277 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.3 154.22 37.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.111 0 C-N-CA 122.928 0.491 . . . . 0.0 110.339 177.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 31.5 t-80 -110.65 138.18 47.37 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.993 0.917 . . . . 0.0 109.507 -179.018 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 25.1 mm -107.49 144.77 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 C-N-CA 122.893 0.477 . . . . 0.0 110.33 -176.228 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -143.01 161.48 38.0 Favored 'General case' 0 C--N 1.338 0.088 0 C-N-CA 123.195 0.598 . . . . 0.0 110.553 -178.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.36 23.51 62.85 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-O 119.498 -0.612 . . . . 0.0 113.488 173.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 76.4 mt -60.87 158.01 13.98 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 118.332 1.066 . . . . 0.0 110.523 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 11.4 pt -72.31 -40.93 65.65 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -173.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -172.12 -38.22 0.02 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 C-N-CA 123.107 0.563 . . . . 0.0 110.079 179.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -176.33 51.91 0.11 Allowed Glycine 0 C--N 1.338 0.646 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -176.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 57.9 t -49.65 144.03 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 123.546 0.738 . . . . 0.0 110.153 178.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.2 m -90.0 161.95 2.57 Favored 'Isoleucine or valine' 0 C--N 1.338 0.072 0 CA-C-O 121.292 0.567 . . . . 0.0 111.655 -174.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -62.0 -24.05 66.8 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.259 0.624 . . . . 0.0 111.766 -176.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.48 -5.5 58.74 Favored 'General case' 0 N--CA 1.454 -0.226 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -95.63 -31.55 13.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 118.312 0.505 . . . . 0.0 110.498 179.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.5 mp -75.56 -34.07 60.68 Favored 'General case' 0 N--CA 1.455 -0.181 0 O-C-N 121.921 -0.487 . . . . 0.0 110.752 -177.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.3 p -78.06 -30.64 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 120.709 -0.396 . . . . 0.0 109.979 -178.68 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -85.72 -12.03 52.17 Favored 'General case' 0 CA--C 1.531 0.219 0 O-C-N 122.274 -0.266 . . . . 0.0 111.558 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -107.84 -11.79 15.31 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 112.806 0.669 . . . . 0.0 112.806 178.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.2 mt -114.8 -9.37 12.52 Favored 'General case' 0 C--N 1.34 0.19 0 CA-C-N 118.457 0.571 . . . . 0.0 112.255 -179.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.64 -3.87 16.92 Favored 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 118.615 0.643 . . . . 0.0 111.71 176.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -78.49 -16.1 57.89 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.865 0.466 . . . . 0.0 110.511 178.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -96.67 -18.94 19.35 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.343 -0.223 . . . . 0.0 111.397 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 165.34 178.14 38.25 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -71.75 140.78 36.22 Favored 'Trans proline' 0 N--CA 1.451 -0.985 0 C-N-CA 124.061 3.174 . . . . 0.0 110.46 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 69.5 mt -110.05 148.44 13.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.129 0 C-N-CA 122.604 0.362 . . . . 0.0 110.449 -177.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -110.63 -39.78 4.78 Favored 'General case' 0 N--CA 1.457 -0.101 0 C-N-CA 123.247 0.619 . . . . 0.0 111.851 -177.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -158.68 158.06 33.02 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 117.76 0.255 . . . . 0.0 111.601 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 79.3 t -143.72 146.29 21.21 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 C-N-CA 124.036 0.934 . . . . 0.0 109.586 179.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 14.9 p -147.53 153.49 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.088 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 174.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 40.8 t -128.75 150.8 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 CA-C-O 120.833 0.349 . . . . 0.0 110.659 -176.299 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -134.54 79.77 52.93 Favored Pre-proline 0 CA--C 1.531 0.237 0 C-N-CA 124.492 1.117 . . . . 0.0 109.195 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -68.96 -14.06 37.86 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.389 2.726 . . . . 0.0 111.778 -175.407 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -81.71 -1.88 48.56 Favored 'General case' 0 CA--C 1.529 0.139 0 C-N-CA 122.824 0.45 . . . . 0.0 111.585 177.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -133.39 4.46 3.69 Favored 'General case' 0 C--N 1.339 0.14 0 C-N-CA 123.797 0.839 . . . . 0.0 111.113 175.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 12.4 tpp85 55.59 35.76 25.84 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 124.069 0.948 . . . . 0.0 111.667 -175.193 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -134.11 170.49 15.58 Favored 'General case' 0 N--CA 1.457 -0.076 0 C-N-CA 123.415 0.686 . . . . 0.0 110.929 -177.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.88 170.94 20.5 Favored 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 176.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 12.7 tp -135.17 142.54 46.12 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 98.5 t -138.21 141.54 37.78 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.1 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -177.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -123.9 125.03 43.91 Favored 'General case' 0 N--CA 1.453 -0.307 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 178.086 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -87.75 154.9 20.2 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.875 0.369 . . . . 0.0 110.341 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -74.97 -12.36 60.32 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.246 -178.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -147.8 152.49 37.77 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 123.988 0.915 . . . . 0.0 109.265 176.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.8 p -68.63 -21.85 26.37 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.0 tp -73.95 -26.08 60.3 Favored 'General case' 0 N--CA 1.453 -0.303 0 O-C-N 121.999 -0.438 . . . . 0.0 110.544 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.24 -29.13 68.92 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.042 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.66 -30.23 23.38 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 117.237 0.519 . . . . 0.0 110.513 178.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 36.8 t -75.55 -17.77 59.97 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 122.49 0.316 . . . . 0.0 110.484 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -93.35 -20.84 19.97 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 122.705 0.402 . . . . 0.0 110.723 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -84.35 -31.01 25.02 Favored 'General case' 0 N--CA 1.455 -0.177 0 O-C-N 122.112 -0.367 . . . . 0.0 111.501 -178.081 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 59.5 t -87.62 -19.4 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.121 0 O-C-N 122.04 -0.413 . . . . 0.0 110.698 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -70.5 -17.54 62.96 Favored 'General case' 0 CA--C 1.529 0.142 0 O-C-N 122.221 -0.3 . . . . 0.0 111.195 -179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 78.9 t80 -97.42 -36.79 10.24 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 122.686 0.394 . . . . 0.0 111.172 178.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -84.25 -6.61 59.42 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.22 -4.81 56.67 Favored 'General case' 0 N--CA 1.454 -0.244 0 O-C-N 122.078 -0.389 . . . . 0.0 111.543 176.238 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -141.64 -4.99 1.07 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 23.9 m-80 -145.01 175.26 10.36 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 123.358 0.663 . . . . 0.0 109.615 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.1 pt20 -99.35 150.52 22.05 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 172.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -118.91 134.51 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -176.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -88.04 151.46 22.74 Favored 'General case' 0 N--CA 1.453 -0.278 0 O-C-N 122.183 -0.323 . . . . 0.0 110.853 -179.051 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 41.2 mt -138.22 -37.3 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.19 -177.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -135.91 29.54 3.14 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.24 0.616 . . . . 0.0 111.087 -176.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 85.73 4.69 84.93 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -176.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -131.36 152.78 81.13 Favored Pre-proline 0 N--CA 1.454 -0.234 0 C-N-CA 124.24 1.016 . . . . 0.0 108.982 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -71.53 146.83 50.52 Favored 'Trans proline' 0 N--CA 1.453 -0.881 0 C-N-CA 123.377 2.718 . . . . 0.0 111.792 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.67 -176.54 5.77 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 124.784 1.234 . . . . 0.0 109.011 178.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -137.83 159.79 41.05 Favored 'General case' 0 CA--C 1.527 0.081 0 CA-C-O 120.776 0.322 . . . . 0.0 111.428 -178.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.3 p -147.84 138.14 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 C-N-CA 123.324 0.649 . . . . 0.0 110.23 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -159.04 151.79 21.88 Favored 'General case' 0 N--CA 1.456 -0.126 0 C-N-CA 123.502 0.721 . . . . 0.0 109.303 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -103.66 133.08 49.27 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-O 121.246 0.546 . . . . 0.0 112.425 178.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 42.1 t -167.89 145.14 4.28 Favored 'General case' 0 N--CA 1.456 -0.148 0 C-N-CA 123.068 0.547 . . . . 0.0 110.852 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 3.1 m 50.34 24.89 1.66 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.914 1.286 . . . . 0.0 114.003 172.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 33.5 t -152.71 153.46 33.28 Favored 'General case' 0 C--O 1.232 0.171 0 O-C-N 121.522 -0.736 . . . . 0.0 111.045 178.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -148.22 -4.91 0.46 Allowed 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 176.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 15.6 tppt? -159.72 136.65 9.38 Favored 'General case' 0 N--CA 1.456 -0.165 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -178.093 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 38.6 mt -89.4 137.44 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.155 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 174.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 50.6 m -82.58 141.72 32.36 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.551 0.215 . . . . 0.0 111.359 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 90.5 mtt-85 44.91 54.73 13.29 Favored Pre-proline 0 CA--C 1.533 0.306 0 C-N-CA 124.335 1.054 . . . . 0.0 112.791 176.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -72.73 81.53 1.59 Allowed 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 123.199 2.599 . . . . 0.0 110.141 179.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 83.56 11.52 79.8 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.637 -0.535 . . . . 0.0 112.1 -177.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 51.3 m-20 -110.2 18.48 19.9 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.263 0.625 . . . . 0.0 111.839 -178.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.5 m -69.18 153.31 43.9 Favored 'General case' 0 CA--C 1.529 0.172 0 O-C-N 122.113 -0.367 . . . . 0.0 111.295 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -146.22 166.02 27.47 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 123.357 0.663 . . . . 0.0 110.69 178.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 19.4 t0 -147.93 142.73 26.75 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.131 0.572 . . . . 0.0 110.331 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 70.7 m -146.79 157.37 43.66 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 124.15 0.98 . . . . 0.0 109.87 179.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -123.57 160.79 26.3 Favored 'General case' 0 N--CA 1.457 -0.116 0 C-N-CA 122.38 0.272 . . . . 0.0 110.666 -176.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.6 p -86.63 5.86 33.82 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 123.384 0.674 . . . . 0.0 112.045 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 30.7 m -133.02 160.29 42.71 Favored 'Isoleucine or valine' 0 C--O 1.231 0.112 0 C-N-CA 122.986 0.514 . . . . 0.0 110.483 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 42.8 m-20 52.24 23.1 2.21 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.047 0.939 . . . . 0.0 112.622 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 45.1 m . . . . . 0 C--O 1.25 1.115 0 CA-C-O 117.447 -1.264 . . . . 0.0 110.057 -178.025 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.161 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -145.95 151.31 37.61 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 122.883 0.473 . . . . 0.0 110.084 179.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 48.9 t30 -150.63 167.2 28.02 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 123.156 0.583 . . . . 0.0 109.509 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -69.53 -22.61 63.56 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 122.488 0.315 . . . . 0.0 111.062 179.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.0 t0 -156.76 157.82 35.76 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 123.066 0.547 . . . . 0.0 109.855 176.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.404 ' N ' ' CD ' ' A' ' 90' ' ' PRO . 34.3 t0 47.73 45.99 3.2 Favored Pre-proline 0 CA--C 1.537 0.457 0 C-N-CA 124.473 1.109 . . . . 0.0 113.6 -179.059 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.404 ' CD ' ' N ' ' A' ' 89' ' ' ASP . 98.3 Cg_endo -73.14 -26.77 14.52 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.128 1.885 . . . . 0.0 110.901 176.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 3.2 p-80 -159.78 17.69 0.16 Allowed 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.349 0.659 . . . . 0.0 111.555 -178.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -78.26 3.32 15.71 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -174.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 23.6 p -71.37 151.04 94.2 Favored Pre-proline 0 CA--C 1.528 0.124 0 O-C-N 122.114 -0.366 . . . . 0.0 110.449 178.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -77.94 -10.91 16.7 Favored 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 123.602 2.868 . . . . 0.0 111.71 179.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 49.07 33.29 4.63 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.392 0.677 . . . . 0.0 111.257 -176.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.481 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 77.8 p -85.22 162.89 47.5 Favored Pre-proline 0 CA--C 1.529 0.147 0 C-N-CA 123.806 0.842 . . . . 0.0 112.016 -173.5 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.481 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 84.6 Cg_endo -70.5 2.15 4.23 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 123.89 3.06 . . . . 0.0 112.854 177.046 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 96.7 t -112.92 139.15 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.141 0 CA-C-N 118.327 0.512 . . . . 0.0 109.926 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 23.0 m -125.51 157.74 34.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 C-N-CA 122.908 0.483 . . . . 0.0 110.359 178.421 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 34.6 t-80 -115.39 137.63 51.84 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 124.179 0.991 . . . . 0.0 109.392 -178.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 14.6 mm -107.67 145.69 14.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 C-N-CA 122.616 0.366 . . . . 0.0 110.044 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -142.64 157.74 44.38 Favored 'General case' 0 N--CA 1.457 -0.119 0 C-N-CA 123.418 0.687 . . . . 0.0 109.947 -178.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.66 24.98 57.51 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.314 174.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 52.3 mt -59.08 156.72 11.43 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 118.026 0.913 . . . . 0.0 109.812 177.562 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 9.1 pt -72.45 -39.07 61.96 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.113 0 O-C-N 122.181 -0.324 . . . . 0.0 111.773 -174.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -173.41 -36.2 0.01 OUTLIER 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 123.653 0.781 . . . . 0.0 110.033 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.31 54.75 0.05 OUTLIER Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -177.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.3 m -52.9 151.57 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 117.156 0.478 . . . . 0.0 110.271 177.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.1 m -88.34 165.74 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.039 0 CA-C-O 121.161 0.505 . . . . 0.0 111.36 -175.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -61.61 -23.92 66.35 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.132 0.573 . . . . 0.0 111.21 -178.173 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -79.2 -6.85 57.53 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 122.743 0.417 . . . . 0.0 111.867 -179.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -91.49 -34.96 14.59 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-N 118.236 0.471 . . . . 0.0 110.617 179.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 10.6 mp -75.87 -33.81 59.98 Favored 'General case' 0 N--CA 1.456 -0.169 0 O-C-N 122.214 -0.304 . . . . 0.0 110.948 -176.793 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.0 p -76.57 -29.49 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.068 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 37.7 mm-40 -84.36 -14.26 50.02 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 122.206 0.202 . . . . 0.0 110.982 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -98.69 -21.79 16.24 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 9.8 mp -109.83 -10.68 14.75 Favored 'General case' 0 CA--C 1.531 0.243 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -177.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.36 -4.43 14.54 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 118.978 0.808 . . . . 0.0 111.956 177.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -83.6 -12.27 56.28 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.881 0.473 . . . . 0.0 110.413 178.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -103.97 -16.41 15.33 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 122.753 0.421 . . . . 0.0 111.425 -179.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.42 178.54 37.2 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -72.37 140.33 33.34 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 124.085 3.19 . . . . 0.0 110.671 179.268 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 79.4 mt -109.72 148.62 13.26 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 C-N-CA 122.889 0.476 . . . . 0.0 110.684 -178.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 12.9 t -114.32 -36.39 4.67 Favored 'General case' 0 C--O 1.231 0.108 0 C-N-CA 123.384 0.673 . . . . 0.0 112.09 -177.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -155.96 156.06 33.86 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.626 0.25 . . . . 0.0 111.589 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 66.0 t -146.49 144.37 20.38 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 C-N-CA 124.038 0.935 . . . . 0.0 109.183 179.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 13.7 p -151.33 152.82 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 175.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 58.9 t -131.8 150.59 34.07 Favored 'Isoleucine or valine' 0 C--N 1.335 -0.055 0 C-N-CA 122.587 0.355 . . . . 0.0 110.393 -175.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 70.0 mtm -132.74 84.74 49.18 Favored Pre-proline 0 N--CA 1.454 -0.237 0 C-N-CA 124.004 0.922 . . . . 0.0 109.048 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.57 -12.5 33.4 Favored 'Trans proline' 0 N--CA 1.457 -0.661 0 C-N-CA 123.325 2.683 . . . . 0.0 111.964 -176.17 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -84.78 -1.75 56.77 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 122.842 0.457 . . . . 0.0 111.107 176.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -132.45 1.24 3.74 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 123.871 0.868 . . . . 0.0 111.157 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.2 tpp85 52.38 34.61 15.39 Favored 'General case' 0 C--N 1.341 0.197 0 C-N-CA 124.257 1.023 . . . . 0.0 111.846 -175.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.26 167.86 20.95 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.554 0.741 . . . . 0.0 110.354 -177.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.62 173.58 16.5 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 122.508 0.323 . . . . 0.0 110.792 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 45.0 mt -134.16 147.09 50.73 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 123.623 0.769 . . . . 0.0 110.14 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 94.6 t -140.06 135.28 37.37 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -116.75 122.63 45.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -84.77 156.02 21.58 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 120.974 0.416 . . . . 0.0 110.193 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -75.94 -12.29 60.12 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.325 -179.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -148.21 153.13 38.34 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 124.099 0.96 . . . . 0.0 109.362 177.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.6 p -70.5 -21.8 23.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 N-CA-C 111.833 0.308 . . . . 0.0 111.833 -175.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.7 tp -74.34 -27.43 60.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 O-C-N 121.939 -0.476 . . . . 0.0 110.742 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.88 -30.63 67.86 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.88 -29.36 29.37 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 117.11 0.455 . . . . 0.0 111.028 179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 49.4 t -77.58 -25.97 50.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 110.537 -0.171 . . . . 0.0 110.537 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -85.21 -17.22 37.75 Favored 'General case' 0 N--CA 1.452 -0.334 0 C-N-CA 122.135 0.174 . . . . 0.0 111.084 178.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -85.01 -28.56 25.66 Favored 'General case' 0 N--CA 1.456 -0.148 0 O-C-N 122.246 -0.284 . . . . 0.0 111.48 179.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.9 t -88.23 -21.91 6.88 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 O-C-N 122.196 -0.315 . . . . 0.0 110.618 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.16 -15.9 62.51 Favored 'General case' 0 CA--C 1.534 0.331 0 O-C-N 122.365 -0.209 . . . . 0.0 111.154 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 58.0 t80 -93.76 -33.09 13.74 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 122.422 0.289 . . . . 0.0 110.927 178.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -90.99 -3.1 57.55 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 112.697 0.628 . . . . 0.0 112.697 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -83.81 -5.08 59.12 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 122.001 -0.437 . . . . 0.0 112.11 178.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -143.59 2.47 1.24 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 122.71 0.404 . . . . 0.0 111.52 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -155.27 173.72 16.23 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.032 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -98.48 156.34 16.82 Favored 'General case' 0 CA--C 1.527 0.094 0 CA-C-N 118.222 0.464 . . . . 0.0 110.276 175.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -119.56 136.49 56.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -177.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -92.89 147.65 22.67 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 121.98 -0.45 . . . . 0.0 110.384 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.8 mt -134.19 -40.15 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.131 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.83 29.78 3.78 Favored 'General case' 0 N--CA 1.455 -0.186 0 C-N-CA 123.012 0.525 . . . . 0.0 111.164 -177.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.11 5.14 83.51 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 111.394 -0.683 . . . . 0.0 111.394 -177.158 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -131.36 152.87 81.29 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 124.526 1.13 . . . . 0.0 108.84 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -71.1 146.23 51.44 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.531 2.821 . . . . 0.0 111.784 -177.212 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.5 -176.11 5.46 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 125.158 1.383 . . . . 0.0 108.772 177.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -138.98 159.43 42.16 Favored 'General case' 0 N--CA 1.456 -0.128 0 O-C-N 122.134 -0.353 . . . . 0.0 111.265 -179.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.6 p -147.08 139.68 19.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 C-N-CA 123.237 0.615 . . . . 0.0 110.606 179.24 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -158.57 155.22 27.91 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.355 0.662 . . . . 0.0 109.582 176.24 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -97.66 127.68 43.8 Favored 'General case' 0 CA--C 1.527 0.069 0 CA-C-O 121.136 0.494 . . . . 0.0 111.375 177.429 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 41.6 m -158.95 144.08 16.07 Favored 'General case' 0 N--CA 1.457 -0.091 0 C-N-CA 123.205 0.602 . . . . 0.0 110.661 -177.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 82.1 p 44.44 26.86 0.19 Allowed 'General case' 0 N--CA 1.464 0.233 0 N-CA-C 115.508 1.67 . . . . 0.0 115.508 171.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 23.9 t -149.78 157.57 43.33 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 118.496 0.589 . . . . 0.0 110.807 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.85 -23.87 0.46 Allowed 'General case' 0 CA--C 1.529 0.166 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 179.714 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 15.7 tppt? -165.09 133.33 3.24 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -173.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 174' ' ' ILE . 1.9 mp -82.67 136.95 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.079 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 172.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 77.4 p -94.39 143.41 26.43 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-O 120.613 0.244 . . . . 0.0 111.52 -176.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 69.8 ttt180 45.09 48.67 5.16 Favored Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 124.176 0.99 . . . . 0.0 112.797 177.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -76.26 -17.16 17.08 Favored 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 123.123 2.549 . . . . 0.0 112.264 -177.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -98.66 5.18 60.02 Favored Glycine 0 CA--C 1.529 0.92 0 CA-C-O 119.369 -0.684 . . . . 0.0 113.31 -175.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -145.79 165.04 29.99 Favored 'General case' 0 C--O 1.231 0.114 0 CA-C-N 118.292 1.046 . . . . 0.0 111.275 -176.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 82.2 p -120.56 163.47 17.94 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 123.845 0.858 . . . . 0.0 110.689 -179.262 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -130.68 5.31 4.65 Favored 'General case' 0 CA--C 1.531 0.239 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -175.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -75.31 159.95 30.88 Favored 'General case' 0 C--O 1.231 0.131 0 O-C-N 122.008 -0.433 . . . . 0.0 111.447 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 17.9 t -152.9 165.75 34.48 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 122.738 0.415 . . . . 0.0 110.229 -179.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -148.68 155.32 40.87 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 122.671 0.388 . . . . 0.0 110.176 178.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 20.3 m -86.24 31.74 0.64 Allowed 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 123.817 0.847 . . . . 0.0 112.688 -175.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 32.6 m -125.2 161.74 28.87 Favored 'Isoleucine or valine' 0 C--O 1.231 0.101 0 C-N-CA 123.125 0.57 . . . . 0.0 110.718 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 43.9 t30 52.81 32.08 11.69 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.466 0.706 . . . . 0.0 111.968 -177.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 50.9 m . . . . . 0 C--O 1.253 1.274 0 CA-C-O 117.357 -1.306 . . . . 0.0 111.073 -179.757 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.27 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.5 tp10 -74.98 -14.67 60.65 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 122.883 0.473 . . . . 0.0 110.397 178.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 49.9 t30 -149.78 176.74 10.44 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.12 0.968 . . . . 0.0 108.704 179.208 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -70.59 -0.37 8.48 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.808 0.443 . . . . 0.0 111.451 177.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 23.8 t0 -141.88 160.09 40.9 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 124.244 1.018 . . . . 0.0 108.854 177.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 42.3 m-20 -67.63 131.13 92.94 Favored Pre-proline 0 CA--C 1.531 0.247 0 CA-C-N 117.654 0.207 . . . . 0.0 110.581 -177.449 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -73.83 -31.33 8.43 Favored 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 123.214 2.609 . . . . 0.0 111.848 -178.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 6.4 p-80 -158.18 -2.4 0.09 Allowed 'General case' 0 CA--C 1.53 0.202 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -179.174 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -84.56 162.62 19.76 Favored 'General case' 0 C--N 1.338 0.103 0 C-N-CA 122.673 0.389 . . . . 0.0 110.327 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 47.1 p -109.35 153.55 42.68 Favored Pre-proline 0 C--N 1.333 -0.135 0 C-N-CA 122.851 0.461 . . . . 0.0 111.02 -178.632 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -77.48 -1.99 12.17 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.967 3.111 . . . . 0.0 112.384 179.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.39 38.15 17.3 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.077 0.551 . . . . 0.0 111.315 -176.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.433 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 48.2 p -62.7 159.71 41.65 Favored Pre-proline 0 CA--C 1.532 0.262 0 C-N-CA 124.564 1.146 . . . . 0.0 112.03 -175.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 88.9 Cg_endo -70.11 4.79 2.14 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.583 3.522 . . . . 0.0 113.362 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 92.3 t -122.84 140.82 45.43 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.076 0 CA-C-N 118.579 0.627 . . . . 0.0 109.855 178.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.95 157.88 43.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 121.07 0.462 . . . . 0.0 110.643 179.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -107.84 142.63 37.61 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.908 0.883 . . . . 0.0 109.723 -179.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 22.0 mm -111.42 144.88 18.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 123.006 0.523 . . . . 0.0 110.016 -176.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -141.36 160.12 40.78 Favored 'General case' 0 C--N 1.334 -0.068 0 C-N-CA 123.514 0.726 . . . . 0.0 110.068 -178.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.67 25.67 58.01 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.432 173.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 47.7 mt -59.07 154.87 14.8 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.388 1.094 . . . . 0.0 109.189 176.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.0 pt -69.95 -40.37 78.61 Favored 'Isoleucine or valine' 0 C--N 1.338 0.076 0 O-C-N 122.184 -0.322 . . . . 0.0 111.652 -172.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -172.91 -35.16 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.484 0.713 . . . . 0.0 109.979 -179.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 174.84 51.96 0.05 OUTLIER Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 -177.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.1 m -53.72 151.64 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 117.138 0.469 . . . . 0.0 110.087 177.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 30.3 m -88.46 163.88 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 CA-C-O 120.881 0.372 . . . . 0.0 110.832 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.68 -22.33 63.8 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 122.819 0.448 . . . . 0.0 111.065 -177.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.82 -8.04 58.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 122.868 0.467 . . . . 0.0 111.991 -179.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -91.12 -32.74 15.73 Favored 'General case' 0 N--CA 1.457 -0.107 0 CA-C-N 118.476 0.58 . . . . 0.0 110.48 178.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -71.41 -39.05 71.37 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 122.119 0.167 . . . . 0.0 110.601 -177.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.8 p -78.71 -31.28 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 C-N-CA 121.191 -0.203 . . . . 0.0 110.783 -175.607 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.7 mm-40 -81.26 -17.23 50.15 Favored 'General case' 0 N--CA 1.455 -0.199 0 O-C-N 122.131 -0.356 . . . . 0.0 111.554 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.9 -12.47 16.21 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.3 mt -114.53 -9.11 12.71 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.491 0.587 . . . . 0.0 112.444 -179.059 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.6 pt20 -70.06 -5.98 30.48 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 118.508 0.595 . . . . 0.0 111.778 176.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.7 tp10 -76.28 -12.78 60.14 Favored 'General case' 0 CA--C 1.532 0.25 0 O-C-N 122.13 -0.356 . . . . 0.0 110.498 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -100.39 -16.9 17.46 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 122.455 0.302 . . . . 0.0 111.523 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 163.12 177.32 35.99 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -71.59 140.97 37.12 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.875 3.05 . . . . 0.0 110.451 -179.549 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 72.8 mt -111.07 146.73 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 122.675 0.39 . . . . 0.0 110.098 -178.125 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.2 t -108.26 -40.33 5.2 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 123.336 0.655 . . . . 0.0 111.436 -177.098 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 57.1 t80 -159.12 158.49 32.98 Favored 'General case' 0 N--CA 1.457 -0.078 0 CA-C-O 120.577 0.227 . . . . 0.0 111.355 178.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 65.1 t -145.23 147.92 18.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 C-N-CA 123.801 0.84 . . . . 0.0 109.602 -179.13 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.4 p -148.2 150.75 14.01 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 174.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 43.9 t -132.28 150.38 33.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.053 0 C-N-CA 122.628 0.371 . . . . 0.0 110.043 -174.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.7 mtm -135.62 80.59 43.98 Favored Pre-proline 0 N--CA 1.456 -0.171 0 C-N-CA 123.858 0.863 . . . . 0.0 109.486 -179.066 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -58.88 -20.37 52.03 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 123.948 3.098 . . . . 0.0 113.041 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -76.09 -12.43 60.12 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.168 0.587 . . . . 0.0 111.139 179.334 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -124.06 3.57 8.65 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 123.644 0.778 . . . . 0.0 111.294 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.1 tpp85 52.83 32.84 13.03 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 124.473 1.109 . . . . 0.0 111.826 -176.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -136.93 166.74 22.94 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 123.435 0.694 . . . . 0.0 110.71 -177.044 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -153.03 172.18 17.25 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 122.748 0.419 . . . . 0.0 110.412 178.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 35.6 mt -132.09 146.52 52.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.728 0.811 . . . . 0.0 109.816 178.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 90.4 t -138.17 131.84 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.71 117.98 31.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.679 0.791 . . . . 0.0 109.169 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -86.26 155.36 20.71 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-O 121.012 0.434 . . . . 0.0 110.267 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -77.94 -11.04 59.86 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.497 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -146.47 152.02 38.34 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.522 0.729 . . . . 0.0 109.183 178.022 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -69.08 -21.48 25.42 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.76 -28.67 44.86 Favored 'General case' 0 N--CA 1.455 -0.217 0 O-C-N 122.039 -0.413 . . . . 0.0 110.594 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.38 -28.73 73.11 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.82 -31.82 25.64 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.887 0.344 . . . . 0.0 110.66 178.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 42.0 t -69.95 -33.12 71.71 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 122.359 0.264 . . . . 0.0 110.578 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -73.72 -20.38 60.54 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 122.277 0.231 . . . . 0.0 111.447 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -82.44 -29.41 30.71 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 117.797 0.271 . . . . 0.0 111.585 -177.185 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 39.1 t -91.36 -21.96 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.096 0 O-C-N 122.312 -0.242 . . . . 0.0 110.648 178.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -68.41 -17.06 64.13 Favored 'General case' 0 CA--C 1.531 0.236 0 O-C-N 122.275 -0.266 . . . . 0.0 110.51 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 50.0 t80 -97.9 -36.0 10.3 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 122.426 0.29 . . . . 0.0 110.611 177.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -76.84 -15.06 59.82 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 122.648 0.379 . . . . 0.0 111.855 -177.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.24 52.4 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 122.982 0.513 . . . . 0.0 111.922 177.175 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -135.29 -18.33 1.75 Allowed 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.129 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -151.33 166.21 31.67 Favored 'General case' 0 CA--C 1.53 0.21 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -81.12 154.25 26.86 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 175.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.638 HD13 ' H ' ' A' ' 158' ' ' TYR . 0.5 OUTLIER -110.04 164.52 6.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.173 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.638 ' H ' HD13 ' A' ' 157' ' ' ILE . 75.9 m-85 -119.52 154.64 33.53 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 122.094 -0.379 . . . . 0.0 110.3 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.6 mt -137.0 -42.28 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.087 0 O-C-N 123.165 0.291 . . . . 0.0 110.802 -177.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.08 29.83 3.69 Favored 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 123.268 0.627 . . . . 0.0 111.11 -177.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.48 6.75 80.3 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 -176.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -129.7 153.67 80.83 Favored Pre-proline 0 C--O 1.233 0.203 0 C-N-CA 124.013 0.925 . . . . 0.0 109.245 178.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -69.97 144.18 52.09 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 123.184 2.589 . . . . 0.0 112.285 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.44 -177.59 6.31 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.473 1.509 . . . . 0.0 108.668 178.099 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -137.99 160.61 38.89 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.114 0.483 . . . . 0.0 111.471 -179.05 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 3.4 p -150.25 140.86 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 123.888 0.875 . . . . 0.0 109.323 179.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -159.14 162.01 36.36 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 123.149 0.58 . . . . 0.0 109.893 178.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 15.1 m-85 -62.61 162.75 10.05 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 117.702 0.228 . . . . 0.0 110.388 176.601 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 14.7 t -145.48 25.27 1.36 Allowed 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 122.29 0.236 . . . . 0.0 111.279 -179.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 6.2 m 57.17 15.71 2.62 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.871 0.868 . . . . 0.0 112.178 -178.313 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 75.7 m -87.99 156.47 19.31 Favored 'General case' 0 N--CA 1.456 -0.168 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 177.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 21.8 pt20 -139.31 -6.26 1.39 Allowed 'General case' 0 CA--C 1.529 0.158 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 1.9 tmtm? -157.54 137.57 12.51 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 178.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 82.4 mt -85.6 149.17 4.33 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.08 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 173.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 45.0 m -78.62 141.58 37.91 Favored 'General case' 0 C--O 1.231 0.097 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -175.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 40.9 mtm180 41.15 53.1 6.49 Favored Pre-proline 0 CA--C 1.533 0.317 0 C-N-CA 125.112 1.365 . . . . 0.0 113.548 176.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -70.92 -8.81 24.43 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.677 2.251 . . . . 0.0 111.822 -175.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -121.85 7.04 10.25 Favored Glycine 0 CA--C 1.529 0.933 0 C-N-CA 123.516 0.579 . . . . 0.0 112.148 179.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -137.21 -12.03 1.65 Allowed 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 117.849 0.825 . . . . 0.0 112.275 -176.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 29.2 t -79.79 149.87 30.94 Favored 'General case' 0 N--CA 1.455 -0.183 0 O-C-N 121.767 -0.583 . . . . 0.0 110.745 177.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 26.9 t70 51.89 24.42 2.54 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.893 0.877 . . . . 0.0 112.769 -178.121 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -73.82 155.45 38.8 Favored 'General case' 0 N--CA 1.455 -0.183 0 CA-C-O 120.906 0.384 . . . . 0.0 110.988 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 78.0 p -143.83 155.69 44.22 Favored 'General case' 0 C--O 1.231 0.079 0 C-N-CA 123.336 0.654 . . . . 0.0 109.387 178.004 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 14.6 ttm180 -151.94 164.06 37.95 Favored 'General case' 0 C--N 1.337 0.035 0 CA-C-O 120.647 0.261 . . . . 0.0 111.343 -174.549 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 36.4 m -80.72 4.15 19.83 Favored 'General case' 0 CA--C 1.529 0.136 0 C-N-CA 123.074 0.55 . . . . 0.0 111.761 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 32.9 m -134.17 158.7 42.25 Favored 'Isoleucine or valine' 0 C--O 1.231 0.109 0 C-N-CA 123.408 0.683 . . . . 0.0 110.423 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 45.5 t30 51.3 29.4 4.99 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.747 0.819 . . . . 0.0 112.177 -179.317 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 38.0 t . . . . . 0 C--O 1.25 1.122 0 CA-C-O 117.434 -1.27 . . . . 0.0 109.739 -178.998 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.273 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -134.15 -4.22 2.74 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 122.969 0.508 . . . . 0.0 110.87 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 58.21 173.03 0.06 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 125.202 1.401 . . . . 0.0 113.332 -177.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -89.39 -5.79 57.15 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 122.89 0.476 . . . . 0.0 111.225 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -152.21 150.76 30.18 Favored 'General case' 0 N--CA 1.455 -0.181 0 C-N-CA 124.322 1.049 . . . . 0.0 108.723 178.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 42.4 m-20 -79.91 127.28 77.83 Favored Pre-proline 0 N--CA 1.454 -0.23 0 O-C-N 122.275 -0.265 . . . . 0.0 110.842 -176.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -76.23 -18.42 16.2 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 123.621 2.881 . . . . 0.0 112.028 178.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 2.1 p-80 -151.11 -126.64 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 123.663 0.785 . . . . 0.0 109.287 179.321 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 82.9 mttt 62.71 179.16 0.14 Allowed 'General case' 0 C--N 1.341 0.196 0 C-N-CA 124.277 1.031 . . . . 0.0 111.346 -176.119 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 50.1 p -130.56 154.64 81.72 Favored Pre-proline 0 CA--C 1.53 0.196 0 C-N-CA 123.192 0.597 . . . . 0.0 110.572 -178.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -74.61 -2.56 12.6 Favored 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 124.025 3.15 . . . . 0.0 112.669 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 51.29 35.79 14.56 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 123.302 0.641 . . . . 0.0 111.545 -176.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.431 ' HB2' ' HD2' ' A' ' 97' ' ' PRO . 71.0 p -66.28 161.63 55.61 Favored Pre-proline 0 CA--C 1.532 0.254 0 C-N-CA 124.602 1.161 . . . . 0.0 111.484 -177.305 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.431 ' HD2' ' HB2' ' A' ' 96' ' ' SER . 80.6 Cg_endo -69.78 4.27 2.3 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 124.098 3.198 . . . . 0.0 112.342 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.5 t -115.06 140.43 36.34 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 C-N-CA 123.076 0.55 . . . . 0.0 109.802 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.6 m -130.12 150.74 34.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.1 0 CA-C-O 121.035 0.445 . . . . 0.0 110.699 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 39.3 t-80 -99.39 136.21 39.67 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.249 1.019 . . . . 0.0 110.178 178.321 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 2.1 mp -110.42 146.4 15.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 C-N-CA 123.463 0.705 . . . . 0.0 109.168 -177.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 44.0 mtm105 -142.3 162.56 35.17 Favored 'General case' 0 N--CA 1.461 0.084 0 C-N-CA 123.573 0.749 . . . . 0.0 110.385 -176.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 80.27 26.99 53.75 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-O 119.66 -0.522 . . . . 0.0 113.239 172.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.4 mt -59.41 155.74 14.27 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 118.176 0.988 . . . . 0.0 109.798 177.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 8.2 pt -71.12 -39.5 74.08 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.111 0 O-C-N 122.189 -0.319 . . . . 0.0 111.308 -174.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -173.21 -37.05 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.258 0 C-N-CA 123.882 0.873 . . . . 0.0 110.107 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.63 52.22 0.06 OUTLIER Glycine 0 C--N 1.337 0.612 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -176.44 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.1 m -54.04 154.4 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 CA-C-N 117.037 0.418 . . . . 0.0 110.203 177.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 35.9 m -90.84 166.11 1.85 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.063 0 CA-C-O 121.213 0.53 . . . . 0.0 111.091 -176.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -60.58 -24.2 65.25 Favored 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 123.24 0.616 . . . . 0.0 111.217 -178.663 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.5 -4.71 54.92 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 122.694 0.398 . . . . 0.0 112.015 -178.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -91.74 -35.76 13.96 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 118.256 0.48 . . . . 0.0 110.471 179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.67 -31.9 52.86 Favored 'General case' 0 N--CA 1.454 -0.264 0 O-C-N 122.225 -0.297 . . . . 0.0 111.105 -176.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.39 -31.5 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 O-C-N 122.057 -0.402 . . . . 0.0 110.184 -178.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 63.8 mm-40 -82.33 -18.55 41.77 Favored 'General case' 0 N--CA 1.456 -0.155 0 O-C-N 122.244 -0.285 . . . . 0.0 111.054 -179.084 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -102.01 -12.19 18.34 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.2 mt -117.6 -8.48 10.93 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 118.627 0.649 . . . . 0.0 112.525 -177.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 24.3 pt20 -68.8 -6.92 29.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 118.575 0.625 . . . . 0.0 111.563 176.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 15.4 tp10 -76.47 -14.65 60.03 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.791 0.436 . . . . 0.0 110.607 179.536 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -99.41 -13.56 19.51 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 122.49 0.316 . . . . 0.0 111.613 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 160.62 176.32 32.59 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -71.27 140.35 36.97 Favored 'Trans proline' 0 N--CA 1.452 -0.93 0 C-N-CA 124.023 3.149 . . . . 0.0 110.51 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 139' ' ' PHE . 75.6 mt -111.28 146.3 16.44 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.939 0.496 . . . . 0.0 110.519 -178.029 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 22.9 t -106.36 -41.26 5.36 Favored 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 123.433 0.693 . . . . 0.0 111.438 -177.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 55.0 t80 -159.29 158.89 33.32 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 122.225 0.21 . . . . 0.0 111.51 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 99.1 t -143.56 147.22 20.34 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 C-N-CA 123.827 0.851 . . . . 0.0 109.815 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 11.5 p -147.43 152.68 12.74 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.064 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 175.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 56.4 t -133.71 150.06 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.048 0 C-N-CA 122.852 0.461 . . . . 0.0 110.352 -176.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 71.8 mtm -133.79 86.47 38.58 Favored Pre-proline 0 N--CA 1.454 -0.262 0 C-N-CA 123.83 0.852 . . . . 0.0 109.318 -179.181 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -68.61 -14.64 39.98 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.463 2.776 . . . . 0.0 111.645 -176.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.0 tttp -79.24 -10.29 59.78 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.114 0.566 . . . . 0.0 110.91 177.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -126.76 1.22 6.73 Favored 'General case' 0 CA--C 1.528 0.128 0 C-N-CA 123.683 0.793 . . . . 0.0 111.369 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.8 tpp85 53.05 32.33 12.75 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 124.358 1.063 . . . . 0.0 111.948 -176.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -135.77 166.56 22.99 Favored 'General case' 0 N--CA 1.455 -0.199 0 C-N-CA 123.551 0.74 . . . . 0.0 110.147 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -154.66 172.22 18.24 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-O 120.773 0.321 . . . . 0.0 110.921 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 39.5 mt -134.09 147.75 50.92 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.41 0.684 . . . . 0.0 109.929 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 81.6 t -138.24 133.61 43.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.8 tt0 -115.44 119.59 36.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 178.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.401 ' HA ' ' HA ' ' A' ' 123' ' ' ILE . 50.2 m-85 -86.13 155.0 20.96 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.987 0.422 . . . . 0.0 110.361 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -75.23 -14.41 60.52 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.379 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -147.29 153.03 39.25 Favored 'General case' 0 N--CA 1.452 -0.331 0 C-N-CA 123.697 0.799 . . . . 0.0 109.456 177.261 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.3 p -68.06 -22.0 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 52.5 tp -73.96 -25.45 59.95 Favored 'General case' 0 N--CA 1.454 -0.267 0 O-C-N 122.184 -0.322 . . . . 0.0 110.494 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.25 -30.17 65.37 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 179.327 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -85.44 -31.17 22.99 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 122.864 0.466 . . . . 0.0 110.612 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.91 -19.98 60.53 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.601 0.36 . . . . 0.0 111.166 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -94.46 -15.48 24.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 122.45 0.3 . . . . 0.0 111.314 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -83.63 -32.6 25.61 Favored 'General case' 0 N--CA 1.454 -0.242 0 O-C-N 122.31 -0.244 . . . . 0.0 111.491 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -84.86 -16.35 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.096 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 178.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -72.54 -4.39 30.34 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 122.656 0.382 . . . . 0.0 111.003 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 40.9 t80 -115.29 -35.78 4.55 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.806 0.442 . . . . 0.0 110.935 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -81.39 -7.77 59.63 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -177.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -86.7 -1.82 58.03 Favored 'General case' 0 CA--C 1.531 0.238 0 O-C-N 121.947 -0.471 . . . . 0.0 112.027 178.36 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -138.87 -6.7 1.45 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.678 0.391 . . . . 0.0 112.043 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -153.85 164.42 38.4 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.226 0.61 . . . . 0.0 109.563 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 8.4 pm0 -82.26 158.18 23.6 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 174.161 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -124.96 135.45 64.01 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 -178.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 67.8 m-85 -86.88 151.41 23.35 Favored 'General case' 0 N--CA 1.454 -0.246 0 O-C-N 122.196 -0.315 . . . . 0.0 110.661 -178.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 49.1 mt -137.09 -40.04 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 C-N-CA 122.429 0.291 . . . . 0.0 111.095 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -133.34 29.12 4.0 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 122.842 0.457 . . . . 0.0 111.058 -178.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 87.92 4.96 78.1 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -177.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -131.58 152.4 80.36 Favored Pre-proline 0 N--CA 1.453 -0.32 0 C-N-CA 124.205 1.002 . . . . 0.0 108.774 177.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.68 145.26 57.06 Favored 'Trans proline' 0 N--CA 1.448 -1.163 0 C-N-CA 123.147 2.565 . . . . 0.0 111.627 -177.101 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -152.09 -175.03 5.08 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 124.846 1.258 . . . . 0.0 108.905 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -138.35 162.01 35.48 Favored 'General case' 0 N--CA 1.456 -0.137 0 CA-C-O 120.915 0.388 . . . . 0.0 111.797 -178.067 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.14 144.05 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.146 0 C-N-CA 123.692 0.797 . . . . 0.0 109.378 178.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -157.18 166.22 33.82 Favored 'General case' 0 N--CA 1.454 -0.226 0 C-N-CA 122.966 0.506 . . . . 0.0 109.875 179.587 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -61.99 168.98 2.87 Favored 'General case' 0 C--O 1.232 0.139 0 CA-C-O 120.882 0.372 . . . . 0.0 111.056 177.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 35.5 t -145.6 165.97 27.14 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 123.175 0.59 . . . . 0.0 109.885 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 40.9 p -74.0 -7.62 53.08 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 175.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 68.8 m -73.8 152.14 40.38 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 123.869 0.868 . . . . 0.0 110.67 176.455 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.4 pt20 -137.29 -3.29 1.95 Allowed 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 122.626 0.37 . . . . 0.0 111.381 177.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -158.05 136.77 11.29 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 124.032 0.933 . . . . 0.0 108.608 -178.401 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 89.5 mt -87.39 137.56 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.212 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 174.12 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.5 m -78.67 141.25 38.1 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -174.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 69.9 ttt180 43.68 60.1 11.64 Favored Pre-proline 0 CA--C 1.533 0.29 0 C-N-CA 124.903 1.281 . . . . 0.0 112.751 174.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -72.02 -9.34 24.45 Favored 'Trans proline' 0 N--CA 1.455 -0.771 0 C-N-CA 123.23 2.62 . . . . 0.0 111.521 178.405 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 65.71 -134.76 35.35 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.516 -0.634 . . . . 0.0 111.516 176.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -152.73 163.42 39.72 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 123.357 0.663 . . . . 0.0 109.832 -176.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 95.3 p -144.83 162.68 36.2 Favored 'General case' 0 C--O 1.232 0.16 0 C-N-CA 123.357 0.663 . . . . 0.0 110.506 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -67.62 -16.46 64.18 Favored 'General case' 0 CA--C 1.53 0.202 0 O-C-N 122.284 -0.26 . . . . 0.0 111.117 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -85.53 -7.53 58.82 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 122.693 0.397 . . . . 0.0 110.758 178.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 46.5 m -113.06 0.16 14.91 Favored 'General case' 0 C--N 1.339 0.131 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -176.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 50.3 mtm180 -81.18 161.79 23.87 Favored 'General case' 0 C--N 1.34 0.171 0 CA-C-O 121.229 0.538 . . . . 0.0 111.309 179.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 62.7 m -71.94 -1.94 16.25 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.65 0.78 . . . . 0.0 111.665 178.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 40.3 t -88.16 -9.79 10.87 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.288 0 C-N-CA 123.655 0.782 . . . . 0.0 110.218 178.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -90.54 7.63 38.09 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 123.247 0.619 . . . . 0.0 111.386 -179.095 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 74.7 p . . . . . 0 C--O 1.254 1.291 0 CA-C-O 118.128 -0.939 . . . . 0.0 111.509 -178.406 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.244 0 N-CA-C 111.229 -0.749 . . . . 0.0 111.229 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -149.89 147.02 27.43 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.149 0.579 . . . . 0.0 110.121 179.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.6 p-10 -151.01 -177.43 6.01 Favored 'General case' 0 N--CA 1.455 -0.189 0 C-N-CA 122.755 0.422 . . . . 0.0 111.117 179.282 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -75.34 7.66 3.34 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.365 0.876 . . . . 0.0 113.365 -176.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -98.94 4.12 47.25 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -176.422 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 47.52 54.46 15.57 Favored Pre-proline 0 CA--C 1.534 0.335 0 C-N-CA 124.037 0.935 . . . . 0.0 112.774 177.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -71.9 -26.62 18.58 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 123.182 2.588 . . . . 0.0 112.106 -173.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . 0.562 ' CD2' ' H ' ' A' ' 92' ' ' LYS . 5.7 p-80 -158.49 -61.02 0.08 Allowed 'General case' 0 N--CA 1.457 -0.123 0 C-N-CA 122.377 0.271 . . . . 0.0 111.141 178.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.562 ' H ' ' CD2' ' A' ' 91' ' ' HIS . 97.7 mttt 44.28 33.25 0.81 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 124.433 1.093 . . . . 0.0 113.093 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 24.8 p -69.59 151.79 96.48 Favored Pre-proline 0 C--O 1.233 0.221 0 C-N-CA 122.614 0.366 . . . . 0.0 110.752 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -76.46 -7.33 17.77 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.675 2.917 . . . . 0.0 111.999 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . 50.71 36.16 13.53 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.538 0.735 . . . . 0.0 112.044 -178.633 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 51.8 m -62.12 157.38 53.04 Favored Pre-proline 0 CA--C 1.531 0.243 0 C-N-CA 123.836 0.854 . . . . 0.0 112.225 -176.112 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -70.98 -1.33 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 124.114 3.209 . . . . 0.0 111.927 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 86.7 t -116.14 140.44 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 176.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.53 152.08 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 CA-C-O 121.062 0.458 . . . . 0.0 110.761 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -102.48 136.38 42.41 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 123.982 0.913 . . . . 0.0 110.162 179.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 101' ' ' ILE . 2.5 mp -111.95 145.87 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -177.174 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -141.39 162.95 34.24 Favored 'General case' 0 C--O 1.231 0.114 0 C-N-CA 123.692 0.797 . . . . 0.0 110.574 -177.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 79.83 27.22 54.31 Favored Glycine 0 CA--C 1.527 0.818 0 CA-C-O 119.469 -0.628 . . . . 0.0 113.185 174.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 54.0 mt -61.42 158.88 13.72 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 117.893 0.847 . . . . 0.0 110.415 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.4 pt -71.87 -47.98 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -172.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -175.69 -35.86 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.208 0.603 . . . . 0.0 110.601 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -171.95 34.18 0.14 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.684 -0.509 . . . . 0.0 111.955 -175.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 8.8 p -52.32 148.49 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 CA-C-N 117.425 0.612 . . . . 0.0 109.732 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.4 m -103.31 168.87 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.082 0 CA-C-O 121.364 0.602 . . . . 0.0 112.141 -172.202 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -57.99 -28.13 64.11 Favored 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 123.985 0.914 . . . . 0.0 111.602 -177.133 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -78.58 -2.31 38.27 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -176.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -104.17 -32.59 9.07 Favored 'General case' 0 N--CA 1.457 -0.121 0 CA-C-N 118.235 0.47 . . . . 0.0 110.415 177.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.75 -34.33 60.27 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.898 -0.501 . . . . 0.0 110.524 -179.325 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 8.0 p -76.5 -31.26 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.216 0 C-N-CA 120.776 -0.37 . . . . 0.0 110.358 -179.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 65.3 mm-40 -83.0 -15.98 49.04 Favored 'General case' 0 N--CA 1.456 -0.151 0 CA-C-O 119.666 -0.207 . . . . 0.0 111.267 -178.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -104.72 -10.89 17.15 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 96.0 mt -116.02 -9.15 11.78 Favored 'General case' 0 CA--C 1.529 0.151 0 CA-C-N 118.632 0.651 . . . . 0.0 112.18 -179.5 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' GLN . . . . . . . . . . . . . 23.4 pt20 -68.9 -7.15 32.13 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 118.719 0.691 . . . . 0.0 111.523 176.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -75.67 -14.45 60.35 Favored 'General case' 0 CA--C 1.532 0.269 0 O-C-N 122.141 -0.35 . . . . 0.0 110.819 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 49.5 m-85 -97.13 -16.02 20.66 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 122.54 0.336 . . . . 0.0 111.591 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 161.78 178.56 35.8 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.85 139.5 33.48 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 124.046 3.164 . . . . 0.0 110.557 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 73.9 mt -110.94 145.76 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 122.688 0.395 . . . . 0.0 110.501 -177.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 23.1 t -106.73 -38.42 6.12 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 123.331 0.652 . . . . 0.0 111.463 -177.296 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' TYR . . . . . . . . . . . . . 64.8 t80 -160.17 157.05 27.67 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 120.668 0.27 . . . . 0.0 111.23 179.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 94.4 t -144.14 146.23 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 C-N-CA 123.858 0.863 . . . . 0.0 109.666 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . . . . . . . . . 8.0 p -149.83 153.79 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.068 0 C-N-CA 123.314 0.645 . . . . 0.0 109.513 176.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 46.0 t -127.34 150.66 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -177.465 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 68.2 mtm -132.27 77.85 69.77 Favored Pre-proline 0 CA--C 1.531 0.222 0 C-N-CA 124.3 1.04 . . . . 0.0 109.104 -177.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.8 -8.81 24.44 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 123.418 2.746 . . . . 0.0 111.72 -175.33 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -72.3 -17.11 61.89 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 122.656 0.382 . . . . 0.0 110.77 178.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 62.9 pttt -138.92 15.08 2.67 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 123.146 0.578 . . . . 0.0 111.91 178.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ARG . . . . . . . . . . . . . 11.5 tpp85 57.53 39.68 27.63 Favored 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 124.079 0.952 . . . . 0.0 113.247 178.255 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -131.58 170.07 15.25 Favored 'General case' 0 CA--C 1.527 0.06 0 C-N-CA 123.043 0.537 . . . . 0.0 110.621 179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -155.43 170.33 22.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 122.863 0.465 . . . . 0.0 110.564 177.003 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 34.1 mt -134.81 147.11 49.87 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.663 0.785 . . . . 0.0 110.179 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 85.0 t -139.08 132.07 38.22 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -114.15 119.79 38.31 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -86.97 154.79 20.51 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.426 -179.471 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -74.39 -14.63 60.89 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.507 -177.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -148.08 152.97 38.27 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.703 0.801 . . . . 0.0 109.108 176.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.1 p -66.72 -22.0 29.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -176.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.61 -26.11 60.64 Favored 'General case' 0 N--CA 1.451 -0.419 0 O-C-N 122.031 -0.418 . . . . 0.0 110.629 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.03 -31.39 64.34 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.57 -32.12 25.98 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.047 0.423 . . . . 0.0 110.335 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.8 t -70.86 -15.64 62.65 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 123.198 0.599 . . . . 0.0 110.938 178.518 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 60.2 t30 -99.89 -14.03 18.92 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.029 0.532 . . . . 0.0 111.412 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -87.23 -31.65 20.18 Favored 'General case' 0 N--CA 1.456 -0.175 0 O-C-N 122.128 -0.358 . . . . 0.0 111.717 -177.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.6 t -86.82 -16.12 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.078 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ASN . . . . . . . . . . . . . 22.0 t-20 -70.43 -4.69 23.78 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 122.913 0.485 . . . . 0.0 111.161 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' TYR . . . . . . . . . . . . . 62.3 t80 -117.32 -32.21 5.03 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 122.969 0.508 . . . . 0.0 111.459 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -93.84 -0.93 55.52 Favored 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 113.083 0.771 . . . . 0.0 113.083 -176.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -81.67 -6.64 59.21 Favored 'General case' 0 CA--C 1.534 0.341 0 O-C-N 121.98 -0.45 . . . . 0.0 112.032 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -145.26 3.75 1.04 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.704 0.402 . . . . 0.0 111.88 179.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 49.0 t30 -151.52 171.3 17.79 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -178.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -95.61 155.88 16.56 Favored 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 118.38 0.536 . . . . 0.0 110.17 177.568 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -123.35 136.31 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -179.15 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -90.58 154.32 19.68 Favored 'General case' 0 N--CA 1.454 -0.235 0 O-C-N 122.047 -0.408 . . . . 0.0 110.851 -178.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 48.3 mt -137.33 -42.24 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.916 -177.337 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -134.49 30.88 3.47 Favored 'General case' 0 N--CA 1.456 -0.161 0 C-N-CA 122.936 0.494 . . . . 0.0 111.002 -177.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 86.7 5.94 80.82 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -176.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -130.59 151.21 78.3 Favored Pre-proline 0 N--CA 1.455 -0.207 0 C-N-CA 124.046 0.938 . . . . 0.0 109.01 177.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -72.17 145.97 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 123.375 2.717 . . . . 0.0 111.936 -176.219 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -151.0 -177.91 6.29 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.757 1.223 . . . . 0.0 108.845 177.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -137.34 158.78 43.66 Favored 'General case' 0 N--CA 1.457 -0.106 0 O-C-N 122.296 -0.253 . . . . 0.0 111.096 -178.552 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.3 p -150.01 142.09 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.23 0.612 . . . . 0.0 109.918 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 -152.59 167.55 28.51 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.187 0.595 . . . . 0.0 110.332 178.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -66.06 164.55 15.15 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 120.976 0.417 . . . . 0.0 110.842 177.384 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' SER . . . . . . . . . . . . . 98.2 p -144.56 174.34 11.03 Favored 'General case' 0 N--CA 1.454 -0.247 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 176.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' THR . . . . . . . . . . . . . 59.7 p -76.26 1.76 15.12 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.675 0.39 . . . . 0.0 111.254 178.612 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 28.9 t -81.48 153.78 26.66 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 122.705 0.402 . . . . 0.0 110.758 179.147 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 19.3 pt20 -139.27 -5.17 1.44 Allowed 'General case' 0 CA--C 1.529 0.169 0 C-N-CA 123.027 0.531 . . . . 0.0 111.08 176.287 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 16.4 tppt? -159.16 130.62 6.27 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 -178.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 69.5 mt -90.96 93.64 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.19 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 179.142 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 47.7 m 50.33 -114.31 0.74 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 123.515 0.726 . . . . 0.0 111.306 -178.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' ARG . . . . . . . . . . . . . 14.9 tpp180 -140.98 82.78 14.69 Favored Pre-proline 0 N--CA 1.455 -0.187 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 -178.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -81.83 61.31 7.86 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 124.694 3.596 . . . . 0.0 110.842 -173.316 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 79.83 11.97 84.01 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -176.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 25.4 t0 61.86 169.01 0.11 Allowed 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 124.778 1.231 . . . . 0.0 113.012 -177.351 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 32.1 m -134.82 161.33 35.49 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 123.113 0.565 . . . . 0.0 110.847 -176.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -146.64 162.8 37.66 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 123.209 0.604 . . . . 0.0 110.138 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -143.21 154.91 44.34 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 123.096 0.558 . . . . 0.0 110.827 -178.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' SER . . . . . . . . . . . . . 54.8 m -138.82 161.97 35.94 Favored 'General case' 0 C--O 1.231 0.131 0 C-N-CA 123.238 0.615 . . . . 0.0 110.821 -177.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -91.81 12.12 22.49 Favored 'General case' 0 C--N 1.34 0.153 0 C-N-CA 123.399 0.68 . . . . 0.0 112.769 -178.211 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 43.7 m 61.92 7.17 1.93 Allowed 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 179.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' VAL . . . . . . . . . . . . . 30.2 m -142.2 166.28 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 CA-C-N 118.426 0.557 . . . . 0.0 110.059 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' ASN . . . . . . . . . . . . . 46.1 t30 -109.36 24.67 12.76 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.506 0.722 . . . . 0.0 110.942 -178.403 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 48.4 m . . . . . 0 C--O 1.251 1.149 0 CA-C-O 117.692 -1.147 . . . . 0.0 110.742 -178.711 . . . . . . . . 0 0 . 1 stop_ save_